<SEC-DOCUMENT>0001437749-22-005888.txt : 20220310
<SEC-HEADER>0001437749-22-005888.hdr.sgml : 20220310
<ACCEPTANCE-DATETIME>20220310172807
ACCESSION NUMBER:		0001437749-22-005888
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		101
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220310
DATE AS OF CHANGE:		20220310

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ACELRX PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001427925
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35068
		FILM NUMBER:		22730204

	BUSINESS ADDRESS:	
		STREET 1:		25821 INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 400
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		650-216-3500

	MAIL ADDRESS:	
		STREET 1:		25821 INDUSTRIAL BOULEVARD
		STREET 2:		SUITE 400
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>acrx20211231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:acrx="http://www.acelrx.com/20211231" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>acrx20211231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/10/2022 2:15:44 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001427925</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">ACELRX PHARMACEUTICALS INC</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
<ix:nonFraction id="c81618454" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c81618455" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="3" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c81618459" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c81618460" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c81618461" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000,000</ix:nonFraction>
<ix:nonFraction id="c81618462" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">200,000,000</ix:nonFraction>
<ix:nonFraction id="c81618463" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">136,819,647</ix:nonFraction>
<ix:nonFraction id="c81618465" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">136,819,647</ix:nonFraction>
<ix:nonFraction id="c81618464" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">98,812,008</ix:nonFraction>
<ix:nonFraction id="c81618466" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">98,812,008</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c81618752" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c81618753" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c81618855" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81618856" contextRef="d_2019-01-01_2019-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81618861" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81618867" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81619034" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:numdotdecimal" decimals="-5">1.1</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember" name="acrx:LicenseAgreementTerm" id="c81619063" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember" name="acrx:LicenseAgreementRenewalTerm" id="c81619067" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember" name="acrx:LicenseAgreementMinimumSalesObligationTerm" id="c81619075" format="ixt-sec:durmonth">12</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" name="acrx:LicenseAgreementRenewalTerm" id="c81619082" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c81619087" contextRef="i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="EUR" name="acrx:LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" scale="6" format="ixt:numdotdecimal" decimals="-6">47.0</ix:nonFraction>
<ix:nonFraction id="c81619088" contextRef="d_2021-07-01_2021-09-30_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="EUR" name="acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" scale="6" format="ixt:numdotdecimal" decimals="-5">2.5</ix:nonFraction>
<ix:nonFraction id="c81619125" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="EUR" name="acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" scale="6" format="ixt:numdotdecimal" decimals="-5">2.5</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-07-01_2021-07-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" name="acrx:LicenseAgreementTerm" id="c81619131" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-07-01_2021-07-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" name="acrx:LicenseAgreementRenewalTerm" id="c81619132" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonFraction id="c81619138" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="USD" name="us-gaap:CapitalizedContractCostAmortization" scale="6" format="ixt:numdotdecimal" decimals="-5">0.3</ix:nonFraction>
<ix:nonFraction id="c81619166" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">623</ix:nonFraction>
<ix:nonFraction id="c81619206" contextRef="i_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">13.15</ix:nonFraction>
<ix:nonFraction id="c81619215" contextRef="i_2020-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">14.35</ix:nonFraction>
<ix:nonNumeric contextRef="i_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c81619236" format="ixt-sec:duryear">2.25</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-03-26_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember" name="acrx:LesseeOperatingLeaseAbatedRentPeriod" id="c81619239" format="ixt-sec:durmonth">1</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2012-12-12" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c81619241" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2012-12-12_2012-12-12" name="acrx:LesseeOperatingLeaseNoticePeriod" id="c81619242" format="ixt-sec:duryear">18</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2021-04-21_CounterpartyNameAxis-CatalentPharmaSolutionsMember" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="c81619247" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2021-04-21_CounterpartyNameAxis-CatalentPharmaSolutionsMember" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="c81619249" format="ixt-sec:duryear">2</ix:nonNumeric>
<ix:nonFraction id="c81619332" contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">5</ix:nonFraction>
<ix:nonNumeric contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c81619342" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonFraction id="c81619346" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember" unitRef="Year" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">10</ix:nonFraction>
<ix:nonFraction id="c81619353" contextRef="d_2021-06-08_2021-06-08_LitigationCaseAxis-PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" unitRef="Pure" name="us-gaap:LossContingencyNumberOfDefendants" scale="0" format="ixt:numdotdecimal" decimals="INF">2</ix:nonFraction>
<ix:nonFraction id="c81619358" contextRef="d_2021-07-06_2021-07-06_LitigationCaseAxis-PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" unitRef="Pure" name="us-gaap:LossContingencyNumberOfDefendants" scale="0" format="ixt:numdotdecimal" decimals="INF">10</ix:nonFraction>
<ix:nonFraction id="c81619560" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">0.72</ix:nonFraction>
<ix:nonFraction id="c81619567" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">1.26</ix:nonFraction>
<ix:nonFraction id="c81619574" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">2.00</ix:nonFraction>
<ix:nonFraction id="c81619581" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">3.10</ix:nonFraction>
<ix:nonFraction id="c81619588" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">4.73</ix:nonFraction>
<ix:nonFraction id="c81619595" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">8.18</ix:nonFraction>
<ix:nonFraction id="c81619742" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction>
<ix:nonFraction id="c81619743" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" scale="3" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonFraction id="c81619713" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:OpenTaxYear" id="c81619715">2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2016 2017 2018 2019 2020 2021</ix:nonNumeric>
<ix:footnote xml:lang="en-us" id="f885b942b-4d82-4328-906f-3d3734a0164b">In May 2020, upon notification of early termination by Gr&#xfc;nenthal, the Company recognized approximately $2.6 million of deferred revenue under the Gr&#xfc;nenthal Agreements.</ix:footnote>
<ix:footnote xml:lang="en-us" id="f40de3ee5-5f1e-4028-af76-e4a0b0310e24">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020.</ix:footnote>
<ix:footnote xml:lang="en-us" id="ff222100c-5872-47bd-9e81-c9770f715bf5">Deductions to sales discounts and allowances relate to discounts or allowances actually taken or paid.</ix:footnote>
<ix:footnote xml:lang="en-us" id="fb2165eae-cac4-48dd-b222-f940250826c6">Deferred revenue under the DZUVEO Agreement with Aguettant.</ix:footnote></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="acrx-20211231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>

<xbrli:context id="d_2021-01-01_2021-12-31_LegalEntityAxis-OUMCoLLPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">acrx:OUMCoLLPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>

<xbrli:context id="d_2021-01-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-03-07"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ContractAndOtherCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ContractAndOtherCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AssetAcquisitionAxis-LowellsIntellectualPropertyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">acrx:LowellsIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AssetAcquisitionAxis-LowellsIntellectualPropertyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">acrx:LowellsIntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:AguettantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:AguettantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-GrunenthalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:GrunenthalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-GrunenthalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:GrunenthalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DoDMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DoDMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:DoDMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-WholesalerAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:WholesalerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-WholesalerAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:WholesalerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:CustomerAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:CustomerBMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-03-16_2020-03-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-16</xbrli:startDate><xbrli:endDate>2020-03-16</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-09-01_2015-09-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-01-01_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acrx:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acrx:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acrx:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acrx:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-AmendedLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:AmendedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-DSUVIAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DSUVIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:ToolingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:ToolingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:PFSProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:PFSProductsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:PFSProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:PFSProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-09-30_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-14</xbrli:startDate><xbrli:endDate>2021-07-14</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:AmendedLicenseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:AmendedLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">acrx:BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponNetSalesTargetAchievementsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:AmendedLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">acrx:BasedUponNetSalesTargetAchievementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2015-07-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-DSUVIAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DSUVIAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ZALVISOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ZALVISOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ZALVISOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ZALVISOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-LicenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-NonCashRoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:NonCashRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NonCashRoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:NonCashRoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherRevenueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ContractAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherRevenueMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ContractAndOtherRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-01_2021-07-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-05-01_2020-05-31_ProductOrServiceAxis-ZALVISOMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ZALVISOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-30</xbrli:startDate><xbrli:endDate>2019-05-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-30</xbrli:startDate><xbrli:endDate>2019-05-30</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-08-01_2019-08-01_LongtermDebtTypeAxis-SiteReadinessAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acrx:SiteReadinessAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acrx:SiteReadinessAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acrx:SiteReadinessAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="SquareFoot"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-12-31_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acrx:LeaseForCorporateHeadquartersInHaywardCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-26_2021-03-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-04-30_BalanceSheetLocationAxis-PrepaidExpensesAndOtherCurrentAssetsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acrx:LeaseForCorporateHeadquartersInHaywardCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-26</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-26_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acrx:LeaseForCorporateHeadquartersInHaywardCaliforniaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-26</xbrli:startDate><xbrli:endDate>2021-03-26</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2012-12-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2012-12-12</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2012-12-12_2012-12-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2012-12-12</xbrli:startDate><xbrli:endDate>2012-12-12</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-04-21_CounterpartyNameAxis-CatalentPharmaSolutionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:CatalentPharmaSolutionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-21</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-CatalentPharmaSolutionsMember_StatementScenarioAxis-ScenarioForecastMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:CatalentPharmaSolutionsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-09-18_2015-09-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-18</xbrli:startDate><xbrli:endDate>2015-09-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">acrx:SWKMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-18</xbrli:startDate><xbrli:endDate>2015-09-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">acrx:SWKMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acrx:FirstFourCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-18</xbrli:startDate><xbrli:endDate>2015-09-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-09-18_2015-09-18_LegalEntityAxis-AcelRXMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">acrx:AcelRXMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acrx:FirstFourCommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-18</xbrli:startDate><xbrli:endDate>2015-09-18</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2015-09-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2015-09-18</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2015-09-19_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-19</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-15</xbrli:startDate><xbrli:endDate>2021-11-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-15_2021-11-15_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-15</xbrli:startDate><xbrli:endDate>2021-11-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-15</xbrli:startDate><xbrli:endDate>2021-11-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-15</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-15_2021-11-15_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-15</xbrli:startDate><xbrli:endDate>2021-11-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-15</xbrli:startDate><xbrli:endDate>2021-11-15</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-08_2021-06-08_LitigationCaseAxis-PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">acrx:PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-08</xbrli:startDate><xbrli:endDate>2021-06-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-07-06_2021-07-06_LitigationCaseAxis-PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">acrx:PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-06</xbrli:startDate><xbrli:endDate>2021-07-06</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-22_2021-01-22_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-22</xbrli:startDate><xbrli:endDate>2021-01-22</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-01-22_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-22</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-27_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-27</xbrli:startDate><xbrli:endDate>2021-01-27</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-27</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-22_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-22</xbrli:startDate><xbrli:endDate>2021-01-27</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-17</xbrli:startDate><xbrli:endDate>2021-11-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-11-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-11-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-11-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-07-23_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-23</xbrli:startDate><xbrli:endDate>2020-07-23</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-23</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-12-11_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-11</xbrli:startDate><xbrli:endDate>2020-12-11</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-11</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2016-06-21_2016-06-21_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-06-21</xbrli:startDate><xbrli:endDate>2016-06-21</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2019-05-09_2019-05-09_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-09</xbrli:startDate><xbrli:endDate>2019-05-09</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:ATMAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2011-01-01_2011-01-31_PlanNameAxis-EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2011-01-01</xbrli:startDate><xbrli:endDate>2011-01-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2011-12-31_PlanNameAxis-EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2011-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-16_PlanNameAxis-EquityIncentivePlan2011Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EquityIncentivePlan2011Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-16_PlanNameAxis-The2020EquityIncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-06-17_2021-06-17_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-17</xbrli:startDate><xbrli:endDate>2021-06-17</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-06-17_PlanNameAxis-The2020EquityIncentivePlanMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-17</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-16_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-06-16_PlanNameAxis-EmployeeStockPurchasePlanESPPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-16</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-EmployeeStockPurchasePlanESPPMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-CostOfSalesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange4Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange5Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange6Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-03-03_2021-03-03_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ExecutiveOfficerMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-03</xbrli:startDate><xbrli:endDate>2021-03-03</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">acrx:RSUsESPPAndEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">acrx:RSUsESPPAndEmployeeStockOptionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-BeforeTaxYear2018Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acrx:BeforeTaxYear2018Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYears2018To2020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acrx:TaxYears2018To2020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementScenarioAxis-SubjectToExpirationMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">acrx:SubjectToExpirationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementScenarioAxis-SubjectToExpirationMember_TaxCreditCarryforwardAxis-ResearchMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementScenarioAxis">acrx:SubjectToExpirationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-07_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acrx:LowellTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-07</xbrli:startDate><xbrli:endDate>2022-01-07</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acrx:LowellTherapeuticsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:AcelrxCommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-01-07</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember_BusinessAcquisitionAxis-LowellTherapeuticsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acrx:LowellTherapeuticsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001427925</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f885b942b-4d82-4328-906f-3d3734a0164b" fromRefs="c81619167"></ix:relationship>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="f40de3ee5-5f1e-4028-af76-e4a0b0310e24" fromRefs="c81618410 c81618412 c81618414 c81618416 c81618418 c81618420 c81618422 c81618424 c81618426 c81618428 c81618432 c81618434 c81618436 c81618438 c81618440 c81618442 c81618446 c81618448 c81618450 c81618452 c81618458 c81618468 c81618470 c81618472 c81618474"></ix:relationship>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="ff222100c-5872-47bd-9e81-c9770f715bf5" fromRefs="c81619790 c81619794"></ix:relationship>
<ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="fb2165eae-cac4-48dd-b222-f940250826c6" fromRefs="c81619169"></ix:relationship></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<hr class="hr-custom" style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0pt 0pt 3pt 0pt;" />
<div>
 &#xa0;
</div>
<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>UNITED STATES </b></p>
<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>SECURITIES AND EXCHANGE COMMISSION </b></p>
<p style="font-family: Times New Roman; font-size: 12pt; font-variant: normal; text-align: center; margin: 0pt;"><b>WASHINGTON, DC 20549</b></p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt auto;" />
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="font-family:Times New Roman;font-size:12pt;"><b>FORM <ix:nonNumeric name="dei:DocumentType" contextRef="d_2021-01-01_2021-12-31">10-K</ix:nonNumeric> </b></span></p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt auto;" />
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2611;</ix:nonNumeric> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES </b><b>EXCHANGE ACT OF 1934 </b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:25pt;"><b>For the fiscal year ended </b><ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2021-01-01_2021-12-31"><b>December</b>&#xa0;<b>31, 2021</b></ix:nonNumeric><b></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>or </b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;"><tbody><tr style="vertical-align: top;"><td style="width: 27pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric> </b></p> </td><td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES </b><b>EXCHANGE ACT OF 1934 </b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the transition period from </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b> to </b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b> </b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Commission File Number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2021-01-01_2021-12-31">001-35068</ix:nonNumeric> </b></p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt auto;" />
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;"><b>ACELRX PHARMACEUTICALS, INC. </b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter) </b></p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt auto;" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2021-01-01_2021-12-31">Delaware</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2021-01-01_2021-12-31">41-2193603</ix:nonNumeric></b></p> </td></tr>
<tr><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction of</b><br /> <b>incorporation or organization)</b></p> </td><td style="vertical-align: top; width: 50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(IRS Employer</b><br /> <b>Identification No.)</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2021-01-01_2021-12-31">25821 Industrial Boulevard, Suite 400</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2021-01-01_2021-12-31">Hayward</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2021-01-01_2021-12-31">CA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2021-01-01_2021-12-31">94545</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2021-01-01_2021-12-31">650</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2021-01-01_2021-12-31">216-3500</ix:nonNumeric> </b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address, including zip code, and telephone number, including area code, of registrant</b>&#x2019;<b>s principal executive offices) </b></p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt auto;" />
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities registered pursuant to Section</b>&#xa0;<b>12(b) of the Act: </b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: bottom; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><b>Title of Each Class</b></span></p> </td><td style="vertical-align: top; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Trading Symbol(s)</span></b></p> </td><td style="vertical-align: bottom; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><b>Name of Each Exchange on Which Registered</b></span></p> </td></tr>
<tr><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2021-01-01_2021-12-31">Common Stock, $0.001 par value</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 34%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;"><b><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2021-01-01_2021-12-31">ACRX</ix:nonNumeric></b></p> </td><td style="vertical-align: top; width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;"><b>The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2021-01-01_2021-12-31">Nasdaq</ix:nonNumeric> Global Market</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Securities registered pursuant to Section</b>&#xa0;<b>12(g) of the Act: </b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>None </b></p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt auto;" />
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.&#xa0;&#xa0;&#xa0;&#xa0;Yes&#xa0;&#xa0;&#x2610;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2021-01-01_2021-12-31">No</ix:nonNumeric>&#xa0;&#xa0;&#x2611;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#xa0;13 or Section&#xa0;15(d) of the Act.&#xa0;&#xa0;&#xa0;&#xa0;Yes&#xa0;&#xa0;&#x2610;&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2021-01-01_2021-12-31">No</ix:nonNumeric>&#xa0;&#xa0;&#x2611;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">Indicate by check mark whether the registrant (1)&#xa0;has filed all reports required to be filed by Section&#xa0;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#xa0;has been subject to such filing requirements for the past 90 days.&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2021-01-01_2021-12-31">Yes</ix:nonNumeric>&#xa0;&#xa0;&#x2611;&#xa0;&#xa0;&#xa0;&#xa0;No&#xa0;&#xa0;&#x2610;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;-232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2021-01-01_2021-12-31">Yes</ix:nonNumeric>&#xa0;&#xa0;&#x2611;&#xa0;&#xa0;&#xa0;&#xa0;No&#xa0;&#xa0;&#x2610;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large&#xa0;accelerated&#xa0;filer</p> </td><td style="vertical-align: bottom; width: 56%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#x2610;</p> </td><td style="vertical-align: bottom; width: 16%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated&#xa0;filer&#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0; &#xa0;</p> </td><td style="vertical-align: bottom; width: 5%;">&#x2610;</td></tr>
<tr><td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2021-01-01_2021-12-31">Non-accelerated filer</ix:nonNumeric></p> </td><td style="vertical-align: bottom; width: 56%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#x2611;</p> </td><td style="vertical-align: bottom; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Smaller&#xa0;reporting&#xa0;company&#xa0;&#xa0;</p> </td><td style="vertical-align: bottom; width: 5%;"><ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2611;</ix:nonNumeric></td></tr>
<tr><td style="vertical-align: bottom; width: 22%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company</p> </td><td style="vertical-align: bottom; width: 56%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 45pt;"><ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric>&#xa0;</p> </td><td style="vertical-align: bottom; width: 16%;">&#xa0;</td><td style="vertical-align: bottom; width: 5%;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. &#xa0;&#xa0;&#xa0;&#xa0;<ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:19pt;">Indicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2)&#xa0;&#xa0;&#xa0;&#xa0;Yes&#xa0;&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric>&#xa0;&#xa0;&#xa0;&#xa0;No&#xa0;&#xa0;&#x2611;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">The aggregate market value of the voting stock held by non-affiliates of the registrant on June&#xa0;30, 2021 (the last business day of the registrant&#x2019;s most recently completed second fiscal quarter), based upon the last sale price reported on the Nasdaq Global Market on that date, was approximately $<ix:nonFraction name="dei:EntityPublicFloat" scale="0" unitRef="USD" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2021-06-30">161,163,094</ix:nonFraction>. The calculation excludes 2,394,955 shares of the registrant&#x2019;s common stock held by current executive officers and directors that the registrant has concluded are affiliates of the registrant. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt;">As of March 7, 2022, the number of outstanding shares of the registrant&#x2019;s common stock was <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2022-03-07">146,949,320</ix:nonFraction>.</p>
<hr class="hr-custom" style="text-align: center;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 3pt auto 3pt auto;" />
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE </b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;"><tbody><tr><td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:43.4%;">&#xa0;</td></tr>
<tr><td style="vertical-align:top;width:43.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 8pt;">Portions of the Registrant's notice of annual meeting of stockholders and proxy statement to be filed pursuant to Regulation&#xa0;14A within 120&#xa0;days after Registrant's fiscal year end of December&#xa0;31, 2021 (the &#x201c;2022 Proxy Statement&#x201d;), are incorporated by reference into Part&#xa0;III of this report.</p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 18pt;">&#xa0;</p>
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
  1
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  &#xa0;
 </div>
</div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Unless the context indicates otherwise, the terms &#x201c;AcelRx,&#x201d; &#x201c;AcelRx Pharmaceuticals,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to AcelRx Pharmaceuticals, Inc., and its consolidated subsidiaries. &#x201c;DZUVEO&#x201d; and &#x201c;Niyad&#x201d; are trademarks, and &#x201c;ACELRX,&#x201d; &#x201c;DSUVIA&#x201d; and &#x201c;Zalviso&#x201d; are registered trademarks, all owned by AcelRx Pharmaceuticals, Inc. This report also contains trademarks and trade names that are the property of their respective owners.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This Annual Report on Form 10-K, or Annual Report, contains statements that discuss future events or expectations, projections of results of operations or financial condition, trends in our business, business prospects and strategies and other &#x201c;forward-looking&#x201d; information. In some cases, you can identify &#x201c;forward-looking statements&#x201d; by words like &#x201c;may,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;expects,&#x201d; &#x201c;plans,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;predicts,&#x201d; &#x201c;intends,&#x201d; &#x201c;potential&#x201d; or &#x201c;continue&#x201d; or the negative of those words and other comparable words. These forward-looking statements are not guarantees of future performance or development and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control. These forward-looking statements may relate to, among other things, our expectations regarding the scope, progress, expansion, and costs of researching, developing and commercializing our product candidates; our opportunity to benefit from various regulatory incentives; expectations for our financial results, revenue, operating expenses and other financial measures in future periods; and the adequacy of our sources of liquidity to satisfy our working capital needs, capital expenditures, and other liquidity requirements. These are only some of the factors that may affect the forward-looking statements contained in this Annual Report. For a discussion identifying additional important factors that could cause actual results to vary materially from those anticipated in the forward-looking statements, see &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and &#x201c;Risk Factors&#x201d; in this Annual Report. You should review these risk factors for a more complete understanding of the risks associated with an investment in our securities. However, we operate in a competitive and rapidly changing environment and new risks and uncertainties emerge, are identified or become apparent from time to time. It is not possible for us to predict all risks and uncertainties that could have an impact on the forward-looking statements contained in this Annual Report. You should be aware that the forward-looking statements contained in this Annual Report are based on our current views and assumptions. We undertake no obligation to revise or update any forward-looking statements made in this Annual Report to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
  2
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  &#xa0;
 </div>
</div>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ACELRX PHARMACEUTICALS, INC.</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>2021 ANNUAL REPORT ON FORM 10-K </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr>
      <td style="vertical-align: bottom; width: 95%;">&#xa0;</td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><b>Page</b>&#xa0;</span></p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Summary of Principal Risk Factors</p> </td>
      <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">PART I</p> </td>
      <td style="vertical-align: bottom; width: 5%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;1. Business&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">4</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;1A. Risk Factors&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">27</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;1B. Unresolved Staff Comments&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%; padding: 0pt; text-align: right;">63</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;2. Properties&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">63</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;3. Legal Proceedings&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">63</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;4. Mine Safety Disclosures&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">63</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">PART II</p> </td>
      <td style="vertical-align: bottom; width: 5%; padding: 0pt; text-align: right;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;5. Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">64</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;6. Reserved&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">64</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;7. Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">65</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;7A. Quantitative and Qualitative Disclosures About Market Risk&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">77</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;8. Financial Statements and Supplementary Data&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">77</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">77</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;9A. Controls and Procedures&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">77</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;9B. Other Information&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">78</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">78</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">PART III</p> </td>
      <td style="vertical-align: bottom; width: 5%; padding: 0pt; text-align: right;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;10. Directors, Executive Officers and Corporate Governance&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">79</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;11. Executive Compensation&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">79</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%; padding: 0pt; text-align: right;">79</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;13. Certain Relationships and Related Transactions, and Director Independence&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">79</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;14. Principal Accounting Fees and Services&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">79</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">PART IV</p> </td>
      <td style="vertical-align: bottom; width: 5%; padding: 0pt; text-align: right;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;15. Exhibits and Financial Statement Schedules&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">79</p> </td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:-12pt;">Item&#xa0;16. Form 10-K Summary&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">83</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Signatures&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
      <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">84</p> </td>
     </tr>

    </tbody>
   </table>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      3
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </div>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PART I </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>1. Business </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Portfolio</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates, as further described below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Sufentanil Sublingual Products/Product Candidates</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 90%; margin-left: 36pt; margin-right: auto;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Product/Product</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Candidate</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Target</b>&#xa0;<b>Use</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Status</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DSUVIA&#xae;&#xa0;</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sufentanil sublingual tablet, 30 mcg</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Moderate-to-severe acute pain in a medically supervised setting, administered by a healthcare professional</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">Received U.S. Food and Drug Administration, or FDA, approval in November 2018; commercial launch began first quarter of 2019.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">DZUVEO&#xae;&#xa0;</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sufentanil sublingual tablet, 30 mcg</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Moderate-to-severe acute pain in a medically monitored setting, administered by a healthcare professional</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">Granted European Commission, or EC, marketing approval in June 2018. Sunset date extended to December 31, 2022 by EC. To be commercialized in Europe by Laboratoire Aguettant, or Aguettant.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Zalviso&#xae;</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Sufentanil sublingual tablet system, 15 mcg</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Moderate-to-severe acute pain in the hospital setting, administered by the patient as needed</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">In the U.S., positive results from Phase 3 trial, IAP312, announced in August 2017. Currently evaluating the timing of the resubmission of the New Drug Application, or NDA, which is in part dependent on the finalization of the FDA&#x2019;s new opioid approval guidelines and process.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">Approved in the European Union, where it was marketed commercially by Gr&#xfc;nenthal GmbH, or Gr&#xfc;nenthal, through May 12, 2021. &#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">ARX-02</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Higher Strength Sufentanil Sublingual Tablet</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Cancer breakthrough pain in opioid-tolerant patients</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">Phase 2 clinical trial and End of Phase 2 meeting completed. Investigational New Drug, or IND, application was inactivated.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">Future development contingent upon identification of corporate partnership resources.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 90%; margin-left: 36pt; margin-right: auto;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Product/Product</b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Candidate</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Description</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Target</b>&#xa0;<b>Use</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Status</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">4ARX-03</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Combination Sufentanil/Triazolam Sublingual Tablet</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Mild sedation and pain relief during painful procedures in a physician&#x2019;s office</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">Phase 2 clinical trial and End of Phase 2 meeting completed. IND application was inactivated.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">Future development contingent upon identification of corporate partnership resources.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have created a proprietary sublingual (under the tongue) formulation of sufentanil intended for the treatment of moderate-to-severe acute pain. We believe our non-invasive, proprietary sublingual sufentanil tablet potentially overcomes many of the limitations of current treatment options available for moderate-to-severe acute pain. The sufentanil pharmacokinetic profile when delivered sublingually avoids the high peak plasma levels and short duration of action observed with IV administration. The sublingual formulation retains the therapeutic value of sufentanil, and novel delivery devices provide a non-invasive route of administration. Sufentanil is highly lipophilic which provides for rapid absorption in the mucosal tissue, or fatty cells, found under the tongue, and for rapid transit across the blood-brain barrier to reach the mu-opioid receptors in the brain. The sublingual route of delivery used by DSUVIA and Zalviso provides a predictable onset of analgesia. The sublingual delivery system also eliminates the risk of intravenous, or IV, complications, such as catheter-related infections. In addition, because patients do not require direct connection to an IV infusion pump, or IV line, DSUVIA and Zalviso may allow for ease of patient mobility.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have chosen sufentanil as the therapeutic ingredient for DSUVIA and Zalviso. Opioids have been utilized for pain relief for centuries and are the standard-of-care for the treatment of moderate-to-severe acute pain. Sufentanil, a high-therapeutic index opioid, which has no active metabolites, is available as an injectable in several markets around the world and is used by anesthesiologists for induction of sedation or as an epidural; however, the injectable formulation is not suitable for the treatment of acute pain. Sufentanil has many pharmacological advantages over other opioids. Published studies demonstrate that sufentanil produces significantly less respiratory depressive effects relative to its analgesic effects compared to other opioids, including morphine and fentanyl. These third-party clinical results correlate well with preclinical trials demonstrating sufentanil&#x2019;s high therapeutic index, or the ratio of the toxic dose to the therapeutic dose of a drug, used as a measure of the relative safety of the drug for a particular treatment. Accordingly, we believe that sufentanil can provide an effective and well-tolerated treatment for acute pain. The following table illustrates the difference between the therapeutic index of different opioids. &#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%; margin-left: 20%; margin-right: 20%;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><span style="text-decoration: underline; "><b>Opioid</b></span></p> </td>
     <td style="vertical-align: bottom; width: 19%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Therapeutic</b><br /> <b>Index</b>&#xa0;</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Meperidine&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">5</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Methadone&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">12</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Morphine&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">71</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Hydromorphone&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">250</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Fentanyl&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">277</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 81%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 12pt; text-indent: -12pt;">Sufentanil&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 19%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">26,716</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the pharmaceutical attributes of sufentanil, including lipid solubility and ionization, result in rapid cell membrane penetration and onset of action, which we believe make sufentanil an optimal opioid for the treatment of acute pain.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Although the analgesic efficacy and safety of sufentanil have been well established, the product&#x2019;s use has been historically limited due to its short duration of action when delivered intravenously. Sublingual delivery of sufentanil avoids the high peak plasma levels and short duration of action of IV administration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Drugs are classified or scheduled by the Drug Enforcement Agency, or DEA, according to their potential for abuse and addiction. Sufentanil is classified as a Schedule II controlled substance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">DSUVIA</span></i><sup style="vertical-align:top;line-height:120%;font-size:pt"><span style="text-decoration: underline; ">&#xae;</span></sup><i></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DSUVIA, known as DZUVEO in Europe, approved by the FDA in November 2018 (and by the European Medicines Agency, or EMA, in June 2018), is indicated for use in adults in certified medically supervised healthcare settings, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. DSUVIA was designed to provide rapid analgesia via a non-invasive route and to eliminate dosing errors associated with IV administration. DSUVIA is a single-strength solid dosage form administered sublingually via a single-dose applicator, or SDA, by healthcare professionals. Sufentanil is an opioid analgesic currently also marketed for IV and epidural anesthesia and analgesia. The sufentanil pharmacokinetic profile when delivered sublingually avoids the high peak plasma levels and short duration of action observed with IV administration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Examples of potential patient populations and settings in which DSUVIA could be used include: emergency room patients; perioperative use for patients who are undergoing inpatient, short-stay or ambulatory surgery; inpatient use for up to 72 hours in patients with moderate-to-severe acute pain; procedural suite use for painful procedures such as oral surgery or cosmetic procedures; patients being treated and transported by paramedics; and for battlefield casualties. In the emergency room and in procedural suite environments, patients often do not have immediate IV access available, or may not require IV access. Moreover, IV dosing results in high peak plasma levels, thereby limiting the opioid dose and requiring frequent redosing intervals to titrate to satisfactory analgesia. Oral pills and liquids generally have slow and erratic onset of analgesia. Based on internal market research conducted to date, we believe that DSUVIA, a treatment option that provides timely analgesia without requiring an IV for moderate-to-severe acute pain, continues to be needed, in both civilian and military settings, as an alternative to other currently available opioids.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DSUVIA was approved with a REMS which restricts distribution to certified medically supervised healthcare settings in order to prevent respiratory depression resulting from accidental exposure. DSUVIA is only distributed to facilities certified in the DSUVIA REMS program following attestation by an authorized representative to comply with appropriate dispensing and use restrictions of DSUVIA. To become certified, a healthcare setting is required to train their healthcare professionals on the proper use of DSUVIA and have the ability to manage respiratory depression. DSUVIA is not available in retail pharmacies or for outpatient use. As part of the REMS program, we monitor distribution and audit wholesalers&#x2019; data, evaluate proper usage within the healthcare settings and monitor for any diversion and abuse. We de-certify healthcare settings that are non-compliant with the REMS program.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 14, 2021, we entered into a License and Commercialization Agreement, or the DZUVEO Agreement, with Aguettant pursuant to which Aguettant obtained the exclusive right to develop and commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom, or the DZUVEO Territory, for the management of acute moderate to severe pain in adults in medically monitored settings. We will supply Aguettant with primary packaged product and Aguettant will then complete secondary packaging of the finished product. We are entitled to receive up to &#x20ac;47.0 million in a combination of up-front and sales-based milestone payments, of which we received &#x20ac;2.5 million, or approximately $2.9 million, in 2021. Refer to Note 6 &#x201c;Out-license Agreements&#x2014;DZUVEO&#x201d; in the accompanying notes to the Consolidated Financial Statements for additional information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Zalviso</span></i><span style="text-decoration: underline; ">&#xae;</span><i></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While still under development in the United States, Zalviso is approved in the European Union, or EU. Zalviso is intended for the management of moderate-to-severe acute pain in hospitalized adult patients. Zalviso consists of a pre-filled cartridge of 40 sufentanil sublingual tablets, 15 mcg, delivered by the Zalviso System, a needle-free, handheld, patient-administered, pain management system. Zalviso is a pre-programmed non-invasive system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets, 15 mcg, to manage their pain. Zalviso is designed to help address certain problems associated with post-operative IV patient-controlled analgesia, or PCA. Zalviso allows patients to self-administer sufentanil sublingual tablets via a pre-programmed, secure system designed in part to eliminate the risk of healthcare provider programming errors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Zalviso System consists of the following components: a disposable dispenser tip, a disposable dispenser cap, an adhesive thumb tag, a cartridge of 40 sufentanil sublingual 15 mcg tablets (approximately a two-day supply) in a disposable radio frequency identification and bar-coded cartridge, a reusable, rechargeable handheld controller, a tether, and an authorized access card.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The potential benefits of Zalviso are the result of combining the following three elements:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">sufentanil, a high therapeutic index opioid;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">sufentanil sublingual tablets, our proprietary, non-invasive sublingual dosage form; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our novel, pre-programmed, handheld PCA device that enables simple patient-controlled delivery of sufentanil sublingual tablets in the hospital setting and eliminates the risk of programming errors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Scheduled drugs, when they are under patient control in a hospital setting, must be secured and have adequate dose access control and tracking mechanisms. Our novel handheld PCA device has the following safety features:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">an authorized access card, which is a wireless system access key for the healthcare professional;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a wireless, electronic, adhesive thumb tag that acts as a single-patient identification key;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">pre-programmed 20-minute lock-out to avoid overdosing;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">tablet singulation, or dispensing, motion that eliminates runaway motor delivery risk;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a security tether that is designed to prevent theft and misuse; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">fully automated inventory record of sufentanil sublingual tablet usage.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We submitted an NDA for Zalviso in September 2013, or the Zalviso NDA, and on July 25, 2014, the Division of Anesthesia, Analgesia, and Addiction Products of the FDA issued a Complete Response Letter, or CRL, for the Zalviso NDA. The CRL contained requests for additional information on the Zalviso System to ensure proper use of the device. The requests include submission of data demonstrating a reduction in the incidence of device errors, changes to address inadvertent dosing, among other items, and submission of additional data to support the shelf life of the product. In March 2015, we received correspondence from the FDA stating that, in addition to the work we had performed to address the items in the CRL, a clinical study would be required to test the modifications to the Zalviso device and mitigations put in place to reduce the risk of inadvertent dosing/misplaced tablets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our IAP312 study was designed to evaluate the effectiveness of changes made to the functionality and usability of the Zalviso device and to take into account comments from the FDA on the study protocol. In the IAP312 study, 320 hospitalized, post-operative patients used Zalviso to self-administer 15 mcg sublingual sufentanil tablets as often as once every 20 minutes for 24-to-72 hours to manage their moderate-to-severe acute pain. Throughout the study, for which top-line results were announced in August 2017, 2.2% of patients experienced a Zalviso device error, which was statistically less than the 5% limit specified in the study objectives. None of these device errors resulted in an over-dosing event. This 2.2% rate was lower (p &lt; 0.001) than the 7.9% rate of device errors during patient use previously reported for the earlier version of the Zalviso device in the Phase 3 IAP311 study. In addition, results of this study supported earlier clinical findings, with favorable tolerability and a significant majority of &#x201c;good&#x201d; or &#x201c;excellent&#x201d; ratings provided by both patients and healthcare providers when assessing the method of pain control. These results will supplement those of our earlier Phase 3 studies (IAP309, IAP310 and IAP311), all of which met safety and efficacy endpoints, in the Zalviso NDA resubmission. The timing of the resubmission of the Zalviso NDA is in part dependent upon the finalization of the FDA&#x2019;s new opioid approval guidelines and process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Zalviso was approved for commercial sale in the European Union, or EU, in September 2015 and Gr&#xfc;nenthal GmbH, or Gr&#xfc;nenthal, began its commercial launch of Zalviso in the EU in April 2016. On May 18, 2020, we received a notice from Gr&#xfc;nenthal that it was exercising its right to terminate the Collaboration and License Agreement, or, as amended, the License Agreement, which granted Gr&#xfc;nenthal the European rights to commercialize Zalviso in the 28 EU member states at the time of the agreement, plus Switzerland, Liechtenstein, Iceland, Norway and Australia, or the Territory, for human use in pain treatment in medically supervised settings, and the related Manufacture and Supply Agreement, or, as amended, the MSA, under which AcelRx exclusively manufactured and supplied Zalviso to Gr&#xfc;nenthal for commercial sales in the Territory. The MSA, together with the License Agreement, are referred to as the Gr&#xfc;nenthal Agreements. Certain terms of the Gr&#xfc;nenthal Agreements were extended to May 2021 to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. The rights to market and sell Zalviso in the Territory reverted back to us in May 2021. Certain terms of the Gr&#xfc;nenthal Agreements were further extended for a period of thirty days after the last Zalviso product distributed by Gr&#xfc;nenthal prior to May 13, 2021 expires to enable the parties to manage applicable pharmacovigilance and other requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On September 18, 2015, we sold a majority of the expected royalty stream and commercial milestones from the sales of Zalviso in Europe by Gr&#xfc;nenthal to PDL BioPharma, Inc., or PDL, in a transaction referred to as the Royalty Monetization. On August 31, 2020, PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK.&#xa0;Under the Royalty Monetization, we have a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement for Zalviso, or New Arrangement; however, we have not yet entered into such an arrangement. For additional information regarding the Gr&#xfc;nenthal Agreements, see Note 7 &#x201c;Revenue from Contracts with Customers&#x201d; in the accompanying notes to the Consolidated Financial Statements. For additional information on the Royalty Monetization, see Note 10 &#x201c;Liability Related to Sale of Future Royalties&#x201d; in the accompanying notes to the Consolidated Financial Statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Pre-filled Syringe Product Candidates</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 36pt; margin-right: auto;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Product/Product </b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Candidate</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Description</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Target</b>&#xa0;<b>Use</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Status</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ephedrine</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Ephedrine pre-filled syringe, containing 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinically important hypotension occurring in the setting of anesthesia</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">Product candidate licensed Aguettant; preparing NDA for submission to FDA.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">Approved in the European Union; owned and marketed by Aguettant.</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Phenylephrine</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Phenylephrine pre-filled syringe containing 10 ml of a solution of 50 mcg/ml phenylephrine hydrochloride for injection</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">Product candidate licensed from Aguettant; preparing NDA for submission to FDA.</p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 19pt;">Approved in the European Union; owned and marketed by Aguettant.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Ephedrine and Phenylephrine</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 14, 2021, we entered into a License and Commercialization Agreement, or the PFS Agreement, with Aguettant pursuant to which we obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing 10 ml of a solution of 50 mcg/ml phenylephrine hydrochloride for injection. Aguettant will supply us with the products for use in commercialization, if they are approved in the U.S. Aguettant is entitled to receive up to $24 million in sales-based milestone payments. Refer to Note 5 &#x201c;In-license Agreements&#x201d; and Note 6 &#x201c;Out-license Agreements&#x2014;DZUVEO&#x201d; in the accompanying notes to the Consolidated Financial Statements for additional information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are in dialogue with the FDA and have submitted a Briefing Book to the FDA supporting our proposed regulatory pathway for the ephedrine pre-filled syringe. We expect feedback from the FDA in the first quarter of 2022 that will direct our regulatory pathway for this product candidate, as well as the phenylephrine pre-filled syringe product candidate. We expect we will be able to submit NDA&#x2019;s for both products in 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These products are innovative ready-to-use formulations of active ingredients that are currently approved in the U.S. in concentrated formulations that must be diluted prior to administration to patients, and more recently in ready-to-use vial formulations. Hospitals currently purchase ready-to-use, pre-filled syringe presentations of these active ingredients from compounding facilities that have not obtained FDA approval for the products, or manually dilute the products in-house. Our product candidates have been developed in a ready-to-use strength and pre-filled into syringes that can be immediately administered to patients, eliminating the need for calculations and additional dilution and filling steps. We believe that, if approved, our pre-filled syringe products will offer significant benefits to hospitals and surgery centers over the current compounded products, including longer shelf-life, reduction of compounding errors, greater sterility assurance, and more consistent supply.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i>Nafamostat Product Candidates</i></b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 95%; margin-left: 18pt; margin-right: auto;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
     <td style="vertical-align: bottom; width: 15%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>Product/Product Candidate</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 15%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Description</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 15%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Target</b>&#xa0;<b>Use</b></p> </td>
     <td style="vertical-align: bottom; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 52%; border-bottom: 1px solid rgb(0, 0, 0); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Status</b></p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Niyad</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lyophilized vial for injection</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Regional anticoagulant for injection into the extracorporeal circuit</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">Submitted an investigational device exemption, or IDE, and received Breakthrough Device Designation from the FDA.</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">LTX-608</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lyophilized vial for injection</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IV infusion as an anti-viral treatment for COVID-19</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">IND to be submitted following toxicology evaluation to enable Phase 2 study</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">LTX-608</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lyophilized vial for injection</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IV infusion for disseminated intravascular coagulation, or DIC</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">IND to be submitted following toxicology evaluation to enable Phase 2 study</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">LTX-608</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lyophilized vial for injection</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IV infusion for acute respiratory distress syndrome, or ARDS</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">IND to be submitted following toxicology evaluation to enable Phase 2 study</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">LTX-608</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Lyophilized vial for injection</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 15%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">IV infusion for acute pancreatitis</p> </td>
     <td style="vertical-align: top; width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#xa0;</td>
     <td style="vertical-align: top; width: 52%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 20pt;">IND to be submitted following toxicology evaluation to enable Phase 2 study</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On January 7, 2022, we acquired Lowell Therapeutics, Inc., or Lowell, pursuant to the Agreement and Plan of Merger, dated as of November 14, 2021, or the Merger Agreement, in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments, and which includes up to approximately $26.0 million of contingent consideration payable in cash or stock at AcelRx&#x2019;s option, upon the achievement of regulatory and sales-based milestones, or the Merger Agreement. For additional information regarding the Merger Agreement, see Note 19. &#x201c;Subsequent Events&#x201d; in the accompanying notes to the Consolidated Financial Statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Niyad</span></i><span style="text-decoration: underline; ">&#x2122;</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Niyad is being developed to become the first and only FDA-approved regional anticoagulant for injection into the extracorporeal circuit. Niyad is expected to be used during renal replacement therapy for acute kidney injury patients in the hospital and for end-stage renal disease patients receiving dialysis in outpatient clinics. Niyad is being studied under an investigational device exemption, or IDE, and has received Breakthrough Device Designation from the FDA. While not approved for commercial use in the U.S., the active drug component of Niyad, nafamostat, has been approved in Japan and South Korea as a regional anticoagulant for the extracorporeal circuit, disseminated intravascular coagulation, and acute pancreatitis. Niyad is a lyophilized formulation of nafamostat, a broad-spectrum, synthetic serine protease inhibitor, with anticoagulant, anti-inflammatory, and potential anti-viral activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The current standards of care being used today are heparin and citrate, neither of which are FDA approved for use in these patient procedures. The use of Niyad is expected to result in longer filter lifespan, less blood loss, fewer platelet transfusions, fewer bleeding events and less downtime. Niyad can be used in patients at risk of bleeding, whereas heparin cannot. The product is much easier to administer than citrate, which is not FDA-approved, and can be used in patients with liver failure (43% of the acute kidney injury patients on continuous dialysis), whereas citrate cannot. Amongst other potential indications, Niyad is expected to be used as an anticoagulant in continuous renal replacement therapy, or CRRT, for patients with acute kidney injury, or AKI, in the hospital, and for intermittent hemodialysis, or IHD, for patients with end-stage renal disease, or ESRD, undergoing treatment in outpatient dialysis clinics. The prevalence of patients with AKI and ESRD has been increasing every year since 2000.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">LTX-608</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LTX-608 is our proprietary nafamostat formulation for direct IV infusion being explored as an investigational product for: (a) antiviral treatment of COVID, (b) acute respiratory distress syndrome, or ARDS, (c) disseminated intravascular coagulation, or DIC, and (d) acute pancreatitis. Our initial focus for LTX-608 will be on its development as an antiviral treatment for COVID in combination with standard-of-care, or SOC. Studies are actively being conducted outside the U.S. where initial results demonstrate nafamostat&#x2019;s effectiveness in shortening time to clinical improvement, increasing the recovery rate and lowering the mortality rate when combined with SOC compared to SOC alone in the category of the sickest COVID patients. We have pending patent applications directed to the use of nafamostat as an antiviral agent, including use as a COVID treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Clinical Trials </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Zalviso</span></i><span style="text-decoration: underline; ">&#xae;</span><i></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have completed three Phase 3 clinical trials for Zalviso: two placebo-controlled efficacy and safety trials and one open-label active comparator trial, in which Zalviso was compared to IV PCA morphine. Each of the three Phase 3 trials successfully achieved its primary endpoint. Based on FDA feedback, we completed a fourth study, IAP312, in a diverse post-surgical population to further evaluate the overall performance of the Zalviso System.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Active comparator trial (IAP309) </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In November 2012, we reported top-line data showing that Zalviso had met its primary endpoint of non-inferiority in the Phase 3 open-label active comparator trial designed to compare the efficacy and safety of Zalviso (15 mcg/dose) to IV PCA with morphine (1mg/dose)&#xa0;for the treatment of moderate-to-severe acute post-operative pain. Utilizing a randomized, open-label, parallel group design, this trial enrolled 359 adult patients at 26 U.S. sites for the treatment of pain immediately following open-abdominal or major orthopedic surgery (hip and knee replacement). Patients were randomized 1:1 to treatment with Zalviso or IV PCA morphine and were treated for a minimum of 48 hours and up to 72 hours.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Double-blind, placebo-controlled, abdominal surgery trial (IAP310) </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In March 2013, we reported top-line data results demonstrating that Zalviso met its primary endpoint in a pivotal Phase 3 trial designed to compare the efficacy and safety of Zalviso to placebo in the management of acute post-operative pain after major open abdominal surgery. Adverse events reported in the trial were generally mild or moderate in nature and similar in both placebo and treatment groups. Utilizing a randomized, double-blind, placebo-controlled design, this Phase 3 trial enrolled 178 adult patients at 13 U.S. sites. Patients were treated for post-operative pain for a minimum of 48 hours, and up to 72 hours. Patients were randomized 2:1, with 119 patients randomized to sufentanil sublingual tablet treatment and 59 to placebo treatment. Both treatments were delivered by the patient, as needed, using Zalviso with a 20-minute lock-out period. Patients in both groups could receive up to 2 mg morphine intravenously per hour as a rescue medication, the primary purpose of this rescue medication being to provide placebo-treated patients access to pain medication to enable them to stay in the trial as long as possible. Pre-rescue pain scores were imputed to minimize the impact of this rescue opioid on efficacy evaluations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The primary endpoint evaluated pain intensity over the 48-hour study period compared to baseline, or Summed Pain Intensity Difference, or SPID-48, in patients following major open abdominal surgery. Patients receiving sufentanil sublingual tablets demonstrated a significantly greater SPID-48 compared to placebo-treated patients during the study period (105.6 and 55.6, respectively; p=0.001).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Double-blind, placebo-controlled, orthopedic surgery trial (IAP311) </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In May 2013, we reported top-line data results demonstrating that Zalviso met its primary endpoint in a pivotal Phase 3 trial designed to compare the efficacy and safety of Zalviso to placebo in the management of acute post-operative pain after major orthopedic surgery. Adverse events reported in the study were generally mild or moderate in nature and were similar in both placebo and treatment groups for the majority of adverse events. Utilizing a randomized, double-blind, placebo-controlled design, this pivotal Phase 3 study enrolled 426 adult patients at 34 U.S. sites for treatment of moderate-to-severe acute pain immediately following major orthopedic surgery.&#xa0;Seven patients did not receive study drug, resulting in 419 patients being included in the ITT population.&#xa0;Patients were treated for a minimum of 48 hours, and up to 72 hours.&#xa0;Patients were randomized 3:1, with 321 patients randomized to sufentanil sublingual tablet treatment and 105 to placebo treatment.&#xa0;Both treatments were delivered by the patient, as needed, using the Zalviso System with a 20-minute lock-out period.&#xa0;Patients in both groups could receive up to 2 mg morphine intravenously per hour as a rescue medication, the primary purpose of this rescue medication being to enable placebo-treated patients to stay in the study.&#xa0;Pain scores recorded just prior to the delivery of rescue medication were gathered and imputed forward to minimize the impact of this rescue opioid on efficacy evaluations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The primary endpoint evaluated SPID-48 in patients following major orthopedic surgery. Patients receiving Zalviso demonstrated a significantly greater SPID-48 compared to placebo-treated patients during the study period (+76.2 and -11.4, respectively; p &lt; 0.001). Two hundred fifteen (68.3%)&#xa0;sufentanil sublingual tablet-treated patients completed the 48-hour study period, compared to 43 (41.3%)&#xa0;placebo-treated patients.&#xa0;Primary reasons for drop-out in the sufentanil sublingual tablet- and placebo-treated groups were adverse events (7.0% and 6.7%, respectively) and lack of efficacy (14.3% and 48.1%, respectively).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Four patients (three in the sufentanil sublingual tablet group and one in the placebo group) experienced a serious adverse event, or SAE, considered possibly or probably related to the study drug by the investigator. The SAEs observed in the patients in the sufentanil sublingual tablet group included severe oxygen saturation decrease, sinus tachycardia, and confusional state.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Combined related adverse events for the two placebo-controlled pivotal studies (IAP310 and IAP311) compared to placebo are shown below. Only pruritus (itching) was statistically different for Zalviso compared to placebo (p&#xa0;= 0.002).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Adverse Events Occurring in <span style="text-decoration: underline; ">&gt;</span> 2% in Either Group</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; ">Possibly or Probably Related Adverse Events</span></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Zalviso<br /> n=429</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Placebo<br /> n=162</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">At least 2% in either group</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 29pt;">Two Placebo-<br /> Controlled<br /> Phase 3 Studies</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nausea</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">29.4</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">22.2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vomiting</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">8.9</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">4.9</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Oxygen Saturation Decreased</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">6.1</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">2.5</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Pruritus</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">4.7</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">0</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dizziness</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">4.4</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">1.2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Constipation</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">3.7</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">0.6</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Headache</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">3.3</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">3.7</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Insomnia</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">3.3</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">1.9</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Hypotension</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">3.0</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">1.2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Confusional state</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">2.1</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: Times New Roman; font-size: 10pt; margin-left: 29pt; text-align: right;">0.6</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

   </tbody>
  </table>
  <hr class="hr-custom" style="text-align: left;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 6pt auto 6pt 0pt;" />
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;text-indent:-25pt;">3 patients (0.7%) in the Zalviso group had treatment-emergent respiratory events that required naloxone reversal.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Multi-center, single-arm, open-label study (IAP312)</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IAP312 was a Phase 3 study designed to evaluate the overall performance of the Zalviso System, in response to the CRL received from the FDA for Zalviso. Throughout the study in 320 enrolled patients, 2.2% of patients experienced a Zalviso device error, which was statistically less than the 5% limit specified in the study objectives. Importantly, none of these device errors resulted in an over-dosing event. This 2.2% rate was lower (p &lt; 0.001) than the 7.9% rate of device errors during patient use previously reported for the earlier version of the Zalviso device in the Phase 3 IAP311 study.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, as requested by FDA, the IAP312 study prospectively evaluated the number of inadvertently misplaced tablets which occurred during patient dosing. A small number of inadvertently misplaced tablets (less than 0.1% of total dispensed tablets) was observed in the original Phase 3 studies. However, the presence of inadvertently misplaced tablets had not been routinely assessed as part of the previous protocols. Throughout the IAP312 study, patients self-administered a total of 7,293 sufentanil tablets. Per the updated Zalviso training instructions electronically displayed on the hand-held device, 6 patients called the nurse when they failed to properly self-administer a single tablet to allow for proper retrieval and disposal of the tablet. Also, during inspection by the nurse, which occurred every two hours per protocol, a total of 7 misplaced tablets (&lt;0.1% of total dispensed tablets) were discovered with 6 additional patients. No patient had a repeat incidence of an inadvertently misplaced tablet following re-training on the device. This combination of patient training and nurse inspection, along with the tracking features of the Zalviso device, could potentially address the FDA's concerns regarding drug accountability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Finally, in this study, 86%, 89% and 100% of patients at the 24, 48 and 72-hour time points, respectively, recorded "good" or "excellent" ratings on the patient global assessment, or PGA, of the method of pain control, which measures a patient's satisfaction with their quality of analgesia. Healthcare professional global assessment, or HPGA, of the method of pain control was similarly strong, with 91%, 95% and 100% of nurses rating Zalviso as "good" or "excellent" over each respective 24-hour period. Zalviso was shown to be well tolerated by study participants, with nausea, hypotension and vomiting representing the most commonly reported adverse events. A total of 5 patients experienced serious adverse events, but all were considered unrelated to study drug by investigators.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">ARX-02</span></i><b><i></i></b><i><span style="text-decoration: underline; ">(higher strength sufentanil sublingual tablet)</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A Phase 2 trial evaluating the efficacy and safety of ARX-02 for the treatment of cancer breakthrough pain in opioid-tolerant patients has been completed. The IND application for ARX-02&#xa0;was inactivated as there is no ongoing clinical development.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">ARX-03</span></i><b><i></i></b><i><span style="text-decoration: underline; ">(combination sufentanil/triazolam sublingual tablet)</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A Phase 2 trial which evaluated the efficacy and safety of this product for procedural anxiety and acute pain has been completed. The IND application for ARX-03&#xa0;was inactivated as there is no ongoing clinical development.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ARX-02 and ARX-03 are investigational product candidates and are not approved by the FDA or any other regulatory agency. We do not intend to invest resources in these development stage product candidates; accordingly, any future development of these development stage product candidates is contingent on funding from a corporate partnership or other external funding source.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>The Market Opportunity for Sufentanil Sublingual Products</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Examples of potential patient populations and settings in which patients might require the short-term management of moderate-to-severe acute pain include emergency room patients; perioperative use for patients who are undergoing inpatient, short-stay or ambulatory surgery; inpatient use for up to 72 hours in patients with moderate-to-severe acute pain; procedural suite use for painful procedures such as oral surgery or cosmetic procedures; patients being treated and transported by paramedics; and for battlefield casualties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">While IV opioids are currently employed to control moderate-to-severe acute pain in many of these settings, the use of IV opioids suffers from the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">potential high peaks and troughs of plasma concentrations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">infection risk associated with the invasive nature of IV delivery;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">consumption of hospital resources including an IV pump, a bed where the patient can be monitored, and nurse time; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">possible impairment of a patient&#x2019;s cognitive abilities, which can make it difficult to provide accurate medical history to physicians during evaluation.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe healthcare providers and hospital administrators caring for patients in moderate-to-severe acute pain in the aforementioned medically supervised settings could significantly benefit from the following items:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a pharmacokinetic profile that avoids the high peak plasma levels and short duration of action observed with IV administration;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">non-invasively delivered analgesic that utilizes fewer hospital resources, thereby incurring less cost;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">effective and rapid-acting pain relief with sufficient duration of effect allowing efficient treatment while assuring patient satisfaction;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">pain relief that does not sacrifice cognitive function; and/or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">avoiding infection risks due to invasive routes of delivery, such as IV.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In our Phase 1 through Phase 3 clinical studies, sublingual sufentanil has demonstrated the following attributes:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">a pharmacokinetic profile that blunts peak plasma levels compared to IV administration;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">ease of administration;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">pain reduction (as much as 3-points on a validated 10-point scale) beginning as early as 15-to-30 minutes after administration;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">maintenance of cognitive function;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">adverse event types similar to IV opioids, such as nausea, headache, vomiting and dizziness; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">lower percentage of patients with decreased oxygen saturation events compared to IV-PCA morphine.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe that sublingual sufentanil provides a safety, efficacy and tolerability profile enabling our products to potentially replace IV opioid use in patients with moderate-to-severe acute pain in the proposed medically supervised settings. This may be especially true for DSUVIA in the post-operative settings where, because of the unique pharmacokinetic profile, the healthcare practitioner may be able to manage patient-flow more efficiently in the recovery room after surgery, and in emergency medical settings. The number of emergency departments is decreasing in the United States, resulting in an increased focus on resource management to treat a growing number of patients in an efficient manner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">United States Market</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on commissioned research conducted in 2016, we estimate that there are over 90 million patients who are treated in various medically supervised settings for their moderate-to-severe acute pain which is significant enough to warrant the use of an opioid. We believe these patients may be eligible for treatment with DSUVIA, and in some cases Zalviso, if approved in the United States. The target patient population for DSUVIA are those patients in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for less than 24 hours. The target patient population for Zalviso are patients in a hospital setting for greater than 24 hours. Our current estimate of patients in moderate-to-severe acute pain in medically supervised settings, by setting, is as follows:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 85%; margin-left: 0pt; margin-right: auto;">
   <tbody>
    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 56.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Emergency services (includes pre-hospital and Emergency Department treatment)</p> </td>
     <td style="vertical-align: top; width: 56.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">52 million</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 56.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Outpatient surgery</p> </td>
     <td style="vertical-align: top; width: 56.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">11 million</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 56.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Hospital/surgery center/office-based procedures</p> </td>
     <td style="vertical-align: top; width: 56.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">20 million</p> </td>
    </tr>

    <tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 56.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Inpatient surgery/inpatient conditions</p> </td>
     <td style="vertical-align: top; width: 56.9%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">10 million</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The market for Zalviso, given the target patients in a hospital setting for greater than 24 hours, is the approximately 10 million inpatient surgeries and inpatient conditions above. There can be no assurance that our estimates regarding the number of patients treated in the various settings will be accurate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">European Market</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Based on commissioned research conducted in 2016, there are an estimated 142 million patients in the EU5 (France, Germany, Italy, Spain, and the United Kingdom) represented across DZUVEO target care settings annually. Each year, there are an estimated 110 million emergency attendances and 32 million surgical procedures performed each year. It is anticipated that there are 51 million patients in emergency medicine with moderate-to-severe acute pain and 16 million with moderate-to- severe acute pain following surgery each year.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>The Market Opportunity for Pre-Filled Syringe Products </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">These products are innovative ready-to-use formulations of molecules that are currently approved in a concentrated formulation that must be diluted prior to administration to patients, and more recently in ready-to-use vial formulations. Hospitals currently purchase non-FDA approved ready-to-use, pre-filled syringe products from compounding facilities, or manually dilute the products in-house. Our product candidates have been developed in a ready-to-use strength and pre-filled into syringes that can be immediately administered to patients, eliminating the need for calculations and additional dilution and filling steps. We believe that, if approved, our products will offer significant benefits to hospitals and surgery centers over the current compounded products, including longer shelf-life, reduction of compounding errors, greater sterility assurance, and more consistent supply.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b>The Market Opportunity for Nafamostat Products</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Niyad is being developed to become the first and only FDA-approved regional anticoagulant for the extracorporeal circuit. The current standards of care being used today are heparin and citrate, neither of which are FDA approved for use in these patient procedures. The use of Niyad is expected to result in longer filter lifespan, less blood loss, fewer platelet transfusions, fewer bleeding events and less downtime. Niyad can be used in patients at risk of bleeding, whereas heparin cannot. The product is much easier to administer than citrate, which is not FDA-approved, and can be used in patients with liver failure (43% of the acute kidney injury patients on continuous dialysis), whereas citrate cannot. Amongst other potential indications, Niyad is expected to be used as an anticoagulant in continuous renal replacement therapy, or CRRT, for patients with acute kidney injury, or AKI, in the hospital, and for intermittent hemodialysis, or IHD, for patients with end-stage renal disease, or ESRD, undergoing treatment in outpatient dialysis clinics. The prevalence of patients with AKI and ESRD has been increasing every year since 2000.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The second indication for our nafamostat product development candidate, LTX-608, on which we are focused is as an IV infusion for the treatment of COVID. Studies are actively being conducted outside the U.S. where initial results demonstrate nafamostat&#x2019;s effectiveness in shortening time to clinical improvement, increasing the recovery rate and lowering the mortality rate when combined with SOC compared to SOC alone in the category of the sickest COVID patients. We have pending patent applications directed to the use of nafamostat as an antiviral agent, including use as a COVID treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Strategy</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our strategy is focused on the marketing of DSUVIA as well as the development, for approval by the FDA, of the recently acquired investigational products. Our commercial focus remains on sales of DSUVIA into the medically supervised healthcare settings market, such as hospitals, surgical centers, emergency departments and most recently, office-based procedural suites. The process of selling into hospital settings and obtaining approval for a product to be used within these types of institutions is complex and takes time, and particularly so since the COVID pandemic. Accordingly, our commercial focus on office-based procedural suites has increased, as they have been less impacted by the COVID pandemic, and obtaining approvals in these settings is often less complex.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our four-pillar strategy for DSUVIA revenue growth is focused on delivering the most effective and efficient commercialization of DSUVIA through different channels, plus business development to expand the number of products in our portfolio.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The first pillar is concentrated on supporting broader use within the DoD after DSUVIA achieved U.S. Army Milestone C approval and was added to the Joint Deployment Formulary in 2020. We believe the opportunity for DSUVIA revenue growth includes deployed or deploying military troops, domestic-based military, military treatment facilities and Veterans Administration facilities. We are using a small internal commercial team focused on achieving our objectives within this first pillar.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The second pillar is centered around the launch of DSUVIA in the United States, focused on medically supervised settings, which includes promotion to hospitals, emergency departments, surgery centers, and more recently office-based procedural suites, with our internal commercial team.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The third pillar is focused on what we call specialty markets, which are typically large market opportunities, but more geographically dispersed with a lower concentration of patient visits than a hospital or surgery center. Examples of these specialty markets include oral/dental surgery, emergency medical services and plastic surgery. We intend to leverage the use of commercial partnerships with more established companies already serving customers in these specific markets. An example of an initiative in this pillar is our partnership with Zimmer Biomet Dental in oral/dental surgery, which was amended in February 2022 to become non-exclusive. Our objective is to focus on finding additional partners for these other specialties that align with our values and goals.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The fourth pillar involves identifying and licensing, or acquiring, complementary products to DSUVIA. We believe having a single product to market and sell into this setting is inherently inefficient and building a portfolio of products is important to mitigate such inefficiency. An example of actions performed in this pillar are the in-licensing of two pre-filled syringe products for the U.S. market, as well as our acquisition of Lowell. We continue to pursue ways to leverage our commercial and development infrastructure by identifying, evaluating and executing transactions to bring in additional products for healthcare institutions and will continue to be opportunistic on business development activities to increase the number of products in our portfolio.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Supporting the DSUVIA commercial strategy is the production strategy, focused on the completion of our transition to automated packaging equipment with our contract manufacturing organization in order to leverage improved technology to lower production cost.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our strategy with respect to Zalviso is to (a) continue to use commercially reasonable efforts to negotiate a New Arrangement as required under the Royalty Monetization; and (b) upon the FDA providing further guidance about new opioid approval guidelines, evaluate resubmission of the Zalviso NDA to seek regulatory approval in the United States and, if successful, promote Zalviso as a follow-on product to DSUVIA, or potentially seek a commercial partner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Sales and Marketing </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our four-pillar commercial strategy is focused on leveraging our internal commercial organization, plus collaboration partners, to commercialize DSUVIA. We have established and will continue developing our distribution capability and commercial organization in the United States to market and sell DSUVIA in the United States. In geographies where we decide not to commercialize ourselves, we will seek to out-license commercialization rights. In specialty areas that are not core to the hospital, ambulatory surgery centers, or ASCs, or emergency room settings, (e.g., plastic surgeries), we will seek commercialization partners that will support accessing these markets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are building commercial capability in the United States progressively to support the launch of DSUVIA in the United States market. We foresee two stages of commercial execution to support successful introduction of DSUVIA in the United States:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To date, we have:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">created and deployed a focused scientific support team to gather a detailed understanding of individual institutional and healthcare professional needs in order to present DSUVIA effectively;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">increased awareness of the clinical profile of sublingual administration of sufentanil through publication of our clinical data;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">engaged appropriate Advisory Boards that include representative physicians, including anesthesiologists and surgeons, nurses, pharmacy and therapeutics, or P&amp;T, committee members and other related experts to provide us with input on appropriate commercial positioning for DSUVIA for each of these key audiences;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">built a sales and marketing organization that can define appropriate segmentation and positioning strategies and tactics for DSUVIA;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">established DSUVIA on hospital and ambulatory surgery center formularies as well as obtained approvals from individual physicians and practices of physicians performing office-based procedures, through deployment of an experienced team to explain the clinical and health economic attributes of DSUVIA; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">gathered relevant clinical and health economic data identifying the limitations of IV opioids and other relevant treatments for moderate-to-severe acute pain in use today.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Next steps in our commercialization plan include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">as needed, continuing to build and progressively deploy a high-quality, customer-focused and experienced sales organization in the United States dedicated to bringing innovative, highly valued healthcare solutions to patients, payers and healthcare providers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">potentially expanding the label to include pediatric populations by conducting post-approval clinical trials for DSUVIA; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">continuing to establish DSUVIA as a suitable choice for moderate-to-severe acute pain in certified medically supervised settings.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unable to establish successful sales and marketing capabilities or enter into agreements with third parties to market and sell our products, we may be unable to generate any product revenue. For a more comprehensive discussion of the risks related to our commercialization, please see &#x201c;Risk Factors&#x2014; Risks Related to Commercialization of DSUVIA and Zalviso&#x201d; appearing elsewhere in this Form&#xa0;10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Distribution Agreement</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On July 17, 2020, we entered into a distribution agreement, or the Distribution Agreement, with Zimmer Biomet Dental, or ZB Dental, pursuant to which ZB Dental obtained the exclusive right to promote, market, sell, and arrange to distribute DSUVIA in the United States to clinicians, dentists, surgeons and other licensed health care practitioners that perform dental (including specialty dental), oral-maxillofacial, cranio-maxillofacial or oral surgery procedures, or Professionals, and their respective institutions and facilities that are permitted to use DSUVIA. ZB Dental&#x2019;s distribution rights do not extend to ambulatory care centers outside the class of trade or into hospitals. On February 15, 2022, we amended the agreement with ZB Dental to remove the exclusivity provided to ZB Dental, now allowing us the right to promote, market, sell and distribute DSUVIA in the specified markets. The dental and oral-maxillofacial surgery markets have similar characteristics to the other office-based procedures on which we are currently focusing the majority of our commercial efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Intellectual Property </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We seek patent protection in the United States and internationally for our commercial products DSUVIA, DZUVEO and Zalviso. We also seek patent protection in the United States and internationally for our product candidates Niyad and LTX-608. Our policy is to pursue, maintain and defend patent rights developed internally or acquired externally and to protect the technology, inventions and improvements that are commercially important to the development of our business. We cannot be sure that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology. We also rely on trade secrets to protect our commercial products and product candidates. Our commercial success also depends in part on our non-infringement of the patents or proprietary rights of third parties. For a more comprehensive discussion of the risks related to our intellectual property, please see &#x201c;Risk Factors&#x2014;Risks Related to Our Intellectual Property&#x201d; appearing elsewhere in this Form&#xa0;10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our success will depend significantly on our ability to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">obtain and maintain patent and other proprietary protection for our commercial products DSUVIA, DZUVEO and Zalviso, as well as for our product candidates ephedrine, phenylephrine, Niyad and LTX-608;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">defend our patents;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">preserve the confidentiality of our trade secrets; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">operate our business without infringing or misappropriating patents and other third-party proprietary rights.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have established and continue to build proprietary positions for our commercial products DSUVIA, DZUVEO and Zalviso and related technology, as well as for our product candidates ephedrine, phenylephrine, Niyad and LTX-608 in the United States and abroad.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December&#xa0;31, 2021, we are the owner of record of 28 issued U.S. patents, which together provide coverage for sufentanil sublingual tablets, and the device components of Zalviso and DSUVIA. We have listed 18 of these U.S. patents in the Orange Book for DSUVIA. These patents have expiry dates extending to at least 2027. We also hold ten issued European patents, each validated and maintained in at least eight countries in Europe, seven patents in Japan, eight in China and seven in Korea, and a number of other international patents have expiry dates extending to at least 2027 excluding any potential patent term adjustments or extensions in those countries. We are also pursuing a number of U.S. and foreign patent applications. The patent applications that we have filed and have not yet been granted may fail to result in issued patents in the United States or in foreign countries. Even if the patents do successfully issue, third parties may challenge the patents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We continue to seek and expand our patent protection for both compositions of matter and delivery devices, as well as methods of treatment related to our DSUVIA, DZUVEO and Zalviso commercial products. In particular, we are pursuing additional patent protection for our DSUVIA, DZUVEO and Zalviso formulations, our Zalviso device, and our Zalviso device, our DSUVIA and DZUVEO SDA, as well as to methods of treatment using such drug and device compositions. We will also seek to expand and develop new patent protection for our product candidates Niyad and LTX-608.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have filed for additional patent coverage in the United States, Europe as well as many other foreign jurisdictions including, Japan, China, India, Canada and Korea. If issued, and if the appropriate maintenance, renewal, annuity or other governmental fees are paid, we expect that these patents will expire between 2027 and 2036, excluding any additional term for patent term adjustments or patent term extensions in the United States. We note that the patent laws of foreign countries differ from those in United States, and the degree of protection afforded by foreign patents may be different from the protection offered by U.S. patents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, we seek trademark protection in the United States and internationally where available and when appropriate. We have registered our ACELRX, DSUVIA and Zalviso marks in Class 5, &#x201c;Pharmaceutical preparations for treating pain; pharmaceutical preparations for treating anxiety,&#x201d; and Class 10, &#x201c;Drug delivery systems; medical device, namely, a mechanical and electronic device used to administer medications, perform timed medication delivery, and to provide secure access to and delivery of medications,&#x201d; in the United&#xa0;States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our ACELRX, DSUVIA and Zalviso marks are also registered in the European Union, as well as other countries. Our DZUVEO mark is also registered in the European Union.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Competition </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Sufentanil Sublingual Products</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our industry is highly competitive and subject to rapid and significant technological change. Our potential competitors include large pharmaceutical and biotechnology companies, specialty pharmaceutical and generic drug companies, and medical technology companies. We believe the key competitive factors that will affect the development and commercial success of our products are the safety, efficacy and tolerability profile, the patient and healthcare professional satisfaction with using our products in relation to available alternatives and the reliability, convenience of dosing, price and reimbursement of our products. Over the past year, we have monitored changes in the pharmaceutical industry in response to opioid use in the United States. Pharmaceutical companies engaged in the distribution and sale of opioids, in particular for the treatment of chronic pain, are refocusing their efforts in order to support responsible opioid use. While our products are designed for the treatment of moderate-to-severe acute pain for use in medically supervised settings, rather than for the treatment of chronic pain or for outpatient use, these industry changes could impact the commercial success of DSUVIA, or Zalviso, if approved, in the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">DSUVIA competes, and Zalviso, if approved in the U.S., will compete, with a number of existing and future pharmaceuticals and drug delivery devices developed, manufactured and marketed by others. In particular, DSUVIA may compete with a wide variety of products and product candidates including (i) injectable opioid products, such as morphine, fentanyl, hydromorphone and meperidine; (ii) oral opioids such as oxycodone and hydrocodone; (iii) generic injectable local anesthetics, such as bupivacaine or branded formulations thereof; (iv) non-steroidal anti-inflammatory drugs, or NSAIDS, including ketorolac in intranasal or generic IV form, and IV meloxicam; and (v) transmucosal fentanyl products. Zalviso, if approved in the U.S., may compete with a number of opioid-based treatment options, including IV PCA pumps, oral PCA devices, and transdermal opioid PCAs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Pre-filled Syringe Products</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Hospitals currently purchase non-FDA approved ready-to-use, pre-filled syringe products from compounding facilities, or manually dilute the products in-house. Our product candidates have been developed in a ready-to-use strength and pre-filled into syringes that can be immediately administered to patients, eliminating the need for calculations and additional dilution and filling steps. We believe that, if approved, our products will offer significant benefits to hospitals and surgery centers over the current compounded products, including longer shelf-life, reduction of compounding errors, greater sterility assurance, and more consistent supply. In addition, our pre-filled syringe product candidates will also compete with existing generic versions of concentrated vial forms of product, ready-to-use diluted vial forms of product candidates will also compete with existing generic versions of concentrated vial forms of product, ready-to-use diluted vial forms of product, and for the ephedrine product, a recently FDA-approved pre-filled syringe with a different formulation and concentration than our product candidate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i><span style="text-decoration: underline; ">Nafamostat Products</span></i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Niyad is the first nafamostat product candidate we are developing to be used as a regional anticoagulant for injection into the extracorporeal circuit. There are currently no products approved by the FDA for use as an anticoagulant in the extracorporeal circuit. Niyad would be the first and only product approved for this indication, if approved. The current standards of care being used today are heparin and citrate. Heparin is a systemic anticoagulant and cannot be used in patients at risk of bleeding. Citrate is complex to administer and requires significant human resource time and attention given the nature of the product, and cannot be used in patients with liver failure, which is approximately 43% of acute kidney injury patients.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The second nafamostat product development candidate on which we are focused is an IV infusion for the treatment of COVID. Studies are actively being conducted outside the U.S. where initial results demonstrate nafamostat&#x2019;s effectiveness in shortening time to clinical improvement, increasing the recovery rate and lowering the mortality rate when combined with SOC compared to SOC alone in the category of the sickest COVID patients. We have pending patent applications directed to the use of nafamostat as an antiviral agent, including use as a COVID treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Pharmaceutical Manufacturing and Supply </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We currently rely on contract manufacturers to produce sufentanil sublingual tablets for commercial production of DSUVIA under current Good Manufacturing Practices, or cGMP, with oversight by our internal managers. Equipment specific to the pharmaceutical manufacturing process was purchased and customized for us and is currently owned by us. We plan to continue to rely on contract manufacturers and, potentially, collaboration partners to manufacture commercial quantities of our products, if and when approved for marketing by the FDA. We currently rely on a single manufacturer for the commercial supplies of the active pharmaceutical ingredient, or API, for DSUVIA and Zalviso, and intend to qualify a second source. For DSUVIA, we currently package the finished goods under a manual process and would package DZUVEO in the same manner. We have purchased and installed an automated filling and packaging line to support increased capacity packaging for DSUVIA and DZUVEO; however, there can be no assurance that we will be able to successfully complete the qualification and validation of this line and obtain the necessary regulatory approvals to manufacture product on this line. We have identified other manufacturers that could satisfy our commercial supply and packaging requirements and we continue to evaluate those manufacturers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Device Manufacturing and Supply </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All contract manufacturers and component suppliers have been selected for their specific competencies in the manufacturing processes and materials that make up DSUVIA and Zalviso. We currently rely on single manufacturers for the commercial supplies of our drug components and packaging for DSUVIA and Zalviso, and do not currently have agreements in place for redundant supply or a second source for either DSUVIA or Zalviso. DSUVIA utilizes an SDA in the delivery of the tablets. FDA regulations require that materials be produced under cGMPs or Quality System Regulation, or QSR, as required for the respective unit operation within the manufacturing process. We outsource injection molding of all the plastic parts for the SDA, and product sub-assemblies; and filling, packaging and labeling of SDAs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The device components of Zalviso are manufactured by contract manufacturers, component fabricators and secondary service providers. We outsource injection molding of all the plastic parts for the cartridge and device and product sub-assemblies; tablet cartridge filling and packaging; and assembly, packaging and labeling of the dispenser and controller.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Government Regulation </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Government authorities in the United States at the federal, state and local level, and in other countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, marketing, export and import of pharmaceutical and medical device products, which must be approved by the FDA before they may legally be marketed in the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act, or FDCA, and its implementing regulations. The process of obtaining regulatory approvals and complying with applicable laws and regulations requires the expenditure of substantial time and financial resources. Failure to comply at any time during the product development and approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include the FDA&#x2019;s refusal to approve pending applications, withdrawal of an approval, a clinical hold, Warning Letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The process required by the FDA before a drug product may be marketed in the United States generally involves the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">completion of non-clinical laboratory tests, animal trials and formulation studies according to Good Laboratory and Manufacturing Practices regulations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">submission to the FDA of an investigational new drug, or IND, application which must become effective before human clinical trials may begin;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">performance of adequate and well-controlled human clinical trials according to Good Clinical Practices, or GCP, to establish the clinical safety and efficacy of the proposed drug product for its intended use;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">submission to the FDA of an NDA for a new drug product;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the drug product and the drug substance(s) are produced to assess compliance with cGMP;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">payment of application, annual program fees; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">FDA review and approval of the NDA.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The testing and approval process requires substantial time, effort and financial resources and we cannot be certain that approval for our product candidates will be granted on a timely basis, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><i>&#x2022; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><i>Phase 1.</i> The product is initially introduced into healthy human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution and excretion. In the case of some products for severe or life-threatening diseases, especially when the product may be too inherently toxic to ethically administer to healthy volunteers, the initial human testing is often conducted in patients.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><i>&#x2022; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><i>Phase 2.</i> Involves trials in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted conditions and to determine dosage tolerance and optimal dosage and schedule.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><i>&#x2022; </i></p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;"><i>Phase 3.</i> Clinical trials are undertaken to further evaluate dosage, clinical safety and efficacy in an expanded patient population at geographically dispersed clinical trial sites. These trials are intended to establish the overall risk/benefit ratio of the product and provide an adequate basis for product labeling.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and safety reports must be submitted to the FDA and the investigators for serious and unexpected adverse events. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an Institutional Review Board, or IRB, can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the drug or biological product has been associated with unexpected serious harm to patients.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Concurrent with clinical trials, companies usually complete additional animal trials and must also develop additional information about the chemistry and physical characteristics of the product and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP and QSR for medical device requirements. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the product candidate does not undergo unacceptable deterioration over its shelf life.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The results of product development, preclinical trials and clinical trials, along with descriptions of the manufacturing process, analytical tests conducted on our drug products, proposed labeling and other relevant information, will be submitted to the FDA as part of an NDA for a new drug product, requesting approval to market the product in the United States. The submission of an NDA is subject to the payment of a substantial user fee; a waiver of such fee may be obtained under certain limited circumstances. During its review of an NDA, the FDA may inspect our manufacturers for GMP and QSR compliance, and our pivotal clinical trial sites for GCP compliance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, under the Pediatric Research Equity Act, an NDA or supplement to an NDA must contain data to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The approval process is lengthy and difficult, and the FDA may refuse to approve an NDA if the applicable regulatory criteria are not satisfied or may require additional clinical data or other data and information. Even if such data and information is submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. The FDA issues a Complete Response Letter at the conclusion of its review if the NDA is not yet deemed ready for approval. A Complete Response Letter generally outlines the deficiencies in the submission and may require substantial additional testing or information for the FDA to reconsider the application. If, or when, those deficiencies have been addressed to the FDA&#x2019;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. The FDA has committed to reviewing such resubmissions in two or six months depending on the type of information included. &#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If a product candidate does receive regulatory approval, the approval may be limited to specific conditions and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. A REMS, which can include a medication guide, patient package insert, a communication plan, elements to assure safe use and implementation system, must include a timetable for assessment of the REMS. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling and may require testing and surveillance programs to monitor the safety of approved products that have been commercialized. In addition, the FDA may require post-approval testing which involves clinical trials designed to further assess a drug product&#x2019;s safety and effectiveness after the NDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Post-Approval Requirements </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any drug products for which we receive FDA approval are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated clinical safety and efficacy information, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. Phase 4 clinical trials are conducted after approval to gain additional experience from the treatment of patients in the intended therapeutic indication or when otherwise requested by the FDA in the form of post marketing requirements or commitments. Failure to promptly conduct any required Phase 4 clinical trials could result in withdrawal of NDA approval. The FDA strictly regulates labeling, advertising, promotion and other types of information on products that are placed on the market. Drug products may be promoted only for the approved indications and in accordance with the provisions of the approved label. Further, manufacturers of drug products must continue to comply with cGMP requirements, which are extensive and require considerable time, resources and ongoing investment to ensure compliance. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Drug product manufacturers and other entities involved in the manufacturing and distribution of approved drug products are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. The cGMP requirements apply to all stages of the manufacturing process, including the production, processing, packaging, labeling, storage and shipment of the drug product. Manufacturers must establish validated systems to ensure that products meet specifications and regulatory standards, and test each product batch or lot prior to its release.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our products. Future FDA and state inspections may identify compliance issues at the facilities of our contract manufacturers that may disrupt production or distribution or may require substantial resources to correct.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The FDA may withdraw a product approval if compliance with regulatory standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product may result in restrictions on the product or even complete withdrawal of the product from the market. Further, the failure to maintain compliance with regulatory requirements may result in administrative or judicial actions, such as fines, Warning Letters, holds on clinical trials, product recalls or seizures, product detention or refusal to permit the import or export of products, refusal to approve pending applications or supplements, restrictions on marketing or manufacturing, injunctions or civil or criminal penalties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Medical Devices</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States, absent certain limited exceptions, human clinical trials intended to support medical device clearance or approval require an investigational device exemption, or IDE, application. If the device presents a &#x201c;significant risk&#x201d; to human health, as defined by the FDA, the sponsor must submit an IDE application to the FDA and obtain IDE approval prior to commencing the human clinical trials. The IDE application must be supported by appropriate data, such as animal and laboratory testing results, showing that it is safe to test the device in humans and that the testing protocol is scientifically sound. Generally, clinical trials for a significant risk device may begin once the IDE application is approved by the FDA and the study protocol and informed consent are approved by appropriate IRBs at the clinical trial sites. Submission of an IDE will not necessarily result in the ability to commence clinical trials, and although the FDA&#x2019;s approval of an IDE allows clinical testing to go forward for a specified number of subjects, it does not bind the FDA to accept the results of the trial as sufficient to prove the product&#x2019;s safety and efficacy, even if the trial meets its intended success criteria.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Clinical trials must further comply with good clinical practice regulations for IRB approval and for informed consent and other human subject protections. Required records and reports are subject to inspection by the FDA for any clinical trials subject to FDA oversight. The results of clinical testing may be unfavorable, or, even if the intended safety and efficacy success criteria are achieved, may not be considered sufficient for the FDA to grant marketing approval or clearance of a product. The commencement or completion of any clinical trial may be delayed or halted, or be inadequate to support approval of a PMA application or clearance of a 510(k) premarket notification, for numerous reasons.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Breakthrough Devices Program is a voluntary program intended to expedite the review, development, assessment and review of certain medical devices that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human diseases or conditions for which no approved or cleared treatment exists or that offer significant advantages over existing approved or cleared alternatives. All submissions for devices designated as breakthrough devices will receive priority review, meaning that the review of the submission is placed at the top of the appropriate review queue and receives additional review resources, as needed. Although breakthrough designation or access to any other expedited program may expedite the development or approval process, it does not change the standards for approval. Breakthrough designation may also be withdrawn by the FDA if it believes that the designation is no longer supported by data from our clinical development program. Additionally, breakthrough designation does not ensure that we will ultimately obtain FDA clearance or approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Foreign Regulation </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to regulations in the United States, we will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of our products to the extent we choose to sell any products outside of the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In June 2018, the European Commission, or EC, granted marketing approval of DZUVEO for the treatment of patients with moderate-to-severe acute pain in medically monitored settings. We intend to commercialize and promote DZUVEO in Europe with one or more strategic partners, and, in July 2021, we entered into a License and Commercialization Agreement with Laboratoire Aguettant, or Aguettant, for Aguettant to commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are responsible for maintaining Zalviso device regulatory approval in the EU in order to support the manufacturing and supply of Zalviso for commercial sales. We completed the Conformit&#xe9; Europ&#xe9;enne approval process for the Zalviso device, more commonly known as a CE Mark approval. We received CE Mark approval in December 2014, which permits the commercial sale of the Zalviso device in Europe. In connection with the CE Mark approval, we were also granted International Standards Organization, or ISO, 13485:2003 certification of our quality management system in November 2014. This is an internationally recognized quality standard for medical devices. The CE Mark was originally issued by the British Standards Institution, or BSI, a Notified Body, or NB, located in the United Kingdom, or U.K., or BSI-U.K. The CE Mark file and certification has been transferred to the Netherlands NB of BSI, or BSI-NL, to mitigate the uncertainty with regards to Brexit. The ISO certification issued through BSI-U.K. was recently upgraded to the latest version of the standard, ISO 13485:2016 through BSI-U.K. and remains in effect. BSI ISO 13485:2016 certification recognizes that consistent quality policies and procedures are in place for the development, design and manufacturing of medical devices. The certification indicates that we have successfully implemented a quality system that conforms to ISO 13485 standards for medical devices. Certification to this standard is one of the key regulatory requirements for a CE Mark in the EU and EEA, as well as to meet equivalent requirements in other international markets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Controlled Substances Regulations </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sufentanil, a Schedule II controlled substance, is the API in DSUVIA and Zalviso. Controlled substances are governed by the DEA. Similarly, sufentanil is regulated as a controlled substance in Europe and other territories outside of the U.S. The handling of controlled substances and/or drug product by us, our contract manufacturers, analytical laboratories, packagers and distributors, are regulated by the Controlled Substances Act and regulations thereunder. Ephedrine is a scheduled listed chemical product under the Combat Methamphetamine Epidemic Act of 2005. Under this law, DEA applies strict controls and quotas on importation of ephedrine containing drug products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Drug Supply Chain Security Act of 2013, or DSCSA, imposes obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements are that manufacturers must provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. Further, manufacturers have drug product investigation, quarantine, disposition, and notification responsibilities related to counterfeit, diverted, stolen, and intentionally adulterated products, as well as products that are the subject of fraudulent transactions or which are otherwise unfit for distribution such that they would be reasonably likely to result in serious health consequences or death.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Unforeseen delays to the drug substance and drug product manufacture and supply chain may occur due to delays, errors or other unforeseen problems with the permitting and quota process. Also, any one of our suppliers, contract manufacturers, laboratories, packagers and/or distributors could be the subject of DEA violations and enforcement could lead to delays or even loss of DEA license by the contractors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Federal and State Fraud and Abuse and Data Privacy and Security and Transparency Laws and Regulations </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition to FDA restrictions on marketing of pharmaceutical products, federal and state healthcare laws restrict certain business practices in the pharmaceutical industry. These laws include, but are not limited to, anti-kickback, false claims, data privacy and security, and transparency statutes and regulations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity from knowingly and willfully offering, paying, soliciting or receiving remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for, purchasing, leasing, ordering or arranging for the purchasing, leasing or ordering of any item or service reimbursable under Medicare, Medicaid or other federal healthcare program. The term &#x201c;remuneration&#x201d; has been broadly interpreted to include anything of value, including for example, gifts, discounts, the furnishing of supplies or equipment, credit arrangements, payments of cash, waivers of payment, ownership interests and providing anything at less than its fair market value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers and/or formulary managers on the other. Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exceptions and safe harbors are drawn narrowly, and practices involving remuneration that may be alleged to be intended to induce purchasing, leasing or ordering may be subject to scrutiny if they do not qualify for an exception or safe harbor. The failure to satisfy all of the requirements of an applicable exception or safe harbor do not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of its facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under an exception or safe harbor.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act to a stricter standard such that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Rather, if &#x201c;one purpose&#x201d; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. In addition, the Affordable Care Act codified case law that a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute also constitutes a false or fraudulent claim for purposes of the civil False Claims Act (discussed below).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The federal civil False Claims Act and related laws prohibit, among other things, any person or entity from knowingly presenting, or causing to be presented, a false or fraudulent claim for payment or approval to the federal government or knowingly making, using or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. Pharmaceutical and other healthcare companies have been prosecuted under these laws for, among other things, allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product. Companies have been prosecuted for causing false claims to be submitted because of the companies&#x2019; marketing of the product for unapproved, and thus non-reimbursable, uses. Further, the Civil Monetary Penalties Law imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to, among others, a federal healthcare program that the person knows or should know is for a medical or other item or service that was not provided as claimed or is false or fraudulent.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, we may be subject to data privacy and security regulation by both the federal government and the states in which we conduct our business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information primarily on covered entities, business associates and their covered subcontractors. Among other things, HITECH makes HIPAA&#x2019;s privacy and security standards directly applicable to business associates that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#x2019;s fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. International laws, such as the European Union General Data Protection Regulation, or GDPR, (EU 2016/679) and Swiss Federal Act on Data Protection, regulate the processing of personal data within the European Union and between countries in the European Union and countries outside of the European Union, including the United States. Failure to provide adequate privacy protections and maintain compliance with safe harbor mechanisms could jeopardize business transactions across borders and result in significant penalties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the federal Physician Payments Sunshine Act within the Affordable Care Act and its implementing regulations, require that certain manufacturers of drugs, devices, biologicals and medical supplies, for which federal healthcare program payment is available, report information related to certain payments or other transfers of value made or distributed to physicians, (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians and their immediate family members.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Also, many states have similar healthcare statutes or regulations that apply to items and services reimbursed under Medicaid and other state programs, or, in several states, apply regardless of the payer. FDA and some states require the posting of information relating to clinical studies. In addition, certain states such as California require pharmaceutical companies to implement a comprehensive compliance program that includes a limit on expenditures for, or payments to, individual medical or health professionals. Moreover, several states have enacted legislation requiring pharmaceutical manufacturers&#xa0;to, among other things, file periodic reports with the state, make periodic public disclosures on sales and marketing activities, report information related to drug pricing, require the registration of sales representatives, and prohibit certain other sales and marketing practices.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our operations are found to be in violation of any of the health regulatory laws described above or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and/or administrative penalties, damages, fines, disgorgement, imprisonment, exclusion of products from reimbursement under government programs, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any of our products will be sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or transfers of value to healthcare professionals.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Pharmaceutical Coverage, Pricing and Reimbursement </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In both domestic and foreign markets, our sales of any approved products will depend in part on the availability of coverage and adequate reimbursement from third-party payers. Third-party payers include government health administrative authorities, managed care providers, private health insurers and other organizations. Sales of our products will depend substantially, both domestically and abroad, on the extent to which the costs of our products will be paid by third-party payers. These third-party payers are increasingly focused on containing healthcare costs by challenging the price and examining the cost-effectiveness of medical products and services. In addition, significant uncertainty exists as to the coverage and reimbursement status of newly approved healthcare products. Such payers may limit coverage to specific drug products on an approved list, also known as a formulary, which might not include all of the FDA-approved drugs for a particular indication. Third-party payers and hospitals may refuse to include a particular branded drug in their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or other alternative is available. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact utilization. Because each third-party payer individually approves coverage and reimbursement levels, obtaining coverage and adequate reimbursement is a time-consuming, costly and sometimes unpredictable process. We may be required to provide scientific and clinical support for the use of any product to each third-party payer and hospital separately with no assurance that approval would be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. This process could delay the market acceptance of any product and could have a negative effect on our future revenues and operating results. We cannot be certain that DSUVIA, or Zalviso, or any of our product candidates, if approved for commercial sale, will be considered medically necessary or cost-effective. Because coverage and reimbursement determinations are made on a payer-by-payer basis, obtaining acceptable coverage and reimbursement from one payer does not guarantee that we will obtain similar acceptable coverage or reimbursement from another payer. If we are unable to obtain coverage of, and adequate reimbursement and payment levels for, our approved products from third-party payers, physicians may limit how much or under what circumstances they will prescribe or administer them. This in turn could affect our ability to successfully commercialize our products and impact our profitability, results of operations, financial condition and future success. Third-party payers, government healthcare programs, wholesalers, group purchasing organizations, and hospitals frequently require that pharmaceutical companies negotiate agreements that provide discounts or rebates from list prices. We expect increasing pressure to offer larger discounts or discounts to a greater number of these organizations to maintain acceptable reimbursement levels for and access to our products.&#xa0;Net prices for drugs may be reduced by these mandatory discounts or rebates required by government healthcare programs, private payers, wholesalers, group purchasing organizations, hospitals, and by any future relaxation of laws that presently restrict imports of drugs from policy and payment limitations in setting their own reimbursement policies.&#xa0;In addition, if our competitors reduce the prices of their products, or otherwise demonstrate that they are better or more cost effective than our products, this may result in a greater level of reimbursement for their products relative to our products, which would reduce sales of our products and harm our results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There have been, and there will continue to be, legislative and regulatory proposals to change the healthcare system in ways that could impact our ability to commercialize our products profitably. We anticipate that the federal and state legislatures and the private sector will continue to consider and may adopt and implement healthcare policies, such as the Affordable Care Act, intended to curb rising healthcare costs. These cost containment measures may include: controls on government-funded reimbursement for drugs; new or increased requirements to pay prescription drug rebates to government health care programs; controls on healthcare providers; challenges to or limits on the pricing of drugs, including pricing controls, or limits or prohibitions on reimbursement for specific products through other means; requirements to try less expensive products or generics before a more expensive branded product; and public funding for cost effectiveness research, which may be used by government and private third-party payers to make coverage and payment decisions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, in many foreign countries, particularly the countries of the European Union, the pricing of prescription drugs is subject to government control. In some non-U.S. jurisdictions, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the EU provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. We may face competition for our products from lower-priced products in foreign countries that have placed price controls on pharmaceutical products. In addition, there may be importation of foreign products that compete with our own products, which could negatively impact our profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Healthcare Reform </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States and foreign jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system that could affect our future results of operations as we begin to commercialize our products. In particular, there have been and continue to be a number of initiatives at the United States federal and state level that seek to reduce healthcare costs. Government payment for some of the costs of prescription drugs may increase demand for our products for which we receive marketing approval. However, any negotiated prices for our future products will likely be lower than the prices we might otherwise obtain from non-governmental payers. Moreover, private payers often follow federal healthcare coverage policy and payment limitations in setting their own payment rates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, political, economic and regulatory influences are subjecting the healthcare industry in the United States to fundamental change. Initiatives to reduce the federal deficit and to reform healthcare delivery are increasing cost-containment efforts. We anticipate that Congress, state legislatures and the private sector will continue to review and assess alternative benefits, controls on healthcare spending through limitations on the growth of private health insurance premiums and Medicare and Medicaid spending, the creation of large insurance purchasing groups, price controls on pharmaceuticals and other fundamental changes to the healthcare delivery system. Any proposed or actual changes could limit or eliminate our spending on development projects and affect our ultimate profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States, the Affordable Care Act was enacted in an effort to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, impose new taxes and fees on the health industry and impose additional health policy reforms. Aspects of Affordable Care Act that may impact our business include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">extension of manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">expansion of eligibility criteria for Medicaid programs, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a requirement to annually report drug samples that manufacturers and distributors provide to physicians; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There have been judicial, executive branch and Congressional challenges to certain aspects of the Affordable Care Act. Congress has considered legislation that would repeal, or repeal and replace all or part of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate&#x201d;. Additionally, the 2020 federal spending package permanently eliminated, effective January 1, 2020, the Affordable Care Act&#x2019;s mandated &#x201c;Cadillac&#x201d; tax on high-cost employer-sponsored health coverage and medical device tax and, effective January 1, 2021, also eliminated the health insurer tax. . Further, the Bipartisan Budget Act of 2018, or the BBA, among other things, amends the Affordable Care Act, effective January 1, 2019, to increase from 50% to 70% the point-of-sale discount that is owed by pharmaceutical manufacturers who participate in Medicare Part D and to close the coverage gap in most Medicare drug plans, commonly referred to as the &#x201c;donut hole&#x201d;. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is unclear how such challenges, and the healthcare reform measures of the Biden administration will impact the Affordable Care Act. We expect that the Affordable Care Act, as currently enacted or as it may be amended or repealed in the future, and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to successfully commercialize DSUVIA, and if approved in the United States, Zalviso.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. Aggregate reductions of Medicare payments to providers of 2% per fiscal year went into effect on April 1, 2013 and will stay in effect through 2031 unless Congressional action is taken. However, COVID-19 relief legislation suspended the 2% Medicare sequester from May 1, 2020 through March 31, 2022. The American Taxpayer Relief Act further reduced Medicare payments to several providers, including hospitals. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Moreover, the DSCSA imposes additional obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this new legislation, manufacturers will be required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product. AcelRx is engaging Contract Manufacturing Organizations, or CMOs, and solution providers in serialization to implement the requirements of the DSCSA on our products. The acceptability of the approach that AcelRx is implementing will be ultimately subject to review by the FDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and further restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our products, if any, may be.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our products may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability, which would adversely affect our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing and reform government program reimbursement methodologies for drugs. For example, at the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy. For example, on July 24, 2020 and September 13, 2020, the Trump administration announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#x2019;s proposals. On November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of this rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which has also been delayed until January 1, 2023. Further, on November 20, 2020, the Centers for Medicare &amp; Medicaid Services, or CMS, issued an interim final rule implementing President Trump&#x2019;s Most Favored Nation executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries. As a result of litigation challenging the Most Favored Nation model, on December 27, 2021, CMS published a final rule that rescinded the Most Favored Nation interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. In addition, Congress is considering drug pricing as part of other health reform initiatives. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Further, there may continue to be additional proposals relating to the reform of the U.S. healthcare system, some of which could further limit the prices we are able to charge for our products, or the amounts of reimbursement available for our products. If future legislation were to impose direct governmental price controls and access restrictions, it could have a significant adverse impact on our business. Managed care organizations, as well as Medicaid and other government agencies, continue to seek price discounts. Some states have implemented, and other states are considering, price controls or patient access constraints under the Medicaid program, and some states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible. Due to the volatility in the current economic and market dynamics, we are unable to predict the impact of any unforeseen or unknown legislative, regulatory, payer or policy actions, which may include cost containment and other healthcare reform measures. Such policy actions could have a material adverse impact on our profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employees and Human Capital Resources </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of December&#xa0;31, 2021, we employed 43 full-time employees, approximately half of whom work out of our corporate offices in Hayward, CA. The rest of our employees work remotely in various locations throughout the United States and are members of our commercial team. AcelRx is committed to pay equity, regardless of gender or race/ethnicity, and conducts pay equity analyses on an annual basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We invest in our workforce by offering competitive salaries, wages, and benefits. We endeavor to foster a strong sense of ownership by offering all employees stock options and restricted stock units under our broad-based stock incentive program. We also offer comprehensive and locally relevant benefits for all eligible employees. We recognize and support the growth and development of our employees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have implemented COVID-19 policies at our Hayward office designed to ensure the safety and well-being of all employees and the people associated with them. In addition, we have implemented COVID-19 policies for our sales force to ensure safe access to hospitals and other medically supervised settings, as appropriate. As a result of the COVID-19 pandemic, to reduce risk, our corporate employees have been asked to work remotely, and all employees have been asked to avoid all non-essential travel, adhere to good hygiene practices, and engage in physical distancing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None of our employees are subject to a collective bargaining agreement. We consider our relationship with our employees to be good.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Corporate Information </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We were originally incorporated as SuRx, Inc. in Delaware on July&#xa0;13, 2005. We subsequently changed our name to AcelRx Pharmaceuticals, Inc. We file electronically with the U.S. Securities and Exchange Commission, or SEC, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section&#xa0;13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. We make available on our website at <span style="text-decoration: underline; ">www.acelrx.com</span>, free of charge, copies of these reports as soon as reasonably practicable after filing these reports with, or furnishing them to, the SEC.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     26
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>1A. Risk Factors </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Our operations and financial results are subject to various risks and uncertainties. You should carefully consider the risks described below, together with all of the other information in this report, including our financial statements and notes thereto. If any of the following risks actually materialize, our business, financial condition, results of operations, liquidity, and future prospects could be materially harmed, the price of our common stock could decline, and you could lose part or all of your investment.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Summary Risk Factors</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Our business is subject to numerous risks, as more fully described in this section below this summary. You should read these risks before you invest in our common stock. We may be unable, for many reasons, including those that are beyond our control, to implement our business strategy. In particular, our risks include</i><b><i>:</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our business is being adversely impacted by the COVID-19 pandemic.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have incurred significant losses since our inception, anticipate that we will continue to incur significant losses in 2022 and may continue to incur losses in the future.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We have not yet generated significant product revenue and may never be profitable.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">We will require additional capital and may be unable to raise capital, which would force us to delay, reduce or eliminate our commercialization efforts and product development programs and could cause us to cease operations.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Positive clinical results obtained to date for Zalviso may be disputed in FDA review, do not guarantee regulatory approval and may not be obtained from future clinical trials.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Existing and future legislation may increase the difficulty and cost for us to commercialize our products and affect the prices we may obtain.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Guidelines and recommendations published by government agencies, as well as non-governmental organizations, and existing laws and regulations can reduce the use of DSUVIA, and Zalviso, if approved in the United States.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Zalviso may cause adverse effects or have other properties that could delay or prevent regulatory approval or limit the scope of any approved label or market acceptance. DSUVIA may cause adverse effects or have other properties that could limit market acceptance.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Although we have obtained regulatory approval for DSUVIA, and even if we obtain regulatory approval for our other product candidates in the United States, we and our collaborators face extensive regulatory requirements, and our products may face future development and regulatory difficulties.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The commercial success of DSUVIA and, if approved, Zalviso and our other product candidates in the United States, as well as DZUVEO and Zalviso in Europe, will depend upon the acceptance of these products by the medical community, including physicians, nurses, patients, and pharmacy and therapeutics committees.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we are unable to maintain or grow our sales and marketing capabilities or enter into agreements with third parties to market and sell our products and, if approved, our product candidates, we may be unable to generate sufficient product revenue.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The success of our merger agreement with Lowell Therapeutics, Inc, or Lowell, depends on our ability to realize the expected benefits and potential value creation related to the acquisition;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">A key part of our business strategy is to establish collaborative relationships to commercialize and fund development and approval of our products, particularly outside of the United States. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize our products successfully, if at all.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">If we cannot defend our issued patents from third party claims or if our pending patent applications fail to issue, our business could be adversely affected.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The market price of our common stock may be highly volatile.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Nasdaq may delist our securities from trading on its exchange, which could limit investors&#x2019;&#xa0;ability to make transactions in our securities and subject us to additional trading restrictions.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Litigation may substantially increase our costs and harm our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x25cf;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Our involvement in securities-related class action litigation could divert our resources and management's attention and harm our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to COVID-19 Pandemic</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our business is being adversely impacted by the COVID-19 pandemic. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our business has been adversely affected by the COVID-19 outbreak. Federal, state, local and foreign government orders on account of the COVID-19 pandemic are preventing us from conducting certain activities. Following local and state government orders in California, where our corporate office is located and many of our employees live, we implemented work from home policies, which are limiting certain of our operations. If the COVID-19 outbreak continues, we may need to limit operations further and implement additional limitations, such as extending our work from home policies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In response to the COVID-19 pandemic, some hospitals, ambulatory surgery centers and other healthcare facilities have barred visitors that are not caregivers or mission-critical and we have no visibility as to when these restrictions on access will be lifted for all of our customers. As a result, our commercial and medical affairs teams&#x2019; educational and promotional efforts have been reduced, and in some cases, stopped. Furthermore, some governments, hospitals and doctors, as a measure to combat the further spread of COVID-19, reduced the number of procedures in which DSUVIA is administered as part of the pain treatment program, and temporarily halted performing elective surgeries, which adversely impacted the level of our sales relating to such procedures. We expect our near-term sales volumes to be adversely impacted for as long as access to healthcare facilities by our commercial and medical affairs personnel and the number of procedures in which DSUVIA is administered continues to be limited. The ultimate impact of the COVID-19 outbreak remains highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, healthcare systems or the global economy as a whole. However, these effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Commercialization </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our success is highly dependent on our ability to successfully commercialize DSUVIA. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We invested a significant portion of our efforts and financial resources to develop and gain regulatory approval for DSUVIA and expect to continue making significant investments to commercialize DSUVIA. We believe our success is highly dependent on, and a significant portion of the value of our company relates to, our ability to successfully commercialize DSUVIA in the United States. The commercial success of DSUVIA depends heavily on numerous factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our ability to market, sell, and distribute DSUVIA;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our ability to establish and maintain commercial manufacturing with third parties;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">acceptance by the medical community, including physicians, nurses, patients and pharmacy and therapeutics committees;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">acceptance of pricing and placement on payers&#x2019; formularies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our ability to effectively compete with other medications for the treatment of moderate-to-severe acute pain in medically supervised settings, including IV-opioids and any subsequently approved products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">effective management of, and compliance with, the DSUVIA Risk Evaluation and Mitigation Strategy, or REMS, program;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">continued demonstration of an acceptable safety profile of DSUVIA; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our ability to obtain, maintain, enforce, and defend our intellectual property rights and claims.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unable to successfully commercialize DSUVIA, our business, financial condition, and results of operations will be materially harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The commercial success of DSUVIA and, if approved, Zalviso and our other product candidates in the United States, as well as DZUVEO and Zalviso in Europe, will depend upon the acceptance of these products by the medical community, including physicians, nurses, patients, and pharmacy and therapeutics committees.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The degree of market acceptance of DSUVIA and, if approved, Zalviso and our other product candidates in the United States, as well as DZUVEO and Zalviso in Europe, by the medical community will depend on a number of factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">demonstration of clinical safety and efficacy compared to other products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the relative convenience, ease of administration and acceptance by physicians, patients and health care payers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the use of our approved products by a healthcare professional for patient types that were not specifically studied in clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the prevalence and severity of any adverse events, or AEs, or serious adverse events, or SAEs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">overcoming any perceptions of sufentanil as a potentially unsafe drug due to its high potency opioid status;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">limitations or warnings contained in the U.S. Food and Drug Administration, or FDA, -approved label for DSUVIA and, if approved, our other product candidates, or the European Medicines Agency, or EMA,-approved label for DZUVEO or Zalviso;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">restrictions or limitations placed on DSUVIA due to the REMS program or, if approved, on our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">availability of alternative treatments;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">existing capital investment by hospitals in IV PCA technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">pricing and cost-effectiveness;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the effectiveness of our current or any future collaborators&#x2019; sales and marketing strategies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our ability to obtain formulary approvals; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our ability to obtain and maintain sufficient third-party coverage and reimbursement.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If our approved products do not achieve an adequate level of acceptance by the medical community, including physicians, nurses, patients and pharmacy and therapeutics committees, we may not generate sufficient revenue and become or remain profitable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to maintain or grow our sales and marketing capabilities or enter into agreements with third parties to market and sell our products and, if approved, our product candidates, we may be unable to generate sufficient product revenue. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In order to commercialize DSUVIA and, if approved, our product candidates in the United States, we must maintain or grow internal sales, marketing, distribution, managerial and other capabilities or make arrangements with third parties to perform these services. We have entered into agreements with third parties for the distribution of DSUVIA and may enter into such agreements for our product candidates, if approved, in the United States, including the product candidates we in-licensed from Laboratoire Aguettant, or Aguettant, in July 2021 pursuant to a License and Commercialization Agreement, or the PFS Agreement, and the product candidates we acquired through our acquisition of Lowell; however, if these third parties do not perform as expected or there are delays in establishing such relationships, our ability to effectively distribute products would suffer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have entered into strategic partnerships with third parties to commercialize our products outside of the United States. For example, in 2013 we entered into a collaboration with Gr&#xfc;nenthal GmbH, or Gr&#xfc;nenthal, for the commercialization of Zalviso in Europe and Australia, and in July 2021, we entered a License and Commercialization Agreement, or the DZUVEO Agreement, with Aguettant for the commercialization of DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom, or the DZUVEO Territory. Gr&#xfc;nenthal ceased commercializing Zalviso on May 12, 2021 and the rights to market and sell Zalviso reverted back to us. We intend to enter into additional strategic partnerships with third parties to commercialize our products outside of the United States, including a replacement license agreement for Zalviso in Europe. Per the terms of the royalty monetization arrangement with SWK Funding, LLC, or SWK (assignee of PDL BioPharma, Inc., or PDL), or the Royalty Monetization, we are obligated to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Accordingly, even if we are able to enter into a New Arrangement, and that licensee is successful in commercializing Zalviso in Europe, we will receive only a portion of any royalties until the capped amount owing to SWK is reached.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We face significant competition in seeking appropriate strategic partners, and these strategic partnerships can be intricate and time consuming to negotiate and document. We may not be able to negotiate future strategic partnerships on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any new strategic partnerships because of the numerous risks and uncertainties associated with establishing strategic partnerships. Our current or future collaboration partners, if any, may not dedicate sufficient resources to the commercialization of our products and product candidates, if approved, or may otherwise fail in their commercialization due to factors beyond our control. If we are unable to establish effective collaborations to enable the sale of our products to healthcare professionals and in geographical regions that will not be covered by our own marketing and sales force, or if our potential future collaboration partners do not successfully commercialize our products, our ability to generate revenues from product sales will be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we are unable to maintain or grow adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate sufficient product revenue and become profitable. We compete with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>A key part of our business strategy is to establish collaborative relationships to commercialize and fund development and approval of our products, particularly outside of the United States. We may not succeed in establishing and maintaining collaborative relationships, which may significantly limit our ability to develop and commercialize our products successfully, if at all. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We will need to establish and maintain successful collaborative relationships to obtain international sales, marketing and distribution capabilities for our products. The process of establishing and maintaining collaborative relationships is difficult, time-consuming and involves significant uncertainty. For example:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our partners may seek to renegotiate or terminate their relationships with us due to unsatisfactory clinical or regulatory results, manufacturing issues, a change in business strategy, a change of control or other reasons;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our contracts for collaborative arrangements are or may be terminable at will on written notice and may otherwise expire or terminate, and we may not have alternatives available to achieve the potential for our products in those territories or markets;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our partners may choose to pursue alternative technologies, including those of our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">we may have disputes with a partner that could lead to litigation or arbitration, including in connection with any contractual force majeure notices tied to the COVID-19 pandemic;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">we have limited control over the decisions of our partners, and they may change the priority of our programs in a manner that would result in termination of the agreement or add significant delays to the partnered program;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our ability to generate future payments and royalties from our partners depends upon the abilities of our partners to establish the safety and efficacy of our drugs, maintain regulatory approvals and our ability to successfully manufacture and achieve market acceptance of our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">we or our partners may fail to properly initiate, maintain or defend our intellectual property rights, where applicable, or a party may use our proprietary information in such a way as to invite litigation that could jeopardize or potentially invalidate our proprietary information or expose us to potential liability;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our partners may not devote sufficient capital or resources towards our products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our partners may not comply with applicable government regulatory requirements necessary to successfully market and sell our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If any collaborator fails to fulfill its responsibilities in a timely manner, or at all, any research, clinical development, manufacturing or commercialization efforts pursuant to that collaboration could be delayed or terminated, or it may be necessary for us to assume responsibility for expenses or activities that would otherwise have been the responsibility of our collaborator. For example, we have a continuing obligation, through the term of the Royalty Monetization with SWK, to use commercially reasonable efforts to negotiate a New Arrangement following Gr&#xfc;nenthal&#x2019;s termination of our collaboration agreement for the commercialization of Zalviso in Europe. More generally, if we are unable to establish and maintain collaborative relationships on acceptable terms we may have to undertake development and commercialization activities at our own expense.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may experience difficulties in retaining our existing employees and managing our operations, including our continued commercialization of DSUVIA. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We need to retain and maintain our existing sales, managerial, operational, finance and other personnel and resources in order to continue the commercialization of DSUVIA and manage our operations. Our current infrastructure may be inadequate to support our strategy and any future workforce reduction, such as the reduction that eliminated approximately 33% of our workforce in March 2020 in connection with a strategic transaction, may be disruptive to our operations, may negatively affect our productivity, and may constrain our commercialization activities. For example, a workforce reduction could yield unanticipated consequences, such as attrition beyond planned staff reductions, negatively impacting employee morale and our corporate culture, or increased difficulties in our day-to-day operations, and prevent us from successfully commercializing DSUVIA as rapidly as planned. If we encounter such unanticipated consequences, we may have difficulty retaining and attracting personnel. In addition, the implementation of any additional workforce or expense reduction programs may divert the efforts of our management team and other key employees, which could adversely affect our business. Furthermore, we may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our cost reduction plan, due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from the cost reduction plan, our operating results and financial condition would be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Guidelines and recommendations published by government agencies, as well as non-governmental organizations, and existing laws and regulations can reduce the use of DSUVIA, and Zalviso, if approved in the United States. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Government agencies and non-governmental organizations promulgate regulations and guidelines applicable to certain drug classes that may include DSUVIA and Zalviso, if approved in the United States. Recommendations of government agencies or non-governmental organizations may relate to such matters as maximum quantities dispensed to patients, dosage, route of administration, and use of concomitant therapies. Government agencies and non-governmental organizations have offered commentary and guidelines on the use of opioid-containing products. We are uncertain how these activities and guidelines may impact DSUVIA and our ability to gain marketing approval of Zalviso in the United States. Regulations or guidelines suggesting the reduced use of certain drug classes that may include DSUVIA or Zalviso, or the use of competitive or alternative products as the standard-of-care to be followed by patients and healthcare providers, could result in decreased use of DSUVIA or Zalviso, if approved, or negatively impact our ability to gain market acceptance and market share. The U.S. government and state legislatures have prioritized combatting the growing misuse and addiction to opioids and opioid overdose deaths and have enacted legislation and regulations as well as other measures intended to fight the opioid epidemic. Addressing opioid drug abuse is a priority for the current U.S. administration and the FDA and is part of a broader initiative led by the U.S. Department of Health and Human Services, or HHS. Overall, there is greater scrutiny of entities involved in the manufacture, sale and distribution of opioids. These initiatives, existing laws and regulations, and any negative publicity related to opioids may have a material impact on our business and our ability to manufacture opioid products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Governmental investigations, inquiries, and regulatory actions and lawsuits brought against us by government agencies and private parties with respect to our commercialization of opioids could adversely affect our business, financial condition, results of operations and cash flows.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result of greater public awareness of the public health issue of opioid abuse, there has been increased scrutiny of, and investigation into, the commercial practices of opioid manufacturers by state and federal agencies. As a result of our manufacturing and commercial sale of DSUVIA in the United States and Zalviso in Europe, we could become the subject of federal, state and foreign government investigations and enforcement actions, focused on the misuse and abuse of opioid medications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, a significant number of lawsuits have been filed against opioid manufacturers, distributors, and others in the supply chain by cities, counties, state Attorney's General and private persons seeking to hold them accountable for opioid misuse and abuse. The lawsuits assert a variety of claims, including, but not limited to, public nuisance, negligence, civil conspiracy, fraud, violations of the Racketeer Influenced and Corrupt Organizations Act, or RICO, or similar state laws, violations of state Controlled Substance Acts or state False Claims Acts, product liability, consumer fraud, unfair or deceptive trade practices, false advertising, insurance fraud, unjust enrichment and other common law and statutory claims arising from defendants&#x2019; manufacturing, distribution, marketing and promotion of opioids and seek restitution, damages, injunctive and other relief and attorneys&#x2019; fees and costs. The claims generally are based on alleged misrepresentations and/or omissions in connection with the sale and marketing of prescription opioid medications and/or an alleged failure to take adequate steps to prevent abuse and diversion. While DSUVIA is designed for use solely in certified medically supervised healthcare settings and administered only by a healthcare professional in these settings, and is not distributed or available at retail pharmacies to patients by prescription, we can provide no assurance that parties will not file lawsuits of this type against us in the future. In addition, current public perceptions of the public health issue of opioid abuse may present challenges to favorable resolution of any potential claims. Accordingly, we cannot predict whether we may become subject to these kinds of investigations and lawsuits in the future, and if we were to be named as a defendant in such actions, we cannot predict the ultimate outcome. Any allegations against us may negatively affect our business in various ways, including through harm to our reputation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">If we were required to defend ourselves in these matters, we would likely incur significant legal costs and could in the future be required to pay significant amounts as a result of fines, penalties, settlements or judgments. It is unlikely that our current product liability insurance would fully cover these potential liabilities, if at all. Moreover, we may be unable to maintain insurance in the future on acceptable terms or with adequate coverage against potential liabilities or other losses. For more information about our product liability insurance and exclusions therefrom, please see the risk factor entitled &#x201c;We face potential product liability claims, and, if such claims are successful, we may incur substantial liability&#x201d; elsewhere in this section. The resolution of one or more of these matters could have a material adverse effect on our business, financial condition, results of operations and cash flows.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, in the current climate, stories regarding prescription drug abuse and the diversion of opioids and other controlled substances are frequently in the media or advocated by public interest groups. Unfavorable publicity regarding the use or misuse of opioid drugs, the limitations of abuse-deterrent formulations, the ability of drug abusers to discover previously unknown ways to abuse opioid products, public inquiries and investigations into prescription drug abuse, litigation, or regulatory activity regarding sales, marketing, distribution or storage of opioids could have a material adverse effect on our reputation and impact on the results of litigation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Finally, various government entities, including Congress, state legislatures or other policy-making bodies, or public interest groups have in the past and may in the future hold hearings, conduct investigations and/or issue reports calling attention to the opioid crisis, and may mention or criticize the perceived role of manufacturers, including us, in the opioid crisis. Similarly, press organizations have and likely will continue to report on these issues, and such reporting may result in adverse publicity for us, resulting in reputational harm.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Approval of Zalviso and DZUVEO in Europe has resulted in a variety of risks associated with international operations that could materially adversely affect our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our collaborations with international partners, including Gr&#xfc;nenthal and Aguettant, have required, and will require, us to supply product to support the commercialization of our products in Europe and it is likely that any New Arrangement would also include such a requirement. Entering into international business relationships subjects us to additional risks including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">multiple, conflicting, and changing laws and regulations such as privacy and data regulations, transparency regulations, tax laws, export and import restrictions, employment laws, regulatory requirements, including for drug approvals, and other governmental approvals, permits, and licenses;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">EMA &#x201c;sunset clause&#x201d; requirements, which apply to DZUVEO, providing that the marketing authorization of a medicine will cease to be valid if it is not placed on the market within three years of the authorization being granted or if it is removed from the market for three consecutive years; however, the European Commission has extended this date to December 31, 2022 for DZUVEO;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">reduced protection for intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">unexpected changes in tariffs, trade barriers and regulatory requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">different payer reimbursement regimes, governmental payers, patient self-pay systems and price controls;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">business interruptions resulting from pandemics, geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any of these factors could have a material adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we, or current and potential partners, are unable to compete effectively, our products may not reach their commercial potential. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The U.S. biotechnology and pharmaceutical industries are characterized by intense competition and cost pressure. DSUVIA competes, and our product candidates, if approved in the U.S., will compete, with a number of existing and future pharmaceuticals and drug delivery devices developed, manufactured and marketed by others. In particular, DSUVIA may compete with a wide variety of products and product candidates including (i) injectable opioid products, such as morphine, fentanyl, hydromorphone and meperidine; (ii) oral opioids such as oxycodone and hydrocodone; (iii) generic injectable local anesthetics, such as bupivacaine or branded formulations thereof; (iv) non-steroidal anti-inflammatory drugs, or NSAIDS, including ketorolac in intranasal or generic IV form, and IV meloxicam; and (v) transmucosal fentanyl products. Zalviso, if approved in the U.S., may compete with a number of opioid-based treatment options, including IV PCA pumps, oral PCA devices, and transdermal opioid PCAs. The PFS product candidates, if approved in the U.S., may compete with other ready-to-use formulations of ephedrine and phenylephrine. The nafamostat product candidates, if approved in the U.S., may compete with heparin and citrate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Key competitive factors affecting the commercial success of our approved products are likely to be efficacy, safety profile, reliability, convenience of dosing, price and reimbursement. Many of our competitors and potential competitors have substantially greater financial, technical and human resources than we do and significantly greater experience in the discovery and development of drug candidates, obtaining FDA and other regulatory approval of products, and the commercialization of those products. Accordingly, our competitors may be more successful than we are in obtaining FDA approval for drugs and achieving widespread market acceptance. Our competitors&#x2019; drugs or drug delivery systems may be more effective, have fewer adverse effects, be less expensive to develop and manufacture, or be more effectively marketed and sold than any product we may seek to commercialize. This may render our products obsolete or non-competitive. We anticipate that we will face intense and increasing competition as new drugs enter the market, additional technologies become available, and competitors establish collaborative or licensing relationships, which may adversely affect our competitive position. These and other competitive risks may materially adversely affect our ability to attain or sustain profitable operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Hospital or other health care facility formulary approvals for DSUVIA or our product candidates, if approved, in the United States may not be achieved, or could be subject to certain restrictions, which could make it difficult for us to sell our products. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Obtaining hospital or other health care facility formulary approvals can be an expensive and time-consuming process. We cannot be certain if and when we will obtain formulary approvals to allow us to sell our products into our target markets. In particular, the COVID-19-related restrictions on our commercial and medical affairs teams&#x2019; access to hospitals and other health care facilities has adversely impacted the number of formulary approvals we achieved to date, and for as long as these restrictions remain in place, or new restrictions are implemented, we may have limited visibility or difficulties in obtaining these formulary approvals. Failure to obtain timely formulary approvals will limit our commercial success. In order to obtain formulary approvals, we often are required to complete evaluation programs whereby DSUVIA, or our product candidates, if approved, are used on a limited basis for certain patient types. The evaluation period may last several months and there can be no assurance that use during the evaluation period will lead to formulary approvals of DSUVIA, or our product candidates, if approved. Further, even successful formulary approvals are subject to certain restrictions based on patient type or hospital protocol. Failure to obtain timely formulary approvals for DSUVIA, or our product candidates, if approved, would materially adversely affect our ability to attain or sustain profitable operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Coverage and adequate reimbursement may not be available for DSUVIA or our product candidates, if approved, in the United States, including Zalviso, or DZUVEO or Zalviso in Europe, which could make it difficult for us, or our partners, to sell our products profitably. </i></b>&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our ability to commercialize DSUVIA or our product candidates, if approved, in the United States, including Zalviso, and any collaboration partner&#x2019;s ability to commercialize DZUVEO or Zalviso in Europe successfully will depend, in part, on the extent to which coverage and adequate reimbursement will be available from government payer programs at the federal and state levels, authorities, including Medicare and Medicaid, private health insurers, managed care plans and other third-party payers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">No uniform policy requirement for coverage and reimbursement for drug products exists among third-party payers in the United States or Europe. Therefore, coverage and reimbursement can differ significantly from payer to payer. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our products to each payer separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such products. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact utilization. Our inability to promptly obtain and sufficiently maintain coverage and adequate reimbursement rates from third party payers could significantly harm our operating results, our ability to raise capital needed to commercialize our approved drugs and our overall financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and other third-party payers have attempted to control costs by limiting coverage and the amount of reimbursement for particular medical products. There have been a number of legislative and regulatory proposals to change the healthcare system in the United States and in some foreign jurisdictions that could affect our ability to sell our products profitably. These legislative and/or regulatory changes may negatively impact the reimbursement for our products, following approval. The availability of numerous generic pain medications may also substantially reduce the likelihood of reimbursement for DSUVIA or Zalviso, if approved, in the United States, and DSUVIA/DZUVEO and Zalviso in Europe and elsewhere. The application of user fees to generic drug products may expedite the approval of additional pain medication generic drugs. We expect to experience pricing pressures in connection with our sales of DSUVIA and Zalviso, if approved, in the United States, and future product sales of Zalviso and DZUVEO in Europe, due to the trend toward managed healthcare, the increasing influence of health maintenance organizations and additional legislative changes. If we fail to successfully secure and maintain reimbursement coverage for our products or are significantly delayed in doing so, we will have difficulty achieving market acceptance of our products and our business will be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Furthermore, market acceptance and sales of our products will depend on reimbursement policies and may be affected by future healthcare reform measures. Government authorities and third-party payers, such as private health insurers, hospitals and health maintenance organizations, decide which drugs they will pay for and establish reimbursement levels. We cannot be sure that reimbursement will be available for DSUVIA or our product candidates, if approved, in the United States, or DZUVEO or Zalviso in Europe. Also, reimbursement amounts may reduce the demand for, or the price of, our products. For example, studies of DZUVEO in Europe may be needed to ensure premium reimbursement in certain countries. If reimbursement is not available, or is available only to limited levels, we may not be able to successfully commercialize DSUVIA or our product candidates, if approved, in the United States, or DZUVEO or Zalviso in Europe.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, the regulations that govern marketing approvals, pricing, coverage and reimbursement for new drugs vary widely from country to country. Current and future legislation may significantly change the approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a product before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product in a particular country, but then be subject to price regulations that delay commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues able to be generated from the sale of the product in that country. For example, separate pricing and reimbursement approvals may impact any future collaboration partners&#x2019; ability to market and successfully commercialize our products in the 27 member states of the European Union. Adverse pricing limitations may hinder our ability to recoup our investment in DSUVIA in the United States, or our other product candidates, even after obtaining FDA marketing approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">If we are found to have improperly promoted off-label uses of our products, including DSUVIA or our product candidates, if approved, in the United States, we may become subject to significant liability. Such enforcement has become more common in the industry. The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription drug products. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product&#x2019;s approved labeling. While we have received marketing approval for DSUVIA for our proposed indication, physicians may nevertheless use our products for their patients in a manner that is inconsistent with the approved label, if the physicians personally believe in their professional medical judgment it could be used in such manner. However, if the FDA determines that our promotional materials or training constitutes promotion of an off-label use, it could request that we modify our training or promotional materials or subject us to regulatory or enforcement actions, including the issuance of an untitled letter, a Warning Letter, injunction, seizure, civil fine or criminal penalties and a requirement for corrective advertising, including Dear Doctor letters. It is also possible that other federal, state or foreign enforcement authorities might take action if they consider our promotional or training materials to constitute promotion of an off-label use, which could result in significant civil, criminal and/or administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government-funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, increased losses and diminished profits and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our financial results. The FDA or other enforcement authorities could also request that we enter into a consent decree or a corporate integrity agreement or seek a permanent injunction against us under which specified promotional conduct is monitored, changed or curtailed. If we cannot successfully manage the promotion of DSUVIA or our product candidates, if approved, in the United States, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we are unable to establish and maintain relationships with group purchasing organizations any future revenues or future profitability could be jeopardized. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Many end-users of pharmaceutical products have relationships with group purchasing organizations, or GPOs, whereby such GPOs provide such end-users access to a broad range of pharmaceutical products from multiple suppliers at competitive prices and, in certain cases, exercise considerable influence over the drug purchasing decisions of such end-users. Hospitals and other end-users contract with the GPO of their choice for their purchasing needs. We expect to derive revenue from end-user customers that are members of GPOs for DSUVIA and our product candidates, if approved. Establishing and maintaining strong relationships with these GPOs will require us to be a reliable supplier, remain price competitive and comply with FDA regulations. The GPOs with whom we have relationships may have relationships with manufacturers that sell competing products, and such GPOs may earn higher margins from these products or combinations of competing products or may prefer products other than ours for other reasons. If we are unable to establish or maintain our GPO relationships, sales of DSUVIA and our product candidates, if approved, and related revenues could be negatively impacted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We intend to rely on a limited number of distributors and pharmaceutical wholesalers to distribute DSUVIA and our product candidates, if approved, in the United States. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We intend to rely primarily upon distributors and pharmaceutical wholesalers in connection with the distribution of DSUVIA and our product candidates, if approved, in the United States. As part of the DSUVIA REMS program, we monitor distribution and audit wholesalers&#x2019; data and will monitor such data from other distributors. If our distributors and wholesalers do not comply with the DSUVIA REMS requirements, or if we are unable to establish or maintain our business relationships with these distributors and pharmaceutical wholesalers on commercially acceptable terms, or if our distributors and wholesalers are unable to distribute our drugs for regulatory, compliance or any other reason, it could have a material adverse effect on our sales and may prevent us from achieving profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Clinical Development and Regulatory Approval </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our expectations for FDA approvability of our product candidates may be inaccurate, and we may be required to conduct additional manufacturing, nonclinical or clinical development work in order to obtain FDA approval for these products, which would add to our expenses and delay any associated revenue.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On July 14, 2021, we entered into the PFS Agreement with Aguettant pursuant to which we obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing 10 ml of a solution of 50 mcg/ml phenylephrine hydrochloride for injection. Aguettant will supply us with the products for use in commercialization, if they are approved in the U.S.&#xa0;Our current expectation is that the PFS products will be approvable by the FDA without additional manufacturing, nonclinical or clinical development, but we have not met with the FDA yet to obtain their feedback on the available data to support the PFS products.&#xa0;If, after meeting with the FDA, we determine that additional development work will be needed for U.S. approval, we would incur additional expense and be delayed in obtaining any revenue from the PFS products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Nafamostat is being developed for both medical device and drug indications for use. Although nafamostat is approved for certain uses in Japan, our ability to leverage that for an expedited development and approval pathway with the FDA may be limited, and we may be required to conduct additional unanticipated nonclinical studies and clinical trials in order to seek approval in the U.S. Niyad is being studied under an investigational device exemption, or IDE, and has received Breakthrough Device Designation from the FDA for regional anticoagulant for injection into the extracorporeal circuit. Niyad is expected to be used during renal replacement therapy for acute kidney injury patients in the hospital and for end-stage renal disease patients receiving dialysis in outpatient clinics. We expect that Niyad will require filing of a PMA; the Breakthrough Designation allows for more frequent and informal FDA communication regarding development plans, and allows for priority review once the marketing application is submitted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The active drug component of Niyad, nafamostat, is also being developed for drug indications for which we expect to submit Investigational New Drug applications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Existing and future legislation may increase the difficulty and cost for us to commercialize our products and affect the prices we may obtain. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States and some foreign jurisdictions, the legislative landscape continues to evolve, including changes to the regulation of opioid-containing products. There have been a number of legislative and regulatory changes and proposed changes regarding healthcare systems that could prevent or delay marketing approval of Zalviso outside of Europe. These changes will restrict or regulate post-approval activities for DSUVIA, DZUVEO and Zalviso, and affect our ability to profitably sell any products for which we obtain marketing approval. For example, in February 2016, the FDA announced a comprehensive action plan to take concrete steps towards reducing the impact of opioid abuse on American families and communities. As part of this plan, the FDA announced that it intended to review product and labeling decisions and re-examine the risk-benefit paradigm for opioids. In June 2019, the FDA issued draft guidance related to a new benefit/risk framework for new opioid analgesic products, which proposes that the new product candidate show some benefit over an existing product. In September 2019, the FDA held a public hearing to receive stakeholder input on the approval process for new opioids. In January 2020, FDA&#x2019;s Anesthetic and Analgesic Drug Products Advisory Committee recommended against the approval of a new opioid analgesic, oxycodegol, the NDA for which was subsequently withdrawn by its sponsor. The timing of the resubmission of the Zalviso NDA is in part dependent upon the finalization of the FDA&#x2019;s new opioid approval guidelines and process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the European Union, or EU, the pricing of prescription drugs is subject to government control. The EU also provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. In addition, the EMA has a &#x201c;sunset clause&#x201d; which provides that the marketing authorization of a medicine will cease to be valid if it is not placed on the market within three years of the authorization being granted or if it is removed from the market for three consecutive years; however, the European Commission has extended this date to December 31, 2022 for DZUVEO.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the Affordable Care Act, was enacted in an effort to, among other things, broaden access to health insurance, reduce or constrain the growth of healthcare spending, enhance remedies against fraud and abuse, impose new taxes and fees on the health industry and impose additional health policy reforms. Aspects of the Affordable Care Act that may impact our business include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">extension of manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">expansion of the entities eligible for discounts under the Public Health Service pharmaceutical pricing program;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">expansion of eligibility criteria for Medicaid programs, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">expansion of healthcare fraud and abuse laws, including the federal False Claims Act and the federal Anti-Kickback Statute, new government investigative powers and enhanced penalties for non-compliance; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Affordable Care Act continues to substantially change health care financing and delivery by both governmental and private insurers, which may increase our regulatory burdens and operating costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">There have been executive, judicial and Congressional challenges to certain aspects of the Affordable Care Act. While Congress has not passed comprehensive repeal legislation, several bills affecting the implementation of certain taxes under the Affordable Care Act have been signed into law. The Tax Cuts and Jobs Act of 2017 includes a provision that repealed, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#x201c;individual mandate&#x201d;. On June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the Affordable Care Act will remain in effect in its current form. Moreover, prior to the U.S. Supreme Court ruling, on January 28, 2021, President Biden issued an executive order that initiated a special enrollment period for purposes of obtaining health insurance coverage through the Affordable Care Act marketplace, which began on February 15, 2021 and remained open through August 15, 2021. The executive order instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the Affordable Care Act. It is possible that the Affordable Care Act will be subject to judicial or Congressional challenges in the future. It is also unclear how any such challenges and the healthcare reform measures of the Biden administration will impact the Affordable Care Act. We expect that the Affordable Care Act and other healthcare reform measures that may be adopted in the future, could have a material adverse effect on our industry generally and on our ability to successfully commercialize our products. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we or our collaborators are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or our collaborators are not able to maintain regulatory compliance, our products may lose regulatory approval and we may not achieve or sustain profitability, which would adversely affect our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. Aggregate reductions of Medicare payments to providers of 2% per fiscal year went into effect on April 1, 2013 and due to subsequent legislative amendments to the statute will stay in effect through 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic, unless Congressional action is taken. Under current legislation the actual reduction in Medicare payments will vary from 1% in 2022 to up to 3% in the final fiscal year of this sequester. The American Taxpayer Relief Act further reduced Medicare payments to several providers, including hospitals. Additionally, on March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminates the statutory Medicaid drug rebate cap, currently set at 100% of a drug&#x2019;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024. Congress is also considering additional health reform measures.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Moreover, the Drug Supply Chain Security Act of 2013 imposes additional obligations on manufacturers of pharmaceutical products, among others, related to product tracking and tracing. Among the requirements of this legislation, manufacturers are required to provide certain information regarding the drug product to individuals and entities to which product ownership is transferred, label drug product with a product identifier, and keep certain records regarding the drug product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the United States, there has been increasing legislative and enforcement interest with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing and reform government program reimbursement methodologies for drugs. At the federal level, the Trump administration used several means to propose or implement drug pricing reform, including through federal budget proposals, executive orders and policy initiatives. For example, on July 24, 2020 and September 13, 2020, President Trump announced several executive orders related to prescription drug pricing that attempt to implement several of the administration&#x2019;s proposals. The FDA concurrently released a final rule and guidance in September 2020, implementing a portion of the importation executive order providing pathways for states to build and submit importation plans for drugs from Canada. Further, on November 20, 2020, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The implementation of the rule has been delayed by the Biden administration from January 1, 2022 to January 1, 2023 in response to ongoing litigation. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers, the implementation of which has also been delayed until January 1, 2023. Further, on November 20, 2020, the Centers for Medicare &amp; Medicaid Services, or CMS, issued an interim final rule implementing President Trump&#x2019;s Most Favored Nation, or MFN, executive order, which would tie Medicare Part B payments for certain physician-administered drugs to the lowest price paid in other economically advanced countries, effective January 1, 2021. As a result of litigation challenging the MFN model, on December 27, 2021, CMS published a final rule that rescinds the MFN Model interim final rule. In July 2021, the Biden administration released an executive order, &#x201c;Promoting Competition in the American Economy,&#x201d; with multiple provisions aimed at prescription drugs. In response to Biden&#x2019;s executive order, on September 9, 2021, HHS released a Comprehensive Plan for Addressing High Drug Prices that outlines principles for drug pricing reform and sets out a variety of potential legislative policies that Congress could pursue to advance these principles. At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, measures designed to encourage importation from other countries and bulk purchasing. Furthermore, even after initial price and reimbursement approvals, reductions in prices and changes in reimbursement levels can be triggered by multiple factors, including reference pricing systems and publication of discounts by third party payers or authorities in other countries. In Europe, prices can be reduced further by parallel distribution and parallel trade (i.e., arbitrage between low-priced and high-priced countries). If any of these events occur, revenue from sales of Zalviso and DZUVEO in Europe would be negatively affected.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Legislative and regulatory proposals have been made to expand post-approval requirements and further restrict sales and promotional activities for pharmaceutical products. We are not sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals of our products, if any, may be.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that additional healthcare reform measures will be adopted within and outside the United States in the future, any of which could negatively impact our business. For instance, it is possible that additional governmental action is taken in response to the COVID-19 pandemic. The continuing efforts of the government, insurance companies, managed care organizations and other payers of healthcare services to contain or reduce costs of healthcare may adversely affect the demand for any drug products for which we have obtained or may obtain regulatory approval, our ability to set a price that we believe is fair for our products, our ability to obtain coverage and reimbursement approval for a product, our ability to generate revenues and achieve or maintain profitability, and the level of taxes that we are required to pay.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may experience market resistance, delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy regarding opioids generally, and sufentanil specifically. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In February 2016, the FDA announced a comprehensive action plan to take concrete steps towards reducing the impact of opioid abuse on American families and communities. As part of this plan, the FDA announced that it intended to review product and labeling decisions and re-examine the risk-benefit paradigm for opioids. In June 2019, the FDA issued draft guidance related to a new benefit/risk framework for new opioid analgesic products, which proposes that the new product candidate show some benefit over an existing product. In September 2019, the FDA held a public hearing to receive stakeholder input on the approval process for new opioids. The timing of the resubmission of the Zalviso NDA is in part dependent upon the finalization of the FDA&#x2019;s new opioid approval guidelines and process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In May 2017, an Opioid Policy Steering Committee was established to address and advise regulators on opioid use. The Committee was charged with three initial questions: (i) should the FDA require mandatory education for healthcare professionals, or HCPs, who prescribe opioids; (ii) should the FDA take steps to ensure the number of prescribed opioid doses is more closely tailored to the medical indication; and (iii) is the FDA properly considering the risk of abuse and misuse of opioids during its drug review process. Zalviso has not been designed with an abuse-deterrent formulation and is not tamper-resistant. As a result, Zalviso has not undergone testing for tamper-resistance or abuse deterrence.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The FDA can delay, limit or deny marketing approval for many reasons, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a product candidate may not be considered safe or effective;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the manufacturing processes or facilities we have selected may not meet the applicable requirements; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">changes in their approval policies or adoption of new regulations may require additional work on our part.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Part of the regulatory approval process includes compliance inspections of manufacturing facilities to ensure adherence to applicable regulations and guidelines. The regulatory agency may delay, limit or deny marketing approval of our product candidate, Zalviso, as a result of such inspections. We, our contract manufacturers, and their vendors, are all subject to preapproval and post-approval inspections at any time. The results of these inspections could impact our ability to obtain FDA approval for Zalviso and, if approved, our ability to launch and successfully commercialize Zalviso in the United States. In addition, results of FDA inspections could impact our ability to maintain FDA approval of DSUVIA, and our ability to expand and sustain commercial sales of DSUVIA in the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any delay in, or failure to receive or maintain, approval for Zalviso in the United States could prevent us from generating meaningful revenues or achieving profitability. Zalviso may not be approved even if we believe it has achieved its endpoints in clinical trials. Regulatory agencies, including the FDA, or their advisors, may disagree with our trial design and our interpretations of data from preclinical studies and clinical trials. Regulatory agencies may change requirements for approval even after a clinical trial design has been approved. The FDA exercises significant discretion over the regulation of combination products, including the discretion to require separate marketing applications for the drug and device components in a combination product. Zalviso is being regulated as a drug product under the NDA process administered by the FDA. The FDA could in the future require additional regulation of Zalviso, or DSUVIA, under the medical device provisions of the Federal Food, Drug and Cosmetic Act, or FDCA. We must comply with the Quality Systems Regulation, or QSR, which sets forth the FDA&#x2019;s current good manufacturing practice, or cGMP, requirements for medical devices, and other applicable government regulations and corresponding foreign standards for drug cGMPs. If we fail to comply with these regulations, it could have a material adverse effect on our business and financial condition.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Regulatory agencies also may approve a product candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing trials. For example, DSUVIA is subject to a deferred post-marketing requirement for study in the pediatric population ages 6-17 years. As required in the DSUVIA FDA approval letter, a final protocol for this trial was submitted to the FDA in August 2020, in conjunction with a previously FDA approved request to defer initiation of pediatric studies until additional post-market safety data is obtained in adult patients using DSUVIA. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our product candidates. For example, we intend to seek approval of Zalviso for the management of moderate-to-severe acute pain in adult patients in the hospital setting; however, our clinical trial data was generated exclusively from the post-operative segment of this population, and the FDA may restrict any approval to post-operative patients only, which would reduce the size of the commercial opportunity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The success of Zalviso relies, in part, on obtaining regulatory approval in the United States. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The success of Zalviso relies, in part, upon our ability to develop and receive regulatory approval of this product candidate in the United States for the management of moderate-to-severe acute pain in adult patients in the hospital setting. Our Phase 3 program for Zalviso initially consisted of three Phase 3 clinical trials. We reported positive top-line data from each of these trials and submitted an NDA for Zalviso to the FDA in September 2013, which the FDA then accepted for filing in December 2013. In July 2014, the FDA issued a Complete Response Letter, or CRL, for our NDA for Zalviso, or the Zalviso CRL. The Zalviso CRL contained requests for additional information on the Zalviso System to ensure proper use of the device. The requests include submission of data demonstrating a reduction in the incidence of device errors, changes to address inadvertent dosing, among other items, and submission of additional data to support the shelf life of the product. Furthermore, in March 2015, we received correspondence from the FDA stating that in addition to the bench testing and two Human Factors studies we had performed in response to the issues identified in the Zalviso CRL, a clinical trial was needed to assess the risk of inadvertent dispensing and overall risk of dispensing failures. Based on the results of our Type C meeting with the FDA in September 2015, we completed the protocol review with the FDA and initiated this study, IAP312, in September 2016.&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IAP312 was a Phase 3 study in post-operative patients designed to evaluate the effectiveness of changes made to the functionality and usability of the Zalviso device and to take into account comments from the FDA on the study protocol. The IAP312 study was designed to rule out a 5% device failure rate. The study design required a minimum of 315 patients. In the IAP312 study, sites proactively looked for tablets that were dispensed by the patient but failed to be placed under the tongue, known as dropped tablets. The FDA refers to dropped tablets as inadvertent dispensing. Correspondence from the FDA suggests that they may include the rate of inadvertent dispensing along with the device failures to calculate a total error rate. The IAP312 study evaluated all incidents of misplaced tablets; however, per the protocol, the error rate calculation does not include the rate of inadvertent dispensing. If the FDA includes the rate of inadvertent dispensing along with the device failures to calculate a total error rate, the resulting error rate may be unacceptable to the FDA. Further, the correspondence from the FDA suggests that we may need to modify the REMS program for Zalviso to address dropped tablets. The IAP312 results will supplement the three Phase 3 trials already completed in the Zalviso NDA resubmission. The timing of the resubmission of the Zalviso NDA is in part dependent upon the finalization of the FDA&#x2019;s new opioid approval guidelines and process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There is no guarantee that the additional work we performed related to Zalviso, including the IAP312 trial, will result in our successfully obtaining FDA approval of Zalviso in a timely fashion, if at all. Although we believe the IAP312 study met safety, satisfaction and device usability expectations, there is no guarantee the IAP312 trial results will address the issues raised by the FDA. For example, the FDA may include the rate of inadvertent dispensing along with the device failures to calculate a total error rate and the resulting error rate may be unacceptable to the FDA, or the FDA may still have concerns regarding the performance of the device, inadvertent dosing (dropped tablets), or other issues. At any future point in time, the FDA could require us to complete further clinical, Human Factors, pharmaceutical, reprocessing or other studies, which could delay or preclude any NDA resubmission or approval of the NDA and could require us to obtain significant additional funding. We may not be able to identify appropriate remediations to issues that the FDA may raise, and we may not have sufficient time or financial resources to conduct future activities to remediate issues raised by the FDA. We intend to seek a label indication for Zalviso for the management of moderate-to-severe acute pain in adult patients in the hospital setting. However, our clinical trial data was generated exclusively from the post-operative segment of this population, and the FDA may restrict any approval to post-operative patients only, which would reduce our commercial opportunity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Upon resubmission of the Zalviso NDA, the FDA may hold an advisory committee meeting to obtain committee input on the safety and efficacy of Zalviso. Typically, advisory committees will provide responses to specific questions asked by the FDA, including the committee&#x2019;s view on the approvability of the drug under review. Advisory committee decisions are not binding, but an adverse decision at the advisory committee may have a negative impact on the regulatory review of Zalviso. Additionally, we may choose to engage in the dispute resolution process with the FDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our proposed trade name of Zalviso has been approved by the EMA and is currently being used in Europe. It has also been conditionally approved by the FDA, which must approve all drug trade names to avoid medication errors and misbranding. However, the FDA may withdraw this approval in which case any brand recognition or goodwill that we establish with the name Zalviso prior to commercialization may be worthless.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any delay in approval by the FDA of the Zalviso NDA, once it is resubmitted, may negatively impact our stock price and harm our business operations. Any delay in obtaining, or inability to obtain, regulatory approval would prevent us from commercializing Zalviso in the United States, generating revenues and potentially achieving profitability. If any of these events occur, we may be forced to delay or abandon our development efforts for Zalviso, which would have a material adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Positive clinical results obtained to date for Zalviso may be disputed in FDA review, do not guarantee regulatory approval and may not be obtained from future clinical trials. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have reported positive top-line data from each of our four Zalviso Phase 3 clinical trials completed to date, as well as our Phase 2 clinical trials for Zalviso. However, even if we believe that the data obtained from clinical trials is positive, the FDA has, and in the future could, determine that the data from our trials was negative or inconclusive or could reach a different conclusion than we did on that same data. Negative or inconclusive results of a clinical trial or difference of opinion could cause the FDA to require us to repeat the trial or conduct additional clinical trials prior to obtaining approval for commercialization, and there is no guarantee that additional trials would achieve positive results or that the FDA will agree with our interpretation of the results. If the FDA were to require any additional clinical trials for Zalviso, our development efforts would be further delayed, which would have a material adverse effect on our business. Any such determination by the FDA would delay the timing of our commercialization plan for Zalviso and adversely affect our business operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have experienced and may in the future experience delays in clinical trials of our product candidates. While we have completed four Phase 3 clinical trials and several Phase 2 clinical trials for Zalviso, future clinical trials may not begin on time, have an effective design, enroll a sufficient number of patients or be completed on schedule, if at all. For example, we postponed the start of IAP312, originally planned for the first quarter of 2016, to September 2016. The postponement was due to a delay in the receipt and testing of final clinical supplies for this trial. As a result, the development timeline for Zalviso was further extended.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our post-approval clinical trials for DSUVIA, or any future FDA-required clinical trials for Zalviso, could be delayed for a variety of reasons, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">inability to raise funding necessary to initiate or continue a trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays in obtaining regulatory approval to commence a trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays in reaching agreement with the FDA on final trial design;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">imposition of a clinical hold by the FDA, Institutional Review Board, or IRB, or other regulatory authorities;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays in reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays in obtaining required IRB approval at each site;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays in recruiting suitable patients to participate in a trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays in the testing, validation, manufacture and delivery of the tablets and device components of DSUVIA or Zalviso;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays in having patients complete participation in a trial or return for post-treatment follow-up;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">clinical sites dropping out of a trial to the detriment of enrollment or being delayed in entering data to allow for clinical trial database closure;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">time required to add new clinical sites; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays by our contract manufacturers to produce and deliver sufficient supply of clinical trial materials.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If any future FDA-required clinical trials are delayed for any reason, our development costs may increase, our approval process for Zalviso could be delayed, our ability to commercialize and commence sales of Zalviso could be materially harmed, and our ability to maintain FDA approval of DSUVIA could be jeopardized, which could have a material adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Zalviso may cause adverse effects or have other properties that could delay or prevent regulatory approval or limit the scope of any approved label or market acceptance. DSUVIA may cause adverse effects or have other properties that could limit market acceptance. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Adverse events, or AEs, caused by Zalviso could cause us, other reviewing entities, clinical trial sites or regulatory authorities to interrupt, delay or halt any future FDA-required clinical trials and could result in the denial of regulatory approval. Phase 2 clinical trials we conducted with Zalviso did generate some AEs, but no significant adverse events, or SAEs, related to the trial drug. In our Phase 3 active-comparator clinical trial (IAP309), 8% of Zalviso-treated patients dropped out of the trial prematurely due to an AE (11% in the IV patient-controlled morphine group), and we observed three SAEs that were assessed as possibly or probably related to study drug (one- respiratory depression in the Zalviso group and two- abdominal distension and ileus in the IV patient-controlled morphine group). In our Phase 3, double-blind, placebo-controlled, abdominal surgery trial (IAP310), 6% of Zalviso-treated patients dropped out of the trial prematurely due to an AE (9% in placebo group). There were no SAEs determined to be related to study drug. In our Phase 3, double-blind, placebo-controlled, orthopedic surgery trial (IAP311), 7% of Zalviso-treated patients dropped out of the trial prematurely due to an AE (7% in placebo group). Four patients (three in the Zalviso group and one in the placebo group) experienced an SAE considered possibly or probably related to the trial drug by the investigator. The SAEs possibly or probably attributed to Zalviso were severe oxygen saturation decrease, sinus tachycardia and confusional state. In our Phase 3 multicenter, open-label study of Zalviso (IAP312), 3% of patients dropped out prematurely due to an AE. Five patients experienced SAEs in the IAP312 study and none of these were considered possibly or probably related to the study drug by the investigator.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In our Phase 2 DSUVIA placebo-controlled bunionectomy study (SAP202), two patients in the DSUVIA 30 mcg group (5%) discontinued treatment due to an AE, one unrelated to study drug and the other probably related to study drug. There were no SAEs deemed related to study drug.&#xa0;In our Phase 3 placebo-controlled abdominal surgery study (SAP301), one DSUVIA-treated patient (1%) dropped out of the trial prematurely due to an AE (4% in placebo group). There were two SAEs determined to be related to study drug in the placebo-treated group and no related SAEs in the DSUVIA group. In our Phase 3 open-label, single-arm emergency room study (SAP302), no DSUVIA-treated patients dropped out of the trial prematurely due to an AE. One patient had an SAE &#x2013; angina pectoris &#x2013; possibly related to study drug. In our post-operative study in patients aged 40 years or older (SAP303), 3% of DSUVIA-treated patients dropped out of the trial prematurely due to an AE. There were no SAEs deemed related to study drug.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If DSUVIA or, if approved, Zalviso cause serious or unexpected side effects after receiving marketing approval, a number of potentially significant negative consequences could result, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">regulatory authorities may withdraw their approval of the product or impose restrictions on its distribution in the form of a modified REMS program;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">regulatory authorities may require the addition of labeling statements, such as warnings or contraindications;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">we may be required to change the way the product is administered or conduct additional clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">we could be sued and held liable for harm caused to patients; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our reputation may suffer.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any of these events could prevent us from achieving or maintaining market acceptance of DSUVIA or, if approved, Zalviso, and could substantially increase the costs of commercializing our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Additional time may be required to obtain U.S. regulatory approval for Zalviso because it is a drug/device combination product candidate. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DSUVIA and Zalviso are combination products with both drug and device components. The FDA requires both the drug and device components of combination product candidates to be reviewed as part of an NDA submission. There are very few examples of the FDA approval process for drug/device combination products such as DSUVIA and Zalviso. As a result, we experienced delays in the development and commercialization of DSUVIA, and may experience future delays in the development and commercialization of Zalviso, due to regulatory uncertainties in the product development and approval process, in particular as it relates to a drug/device combination product approval under an NDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The process for obtaining approval of an NDA is time consuming, subject to unanticipated delays and costs, and requires the commitment of substantial resources. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If the FDA determines that any of the clinical work submitted, including the clinical trials, Human Factors studies and bench testing submitted for a product candidate in support of an NDA were not conducted in full compliance with the applicable protocols for these trials, studies and testing as well as with applicable regulations and standards, or if the FDA does not agree with our interpretation of the results of such trials, studies and testing, the FDA may reject the data and results. The FDA may audit some or all of our clinical trial sites to determine the integrity of our clinical data. The FDA may audit some or all of our Human Factors study sites to determine the integrity of our data and may audit the data and results of bench testing. Any rejection of any of our data would negatively impact our ability to obtain marketing authorization for our product candidate, Zalviso, and would have a material adverse effect on our business and financial condition. In addition, an NDA may not be approved, or approval may be delayed, as a result of changes in FDA policies for drug approval during the review period. For example, although many products have been approved by the FDA in recent years under Section&#xa0;505(b)(2) of the FDCA, objections have been raised to the FDA&#x2019;s interpretation of Section&#xa0;505(b)(2). If challenges to the FDA&#x2019;s interpretation of Section&#xa0;505(b) (2) are successful, the FDA may be required to change its interpretation, which could delay or prevent the approval of such an NDA. More generally, the FDA&#x2019;s comprehensive action plan to take concrete steps towards reducing the impact of opioid abuse on American families and communities may result in delays and challenges in obtaining NDA approval. Any significant delay in the acceptance, review or approval of an NDA that we have submitted would have a material adverse effect on our business and financial condition and would require us to obtain significant additional funding.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Although we have obtained regulatory approval for DSUVIA, and even if we obtain regulatory approval for our product candidates in the United States, we and our collaborators face extensive regulatory requirements, and our products may face future development and regulatory difficulties. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Although we have obtained regulatory approval for DSUVIA, and even if we obtain regulatory approval for our product candidates in the United States, the FDA may impose significant restrictions on the indicated uses or marketing of our products or impose ongoing requirements for potentially costly post-approval trials or post-market surveillance. For example, DSUVIA is subject to a deferred post-marketing requirement for study in the pediatric population ages 6-17 years. A final protocol for this trial was submitted to the FDA in August 2020, in conjunction with a previously FDA approved request to defer initiation of pediatric studies until additional post-market safety data is obtained in adult patients using DSUVIA. Additionally, the labeling approved for DSUVIA includes restrictions on use due to the opioid nature of sufentanil. If approved, the labeling for Zalviso will likely include similar restrictions on use.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">DSUVIA in the United States is also subject to ongoing FDA requirements governing the labeling, packaging, storage, distribution, safety surveillance, advertising, promotion, record-keeping and reporting of safety and other post-market information. The holder of an approved NDA is obligated to monitor and report AEs and any failure of a product to meet the specifications in the NDA. The holder of an approved NDA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Advertising and promotional materials must comply with FDA rules concerning the advertising and promotion of DSUVIA and are subject to FDA review, in addition to other potentially applicable federal and state laws. Failure to comply with these regulations can result in the receipt of Warning Letters and further liability if off-label promotion is involved. For example, on February 11, 2021, we received a Warning Letter from the Office of Prescription Drug Promotion, or OPDP, of the FDA relating to a banner advertisement we submitted to the OPDP on December 6, 2019, and a tabletop display we submitted on February 28, 2020, and resubmitted to the OPDP at its request on September 23, 2020.&#xa0;We submitted the materials to the OPDP pursuant to the FDA requirement that sponsors submit all promotional materials to the FDA at the time of their initial dissemination or publication. The FDA&#x2019;s concerns identified in the letter include its view that the promotional material makes misleading claims and representations about the risks and efficacy of DSUVIA&#xa0;because the material does not reveal facts that are material in light of the representations made.&#xa0;As a result, we conducted a review of our marketing materials to identify any potential revisions in light of the letter.&#xa0;We responded to the FDA within the timeframe requested in the letter and, on March 23, 2021, held a teleconference with OPDP to seek guidance and clarification on the concerns raised in the letter. Following our meeting with OPDP, we conducted a further review of our marketing materials to identify any potential revisions in light of the letter and OPDP&#x2019;s guidance. We submitted a second response to FDA on April 7, 2021, and on June 17, 2021 we announced that the FDA agreed with our proposed plan to update certain promotional materials, including providing a letter to healthcare professionals, or the DHCP letter, explaining the corrections to the discontinued promotional materials. We included this DHCP letter on the DSUVIA.com website for a period of eight months. On February 18, 2022, in agreement with OPDP, the link to the corrective DCHP letter was removed from the DSUVIA.com website. Although we believe we have updated all promotional materials currently in use by our commercial team to address the FDA's concerns and we received word from FDA in mid-February that they are working on a Close-out Letter to the Warning Letter, we cannot give any assurances that we will receive such Close-out Letter or that we will not receive additional FDA Warning Letters in the future. If approved, our product candidates will be subject to these same requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We must also register and obtain various state prescription drug distribution licenses and controlled substance permits, and any delay or failure to obtain or maintain these licenses or permits may limit our market and materially impact our business. In certain states we cannot apply for a license until a drug is approved by the FDA. The state licensing process may take several months which would delay commercialization in those states. In addition, manufacturers of drug products and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMPs and adherence to commitments made in the NDA. If we, or a regulatory agency, discover previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or problems with the facilities where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facilities, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to comply with applicable regulatory requirements following approval of our products, a regulatory agency may:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">issue a Warning Letter asserting that we are in violation of the law;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">seek an injunction or impose civil or criminal penalties or monetary fines;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">suspend or withdraw regulatory approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">suspend any ongoing clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">refuse to approve a pending NDA or supplements to an NDA submitted by us;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">seize product; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">refuse to allow us to enter into supply contracts, including government contracts.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize DSUVIA, or, if approved, our product candidates, and generate revenues.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Except for Zalviso and DZUVEO, which are both approved in Europe, we may never obtain additional regulatory approvals for our products and product candidates outside of the United States, which would limit our ability to realize their full market potential. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In order to market any products outside of the United States, we or our commercial partners, must establish and comply with numerous and varying regulatory requirements of other countries regarding safety and efficacy. On September 22, 2015, we announced that the EC had granted marketing approval for Gr&#xfc;nenthal&#x2019;s MAA for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. In April 2016, Gr&#xfc;nenthal completed the first commercial sale of Zalviso. Gr&#xfc;nenthal terminated the collaboration, effective November 13, 2020. The terms of the Gr&#xfc;nenthal Agreements were extended to May 12, 2021 to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. Gr&#xfc;nenthal&#x2019;s rights to market and sell Zalviso reverted back to us on May 12, 2021. We have not yet negotiated a New Arrangement and there can be no assurance that we will successfully enter into a New Arrangement. In June 2018, we announced that the EC had granted marketing approval of DZUVEO for the treatment of patients with moderate-to-severe acute pain in medically monitored settings. In July 2021, we entered into the DZUVEO Agreement with Aguettant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Part of the foreign regulatory approval process includes compliance inspections of manufacturing facilities to ensure adherence to applicable regulations and guidelines. The foreign regulatory agency may delay, limit or deny marketing approval as a result of such inspections. We, our contract manufacturers, and their vendors, are all subject to preapproval and post-approval inspections at any time. The results of these inspections could impact our ability to obtain regulatory approval of DSUVIA and Zalviso in countries outside of the United States and Europe, or our ability to launch and successfully commercialize these products, once approved. In addition, results of EMA inspections could impact our ability to maintain EC approval of Zalviso and DZUVEO, and any future collaboration partner&#x2019;s ability to expand and sustain commercial sales of Zalviso or DZUVEO in Europe.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Outside of Europe, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and costs for us and require additional non-clinical trials or clinical trials, which could be costly and time consuming. Regulatory requirements can vary widely from country-to-country and could delay or prevent the introduction of our products in those countries. Our current clinical trial data may not be sufficient to support marketing approval or premium reimbursement in all territories. For example, we anticipate we may need comparator studies for DZUVEO in Europe to ensure premium reimbursement in certain countries. While we have obtained approval of DZUVEO in Europe, we will be substantially dependent on Aguettant to comply with regulatory requirements. If we, or our commercial partners, fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of our products will be harmed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>DSUVIA requires, and, if approved, Zalviso will require, a REMS program. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DSUVIA was approved in the United States with a REMS program. If Zalviso is approved in the United States, it will also require a REMS program. The DSUVIA REMS program includes restrictions on product distribution and use only in certified medically supervised settings. Before DSUVIA is distributed, an authorized representative from each medically supervised setting must sign an attestation that they have the ability to manage acute opioid overdose and will train all relevant staff on administration of DSUVIA, including the importance of only dispensing the product in a medically supervised setting. Therefore, REMS-certification is a key gating item to generating product revenues for DSUVIA. In addition, the REMS program for DSUVIA may significantly increase our costs to commercialize this product. While we have received pre-clearance from the FDA regarding certain aspects of the proposed required REMS program for Zalviso, we cannot predict the final REMS program to be required as part of any FDA approval of Zalviso. Depending on the extent of the REMS requirements, any U.S. launch may be delayed, the costs to commercialize Zalviso may increase substantially and the potential commercial market could be restricted. Furthermore, risks of sufentanil that are not adequately addressed through the proposed REMS program for Zalviso may also prevent or delay its approval for commercialization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Financial Condition and Need for Additional Capital </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have incurred significant losses since our inception, anticipate that we will continue to incur significant losses in 2022 and may continue to incur losses in the future. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have incurred significant net losses in each year since our inception in July 2005, and as of December 31, 2021, we had an accumulated deficit of $473.6 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have devoted most of our financial resources to research and development, including our non-clinical development activities and clinical trials. To date, we have financed our operations primarily through the issuance of equity securities, borrowings, payments from Gr&#xfc;nenthal, the monetization of certain future royalties and commercial sales milestones from the European sales of Zalviso by Gr&#xfc;nenthal, funding from the Department of Defense, or DoD, and more recently with revenues from sales of DSUVIA since the commercial launch in the first quarter of 2019 and the upfront payment under the DZUVEO Agreement with Aguettant. The size of our future net losses will depend, in part, on the rate of future expenditures and our ability to generate revenues. We expect to continue to incur substantial expenses as we support commercialization activities for DSUVIA, manufacturing and supply activities for DZUVEO, and research and development activities for our product candidates, including the FDA regulatory review of the Zalviso NDA, once resubmitted. If DSUVIA is not successfully commercialized in the U.S., if our product candidates are not successfully developed or commercialized in the U.S., or if revenues are insufficient following marketing approval, we will not achieve profitability and our business may fail. Our success is also dependent on current and future collaborations to market our products outside of the United States, which may not materialize or prove to be successful.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have not yet generated significant product revenue and may never be profitable. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our ability to generate revenue from commercial sales and achieve profitability depends on our ability, alone and with collaborators, to successfully complete the development of, obtain the necessary regulatory approvals for, and commercialize our products. Although we received FDA approval of DSUVIA and began the commercial launch of DSUVIA in the United States, we may never generate enough revenues from sales of DSUVIA, or our product candidates, if approved, in the United States to become profitable. Although the EC granted marketing approval of DZUVEO in June 2018, we only recently entered into the DZUVEO Agreement with Aguettant to commercialize DZUVEO in Europe and there can be no assurance that Aguettant will successfully commercialize DZUVEO. Although we had a collaboration agreement with Gr&#xfc;nenthal for commercialization of Zalviso in Europe and Australia, Gr&#xfc;nenthal was unable to achieve a level of commercial sales of Zalviso to trigger sales milestone payments that would have been payable to us. The Gr&#xfc;nenthal Agreements have been terminated and Gr&#xfc;nenthal&#x2019;s rights to market and sell Zalviso reverted back to us on May 12, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In September 2015, we consummated a monetization transaction with PDL pursuant to which we sold to PDL for $65.0 million 75% of the European royalties from sales of Zalviso and 80% of the first four commercial milestones under the Amended License Agreement, subject to a capped amount. PDL sold its royalty interest for Zalviso to SWK in 2020. As mentioned above, Gr&#xfc;nenthal has terminated the Gr&#xfc;nenthal Agreements and the rights reverted back to us on May 12, 2021. Per the terms of the Royalty Monetization, we are obligated to use commercially reasonable efforts to negotiate a New Arrangement. Accordingly, even if we are able to enter into a New Arrangement, and that licensee is successful in commercializing Zalviso in Europe, we will receive only a portion of any royalties until the capped amount owing under the Royalty Monetization is reached. We do not anticipate generating significant near-term revenues from DSUVIA or our product candidates, if approved, in the United States. Our ability to generate future revenues from product sales depends heavily on our success in:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">maintaining regulatory approval for DSUVIA and obtaining and maintaining regulatory approval for our product candidates in the United States; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">launching and commercializing DSUVIA and our product candidates, if approved, in the United States by building, internally or through collaborations, an institutionally focused sales force, and launching and commercializing DZUVEO and Zalviso internationally through collaborations, which may require additional funding.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because of the numerous risks and uncertainties associated with launching a commercial pharmaceutical product, pharmaceutical product development and the regulatory environment, we are unable to predict the timing or amount of increased expenses, or when, or if, we will be able to achieve or maintain profitability. Our expenses could increase beyond expectations if we are delayed in receiving regulatory approval for our product candidates in the United States, or if we are required by the FDA to complete activities in addition to those we currently anticipate or have already completed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We anticipate continuing to incur significant costs associated with commercializing DSUVIA in the United States. Even if we are able to generate revenues from the sale of DSUVIA or our product candidates, if approved, in the United States, we may not become profitable and may need to obtain additional funding to continue operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future sales of DSUVIA to the DoD are not predictable, may occur on an irregular basis and may not meet our expectations due to various U.S. government-related factors that are beyond our control and into which we have little to no visibility, including the timing and extent of future U.S. military deployments. If DoD spending on DSUVIA does not meet our expectations, it could adversely affect our expected results of operations, financial condition and liquidity. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In April 2020, DSUVIA achieved Milestone C approval by the DoD, a decision that clears the path for the DoD to begin placing orders for DSUVIA to fulfill its updating requirements for all Army Sets, Kits, and Outfits, or SKOs, for deployed/deploying troops. Completion of this SKO fulfillment process is dependent on the Army&#x2019;s completion of their product information package including instructions on fulfillment and training which remains in process. In September 2020, we announced that DSUVIA was added to the DoD Joint Deployment Formulary, a core list of pharmaceutical products that are designated for deploying military units across all service branches. Future sales of DSUVIA to the DoD are not predictable, may occur on an irregular basis, and may not meet our expectations due to various U.S. government-related factors that are beyond our control and into which we have little to no visibility, including the timing and extent of future U.S. military deployments. Even if we do generate revenue from such sales, we may never generate revenue that is significant or predictable, which could impair our value and our ability to raise capital, expand our business or continue our operations. The placement of new orders by the DoD is, among other things, contingent upon overall U.S. government policies, budget and appropriation decisions and processes which are driven by numerous factors, including geo-political events, deployment of military units, macroeconomic conditions, and the ability of the U.S. government to enact relevant legislation, such as appropriations bills and accords on the debt ceiling. Our expectations about the timing and size of initial stocking orders for the SKOs and other orders by the DoD are based on our understanding of troop deployment schedules. If DoD spending on DSUVIA does not meet our expectations, it could have a material adverse effect on our expected results of operations, financial condition and liquidity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have been substantially dependent on Gr</i></b>&#xfc;<b><i>nenthal to successfully commercialize Zalviso in Europe and they have terminated their collaboration agreement with us. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under our agreements with Gr&#xfc;nenthal, we granted Gr&#xfc;nenthal rights to commercialize Zalviso in Europe for human use in pain treatment within, or dispensed by, hospitals, hospices, nursing homes and other medically supervised settings. In September 2015, the EC granted marketing approval for Gr&#xfc;nenthal&#x2019;s MAA for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients, and Gr&#xfc;nenthal began its European launch of Zalviso with the first commercial sale occurring in April 2016. Gr&#xfc;nenthal terminated the collaboration, effective November 13, 2020. The terms of the Gr&#xfc;nenthal Agreements were extended to May 12, 2021 to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. Gr&#xfc;nenthal&#x2019;s rights to market and sell Zalviso reverted back to us on May 12, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the pilot and launch phases in the various European countries, Gr&#xfc;nenthal reported certain issues from HCPs with the initial set up of the Zalviso controllers before being given to patients for use. To address the issues, we assisted Gr&#xfc;nenthal with implementing additional training for HCPs and revised the controller software. Controllers with the revised software, which were delivered in December 2016, underwent extensive bench testing and we believe we successfully addressed the issues presented. Additional devices were delivered beginning in early 2017. Controllers with the U.S. version of the revised software were also used in the IAP312 clinical study that was initiated in September 2016. There can be no assurance that the issues identified in the initial pilot and launch phases by Gr&#xfc;nenthal will not have a material adverse impact on future sales of Zalviso in Europe under a New Arrangement. Further, if new issues occur, there may be a material adverse impact on the future sales of Zalviso in Europe under a New Arrangement which may have a negative impact on future revenues received and recognized by us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We did not realize the expected benefits from our collaboration with Gr&#xfc;nenthal, and may not realize the expected benefits from any New Arrangement, due to a number of important factors, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">The timing and amount of any payments we may receive under our agreements will depend on, among other things, the efforts, allocation of resources, and successful commercialization of Zalviso by any future collaboration partner in Europe;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Gr&#xfc;nenthal changed the focus of its commercialization efforts to pursue higher-priority programs and any future collaboration partner may do the same;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Gr&#xfc;nenthal stopped its commercialization efforts in countries where it had the sole right to commercialize Zalviso, requiring us to find another collaboration partner for Zalviso in Europe; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Gr&#xfc;nenthal terminated its agreements with us, and any future collaboration partner may also terminate any future agreement with us, adversely affecting our potential revenue from Zalviso;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any failures in commercialization of Zalviso outside the United States could have a material adverse impact on our business, including an adverse impact on the commercialization of DSUVIA or the development of Zalviso in the United States, if related to issues underlying the sufentanil sublingual tablet technology, safety or efficacy. Additionally, we agreed to certain representations and covenants relating to the Gr&#xfc;nenthal Agreements under our agreements with PDL, and, if we breach those representations or covenants, we may become subject to indemnification claims by SWK (assignee of PDL) and liable to SWK for its indemnifiable losses relating to such breaches. The amount of such losses could be material and could have a material adverse impact on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will be substantially dependent on Aguettant to successfully commercialize DZUVEO in Europe. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In June 2018, the EC granted marketing approval for DZUVEO and in July 2021 we entered into the DZUVEO Agreement with Aguettant to commercialize DZUVEO in Europe. We will be substantially dependent on Aguettant to successfully commercialize DZUVEO in Europe. Any failures in the commercialization of DZUVEO in Europe could have a significant adverse impact on our revenues and operating results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DZUVEO Agreement requires us to support the manufacturing and supply of DZUVEO for Aguettant. In addition, we anticipate we may need comparator studies in Europe to ensure premium reimbursement in certain countries. Our inability to profitably manufacture and supply DZUVEO to Aguettant, or to successfully complete these additional comparator studies and obtain premium reimbursement in certain countries, may prevent, limit or delay commercialization and any associated future revenues from DZUVEO in Europe.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have limited experience commercializing DSUVIA, which may make it difficult to predict our future performance or evaluate our business and prospects. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Since inception, our operations have been primarily focused on developing our technology and undertaking pharmaceutical development and clinical trials for DSUVIA and Zalviso, understanding the market potential for DSUVIA and Zalviso, and preparing for the commercialization of DSUVIA and the potential commercialization of Zalviso in the United States. We launched commercialization efforts for DSUVIA in February 2019. As a result of our limited commercialization experience, any predictions that are made about our future performance, or viability, or evaluation of our business and prospects, may not be accurate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We will require additional capital and may be unable to raise capital, which would force us to delay, reduce or eliminate our commercialization efforts and product development programs and could cause us to cease operations. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Launch of a commercial pharmaceutical product and pharmaceutical development activities can be time consuming and costly. We expect to incur significant expenditures in connection with supporting our ongoing commercialization activities for DSUVIA, manufacturing and supply activities for DZUVEO, and research and development activities for our product candidates, including the FDA regulatory review of the Zalviso NDA, once resubmitted. While we believe we have sufficient capital resources to continue planned operations for at least the next twelve months, we will need additional capital to pursue full commercialization of DSUVIA and our product candidates, if approved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Clinical trials, regulatory reviews, and the launch of commercial product are expensive activities. In addition, commercialization costs for DSUVIA and our product candidates, if approved, in the United States may be significantly higher than estimated as a result of technical difficulties or otherwise. Revenues may be lower than expected and costs to produce such revenues may exceed those revenues. We will need to seek additional capital to continue operations. Such capital demands could be substantial. In the future, we may seek to sell additional equity securities, including under the Sales Agreement with Cantor, and debt securities, monetize or securitize certain assets including future royalty streams and milestones, refinance our loan agreement, obtain a revolving credit facility, enter into product development, license or distribution agreements with third parties, or divest DSUVIA, DZUVEO, Zalviso in Europe, or any of our product candidates. Such arrangements may not be available on favorable terms, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Future events and circumstances, including those beyond our control, may cause us to consume capital more rapidly than we currently anticipate. Furthermore, any product development, licensing, distribution or sale agreements that we enter into may require us to relinquish valuable rights. We may not be able to obtain sufficient additional funding or enter into a strategic transaction in a timely manner. If adequate funds are not available, we would be required to reduce our workforce, reduce the scope of, or cease, the commercial launch of DSUVIA, or the development of our product candidates in advance of the date on which we exhaust our cash resources to ensure that we have sufficient capital to meet our obligations and continue on a path designed to preserve stockholder value.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securing additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to commercialize DSUVIA or develop our product candidates. In addition, we cannot guarantee that future financing will be available in sufficient amounts or on terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">significantly scale back or discontinue the commercialization of DSUVIA, or the development of our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">seek additional corporate partners for Zalviso on terms that might be less favorable than might otherwise be available;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">seek corporate partners for DSUVIA/DZUVEO on terms that might be less favorable than might otherwise be available; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">relinquish, or license on unfavorable terms, our rights to technologies, products or product candidates that we otherwise would seek to develop or commercialize ourselves.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>To fund our operations, we may sell additional equity securities, which may result in dilution to our stockholders, or debt securities, which may impose restrictions on our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We expect that significant additional capital will be needed in the future to continue our planned operations. In order to raise additional funds to support our operations, we may sell additional equity securities, including under the Controlled Equity Offering<sup style="vertical-align:top;line-height:120%;font-size:pt">SM </sup>Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald &amp; Co., or Cantor, as agent. We may sell common stock, convertible securities, or other equity securities in one or more transactions at prices and in a manner we determine from time to time. Selling additional equity securities may result in dilution to our existing stockholders and new investors may be materially diluted by subsequent sales. Incurring additional indebtedness, including through the sale of debt securities, would result in increased fixed payment obligations and could also result in additional restrictive covenants, such as limitations on our ability to incur additional debt, limitations on our ability to acquire, sell or license intellectual property rights and other operating restrictions, such as minimum cash balances, that could adversely impact our ability to conduct our business. Sales of equity or debt securities may also provide new investors with rights superior to our existing stockholders. If we are unable to expand our operations or otherwise capitalize on our business opportunities, our business, financial condition and results of operations could be materially adversely affected, and we may not be able to meet our debt service obligations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, worsening economic conditions and other adverse effects or developments relating to the ongoing COVID-19 pandemic may negatively affect the market price of our stock, regardless of our actual operating performance. The market price for our common stock is likely to continue to be volatile, particularly due to the ongoing COVID-19 pandemic, and subject to significant price and volume fluctuations in response to market, industry and other factors. If additional funding is not available on favorable terms, if at all, due to these factors, we may not be able to obtain sufficient additional funding to support our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The terms of our loan agreement with Oxford may restrict our current and future operations, particularly our ability to respond to changes in business or to take certain actions, including to pay dividends to our stockholders.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On May 30, 2019, we entered into the Loan Agreement with Oxford Finance LLC, or Oxford, a Delaware limited liability company, as the Lender. The Loan Agreement contains, and any future indebtedness we incur will likely contain, a number of restrictive covenants that impose operating restrictions, including restrictions on our ability to engage in acts that may be in our best long-term interests. The Loan Agreement includes covenants that, among other things, restrict our ability to (i) declare dividends or redeem or repurchase equity interests; (ii) incur additional liens; (iii) make loans and investments; (iv) incur additional indebtedness; (v) engage in mergers, acquisitions, and asset sales; (vi) transact with affiliates; (vii) undergo a change in control; (viii) add or change business locations; and (ix) engage in businesses that are not related to our existing business. The Loan Agreement also requires that we at all times maintain unrestricted cash of not less than $5.0 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A breach of any of these covenants could result in an event of default under the Loan Agreement. Upon the occurrence of such an event of default, a default interest rate of an additional 5% may be applied to the outstanding loan balances and all outstanding obligations under the Loan Agreement can be declared to be immediately due and payable If our indebtedness is accelerated, we cannot assure you that we will have sufficient assets to repay the indebtedness. The restrictions and covenants in the Loan Agreement and any future financing agreements may adversely affect our ability to finance future operations or capital needs or to engage in other business activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We might be unable to service our existing debt due to a lack of cash flow and might be subject to default. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As of December 31, 2021, we had approximately $13.3 million of outstanding debt under the Loan Agreement. The Loan Agreement has a scheduled maturity date of June 1, 2023 and is secured by a first priority security interest in substantially all of our assets, with the exception of our intellectual property and those assets sold under the Royalty Monetization, where the security interest is limited to proceeds of intellectual property if it is licensed or sold.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we do not make the required payments when due, either at maturity, or at applicable installment payment dates, or if we breach the agreement or become insolvent, the Lender could elect to declare all amounts outstanding, together with accrued and unpaid interest, and other payments, to be immediately due and payable. Additional capital may not be available on terms acceptable to us, or at all. Even if we were able to repay the full amount in cash, any such repayment could leave us with little or no working capital for our business. If we are unable to repay those amounts, the Lender will have a first claim on our assets pledged under the Loan Agreement. If the lender should attempt to foreclose on the collateral, it is unlikely that there would be any assets remaining after repayment in full of such secured indebtedness. Any default under the Loan Agreement and resulting foreclosure would have a material adverse effect on our financial condition and our ability to continue our operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Reliance on Third Parties </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely on third party manufacturers to produce commercial supplies of DSUVIA in the United States, commercial supplies of Zalviso in Europe, and clinical supplies of Zalviso in the United States, and will rely on third party manufacturers to produce DZUVEO for Aguettant and on Aguettant to produce commercial supplies of our product candidates, if approved, in the United States. The failure of third-party manufacturers to provide us with adequate commercial and clinical supplies could result in a material adverse effect on our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Third party manufacturers produce commercial and clinical supplies of our products and product candidates. Reliance on third party manufacturers entails many risks including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the inability to meet our product specifications and quality requirements consistently;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">the inability to procure raw materials in a timely fashion due to ongoing challenges in the global supply chain;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a delay or inability to procure or expand sufficient manufacturing capacity;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">manufacturing and product quality issues related to scale-up of manufacturing;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">costs and validation of new equipment and facilities required for scale-up;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a failure to maintain in good order our production and manufacturing equipment for our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a failure to comply with cGMP and similar foreign standards;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the inability to negotiate manufacturing or supply agreements with third parties under commercially reasonable terms;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">termination or nonrenewal of manufacturing or supply agreements with third parties in a manner or at a time that is costly or damaging to us;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the reliance on a limited number of sources, and in some cases, single sources for product components, such that if we are unable to secure a sufficient supply of these product components, we will be unable to manufacture and sell our products in a timely fashion, in sufficient quantities or under acceptable terms;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the lack of qualified backup suppliers for those components that are currently purchased from a sole or single source supplier;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">operations of our third-party manufacturers or suppliers could be disrupted by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier, or government orders related to the COVID-19 pandemic;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">carrier disruptions or increased costs that are beyond our control; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the failure to deliver our products under specified storage conditions and in a timely manner.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any of these events could lead to stock outs, inability to successfully commercialize our products, clinical trial delays, or failure to obtain regulatory approval. Some of these events could be the basis for FDA action, including injunction, recall, seizure, or total or partial suspension of production.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the DZUVEO Agreement requires us to manufacture and supply DZUVEO to Aguettant. As mentioned above, we were obligated to manufacture and supply Zalviso under the Gr&#xfc;nenthal Agreements for use in Europe and their other licensed territories and will likely be required to do so under any New Arrangement. If we are unable to establish a reliable commercial supply of DZUVEO for Aguettant, and, if a New Arrangement is entered into, Zalviso for Europe, we may be unable to satisfy our obligations under the DZUVEO Agreement or any New Arrangement in a timely manner or at all, and we may, as a result, be in breach of such agreements. If any such breach, or other breach, were to be material and remain uncured, it could result in termination of the agreement, which in turn could, in the case of a New Arrangement, result in us being responsible for indemnification of losses suffered by SWK under the Royalty Monetization. If any of these events were to occur, our business would be materially adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely on limited sources of supply for the active pharmaceutical ingredient, or API, of DSUVIA and Zalviso and any disruption in the chain of supply may cause a delay in supplying DSUVIA and Zalviso. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Currently we only have one supplier qualified as a vendor for the manufacture of DSUVIA, known as DZUVEO in Europe, and Zalviso with the FDA and EMA, respectively. If supply from the approved vendor is interrupted, there could be a significant disruption in commercial supply. Any alternate vendor would need to be qualified through an NDA supplement and/or an MAA variation which could result in delays. The FDA or other regulatory agencies outside of the United States may also require additional trials if a new sufentanil supplier is relied upon for commercial production.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Manufacture of sufentanil sublingual tablets requires specialized equipment and expertise. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ethanol, which is used in the manufacturing process for our sufentanil sublingual tablets, is flammable, and sufentanil is a highly potent, Schedule II controlled substance. These factors necessitate the use of specialized equipment and facilities for manufacture of sufentanil sublingual tablets. There are a limited number of facilities that can accommodate our manufacturing process and we or our partners need to use dedicated equipment throughout development and commercial manufacturing to avoid the possibility of cross-contamination. If our or our partners&#x2019; equipment breaks down or needs to be repaired or replaced, it may cause significant disruption in clinical or commercial supply, which could result in delay in the process of obtaining approval for or sale of our products. Furthermore, we are using one manufacturer to produce our sufentanil sublingual tablets. Any problems with our or our partners&#x2019; facilities or equipment may impair our ability to successfully commercialize DSUVIA or Zalviso, if approved, and to complete our clinical trials, and increase our cost.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Manufacturing issues may arise that could delay or increase costs related to commercialization, product development and regulatory approval. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have relied, and will continue to rely, on contract manufacturers, component fabricators and third-party service providers to produce the necessary DSUVIA single-dose applicator, or SDA, and Zalviso devices for the commercial marketplace. We currently outsource manufacturing and packaging of the DSUVIA SDA and the controller, dispenser and cartridge components of the Zalviso device to third parties and intend to continue to do so. Some of these component purchases were made and will continue to be made utilizing short-term purchase agreements and we may not be able to enter into long-term agreements for commercial supply of DSUVIA, DZUVEO or Zalviso devices with each of the third-party manufacturers or may be unable to do so on acceptable terms. In addition, we have encountered and may continue to encounter production issues with our current or future contract manufacturers and other third party service providers, including the reliability of the production equipment, quality of the components produced, their inability to meet demand or other unanticipated delays including scale-up and automating processes, which could adversely impact our ability to supply our customers with DSUVIA, Zalviso and DZUVEO in Europe, and, if approved, Zalviso in the U.S. and any other foreign territories.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As we scale up manufacturing of DSUVIA and Zalviso, if approved, and conduct required production and stability testing, these processes may require refinement or resolution. For example, as we scale up, we may identify significant issues which could result in failure to maintain regulatory approval of DSUVIA, increased scrutiny by regulatory agencies, delays in clinical program and regulatory approval, increases in our operating expenses, or failure to obtain approval for our product candidates in the United States.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have built out a suite within our CMO&#x2019;s production facility in Cincinnati, Ohio that serves as a manufacturing facility for clinical and commercial supplies of sufentanil sublingual tablets. Late-stage development and manufacture of registration stability lots, which were utilized in clinical trials, were manufactured at this location. While we produced a number of commercial lots to support Gr&#xfc;nenthal&#x2019;s launch in Europe, our experience is limited, which impacted our ability to deliver commercial supplies to Gr&#xfc;nenthal on a timely basis, and may in the future impact our ability to deliver commercial supplies under any New Arrangement, if required, on a timely basis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In January 2013, we entered into an agreement with a CMO to manufacture, supply, and provide certain validation and stability services with respect to Zalviso for potential sales in the United States, Canada, Mexico and other countries, subject to agreement by the parties to any additional fees for such other countries. On August 22, 2017, we entered into an amendment to this agreement to manufacture, supply, and provide certain validation and stability services with respect to DSUVIA for sales in the United States, and potential sales in Canada and Mexico, and other countries. There is no guarantee that our CMO&#x2019;s services will be satisfactory or that they will continue to meet the strict regulatory guidelines of the FDA or other foreign regulatory agencies. If our CMO cannot provide us with an adequate supply of sufentanil sublingual tablets, we may be required to pursue alternative sources of manufacturing capacity. Switching or adding commercial manufacturing capability can involve substantial cost and require extensive management time and focus, as well as additional regulatory filings which may result in significant delays. In addition, there is a natural transition period when a new manufacturing facility commences work. As a result, delays may occur, which can materially impact our ability to meet our desired commercial timelines, thereby increasing our costs and reducing our ability to generate revenue.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The facilities of any of our future manufacturers of sufentanil-containing sublingual tablets must be approved by the FDA or the relevant foreign regulatory agency, such as the EMA, before commercial distribution from such manufacturers occurs. We do not fully control the manufacturing process of sufentanil sublingual tablets and are completely dependent on these third-party manufacturing partners for compliance with the FDA or other foreign regulatory agency&#x2019;s requirements for manufacture. In addition, although our third-party manufacturers are well-established commercial manufacturers, we are dependent on their continued adherence to cGMP manufacturing and acceptable changes to their process. If our manufacturers do not meet the FDA or other foreign regulatory agency&#x2019;s strict regulatory requirements, they will not be able to secure FDA or other foreign regulatory agency approval for their manufacturing facilities. Although European inspectors have approved our tablet manufacturing site, our third-party manufacturing partner is responsible for maintaining compliance with the relevant foreign regulatory agency&#x2019;s requirements. If the FDA or the relevant foreign regulatory agency does not approve these facilities for the commercial manufacture of sufentanil sublingual tablets, we will need to find alternative suppliers, which would result in significant delays in obtaining FDA approval for Zalviso, and other foreign regulatory agency approval of DSUVIA/DZUVEO and Zalviso outside Europe. These challenges may have a material adverse impact on our business, results of operations, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We may not be able to establish additional sources of supply for sufentanil-containing sublingual tablets or device manufacture. Such suppliers are subject to FDA and other foreign regulatory agency&#x2019;s regulations requiring that materials be produced under cGMPs or Quality System Regulations, or QSR, or in ISO 13485 accredited facilities, and subject to ongoing inspections by regulatory agencies. Failure by any of our suppliers to comply with applicable regulations may result in delays and interruptions to our product supply while we seek to secure another supplier that meets all regulatory requirements. In addition, if we are unable to establish a reliable commercial supply of Zalviso for Europe, we may be unable to satisfy our obligations under any New Arrangement, if required, in a timely manner or at all, and we may, as a result, be in breach of any New Arrangement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">For DSUVIA, we currently package the finished goods under a manual process and would package DZUVEO in the same manner. The capacity and cost to package the goods under this manual process are not optimal to support successful future sales of DSUVIA and DZUVEO. We have purchased and installed an automated filling and packaging line to support increased capacity packaging for DSUVIA and DZUVEO. We have experienced delays to final implementation of our automated line due to the impact of COVID-19, in addition to testing requirements of our vendor. While we have now completed the acquisition and installation of this line; there can be no assurance that we will be able to successfully complete the qualification and validation of this line and obtain the necessary regulatory approvals to manufacture commercial product on this line. Due to the recent strains on the global supply chain, the lead time for many components used in our production are getting longer and may impact our ability to manufacture our products in a timely manner.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We rely on third parties to conduct, supervise and monitor our clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We utilized contract research organizations, or CROs, for the conduct of the Phase 2 and 3 clinical trials of DSUVIA, as well as our Phase 3 clinical program for Zalviso. We rely on CROs, as well as clinical trial sites, to ensure the proper and timely conduct of our clinical trials and document preparation. While we have agreements governing their activities, we have limited influence over their actual performance. We have relied and plan to continue to rely upon CROs to monitor and manage data for our post-approval clinical programs for DSUVIA and any FDA-required clinical programs for our product candidates, as well as the execution of nonclinical and clinical trials. We control only certain aspects of our CROs&#x2019; activities. Nevertheless, we are responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards and our reliance on the CROs does not relieve us of our regulatory responsibilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We, and our CROs, are required to comply with the FDA&#x2019;s current good clinical practices, or cGCPs, which are regulations and guidelines enforced by the FDA for all product candidates in clinical development. The FDA enforces these cGCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA may require us to perform additional clinical trials before approving our marketing applications. Upon inspection, the FDA may determine that our clinical trials do not comply with cGCPs. Accordingly, if our CROs or clinical trial sites fail to comply with these regulations, we may be required to repeat clinical trials, which would delay the regulatory process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our CROs are not our employees, and we cannot control whether or not they devote sufficient time and resources to our ongoing clinical and nonclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may allow our potential competitors to access our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements, or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for Zalviso, if approved, would be harmed, our costs could increase, and our ability to generate revenues could be delayed.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Business Operations and Industry </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Failure to receive required quotas of controlled substances or comply with the Drug Enforcement Agency regulations, or the cost of compliance with these regulations, may adversely affect our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our sufentanil-based products are subject to extensive regulation by the DEA, due to their status as scheduled drugs. Sufentanil is classified as a Schedule II controlled substance, considered to present a high risk of abuse. The manufacture, shipment, storage, sale and use of controlled substances are subject to a high degree of regulation, including security, record-keeping and reporting obligations enforced by the DEA and also by comparable state agencies. In addition, our contract manufacturers are required to maintain relevant licenses and registrations. This high degree of regulation can result in significant compliance costs, which may have an adverse effect on the commercialization of DSUVIA and the development and commercialization of Zalviso, if approved.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DEA limits the availability and production of all Schedule II controlled substances, including sufentanil, through a quota system. The DEA requires substantial evidence and documentation of expected legitimate medical and scientific needs before assigning quotas to manufacturers. Our contract manufacturers apply for quotas on our behalf. We will need significantly greater amounts of sufentanil to successfully commercialize DSUVIA, to support European commercialization of DZUVEO and Zalviso, and to commercialize Zalviso, if approved in the United States. Any delay by the DEA in establishing the procurement quota, reduction in our quota for sufentanil, failure to increase our quota over time to meet anticipated increases in demand, or refusal by the DEA to establish the procurement quota could delay or stop the commercial sale of our approved products or the clinical development of Zalviso in the United States. This, in turn, could have a material adverse effect on our business, results of operations, financial condition and prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our relationships with clinical investigators, health care professionals, consultants, commercial partners, third-party payers, hospitals, and other customers are subject to applicable anti-kickback, fraud and abuse and other healthcare laws, which could expose us to significant penalties. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Healthcare providers, including physicians, and others play a primary role in the recommendation and prescribing of any products for which we may obtain marketing approval. Our business operations and arrangements with investigators, healthcare professionals, consultants, commercial partners, hospitals, third-party payers and customers may expose us to broadly applicable fraud and abuse and other healthcare laws. These laws may constrain the business or financial arrangements and relationships through which we research, market, sell and distribute the products for which we obtain marketing approval. Applicable federal and state healthcare laws include, but are not limited to, the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the federal healthcare Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under federal healthcare programs such as Medicare and Medicaid;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the federal civil and criminal false claims laws, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, to the federal government, claims for payment or approval that are false or fraudulent or from knowingly making a false statement to improperly avoid, decrease or conceal an obligation to pay money to the federal government;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which, among other things, imposes criminal liability for knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or to obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payer (e.g., public or private) and knowingly or willfully falsifying, concealing, or covering up by any trick or device a material fact or making any materially false statement in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose certain obligations, including mandatory contractual terms, on covered healthcare providers, health plans and clearinghouses, and their respective business associates that perform services for them that involve the use, or disclosure of, individually identifiable health information, as well as their covered subcontractors with respect to safeguarding the privacy, security and transmission of individually identifiable health information;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">foreign laws, regulations, standards and regulatory guidance which govern the collection, use, disclosure, retention, security and transfer of personal data, including the European Union General Data Privacy Regulation, or GDPR, which introduces strict requirements for processing personal data of individuals within the European Union;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the federal transparency law, enacted as part of the Affordable Care Act, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologicals and medical supplies to report annually to the CMS information related to payments and other transfers of value provided to physicians, (defined to include, doctors, dentists, optometrists, podiatrists and chiropractors), other healthcare professionals (such as physician assistants and nurse practitioners), and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">analogous state laws that may apply to our business practices, including but not limited to, state laws that require pharmaceutical companies to implement compliance programs and/or comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines; state laws that impose restrictions on pharmaceutical companies&#x2019; marketing practices and require manufacturers to track and file reports relating to pricing and marketing information, which requires tracking and reporting gifts, compensation and other remuneration and items of value provided to healthcare professionals and entities, state and local laws that require the registration of pharmaceutical sales representatives, and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways, with differing effects; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the federal Foreign Corrupt Practices Act of 1977, United Kingdom Bribery Act 2010 and other similar anti-bribery laws in other jurisdictions which generally prohibit companies and their intermediaries from providing money or anything of value to officials of foreign governments, foreign political parties, or international organizations with the intent to obtain or retain business or seek a business advantage.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Recently, there has been a substantial increase in anti-bribery law enforcement activity by U.S. regulators, with more frequent and aggressive investigations and enforcement proceedings by both the Department of Justice and the SEC. A determination that our operations or activities are not, or were not, in compliance with United States or foreign laws or regulations could result in the imposition of substantial fines, interruptions of business, loss of supplier, vendor or other third-party relationships, termination of necessary licenses and permits, and other legal or equitable sanctions. Other internal or government investigations or legal or regulatory proceedings, including lawsuits brought by private litigants, may also follow as a consequence.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws. If our operations are found to be in violation of any of these or any other healthcare regulatory laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, contractual damages, reputational harm, increased losses and diminished profits, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations any of which could adversely affect our ability to operate our business and our financial results. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses or divert our management&#x2019;s attention from the operation of our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>In order to supply the Zalviso device to any future collaborator for commercial sales in Europe, we must maintain conformity of our quality system to applicable ISO standards and must comply with applicable European laws and directives.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We underwent a Conformit&#xe9; Europ&#xe9;enne approval process for the Zalviso device, more commonly known as a CE Mark approval process. We received CE Mark approval in December 2014, which permits the commercial sale of the Zalviso device in Europe. In connection with the CE Mark approval, we were also granted International Standards Organization, or ISO, 13485:2003 certification of our quality management system in November 2014. This is an internationally recognized quality standard for medical devices. The CE Mark was originally issued by the British Standards Institution, or BSI, a Notified Body, or NB, located in the United Kingdom, or U.K., or BSI-U.K. The CE Mark file and certification has been transferred to the Netherlands NB of BSI, or BSI-NL, to mitigate the uncertainty with regards to Brexit. The ISO certification issued through BSI-U.K. was recently upgraded to the latest version of the standard, ISO 13485:2016 through BSI-U.K. and remains in effect. BSI ISO 13485:2016 certification recognizes that consistent quality policies and procedures are in place for the development, design and manufacturing of medical devices. The certification indicates that we have successfully implemented a quality system that conforms to ISO 13485 standards for medical devices. Certification to this standard is one of the key regulatory requirements for a CE Mark in the EU and European Economic Area (which includes the 27 EU member states as well as Norway, Iceland and Liechtenstein), or EEA, as well as to meet equivalent requirements in other international markets. The certification applies to the Hayward, California location which designs, manufactures and distributes finished medical devices, and includes critical suppliers. If we fail to remain in compliance with applicable European laws and directives, we would be unable to continue to affix the CE Mark to our Zalviso device, which would prevent any future collaboration partner from selling these devices within the EU and EEA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       52
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Significant disruptions of our information technology systems or data security incidents could result in significant financial, legal, regulatory, business and reputational harm to us. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, store, process and transmit large amounts of sensitive information, including intellectual property, proprietary business information, personal information and other confidential information. It is critical that we do so in a secure manner to maintain the confidentiality, integrity and availability of such sensitive information. We have also outsourced elements of our operations (including elements of our information technology infrastructure) to third parties, and as a result, we manage a number of third-party vendors who may or could have access to our computer networks or our confidential information. In addition, many of those third parties in turn subcontract or outsource some of their responsibilities to third parties. While all information technology operations are inherently vulnerable to inadvertent or intentional security breaches, incidents, attacks and exposures, the accessibility and distributed nature of our information technology systems, and the sensitive information stored on those systems, make such systems potentially vulnerable to unintentional or malicious internal and external attacks on our technology environment. Potential vulnerabilities can be exploited from inadvertent or intentional actions of our employees, third-party vendors, business partners, or by malicious third parties. Attacks of this nature are increasing in their frequency, levels of persistence, sophistication and intensity, and are being conducted by sophisticated and organized groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#x201c;hacktivists,&#x201d; nation states and others. In addition to the extraction of sensitive information, such attacks could include the deployment of harmful malware, ransomware, denial-of-service attacks, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. In addition, the prevalent use of mobile devices increases the risk of data security incidents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant disruptions of our third-party vendors&#x2019; and/or business partners&#x2019; information technology systems or other similar data security incidents could adversely affect our business operations and result in the loss, misappropriation, and/or unauthorized access, use or disclosure of, or the prevention of access to, sensitive information, which could result in financial, legal, regulatory, business and reputational harm to us. In addition, information technology system disruptions, whether from attacks on our technology environment or from computer viruses, natural disasters, terrorism, war and telecommunication and electrical failures, could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There is no way of knowing with certainty whether we have experienced any data security incidents that have not been discovered. While we have no reason to believe this to be the case, attackers have become very sophisticated in the way they conceal access to systems, and many companies that have been attacked are not aware that they have been attacked. Any event that leads to unauthorized access, use or disclosure of personal information, including but not limited to personal information regarding our patients or employees, could disrupt our business, harm our reputation, compel us to comply with applicable federal and state breach notification laws and foreign law equivalents, subject us to time consuming, distracting and expensive litigation, regulatory investigation and oversight, mandatory corrective action, require us to verify the correctness of database contents, or otherwise subject us to liability under laws, regulations and contractual obligations, including those that protect the privacy and security of personal information. This could result in increased costs to us, and result in significant legal and financial exposure and/or reputational harm. In addition, any failure or perceived failure by us or our vendors or business partners to comply with our privacy, confidentiality or data security-related legal or other obligations to third parties, or any further security incidents&#xa0;or other inappropriate access events that result in the unauthorized access, release or transfer of sensitive information, which could include personally identifiable information, may result in governmental investigations, enforcement actions, regulatory fines, litigation, or public statements against us by advocacy groups or others, and could cause third parties, including clinical sites, regulators or current and potential partners, to lose trust in us or we could be subject to claims by third parties that we have breached our privacy- or confidentiality-related obligations, which could materially and adversely affect our business and prospects. Moreover, data security incidents and other inappropriate access can be difficult to detect, and any delay in identifying them may lead to increased harm of the type described above. While we have implemented security measures intended to protect our information technology systems and infrastructure, there can be no assurance that such measures will successfully prevent service interruptions or security incidents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       53
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Business interruptions could delay our operations and sales efforts. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our headquarters is located in the San Francisco Bay Area, near known earthquake fault zones and is vulnerable to significant damage from earthquakes. Our contract manufacturers, suppliers, clinical trial sites and local and national transportation vendors are all subject to business interruptions due to weather, outbreaks of pandemic diseases, natural disasters, or man-made incidents. We are also vulnerable to other types of natural disasters and other events that could disrupt our operations. If any of these events occurred and prevented us or third parties on which we rely from using all or a significant portion of our or their facilities, it may be difficult or, in certain cases, impossible for us to continue our business and operations for a substantial period of time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We do not carry insurance for earthquakes or other natural disasters, and we may not carry sufficient business interruption insurance to compensate us for losses that may occur. Any losses or damages we incur could have a material adverse effect on our business operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our future success depends on our ability to retain key executives and to attract, retain and motivate qualified personnel. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are highly dependent on principal members of our executive team, the loss of whose services may adversely impact the achievement of our objectives. While we have entered into offer letters with each of our executive officers, any of them could leave our employment at any time, as all of our employees are &#x201c;at will&#x201d; employees. Recruiting and retaining qualified scientific, manufacturing, and commercial personnel will also be critical to our success. We may not be able to attract and retain these personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. There is currently a shortage of skilled executives in our industry, which is likely to continue. As a result, competition for skilled personnel is intense and the turnover rate can be high. In addition, failure to succeed in clinical trials, or delays in the regulatory approval process, may make it more challenging to recruit and retain qualified personnel. The inability to recruit or loss of the services of any executive or key employee might impede the progress of our research, development and commercialization objectives.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may fail to realize the benefits expected from our acquisition of Lowell, which could adversely affect our stock price.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our acquisition of Lowell is our largest acquisition to date. The anticipated benefits we expect from this acquisition are, necessarily, based on projections and assumptions about the combined businesses of our company and Lowell, which may not materialize as expected or which may prove to be inaccurate. The value of our common stock could be adversely affected if we are unable to realize the anticipated benefits from the acquisition on a timely basis or at all. Achieving the benefits of the acquisition of Lowell will depend, in part, on our ability to integrate the business, operations and products of Lowell successfully and efficiently with our business. The challenges involved in this integration include, but are not limited to, (i) difficulties entering new markets and integrating new product candidates with which we have no or limited direct prior experience; and (ii) successfully managing relationships with our combined supplier base.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The financial results of the combined company may be adversely affected by cash expenses and non-cash accounting charges incurred in connection with our integration of the business and operations of Lowell. The amount and timing of these possible charges are not yet known. Further, our failure to identify or accurately assess the magnitude of certain liabilities we assumed in the acquisition could result in unexpected litigation or regulatory exposure, unfavorable accounting charges, unexpected increases in taxes due, a loss of anticipated tax benefits or other adverse effects on our business, operating results or financial condition. The price of our common stock could decline to the extent the combined company&#x2019;s financial results are materially affected by any of these events.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may acquire companies, product candidates or products or engage in strategic transactions, which could divert our management</i></b>&#x2019;<b><i>s attention and cause us to incur various costs and expenses. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We may acquire or invest in companies, product candidates or products that we believe could complement or expand our business or otherwise offer growth opportunities. The pursuit of potential acquisitions or investments may divert the attention of management and has caused, and in the future may cause, us to incur various costs and expenses in identifying, investigating, and pursuing them, whether or not they are consummated. We may not be able to identify desirable acquisitions or investments or be successful in completing or realizing anticipated benefits from such transactions. In addition, the acquisition of product candidates and products is a highly competitive area, and many other companies are pursuing the same or similar product candidates to those that we may consider attractive. Larger companies with more well-established and diverse revenue streams may have a competitive advantage over us due to their size, financial resources and more extensive clinical development and commercialization capabilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, we receive inquiries relating to potential strategic transactions, including collaborations, licenses, and acquisitions. Such potential transactions may divert the attention of management and may cause us to incur various costs and expenses in investigating and evaluating such transactions, whether or not they are consummated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We face potential product liability claims, and, if such claims are successful, we may incur substantial liability. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Commercial sales of DSUVIA and Zalviso expose us to the risk of product liability claims. Product liability claims might be brought against us by patients, health care providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. In addition, regardless of merit or eventual outcome, product liability claims may result in:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">impairment of our business reputation;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">costs due to related litigation;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">distraction of management&#x2019;s attention from our primary business;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">substantial monetary awards to patients or other claimants;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the inability to commercialize our products; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">decreased demand for our products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our current product liability insurance coverage may not be sufficient to reimburse us for any expenses or losses we may suffer. In addition, our current product liability insurance contains an exclusion related to any claims related to our products from a governmental body, or payer, or those claims arising from a multi-plaintiff action for bodily injury or property damage. Multi-plaintiff claims caused by product defects are covered. This exclusion does not apply to any bodily injury claim related to our products made by an individual. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. A successful product liability claim, or series of claims, brought against us could cause our stock price to decline and, if judgments are excluded from our insurance coverage or exceed our insurance coverage, could adversely affect our results of operations and business. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our insurance coverage included the sale of Zalviso to our former commercial partner, Gr&#xfc;nenthal, and will likely include the sale of Zalviso by any future commercial partner. We intend to commercialize and promote DZUVEO in Europe with a strategic partner which may result in further expansion of our insurance coverage to include sales of DZUVEO in Europe. There can be no assurance that such coverage will be adequate to protect us against any future losses due to liability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our employees, independent contractors, principal investigators, consultants, commercial partners and vendors may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are exposed to the risk that our employees, independent contractors, investigators, consultants, commercial partners and vendors may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include intentional, reckless and/or negligent conduct that violates (1)&#xa0;regulations implemented by the FDA and similar foreign regulatory bodies; (2) laws requiring the reporting of true, complete and accurate information to such regulatory bodies; (3)&#xa0;healthcare fraud and abuse laws of the United States and similar foreign fraudulent misconduct laws; and (4)&#xa0;laws requiring the reporting of financial information or data accurately. The promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry are subject to extensive laws designed to prevent misconduct, including fraud, kickbacks, self-dealing and other abusive practices. These laws may restrict or prohibit a wide range of pricing, discounting, marketing, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials. It is not always possible to identify and deter employee and other third-party misconduct. The precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws. If any such actions are instituted against us, and we are not successful in defending ourselves, those actions could have a significant impact on our business, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, imprisonment, additional oversight and reporting obligations if we become subject to a corporate integrity agreement or similar agreements to resolve allegations of non-compliance with these laws, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Our Intellectual Property </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>If we cannot defend our issued patents from third party claims or if our pending patent applications fail to issue, our business could be adversely affected. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">To protect our proprietary technology, we rely on patents as well as other intellectual property protections including trade secrets, nondisclosure agreements, and confidentiality provisions.&#xa0;As of December 31, 2021, we are the owner of record of 93 issued patents worldwide drawn to AcelRx&#x2019;s sufentanil sublingual tablets, medication delivery devices and other platform technologies. These issued patents include 18 patents that we have listed in the FDA&#x2019;s Orange Book for DSUVIA, some of which have expiration dates that extend into 2031. These issued patents also include a European patent drawn to the DZUVEO device that has an expiration date that extends into 2036.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Because sufentanil is not a new chemical entity, potential regulatory (data) exclusivity periods for new formulation, dosage form and/or dosage strength sufentanil products in the United States is limited to three years under the Hatch-Waxman Act. While the FDA was not able to approve a 505(b)(2) NDA or an abbreviated new drug application, or ANDA, using DSUVIA as its reference listed drug prior to November 2, 2021, we may now be subject to a third party&#x2019;s Paragraph IV or other patent certification based on the patents we have listed in the FDA&#x2019;s Orange Book for DSUVIA and engage in litigation against such a 505(b)(2) or ANDA applicant at any time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, we are pursuing a number of U.S. patent applications and foreign national applications directed to DSUVIA, Zalviso, Niyad, and LTX-608. The patent applications that we have filed and have not yet been granted may fail to result in issued patents in the United States or in foreign countries. Even if the patents do successfully issue, third parties may challenge the patents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As we continue to develop our product candidates ephedrine, phenylephrine, Niyad and LTX-608, we expect to pursue 505(b)(2) NDA application pathways since all of the base pharmacological agents are not new chemical entities. As a result of this filing avenue, we will need to include patent certifications regarding the reference listed drugs that our applications are based upon. These patent certifications could trigger patent litigation by the patent holders that we have certified against.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our commercial success will depend in part on successfully defending our current patents against third party challenges and expanding our existing patent portfolio to provide additional layers of patent protection, as well as extending patent protection.&#xa0;There can be no assurance that we will be successful in defending our existing and future patents against third party challenges, or that our pending patent applications will result in additional issued patents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The patent positions of pharmaceutical companies, including ours, can be highly uncertain and involve complex and evolving legal and factual questions. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States. Legal developments may preclude or limit the scope of available patent protection.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">There is also no assurance that any patents issued to us will not become the subject of adversarial or post-issuance proceedings such as opposition, <i>inter partes</i> review, post-grant review, <i>ex parte</i> re-examination or other post-issuance proceedings. In addition, there is no assurance that the relevant patent office court or agency in such adversarial proceedings would not make unfavorable decisions, such as reducing the scope of a patent of ours, invalidating issued claims or determining that a patent of ours is invalid or unenforceable. There is also no assurance that any patents issued to us will provide us with competitive advantages, will not be challenged by any third parties, or that the patents of others will not prevent the commercialization of products incorporating our technology. Furthermore, there can be no guarantee that others will not independently develop similar products, duplicate any of our products, or design around our patents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Litigation involving patents, patent applications and other proprietary rights is expensive and time consuming. If we are involved in such litigation, it could cause delays in bringing our products to market and interfere with our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our commercial success depends in part on our not infringing patents or trademarks, or misappropriating other third-party intellectual property. Although we are not currently aware of litigation or other proceedings or third-party claims of intellectual property infringement related to DSUVIA or Zalviso, the pharmaceutical industry is especially prone to extensive litigation proceedings between competitors regarding their patents and other intellectual property rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As we enter our target markets, it is possible that competitors or other third parties will claim that our products and/or processes infringe or misappropriate their intellectual property rights. These third parties may have obtained and may in the future obtain patents covering products or processes that are similar to our products, or may include composition or method claims that encompass our technology, allowing them to assert that our continued use of our own technologies infringes such newly emerging patent rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event that a patent infringement claim is asserted against us, we may counter, as an affirmative defense, that we do not infringe the relevant patent claims, that the patent is invalid or otherwise unenforceable or any combination thereof. The strength of our defenses will depend on the patents asserted, the interpretation of those patents, and our ability to establish the invalidity of the asserted patents. However, we could be unsuccessful in advancing non-infringement, invalidity or unenforceability arguments in our defense. In the United States, issued patents enjoy a presumption of validity, and the party challenging the validity of a patent claim must present clear and convincing evidence of invalidity, which is a high burden of proof. Conversely, the patent owner need only prove infringement by a preponderance of the evidence, which is a lower burden of proof.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If a court in a final and non-appealable decision were to hold that we have infringed someone else&#x2019;s valid patent claim, we could be prevented from using that third-party patented technology and may also be required to pay the owner of the patent for damages for past sales and need to seek license access to the patented technology for future sales. If we decide to pursue such a license to one or more of these patents, we may not be able to obtain a license on commercially reasonable terms, if at all, or the license we obtain may require us to pay substantial royalties or grant cross licenses to our patent rights. For example, if the relevant patent is owned by a competitor, that competitor may choose not to license patent rights to us. If we decide to develop alternative technology to avoid the third-party patent claims, we may not be able to do so in a timely or cost-effective manner, if at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, because patent applications remain unpublished for 18 months from their initial filing date and some applications may be afforded confidentiality during prosecution that can take years to issue, there may currently be pending applications that are unknown to us and that may later result in issued patents that could cover one or more of our products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">It is possible that we may in the future receive communications from competitors and other companies alleging that we may be infringing their patents, misappropriating their trade secrets or otherwise violating their intellectual property rights, where they may offer license access to such intellectual property or threaten litigation. In addition to patent infringement claims, third parties may assert copyright, trademark or other intellectual property rights against us. We may need to expend considerable resources to counter such claims and may not be successful in our defense. Our business may suffer if a finding of infringement or misappropriation is established.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>It is difficult and costly to protect our proprietary rights, and we may not be able to ensure their protection. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal and factual questions for which important legal principles remain unresolved. No consistent policy regarding the breadth of claims allowed in pharmaceutical patents has emerged to date in the United States. The pharmaceutical patent situation outside the United States is just as uncertain. Changes in either the patent laws or in interpretations of patent laws in the United States and other countries may diminish the value of our intellectual property estate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We cannot predict the breadth of claims that may be allowed or enforced in the patents that may issue from the applications that we currently have pending, or may in the future acquire or license from third parties. Claims could be brought regarding the validity of our patents by third parties. Further, if any patent right that we obtain is deemed invalid and/or unenforceable, it could impact our ability to commercialize or partner our technology.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Competitors or third parties may infringe our patents. We may decide it is necessary to assert patent infringement claims against such entities, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours is not valid or is unenforceable, or that the third party&#x2019;s technology does not in fact infringe upon our patents. An adverse determination of any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our related pending patent applications at risk of not issuing. Litigation may fail and, even if successful, may result in substantial costs and be a distraction to our management. We may not be able to prevent misappropriation of our intellectual property rights, particularly in countries outside the United States where national laws and court systems are less robust, making patent rights more difficult to enforce, and very expensive to pursue.&#xa0;Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential or sensitive information could be compromised by disclosure in the event of litigation. In addition, during the course of litigation there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">we were the first to make the inventions covered by each of our pending patent applications or issued patents;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our patent applications were filed before the inventions covered by each patent or patent application was published by a third-party;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">we were the first to file patent applications for these inventions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">others will not independently develop similar or alternative technologies or duplicate any of our technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">any patents issued to us or our collaborators will provide a basis for commercially viable products, will provide us with any competitive advantages or will not be challenged by third parties; or</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the patents of others will not have an adverse effect on our business.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">If we do not adequately protect our intellectual property rights, competitors may be able to use our technologies and erode or negate any competitive advantage we may have, which could materially harm our business, negatively affect our position in the marketplace, limit our ability to commercialize DSUVIA, DZUVEO and Zalviso in Europe or any of our ephedrine, phenylephrine, Niyad or LTX-608 product opportunities, if approved, and delay or render impossible our achievement of profitability.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may be unable to adequately prevent disclosure of trade secrets and other proprietary information. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We rely on trade secrets to protect our proprietary know-how and technological advances, especially where we do not believe patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. We rely in part on confidentiality agreements with our employees, consultants, outside scientific collaborators, sponsored researchers and other advisors to protect our trade secrets and other proprietary information. These agreements may not effectively prevent disclosure of confidential information and may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. In addition, others may independently discover our trade secrets and proprietary information without misappropriating our rights. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights. Failure to obtain or maintain trade secret protection could enable competitors to use our proprietary information to develop products that compete with our products or cause additional, material adverse effects upon our competitive business position.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and applications will be due to be paid to the United States Patent and Trademark Office and various foreign governmental patent agencies in several stages over the lifetime of the patents and/or applications. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have systems in place, including use of third-party vendors, to manage payment of periodic maintenance fees, renewal fees, annuity fees and various other patent and application fees. The United States Patent and Trademark Office, or the USPTO, and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. There are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. If this occurs, our competitors might be able to enter the market, which would have a material adverse effect on our business.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We may not be able to enforce our intellectual property rights throughout the world. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the United States. Many companies have encountered significant problems in protecting and defending intellectual property rights in certain foreign jurisdictions. The legal systems of some countries, particularly developing countries, do not favor the enforcement of patents and other intellectual property protection, especially those relating to life sciences. This could make it difficult for us to stop the infringement of our patents or the misappropriation of our other intellectual property rights. For example, many foreign countries have compulsory licensing laws under which a patent owner must grant licenses to third parties. In addition, many countries limit the enforceability of patents against third parties, including government agencies or government contractors. In these countries, patents may provide limited or no benefit.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate. Additionally, claims may be brought regarding the validity of our patents by third parties in the United States and foreign countries. In addition, changes in the law and legal decisions by courts in the United States and foreign countries may affect our ability to obtain adequate protection for our technology and the enforcement of our intellectual property rights.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We have not yet registered our trademarks in all our potential markets, and failure to secure those registrations could adversely affect our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have registered our ACELRX mark in the United States, Canada, the EU and India. In early 2014, the FDA accepted the Zalviso mark and, in November 2018, the FDA accepted the DSUVIA mark. Although we are not currently aware of any oppositions to or cancellations of our registered trademarks or pending applications, it is possible that one or more of the applications could be subject to opposition or cancellation after the marks are registered. The registrations will be subject to use and maintenance requirements. It is also possible that we have not yet registered all of our trademarks in all of our potential markets, such as securing the registration of DSUVIA in Canada, and that there are names or symbols other than &#x201c;ACELRX&#x201d; that may be protectable marks for which we have not sought registration, and failure to secure those registrations could adversely affect our business. Opposition or cancellation proceedings may be filed against our trademarks and our trademarks may not survive such proceedings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       58
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks Related to Ownership of Our Common Stock </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The market price of our common stock may be highly volatile. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The trading price of our common stock has experienced significant volatility and is likely to be volatile in the future. For example, the closing price of our common stock ranged between $0.49 and $2.77 during the year ended December 31, 2021, and between $0.76 and $2.07 during the year ended December 31, 2020. Our stock price could be subject to wide fluctuations in response to a variety of factors, including the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">failure to successfully commercialize DSUVIA in the United States or to successfully develop and commercialize our product candidates in the United States;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">inability to obtain additional funding needed to conduct our planned business operations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;">inability to satisfactorily comply with FDA regulations concerning the advertising and promotion of DSUVIA, including receiving a Close-out Letter resolving the concerns raised by FDA in the Warning Letter delivered to us on February 11, 2021;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the integration and performance of any assets or businesses we acquire;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">our inability to develop and commercialize products and product candidates that we in-license;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">uncertainties regarding the magnitude and duration of impacts we are experiencing due to COVID-19;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the perception of limited market sizes or pricing for our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">further delays in resubmitting the NDA for Zalviso, and any additional adverse developments or perceived adverse developments with respect to the FDA&#x2019;s review of the Zalviso NDA, upon resubmission;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">inability to enter into, or unfavorable terms associated with, a New Arrangement for the commercialization of Zalviso in Europe;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">safety issues;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">adverse results or delays in future clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">changes in laws or regulations applicable to our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">inability to obtain adequate product supply for our products, or the inability to do so at acceptable prices;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">adverse regulatory decisions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">changes in the structure of the healthcare payment systems;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">inability to maintain regulatory approvals for DZUVEO and Zalviso in the European Union, including ISO 13485 certification and CE Mark approval for Zalviso;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">introduction of new products, services or technologies by our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">failure to meet or exceed financial projections we provide to the public;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">failure to meet or exceed the estimates and projections of the investment community;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">decisions by our collaboration partners regarding market access, pricing, and commercialization efforts in countries where they have the right to commercialize our products;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">failure to maintain our existing collaborations or enter into new collaborations;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the perception of the pharmaceutical industry generally, and of opioid manufacturers more specifically, by the public, legislatures, regulators and the investment community;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">announcements of significant acquisitions, strategic partnerships, joint ventures, or other significant transactions, including disposition transactions, or capital commitments by us or our competitors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">disputes or other developments relating to employment matters, business development efforts, proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">additions or departures of key management or scientific personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">costs associated with potential governmental investigations, inquiries, regulatory actions or lawsuits that may be brought against us as a result of us being an opioid manufacturer;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       59
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">other types of significant lawsuits, including patent, stockholder, securities class action and derivative litigation;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">changes in the market valuations of similar companies;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">sales of our common stock by us or our stockholders in the future; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">trading volume of our common stock.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, the stock market in general, and The Nasdaq Global Market, or Nasdaq, in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our common stock may be</i></b>&#xa0;<b><i>delisted</i></b>&#xa0;<b><i>from The</i></b>&#xa0;<b><i>Nasdaq</i></b>&#xa0;<b><i>Global Market if we cannot regain compliance with Nasdaq</i></b>&#x2019;<b><i>s continued listing requirements.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In order to maintain our listing on Nasdaq, we are required to comply with the Nasdaq requirements, which includes maintaining a minimum bid price and a minimum public float. In particular, we are required to maintain a minimum bid price of $1.00 per share. On December 2, 2021, we received a notice from Nasdaq stating that we were not in compliance with Nasdaq Listing Rule 5450(a)(1) (the &#x201c;Minimum Bid Price Rule&#x201d;) because our common stock failed to maintain a minimum closing bid price of $1.00 for 30 consecutive business days. This notice had no immediate effect on the Nasdaq listing or trading of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have a compliance period for the Minimum Bid Price Rule of 180 calendar days, or until May 31, 2022, in which to regain compliance, pursuant to Nasdaq Marketplace Rule 5810(c)(3)(A). If, at any time before that date the bid price of our common stock closes at $1.00 per share or more for a minimum of 10 consecutive business days, Nasdaq will notify us that we have achieved compliance with the Rule.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we do not achieve compliance with the Minimum Bid Price Rule during the initial 180 calendar day period, we may be eligible for an additional 180 calendar day compliance period. To qualify, we would need to transfer the listing of our common stock to the Nasdaq Capital Market, provided that it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards of the Nasdaq Capital Market, with the exception of the Minimum Bid Price Rule. In addition, the Company would also be required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split. However, if it appears to Nasdaq that we will not be able to cure the deficiency, or if we do not meet the other listing standards, Nasdaq could provide notice that the common stock will become subject to delisting. In the event we receive notice that our common stock is being delisted, Nasdaq rules permit us to appeal any delisting determination by Nasdaq to a Hearings Panel (the &#x201c;Panel&#x201d;). We expect that our common stock would remain listed pending the Panel's decision. However, there can be no assurance that, if we do appeal the delisting determination by Nasdaq to the Panel, that such appeal would be successful, or that we will be able to regain compliance with the Minimum Bid Price Rule or maintain compliance with the other listing requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If we fail to effect a reverse stock split, thus regaining compliance with the Minimum Bid Price Rule, our common stock may be delisted. Delisting from the Nasdaq Global Market or any Nasdaq market could make trading our common stock more difficult for investors, potentially leading to declines in our share price and liquidity. In addition, without a Nasdaq market listing, stockholders may have a difficult time getting a quote for the sale or purchase of our common stock, the sale or purchase of our common stock would likely be made more difficult and the trading volume and liquidity of our common stock could decline. Delisting from Nasdaq could also result in negative publicity and could also make it more difficult for us to raise additional capital. The absence of such a listing may adversely affect the acceptance of our common stock as currency or the value accorded by other parties. Further, if we are delisted, we would also incur additional costs under state blue sky laws in connection with any sales of our securities. These requirements could severely limit the market liquidity of our common stock and the ability of our stockholders to sell our common stock in the secondary market. If our common stock is delisted by Nasdaq, our common stock may be eligible to trade on an over-the-counter quotation system, such as the OTCQB market, where an investor may find it more difficult to sell our common stock or obtain accurate quotations as to the market value of our common stock. We cannot assure you that our common stock, if delisted from Nasdaq, will be listed on another national securities exchange or quoted on an over-the counter quotation system. If our common stock is delisted, it may come within the definition of &#x201c;penny stock&#x201d; as defined in the Exchange Act, and would be covered by Rule 15g-9 of the Exchange Act. That Rule imposes additional sales practice requirements on broker-dealers who sell securities to persons other than established customers and accredited investors. For transactions covered by Rule 15g-9, the broker-dealer must make a special suitability determination for the purchaser and receive the purchaser&#x2019;s written agreement to the transaction prior to the sale. Consequently, Rule 15g-9, if it were to become applicable, would affect the ability or willingness of broker-dealers to sell our securities, and accordingly would affect the ability of stockholders to sell their securities in the public market. These additional procedures could also limit our ability to raise additional capital in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       60
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Sales of a substantial number of shares of our common stock in the public market by our stockholders could cause our stock</i></b>&#xa0;<b><i>price to fall. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Because we will continue to need additional capital in the future to continue to expand our business and our research and development activities, among other things, we may conduct additional equity offerings. For example, under the universal shelf registration statement filed by us in June 2020 and declared effective by the SEC in July 2020, we may offer and sell any combination of common stock, preferred stock, debt securities and warrants in one or more offerings, up to a cumulative value of $150 million. To date, we have approximately $54.5 million remaining under such universal shelf registration statement. Sales of a substantial number of shares of our common stock in the public market or the perception that these sales might occur, could depress the market price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. Our management is authorized to grant stock options and other equity-based awards to our employees, directors and consultants under our equity incentive plans. Grants under our equity incentive plans may also cause our stockholders to experience additional dilution, which could cause our stock price to fall. We may also issue shares of our common stock as consideration in mergers, acquisitions and other business development transactions. We are unable to predict the effect that sales may have on the prevailing market price of our common stock. All of our shares of common stock outstanding are eligible for sale in the public market, subject in some cases to the volume limitations and manner of sale requirements of Rule&#xa0;144 under the Securities Act. Sales of stock by our stockholders could have a material adverse effect on the trading price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have never declared or paid any cash dividends on our capital stock, and we are prohibited from doing so under the terms of the Loan Agreement. Regardless of the restrictions in the Loan Agreement or the terms of any potential future indebtedness, we anticipate that we will retain all available funds and any future earnings to support our operations and finance the growth and development of our business and, therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board of Directors may deem relevant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Provisions in our amended and restated certificate of incorporation and bylaws, as well as provisions of Delaware law, could make it more difficult for a third party to acquire us or increase the cost of acquiring us, even if doing so would benefit our stockholders or remove our current management. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Some provisions of our charter documents and Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders and may prevent attempts by our stockholders to replace or remove our current management. These provisions include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">authorizing the issuance of &#x201c;blank check&#x201d; preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">limiting the removal of directors by the stockholders;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">a staggered Board of Directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">prohibiting stockholder action by written consent, thereby requiring all stockholder actions to be taken at a meeting of our stockholders;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">eliminating the ability of stockholders to call a special meeting of stockholders; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">establishing advance notice requirements for nominations for election to our Board of Directors or for proposing matters that can be acted upon at stockholder meetings.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">These provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our Board of Directors, which is responsible for appointing the members of our management. In addition, we are subject to Section&#xa0;203 of the Delaware General Corporation Law, which generally prohibits a Delaware corporation from engaging in any of a broad range of business combinations with an interested stockholder for a period of three years following the date on which the stockholder became an interested stockholder, unless such transactions are approved by our Board of Directors. This provision could have the effect of delaying or preventing a change of control, whether or not it is desired by or beneficial to our stockholders. Further, other provisions of Delaware law may also discourage, delay or prevent someone from acquiring us or merging with us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       61
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Risks of a General Nature </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Litigation may substantially increase our costs and harm our business.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have been, are, and may in the future become, party to lawsuits including, without limitation, actions and proceedings in the ordinary course of business relating to our directors, officers, stockholders, intellectual property rights, employment matters and the safety or efficacy of our products, which will cause us to incur legal fees and other costs related thereto, including potential expenses for the reimbursement of legal fees of officers and directors under indemnification obligations. The expense of defending against such litigation may be significant and there can be no assurance that we will be successful in any defense. Further, the amount of time that may be required to resolve such lawsuits is unpredictable, and these actions may divert management&#x2019;s attention from the day-to-day operations of our business, which could adversely affect our business, results of operations, and cash flows. Our insurance carriers may deny coverage, may be inadequately capitalized to pay on valid claims, or our policy limits may be inadequate to fully satisfy any damage awards or settlements. If this were to happen, the payment of any such awards could have a material adverse effect on our consolidated operations, cash flows and financial position. Additionally, any such claims, whether or not successful, could damage our reputation and business. Litigation is subject to inherent uncertainties, and an adverse result in such matters that may arise from time to time could have a material adverse effect on our business, results of operations, and financial condition. Please see &#x201c;Part I.&#x2014;Item 3. Legal Proceedings&#x201d; for additional information about pending legal proceedings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our involvement in securities-related class action litigation could divert our resources and management's attention and harm our business. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The stock markets have from time-to-time experienced significant price and volume fluctuations that have affected the market prices for the common stock of pharmaceutical companies. These broad market fluctuations may cause the market price of our common stock to decline. In addition, the market price of our common stock may vary significantly based on AcelRx-specific events, such as receipt of Complete Response Letters, Warnings Letters, such as the Warning Letter we received from the FDA on February 11, 2021, negative clinical results, a negative vote or decision by an FDA advisory committee, or other negative feedback from the FDA, EMA, or other regulatory agencies. In the past, securities-related class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because biotechnology and biopharmaceutical companies often experience significant stock price volatility in connection with their investigational drug candidate development programs and the FDA's review of their NDAs. Following receipt of the FDA&#x2019;s Warning Letter, a securities class action complaint was filed against us and two of our officers on June 8, 2021 in the United States District Court for the Northern District of California. The amended securities class action complaint, which was filed on March 7, 2022, named a third officer as a defendant. On July 6, 2021, September 30, 2021, October 26, 2021 and November 17, 2021, four purported shareholder derivative complaints were filed in the United States District Court for the Northern District of California asserting state and federal claims based on the same alleged misstatements as the securities class action complaint. On December 6, 2021, the Court entered an order consolidating all four actions and staying the consolidated action pending the outcome of any motion to dismiss the securities class action. Please see &#x201c;Part I.&#x2014;Item 3. Legal Proceedings&#x201d; for additional information about these pending legal proceedings. Securities-related class action litigation often is expensive and diverts management's attention and our financial resources, which could harm our business. Additional lawsuits related to the pending litigation may follow. Moreover, if AcelRx experiences a decline in its stock price, we could face additional securities class action lawsuits.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As of December 31, 2021, we had federal net operating loss carryforwards of $308.5 million, of which $114.9 million federal net operating losses generated before January 1, 2018 will begin to expire in 2029. Federal net operating losses of $193.6 million generated after January 1, 2018 will carryforward indefinitely but are subject to the 80% taxable income limitation. As of December 31, 2021, we had state net operating loss carryforwards of $154.7 million, which begin to expire in 2028. Our ability to use our federal and state net operating losses to offset potential future taxable income and related income taxes that would otherwise be due is dependent upon our generation of future taxable income before the expiration dates of the net operating losses, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses. Federal net operating losses generated prior to 2018 will continue to be governed by the net operating loss tax rules as they existed prior to the adoption of the Tax Cuts and Jobs Act of 2017, or Tax Act, which means that generally they will expire 20 years after they were generated if not used prior thereto. Many states have similar laws. Accordingly, our federal and state net operating losses could expire unused and be unavailable to offset future income tax liabilities. Under the newly enacted Tax Act as modified by CARES Act, federal net operating losses incurred in tax years beginning after December 31, 2017 and before January 1, 2021 may be carried back to each of the five tax years preceding such loss, and federal net operating losses arising in tax years beginning after December 31, 2020 may not be carried back. Moreover, federal net operating losses generated in tax years ending after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited to 80% of current year taxable income for tax years beginning after December 31, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       62
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In addition, under Section&#xa0;382 of the Internal Revenue Code of 1986, as amended, if a corporation undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50% change (by value) in its equity ownership over a three-year period, the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes (such as research tax credits) to offset its post-change income may be limited. The completion of the July 2013 public equity offering, together with our public equity offering in December 2012, our initial public offering, private placements and other transactions that have occurred, have triggered such an ownership change. In addition, since we will need to raise substantial additional funding to finance our operations, we may undergo further ownership changes in the future. In the future, if we earn net taxable income, our ability to use our pre-change net operating loss carryforwards to offset United States federal taxable income may be subject to limitations, which could potentially result in increased future tax liability to us.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of the newly enacted federal income tax law, changes in the mix of our profitability from state to state, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>1B. Unresolved Staff Comments </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>2. Properties </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We lease approximately 13,322 square feet of office space in Hayward, California under a sublease agreement that expires on January 30, 2023. We believe that our facilities are adequate to meet our current needs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>3. Legal Proceedings </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">From time to time we may be involved in legal proceedings relating to intellectual property, commercial, employment and other matters arising in the ordinary course of business. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position or cash flows. Please see the matters under the caption &#x201c;Part II.&#x2014;Item 8. Financial Statements and Supplementary Data&#x2014;Note 12. Commitments and Contingencies&#x2014;Litigation.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>4. Mine Safety Disclosures </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not Applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       63
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>PART II </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>5. Market for Registrant</b>&#x2019;<b>s Common Equity, Related Stockholder Matters and Issuer Purchases of </b><b>Equity Securities </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Market Information</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our common stock has been traded on The Nasdaq Global Market since February 11, 2011 under the symbol &#x201c;ACRX&#x201d;. As of March 7, 2022, there were 40 holders of record of our common stock. This number does not include &#x201c;street name&#x201d; or beneficial holders, whose shares are held of record by banks, brokers, financial institutions and other nominees.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dividend Policy </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have never declared or paid any cash dividends on our capital stock, and we are prohibited from doing so under the terms of our Loan Agreement. Regardless of the restrictions in our Loan Agreement or the terms of any potential future indebtedness, we anticipate that we will retain all available funds and any future earnings to support our operations and finance the growth and development of our business and, therefore, we do not expect to pay cash dividends in the foreseeable future. Any future determination related to our dividend policy will be made at the discretion of our Board of Directors and will depend on then-existing conditions, including our financial condition, operating results, contractual restrictions, capital requirements, business prospects and other factors our Board of Directors may deem relevant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Sales of Unregistered Securities</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item 6. Reserved</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       64
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>7. Management</b>&#x2019;<b>s Discussion and Analysis of Financial Condition and Results of Operations </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>The following discussion and analysis should be read in conjunction with our audited financial statements and the related notes that appear elsewhere in this Annual Report on Form 10-K. </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>This discussion and analysis generally covers our financial condition and results of operations for the year ended December 31, 2021, including year-over-year comparisons versus the year ended December 31, 2020. Our Annual Report on Form 10-K for the year ended</i>&#xa0;<i>December</i>&#xa0;<i>31, 2020</i>&#xa0;<i>includes a discussion and analysis of our financial condition and results of operations for the year ended</i>&#xa0;<i>December</i>&#xa0;<i>31, 2019</i>&#xa0;<i>in Item 7 of Part II, </i>&#x201c;<i>Management</i>&#x2019;<i>s Discussion and Analysis of Financial Condition and Results of Operations.</i>&#x201d;<i> This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as statements regarding our plans, objectives, expectations, intentions, and projections. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in </i>&#x201c;<i>Part I, Item 1A - Risk Factors</i>&#x201d;<i> of this Annual Report on Form 10-K.</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Overview </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Our portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates, and nafamostat product candidates as further described in &#x201c;Item 1. Business.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On July 14, 2021, we entered into a License and Commercialization Agreement, or the PFS Agreement, with Laboratoire Aguettant, or Aguettant, pursuant to which we obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing 10 ml of a solution of 3 mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing 10 ml of a solution of 50 mcg/ml phenylephrine hydrochloride for injection. Aguettant is entitled to receive up to $24 million in sales-based milestone payments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On July 14, 2021, we also entered into a License and Commercialization Agreement, or the DZUVEO Agreement, with Aguettant pursuant to which Aguettant obtained the exclusive right to develop and commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom, or the DZUVEO Territory, for the management of acute moderate to severe pain in adults in medically monitored settings. We are entitled to receive up to &#x20ac;47.0 million in a combination of up-front and sales-based milestone payments, of which we received &#x20ac;2.5 million, or approximately $2.9 million, in 2021. Refer to Note 5 &#x201c;In-license Agreements&#x201d; and Note 6 &#x201c;Out-license Agreements&#x2014;DZUVEO&#x201d; in the accompanying notes to the Consolidated Financial Statements for additional information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On January 7, 2022, we acquired Lowell Therapeutics, Inc., or Lowell, in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments, and includes approximately $26.0 million of contingent consideration payable in cash or stock at AcelRx's option, upon the achievement of regulatory and sales-based milestones. For additional information regarding the acquisition of Lowell, see Note 19. &#x201c;Subsequent Events&#x201d; in the accompanying notes to the Consolidated Financial Statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We are further developing a distribution capability and commercial organization to continue to market and sell DSUVIA in the United States. In geographies where we decide not to commercialize ourselves, we may seek to out-license commercialization rights. We currently intend to commercialize and promote DSUVIA/DZUVEO outside the United States and Europe with one or more strategic partners.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i><span style="text-decoration: underline; ">Product Development Programs </span></i></b><span style="text-decoration: underline; ">&#xa0;</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our product development portfolio features two innovative therapies for the treatment of acute pain, two ready-to-use pre-filled syringe product candidates (ephedrine and phenylephrine), Niyad (a regional anticoagulant for the dialysis circuit) and LTX-608 (a proprietary nafamostat formulation for direct IV infusion as an anti-viral treatment for COVID-19, for disseminated intravascular coagulation, or DIC, for acute respiratory distress syndrome, or ARDS, and for acute pancreatitis). Please refer to &#x201c;Part I. Item 1. Business&#x2014;Our Portfolio&#x201d; for a detailed discussion of our approved products and product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       65
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><i><span style="text-decoration: underline; ">Distribution Agreement</span></i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our distribution agreement, or the Distribution Agreement, with Zimmer Biomet Dental, or ZB Dental, provided ZB Dental the exclusive right to promote, market, sell, and arrange to distribute DSUVIA in the United States to clinicians, dentists, surgeons and other licensed health care practitioners that perform dental (including specialty dental), oral-maxillofacial, cranio-maxillofacial or oral surgery procedures, or Professionals, and their respective institutions and facilities that are permitted to use DSUVIA. On February 15, 2022, we amended the Distribution Agreement to remove the exclusivity provided to ZB Dental, allowing us to promote, market, sell and distribute DSUVIA in the specified classes of trade. The dental and oral-maxillofacial surgery markets have similar characteristics to the other office-based procedures on which we are currently focusing the majority of our commercial efforts.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>General Trends and Outlook </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><span style="text-decoration: underline; ">COVID-19-related</span></i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Government-mandated orders and related safety policies on account of the COVID-19 pandemic continue to prevent us from operating our business in the normal course. Beginning in early 2020, state and local officials issued orders in response to the pandemic which included, among other things, requirements for residents to shelter in place and for non-essential businesses to cease activities at facilities within certain cities, counties, and states. State and local officials have taken different approaches to these orders, and some have not issued any such orders. Once issued, the orders have been relaxed and then tightened, depending on the rate of COVID-19 cases. As a result of these orders, we implemented a work from home policy for our California-based employees and we continue to adhere to the various and diverse orders issued by government officials in the jurisdictions in which we operate. In addition, some hospitals, ambulatory surgery centers and other healthcare facilities have barred visitors that are not caregivers or mission-critical and otherwise restricted access to such facilities. As a result, the educational and promotional efforts of our commercial and medical affairs personnel have been substantially reduced, and in some cases, stopped. Cancellation or delays of formulary committee meetings and delays of elective surgeries have also affected the pace of formulary approvals and, consequently, the rate of adoption and use of DSUVIA. We expect our near-term sales volumes to continue to be adversely impacted as long as access to healthcare facilities by our commercial and medical affairs personnel continues to be limited, especially in light of the rise in COVID-19 cases associated with the emerging variants. We will continue to evaluate the impact on our revenues and related metrics and operating expenses during this period and assess the need to adjust our expenses and expectations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As a result of COVID-19 and related international travel restrictions, in addition to the testing requirements of our vendor, the timing for testing and acceptance of our DSUVIA fully automated packaging line, and subsequent FDA approval, has been delayed. Based on our best estimate, now that the line has been installed, we expect FDA approval in the first half of 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We will continue to engage with various elements of our supply chain and distribution channel, including our customers, contract manufacturers, and logistics and transportation providers, to meet demand for products and to remain informed of any challenges within our supply chain. We continue to monitor demand and intend to adapt our plans as needed to continue to drive our business and meet our obligations during the evolving COVID-19 pandemic. However, if the COVID-19 pandemic continues and persists for an extended period of time, we may face disruptions to our supply chain and operations, and associated delays in the manufacturing and supply of our products. Such supply disruptions may adversely impact our ability to generate sales of and revenues from our products and our business, financial condition, results of operations and growth prospects could be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As the global pandemic of COVID-19 continues to rapidly evolve, it could result in a significant long-term disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. The extent to which the COVID-19 pandemic impacts our business, our ability to generate sales of and revenues from our approved products, and our future clinical development and regulatory efforts will depend on future developments that are highly uncertain and cannot be predicted with confidence, such as the ultimate geographic spread of the disease, the duration of the outbreak, travel restrictions, quarantines and social distancing requirements in the United States and other countries, business closures or business disruptions and the effectiveness of actions taken in the United States and other countries to contain and treat the virus.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><span style="text-decoration: underline; ">Department of Defense</span></i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In April 2020, DSUVIA achieved Milestone C approval by the Department of Defense, or DoD, a decision that clears the path for the DoD to begin placing orders for DSUVIA for inclusion in all Army Sets, Kits, and Outfits, or SKOs, for deployed/deploying troops. This SKO fulfillment is dependent on the Army&#x2019;s completion of their product information package including instructions on fulfillment and training which remains in process. In September 2020, we announced that DSUVIA was added to the DoD Joint Deployment Formulary, a core list of pharmaceutical products that are designated for deploying military units across all service branches. Also in September 2020, the U.S. Army awarded AcelRx with an initial contract of up to $3.6 million over the next four years for the purchase of DSUVIA to support a DoD-sponsored study to aid the development of clinical practice guidelines. We believe that study will initiate clinically in 2022. Since the fourth quarter of 2020, DSUVIA orders are being fulfilled for the Army Prepositioned Stock Program, or APS. The aforementioned clinical and APS orders are separate from the planned SKO fulfillment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       66
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Financial Overview </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have incurred net losses and generated negative cash flows from operations since inception and expect to incur losses in the future as we continue commercialization activities to support the U.S. launch of DSUVIA, support European sales of DZUVEO by Aguettant, and of Zalviso by any replacement partner, and fund any future research and development activities needed to support the FDA regulatory review of our product candidates.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We will incur capital expenditures related to our fully automated packaging line for DSUVIA, which has now been installed, and for which we expect FDA approval in the first half of 2023. We anticipate that the fully automated line for DSUVIA will contribute to a significant decrease in costs of goods sold in 2023 and beyond.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our net losses were $35.1 million and $40.4 million for the years ended December&#xa0;31, 2021 and 2020, respectively. As of December&#xa0;31, 2021, we had an accumulated deficit of $473.6 million. As of December&#xa0;31, 2021, we had cash, cash equivalents and short-term investments totaling $51.6 million compared to $42.9 million as of December&#xa0;31, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Estimates </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The accompanying discussion and analysis of our financial condition and results of operations are based upon our Consolidated Financial Statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. To the extent that there are material differences between these estimates and actual results, our future financial statement presentation, financial condition, results of operations and cash flows will be affected. Note&#xa0;1 &#x201c;Organization and Summary of Significant Accounting Policies&#x201d; in the accompanying Notes to Consolidated Financial Statements describes the significant accounting policies used in the preparation of the financial statements. Certain of these significant accounting policies are considered to be critical accounting policies, as defined below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A critical accounting policy is defined as one that is both material to the presentation of our financial statements and requires management to make difficult, subjective or complex judgments that could have a material effect on our financial condition and results of operations. Specifically, critical accounting estimates have the following attributes: (i)&#xa0;we are required to make assumptions about matters that are highly uncertain at the time of the estimate; and (ii)&#xa0;different estimates we could reasonably have used, or changes in the estimate that are reasonably likely to occur, would have a material effect on our financial condition or results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain. Management has discussed the development, selection and disclosure of the following estimates with the Audit Committee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Revenue from Contracts with Customers </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We follow the provisions of ASC Topic 606,&#xa0;<i>Revenue from Contracts with Customers</i>. The guidance provides a unified model to determine how revenue is recognized. We recognize revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration we expect to receive in exchange for those products or services. We sell our products primarily through wholesale and specialty distributors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In determining the appropriate amount of revenue to be recognized as we fulfill our obligations under our agreements, we perform the following steps: (i)&#xa0;identification of the promised goods or services in the contract; (ii)&#xa0;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#xa0;measurement of the transaction price, including the constraint on variable consideration; (iv)&#xa0;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#xa0;recognition of revenue when (or as) we satisfy each performance obligation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       67
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Product sales revenue</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We sell our product primarily through distributors. Revenues from product sales are recognized when distributors obtain control of our product, which occurs at a point in time, upon delivery to such distributors. These distributors subsequently resell the product to certified medically supervised healthcare settings. In addition to distribution agreements with these customers, we enter into arrangements with group purchasing organizations, or GPOs, and other certified medically supervised healthcare settings that provide for privately negotiated discounts with respect to the purchase of our products. For revenue recognition under bill-and-hold arrangements, wherein the customer agrees to buy product from us but requests delivery at a later date, we deem that control passes to the customer when the product is ready for delivery. We recognize revenue under these types of arrangements when a signed agreement is in place, the transaction is billable, the customer has significant risk and rewards for the product and the ability to direct the asset, the product has been set aside specifically for the customer, and the product cannot be redirected to another customer. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, government rebates, returns, distribution fees and GPO fees.&#xa0;Variable consideration is recorded at the time product sales are recognized resulting in a reduction in product revenue. The amount of variable consideration that is included in the transaction price may be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will not occur in a future period. Variable consideration is estimated using the most-likely amount method, which is the single-most likely outcome under a contract and is typically at the stated contractual rate.&#xa0;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method under ASC Topic 606 for relevant factors. These factors include current contractual and statutory requirements, specific known market events and trends, industry data, and/or forecasted customer buying and payment patterns. Actual amounts of consideration ultimately received may differ from our estimates.&#xa0;If actual results vary materially from our estimates, we will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These estimates include:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Chargebacks</span> - Our customers subsequently resell our product to qualified healthcare providers. In addition to distribution agreements with customers, we enter into arrangements with qualified healthcare providers that provide discounts with respect to the purchase of our product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from us. Customers charge us for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue-related accrued liabilities on the Consolidated Balance Sheets. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by customers, and we issue credits for such amounts generally within a few weeks of the customer's notification to us of the resale. Reserves for chargebacks consists of credits that we expect to issue for units that remain in the distribution channel inventories at each reporting period end that we expect will be sold to the qualified healthcare providers, and chargebacks for units that our customers have sold to the qualified healthcare providers, but for which credits have not been issued.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Government Rebates</span> - We are subject to discount obligations under state Medicaid programs. We estimate our Medicaid rebates and record them in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued liabilities on the Consolidated Balance Sheets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Returns</span> -<i> </i>We allow our distributors to return product for credit 6 months prior to, and up to 12 months after, the product expiration date. As such, there may be a significant period of time between the time the product is shipped and the time the credit is issued on returned product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Distribution Fees</span> - Distribution fees include fees paid to certain customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">GPO Fees</span><i> </i>- We pay administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs&#x2019; members.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Trade Discounts and Allowances</span> - We provide our customers with discounts which include early payment incentives that are explicitly stated in our contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We believe our estimated allowances for chargebacks, government rebates and product returns require a high degree of judgment and are subject to change based on our limited experience and certain quantitative and qualitative factors. We believe our estimated allowances for distribution fees, GPO fees and trade discounts and allowances do not require a high degree of judgment because the amounts are settled within a relatively short period of time. We will continue to assess our estimates of variable consideration as we accumulate additional historical data and will adjust these estimates accordingly. Changes in product revenue allowance estimates could materially affect our results of operations and financial position.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Contract and other collaboration revenue</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We entered into award contracts with the DoD to support the development of DSUVIA. These contracts provided for the reimbursement of qualified expenses for research and development activities. Revenue under these arrangements was recognized when the related qualified research expenses were incurred. We were entitled to reimbursement of overhead costs associated with the study costs under the DoD arrangements. We estimated this overhead rate by utilizing forecasted expenditures. Final reimbursable overhead expenses were dependent on direct labor and direct reimbursable expenses throughout the life of each contract, which increased or decreased based on actual expenses incurred.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We also generate revenue from collaboration agreements. These agreements typically include payments for upfront signing or license fees, cost reimbursements for development and manufacturing services, milestone payments, product sales, and royalties on licensee&#x2019;s future product sales. Product sales related revenue under these collaboration agreements is classified as product sales revenue, while other revenue generated from collaboration agreements is classified as contract and other collaboration revenue.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Performance Obligations</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic 606. Our performance obligations include delivering product to our distributors, commercialization license rights, development services, services associated with the regulatory approval process, joint steering committee services, demonstration devices, manufacturing services, material rights for discounts on manufacturing services, and product supply.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#x2019;s or our discretion are generally considered as options. We assess if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. If we are entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Transaction Price</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have both fixed and variable consideration. Non-refundable&#xa0;upfront fees and product supply selling prices are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. We allocate the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the inception of each arrangement that includes milestone payments, we evaluate whether the milestones are considered probable of being achieved and estimate the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would not occur, the value of the associated milestone (such as a regulatory submission by us) is included in the transaction price. Milestone payments that are not within our control, such as approvals from regulators, are not considered probable of being achieved until those approvals are received.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, we recognize revenue at the later of (a)&#xa0;when the related sales occur, or (b)&#xa0;when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Allocation of Consideration</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the accounting for these arrangements, we must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract.&#xa0;Estimated selling prices for license rights and material rights for discounts on manufacturing services are calculated using an income approach model and can include the following key assumptions: the development timeline, sales forecasts, costs of product sales, commercialization expenses, discount rate, the time which the manufacturing services are expected to be performed, and probabilities of technical and regulatory success. For all other performance obligations, we use a cost-plus margin approach.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Timing of Recognition</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant management judgment is required to determine the level of effort required under an arrangement and the period over which we expect to complete our performance obligations under the arrangement. We estimate the performance period or measure of progress at the inception of the arrangement and re-evaluate it each reporting period. This re-evaluation may shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If we cannot reasonably estimate when our performance obligations either are completed or become inconsequential, then revenue recognition is deferred until we can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative&#xa0;catch-up&#xa0;method. Revenue is recognized for products at a point in time when control of the product is transferred to the customer in an amount that reflects the consideration we expect to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer, and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that we have incurred to perform the services using the cost-to-cost input method.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Inventories</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using the first-in, first-out method for all inventories. Inventory includes the cost of the active pharmaceutical ingredients, or API, raw materials and third-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are allocated to the appropriate cost pool and then absorbed into inventory based on the units produced or distributed, assuming normal capacity, in the applicable period. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred. DSUVIA was approved by the FDA in November 2018. Prior to FDA approval, all manufacturing costs for DSUVIA were expensed to research and development. Upon FDA approval, manufacturing costs for DSUVIA manufactured for commercial sale have been capitalized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. We periodically evaluate the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or net realizable value approach as that used to value the inventory. Because the predetermined, contractual transfer prices we received from Gr&#xfc;nenthal GmbH, or Gr&#xfc;nenthal, were less than the direct costs of manufacturing, all Zalviso inventories were carried at net realizable value.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Non-Cash Interest Expense on Liability Related to Sale of Future Royalties </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In September 2015, we sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by our former commercial partner, Gr&#xfc;nenthal pursuant to the Collaboration and License Agreement, dated as of December 16, 2013, as amended, to PDL BioPharma, Inc., or PDL, for an upfront cash purchase price of $65.0 million. Under the relevant accounting guidance, because of our significant continuing involvement, the Royalty Monetization has been accounted for as a liability that will be amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, we are required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and paid to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $61.2 million of net proceeds we received, are recorded as interest expense over the life of the liability. Consequently, we impute interest on the unamortized portion of the liability and record interest expense related to the Royalty Monetization accordingly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the three months ended June 30, 2020, Gr&#xfc;nenthal notified us that it was terminating the Amended License Agreement, effective November 13, 2020. The terms of the Gr&#xfc;nenthal Agreements were extended to May 2021 to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. The rights to market and sell Zalviso in the Territory reverted back to us in May 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There is a continuing obligation on our part, through the term of the Royalty Monetization, to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. However, without a New Arrangement to commercialize Zalviso in Europe, we are currently unable to reliably estimate the future payments to SWK Funding LLC, or SWK, (assignee of PDL) over the remaining life of the Royalty Monetization. If we are unable to find a New Arrangement, a contingent gain of up to approximately $64 million may be recognized when it is realized upon expiration of the liability at the end of the Royalty Monetization term. Due to the significant judgments and factors related to the estimates of future payments under the Royalty Monetization, there are significant uncertainties surrounding the amount and timing of future payments and the probability of realization of the estimated contingent gain.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We will record non-cash royalty revenues and non-cash interest (income) expense within our Consolidated Statements of Operations over the term of the Royalty Monetization.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When the expected payments under the Royalty Monetization are lower than the gross proceeds of $65.0 million received, we defer recognition of any probable contingent gain until the Royalty Monetization liability expires.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our results of operations have fluctuated from period to period and may continue to fluctuate in the future, based upon the progress of our commercial launch of DSUVIA, our research and development efforts, variations in the level of expenditures related to commercial launch, development efforts and debt service obligations during any given period, and the uncertainty as to the extent and magnitude of the impact from the COVID-19 pandemic. Results of operations for any period may be unrelated to results of operations for any other period. In addition, historical results should not be viewed as indicative of future operating results. In particular, to the extent our commercial and medical affairs personnel continue to be subject to varying levels of restriction on accessing hospitals and ambulatory surgical centers due to COVID-19, and to the extent government authorities and certain healthcare providers are continuing to limit elective surgeries, we expect our sales volume to be adversely affected.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Years Ended December</i></b>&#xa0;<b><i>31, 2021 and 2020</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Revenue </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Product Sales Revenue</span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Product sales revenue consists of sales of DSUVIA in the U.S. and, prior to May 13, 2021, Zalviso in Europe.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Product sales revenue by product for the years ended December 31, 2021 and 2020, was as follows (in thousands, except percentages):</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, </b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Change</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Change</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 </b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020 </b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020 </b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">DSUVIA</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">735</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,409</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(674</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(48</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Zalviso</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">270</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,112</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(842</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(76</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total product sales revenue</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,005</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,521</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,516</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(60</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The decrease in product sales revenue for the year ended December 31, 2021, as compared to the year ended December 31, 2020, was primarily the result of a significant purchase from the Department of Defense in the third quarter of 2020 and the termination of the Collaboration and License Agreement and the Manufacture and Supply Agreement, or the Gr&#xfc;nenthal Agreements, pursuant to which Gr&#xfc;nenthal sold Zalviso in the European Union through May 12, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Contract and Other Collaboration Revenue </span></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Contract and other collaboration revenue included revenue under the DZUVEO Agreement related to the upfront payment received in the third quarter of 2021, and prior to May 13, 2021, included revenue under the Gr&#xfc;nenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization, and royalty revenue for sales of Zalviso in Europe.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Contract and other collaboration revenue for the years ended December 31, 2021 and 2020, was as follows (in thousands, except percentages):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">License revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,696</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,696</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-cash royalty revenue related to Royalty Monetization (See Note 10)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">242</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(159</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(66</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Royalty revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(53</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(65</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,572</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,566</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(100</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total contract and other collaboration revenue</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,813</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,895</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1,082</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(37</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On July 14, 2021, we granted Aguettant the license rights to DZUVEO in the European Union. Accordingly, for the year ended December 31, 2021, we recognized $1.7 million of the $2.9 million upfront fee as license revenue under the DZUVEO Agreement. As of December 31, 2021, we had current and non-current portions of deferred revenue under the DZUVEO Agreement of $0.1 million and $1.1 million, respectively. In May 2020, Gr&#xfc;nenthal terminated the Gr&#xfc;nenthal Agreements, accordingly the rights to market and sell Zalviso in Europe reverted back to us on May 12, 2021. Upon notification of early termination by Gr&#xfc;nenthal, we recognized approximately $2.6 million of deferred revenue for the discount on Zalviso manufacturing services which were no longer a performance obligation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cost of goods sold </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total costs of goods sold for the years ended December 31, 2021 and 2020, were as follows (in thousands, except percentages):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Direct costs</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,204</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,900</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(696</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(37</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Indirect costs</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,549</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">4,132</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,583</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(38</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total costs of goods sold</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,753</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,032</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(2,279</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(38</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Direct costs from contract manufacturers for DSUVIA and Zalviso totaled $1.2 million and $1.9 million in the years ended December 31, 2021 and 2020, respectively. Direct cost of goods sold for DSUVIA and Zalviso includes the inventory costs of the active pharmaceutical ingredient, or API, third-party contract manufacturing costs, estimated warranty costs, packaging and distribution costs, shipping, handling and storage costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We periodically evaluate the carrying value of inventory on hand for potential excess amounts over demand using the same lower of cost or net realizable value approach as that used to value the inventory. During the year ended December 31, 2021, we recorded inventory impairment charges of $0.8 million, primarily as a result of DSUVIA inventory that may expire before being sold. During the year ended December 31, 2020, we recorded inventory impairment charges of $0.7 million, of which $0.3 million related to the termination of the Gr&#xfc;nenthal Agreements, and $0.4 million related to DSUVIA, primarily as a result of inventory that may expire before being sold.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The indirect costs to manufacture DSUVIA and Zalviso totaled $2.5 million and $4.1 million in the years ended December 31, 2021 and 2020, respectively. Indirect costs include internal personnel and related costs for purchasing, supply chain, quality assurance, depreciation and related expenses. We expect these indirect costs to represent a smaller percentage of revenue as our product sales increase.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Research and Development Expenses </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The majority of our operating expenses to date have been for research and development activities related to Zalviso and DSUVIA. Research and development expenses included the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">expenses incurred under agreements with contract research organizations and clinical trial sites;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">employee-related expenses, which include salaries, benefits and stock-based compensation;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">payments to third party pharmaceutical and engineering development contractors;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">payments to third party manufacturers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">depreciation and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities and equipment, and equipment and laboratory and other supply costs; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">costs for equipment and laboratory and other supplies.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We expect to incur future research and development expenditures to support the FDA regulatory review of our product candidates and anticipated activities required for the development of our nafamostat product candidates, and the preparation and submission of the NDAs for our two in-licensed product candidates from Aguettant. The timing of the resubmission of the Zalviso NDA is in part dependent on the finalization of the FDA&#x2019;s new opioid approval guidelines and process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We track external development expenses on a program-by-program basis. Our development resources are shared among all our programs. Compensation and benefits, facilities, depreciation, stock-based compensation, and development support services are not allocated specifically to projects and are considered research and development overhead.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       72
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Below is a summary of our research and development expenses for the years ended December&#xa0;31, 2021 and 2020 (in thousands, except percentages):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended December 31, </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">DSUVIA</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,401</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">812</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">589</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Zalviso</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">49</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">95</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(46</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(48</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other product candidates</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">50</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">50</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">100</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Overhead</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,595</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,110</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(515</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(17</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total research and development expenses</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,095</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,017</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">78</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Research and development expenses during the year ended December 31, 2021, as compared to the year ended December 31, 2020, increased by $0.1 million primarily due to increased Catalent manufacturing-related DSUVIA development expenses, partially offset by decreases in personnel-related overhead expenses and Zalviso-related spending.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Selling, General and Administrative Expenses </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Selling, general and administrative expenses consisted primarily of salaries, benefits and stock-based compensation for personnel engaged in commercialization, administration, finance and business development activities. Other significant expenses included allocated facility costs and professional fees for general legal, audit and consulting services.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total selling, general and administrative expenses for the years ended December&#xa0;31, 2021 and 2020, were as follows (in thousands, except percentages):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, </b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Change</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Change</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 </b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020 </b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020 </b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative expenses</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">30,935</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">36,330</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(5,395</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(15</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Selling, general and administrative expenses decreased by $5.4 million during the year ended December 31, 2021, as compared to the year ended December 31, 2020. The decrease is primarily due to a $3.4 million reduction in personnel-related costs, a decrease in business development expenses of $0.8 million, a $0.8 million reduction in DSUVIA commercialization-related expenses, such as travel, and a $0.7 million decrease in legal fees, partially offset by an increase in other net selling, general and administrative expenses of $0.3 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In March 2020, we eliminated 30 positions, mainly within the commercial organization. For additional information regarding the Restructuring Costs see Note 1 &#x201c;Organization and Summary of Significant Accounting Policies&#x201d; in the notes to the Consolidated Financial Statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Other Income (Expense)</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Total other income (expense) for the years ended December&#xa0;31, 2021 and 2020, was as follows (in thousands, except percentages):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years Ended</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>$ Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>% Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021 vs. 2020 </b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest expense</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,291</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(3,305</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,014</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(31</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Interest income and other income (expense), net</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">583</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(459</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(79</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Non-cash interest income (expense) on liability related to sale of future royalties</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,038</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,310</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(272</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)%</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total other income (expense)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">871</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">588</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">283</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 10%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">48</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Interest expense consisted primarily of interest accrued or paid on our debt obligation agreements and amortization of debt discounts. Interest expense decreased for the year ended December 31, 2021, as compared to the year ended December 31, 2020, primarily as a result of a lower average outstanding loan balance. As of December 31, 2021, the outstanding balance due under the Loan Agreement with Oxford was $13.3 million. Refer to Note 8 &#x201c;Long-Term Debt&#x201d; in the notes to the Consolidated Financial Statements for additional information.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Interest income and other income (expense), net, for the years ended December 31, 2021 and 2020 primarily consisted of interest earned on our investments and the change in the fair value of our contingent put option. The decrease in interest income and other income (expense), net, in the year ended December 31, 2021, compared to the year ended December 31, 2020, was primarily due to lower yields on our investments and the change in the fair value of our contingent put option.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The non-cash interest income on the liability related to the sale of future royalties is attributable to the Royalty Monetization that we completed in September 2015. As described in Note 10 &#x201c;Liability Related to Sale of Future Royalties&#x201d;, the Royalty Monetization has been recorded as debt under the applicable accounting guidance. We periodically assess the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than our initial estimates or the timing of such payments is materially different than our original estimates, we will prospectively adjust the amortization of the liability and the interest rate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The effective interest income rate for the years ended December 31, 2021 and 2020, was approximately 3.5% and 3.6%, respectively. We anticipate that we will record approximately $3 million in non-cash interest income related to the Royalty Monetization for the year ended December 31, 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Liquidity </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have incurred losses and generated negative cash flows from operations since inception. We expect to continue to incur significant losses in 2022 and may incur significant losses and negative cash flows from operations in the future. We have funded our operations primarily through issuance of equity securities, borrowings, payments from Gr&#xfc;nenthal, monetization of certain future royalties and commercial sales milestones from the European sales of Zalviso by Gr&#xfc;nenthal, funding of approximately $22.6 million from the DoD, and more recently with revenues from sales of DSUVIA since the commercial launch in the first quarter of 2019 and the upfront payment under the DZUVEO Agreement with Aguettant.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As of December 31, 2021, we had cash, cash equivalents and investments totaling $51.6 million, compared to $42.9 million as of December&#xa0;31, 2020. The increase was primarily due to net proceeds received from the issuance of common stock and warrants in connection with equity offerings in the year ended December 31, 2021, partially offset by cash required to fund our continuing operations, including debt service, as we continued our commercialization activities for DSUVIA, including installation of our fully automated packaging line for DSUVIA, and business development activities. We anticipate that our existing capital resources will permit us to meet our capital and operational requirements for at least the next twelve months; however, our expectations may change depending on a number of factors including the extent and magnitude of the impact from the COVID-19 pandemic, in particular the negative impact on sales volumes as our sales force is limited in its access to potential customers, our expenditures related to the development of our product candidates and the United States commercial launch of DSUVIA, and the timing of business development activities. Our existing capital resources will not be sufficient to fund our operations until such time as we may be able to generate sufficient revenues to sustain our operations.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On November 17, 2021, we completed a registered direct offering in which we issued and sold 17,500,000 shares of our common stock at a price of $0.80 per share and warrants exercisable for an aggregate of 17,500,000 shares of our common stock at a price of $1.00 per share. The total net proceeds from this offering were approximately $13.9 million. As of December 31, 2021, the 17,500,000 warrants remain outstanding and will be exercisable following the six-month anniversary of the closing date of this offering and expire on November 15, 2026.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On January 22, 2021, we completed an underwritten public offering in which we issued and sold 14,500,000 shares of our common stock to the underwriter at a price of $1.7625 per share. On January 27, 2021, the underwriters exercised their option in full and purchased an additional 2,175,000 shares at a price of $1.7625 per share. The total net proceeds from this offering of an aggregate 16,675,000 shares were approximately $28.9 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On December 11, 2020, we completed a registered direct offering in which we issued and sold 8,333,333 shares of our common stock at a price of $1.20 per share. The total net proceeds from this offering were approximately $9.9 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On July 23, 2020, we completed a registered direct offering in which we issued and sold 9,433,962 shares of our common stock at a price of $1.06 per share. The total net proceeds from this offering were approximately $10.0 million.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We entered into a Controlled Equity Offering<sup style="vertical-align:top;line-height:120%;font-size:pt">SM </sup>Sales Agreement, or, as amended, the ATM Agreement, with Cantor Fitzgerald &amp; Co., or Cantor, as agent, pursuant to which we may offer and sell, from time to time through Cantor, shares of our common stock. During the year ended December 31, 2021, we had issued and sold an aggregate of approximately 3.0 million shares of common stock pursuant to the ATM Agreement, for which we had received net proceeds of approximately $7.5 million, after deducting fees and expenses. During the year ended December 31, 2020, we issued and sold an aggregate of approximately 0.9 million shares of common stock pursuant to the ATM Agreement, for which we received net proceeds of approximately $1.4 million. As of December 31, 2021, we had the ability to sell approximately $36.1 million of our common stock under the ATM Agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       74
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On May 30, 2019, we entered into the Loan Agreement with Oxford. Under the Loan Agreement, we borrowed an aggregate principal amount of $25.0 million under a term loan. After deducting all loan initiation costs and outstanding interest on the prior loan agreement with Hercules, we received $15.9 million in net proceeds. As of December 31, 2021, the outstanding balance under the Loan Agreement was $13.3 million. For more information, see Note 8 &#x201c;Long-Term Debt&#x201d; in the accompanying notes to the Consolidated Financial Statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On May 18, 2020, we received a notice from Gr&#xfc;nenthal that it was exercising its right to terminate the Gr&#xfc;nenthal Agreements. Certain terms of the Gr&#xfc;nenthal Agreements were extended to May 2021 to enable Gr&#xfc;nenthal to sell down its Zalviso inventory. Certain terms of the Gr&#xfc;nenthal Agreements were further extended for a period of thirty days after the last Zalviso product distributed by Gr&#xfc;nenthal prior to May 13, 2021 expires to enable the parties to manage applicable pharmacovigilance and other requirements. There is a continuing obligation on our part, through the term of the Royalty Monetization, to use commercially reasonable efforts to negotiate a New Arrangement. The Royalty Monetization will be repaid to SWK (assignee of PDL) over the life of the agreement through a portion of the European royalties and milestones received under the Gr&#xfc;nenthal Agreements and any New Arrangement, if executed. For more information, see Note 10 &#x201c;Liability Related to the Sale of Future Royalties&#x201d; in the accompanying notes to the Consolidated Financial Statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our cash and investment balances are held in a variety of interest-bearing instruments, including obligations of commercial paper, corporate debt securities, U.S. government sponsored enterprise debt securities and money market funds. Cash in excess of immediate requirements is invested with a view toward capital preservation and liquidity. We do not expect COVID-19 to have a material impact on our high quality, short-dated investments.</p>
  <p style="margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cash Flows </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Years</b> <b>Ended</b> <b>December 31,</b> </b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash used in operating activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(30,002</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(38,505</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash (used in)/provided by investing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(26,123</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,139</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by financing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">41,514</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,956</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash Flows from Operating Activities </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The primary use of cash for our operating activities during these periods was to fund commercial activities for our approved product, DSUVIA. Our cash used in operating activities also reflected changes in our working capital, net of adjustments for non-cash charges, such as depreciation and amortization of our fixed assets, stock-based compensation, non-cash interest income (expense) related to the sale of future royalties and interest expense related to our debt financings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash used in operating activities of $30.0 million during the year ended December 31, 2021, reflected a net loss of $35.1 million, partially offset by aggregate non-cash charges of $4.9 million and included an approximate $0.2 million net change in our operating assets and liabilities. Non-cash charges included $4.6 million for stock-based compensation expense, $3.0 million in non-cash interest income on the liability related to the Royalty Monetization, and $2.0 million in depreciation and amortization expense. The net change in our operating assets and liabilities included a $1.2 million increase in deferred revenue and a $0.9 million increase in prepaid expenses and other assets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Cash used in operating activities of $38.5 million during the year ended December 31, 2020, reflected a net loss of $40.4 million, partially offset by aggregate non-cash charges of $4.2 million and included an approximate $2.3 million net change in our operating assets and liabilities. Non-cash charges included $4.4 million for stock-based compensation expense, $3.3 million in non-cash interest income on the liability related to the Royalty Monetization, $1.9 million in depreciation expense and $1.1 million in non-cash interest expense related to debt financing. The net change in our operating assets and liabilities included a $1.0 million increase in accounts payable and a $3.2 million decrease in deferred revenue.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash Flows from Investing Activities </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Our investing activities have consisted primarily of our capital expenditures and purchases and sales and maturities of our available-for-sale investments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">During the year ended December 31, 2021, cash used in investing activities of $26.1 million was primarily the net result of $70.5 million for purchases of investments, $1.8 million for purchases of property and equipment, and $0.8 million in asset acquisition costs related to our acquisition of Lowell, partially offset by $47.0 million in proceeds from the sale and maturity of investments.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended December 31, 2020, cash provided by investing activities of $34.1 million was the net result of $80.6 million in proceeds from maturity of investments, offset by $44.6 million for purchases of investments and purchases of property and equipment of $1.9 million.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Cash Flows from Financing Activities </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cash flows from financing activities primarily reflect proceeds from the sale of our securities and payments made on debt financings.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended December 31, 2021, cash provided by financing activities of $41.5 million was primarily due to $50.3 million in net proceeds received in connection with equity financings, including the issuance of warrants and shares sold under our ATM Agreement, partially offset by $8.8 million used for payment of long-term debt.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended December 31, 2020, cash provided by financing activities was primarily due to $21.3 million in net proceeds received in connection with equity financings, and $0.4 million in net proceeds received through our equity plans, partially offset by $4.7 million used for payment of long-term debt.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Capital Commitments and Capital Resources </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our current operating plan includes expenditures related to the development of our product candidates and the continued launch of DSUVIA in the United States. This plan includes an assumption that COVID-19 related restrictions will not increase considerably, and includes anticipated activities required to resubmit the Zalviso NDA and anticipated activities required for the development of our nafamostat product candidates, and the preparation and submission of the NDAs for our two in-licensed product candidates from Aguettant. These assumptions may change as a result of many factors. We will continue to evaluate the work necessary to successfully launch DSUVIA and gain approval of our product candidates in the United States and intend to update our cash forecasts accordingly. Our forecast that our existing capital resources will permit us to meet our capital and operational requirements through at least the next twelve months is a forward-looking statement that involves risks and uncertainties, and actual results could vary materially.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our future capital requirements may vary materially from our expectations based on numerous factors, including, but not limited to, the following:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the impact and timing of COVID-19 on our operations, our sales representatives&#x2019; access to hospitals or other healthcare facilities, and our level of sales;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">expenditures related to the launch of DSUVIA and potential commercialization of our product candidates, if approved;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">future manufacturing, selling and marketing costs related to DSUVIA and our product candidates, if approved, including our contractual obligations to Aguettant under the DZUVEO Agreement;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">costs associated with business development activities and licensing transactions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the outcome, timing and cost of the regulatory submissions for our product candidates, including our two in-licensed product candidates from Aguettant, and any approvals for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the outcome, timing and cost of the development of our nafamostat product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the initiation, progress, timing and completion of any post-approval clinical trials for DSUVIA, or our product candidates, if approved;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">changes in the focus and direction of our business strategy and/or research and development programs;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">milestone and royalty revenue we receive under our collaborative development and commercialization arrangements, including the DZUVEO Agreement;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">delays that may be caused by changing regulatory requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the timing and terms of future in-licensing and out-licensing transactions;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the cost of procuring clinical and commercial supplies of DSUVIA and our product candidates, if approved;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       76
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the extent to which we acquire or invest in businesses, products and product candidates or technologies; and</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 27pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">the expenses associated with litigation.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the long-term, our existing capital resources will not be sufficient to fund our operations until such time as we may be able to generate sufficient revenues to sustain our operations. We will have to raise additional funds through the sale of our equity securities, monetization of current and future assets, issuance of debt or debt-like securities or from development and licensing arrangements to sustain our operations and continue our development programs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Please see &#x201c;Part II., Item 1A. Risk Factors&#x2014;Risks Related to Our Financial Condition and Need for Additional Capital.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have material cash requirements and other contractual obligations related to our Loan Agreement with Oxford (as described in Note 8 &#x201c;Long-Term Debt&#x201d;), contract manufacturing services and office rent (as described in Note 9 &#x201c;Leases&#x201d; in the accompanying notes to the Consolidated Financial Statements) and the Royalty Monetization that we completed in September 2015 (as described in Note 10 &#x201c;Liability Related to Sale of Future Royalties&#x201d;).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>7A. Quantitative and Qualitative Disclosures about Market Risk </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We are a smaller reporting company as defined by Rule 12b-2 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, and are not required to provide the information specified under this item.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>8. Financial Statements and Supplementary Data </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The financial statements required by this item are attached to this Form 10-K beginning with page F-1.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On July 15, 2021, WithumSmith+Brown, PC, an independent registered public accounting firm (Withum), acquired certain assets of OUM &amp; Co. LLP (OUM), the independent registered public accounting firm for AcelRx Pharmaceuticals, Inc. (the Company) (the Transaction). As a result of this Transaction, on July 15, 2021, OUM resigned as the Company's independent registered public accounting firm. Concurrent with such resignation, the Company, with the approval of its Audit Committee, consented to the engagement of Withum as the Company's new independent registered public accounting firm, effective July 15, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prior to the Transaction, the Company did not consult with Withum regarding the application of accounting principles to any specific completed or contemplated transaction or regarding the type of audit opinion that might be rendered by Withum on the Company's financial statements, and Withum did not provide any written or oral advice that was an important factor considered by the Company in reaching a decision as to any accounting, auditing or financial reporting issue.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">OUM's Report of Independent Registered Public Accounting Firm (the Audit Report) on the Company's financial statements for the fiscal years ended December 31, 2020 and 2019 did not contain any adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">During the years ended December 31, 2020 and 2019, and during the interim period from the end of the most recently completed fiscal year through July 15, 2021, the date of resignation, there were no &#x201c;disagreements&#x201d; (as such term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions to Item 304) with OUM on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedures, which disagreements, if not resolved to the satisfaction of OUM would have caused it to make reference to such disagreement in its reports. During the fiscal years ended December 31, 2020 and 2019, and the subsequent interim period through July 15, 2021, there have been no &#x201c;reportable events&#x201d; (as such term is defined in Item 304 (a)(1)(v) of Regulation S-K).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>9A. Controls and Procedures </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Evaluation of Disclosure Controls and Procedures </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have carried out an evaluation, under the supervision, and with the participation, of management including our principal executive officer and principal financial officer, of our disclosure controls and procedures (as defined in Rule 13a-15(e)) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) as of the end of the period covered by this Annual Report on Form 10&#x2013;K. Based on their evaluation, our principal executive officer and principal financial officer concluded that, subject to the limitations described below, our disclosure controls and procedures were effective as of<br /> December&#xa0;31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       77
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Management</b>&#x2019;<b>s Annual Report on Internal Control over Financial Reporting </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following report is provided by management in respect of AcelRx Pharmaceuticals&#x2019; internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act):</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">1. AcelRx Pharmaceuticals&#x2019; management is responsible for establishing and maintaining adequate internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">2. AcelRx Pharmaceuticals management has used the Committee of Sponsoring Organizations of the Treadway Commission, or COSO, framework (2013 framework) to evaluate the effectiveness of internal control over financial reporting. Management believes that the COSO framework is a suitable framework for its evaluation of financial reporting because it is free from bias, permits reasonably consistent qualitative and quantitative measurements of AcelRx Pharmaceuticals&#x2019; internal control over financial reporting, is sufficiently complete so that those relevant factors that would alter a conclusion about the effectiveness of AcelRx Pharmaceuticals&#x2019; internal control over financial reporting are not omitted and is relevant to an evaluation of internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">3. Management has assessed the effectiveness of AcelRx Pharmaceuticals&#x2019; internal control over financial reporting as of December&#xa0;31, 2021 and has concluded that such internal control over financial reporting was effective.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">This Annual Report does not include an attestation report of our registered public accounting firm regarding internal control over financial reporting. Management's report was not subject to attestation by our registered public accounting firm pursuant to the rules of the Securities and Exchange Commission applicable to smaller reporting companies that permit us to provide only management's report in this Annual Report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Changes in Internal Control over Financial Reporting </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There have been no significant changes in our internal control over financial reporting that have materially affected, or are reasonably likely to materially affect, internal control over financial reporting during the fiscal quarter ended December&#xa0;31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Limitations on the Effectiveness of Controls.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable, not absolute, assurance that the objectives of the control system are met. We continue to implement, improve and refine our disclosure controls and procedures and our internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>9B. Other Information </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Not applicable.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PART III</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>10. Directors, Executive Officers and Corporate Governance </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information regarding our directors and executive officers set forth under the headings &#x201c;Proposal No.1&#x2014;Election of Directors,&#x201d; &#x201c;Information Regarding the Board of Directors and Corporate Governance,&#x201d; and &#x201c;Executive Officers of the Registrant&#x201d; of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information regarding our Audit Committee, including the members of our Audit Committee, set forth under the heading &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Audit Committee&#x201d; of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information regarding the procedures by which our shareholders may recommend nominees to our Board of Directors set forth under the heading &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Nominating and Corporate Governance Committee&#x201d; of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information regarding our Code of Business Conduct and Ethics set forth under the heading &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x2014;Code of Business Conduct and Ethics&#x201d; of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>11. Executive Compensation </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information regarding executive compensation and director compensation set forth under the headings &#x201c;Executive Compensation&#x201d; and &#x201c;Director Compensation,&#x201d; respectively, of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information contained in the sections captioned &#x201c;Security Ownership of Certain Beneficial Owners and Management&#x201d; and &#x201c;Equity Compensation Plan Information&#x201d; of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>13. Certain Relationships and Related Transactions and Director Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Information contained in the section captioned &#x201c;Related Person Transactions and Indemnification&#x201d; of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Information regarding director independence set forth under the heading &#x201c;Information Regarding the Board of Directors and Corporate Governance&#x201d; of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>14. Principal Accounting Fees and Services </b><b><i> </i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Information regarding our independent auditor fees and services in the section captioned &#x201c;Proposal No. 2&#x2014;Ratification of Selection of Independent Registered Public Accounting Firm&#x201d; of the 2022 Proxy Statement is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PART IV </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>15. Exhibits and Financial Statement Schedules </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(a) The following documents are filed as part of this Form 10-K:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">1.</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#xa0; Financial Statements:</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">See Index to Financial Statements in Item&#xa0;8 of this Form 10-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">2.</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#xa0; Financial Statement Schedules:</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reference is made to the financial statement schedules included under Item 8 of Part II hereof. All other schedules are omitted because they are not applicable, not required or the information is shown in the financial statements or the notes thereto.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(b) Exhibits</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td colspan="7" style="vertical-align: bottom; width: 25%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporation By Reference</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit</b><br /> <b>Number</b></td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 57%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit Description </b></td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SEC</b><br /> <b>File</b>&#xa0;<b>No.</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>&#xa0;&#xa0;&#xa0;Filing</b>&#xa0;<b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2.1&#xa7;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774921026589/ex_306800.htm" style="-sec-extract:exhibit;">Agreement and Plan of Merger, dated as of November 14, 2021, by and among the Registrant, Lowell, Merger Sub 1, Merger Sub 2 and the Stockholder Representative.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: center;">10-Q</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">2.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">11/15/2021&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511040233/dex31.htm" style="-sec-extract:exhibit;">Amended and Restated Certificate of Incorporation of the Registrant.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">3.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2/18/2011&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774919012706/ex_148566.htm" style="-sec-extract:exhibit;">Certificate of Amendment of Amended and Restated Certificate of Incorporation of the Registrant.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">3.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">6/25/2019&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511003822/dex34.htm" style="-sec-extract:exhibit;">Amended and Restated Bylaws of the Registrant.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-170594</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">3.4</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">1/7/2011&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774921006074/ex_232263.htm" style="-sec-extract:exhibit;">Description of Capital Stock.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">4.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">3/15/2021&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511040233/dex31.htm" style="-sec-extract:exhibit;">Reference is made to Exhibits 3.1 through 3.3.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.3</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511019097/dex42.htm" style="-sec-extract:exhibit;">Specimen Common Stock Certificate of the Registrant.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-170594</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">4.2</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">1/31/2011&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.4</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774919011209/ex_146212.htm" style="-sec-extract:exhibit;">Form of Warrant to Purchase Common Stock of the Registrant, dated as of May 30, 2019.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">4.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6/3/2019&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.5</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774921026596/ex_307243.htm" style="-sec-extract:exhibit;">Form of Warrant to Purchase Common Stock of the Registrant, dated as of November 15, 2021.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">4.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11/15/2021&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.1+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511003822/dex101.htm" style="-sec-extract:exhibit;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-170594</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;&#xa0;1/7/2011&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.2+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511043852/dex993.htm" style="-sec-extract:exhibit;">2011 Equity Incentive Plan.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-8</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-172409</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">99.3</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;2/24/2011&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.3+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511082980/dex105.htm" style="-sec-extract:exhibit;">Forms of Stock Option Grant Notice, Notice of Exercise and Option Agreement under 2011 Equity Incentive Plan.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.5</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;3/30/2011&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.4+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511082980/dex106.htm" style="-sec-extract:exhibit;">Forms of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under 2011 Equity Incentive Plan.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.6</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;3/30/2011&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.5+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/0001427925/000143774921015096/ex_258026.htm" style="-sec-extract:exhibit;">Amended and Restated 2020 Equity Incentive Plan.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-350683</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;6/17/2021&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.6+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774920013240/ex_190601.htm" style="-sec-extract:exhibit;">Forms of Stock Option Grant Notice, Stock Option Agreement and Notice of Exercise under the Amended and Restated 2020 Equity Incentive Plan.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-8</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-239213</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">99.2</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;6/16/2020&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.7+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774920013240/ex_190602.htm" style="-sec-extract:exhibit;">Forms of RSU Award Grant Notice and Award Agreement (RSU Award) under the Amended and Restated 2020 Equity Incentive Plan.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-8</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-239213</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">99.3</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;6/16/2020&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.8+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774920013240/ex_190403.htm" style="-sec-extract:exhibit;">Amended and Restated 2011 Employee Stock Purchase Plan.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-8</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-239213</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">99.4</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;6/16/2020&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.9+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511003822/dex1015.htm" style="-sec-extract:exhibit;">Amended and Restated Offer Letter between the Registrant and Badri (Anil) Dasu, dated December&#xa0;30, 2010.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-170594</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.15</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">1/7/2011</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.10+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312511003822/dex1016.htm" style="-sec-extract:exhibit;">Amended and Restated Offer Letter between the Registrant and Pamela Palmer, dated December&#xa0;29, 2010.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-170594</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.16</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">1/7/2011</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.11+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774917008313/ex10-4.htm" style="-sec-extract:exhibit;">Offer Letter between the Registrant and Vincent J. Angotti, effective as of March 6, 2017.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.4</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">5/8/2017</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.12+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774917012802/ex10-1.htm" style="-sec-extract:exhibit;">Offer Letter between the Registrant and Raffi Asadorian, dated July 18, 2017.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;">10.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;&#xa0;&#xa0;7/19/2017</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.13+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="ex_343550.htm" style="-sec-extract:exhibit;">Non-Employee Director Compensation Policy.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       80
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td colspan="7" style="vertical-align: bottom; width: 25%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporation By Reference</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit</b><br /> <b>Number</b></td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 57%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit Description </b></td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SEC</b><br /> <b>File</b>&#xa0;<b>No.</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>&#xa0;&#xa0;&#xa0;Filing</b>&#xa0;<b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.14+</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774917002051/ex10-2.htm" style="-sec-extract:exhibit;">Amended and Restated Severance Benefit Plan effective as of February 7, 2017.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.2</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">2/9/2017</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.15&#xa7;</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774921012540/ex_248730.htm" style="-sec-extract:exhibit;">Sublease for a Single Sublessee, dated March 26, 2021, by and between the Registrant and Weichert Workforce Mobility Inc., as successor in interest to The MI Group, Inc.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.3</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;5/17/2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.16&#xa7;#</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774921026589/ex_300099.htm" style="-sec-extract:exhibit;">License and Commercialization Agreement (DZUVEO), dated July 14, 2021, between the Registrant and Laboratoire Aguettant.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;11/15/2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.17&#xa7;#</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774921026589/ex_300100.htm" style="-sec-extract:exhibit;">License and Commercialization Agreement (PFS), dated July 14, 2021, between the Registrant and Laboratoire Aguettant.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.2</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;11/15/2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.18</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774922000792/ex_323104.htm" style="-sec-extract:exhibit;">Contingent Value Rights Agreement, dated as of January 7, 2022, by and among AcelRx Pharmaceuticals, Inc., James Wilkie, solely in his capacity as the representative of the Lowell stockholders and option holders, and Computershare Inc., and its wholly-owned subsidiary, Computershare Trust Company, N.A., a federally chartered trust company, collectively as Rights Agent</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;1/12/2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.19&#xa7;#</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774921020165/ex_274502.htm" style="-sec-extract:exhibit;">Commercial Supply Agreement, effective March 31, 2021 by and between the Registrant and Catalent Pharma Solutions, LLC.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;8/16/2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.20</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312513207876/d515467dex101.htm" style="-sec-extract:exhibit;">Manufacturing Services Agreement between Registrant and Patheon Pharmaceuticals, Inc., dated as of January 18, 2013.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;5/8/2013</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.21</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312513207876/d515467dex102.htm" style="-sec-extract:exhibit;">Amended and Restated Capital Expenditure Agreement between Registrant and Patheon Pharmaceuticals, Inc., dated as of January 18, 2013.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.2</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;&#xa0;5/8/2013</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.22</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000119312514190281/d717969dex104.htm" style="-sec-extract:exhibit;">Second Amendment to Amended and Restated Capital Expenditure and Equipment Agreement, between the Registrant and Patheon Pharmaceuticals, Inc. effective as of January 30, 2014.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.4</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;&#xa0;5/8/2014</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.23#</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774916030547/ex10-6.htm" style="-sec-extract:exhibit;">Amendment #1 to Manufacturing Services Agreement between the Registrant and Patheon Pharmaceuticals, Inc., effective as of January 19, 2016.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.6</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;&#xa0;5/2/2016</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.24#</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774917018899/ex_98728.htm" style="-sec-extract:exhibit;">Amendment #2 to Manufacturing Services Agreement between the Registrant and Patheon Pharmaceuticals, Inc., effective as of August 4, 2017.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;&#xa0;11/9/2017</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">&#xa0;&#xa0;10.25#</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774915019387/ex10-6.htm" style="-sec-extract:exhibit;">Purchase and Sale Agreement between Registrant and ARPI LLC, dated as of September 18, 2015.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.6</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;11/3/2015</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.26#</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774915019387/ex10-7.htm" style="-sec-extract:exhibit;">Subsequent Purchase and Sale Agreement between ARPI LLC (a wholly owned subsidiary of the Registrant) and SWK Funding, LLC (assigned of PDL BioPharma, Inc.), dated as of September 18, 2015.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.7</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;11/3/2015</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.27</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774916034183/ex10-1.htm" style="-sec-extract:exhibit;">Controlled Equity Offering<sup style="vertical-align:top;line-height:120%;font-size:pt">SM</sup>&#xa0;Sales Agreement between the Registrant and Cantor Fitzgerald &amp; Co., dated as of June 21, 2016.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;6/21/2016</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.28</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774920013055/ex_190128.htm" style="-sec-extract:exhibit;">Amendment No. 1 to the Controlled Equity Offering<sup style="vertical-align:top;line-height:120%;font-size:pt">SM</sup>&#xa0;Sales Agreement between the Registrant and Cantor Fitzgerald &amp; Co., dated as of August 29, 2020.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">S-3</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">333-239156</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">1.3</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;6/12/2020</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td colspan="7" style="vertical-align: bottom; width: 25%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporation By Reference</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit</b><br /> <b>Number</b></td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 57%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit Description </b></td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SEC</b><br /> <b>File</b>&#xa0;<b>No.</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>&#xa0;&#xa0;&#xa0;Filing</b>&#xa0;<b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.29</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774919011209/ex_146213.htm" style="-sec-extract:exhibit;">Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of May 30, 2019.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">8-K</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;6/3/2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.30</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774921026589/ex_306589.htm" style="-sec-extract:exhibit;">First Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of May 5, 2021.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.4</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;11/15/2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.31</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="ex_343559.htm" style="-sec-extract:exhibit;">Second Amendment to Loan and Security Agreement between the Registrant and Oxford Finance, LLC, dated as of November 14, 2021.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.32#</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774919021796/ex_162768.htm" style="-sec-extract:exhibit;">Agreement between the Registrant and SpecGX, LLC, dated June 16, 2017.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.1</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;11/7/2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">10.33</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="http://www.sec.gov/Archives/edgar/data/1427925/000143774919021796/ex_162769.htm" style="-sec-extract:exhibit;">Amendment to Agreement between the Registrant and SpecGX, LLC, dated September 23, 2019.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: center;">10-Q</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">001-35068</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%; text-align: right;">10.2</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;11/7/2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">23.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="ex_341620.htm" style="-sec-extract:exhibit;">Consent of Withum Smith &amp; Brown, LLP, Independent Registered Public Accounting Firm.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%; text-align: right;">23.2</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"><a href="ex_341621.htm" style="-sec-extract:exhibit;">Consent of OUM &amp; Co. LLP, Independent Registered Public Accounting Firm.</a></td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">24.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="#poa" style="-sec-extract:exhibit;">Power of Attorney (included in signature page).</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">31.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="ex_341622.htm" style="-sec-extract:exhibit;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">31.2</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="ex_341623.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) promulgated under the Securities Exchange Act of 1934, as amended.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">32.1</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;"><a href="ex_341624.htm" style="-sec-extract:exhibit;">Certifications of Chief Executive Officer and Chief Financial Officer pursuant to 18 U.S.C. Section&#xa0;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">101.INS</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;">XBRL Instance Document- the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">101.SCH</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;">Inline XBRL Taxonomy Schema Document</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">101.CAL</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;">Inline XBRL Taxonomy Calculation Linkbase Document</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">101.DEF</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;">Inline XBRL Taxonomy Definition Linkbase Document</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">101.LAB</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;">Inline XBRL Taxonomy Label Linkbase Document</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       82
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td colspan="7" style="vertical-align: bottom; width: 25%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Incorporation By Reference</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit</b><br /> <b>Number</b></td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 57%; text-align: center; border-bottom: 1px solid rgb(0, 0, 0);"><b>Exhibit Description </b></td>
     <td style="vertical-align: bottom; width: 1%; text-align: center;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Form</b></p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SEC</b><br /> <b>File</b>&#xa0;<b>No.</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Exhibit</b></p> </td>
     <td style="vertical-align: bottom; width: 1%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 10%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><b>&#xa0;&#xa0;&#xa0;Filing</b>&#xa0;<b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">101.PRE</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;">Inline XBRL Taxonomy Presentation Linkbase Document</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 57%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 6%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 1%;">&#xa0;</td>
     <td style="vertical-align: middle; width: 10%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">104</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 57%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 4pt;">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.INS, 101.SCH, 101.CAL, 101.DEF, 101.LAB, and 101.PRE).</p> </td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 6%;">&#xa0;</td>
     <td style="vertical-align: top; width: 1%;">&#xa0;</td>
     <td style="vertical-align: top; width: 10%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr class="hr-custom" style="text-align: left;height: 1px; color: #000000; background-color: #000000; width: 10%; border: none; margin: 0pt auto 3pt 0pt;" />
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#xa7;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Schedules omitted pursuant to Item 601(a)(5) of Regulation S-K. The Registrant agrees to furnish supplementally a copy of any omitted schedule upon request by the SEC.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">+</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Indicates management contract or compensatory plan.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">#</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">Material in the exhibit marked with am &#x201c;[*]&#x201d; has been omitted because it is confidential, not material, and would be competitively harmful if publicly disclosed.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">&#xa0;</p> </td>
     <td style="width: auto;"> <p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#x201c;filed&#x201d; by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Item</b>&#xa0;<b>16. Form 10-K Summary</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of Section&#xa0;13 or 15(d) of the Securities Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Date: March&#xa0;10, 2022</p> </td>
     <td style="vertical-align:bottom;width:50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>AcelRx Pharmaceuticals, Inc.</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:50%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Registrant)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:50%;">&#xa0;</td>
     <td style="vertical-align:middle;width:50%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:50%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Vincent J. Angotti&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:50%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Vincent J. Angotti</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Chief Executive Officer and Director</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Principal Executive Officer)</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:50%;">&#xa0;</td>
     <td style="vertical-align:middle;width:50%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:50%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Raffi Asadorian&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:50%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:50%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Raffi Asadorian</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Chief Financial Officer</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Principal Financial and Accounting Officer)</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     84
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><a id="poa" title="poa" href="#"></a>POWER OF ATTORNEY </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Vincent J. Angotti and Raffi Asadorian, and each of them, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution for him or her, and in his or her name in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, and any of them, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:43.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><b>Signature</b></span></p> </td>
     <td style="vertical-align:bottom;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><b>Title</b></span></p> </td>
     <td style="vertical-align:bottom;width:15.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><span style="text-decoration: underline; "><b>Date</b></span></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:middle;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:middle;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Vincent J. Angotti&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Chief&#xa0;Executive&#xa0;Officer and Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Vincent J. Angotti</b></td>
     <td style="vertical-align: top; width: 40.9%; padding: 0pt 0pt 0pt 7pt;"><i>(Principal Executive Officer)</i></td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:middle;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:middle;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Raffi Asadorian&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Chief Financial Officer</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Raffi Asadorian</b></td>
     <td style="vertical-align: top; width: 40.9%; padding: 0pt 0pt 0pt 7pt;"><i>(Principal</i>&#xa0;<i>Financial</i>&#xa0;<i>and</i>&#xa0;<i>Accounting</i>&#xa0;<i>Officer)</i></td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:middle;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:middle;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Adrian Adams&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Chairman</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Adrian Adams</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: middle; width: 43.6%;">&#xa0;</td>
     <td style="vertical-align:middle;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:middle;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Richard Afable, M.D.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Richard Afable, M.D.</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Marina Bozilenko&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Marina Bozilenko</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:middle;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:middle;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Jill Broadfoot&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Jill Broadfoot</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:middle;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:middle;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Mark G. Edwards&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Mark G. Edwards</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:middle;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:middle;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Stephen J. Hoffman, Ph.D., M.D.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Stephen J. Hoffman, Ph.D., M.D.</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:middle;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:middle;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Pamela P. Palmer, M.D., Ph.D.&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Pamela P. Palmer, M.D., Ph.D.</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Howard B. Rosen&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Howard B. Rosen</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:43.6%;">&#xa0;</td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/&#xa0;&#xa0;&#xa0;&#xa0;Mark Wan&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p> </td>
     <td style="vertical-align:top;width:40.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 7pt;">Director</p> </td>
     <td style="vertical-align:top;width:15.5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;">March&#xa0;10, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 43.6%; text-align: center;"><b>Mark Wan</b></td>
     <td style="vertical-align:top;width:40.9%;">&#xa0;</td>
     <td style="vertical-align:top;width:15.5%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       85
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>ACELRX PHARMACEUTICALS, INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 95%;">&#xa0;</td>
     <td style="vertical-align: bottom; width: 5%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Page</b>&#xa0;</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Reports of Independent Registered Public Accounting Firms&#xa0;</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">F-2</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Consolidated Balance Sheets at December&#xa0;31, 2021 and 2020</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">F-6</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Consolidated Statements of Operations for the years ended December&#xa0;31, 2021 and 2020</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">F-7</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Consolidated Statements of Stockholders&#x2019;&#xa0;Deficit for the years ended December&#xa0;31, 2021 and 2020</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">F-8</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Consolidated Statements of Cash Flows for the years ended December&#xa0;31, 2021 and 2020</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">F-9</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Notes to Consolidated Financial Statements</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">F-9</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align: top; width: 95%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Financial Statement Schedule II</p> </td>
     <td style="vertical-align: bottom; width: 5%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 9pt; text-align: right;">F-37</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     F-1
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Report of Independent Registered Public Accounting Firm</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">To the Stockholders and the Board of Directors of</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AcelRx Pharmaceuticals, Inc.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Hayward, California</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Opinion on the Financial Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">We have audited the accompanying consolidated balance sheet of AcelRx Pharmaceuticals, Inc. (the "Company") as of December&#xa0;31, 2021, the related consolidated statements of operations, stockholders&#x2019; deficit, and cash flows for the year ended December&#xa0;31, 2021, and the related notes and schedule II (collectively referred to as the "consolidated financial statements"). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December&#xa0;31, 2021, and the results of its operations and its cash flows for the year ended December&#xa0;31, 2021, in conformity with accounting principles generally accepted in the United States of America.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The consolidated financial statements of the Company as of and for the year ended December 31, 2020 were audited by OUM &amp; Co. LLP, who joined WithumSmith+Brown, PC on July 15, 2021, and rendered their opinion on such statements on March 15, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Basis for Opinion</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#xa0;and regulations of the Securities and Exchange Commission and the PCAOB.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Critical Audit Matters</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing a separate opinion on the critical audit matters or on the accounts or disclosures to which they relate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Product Revenue Allowances for Chargebacks, Government Rebates and Product Returns</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Description of the Matter </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">As described in Note 1 to the consolidated financial statements, revenue from product sales is recognized net of estimates for variable consideration consisting of chargebacks, government rebates, returns, distribution fees, GPO fees and product returns. This variable consideration is recorded in the same period that the related revenue is recognized and creates variability for the consideration that the Company expects to receive. Liabilities related to government rebates and rebate programs of managed healthcare organizations involve the use of significant assumptions and judgments that include consideration of legal interpretations of applicable laws and regulations, historical claims experience, the payer channel mix, current contract prices, unbilled claims, claims submission time lags, and inventory levels in the distribution channel. Estimates for product returns consider existing return policies with customers, historical sales and return rates, inventory levels in the distribution channel, and product shelf lives.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Management&#x2019;s estimated allowance for chargebacks, government rebates, and product returns requires a high degree of judgment and is subject to change based on various quantitative and qualitative factors. Accordingly, extensive audit effort and a high degree of auditor judgment were needed to evaluate management&#x2019;s estimates and assumptions used in the determination of chargebacks, government rebates, and product returns.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>How We Addressed the Matter in Our Audit</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We obtained an understanding of and evaluated the design of controls relating to the Company&#x2019;s processes for estimating chargebacks, government rebates, and product returns.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We evaluated the significant accounting policies relating to chargebacks, government rebates, and product returns, as well as management&#x2019;s application of the policies, for appropriateness and reasonableness.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">To test management&#x2019;s estimates of chargebacks, rebates and returns, we obtained management&#x2019;s calculations for the respective estimates and performed one or more of the following procedures: clerically tested the calculation, agreed relevant inputs to the terms of relevant contracts, performed retrospective reviews, performed a sensitivity analysis on the inputs and assumptions used in the estimates and assessed subsequent events, evaluated the methodologies and assumptions used and the underlying data used by the Company, evaluated the assumptions used by management against historical trends, evaluated the change in estimated accruals from the prior periods, and assessed the historical accuracy of the Company&#x2019;s estimates against actual results.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Contract and Other Collaboration Revenue </i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>Description of the Matter</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company recognized contract and other collaboration revenue of $1.8 million for the year ended December 31, 2021.&#xa0; As described in Note 1 to the consolidated financial statements, these arrangements may include payments for upfront signing or license fees, cost reimbursements for development and manufacturing services, milestone payments, revenue from product sales, and royalties on licensee&#x2019;s future product sales. As discussed in Notes 6 and 7 to the consolidated financial statements, the Company entered into a License and Commercialization Agreement with Laboratoire Aguettant to commercialize Dzuveo in the European Union and certain non-European Union countries. Under the agreement, the Company is entitled to receive up to &#x20ac;47.0 million in a combination of upfront and sales-based milestone payments, of which the Company has received an upfront cash payment of $2.9 million. The license and collaboration agreement contains multiple performance obligations that may require the Company to deliver goods and/or services throughout the term of the agreement.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Auditing the Company&#x2019;s accounting for revenue from collaboration arrangements was complex and required significant judgment, primarily in identifying the performance obligations, determining the standalone selling prices underlying each performance obligation, determining the allocation of arrangement consideration and determining the variable consideration, including variable consideration that is subject to a constraint. The determination of standalone selling prices for certain of the Company&#x2019;s arrangements involves significant judgement as a performance obligation may not have readily observable inputs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><i>How the Critical Audit Matter Was Addressed in the Audit</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We obtained an understanding and evaluated the design of controls over the Company&#x2019;s processes for revenue recognition, including identification of performance obligations, determination of standalone selling price underlying each performance obligation, and estimation of variable consideration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">To test the accounting for revenue from the collaboration agreement we tested and evaluated, among other things, the performance obligations identified, the manner in which the performance obligation is satisfied, the estimates and assumptions used to determine transaction price, and the allocation of transaction price to performance obligations.&#xa0; Our audit procedures also included, among other things, reading the agreements and related schedules, reviewing management&#x2019;s analysis for completeness and accuracy by agreeing data to underlying agreements, understanding the methodologies utilized in accordance with the relevant accounting guidance and assessing the reasonableness of management&#x2019;s estimates and judgments through a review of the agreements, inspecting communications from the collaborative partner, and performing a sensitivity analysis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorName">WithumSmith+Brown, PC</ix:nonNumeric></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We have served as the Company's auditor since 2015.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorLocation">San Francisco, California</ix:nonNumeric></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 10, 2022</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">PCAOB ID Number <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AuditorFirmId">100</ix:nonNumeric></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     F-4
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Stockholders and Board of Directors</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">AcelRx Pharmaceuticals, Inc.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Hayward, California</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Opinion on the Consolidated Financial Statements </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">We have audited the accompanying consolidated balance sheet of AcelRx Pharmaceuticals, Inc. (the &#x201c;Company&#x201d;) as of December 31, 2020, the related consolidated statements of operations, stockholders&#x2019; deficit, and cash flows for the year ended December 31, 2020, and the related notes and schedule (collectively referred to as the &#x201c;consolidated financial statements&#x201d;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2020, and the results of its operations and its cash flows for the year ended December&#xa0;31, 2020<b>,</b> in conformity with accounting principles generally accepted in the United States of America.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Basis for Opinion</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on the Company&#x2019;s consolidated financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (&#x201c;PCAOB&#x201d;) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audit we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Our audit included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audit provides a reasonable basis for our opinion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_LegalEntityAxis-OUMCoLLPMember" name="dei:AuditorName">OUM &amp; CO. LLP</ix:nonNumeric></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We have served as the Company's auditor since 2015.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_LegalEntityAxis-OUMCoLLPMember" name="dei:AuditorLocation">San Francisco, California</ix:nonNumeric></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">March 15, 2021</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">PCAOB ID Number <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_LegalEntityAxis-OUMCoLLPMember" name="dei:AuditorFirmId">252</ix:nonNumeric></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
     F-5
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
     &#xa0;
   </div>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AcelRx Pharmaceuticals, Inc. </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Balance Sheets </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands, except share data) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current Assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618409" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">12,663</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618410" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">27,274</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Short-term investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618411" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">38,967</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618412" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">15,612</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accounts receivable, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618413" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">160</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618414" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsReceivableNetCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">635</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Inventories, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618415" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,111</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618416" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,626</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Prepaid expenses and other current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618417" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,588</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618418" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,683</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;">Total current assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618419" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">55,489</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618420" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">46,830</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease right-of-use assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618421" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-3">4,302</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618422" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" format="ixt:numdotdecimal" decimals="-4">3,150</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618423" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">15,928</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618424" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">15,659</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618425" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,174</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618426" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">656</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618427" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">77,893</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618428" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="3" format="ixt:numdotdecimal" decimals="-3">66,295</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities and Stockholders</b>&#x2019;<b> Deficit</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current Liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618431" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,121</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618432" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,737</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accrued and other liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618433" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">6,524</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618434" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,045</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Long-term debt, current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618435" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LongTermDebtCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8,796</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618436" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermDebtCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8,735</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Operating lease liabilities, current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618437" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618438" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,118</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618439" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">18,509</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618440" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">17,635</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618441" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,007</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618442" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">13,140</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred revenue, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618443" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,151</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618444" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618445" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">3,750</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618446" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,606</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liability related to the sale of future royalties</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618447" contextRef="i_2021-12-31" unitRef="USD" name="acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">85,288</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618448" contextRef="i_2020-12-31" unitRef="USD" name="acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">88,365</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other long-term liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618449" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618450" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">299</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;">Total liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618451" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">113,786</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618452" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">122,045</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commitments and Contingencies</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c81618454">&#xa0;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c81618455">&#xa0;</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stockholders&#x2019; Deficit:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt; text-indent: -9pt;">Common stock, $<span style="-sec-ix-hidden:c81618459"><span style="-sec-ix-hidden:c81618460">0.001</span></span> par value&#x2014;<span style="-sec-ix-hidden:c81618461"><span style="-sec-ix-hidden:c81618462">200,000,000</span></span> shares authorized as of December 31, 2021 and 2020; <span style="-sec-ix-hidden:c81618463"><span style="-sec-ix-hidden:c81618465">136,819,647</span></span> and <span style="-sec-ix-hidden:c81618464"><span style="-sec-ix-hidden:c81618466">98,812,008</span></span> shares issued and outstanding as of December 31, 2021 and 2020, respectively</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618457" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">137</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618458" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="3" format="ixt:numdotdecimal" decimals="-3">98</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618467" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">437,554</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618468" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapital" scale="3" format="ixt:numdotdecimal" decimals="-3">382,637</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618469" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">473,584</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618470" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">438,485</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 45pt;">Total stockholders&#x2019; deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618471" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,893</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618472" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">55,750</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Total Liabilities and Stockholders&#x2019; Deficit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618473" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">77,893</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618474" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">66,295</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See notes to consolidated financial statements.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AcelRx Pharmaceuticals, Inc. </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Operations</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands, except share and per share data) </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Revenue:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Product sales</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;"><ix:nonFraction id="c81618476" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,005</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;"><ix:nonFraction id="c81618477" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,521</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Contract and other collaboration</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618478" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,813</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618479" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,895</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618480" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,818</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618481" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">5,416</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating costs and expenses:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Cost of goods sold</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;"><ix:nonFraction id="c81618483" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:numdotdecimal" decimals="-3">3,753</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;"><ix:nonFraction id="c81618484" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" format="ixt:numdotdecimal" decimals="-3">6,032</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;"><ix:nonFraction id="c81618485" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;"><ix:nonFraction id="c81618486" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,017</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Selling, general and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618487" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">30,935</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618488" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" format="ixt:numdotdecimal" decimals="-4">36,330</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total operating costs and expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618489" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">38,783</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618490" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CostsAndExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">46,379</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss from operations</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;">(<ix:nonFraction id="c81618491" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,965</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;">(<ix:nonFraction id="c81618492" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,963</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Interest expense</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;">(<ix:nonFraction id="c81618494" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">2,291</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;">(<ix:nonFraction id="c81618495" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,305</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 27pt;">Interest income and other income, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;"><ix:nonFraction id="c81618496" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeNet" scale="3" format="ixt:numdotdecimal" decimals="-3">124</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;"><ix:nonFraction id="c81618497" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InvestmentIncomeNet" scale="3" format="ixt:numdotdecimal" decimals="-3">583</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 27pt;">Non-cash interest income on liability related to sale of future royalties</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618498" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" scale="3" format="ixt:numdotdecimal" decimals="-3">3,038</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618499" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" scale="3" format="ixt:numdotdecimal" decimals="-4">3,310</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 54pt;">Total other income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618500" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">871</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618501" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NonoperatingIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">588</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss before income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;">(<ix:nonFraction id="c81618502" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,094</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right;">(<ix:nonFraction id="c81618503" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,375</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618504" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618505" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81618506" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,099</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81618507" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,379</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Comprehensive loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81618508" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,099</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81618509" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,379</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, basic and diluted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81618510" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.29</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81618511" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.47</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Shares used in computing net loss per share of common stock, basic and diluted &#x2013;see Note 15</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618512" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">119,860,266</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 10pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618513" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">85,257,008</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AcelRx Pharmaceuticals, Inc.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Stockholders</b>&#x2019;<b> Deficit </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands, except share data) </b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 12%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Common Stock</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"><b><b>Additional</b><br /> <b>Paid-in</b><br /> <b>Capital </b></b></td><td style="padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated</b><br /> <b>Deficit</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b><br /> <b>Stockholders</b>&#x2019;<br /> <b>Deficit</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 8%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 8%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt; width: 8%;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Balance as of December 31, 2019</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618514" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">79,573,101</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt;">$</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonFraction id="c81618515" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">79</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618516" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">356,609</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt;">$</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt; text-align: right;">(<ix:nonFraction id="c81618517" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">398,106</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt;">$</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;">(<ix:nonFraction id="c81618518" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">41,418</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618520" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618521" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,424</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618522" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81618523" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,424</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Restricted stock units vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618524" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:numdotdecimal" decimals="INF">254,684</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618525" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618526" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618527" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618528" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Tax payments related to shares withheld for restricted stock units vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618530" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81618531" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">86</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618532" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;">(<ix:nonFraction id="c81618533" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">86</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net proceeds from issuance of common stock in connection with equity financings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618534" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">18,644,095</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonFraction id="c81618535" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">19</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618536" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">21,318</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618537" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81618538" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">21,337</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Issuance of common stock upon ESPP purchase</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618539" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" format="ixt:numdotdecimal" decimals="INF">340,128</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonFraction id="c81618540" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618541" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">372</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618542" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81618543" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">372</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81618545" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c81618546" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81618547" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,379</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">(<ix:nonFraction id="c81618548" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,379</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Balance as of December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618549" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">98,812,008</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonFraction id="c81618550" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">98</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618551" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">382,637</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt; text-align: right;">(<ix:nonFraction id="c81618552" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">438,485</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;">(<ix:nonFraction id="c81618553" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">55,750</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618555" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618556" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,609</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618557" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81618558" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" format="ixt:numdotdecimal" decimals="-3">4,609</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Restricted stock units vested</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618559" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" scale="0" format="ixt:numdotdecimal" decimals="INF">488,715</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618560" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618561" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618562" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618563" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Tax payments related to shares withheld for restricted stock units vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618565" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81618566" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">249</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618567" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;">(<ix:nonFraction id="c81618568" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">249</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net proceeds from issuance of common stock in connection with equity financings</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618569" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">37,201,562</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonFraction id="c81618570" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">38</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618571" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">44,678</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618572" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81618573" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" format="ixt:numdotdecimal" decimals="-3">44,716</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net proceeds from issuance of warrants in connection with equity financings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonFraction id="c81618575" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618576" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">5,562</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618577" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81618578" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued" scale="3" format="ixt:numdotdecimal" decimals="-3">5,562</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Issuance of common stock upon exercise of stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618579" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">19,403</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonFraction id="c81618580" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">1</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618581" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">16</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618582" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81618583" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" format="ixt:numdotdecimal" decimals="-3">17</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Issuance of common stock upon ESPP purchase</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618584" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" format="ixt:numdotdecimal" decimals="INF">297,959</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonFraction id="c81618585" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618586" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">301</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618587" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81618588" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" format="ixt:numdotdecimal" decimals="-3">301</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618590" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618591" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618592" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,099</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618593" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,099</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 45%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Balance as of December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 8%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618594" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">136,819,647</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 8pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618595" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">137</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618596" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3">437,554</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 6pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81618597" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">473,584</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 8%; font-family: Times New Roman; font-size: 10pt; margin-left: 11pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c81618598" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,893</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>
  </div>
  <p style="margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See notes to consolidated financial statements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>AcelRx Pharmaceuticals, Inc.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consolidated Statements of Cash Flows</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(in thousands)</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="6" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 70%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">CASH FLOWS FROM OPERATING ACTIVITIES:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net loss</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618600" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">35,099</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618601" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">40,379</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Non-cash royalty revenue related to royalty monetization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618603" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" scale="3" format="ixt:numdotdecimal" decimals="-3">83</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618604" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" scale="3" format="ixt:numdotdecimal" decimals="-3">242</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Non-cash interest income on liability related to royalty monetization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618605" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:NoncashInterestExpenseRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,038</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618606" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:NoncashInterestExpenseRecognized" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">3,310</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Depreciation and amortization</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618607" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">1,973</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618608" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" format="ixt:numdotdecimal" decimals="-3">1,853</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Non-cash interest expense related to debt financing</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618609" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" format="ixt:numdotdecimal" decimals="-3">761</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618610" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="3" format="ixt:numdotdecimal" decimals="-3">1,069</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Stock-based compensation</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618611" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">4,609</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618612" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">4,424</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Inventory impairment charge</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618613" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="3" format="ixt:numdotdecimal" decimals="-4">810</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618614" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="3" format="ixt:numdotdecimal" decimals="-3">712</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618615" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherNoncashIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">138</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618616" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OtherNoncashIncomeExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">344</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Changes in operating assets and liabilities:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 81pt;">Accounts receivable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618618" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">475</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618619" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" format="ixt:numdotdecimal" decimals="-3">203</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 81pt;">Inventories</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618620" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3">295</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618621" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInInventories" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">957</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 81pt;">Prepaid expenses and other assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618622" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">908</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618623" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">661</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 81pt;">Accounts payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618624" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">111</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618625" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">1,016</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 81pt;">Accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618626" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3">79</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618627" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">638</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 81pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618628" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">447</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618629" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">886</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 81pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618630" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">1,188</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618631" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,195</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 108pt;">Net cash used in operating activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618632" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">30,002</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618633" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">38,505</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">CASH FLOWS FROM INVESTING ACTIVITIES:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Purchase of property and equipment</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618635" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">1,827</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618636" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">1,855</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Purchase of investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618637" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">70,459</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618638" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsToAcquireShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">44,611</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Asset acquisition&#xa0;costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618639" contextRef="d_2021-01-01_2021-12-31_AssetAcquisitionAxis-LowellsIntellectualPropertyMember" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:numdotdecimal" decimals="-3">821</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618640" contextRef="d_2020-01-01_2020-12-31_AssetAcquisitionAxis-LowellsIntellectualPropertyMember" unitRef="USD" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Proceeds from sale of investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618641" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">2,996</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618642" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Proceeds from maturities of investments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618643" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">43,988</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618644" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">80,605</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 108pt;">Net cash&#xa0;(used in) provided by&#xa0;investing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618645" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">26,123</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618646" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">34,139</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">CASH FLOWS FROM FINANCING ACTIVITIES:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Payment of long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618648" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">8,833</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618649" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RepaymentsOfLongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">4,667</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net proceeds from issuance of common stock in connection with equity financings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618650" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">44,716</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618651" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="3" format="ixt:numdotdecimal" decimals="-3">21,337</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net proceeds from issuance of warrants in connection with equity financings</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618652" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" format="ixt:numdotdecimal" decimals="-3">5,562</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618653" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net proceeds from issuance of common stock through equity plans</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618654" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" format="ixt:numdotdecimal" decimals="-3">318</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618655" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" format="ixt:numdotdecimal" decimals="-3">372</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax payments related to shares withheld for restricted stock units vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618656" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">249</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81618657" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" format="ixt:numdotdecimal" decimals="-3">86</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 108pt;">Net cash provided by financing activities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618658" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">41,514</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618659" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" format="ixt:numdotdecimal" decimals="-3">16,956</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618660" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">14,611</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618661" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" format="ixt:numdotdecimal" decimals="-4">12,590</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">CASH, CASH EQUIVALENTS &#x2014;Beginning of year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618662" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">27,274</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618663" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">14,684</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">CASH, CASH EQUIVALENTS &#x2014;End of year</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618664" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">12,663</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618665" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" scale="3" format="ixt:numdotdecimal" decimals="-3">27,274</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Cash paid for interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618667" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestPaidNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,595</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618668" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestPaidNet" scale="3" format="ixt:numdotdecimal" decimals="-3">2,269</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Income taxes paid (refunded)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618669" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaidNet" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618670" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxesPaidNet" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">347</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">NONCASH INVESTING AND FINANCING ACTIVITIES:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Purchases of property and equipment in accounts payable&#xa0;and accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618672" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:PurchasesOfPropertyAndEquipmentInAccountsPayable" scale="3" format="ixt:numdotdecimal" decimals="-3">1,095</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618673" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:PurchasesOfPropertyAndEquipmentInAccountsPayable" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Asset acquisition costs in accounts payable and accrued expenses</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618674" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" scale="3" format="ixt:numdotdecimal" decimals="-3">1,087</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618675" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Establishment of right-of-use asset and lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618676" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">4,669</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618677" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Write-off of right-of-use asset and lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;">(<ix:nonFraction id="c81618678" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:WriteoffOfRightofuseAssetAndLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,128</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618679" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:WriteoffOfRightofuseAssetAndLeaseLiability" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Gain on termination of sublease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618680" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:GainOnTerminationOfSublease" scale="3" format="ixt:numdotdecimal" decimals="-3">522</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618681" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:GainOnTerminationOfSublease" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Leasehold improvements paid with note payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618682" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:LeaseholdPaidWithNotePayable" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: right;"><ix:nonFraction id="c81618683" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:LeaseholdPaidWithNotePayable" scale="3" format="ixt:numdotdecimal" decimals="-3">326</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">See notes to consolidated financial statements.&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       F-9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="c2050888" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em> Organization and Summary of Significant Accounting Policies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:BusinessDescriptionOfEntityPolicyTextBlock" id="c81624726" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The Company </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on <em style="font: inherit;"> July 13, 2005 </em>as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. The Company&#x2019;s operations are based in Hayward, California.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA&#xae;<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>(known as DZUVEO&#xae; in Europe) and Zalviso&#xae; are<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. On <em style="font: inherit;"> November 2, 2018, </em>the U.S. Food and Drug Administration, or FDA, approved DSUVIA for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The commercial launch of DSUVIA in the United States occurred in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2019.</em> In <em style="font: inherit;"> June 2018, </em>the European Commission, or EC, granted marketing approval of DZUVEO for the management of acute moderate to severe pain in adults in medically monitored settings. AcelRx is further developing a distribution capability and commercial organization to continue to market and sell DSUVIA in the United States. In geographies where AcelRx decides <em style="font: inherit;">not</em> to commercialize products by itself, the Company <em style="font: inherit;"> may </em>seek to out-license commercialization rights. The Company currently intends to commercialize and promote DSUVIA/DZUVEO outside the United States with <em style="font: inherit;">one</em> or more strategic partners, and, in <em style="font: inherit;"> July 2021, </em>entered into a License and Commercialization Agreement with Laboratoire Aguettant, or Aguettant, for Aguettant to commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom (see Note <em style="font: inherit;">6.</em> &#x201c;Out-License Agreements&#x2014;DZUVEO&#x201d;<i> </i>below). The timing of the resubmission of the Zalviso new drug application, or NDA, is in part dependent upon the finalization of the FDA&#x2019;s new opioid approval guidelines and process. AcelRx intends to seek regulatory approval for Zalviso in the United States and, if successful, potentially promote Zalviso either by itself or with strategic partners. Zalviso is approved in Europe and was commercialized by Gr&#xfc;nenthal GmbH, or Gr&#xfc;nenthal, through <em style="font: inherit;"> May 12, 2021 (</em>see <i>Termination of Gr</i>&#xfc;<i>nenthal Agreements</i> below). In <em style="font: inherit;"> July 2021, </em>the Company also entered into a separate License and Commercialization Agreement with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">3</em> mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">50</em> mcg/ml phenylephrine hydrochloride for injection (see Note <em style="font: inherit;">5.</em> &#x201c;In-License Agreement&#x201d; below). On <em style="font: inherit;"> January 7, 2022, </em>the Company closed the definitive merger agreement dated as of <em style="font: inherit;"> November 14, 2021, </em>or the Merger Agreement, to acquire Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note <em style="font: inherit;">19.</em> &#x201c;Subsequent Events&#x201d; below).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;"> December 31, 2020, </em>the Company had cash, cash equivalents and short-term investments of $<ix:nonFraction id="c81618708" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:numdotdecimal" decimals="-5">51.6</ix:nonFraction> million and $<ix:nonFraction id="c81618710" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="6" format="ixt:numdotdecimal" decimals="-5">42.9</ix:nonFraction> million, respectively. Based on the Company&#x2019;s current operating plans and projections, the Company expects that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least <em style="font: inherit;">one</em> year from the date this Annual Report on Form <em style="font: inherit;">10</em>-K is filed with the United States Securities and Exchange Commission, or SEC. Although Zalviso was approved for sale in Europe on <em style="font: inherit;"> September 18, 2015, </em>the Company sold the majority of the royalty rights and certain commercial sales milestones it is entitled to receive under the Amended License Agreement (defined below) with Gr&#xfc;nenthal to PDL BioPharma, Inc., or PDL, in a transaction referred to as the Royalty Monetization. On <em style="font: inherit;"> August 31, 2020, </em>PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK. In consideration of the termination of the Amended License Agreement, under the Royalty Monetization, the Company must use commercially reasonable efforts to negotiate a replacement license agreement with a <em style="font: inherit;">third</em> party.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Termination of Gr</span></i>&#xfc;<i><span style="text-decoration: underline; ">nenthal Agreements </span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 16, 2013, </em>AcelRx and Gr&#xfc;nenthal entered into a Collaboration and License Agreement, or the License Agreement, which was amended effective <em style="font: inherit;"> July 17, 2015 </em>and <em style="font: inherit;"> September 20, 2016, </em>or the Amended License Agreement, which granted Gr&#xfc;nenthal rights to commercialize the Zalviso PCA system, or the Product, in the <em style="font: inherit;">28</em> European Union, or EU, member states, at the time of the agreement, plus Switzerland, Liechtenstein, Iceland, Norway and Australia (collectively, the Zalviso Territory) for human use in pain treatment within, or dispensed by, hospitals, hospices, nursing homes and other medically supervised settings, (collectively, the Field). In <em style="font: inherit;"> September 2015, </em>the EC granted marketing approval for the marketing authorization application, or MAA, previously submitted to the EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. On <em style="font: inherit;"> December 16, 2013, </em>AcelRx and Gr&#xfc;nenthal entered into a Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. Under the MSA, the Company exclusively manufactured and supplied the Product to Gr&#xfc;nenthal for the Field in the Zalviso Territory. On <em style="font: inherit;"> July 22, 2015, </em>the Company and Gr&#xfc;nenthal amended the MSA, or the Amended MSA, effective as of <em style="font: inherit;"> July 17, 2015. </em>The Amended MSA and the Amended License Agreement are referred to as the Gr&#xfc;nenthal Agreements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">10</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 18, 2020, </em>the Company received a notice from Gr&#xfc;nenthal that it had exercised its right to terminate the Gr&#xfc;nenthal Agreements, effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#xfc;nenthal Agreements were extended to <em style="font: inherit;"> May 12, 2021 </em>to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on <em style="font: inherit;"> May 12, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c81624727" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Presentation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="c81624728" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Reclassifications </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the amounts reported in the Consolidated Balance Sheets as deferred revenue, current portion and liability related to the sale of future royalties, current portion have been reclassified to accrued and other liabilities at <em style="font: inherit;"> December 31, 2020, </em>and the amount reported as an inventory impairment charge in the Consolidated Statements of Cash Flows was recorded as other in the year ended <em style="font: inherit;"> December 31, 2020.</em></p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;"></em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ConsolidationPolicyTextBlock" id="c81624729" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Principles of Consolidation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiary, ARPI&#xa0;LLC, which was formed in <em style="font: inherit;"> September 2015 </em>for the sole purpose of facilitating the Royalty Monetization with PDL of the expected royalty stream and milestone payments due from the sales of Zalviso in the European Union by its commercial partner, Gr&#xfc;nenthal, pursuant to the Amended License Agreement. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note <em style="font: inherit;">10</em> &#x201c;Liability Related to Sale of Future Royalties&#x201d; for additional information.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:UseOfEstimates" id="c81624730" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management believes its most significant accounting estimates relate to revenue recognition, inventory valuation and the liability related to the sale of future royalties. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" id="c81624731" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cash, Cash Equivalents and Short-Term Investments </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all highly liquid investments with an original maturity (at date of purchase) of <em style="font: inherit;">three</em> months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All marketable securities are classified as available-for-sale and consist of commercial paper, U.S. government sponsored enterprise debt securities and corporate debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. The Company&#x2019;s investments are subject to a periodic impairment review for other-than-temporary declines in fair value. The Company&#x2019;s review includes the consideration of the cause of the impairment including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss in the amount of such decline.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">11</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="c81624764" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosure of fair value measurements as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level I&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level II&#x2014;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level III&#x2014;Unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity for the related assets or liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="c81624765" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Segment Information </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company operates in a single segment, the development and commercialization of product candidates and products for the treatment of pain. The Company&#x2019;s product sales revenue consists of sales of DSUVIA in the United States and, through <em style="font: inherit;"> May 2021, </em>sales of Zalviso in Europe by Gr&#xfc;nenthal. The Company&#x2019;s contract and collaboration revenue consists of non-cash royalty revenue, royalty revenue, and other revenue under the Gr&#xfc;nenthal Agreements and license revenue under the DZUVEO Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c81624837" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Risk </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company invests cash that is currently <em style="font: inherit;">not</em> being used for operational purposes in accordance with its investment policy in debt securities of U.S. government sponsored agencies, commercial paper and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company relies on a single <em style="font: inherit;">third</em>-party supplier for the supply of sufentanil, the active pharmaceutical ingredient in DSUVIA and Zalviso, and various sole-source <em style="font: inherit;">third</em>-party contract manufacturer organizations to manufacture the DSUVIA SDA.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">DSUVIA&#xa0;sales are concentrated with the DoD and with a limited number of wholesalers in the United States. Zalviso was sold in Europe by Gr&#xfc;nenthal through <em style="font: inherit;"> May 2021. </em>In <em style="font: inherit;"> July 2021, </em>Aguettant was granted an exclusive license to commercialize DZUVEO in Europe. DZUVEO sales in Europe by Aguettant have <em style="font: inherit;">not</em> commenced as of <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenue and accounts receivable have been concentrated with these customers.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues from customers that accounted for <em style="font: inherit;">10%</em> or more of our total revenues during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="c31D4AAC7-3711-4B48-98BE-2E21463C76B6" escape="true" continuedAt="BFB3E6C8-9AB6-47F5-A06C-E27D5B13DB08">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Year Ended December 31,</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Percent of Total Revenue</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Aguettant</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618834" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">61.9</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618835" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gr&#xfc;nenthal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618836" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-GrunenthalMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">11.7</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618837" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-GrunenthalMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">74.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">DoD</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618838" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DoDMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">0.3</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618839" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DoDMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">16.9</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Wholesaler A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618840" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-WholesalerAMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">15.9</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618841" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-WholesalerAMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="3">3.9</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
    </ix:nonNumeric> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ReceivablesPolicyTextBlock" id="c81624838" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Accounts Receivable, net</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The need for a bad debt allowance is evaluated each reporting period based on the Company&#x2019;s assessment of the credit worthiness of its customers or any other potential circumstances that could result in bad debt.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">12</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company believes that the entire accounts receivable balance as of <em style="font: inherit;"> December 31, 2021 </em>is collectible and there was <em style="font: inherit;">no</em> bad debt allowance provided as of <em style="font: inherit;"> December 31, 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable, net from customers that accounted for <em style="font: inherit;">10%</em> or more of our total accounts receivable balance as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:continuation id="BFB3E6C8-9AB6-47F5-A06C-E27D5B13DB08">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Percent of Accounts Receivable, Net</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618844" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">73</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618845" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">12</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer B</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618846" contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81618847" contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember" unitRef="Pure" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" format="ixt:numdotdecimal" decimals="2">79</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
    </ix:continuation> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:InventoryPolicyTextBlock" id="c81624839" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Inventories, net </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method for all inventories. Inventory includes the cost of the active pharmaceutical ingredients, or API, raw materials and <em style="font: inherit;">third</em>-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are allocated to the appropriate cost pool and then absorbed into inventory based on the units produced or distributed, assuming normal capacity, in the applicable period. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company's policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The Company periodically evaluates the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or net realizable value approach as that used to value the inventory.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c81624840" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Property and Equipment, net </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:c81618752">three</span> to <span style="-sec-ix-hidden:c81618753">five</span> years. Leasehold improvements are amortized over the shorter of the estimated useful life of the improvements or the remaining lease term. Expenditures for repairs and maintenance, which do <em style="font: inherit;">not</em> extend the useful life of the property and equipment, are expensed as incurred. Upon retirement, the asset cost and related accumulated depreciation are relieved from the accompanying Consolidated Balance Sheets. Gains and losses associated with dispositions are reflected as a component of interest income and other income, net in the accompanying Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="c81624841" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Impairment of Long-Lived Assets </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. For example, if the Company is <em style="font: inherit;">not</em> successful in its commercialization of DSUVIA, and if approved, Zalviso, purchased equipment and manufacturing-related facility improvements the Company has made at its contract manufacturers could become impaired. The Company <em style="font: inherit;"> may </em>determine that it is <em style="font: inherit;">no</em> longer probable that the Company will realize the future economic benefit associated with the costs of these assets through future manufacturing activities, and if so, the Company would record an impairment charge associated with these assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:ContingentPutOptionPolicyPolicyTextBlock" id="c81624842" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contingent put option</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The contingent put option associated with the Company&#x2019;s Loan Agreement with Oxford is recorded as a liability. Changes in the fair value of the contingent put option are recognized as interest income and other income (expense), net in the Consolidated Statements of Operations. For further discussion, see Note <em style="font: inherit;">8</em> &#x201c;Long-Term Debt&#x201d;.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> <b><i> </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:LesseeLeasesPolicyTextBlock" id="c81624843" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company follows the provisions of ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>. At the inception of an arrangement, the Company determines whether the arrangement is, or contains, a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically <em style="font: inherit;">not</em> readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset <em style="font: inherit;"> may </em>be required for items such as initial direct costs paid or incentives received.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">13</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the Consolidated Balance Sheets as operating lease right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="c81624852" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Revenue from Contracts with Customers </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company follows the provisions of Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">606,</em> <i>Revenue from Contracts with Customers</i>. This guidance provides a unified model to determine how revenue is recognized. The Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company sells its products primarily through wholesale and specialty distributors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#xa0;identification of the promised goods or services in the contract; (ii)&#xa0;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#xa0;measurement of the transaction price, including the constraint on variable consideration; (iv)&#xa0;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#xa0;recognition of revenue when (or as) the Company satisfies each performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Product sales revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company sells its product primarily through distributors. Revenues from product sales are recognized when distributors obtain control of the Company&#x2019;s product, which occurs at a point in time, upon delivery to such distributors. These distributors subsequently resell the product to certified medically supervised healthcare settings. In addition to distribution agreements with these customers, the Company enters into arrangements with group purchasing organizations, or GPOs, and other certified medically supervised healthcare settings that provide for privately negotiated discounts with respect to the purchase of its products. For revenue recognition under bill-and-hold arrangements, wherein the customer agrees to buy product from the Company but requests delivery at a later date, the Company deems that control passes to the customer when the product is ready for delivery. The Company recognizes revenue under these types of arrangements when a signed agreement is in place, the transaction is billable, the customer has significant risk and rewards for the product and the ability to direct the asset, the product has been set aside specifically for the customer, and the product cannot be redirected to another customer. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, government rebates, returns, distribution fees, GPO fees and product returns.&#xa0;Variable consideration is recorded at the time product sales are recognized resulting in a reduction in product revenue. The amount of variable consideration that is included in the transaction price <em style="font: inherit;"> may </em>be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will <em style="font: inherit;">not</em> occur in a future period. Variable consideration is estimated using the most-likely amount method, which is the single-most likely outcome under a contract and is typically at the stated contractual rate.&#xa0;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method under ASC Topic <em style="font: inherit;">606</em> for relevant factors. These factors include current contractual and statutory requirements, specific known market events and trends, industry data, and/or forecasted customer buying and payment patterns. Actual amounts of consideration ultimately received <em style="font: inherit;"> may </em>differ from the Company&#x2019;s estimates.&#xa0;If actual results vary materially from the Company&#x2019;s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These estimates include:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Chargebacks</span> &#x2013; The Company&#x2019;s customers subsequently resell its product to qualified healthcare providers. In addition to distribution agreements with customers, the Company enters into arrangements with qualified healthcare providers that provide discounts with respect to the purchase of its product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue-related accrued liabilities on the Consolidated Balance Sheets. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by customers, and the Company issues credits for such amounts generally within a few weeks of the customer's notification to the Company of the resale. Reserves for chargebacks consists of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period end that the Company expects will be sold to the qualified healthcare providers, and chargebacks for units that the Company&#x2019;s customers have sold to the qualified healthcare providers, but for which credits have <em style="font: inherit;">not</em> been issued.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Government Rebates</span> &#x2013; The Company is subject to discount obligations under state Medicaid programs. The Company estimates its Medicaid rebates, and reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued liabilities on the Consolidated Balance Sheet.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">14</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Returns</span> &#x2013;<i> </i>The Company allows its distributors to return product for credit <em style="font: inherit;">6</em> months prior to, and up to <em style="font: inherit;">12</em> months after, the product expiration date. As such, there <em style="font: inherit;"> may </em>be a significant period of time between the time the product is shipped and the time the credit is issued on returned product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Distribution Fees</span> &#x2013;<i> </i>Distribution fees include fees paid to certain customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">GPO Fees</span><i> </i>&#x2013; The Company pays administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs&#x2019; members.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Trade Discounts and Allowances</span> - The Company provides its customers with discounts which include early payment incentives that are explicitly stated in its contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company believes its estimated allowances for chargebacks, government rebates and product returns require a high degree of judgment and are subject to change based on its limited experience and certain quantitative and qualitative factors. The Company believes its estimated allowances for distribution fees, GPO fees and trade discounts and allowances do <em style="font: inherit;">not</em> require a high degree of judgment because the amounts are settled within a relatively short period of time. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. Changes in product revenue allowance estimates could materially affect the Company&#x2019;s results of operations and financial position.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Contract and other collaboration revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company generates revenue from collaboration agreements. These agreements typically include payments for upfront signing or license fees, cost reimbursements for development and manufacturing services, milestone payments, product sales, and royalties on licensee&#x2019;s future product sales. Product sales related revenue under these collaboration agreements is classified as product sales revenue, while other revenue generated from collaboration agreements is classified as contract and other collaboration revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Performance Obligations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic <em style="font: inherit;">606.</em> The Company&#x2019;s performance obligations include delivering product to its distributors, commercialization license rights, development services, services associated with the regulatory approval process, joint steering committee services, demonstration devices, manufacturing services, material rights for discounts on manufacturing services, and product supply.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#x2019;s or the Company&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. If the Company is entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Transaction Price</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has both fixed and variable consideration. Variable consideration for product revenue is described as Net product sales in the Consolidated Statements of Operations. For collaboration agreements, non-refundable upfront fees and product supply selling prices are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would <em style="font: inherit;">not</em> occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are <em style="font: inherit;">not</em> within the control of the Company, such as approvals from regulators, are <em style="font: inherit;">not</em> considered probable of being achieved until those approvals are received.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">15</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Allocation of Consideration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights and material rights for discounts on manufacturing services are calculated using an income approach model and can include the following key assumptions: the development timeline, sales forecasts, costs of product sales, commercialization expenses, discount rate, the time which the manufacturing services are expected to be performed, and probabilities of technical and regulatory success. For all other performance obligations, the Company uses a cost-plus margin approach.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Timing of Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant management judgment is required to determine the level of effort required under collaboration arrangements and the period over which the Company expects to complete its performance obligations under the arrangement. The Company estimates the performance period or measure of progress at the inception of the arrangement and re-evaluates it each reporting period. This re-evaluation <em style="font: inherit;"> may </em>shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer, and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CostOfSalesPolicyTextBlock" id="c81624861" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cost of Goods Sold </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cost of goods sold for product revenue includes <em style="font: inherit;">third</em> party manufacturing costs, shipping and handling costs, and indirect overhead costs associated with production and distribution which are allocated to the appropriate cost pool and recognized when revenue is recognized. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Gr&#xfc;nenthal Agreements, the Company sold Zalviso to Gr&#xfc;nenthal at predetermined, contractual transfer prices that were less than the direct costs of manufacturing and recognized indirect costs as period costs where they were in excess of normal capacity and <em style="font: inherit;">not</em> recoverable on a lower of cost or net realizable value basis. Cost of goods sold for Zalviso shipped to Gr&#xfc;nenthal included the inventory costs of API, <em style="font: inherit;">third</em>-party contract manufacturing costs, packaging and distribution costs, shipping, handling and storage costs, depreciation and costs of the employees involved with production.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c81624862" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research and Development Expenses </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c81624871" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock-Based Compensation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compensation expense for all stock-based payment awards made to employees and directors, including employee stock options and restricted stock units related to the <em style="font: inherit;">2020</em> Equity Incentive Plan, or <em style="font: inherit;">2020</em> EIP, the <em style="font: inherit;">2011</em> Equity Incentive Plan, or <em style="font: inherit;">2011</em> EIP, and employee share purchases related to the Amended and Restated <em style="font: inherit;">2011</em> Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. The Company applies the graded-vesting attribution method to awards with market conditions that include graded-vesting features. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">16</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. The expected term, which represents the period of time that options granted are expected to be outstanding, is derived by analyzing the historical experience of similar awards, giving consideration to the contractual terms of the stock&#x2011;based awards, vesting schedules and expectations of future employee behavior. Expected volatilities are estimated using the historical stock price performance over the expected term of the option, which are adjusted as necessary for any other factors which <em style="font: inherit;"> may </em>reasonably affect the volatility of AcelRx&#x2019;s stock in the future. The risk&#x2011;free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company recognizes forfeitures when they occur and does <em style="font: inherit;">not</em> anticipate paying dividends in the near future.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:WarrantsPolicyPolicyTextBlock" id="c81624872" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Warrants Issued in Connection with Financings</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company <em style="font: inherit;"> may </em>need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="c81624873" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Restructuring Costs</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> March 16, 2020, </em>in connection with entering into the Co-Promotion Agreement, the Company initiated a reduction in headcount, designed to eliminate the overlap with the Tetraphase commercial team in order to more efficiently commercialize DSUVIA alongside the Tetraphase commercial team and reduce operating expenses. The Company eliminated <ix:nonFraction id="c81618787" contextRef="d_2020-03-16_2020-03-16" unitRef="Pure" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated" scale="0" format="ixt:numdotdecimal" decimals="INF">30</ix:nonFraction> positions, primarily within the commercial organization. For the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company incurred and paid $<ix:nonFraction id="c81618788" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RestructuringCharges" scale="6" format="ixt:numdotdecimal" decimals="-5">0.5</ix:nonFraction> million in employee termination benefits related to this restructuring. The headcount reduction was completed in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> There were <em style="font: inherit;">no</em> such restructuring costs for the year ended <em style="font: inherit;"> December 31, 2021.</em></p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"></em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i></i></b></p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:InterestExpensePolicyTextBlock" id="c81630872" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Non-Cash Interest Income (Expense) on Liability Related to Sale of Future Royalties</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> September 2015, </em>the Company sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Gr&#xfc;nenthal to PDL for gross proceeds of $<ix:nonFraction id="c81618791" contextRef="d_2015-09-01_2015-09-30" unitRef="USD" name="acrx:ProceedsFromSaleOfRoyaltyAndMilestoneRights" scale="6" format="ixt:numdotdecimal" decimals="-6">65.0</ix:nonFraction> million. Gr&#xfc;nenthal terminated the Gr&#xfc;nenthal Agreements effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#xfc;nenthal Agreements were extended to <em style="font: inherit;"> May 2021 </em>to enable Gr&#xfc;nenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Territory reverted back to the Company in <em style="font: inherit;"> May 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Royalty Monetization, the Company has a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Under the relevant accounting guidance, because of the Company&#x2019;s significant continuing involvement, the Royalty Monetization is accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and payments made to PDL, up to a capped amount of $<ix:nonFraction id="c81618792" contextRef="d_2015-09-01_2015-09-30" unitRef="USD" name="acrx:RoyaltyArrangmentMaximumPayments" scale="6" format="ixt:numdotdecimal" decimals="-6">195.0</ix:nonFraction> million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $<ix:nonFraction id="c81618793" contextRef="d_2015-09-01_2015-09-30" unitRef="USD" name="acrx:NetProceedsFromSaleOfFutureRoyalties" scale="6" format="ixt:numdotdecimal" decimals="-5">61.2</ix:nonFraction> million of net proceeds the Company received, are amortized as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense, or interest income, as these estimates are updated.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">17</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are a number of factors that could materially affect the amount and timing of royalty and milestone payments from Zalviso in Europe, most of which are <em style="font: inherit;">not</em> within the Company&#x2019;s control. Such factors include, but are <em style="font: inherit;">not</em> limited to, the success of any future sales and promotion of Zalviso under any New Arrangement, if achieved; changing standards of care; the introduction of competing products; manufacturing or other delays; intellectual property matters; adverse events that result in governmental health authority imposed restrictions on the use of Zalviso; significant changes in foreign exchange rates as the royalties remitted to ARPI LLC are made in U.S. dollars; and other events or circumstances that could result in reduced royalty payments from European sales of Zalviso, all of which <em style="font: inherit;"> may </em>result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Monetization. Conversely, if sales of Zalviso in Europe are greater than expected, the non-cash royalty revenues and the non-cash interest expense recorded by the Company would be greater over the term of the Royalty Monetization. The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. Because estimated sales forecasts and payments <em style="font: inherit;"> may </em>vary over the life of the Royalty Monetization, the Company <em style="font: inherit;"> may </em>be required to recognize interest income as the imputed interest rate is adjusted prospectively to reflect the revised effective interest rate over the term of the Royalty Monetization.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company records non-cash royalty revenues and non-cash interest income (expense), net, within its Consolidated Statements of Operations over the term of the Royalty Monetization.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When the expected payments under the Royalty Monetization are lower than the gross proceeds of <em style="font: inherit;">$65.0</em> million received, the Company defers recognition of any probable contingent gain until the Royalty Monetization liability expires.</p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="c81624874" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Comprehensive Loss </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss is comprised of net loss and other comprehensive income (loss) and is disclosed in the Consolidated Statements of Operations. For the Company, other comprehensive income (loss) consists of changes in unrealized gains and losses on the Company&#x2019;s investments.</p></ix:nonNumeric>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c81624875" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Income Taxes </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than <em style="font: inherit;">not.</em></p></ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;"></em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c81624876" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Net Loss per Share of Common Stock </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#x2019;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, options to purchase common stock, restricted stock subject to repurchase, restricted stock units, warrants to purchase convertible preferred stock and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. For additional information regarding the net loss per share, see Note <em style="font: inherit;">15</em> &#x201c;Net Loss per Share of Common Stock&#x201d;.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c81624877" escape="true"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Recently Adopted Accounting Standards</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> December 2019, </em>the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> &#x201c;<i>Simplifying the Accounting for Income Taxes</i>&#x201d;. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020, </em>and interim periods within those fiscal years. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> on <em style="font: inherit;"> January 1, 2021, </em>which did <em style="font: inherit;">not</em> have a material impact on the Company&#x2019;s Consolidated Financial Statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> August 2020, </em>the FASB issued ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em> &#x201c;<i>Debt - Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</i>&#x201d;. The standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with <em style="font: inherit;">no</em> separate accounting for embedded conversion features. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within those fiscal years for smaller reporting companies, with early adoption permitted. The Company early adopted ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> on <em style="font: inherit;"> January 1, 2021, </em>which did <em style="font: inherit;">not</em> have a material impact on the Company&#x2019;s Consolidated Financial Statements on the date of adoption.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Recently Issued Accounting Pronouncements </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> &#x201c;<i>Financial Instruments </i>&#x2013;<i> Credit Losses: Measurement of Credit Losses on Financial Instruments,</i>&#x201d; or ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> replaces the incurred loss impairment model in current GAAP with a model that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for the Company beginning <em style="font: inherit;"> January 1, 2023, </em>with early adoption allowed beginning <em style="font: inherit;"> January 1, 2020. </em>In <em style="font: inherit;"> May 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> &#x201c;<i>Financial Instruments </i>&#x2013;<i> Credit Losses,</i>&#x201d; or ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost upon adoption of the new credit losses standard. The new effective dates and transition align with those of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> Management is currently assessing the date of adoption and the impact ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05</em> will have on the Company, but it does <em style="font: inherit;">not</em> anticipate adoption of these new standards to have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
    <ix:exclude>
     <div class="PGFTR" style="text-align: center; width: 100%">
      <div class="hf-row">
       <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
         F-
        <em style="font: inherit;">18</em>
       </div>
      </div>
     </div>
     <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
     <div class="PGHDR" style="text-align: left; width: 100%">
      <div class="hf-row">
       <div class="hf-cell TOCLink">
         &#xa0;
       </div>
      </div>
     </div>
    </ix:exclude> <ix:exclude>&#xa0;</ix:exclude> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2020, </em>the FASB issued ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> &#x201c;<i>Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,</i>&#x201d; which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments are effective immediately and <em style="font: inherit;"> may </em>be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before <em style="font: inherit;"> December 31, 2022. </em>In <em style="font: inherit;"> January 2021, </em>the FASB issued ASU <em style="font: inherit;">2021</em>-<em style="font: inherit;">01,</em> &#x201c;<i>Reference Rate Reform (Topic <em style="font: inherit;">848</em>),</i>&#x201d; to expand and clarify the scope of Topic <em style="font: inherit;">848</em> to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">04.</em> The Company is currently evaluating the impact this guidance will have on its Consolidated Financial Statements.</p></ix:nonNumeric>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock" id="c2050891" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em> Investments and Fair Value Measurement </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Investments </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond <em style="font: inherit;">one</em> year as of the end of the reporting period are classified as non-current.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The table below summarizes the Company&#x2019;s cash, cash equivalents and investments (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" id="D01D4045-1EF5-4D25-B758-332A294EFAD1" escape="true" continuedAt="B3116305-14DC-439F-95A5-F940BA16082A">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized</b> <b>Cost</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br /> <b>Gains</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br /> <b>Losses</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b><br /> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618894" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:Cash" scale="3" format="ixt:numdotdecimal" decimals="-3">1,443</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618897" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">1,443</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618898" contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">2,822</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618901" contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">2,822</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618902" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">8,398</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618903" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618904" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618905" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">8,398</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618906" contextRef="i_2021-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">12,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618909" contextRef="i_2021-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">12,663</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 40%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618911" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">29,504</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618912" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618913" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618914" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">29,504</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618915" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">9,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618916" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618917" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618918" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">9,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618919" contextRef="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">38,967</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618920" contextRef="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618921" contextRef="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618922" contextRef="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">38,967</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash, cash equivalents and short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618923" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-4">51,630</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618924" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618925" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618926" contextRef="i_2021-12-31" unitRef="USD" name="acrx:CashCashEquivalentsAndShorttermInvestmentsFairValue" scale="3" format="ixt:numdotdecimal" decimals="-4">51,630</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">19</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <ix:continuation id="B3116305-14DC-439F-95A5-F940BA16082A">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized</b> <b>Cost</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br /> <b>Gains</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br /> <b>Losses</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b><br /> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618928" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:Cash" scale="3" format="ixt:numdotdecimal" decimals="-3">5,181</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618931" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">5,181</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618932" contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:MoneyMarketFundsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">3,996</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618935" contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">3,996</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618936" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CommercialPaperAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">18,097</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618939" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">18,097</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618940" contextRef="i_2020-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" format="ixt:numdotdecimal" decimals="-3">27,274</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618943" contextRef="i_2020-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember" unitRef="USD" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">27,274</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 40%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td><td style="width: 12%;">&#xa0;</td><td style="width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">U.S. government agency securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618945" contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">5,818</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618946" contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618947" contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618948" contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">5,818</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618949" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">9,794</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618950" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618951" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618952" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">9,794</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618953" contextRef="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" format="ixt:numdotdecimal" decimals="-3">15,612</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618954" contextRef="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618955" contextRef="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618956" contextRef="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" format="ixt:numdotdecimal" decimals="-3">15,612</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash, cash equivalents and short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618957" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" scale="3" format="ixt:numdotdecimal" decimals="-3">42,886</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618958" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618959" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618960" contextRef="i_2020-12-31" unitRef="USD" name="acrx:CashCashEquivalentsAndShorttermInvestmentsFairValue" scale="3" format="ixt:numdotdecimal" decimals="-3">42,886</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">None</em> of the available-for-sale securities held by the Company had material unrealized losses and there were <ix:nonFraction id="c81618854" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> realized losses for the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020.</em> There were <ix:nonFraction id="c81618860" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> other-than-temporary impairments for these securities as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> or <em style="font: inherit;">2020.</em> <em style="font: inherit;"><span style="-sec-ix-hidden:c81618861">No</span></em> gross realized gains or losses were recognized on the available-for-sale securities and, accordingly, there were <ix:nonFraction id="c81618866" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> amounts reclassified out of accumulated other comprehensive income (loss) to earnings during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> the contractual maturity of all investments held was less than <em style="font: inherit;">one</em> year.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value Measurement </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#x2019;s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level <em style="font: inherit;">1</em> of the fair value hierarchy. For Level II instruments, the Company estimates fair value by utilizing <em style="font: inherit;">third</em> party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. Such Level II instruments typically include U.S. treasury, U.S. government agency securities and commercial paper. As of <em style="font: inherit;"> December 31, 2021, </em>and <em style="font: inherit;"> December 31, 2020, </em>the Company held, in addition to Level II assets, a contingent put option liability associated with the Loan Agreement with Oxford. See Note <em style="font: inherit;">8</em> &#x201c;Long-Term Debt&#x201d; for further description. The Company&#x2019;s estimate of fair value of the contingent put option liability was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated both with and without the presence of the default provisions, holding all other assumptions constant. The resulting difference between the <em style="font: inherit;">two</em> estimated fair values is the estimated fair value of the default provisions, or the contingent put option, which is included under other long-term liabilities on the Consolidated Balance Sheets. Changes to the estimated fair value of this liability is recorded in interest income and other income (expense), net in the Consolidated Statements of Operations. The fair value of the underlying debt facility is estimated by calculating the expected cash flows in consideration of an estimated probability of default and expected recovery rate in default and discounting such cash flows back to the reporting date using a risk-free rate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth the fair value of the Company&#x2019;s financial assets and liabilities by level within the fair value hierarchy (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" id="C6739F65-1FE0-4DD0-B522-F6084C90642A" escape="true" continuedAt="DD0B5F4C-64A7-4E64-BF42-0A2C30AB0C91">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>I</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>II</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>III</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><b>Assets</b></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618962" contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">2,822</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618963" contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">2,822</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618964" contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618965" contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618966" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">37,902</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618967" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618968" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">37,902</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618969" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618970" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">9,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618971" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618972" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">9,463</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618973" contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618974" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">50,187</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618975" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">2,822</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618976" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">47,365</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618977" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><span style="text-decoration: underline; ">Liabilities</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingent put option liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618979" contextRef="i_2021-12-31_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618980" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618981" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618982" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618983" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618984" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618985" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81618986" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">20</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <ix:continuation id="DD0B5F4C-64A7-4E64-BF42-0A2C30AB0C91">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>I</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>II</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>III</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><b>Assets</b></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618988" contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">3,996</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618989" contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">3,996</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618990" contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618991" contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. government agency securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618992" contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">5,818</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618993" contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618994" contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">5,818</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81618995" contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618996" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">27,891</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618997" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618998" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">27,891</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81618999" contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619000" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">37,705</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619001" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">3,996</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619002" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">33,709</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619003" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:AssetsFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><span style="text-decoration: underline; ">Liabilities</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingent put option liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619005" contextRef="i_2020-12-31_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619006" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619007" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619008" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619009" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619010" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619011" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619012" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:LiabilitiesFairValueDisclosure" scale="3" format="ixt:numdotdecimal" decimals="-3">246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level III financial liabilities for the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" id="c0974F29A-90CE-4F5E-A9C4-FF390B4918BC" escape="true" continuedAt="c13B599D2-03DC-4D50-910B-2FB9351D2AC5">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended</b><br /> <b>December</b> <b>31,</b><br /> <b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#x2014;beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619013" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:numdotdecimal" decimals="-3">246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change in fair value of contingent put option associated with the Loan Agreement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619014" contextRef="d_2021-01-01_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" scale="3" format="ixt:numdotdecimal" decimals="-3">165</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#x2014;end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619015" contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:numdotdecimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="c13B599D2-03DC-4D50-910B-2FB9351D2AC5">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended</b><br /> <b>December</b> <b>31,</b><br /> <b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#x2014;beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619016" contextRef="i_2019-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:numdotdecimal" decimals="-3">437</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change in fair value of contingent put option associated with the Loan Agreement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619017" contextRef="d_2020-01-01_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">191</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#x2014;end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619018" contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member" unitRef="USD" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" scale="3" format="ixt:numdotdecimal" decimals="-3">246</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:InventoryDisclosureTextBlock" id="c2050898" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em> Inventories, net </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inventories consist of finished goods, raw materials and work in process and are stated at the lower of cost or net realizable value and consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="c2050899" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As</b> <b>of</b> <b>December</b> <b>31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619024" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">722</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619025" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryRawMaterialsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">257</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Work-in-process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619026" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">159</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619027" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryWorkInProcessNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-4">30</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619028" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-4">230</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619029" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryFinishedGoodsNetOfReserves" scale="3" format="ixt:numdotdecimal" decimals="-3">1,339</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619030" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,111</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619031" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:InventoryNet" scale="3" format="ixt:numdotdecimal" decimals="-3">1,626</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company recorded inventory impairment charges of approximately $<ix:nonFraction id="c81619020" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="6" format="ixt:numdotdecimal" decimals="-5">0.8</ix:nonFraction> million, primarily as a result of DSUVIA inventory that <em style="font: inherit;"> may </em>expire before being sold. During the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company recorded inventory impairment charges of approximately $<ix:nonFraction id="c81619021" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="6" format="ixt:numdotdecimal" decimals="-5">0.7</ix:nonFraction> million, of which $<ix:nonFraction id="c81619022" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-AmendedLicenseAgreementMember" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="6" format="ixt:numdotdecimal" decimals="-5">0.3</ix:nonFraction> million related to the termination of the Amended Agreements, while $<ix:nonFraction id="c81619023" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-DSUVIAMember" unitRef="USD" name="us-gaap:InventoryWriteDown" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million related to DSUVIA inventory, primarily inventory that <em style="font: inherit;"> may </em>expire before being sold.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="c2050900" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em> Property and Equipment, net </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="c2050901" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As</b> <b>of</b> <b>December</b> <b>31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619039" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">4,406</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619040" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">4,406</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619041" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">5,838</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619042" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">4,616</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619043" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,589</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619044" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,724</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Construction in process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619045" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">13,805</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619046" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">14,101</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tooling</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619047" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">826</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619048" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">1,109</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619049" contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-4">250</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619050" contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">292</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619051" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">26,714</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"><ix:nonFraction id="c81619052" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" format="ixt:numdotdecimal" decimals="-3">26,248</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619053" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">10,786</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619054" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" format="ixt:numdotdecimal" decimals="-3">10,589</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619055" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">15,928</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619056" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" format="ixt:numdotdecimal" decimals="-3">15,659</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">21</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation and amortization expense was <span style="-sec-ix-hidden:c81619034">$<ix:nonFraction id="c81619035" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:Depreciation" scale="6" format="ixt:numdotdecimal" decimals="-5">1.1</ix:nonFraction></span> million for each of the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:InlicenseAgreementTextBlock" id="c2050902" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em> In-License Agreement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> July 14, 2021, </em>the Company entered into a License and Commercialization Agreement, or the PFS Agreement, with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">3</em> mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">50</em> mcg/ml phenylephrine hydrochloride for injection. Aguettant will supply the Company with the products for use in commercialization, if they are approved in the U.S.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The PFS Agreement has an initial term of <em style="font: inherit;">ten</em> (<span style="-sec-ix-hidden:c81619063">10</span>) marketing years, with the <em style="font: inherit;">first</em> marketing year ending on <em style="font: inherit;"> December 31 </em>of the calendar year after the <em style="font: inherit;">first</em> launch of a product (or <em style="font: inherit;"> December 31 </em>of the same calendar year if the <em style="font: inherit;">first</em> launch of a product occurs between <em style="font: inherit;"> January 1 </em>and <em style="font: inherit;"> April 30 </em>of a calendar year). The term will automatically renew for successive <span style="-sec-ix-hidden:c81619067">five</span> marketing year periods unless a party notifies the other party of its intention <em style="font: inherit;">not</em> to renew at least <em style="font: inherit;">six</em> (<em style="font: inherit;">6</em>) months prior to the expiration of the then-current term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Aguettant is entitled to receive up to $<ix:nonFraction id="c81619071" contextRef="i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember" unitRef="USD" name="acrx:LicenseAgreementMilestonePaymentsToBePaidMaximum" scale="6" format="ixt:numdotdecimal" decimals="-6">24.0</ix:nonFraction> million in sales-based milestone payments. The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from <ix:nonFraction id="c81619072" contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember_RangeAxis-MinimumMember" unitRef="Pure" name="acrx:LicenseAgreementPercentOfRevenueSharePaymentToBePaid" scale="-2" format="ixt:numdotdecimal" decimals="1">40</ix:nonFraction>% to <ix:nonFraction id="c81619073" contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember_RangeAxis-MaximumMember" unitRef="Pure" name="acrx:LicenseAgreementPercentOfRevenueSharePaymentToBePaid" scale="-2" format="ixt:numdotdecimal" decimals="2">45</ix:nonFraction>% of net sales in the United States.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company and Aguettant will agree on minimum sales obligations <em style="font: inherit;">twelve</em> (<span style="-sec-ix-hidden:c81619075">12</span>) months prior to the launch of each product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has the right to grant sublicenses to its affiliates or, with the prior approval of Aguettant, <em style="font: inherit;">third</em> parties, subject to certain limitations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2021, </em>there have been <em style="font: inherit;">no</em> payments by the Company to Aguettant under the PFS Agreement.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:OutlicenseAgreementTextBlock" id="c2050903" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em> Out-license Agreements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>DZUVEO</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> July 14, 2021, </em>the Company entered into a License and Commercialization Agreement, or the DZUVEO Agreement, with Aguettant, pursuant to which Aguettant obtained the exclusive right to develop and commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom, or the DZUVEO Territory, for the management of acute moderate to severe pain in adults in medically monitored settings. The Company will supply Aguettant with product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DZUVEO Agreement has an initial term of <em style="font: inherit;">ten</em> (<em style="font: inherit;">10</em>) marketing years, with the <em style="font: inherit;">first</em> marketing year ending on <em style="font: inherit;"> December 31 </em>of the calendar year after the launch of DZUVEO (or <em style="font: inherit;"> December 31, 2022, </em>if the launch occurs between <em style="font: inherit;"> January 1, 2022 </em>and <em style="font: inherit;"> April 30, 2022). </em>The term will automatically renew for successive <span style="-sec-ix-hidden:c81619082">five</span> marketing year periods unless a party notifies the other party of its intention <em style="font: inherit;">not</em> to renew at least <em style="font: inherit;">six</em> (<em style="font: inherit;">6</em>) months prior to the expiration of the then-current term. The DZUVEO Agreement <em style="font: inherit;"> may </em>be terminated for cause by either party based on uncured material breach by the other party, insolvency of the other party, or force majeure event. Upon early termination, all ongoing activities under the agreement and all rights and commercialization licenses and sublicenses with respect to DZUVEO will terminate. Additionally, if terminated early by either party, any accrued liability at the time of such termination will <em style="font: inherit;">not</em> be released.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is entitled to receive up to <span style="-sec-ix-hidden:c81619087">&#x20ac;47.0</span> million in a combination of up-front and sales-based milestone payments, of which the Company received <span style="-sec-ix-hidden:c81619088">&#x20ac;2.5</span> million, or approximately $<ix:nonFraction id="c81619089" contextRef="d_2021-07-01_2021-09-30_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="USD" name="acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" scale="6" format="ixt:numdotdecimal" decimals="-5">2.9</ix:nonFraction> million, in the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021,</em> for which it recognized revenue of $<ix:nonFraction id="c81619092" contextRef="d_2021-07-01_2021-09-30_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-5">1.7</ix:nonFraction> million in the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021.</em> Aguettant will purchase product from the Company at an agreed price, or the DZUVEO Purchase Price, subject to adjustment. Aguettant will also make revenue share payments that, combined with the DZUVEO Purchase Price, range from <ix:nonFraction id="c81619095" contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember_RangeAxis-MinimumMember" unitRef="Pure" name="acrx:LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" scale="-2" format="ixt:numdotdecimal" decimals="2">35</ix:nonFraction>% to <ix:nonFraction id="c81619096" contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember_RangeAxis-MaximumMember" unitRef="Pure" name="acrx:LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" scale="-2" format="ixt:numdotdecimal" decimals="2">45</ix:nonFraction>% of net sales in the DZUVEO Territory.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">22</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beginning in the <em style="font: inherit;">third</em> marketing year, the parties will establish binding annual minimums for purchase orders to be submitted by Aguettant. Aguettant has the right to grant sublicenses to its affiliates or, with the prior approval of the Company, <em style="font: inherit;">third</em> parties, subject to certain limitations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The DZUVEO Agreement also provides Aguettant with a right of <em style="font: inherit;">first</em> negotiation for <em style="font: inherit;">eighteen</em> (<em style="font: inherit;">18</em>) months before the Company can enter into a collaboration regarding Zalviso&#xa0;in Europe.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Zalviso</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 18, 2020, </em>the Company received a notice from Gr&#xfc;nenthal that it had exercised its right to terminate the Gr&#xfc;nenthal Agreements, effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#xfc;nenthal Agreements were extended to <em style="font: inherit;"> May 12, 2021 </em>to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on <em style="font: inherit;"> May 12, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Amended License Agreement </span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Amended License Agreement with Gr&#xfc;nenthal, the Company was eligible to receive approximately $<ix:nonFraction id="c81619103" contextRef="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember" unitRef="USD" name="acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" scale="6" format="ixt:numdotdecimal" decimals="-5">194.5</ix:nonFraction> million in additional milestone payments, based upon successful regulatory and product development efforts ($<ix:nonFraction id="c81619104" contextRef="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" unitRef="USD" name="acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" scale="6" format="ixt:numdotdecimal" decimals="-5">28.5</ix:nonFraction> million) and net sales target achievements ($<ix:nonFraction id="c81619105" contextRef="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponNetSalesTargetAchievementsMember" unitRef="USD" name="acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" scale="6" format="ixt:numdotdecimal" decimals="-6">166.0</ix:nonFraction> million). A portion of the tiered royalty payments earned were paid to PDL in connection with the Royalty Monetization. For additional information on the Royalty Monetization with PDL, see Note <em style="font: inherit;">10</em> &#x201c;Liability Related to Sale of Future Royalties&#x201d;. On <em style="font: inherit;"> August 31, 2020, </em>PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Amended MSA </span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Amended MSA with Gr&#xfc;nenthal, the Company manufactured and supplied the Product for use in the Field for the Territory exclusively for Gr&#xfc;nenthal. The Product was supplied at prices approximating the Company&#x2019;s manufacturing cost, subject to certain caps, as defined in the MSA Amendment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Gr&#xfc;nenthal Agreements entitled the Company to receive additional payments upon the achievement of certain development milestones which related to post approval product enhancements, expanded market opportunities and manufacturing efficiencies for Zalviso and required future research, development and regulatory activities. These payments were excluded from the transaction price as they were considered payments for optional additional services elected by Gr&#xfc;nenthal.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Gr&#xfc;nenthal Agreements also included milestone payments related to specified net sales targets, totaling $<ix:nonFraction id="c81619107" contextRef="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponNetSalesTargetAchievementsMember" unitRef="USD" name="acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" scale="6" format="ixt:numdotdecimal" decimals="-6">166.0</ix:nonFraction> million. These payments were considered sales-based license royalties under ASC Topic <em style="font: inherit;">606</em> and would have been recognized apart from the other contract consideration when the related sales occurred. These net sales targets were <em style="font: inherit;">not</em> achieved prior to the termination of the Gr&#xfc;nenthal Agreements.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="c2050904" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7</em></b>. <b>Revenue from Contracts with Customers</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes revenue from contracts with customers for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="c2050905" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">DSUVIA</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619145" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-DSUVIAMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">735</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619146" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-DSUVIAMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,409</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Zalviso</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619147" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ZALVISOMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-4">270</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619148" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ZALVISOMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,112</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total product sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619149" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,005</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619150" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,521</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contract and other collaboration:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">License revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619152" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,696</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619153" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-LicenseMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Non-cash royalty revenue related to Royalty Monetization (See Note 10)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619154" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-NonCashRoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">83</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619155" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NonCashRoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">242</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619156" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">28</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619157" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">81</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619158" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherRevenueMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">6</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619159" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherRevenueMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,572</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total revenues from contract and other collaboration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619160" contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">1,813</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619161" contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,895</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619162" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">2,818</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619163" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="3" format="ixt:numdotdecimal" decimals="-3">5,416</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">23</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For additional detail on the Company&#x2019;s accounting policy regarding revenue recognition, refer to Note <em style="font: inherit;">1</em> &#x201c;Organization and Summary of Significant Accounting Policies - Revenue from Contracts with Customers.&#x201d;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Product Sales</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#x2019;s commercial launch of DSUVIA in the United States occurred in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2019.</em> Zalviso was sold in Europe by Gr&#xfc;nenthal through <em style="font: inherit;"> May 12, 2021. </em>DZUVEO sales in Europe by the Company&#x2019;s collaboration partner, Aguettant, have <em style="font: inherit;">not</em> commenced as of <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contract and Other Collaboration</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Contract and other collaboration revenue includes revenue under the Gr&#xfc;nenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe and license revenue recognized under the DZUVEO Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company concluded that Aguettant is a customer and therefore revenue recognition for the DZUVEO Agreement in Europe should be accounted for in accordance with FASB Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">606,</em> &#x201c;<i>Revenue from Contracts with Customers</i>&#x201d;, because the Company granted to Aguettant licenses and will provide the supply of product, as defined below, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company identified the following promises under the DZUVEO Agreement at inception, namely: (a) granting of the licenses, (b) manufacturing services inclusive of quality control testing and stability testing which are options in the initial arrangement, and (c) a material right associated with the discounted price for future optional orders of DZUVEO commercial product supply.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The licenses are considered to be functional intellectual property. The Company determined that the licenses are capable of being distinct because Aguettant can benefit from the license on its own by commercializing the underlying product using its own resources. The Company manufacturing services are <em style="font: inherit;">not</em> highly specialized in nature and can be performed by <em style="font: inherit;">third</em> party contract manufacturing organizations. There are <em style="font: inherit;">no</em> binding commitments for manufacturing purchase orders at inception of the arrangement. Therefore, the manufacturing services are considered to be an option and <em style="font: inherit;">not</em> a performance obligation in the initial arrangement. However, the Company has determined that the discounted price per unit on future optional product orders constitutes a material right and is a performance obligation. The right to purchase at a discount is capable of being used by the customer on a standalone basis, because this relates to future product purchases and occur after the licenses&#x2019; performance obligations are transferred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company evaluated if there is an interdependence between the performance obligations and determined that the licenses are a combined solution and the predominant performance obligation. The material right is separately identifiable in the context of the contract and is <em style="font: inherit;">not</em> modified by, and does <em style="font: inherit;">not</em> modify, the license performance obligation and is <em style="font: inherit;">not</em> highly interdependent or interrelated with the material right performance obligations in the contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The transaction price at the inception of the DZUVEO Agreement consisted of the upfront fee of <span style="-sec-ix-hidden:c81619125">&#x20ac;2.5</span> million, or approximately $<ix:nonFraction id="c81619126" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="USD" name="acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" scale="6" format="ixt:numdotdecimal" decimals="-5">2.9</ix:nonFraction> million. The variable consideration related to product supply and reimbursables has been constrained as of <em style="font: inherit;"> December 31, 2021 </em>as there has been <em style="font: inherit;">no</em> forecast provided by Aguettant. The Company will re-evaluate the transaction price each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company determined that the $<ix:nonFraction id="c81619128" contextRef="i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="USD" name="acrx:LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" scale="6" format="ixt:numdotdecimal" decimals="-5">52.2</ix:nonFraction> million<i> </i>sales-based milestone payments and revenue share payments were probable of significant revenue reversal, as their achievement was highly dependent on factors outside the Company&#x2019;s control. As a result, these payments were fully constrained and were <em style="font: inherit;">not</em> included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the licenses granted to Aguettant and the optional manufacturing services provided by the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The transaction price is allocated to the performance obligations based on relative standalone selling price which were determined for the licenses using the adjusted market approach, and for the manufacturing services and the material right associated with discounted DZUVEO product supply using the cost-plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">24</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in <em style="font: inherit;"> July 2021 </em>and ends after an initial term of <span style="-sec-ix-hidden:c81619131">10</span> marketing years, unless it automatically renews for a successive <span style="-sec-ix-hidden:c81619132">five</span> marketing years. The Company also analyzed the impact if Aguettant terminated the agreement prior to the end of the term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Aguettant for doing so.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Revenue for the granting of the licenses was recognized on the effective date of the DZUVEO Agreement at the point in time that the licenses are effective. The manufacturing services inclusive of quality control testing and stability testing will be recognized at a point in time when, or as, the Company transfers the associated promised goods and services to Aguettant. The material right for the discounted price per unit on future optional orders will be recognized over time with the measure of progress being straight-line over the period in which the Company stands ready to provide the discounted price per unit on the manufacturing services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company recorded $<ix:nonFraction id="c81619133" contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="USD" name="us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax" scale="6" format="ixt:numdotdecimal" decimals="-5">1.7</ix:nonFraction> million in contract and other collaboration revenue as a result of satisfying its licenses performance obligation by transferring the license rights to Aguettant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contract Liabilities</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">A contract liability of $<ix:nonFraction id="c81619134" contextRef="i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="6" format="ixt:numdotdecimal" decimals="-5">1.2</ix:nonFraction> million was recorded on the Consolidated Balance Sheets as deferred revenue as of <em style="font: inherit;"> December 31, 2021, </em>$<ix:nonFraction id="c81619135" contextRef="i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction> million of which represented the current portion, for the portion of the upfront fee received under the DZUVEO Agreement allocated to the material right for discounted price on future optional product supply which has <em style="font: inherit;">not</em> yet been satisfied. The material right contract liability will be recognized over the period the discount on future product supply is made available. There was <em style="font: inherit;">no</em> contract asset as of <em style="font: inherit;"> December 31, 2021 </em>associated with the DZUVEO Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2021, </em>deferred contract acquisition costs were negligible and deferred contract acquisition costs amortized during the year ended <em style="font: inherit;"> December 31, 2021 </em>were <span style="-sec-ix-hidden:c81619138">$0.3</span> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table presents changes in the Company&#x2019;s contract liability for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="c2050906" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 36pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619164" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">3,244</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deductions for performance obligations satisfied:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In current period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c81619166">( 623</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In prior periods<span style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619167" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="3" format="ixt:numdotdecimal" decimals="-3">2,572</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619168" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">49</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions<span style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619169" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:ContractWithCustomerLiabilityAdditions" scale="3" format="ixt:numdotdecimal" decimals="-3">1,237</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deductions for performance obligations satisfied:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In current period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619171" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" scale="3" format="ixt:numdotdecimal" decimals="-3">49</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619172" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ContractWithCustomerLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">1,237</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-size:10pt;"><span style="font-family: &quot;Times New Roman&quot;;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>)</sup></span></span> In <em style="font: inherit;"> May 2020, </em>upon notification of early termination by Gr&#xfc;nenthal, the Company recognized approximately $<ix:nonFraction id="c81619141" contextRef="d_2020-05-01_2020-05-31_ProductOrServiceAxis-ZALVISOMember" unitRef="USD" name="acrx:ContractWithCustomerLiabilityLiabilityEliminated" scale="6" format="ixt:numdotdecimal" decimals="-5">2.6</ix:nonFraction> million of deferred revenue under the Gr&#xfc;nenthal Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">2</em>)</sup><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>Deferred revenue under the DZUVEO Agreement with Aguettant.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:LongTermDebtTextBlock" id="c2050907" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em> Long-Term Debt </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Loan Agreement with Oxford</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 30, 2019, </em>the Company entered into the Loan Agreement with Oxford as the Lender. Under the Loan Agreement, the Lender made a term loan to the Company in an aggregate principal amount of $<ix:nonFraction id="c81619174" contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="us-gaap:DebtInstrumentFaceAmount" scale="6" format="ixt:numdotdecimal" decimals="-6">25.0</ix:nonFraction> million, or the Loan, which was funded on <em style="font: inherit;"> May 30, 2019. </em>The Company used approximately $<ix:nonFraction id="c81619175" contextRef="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" format="ixt:numdotdecimal" decimals="-5">8.9</ix:nonFraction> million of the proceeds from the Loan to repay its outstanding obligations under its prior debt agreement. After deducting all loan initiation costs and outstanding interest on the prior debt agreement, the Company received $<ix:nonFraction id="c81619176" contextRef="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="acrx:ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" scale="6" format="ixt:numdotdecimal" decimals="-5">15.9</ix:nonFraction> million in net proceeds.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">25</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The interest rate is calculated at a rate equal to the sum of (a) the greater of (i) the <em style="font: inherit;">30</em>-day U.S. LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) <ix:nonFraction id="c81619179" contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="Pure" name="acrx:DebtInstrumentInterestRateBasePercentage" scale="-2" format="ixt:numdotdecimal" decimals="3">2.50</ix:nonFraction>%, plus (b) <ix:nonFraction id="c81619180" contextRef="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember" unitRef="Pure" name="us-gaap:DebtInstrumentBasisSpreadOnVariableRate1" scale="-2" format="ixt:numdotdecimal" decimals="4">6.75</ix:nonFraction>%. On <em style="font: inherit;"> July 27, 2017, </em>the Financial Conduct Authority, or FCA, in the U.K. announced that it would phase out LIBOR as a benchmark by the end of <em style="font: inherit;">2021.</em> It is unclear whether new methods of calculating LIBOR will be established such that it continues to exist after <em style="font: inherit;">2021</em> or if LIBOR will be replaced with an alternative reference rate; however, the Company does <em style="font: inherit;">not</em> believe such changes would have a material adverse effect on its financing costs. Payments on the Loan were interest-only until <em style="font: inherit;"> July 1, 2020 </em>followed by equal principal payments and monthly accrued interest payments through the scheduled maturity date of <em style="font: inherit;"> June 1, 2023. </em>The Company&#x2019;s obligations under the Loan Agreement are secured by a security interest in all the assets of the Company, other than the Company&#x2019;s intellectual property which is subject to a negative pledge.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company <em style="font: inherit;"> may </em>prepay the Loan at any time. If the Loan is paid prior to the maturity date, the Company will pay the Lender a prepayment charge, based on a percentage of the then outstanding principal balance, equal to <ix:nonFraction id="c81619184" contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="Pure" name="acrx:PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" scale="-2" format="ixt:numdotdecimal" decimals="2">1</ix:nonFraction>%. Upon voluntary or mandatory prepayment, in addition to the prepayment charge, the Company is required to pay the EOT Fee, Lender&#x2019;s expenses and all outstanding principal and accrued interest through the prepayment date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Loan Agreement includes customary representations and covenants that, subject to exceptions, will restrict the Company&#x2019;s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are <em style="font: inherit;">not</em> related to its existing business. The Loan Agreement requires that the Company always maintain unrestricted cash of <em style="font: inherit;">not</em> less than $<ix:nonFraction id="c81619187" contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="acrx:DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" scale="6" format="ixt:numdotdecimal" decimals="-6">5.0</ix:nonFraction> million in accounts subject to control agreements in favor of Lender, tested monthly as of the last day of the month.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Loan Agreement also includes standard events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of the Lender&#x2019;s security interest or in the value of the collateral, a material adverse change in business, operations or the prospect of repayment, events relating to bankruptcy or insolvency. The Loan also contains a cross default provision, under which if a <em style="font: inherit;">third</em> party (under any agreement) has the right to accelerate indebtedness greater than $<ix:nonFraction id="c81619189" contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="acrx:DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction>, the Loan would also be considered in default. In addition, the Loan defines events which negatively impact government approvals, judgments in excess of $<ix:nonFraction id="c81619190" contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="acrx:LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" scale="0" format="ixt:numdotdecimal" decimals="INF">500,000</ix:nonFraction> and the delisting of the Company&#x2019;s shares of common stock on the Nasdaq Global Market, or Nasdaq, as events of default. Upon the occurrence of an event of default, a default interest rate of an additional <ix:nonFraction id="c81619191" contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="Pure" name="acrx:DebtInstrumentDefaultAdditionalInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="2">5</ix:nonFraction>% <em style="font: inherit;"> may </em>be applied to the outstanding loan balances, and the Lender <em style="font: inherit;"> may </em>declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. Acceleration would result in the payment of any applicable prepayment charges and application of the default interest rate to the outstanding balance until payment is made in full. The Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to the Lender. The bifurcated embedded derivative must be valued and separately accounted for in the Company&#x2019;s Consolidated Financial Statements. The contingent put option liability is classified as a component of other long-term liabilities. As of <em style="font: inherit;"> December 31, 2021, </em>the estimated fair value of the contingent put option liability was $<ix:nonFraction id="c81619192" contextRef="i_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="acrx:FairValueOfContingentPutOptionLiability" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction> million which was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated, both with and without the presence of the default provisions, holding all other assumptions constant. See Note <em style="font: inherit;">2</em> &#x201c;Investments and Fair Value Measurement&#x201d; for further description.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Loan Agreement, on <em style="font: inherit;"> May 30, 2019, </em>the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of <ix:nonFraction id="c81619194" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">176,679</ix:nonFraction> shares of the Company&#x2019;s common stock with a per share exercise price of $<ix:nonFraction id="c81619195" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">2.83</ix:nonFraction>, or the Warrants. The Warrants have been classified within stockholders&#x2019; (deficit) equity and accounted for as a discount to the loan by allocating the gross proceeds on a relative fair value basis. For further discussion, see Note <em style="font: inherit;">11</em> &#x201c;Warrants&#x201d;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The outstanding balance due under the Loan Agreement was $<ix:nonFraction id="c81619197" contextRef="i_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="us-gaap:LongTermDebt" scale="6" format="ixt:numdotdecimal" decimals="-5">13.3</ix:nonFraction> million and $<ix:nonFraction id="c81619198" contextRef="i_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="us-gaap:LongTermDebt" scale="6" format="ixt:numdotdecimal" decimals="-6">21.0</ix:nonFraction> million at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively. Interest expense related to the Loan Agreement was $<ix:nonFraction id="c81619200" contextRef="d_2021-01-01_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:numdotdecimal" decimals="-5">2.2</ix:nonFraction> million, of which $<ix:nonFraction id="c81619201" contextRef="d_2021-01-01_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" format="ixt:numdotdecimal" decimals="-5">0.7</ix:nonFraction> million represented amortization of the debt discount, and $<ix:nonFraction id="c81619202" contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="us-gaap:InterestExpenseDebt" scale="6" format="ixt:numdotdecimal" decimals="-5">3.2</ix:nonFraction> million, $<ix:nonFraction id="c81619203" contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="USD" name="us-gaap:AmortizationOfDebtDiscountPremium" scale="6" format="ixt:numdotdecimal" decimals="-5">0.9</ix:nonFraction> million of which represented amortization of the debt discount, for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively, and the effective interest rate was <ix:nonFraction id="c81619205" contextRef="i_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">13.15</ix:nonFraction>% in both periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Non-Interest Bearing Payments for the Construction of Leasehold Improvements </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> August 2019, </em>the Company entered into a Site Readiness Agreement, or SRA, with a potential Contract Manufacturing Organization, or CMO, in contemplation of entering into a commercial supply agreement for its product DSUVIA&#xae; at a future date. Under the SRA, the Company is building out a suite within the CMO&#x2019;s production facility. If additional equipment and facility modifications are required to meet the Company&#x2019;s product needs, the Company <em style="font: inherit;"> may </em>be required to contribute to the cost of such additional equipment and facility modifications. The Company has determined that it is the owner of the leasehold improvements related to the build-out which will be paid for in <em style="font: inherit;">four</em> annual installments of $<ix:nonFraction id="c81619208" contextRef="d_2019-08-01_2019-08-01_LongtermDebtTypeAxis-SiteReadinessAgreementMember" unitRef="USD" name="us-gaap:DebtInstrumentPeriodicPaymentPrincipal" scale="6" format="ixt:numdotdecimal" decimals="-5">0.5</ix:nonFraction> million through <em style="font: inherit;"> July 2022. </em>As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the accrued balance under the SRA is $<ix:nonFraction id="c81619210" contextRef="i_2021-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember" unitRef="USD" name="acrx:TotalObligationUnderLeaseholdAgreement" scale="6" format="ixt:numdotdecimal" decimals="-5">0.5</ix:nonFraction> million and $<ix:nonFraction id="c81619211" contextRef="i_2020-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember" unitRef="USD" name="acrx:TotalObligationUnderLeaseholdAgreement" scale="6" format="ixt:numdotdecimal" decimals="-5">0.8</ix:nonFraction> million, respectively, and $<ix:nonFraction id="c81619212" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LeaseholdImprovementsGross" scale="6" format="ixt:numdotdecimal" decimals="-5">1.7</ix:nonFraction> million of these leasehold improvements have been capitalized. The effective interest rate related to the payments at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was <ix:nonFraction id="c81619214" contextRef="i_2021-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember" unitRef="Pure" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" format="ixt:numdotdecimal" decimals="4">14.35</ix:nonFraction>%. The leasehold improvements are recorded as property and equipment, net, in the Consolidated Balance Sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">26</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future Payments on Long-Term Debt </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes the outstanding future payments associated with the Company&#x2019;s long-term debt as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="c2050908" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619219" contextRef="i_2021-12-31" unitRef="USD" name="acrx:LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">9,647</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619220" contextRef="i_2021-12-31" unitRef="USD" name="acrx:LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" scale="3" format="ixt:numdotdecimal" decimals="-4">5,530</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619221" contextRef="i_2021-12-31" unitRef="USD" name="acrx:LongTermDebtTotalMinimumPayments" scale="3" format="ixt:numdotdecimal" decimals="-3">15,177</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less amount representing interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619222" contextRef="i_2021-12-31" unitRef="USD" name="acrx:LongTermDebtMaturitiesRepaymentsOfInterest" scale="3" format="ixt:numdotdecimal" decimals="-3">927</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619223" contextRef="i_2021-12-31" unitRef="USD" name="acrx:NotesPayableGross" scale="3" format="ixt:numdotdecimal" decimals="-4">14,250</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Unamortized portion of EOT Fee</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81619224" contextRef="i_2021-12-31" unitRef="USD" name="acrx:DebtInstrumentUnamortizedEotFee" scale="3" format="ixt:numdotdecimal" decimals="-5">200</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Unamortized discount on notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619225" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DebtInstrumentUnamortizedDiscount" scale="3" format="ixt:numdotdecimal" decimals="-3">247</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619226" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LongTermDebt" scale="3" format="ixt:numdotdecimal" decimals="-3">13,803</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619227" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LongTermDebtCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">8,796</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619228" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LongTermDebtNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,007</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:LesseeOperatingLeasesTextBlock" id="c2050909" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em> Leases </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Office Lease </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company leased office and laboratory space for its former corporate headquarters, located at <em style="font: inherit;">301</em> &#x2013; <em style="font: inherit;">351</em> Galveston Drive, Redwood City, California, and entered into an agreement to sublease approximately <ix:nonFraction id="c81619232" contextRef="i_2021-12-31_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember" unitRef="SquareFoot" name="us-gaap:AreaOfRealEstateProperty" scale="0" format="ixt:numdotdecimal" decimals="INF">12,106</ix:nonFraction> square feet of this office and laboratory space.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 26, 2021, </em>the Company entered into a Lease Termination Agreement with its landlord and a Sublease Termination Agreement with its sublessee, to terminate the lease and sublease agreements at its former corporate headquarters. The termination of both the lease and sublease was effective on <em style="font: inherit;"> April 30, 2021. </em>As of the date of the Lease Termination Agreement, the Company remeasured its lease liability and recorded a gain of $<ix:nonFraction id="c81619233" contextRef="d_2021-03-26_2021-03-26" unitRef="USD" name="us-gaap:GainLossOnTerminationOfLease" scale="6" format="ixt:numdotdecimal" decimals="-5">0.5</ix:nonFraction> million upon derecognition of the lease liability and right of use asset for the master lease, which was included in operating expenses for the year ended <em style="font: inherit;"> December 31, 2021. </em>In connection with the Sublease Termination, the remaining deferred costs of $<ix:nonFraction id="c81619234" contextRef="i_2021-04-30_BalanceSheetLocationAxis-PrepaidExpensesAndOtherCurrentAssetsMember" unitRef="USD" name="acrx:LesseeOperatingSubleaseDeferredCosts" scale="6" format="ixt:numdotdecimal" decimals="-5">0.3</ix:nonFraction> million were fully amortized through <em style="font: inherit;"> April 30, 2021, </em>the effective date of the Sublease Termination, and included in operating expenses for the year ended <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 26, 2021, </em>the Company entered into a Sublease Agreement to sublet space for its new corporate headquarters, located at <em style="font: inherit;">25821</em> Industrial Boulevard, Hayward, California. The Sublease Agreement commencement date was <em style="font: inherit;"> April 1, 2021. </em>The Sublease Agreement is for a period of <span style="-sec-ix-hidden:c81619236">two</span> years and <em style="font: inherit;">three</em> months with monthly rental payments of $<ix:nonFraction id="c81619238" contextRef="d_2021-03-26_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember" unitRef="USD" name="acrx:LesseeOperatingLeaseMonthlyRent" scale="0" format="ixt:numdotdecimal" decimals="INF">17,000</ix:nonFraction>, including <span style="-sec-ix-hidden:c81619239">one</span> month of abated rent. On the lease commencement date, the Company recognized an operating lease right-of-use asset in the amount of $<ix:nonFraction id="c81619240" contextRef="i_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contract Manufacturing Leases</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 12, 2012, </em>the Company entered into an agreement for commercial supply manufacturing services related to the Company&#x2019;s Zalviso drug product with a contract manufacturing organization. The initial term of the agreement was through <em style="font: inherit;"> December 31, 2017, </em>which term automatically renews in <span style="-sec-ix-hidden:c81619241">two</span>-year increments unless earlier terminated by either party by giving <span style="-sec-ix-hidden:c81619242">eighteen</span> months&#x2019; notice. Commencing in <em style="font: inherit;">2013,</em> the Company is required to make overhead fee payments each year of $<ix:nonFraction id="c81619244" contextRef="d_2012-12-12_2012-12-12" unitRef="USD" name="acrx:LesseeOperatingLeaseAnnualOverheadFeePayments" scale="6" format="ixt:numdotdecimal" decimals="-5">0.2</ix:nonFraction> million, prorated based on aggregate revenues. The Company has determined that this fee is an in-substance fixed lease payment as it represents the minimum annual payment under the contract. The Company concluded that this agreement contains an embedded lease as the clean rooms have been built specifically for production of the Company&#x2019;s product and their use is effectively controlled by the Company as it has priority over the space during the term of the agreement. The Company accounts for the agreement as an operating lease and has evaluated the non-cancelable term to be through the binding commitment date of <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> April 21, 2021, </em>the Company entered into a Commercial Supply Agreement, or the CSA, with Catalent Pharma Solutions, LLC, or Catalent, effective <em style="font: inherit;"> March 31, 2021, </em>under which Catalent provides certain services to the Company in connection with the processing and packaging of a packaged single dose applicator containing the sublingual tablet <em style="font: inherit;">30</em> mcg sufentanil dosage form contained in the pharmaceutical product, DSUVIA (sufentanil), intended for commercialization.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">27</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of the CSA is for a period of <span style="-sec-ix-hidden:c81619247">five</span> years from the <em style="font: inherit;">first</em> date upon which the FDA approves Catalent as a manufacturer of DSUVIA in the United States, or the Commencement Date. The term shall automatically be extended for successive <span style="-sec-ix-hidden:c81619249">two</span>-year periods, unless and until <em style="font: inherit;">one</em> party gives the other party at least <em style="font: inherit;">24</em> months&#x2019; prior written notice of its desire to terminate as of the end of the then-current term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company will pay Catalent an annual fee of $<ix:nonFraction id="c81619252" contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-CatalentPharmaSolutionsMember_StatementScenarioAxis-ScenarioForecastMember" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="6" format="ixt:numdotdecimal" decimals="-6">1.0</ix:nonFraction> million beginning <em style="font: inherit;"> January 1, 2022. </em>Pursuant to the CSA, the Company will purchase each <em style="font: inherit;">10</em>-pack carton of DSUVIA from Catalent at an agreed price through <em style="font: inherit;"> December 31, 2022, </em>and pay other fees set forth in the CSA. All pricing and fees, with the exception of raw materials, <em style="font: inherit;"> may </em>be adjusted on an annual basis, effective on <em style="font: inherit;"> January 1 </em>of each calendar year, beginning with <em style="font: inherit;"> January 1, 2023, </em>subject to certain limitations. Price increases for raw materials will be passed through to the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has determined that the fixed fees in the CSA are in-substance lease payments. The Company concluded that this agreement contains an embedded lease as the clean rooms have been built specifically for production of the Company&#x2019;s product and their use is effectively controlled by the Company as it has sole use over the space during the term of the agreement. The Company accounts for the agreement as an operating lease and has evaluated the non-cancelable lease term to be through the binding commitment date of <em style="font: inherit;"> May 15, 2027.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The components of lease expense are presented in the following table (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:LeaseCostTableTextBlock" id="BB990736-8B2D-4097-8022-1CBABFCCD006" escape="true" continuedAt="c073CB979-D139-49C0-BE7E-373227758046">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br /> <b>December</b> <b>31,</b><br /> <b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br /> <b>December</b> <b>31,</b><br /> <b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619255" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">1,467</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619256" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-4">1,360</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gain on derecognition of operating lease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81619257" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GainLossOnTerminationOfLease" scale="3" format="ixt:numdotdecimal" decimals="-3">522</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619258" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GainLossOnTerminationOfLease" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81619259" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:SubleaseIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">199</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81619260" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:SubleaseIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">598</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss on termination of sublease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619261" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:GainLossOnTerminationOfSublease" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">331</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619262" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:GainLossOnTerminationOfSublease" scale="3" format="ixt:zerodash" decimals="-3" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net lease costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619263" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">1,077</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619264" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:LeaseCost" scale="3" format="ixt:numdotdecimal" decimals="-3">762</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="c073CB979-D139-49C0-BE7E-373227758046">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term &#x2013; operating leases (in years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="i_2021-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c81619265" format="ixt-sec:duryear">4.97</ix:nonNumeric></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><ix:nonNumeric contextRef="i_2020-12-31" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="c81619266" format="ixt-sec:duryear">3.1</ix:nonNumeric></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining discount rate &#x2013; operating leases&#xa0;(in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619267" contextRef="i_2021-12-31" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">12.8</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619268" contextRef="i_2020-12-31" unitRef="Pure" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" format="ixt:numdotdecimal" decimals="3">11.7</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
</tbody></table>
   </ix:continuation>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maturities of lease liabilities as of <em style="font: inherit;"> December 31, 2021 </em>are presented in the following table (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="c82EBC742-6455-4E52-8F8A-94168F119E13" escape="true" continuedAt="F3D9369B-9571-47A8-9745-2B96D0FAAE51">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619269" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" format="ixt:numdotdecimal" decimals="-3">1,608</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619270" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" format="ixt:numdotdecimal" decimals="-3">1,244</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619271" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" format="ixt:numdotdecimal" decimals="-4">1,040</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619272" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" format="ixt:numdotdecimal" decimals="-4">1,040</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619273" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" format="ixt:numdotdecimal" decimals="-4">1,040</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619274" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" format="ixt:numdotdecimal" decimals="-3">415</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;"><ix:nonFraction id="c81619275" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" format="ixt:numdotdecimal" decimals="-3">6,387</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619276" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">1,569</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619277" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">4,818</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">Reported as:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:continuation id="F3D9369B-9571-47A8-9745-2B96D0FAAE51">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;"><ix:nonFraction id="c81619278" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiability" scale="3" format="ixt:numdotdecimal" decimals="-3">4,818</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating lease liabilities, current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619279" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,068</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619280" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-4">3,750</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:continuation>
   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">28</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" id="c2050914" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em> Liability Related to Sale of Future Royalties </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 18, 2015, </em>the Company entered into the Royalty Monetization with PDL for which it received gross proceeds of $<ix:nonFraction id="c81619282" contextRef="d_2015-09-18_2015-09-18" unitRef="USD" name="acrx:ProceedsFromSaleOfRoyaltyAndMilestoneRights" scale="6" format="ixt:numdotdecimal" decimals="-6">65.0</ix:nonFraction> million. Under the Royalty Monetization, PDL was to receive <ix:nonFraction id="c81619283" contextRef="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember" unitRef="Pure" name="acrx:PercentageOfRoyaltiesAndRightsUnderAgreement" scale="-2" format="ixt:numdotdecimal" decimals="2">75</ix:nonFraction>% of the European royalties under the Amended License Agreement with Gr&#xfc;nenthal, as well as <ix:nonFraction id="c81619284" contextRef="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember" unitRef="Pure" name="acrx:PercentageOfRoyaltiesAndRightsUnderAgreement" scale="-2" format="ixt:numdotdecimal" decimals="1">80</ix:nonFraction>% of the <em style="font: inherit;">first</em> <em style="font: inherit;">four</em> commercial milestones worth $<ix:nonFraction id="c81619287" contextRef="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember" unitRef="USD" name="acrx:CommercialMilestonesValueMaximumAmountAvailable" scale="6" format="ixt:numdotdecimal" decimals="-5">35.6</ix:nonFraction> million (or <em style="font: inherit;">80%</em> of $<ix:nonFraction id="c81619289" contextRef="d_2015-09-18_2015-09-18_LegalEntityAxis-AcelRXMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember" unitRef="USD" name="acrx:CommercialMilestonesValueMaximumAmountAvailable" scale="6" format="ixt:numdotdecimal" decimals="-5">44.5</ix:nonFraction> million), up to a capped amount of <em style="font: inherit;">$195.0</em> million over the life of the arrangement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the relevant accounting guidance, because of the Company&#x2019;s significant continuing involvement, the Royalty Monetization has been accounted for as a liability that will be amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and paid to PDL, up to a capped amount of $<ix:nonFraction id="c81619291" contextRef="d_2015-09-18_2015-09-18" unitRef="USD" name="acrx:RoyaltyArrangmentMaximumPayments" scale="6" format="ixt:numdotdecimal" decimals="-6">195.0</ix:nonFraction> million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $<ix:nonFraction id="c81619292" contextRef="d_2015-09-18_2015-09-18" unitRef="USD" name="acrx:NetProceedsFromSaleOfFutureRoyalties" scale="6" format="ixt:numdotdecimal" decimals="-5">61.2</ix:nonFraction> million of net proceeds the Company received will be recorded as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense relating to the Royalty Monetization accordingly.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020, </em>Gr&#xfc;nenthal notified the Company that it was terminating the Amended License Agreement, effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#xfc;nenthal Agreements were extended to <em style="font: inherit;"> May 12, 2021 </em>to enable Gr&#xfc;nenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on <em style="font: inherit;"> May 12, 2021. </em>There is a continuing obligation on the Company&#x2019;s part, through the term of the Royalty Monetization with SWK (assignee of PDL), to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. If the Company is unable to find a New Arrangement, a contingent gain of up to approximately $<ix:nonFraction id="c81619294" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:ContingentGainLossOnRoyaltyMonetizationArrangement" scale="6" format="ixt:numdotdecimal" decimals="-6">64</ix:nonFraction> million <em style="font: inherit;"> may </em>be recognized when it is realized upon expiration of the liability at the end of the Royalty Monetization term. Due to the significant judgments and factors related to the estimates of future payments under the Royalty Monetization, there are significant uncertainties surrounding the amount and timing of future payments and the probability of realization of the estimated contingent gain.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The effective interest rate over the life of the liability will be <ix:nonFraction id="c81619295" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="acrx:EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>% as the Company records interest income over the remaining term of the arrangement as an offset to the interest expense that was recognized in prior periods. The effective interest income rate for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was approximately <ix:nonFraction id="c81619297" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="acrx:EffectiveAnnualInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">3.5</ix:nonFraction>% and <ix:nonFraction id="c81619298" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="acrx:EffectiveAnnualInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">3.6</ix:nonFraction>%, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table shows the activity within the liability account during the year ended <em style="font: inherit;"> December 31, 2021 (</em>in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:OtherLiabilitiesTableTextBlock" id="c2050915" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br /> <b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Period from</b><br /> <b>inception to </b><br /> <b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liability related to sale of future royalties &#x2014; beginning balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619309" contextRef="i_2020-12-31" unitRef="USD" name="acrx:LiabilityRelatedToSaleOfFutureRoyalties" scale="3" format="ixt:numdotdecimal" decimals="-3">88,471</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619310" contextRef="i_2015-09-18" unitRef="USD" name="acrx:LiabilityRelatedToSaleOfFutureRoyalties" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from sale of future royalties</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619311" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:NetProceedsFromSaleOfFutureRoyalties" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619312" contextRef="d_2015-09-19_2021-12-31" unitRef="USD" name="acrx:NetProceedsFromSaleOfFutureRoyalties" scale="3" format="ixt:numdotdecimal" decimals="-3">61,184</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-cash royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81619313" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" scale="3" format="ixt:numdotdecimal" decimals="-3">145</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81619314" contextRef="d_2015-09-19_2021-12-31" unitRef="USD" name="acrx:NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" scale="3" format="ixt:numdotdecimal" decimals="-3">1,083</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-cash interest (income) expense recognized</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619315" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" scale="3" format="ixt:numdotdecimal" decimals="-3">3,038</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619316" contextRef="d_2015-09-19_2021-12-31" unitRef="USD" name="acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">25,187</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liability related to sale of future royalties as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619317" contextRef="i_2021-12-31" unitRef="USD" name="acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNet" scale="3" format="ixt:numdotdecimal" decimals="-3">85,288</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619318" contextRef="i_2021-12-31" unitRef="USD" name="acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNet" scale="3" format="ixt:numdotdecimal" decimals="-3">85,288</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As royalties are remitted to PDL from ARPI LLC, as described in Note&#xa0;<em style="font: inherit;">1</em> &#x201c;Organization and Summary of Significant Accounting Policies,&#x201d; the balance of the liability will be effectively repaid over the life of the agreement. The Company will record non-cash royalty revenues and non-cash interest (income) expense within its Consolidated Statements of Operations over the term of the Royalty Monetization. The liability related to the sale of future royalties, current portion, is recorded as accrued liabilities in the Company&#x2019;s Consolidated Balance Sheets.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:WarrantsDisclosureTextBlock" id="c2050916" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em> Warrants </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><em style="font: inherit;"> November 2021 </em>Financing Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> November 15, 2021, </em>the Company entered into a securities purchase agreement with certain investors pursuant to which the Company, in a registered direct offering, sold (i) an aggregate of <ix:nonFraction id="c81619320" contextRef="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">17,500,000</ix:nonFraction> shares of the Company's common stock, and (ii) warrants to purchase up to an aggregate of <ix:nonFraction id="c81619321" contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">17,500,000</ix:nonFraction> shares of common stock, for an aggregate purchase price of $<ix:nonFraction id="c81619322" contextRef="d_2021-11-15_2021-11-15_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-6">14.0</ix:nonFraction> million (see Note <em style="font: inherit;">13</em> &#x201c;Stockholders&#x2019; Equity&#x201d;). The <em style="font: inherit;"> November 2021 </em>Financing Warrants have an exercise price of $<ix:nonFraction id="c81619324" contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.00</ix:nonFraction> per share and become exercisable, if the holder&#x2019;s post-exercise beneficial ownership is less than or equal to <ix:nonFraction id="c81619325" contextRef="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_RangeAxis-MaximumMember" unitRef="Pure" name="acrx:ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" scale="-2" format="ixt:numdotdecimal" decimals="4">9.99</ix:nonFraction>%, <em style="font: inherit;">6</em> months after their issuance date and have a <em style="font: inherit;">five</em>-year term (<em style="font: inherit;"> November 15, 2026). </em>All common stock issuable under the issued warrants, were added to the Company&#x2019;s effective registration statement on <em style="font: inherit;"> November 15, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">29</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;"> November 2021 </em>Financing warrants were valued at approximately $<ix:nonFraction id="c81619329" contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:numdotdecimal" decimals="-5">8.6</ix:nonFraction> million using the Black-Scholes option pricing model as follows: exercise price of $<ix:nonFraction id="c81619330" contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.00</ix:nonFraction> per share, stock price of $<ix:nonFraction id="c81619331" contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">0.7461</ix:nonFraction> per share, expected life of <span style="-sec-ix-hidden:c81619332">five</span> years, volatility of <ix:nonFraction id="c81619333" contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="4">91.77</ix:nonFraction>%, and a risk-free rate of <ix:nonFraction id="c81619334" contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="4">1.26</ix:nonFraction>%. The common stock and warrants were issued in a unit structure; therefore, in accordance with ASC Topic <em style="font: inherit;">815,</em> the aggregate gross proceeds of $<ix:nonFraction id="c81619336" contextRef="d_2021-11-15_2021-11-15_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-6">14.0</ix:nonFraction> million were allocated to the <em style="font: inherit;">two</em> securities using the relative fair value method, resulting in the common stock and warrants being allocated values of $<ix:nonFraction id="c81619338" contextRef="d_2021-11-15_2021-11-15_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">8.4</ix:nonFraction> million and $<ix:nonFraction id="c81619339" contextRef="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfWarrants" scale="6" format="ixt:numdotdecimal" decimals="-5">5.6</ix:nonFraction> million, respectively, and recorded to stockholders' equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Loan Agreement Warrants </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Loan Agreement, on <em style="font: inherit;"> May 30, 2019, </em>the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of <ix:nonFraction id="c81619340" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">176,679</ix:nonFraction> shares of the Company&#x2019;s common stock with a per share exercise price of $<ix:nonFraction id="c81619341" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">2.83</ix:nonFraction>, or the Loan Agreement Warrants. The Loan Agreement Warrants <em style="font: inherit;"> may </em>be exercised on a cashless basis. The Loan Agreement Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of <span style="-sec-ix-hidden:c81619342">ten</span> years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Loan Agreement Warrants. The number of shares for which the Loan Agreement Warrants are exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Loan Agreement Warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company estimated the fair value of these Loan Agreement Warrants as of the issuance date to be $<ix:nonFraction id="c81619343" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million, which was used in estimating the fair value of the debt instrument and was recorded as equity. The fair value of the Loan Agreement Warrants was calculated using the Black-Scholes option-valuation model, and was based on the strike price of $<ix:nonFraction id="c81619344" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">2.83</ix:nonFraction>, the stock price at issuance of $<ix:nonFraction id="c81619345" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember" unitRef="USDPerShare" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="0" format="ixt:numdotdecimal" decimals="INF">2.66</ix:nonFraction>, the <span style="-sec-ix-hidden:c81619346">ten</span>-year contractual term of the warrants, a risk-free interest rate of <ix:nonFraction id="c81619347" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="4">2.22</ix:nonFraction>%, expected volatility of <ix:nonFraction id="c81619348" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="4">80.22</ix:nonFraction>% and <ix:nonFraction id="c81619349" contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember" unitRef="Pure" name="us-gaap:WarrantsAndRightsOutstandingMeasurementInput" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>% expected dividend yield.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2021, </em>Loan Agreement Warrants to purchase <ix:nonFraction id="c81619350" contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">176,679</ix:nonFraction> shares of common stock issued to the Lender and its affiliates had <em style="font: inherit;">not</em> been exercised and were still outstanding. These warrants expire in <em style="font: inherit;"> May 2029.</em></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2050917" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em> Commitments and Contingencies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Litigation </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> June 8, 2021, </em>a securities class action complaint was filed in the U.S. District Court for the Northern District of California against the Company and <span style="-sec-ix-hidden:c81619353">two</span> of its officers. The plaintiff is a purported stockholder of the Company. The complaint alleges that defendants violated Sections <em style="font: inherit;">10</em>(b) and <em style="font: inherit;">20</em>(a) of the Exchange Act and SEC Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">5</em> by making false and misleading statements and omissions of material fact about the Company&#x2019;s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint seeks unspecified damages, interest, attorneys&#x2019; fees, and other costs. On <em style="font: inherit;"> December 16, 2021, </em>the Court appointed co-lead plaintiffs. Plaintiffs&#x2019; amended complaint was filed on <em style="font: inherit;"> March 7, 2022. </em>The amended complaint names the Company and <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">three</em> of its officers and continues to allege that defendants violated Sections <span style="-sec-ix-hidden:c81619358">10</span>(b) and <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">20</em>(a) of the Exchange Act and SEC Rule <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">10b</em>-<em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">5</em> by making false and misleading statements and omissions of material fact about the Company&#x2019;s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint also alleges a violation of Section <em style="font: inherit;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted">20A</em> of the Exchange Act against the individual defendants for alleged insider trading. Defendants&#x2019; motion to dismiss the amended complaint is due <em style="font: inherit;"> May 6, 2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> July 6, 2021, </em>a purported shareholder derivative complaint was filed in the U.S. District Court for the Northern District of California. The complaint names <em style="font: inherit;">ten</em> of the Company&#x2019;s officers and directors and asserts state and federal claims based on the same alleged misstatements as the shareholder class action complaint. On <em style="font: inherit;"> September 30, 2021, </em><em style="font: inherit;"> October 26, 2021, </em>and <em style="font: inherit;"> November 17, 2021, </em><em style="font: inherit;">three</em> additional purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California. The complaints name <em style="font: inherit;">nine</em> of the Company&#x2019;s officers and directors and also assert state and federal claims based on the same alleged misstatements as the shareholder class action complaint. All <em style="font: inherit;">four</em> complaints seek unspecified damages, attorneys&#x2019; fees, and other costs. On <em style="font: inherit;"> December 6, 2021, </em>the Court entered an order consolidating all <em style="font: inherit;">four</em> actions and staying the consolidated action pending the outcome of any motion to dismiss the securities class action. Please see &#x201c;Part II., Item <em style="font: inherit;">1A.</em> Risk Factors&#x2014;Risks of a General Nature&#x2014;Litigation <em style="font: inherit;"> may </em>substantially increase our costs and harm our business<i>.</i>&#x201d;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that <em style="font: inherit;"> may </em>result from these actions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">30</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2050918" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em> Stockholders</b>&#x2019;<b> Equity </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Common Stock </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Underwritten Public Offering</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 22, 2021, </em>the Company completed an underwritten public offering in which the Company issued and sold <ix:nonFraction id="c81619369" contextRef="d_2021-01-22_2021-01-22_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">14,500,000</ix:nonFraction> shares of its common stock to the underwriter at a price of $<ix:nonFraction id="c81619370" contextRef="i_2021-01-22_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1.7625</ix:nonFraction> per share. On <em style="font: inherit;"> January 27, 2021, </em>the underwriters exercised their option in full and purchased an additional <ix:nonFraction id="c81619371" contextRef="d_2021-01-27_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">2,175,000</ix:nonFraction> shares at a price of $<ix:nonFraction id="c81619372" contextRef="i_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1.7625</ix:nonFraction> per share. The total net proceeds from this offering of an aggregate <ix:nonFraction id="c81619373" contextRef="d_2021-01-22_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">16,675,000</ix:nonFraction> shares were approximately $<ix:nonFraction id="c81619374" contextRef="d_2021-01-22_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">28.9</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Registered Direct Offering</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> November 17, 2021, </em>the Company completed a registered direct offering in which the Company issued and sold <ix:nonFraction id="c81619376" contextRef="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">17,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction id="c81619377" contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.80</ix:nonFraction> per share and warrants exercisable for an aggregate of <ix:nonFraction id="c81619378" contextRef="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">17,500,000</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction id="c81619379" contextRef="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.00</ix:nonFraction> per share. The total net proceeds from this offering were approximately $<ix:nonFraction id="c81619380" contextRef="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="acrx:NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" scale="6" format="ixt:numdotdecimal" decimals="-5">13.9</ix:nonFraction> million. The <em style="font: inherit;"> November 2021 </em>issued shares were valued at approximately $<ix:nonFraction id="c81619381" contextRef="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" format="ixt:numdotdecimal" decimals="-5">13.1</ix:nonFraction> million based on the closing stock price of $<ix:nonFraction id="c81619382" contextRef="i_2021-11-17" unitRef="USDPerShare" name="us-gaap:SharePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.7491</ix:nonFraction> per share on <em style="font: inherit;"> November 15, 2021. </em>The common stock and warrants were issued in a unit structure; therefore, in accordance with ASC Topic <em style="font: inherit;">815,</em> the aggregate gross proceeds of $<ix:nonFraction id="c81619384" contextRef="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOrSaleOfEquity" scale="6" format="ixt:numdotdecimal" decimals="-6">14.0</ix:nonFraction> million were allocated to the <em style="font: inherit;">two</em> securities using the relative fair value method, resulting in the common stock and warrants being allocated values of $<ix:nonFraction id="c81619386" contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember" unitRef="USD" name="us-gaap:CommonStockValue" scale="6" format="ixt:numdotdecimal" decimals="-5">8.4</ix:nonFraction> million and $<ix:nonFraction id="c81619387" contextRef="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember" unitRef="USD" name="us-gaap:WarrantsAndRightsOutstanding" scale="6" format="ixt:numdotdecimal" decimals="-5">5.6</ix:nonFraction> million, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Registered Direct Offerings</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> July 23, 2020, </em>the Company completed a registered direct offering in which it issued and sold <ix:nonFraction id="c81619389" contextRef="d_2020-07-23_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">9,433,962</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction id="c81619390" contextRef="i_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1.06</ix:nonFraction> per share. The total net proceeds from this offering were approximately $<ix:nonFraction id="c81619391" contextRef="d_2020-07-23_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-7">10.0</ix:nonFraction> million, after deducting estimated expenses payable by the Company of $<ix:nonFraction id="c81619392" contextRef="i_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="acrx:EstimatedOfferingCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">49,000</ix:nonFraction>. <em style="font: inherit;">No</em> underwriter or placement agent participated in the offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 11, 2020, </em>the Company completed a registered direct offering in which it issued and sold <ix:nonFraction id="c81619394" contextRef="d_2020-12-11_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">8,333,333</ix:nonFraction> shares of its common stock at a price of $<ix:nonFraction id="c81619395" contextRef="i_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1.20</ix:nonFraction> per share. The total net proceeds from this offering were approximately $<ix:nonFraction id="c81619396" contextRef="d_2020-12-11_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">9.9</ix:nonFraction> million, after deducting estimated expenses payable by the Company of $<ix:nonFraction id="c81619397" contextRef="i_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember" unitRef="USD" name="acrx:EstimatedOfferingCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">51,000</ix:nonFraction>. <em style="font: inherit;">No</em> underwriter or placement agent participated in the offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>ATM Agreement </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> June 21, 2016, </em>the Company entered into a Controlled Equity Offering<sup style="vertical-align:top;line-height:120%;font-size:pt">SM</sup> Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald &amp; Co., or Cantor, as agent, pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell, from time to time through Cantor, shares of the Company&#x2019;s common stock, or the Common Stock having an aggregate offering price of up to $<ix:nonFraction id="c81619399" contextRef="d_2016-06-21_2016-06-21_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="acrx:AggregateOfferingPriceMaximum" scale="6" format="ixt:numdotdecimal" decimals="-7">40.0</ix:nonFraction> million, or the Shares. On <em style="font: inherit;"> May 9, 2019, </em>the Company increased the aggregate offering price of shares of the Company&#x2019;s common stock which <em style="font: inherit;"> may </em>be offered and sold under the ATM Agreement by $<ix:nonFraction id="c81619400" contextRef="d_2019-05-09_2019-05-09_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="acrx:AggregateOfferingPriceIncreaseDuringPeriod" scale="6" format="ixt:numdotdecimal" decimals="-7">40.0</ix:nonFraction> million, for a total of $<ix:nonFraction id="c81619401" contextRef="d_2019-05-09_2019-05-09_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="acrx:AggregateOfferingPriceMaximum" scale="6" format="ixt:numdotdecimal" decimals="-7">80.0</ix:nonFraction> million, or the Shares. The offering of Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the ATM Agreement or (b) the termination of the ATM Agreement by Cantor or the Company, as permitted therein. The Company will pay Cantor a commission rate in the low single digits on the aggregate gross proceeds from each sale of Shares and have agreed to provide Cantor with customary indemnification and contribution rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company issued and sold approximately <ix:nonFraction id="c81619402" contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" format="ixt:numdotdecimal" decimals="-6">3.0</ix:nonFraction> million shares of common stock pursuant to the ATM Agreement, and received net proceeds of approximately $<ix:nonFraction id="c81619403" contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">7.5</ix:nonFraction> million, after deducting fees and expenses. During the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company issued and sold <ix:nonFraction id="c81619404" contextRef="d_2020-01-01_2020-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">876,800</ix:nonFraction> shares of common stock pursuant to the ATM Agreement, for which the Company received net proceeds of approximately $<ix:nonFraction id="c81619405" contextRef="d_2020-01-01_2020-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">1.4</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2021, </em>the Company had the ability to offer and sell shares of the Company&#x2019;s common stock having an aggregate offering price of up to $<ix:nonFraction id="c81619406" contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember" unitRef="USD" name="acrx:AggregateOfferingPriceMaximum" scale="6" format="ixt:numdotdecimal" decimals="-5">36.1</ix:nonFraction> million under the ATM Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock Plans </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2011</em> Equity Incentive Plan </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> January 2011, </em>the Board of Directors adopted, and the Company&#x2019;s stockholders approved, the <em style="font: inherit;">2011</em> Equity Incentive Plan, or <em style="font: inherit;">2011</em> EIP. The initial aggregate number of shares of the Company&#x2019;s common stock that were issuable pursuant to stock awards under the <em style="font: inherit;">2011</em> EIP was approximately <ix:nonFraction id="c81619411" contextRef="d_2011-01-01_2011-01-31_PlanNameAxis-EquityIncentivePlan2011Member" unitRef="Share" name="acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" scale="6" format="ixt:numdotdecimal" decimals="-5">1.9</ix:nonFraction> million shares. The number of shares of common stock reserved for issuance under the <em style="font: inherit;">2011</em> EIP automatically increased on <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">1</em> of each year, starting on <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2012</em> and continuing through <em style="font: inherit;"> January&#xa0;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2020,</em> by <ix:nonFraction id="c81619418" contextRef="i_2011-12-31_PlanNameAxis-EquityIncentivePlan2011Member" unitRef="Pure" name="acrx:StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" scale="-2" format="ixt:numdotdecimal" decimals="2">4</ix:nonFraction>% of the total number of shares of the Company&#x2019;s common stock outstanding on <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31</em> of the preceding calendar year, or such lesser number of shares of common stock as determined by the Board of Directors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> June 16, 2020, </em><em style="font: inherit;">no</em> more awards <em style="font: inherit;"> may </em>be granted under the <em style="font: inherit;">2011</em> Equity Incentive Plan, or the <em style="font: inherit;">2011</em> EIP, although all outstanding stock options and other stock awards previously granted under the <em style="font: inherit;">2011</em> EIP will continue to remain subject to the terms of the <em style="font: inherit;">2011</em> EIP.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">31</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Amended <em style="font: inherit;">2020</em> Plan </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> June 16, 2020, </em>at the <em style="font: inherit;">2020</em> Annual Meeting of Stockholders of the Company, the Company&#x2019;s stockholders, upon the recommendation of the Company&#x2019;s Board of Directors, approved the Company&#x2019;s <em style="font: inherit;">2020</em> Equity Incentive Plan, or the <em style="font: inherit;">2020</em> EIP.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The initial aggregate number of shares of the Company&#x2019;s common stock issuable pursuant to stock awards under the <em style="font: inherit;">2020</em> EIP was <ix:nonFraction id="c81619431" contextRef="i_2020-06-16_PlanNameAxis-EquityIncentivePlan2011Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">5,500,000</ix:nonFraction> shares. In addition, the share reserve will be increased by the number of returning shares, if any, as such shares become available from time to time under the <em style="font: inherit;">2011</em> EIP, for an additional number of shares <em style="font: inherit;">not</em> to exceed <ix:nonFraction id="c81619434" contextRef="i_2020-06-16_PlanNameAxis-The2020EquityIncentivePlanMember_RangeAxis-MaximumMember" unitRef="Share" name="acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" scale="0" format="ixt:numdotdecimal" decimals="INF">14,892,170</ix:nonFraction> shares. The term of any option granted under the <em style="font: inherit;">2020</em> EIP is determined on the date of grant but shall <em style="font: inherit;">not</em> be longer than <em style="font: inherit;">10</em> years. The Company issues new shares for settlement of vested restricted stock units and exercises of stock options. The Company does <em style="font: inherit;">not</em> have a policy of purchasing its shares relating to its stock-based programs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> June 17, 2021, </em>at the <em style="font: inherit;">2021</em> Annual Meeting of Stockholders of the Company, upon the recommendation of the Company&#x2019;s Board of Directors, the Company&#x2019;s stockholders approved an amendment and restatement of the Company&#x2019;s <em style="font: inherit;">2020</em> Equity Incentive Plan, or <em style="font: inherit;">2020</em> Plan, or as amended and restated, the Amended <em style="font: inherit;">2020</em> Plan, to increase the number of authorized shares reserved for issuance thereunder by <ix:nonFraction id="c81619443" contextRef="d_2021-06-17_2021-06-17_PlanNameAxis-The2020EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">4,300,000</ix:nonFraction> shares, subject to adjustment for certain changes in the Company&#x2019;s capitalization. The aggregate number of shares of the Company&#x2019;s common stock that <em style="font: inherit;"> may </em>be issued under the Amended <em style="font: inherit;">2020</em> Plan will <em style="font: inherit;">not</em> exceed the sum of: (i) <ix:nonFraction id="c81619446" contextRef="i_2021-06-17_PlanNameAxis-The2020EquityIncentivePlanMember_RangeAxis-MaximumMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">4,300,000</ix:nonFraction> shares approved in connection with the adoption of the Amended <em style="font: inherit;">2020</em> Plan, (ii) <ix:nonFraction id="c81619448" contextRef="i_2020-06-16_PlanNameAxis-The2020EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">5,500,000</ix:nonFraction> shares approved in connection with the original adoption of the <em style="font: inherit;">2020</em> Plan, and (iii) certain shares subject to outstanding awards granted under the <em style="font: inherit;">2011</em> Equity Incentive Plan that <em style="font: inherit;"> may </em>become available for issuance under the <em style="font: inherit;">2020</em> Plan and Amended <em style="font: inherit;">2020</em> Plan, as such shares become available from time to time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Amended and Restated <em style="font: inherit;">2011</em> Employee Stock Purchase Plan </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, on <em style="font: inherit;"> June 16, 2020, </em>the Company&#x2019;s stockholders, upon the recommendation of the Company&#x2019;s Board of Directors, approved the Amended and Restated <em style="font: inherit;">2011</em> Employee Stock Purchase Plan, or the Amended ESPP, which increased the aggregate number of shares of the Company&#x2019;s common stock reserved for issuance under the <em style="font: inherit;">2011</em> Employee Stock Purchase Plan, or ESPP, to <ix:nonFraction id="c81619456" contextRef="i_2020-06-16_PlanNameAxis-EmployeeStockPurchasePlanESPPMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">4,900,000</ix:nonFraction> shares, subject to adjustment for certain changes in the Company&#x2019;s capitalization, and removed the &#x201c;evergreen&#x201d; provision from the ESPP.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the year ended <em style="font: inherit;"> December 31, 2021, </em>there were <ix:nonFraction id="c81619457" contextRef="i_2021-12-31_PlanNameAxis-EmployeeStockPurchasePlanESPPMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">297,959</ix:nonFraction> shares issued under the Amended ESPP. The weighted average fair value of shares issued under the Amended ESPP in <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c81619460" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="acrx:EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.01</ix:nonFraction> and $<ix:nonFraction id="c81619461" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="acrx:EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.09</ix:nonFraction> per share, respectively. As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were <ix:nonFraction id="c81619464" contextRef="i_2021-12-31_PlanNameAxis-EmployeeStockPurchasePlanESPPMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">4,456,364</ix:nonFraction> shares available for future grant under the Amended ESPP.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2050919" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">14.</em> Stock-Based Compensation </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company recorded total stock-based compensation expense for stock options, stock awards and the Amended ESPP as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2050920" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br /> <b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br /> <b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619496" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-CostOfSalesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">92</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619497" contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-CostOfSalesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">123</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619498" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">813</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619499" contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">764</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619500" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,704</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619501" contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">3,537</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619502" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,609</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619503" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">4,424</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes restricted stock unit activity under the Company&#x2019;s Equity Incentive Plans:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" id="c2050921" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b> <b>of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Average</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Restricted</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Grant</b> <b>Date</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stock</b> <b>Units</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, January 1, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619510" contextRef="i_2019-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">988,645</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619511" contextRef="i_2019-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.53</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619512" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">908,300</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619513" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.30</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81619514" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">304,810</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619515" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.53</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619516" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">194,152</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619517" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">2.16</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619518" contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">1,397,983</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619519" contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.79</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619520" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">1,149,632</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619521" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.68</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c81619522" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">587,214</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619523" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.89</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619524" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">186,025</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619525" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.58</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619526" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">1,774,376</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619527" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.71</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">32</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes stock&#xa0;option activity under the Company&#x2019;s Equity Incentive Plans:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2050922" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b><br /> <b>of</b> <b>Stock</b> <b>Options</b><br /> <b>Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;"><b><b>Weighted-</b><br /> <b>Average</b><br /> <b>Exercise</b><br /> <b>Price</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-</b><br /> <b>Average</b><br /> <b>Remaining</b><br /> <b>Contractual</b><br /> <b>Life (Years)</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Aggregate</b><br /> <b>Intrinsic</b><br /> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in</b> <b>thousands)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;"><ix:nonFraction id="c81619528" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">12,813,022</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"><ix:nonFraction id="c81619529" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619532" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">2,667,612</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619533" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.82</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">(<ix:nonFraction id="c81619536" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">375,432</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"><ix:nonFraction id="c81619537" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.79</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">(<ix:nonFraction id="c81619540" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">801,749</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"><ix:nonFraction id="c81619541" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.03</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619544" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="INF">19,403</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"><ix:nonFraction id="c81619545" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.84</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619548" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">14,284,050</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"><ix:nonFraction id="c81619549" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.99</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81619550" format="ixt-sec:duryear">5.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"><ix:nonFraction id="c81619551" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and exercisable options&#x2014;December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;"><ix:nonFraction id="c81619552" contextRef="i_2021-12-31" unitRef="Share" name="acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">10,496,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"><ix:nonFraction id="c81619553" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.42</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" id="c81619554" format="ixt-sec:duryear">4.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"><ix:nonFraction id="c81619555" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest&#x2014;December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;"><ix:nonFraction id="c81619556" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">14,284,050</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"><ix:nonFraction id="c81619557" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.99</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c81619558" format="ixt-sec:duryear">5.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"><ix:nonFraction id="c81619559" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were <ix:nonFraction id="c81619472" contextRef="i_2021-12-31_PlanNameAxis-The2020EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">7,858,933</ix:nonFraction> shares available for future grant under the <em style="font: inherit;">2020</em> EIP.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional information regarding the Company&#x2019;s stock options outstanding and vested and exercisable as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>&#xa0;is summarized below:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" id="c2050923" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b> <b>Vested</b> <b>and</b> <b>Exercisable</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Exercise Prices</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b><br /> <b>Stock</b> <b>Options</b><br /> <b>Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br /> <b>Remaining</b><br /> <b>Contractual</b> <b>Life</b><br /> <b>(Years)</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br /> <b>Exercise</b> <b>Price</b> <b>per</b><br /> <b>Share</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b> <b>Subject</b><br /> <b>to Stock</b><br /> <b>Options</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br /> <b>Exercise</b> <b>Price</b> <b>per</b><br /> <b>Share</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$0.72</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619560">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$<ix:nonFraction id="c81619561" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">1.12</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81619562" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">695,482</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81619563" format="ixt-sec:duryear">8.1</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619564" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.85</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;"><ix:nonFraction id="c81619565" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">280,047</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619566" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member" unitRef="USDPerShare" name="acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.84</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$1.26</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619567">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$<ix:nonFraction id="c81619568" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">1.89</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81619569" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">3,402,418</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81619570" format="ixt-sec:duryear">8.9</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619571" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.80</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;"><ix:nonFraction id="c81619572" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">496,679</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619573" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member" unitRef="USDPerShare" name="acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.67</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.00</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619574">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$<ix:nonFraction id="c81619575" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">3.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81619576" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">5,310,550</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81619577" format="ixt-sec:duryear">6.1</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619578" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.44</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;"><ix:nonFraction id="c81619579" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">4,856,618</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619580" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member" unitRef="USDPerShare" name="acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.43</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$3.10</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619581">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$<ix:nonFraction id="c81619582" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">4.65</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81619583" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">3,066,819</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81619584" format="ixt-sec:duryear">3.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619585" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.37</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;"><ix:nonFraction id="c81619586" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">3,054,619</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619587" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member" unitRef="USDPerShare" name="acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.38</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$4.73</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619588">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$<ix:nonFraction id="c81619589" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">7.10</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"><ix:nonFraction id="c81619590" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">1,295,781</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81619591" format="ixt-sec:duryear">1.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619592" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.71</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;"><ix:nonFraction id="c81619593" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">1,295,781</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619594" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member" unitRef="USDPerShare" name="acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.71</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$8.18</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619595">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$<ix:nonFraction id="c81619596" contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" format="ixt:numdotdecimal" decimals="INF">12.27</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619597" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">513,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81619598" format="ixt-sec:duryear">2.1</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619599" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">10.28</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619600" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">513,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619601" contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member" unitRef="USDPerShare" name="acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">10.28</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><ix:nonFraction id="c81619603" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" scale="0" xsi:nil="true"></ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 7pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619604" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">14,284,050</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c81619605" format="ixt-sec:duryear">5.8</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619606" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">2.99</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619607" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">10,496,744</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"><ix:nonFraction id="c81619608" contextRef="i_2021-12-31" unitRef="USDPerShare" name="acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">3.42</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted average grant-date fair value of options granted during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c81619479" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.24</ix:nonFraction> and $<ix:nonFraction id="c81619480" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.92</ix:nonFraction> per share, respectively. As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> total stock-based compensation expense related to unvested options to be recognized in future periods was $<ix:nonFraction id="c81619483" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">3.8</ix:nonFraction> million which is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c81619484" format="ixt-sec:duryear">2.1</ix:nonNumeric> years. The grant date fair value of shares vested during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c81619488" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:numdotdecimal" decimals="-5">2.4</ix:nonFraction> million and $<ix:nonFraction id="c81619489" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:numdotdecimal" decimals="-5">3.6</ix:nonFraction> million, respectively. The total intrinsic value of options exercised during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $<ix:nonFraction id="c81619493" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" format="ixt:numdotdecimal" decimals="-5">5.7</ix:nonFraction> thousand and $<ix:nonFraction id="c81619494" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" format="ixt:numdotdecimal" decimals="-3">0.0</ix:nonFraction> million, respectively.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> March 3, 2021, </em>the Company granted <ix:nonFraction id="c81621094" contextRef="d_2021-03-03_2021-03-03_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="6" format="ixt:numdotdecimal" decimals="-4">1.27</ix:nonFraction> million performance-based stock options to certain of its executive officers, which are included in the stock option tables and associated disclosures above. The awards were granted under the <em style="font: inherit;">2020</em> EIP with an exercise price of $<ix:nonFraction id="c81621096" contextRef="d_2021-03-03_2021-03-03_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ExecutiveOfficerMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">1.88</ix:nonFraction> per share, the closing sales price as reported on the Nasdaq on the date of grant. The performance-based stock options are eligible to vest subject to the satisfaction of the service-based vesting requirements and attainment of share price target goals, a market-based condition. <ix:nonFraction id="c81621097" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember" unitRef="Share" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" scale="0" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> performance-based stock options vested during the year ended <em style="font: inherit;"> December 31, 2021, </em>and there were <ix:nonFraction id="c81621098" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> performance-based stock options granted for the year ended <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company used the following assumptions to calculate the fair value of each performance-based stock option: &#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2050991" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 15%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Year</b> <b>Ended</b> <b>December</b> <b>31,</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Derived service period (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81620442" format="ixt-sec:duryear">2.3</ix:nonNumeric></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#x2013;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81620444" format="ixt-sec:duryear">2.6</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><ix:nonFraction id="c81620447" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">1.5</ix:nonFraction>%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonFraction id="c81620449" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c81620451" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="1">90</ix:nonFraction>%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81620453" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c81620455" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>%</td><td style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81620457" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:zerodash" decimals="0">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company used the following assumptions to calculate the fair value of each time-based stock option:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2050924" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td><td colspan="10" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year</b> <b>Ended</b> <b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td><td colspan="5" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b style="font-size: 10pt;">2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td><td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b style="font-size: 10pt;">2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81619609" format="ixt-sec:duryear">6.0</ix:nonNumeric></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81619611" format="ixt-sec:duryear">6.2</ix:nonNumeric></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: center;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c81619613" format="ixt-sec:duryear">6.2</ix:nonNumeric></td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><ix:nonFraction id="c81619615" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="3">0.9</ix:nonFraction>%</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><ix:nonFraction id="c81619617" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="3">1.3</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><ix:nonFraction id="c81619618" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" format="ixt:numdotdecimal" decimals="3">0.4</ix:nonFraction>%</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c81619620" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" format="ixt:numdotdecimal" decimals="3">1.5</ix:nonFraction>%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><ix:nonFraction id="c81619622" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="1">90</ix:nonFraction>%</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><ix:nonFraction id="c81619625" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="2">83</ix:nonFraction>%</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><ix:nonFraction id="c81619628" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>%</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><ix:nonFraction id="c81619631" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>%</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">33</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:EarningsPerShareTextBlock" id="c2050925" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">15.</em> Net Loss per Share of Common Stock </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#x2019;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock units and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: &#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c2050926" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ESPP, RSUs and stock options to purchase common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;"><ix:nonFraction id="c81619635" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">16,328,426</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619636" contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">14,541,005</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;"><ix:nonFraction id="c81619637" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">17,676,679</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619638" contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">176,679</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="c2050927" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">16.</em> Accrued Liabilities </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued liabilities consist of the following (in thousands): &#xa0;&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="c2050928" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation and employee benefits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619640" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">2,974</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619641" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">3,323</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619642" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,523</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619643" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">179</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Accrued product returns and sales allowances</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619644" contextRef="i_2021-12-31" unitRef="USD" name="acrx:AccruedProductReturnsAndSalesAllowancesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">775</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619645" contextRef="i_2020-12-31" unitRef="USD" name="acrx:AccruedProductReturnsAndSalesAllowancesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">656</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Deferred revenue</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619646" contextRef="i_2021-12-31" unitRef="USD" name="acrx:AccruedDeferredRevenueCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">86</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619647" contextRef="i_2020-12-31" unitRef="USD" name="acrx:AccruedDeferredRevenueCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">49</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81620494" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">1,166</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81620495" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">838</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619648" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">6,524</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619649" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedLiabilitiesCurrent" scale="3" format="ixt:numdotdecimal" decimals="-3">5,045</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="c2050929" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">17.</em> <em style="font: inherit;">401</em>(k) Plan </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company sponsors a <em style="font: inherit;">401</em>(k) plan that stipulates that eligible employees can elect to contribute to the <em style="font: inherit;">401</em>(k) plan, subject to certain limitations. Pursuant to the <em style="font: inherit;">401</em>(k) plan, the Company makes a matching contribution of up to <ix:nonFraction id="c81619655" contextRef="d_2019-01-01_2019-12-31" unitRef="Pure" name="acrx:DefinedContributionPlanEmployerDiscretionaryContributionPercentage" scale="-2" format="ixt:numdotdecimal" decimals="2">4</ix:nonFraction>% of the related compensation. Under the vesting schedule, employees have ownership in the matching employer contributions based on the number of years of vesting service completed. Company contributions were $<ix:nonFraction id="c81619656" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="acrx:ContributionsByEmployerToPostemploymentBenefitObligations" scale="6" format="ixt:numdotdecimal" decimals="-5">0.4</ix:nonFraction> million and $<ix:nonFraction id="c81619657" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="acrx:ContributionsByEmployerToPostemploymentBenefitObligations" scale="6" format="ixt:numdotdecimal" decimals="-5">0.5</ix:nonFraction> million for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2050930" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">18.</em> Income Taxes </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company recorded a provision for income taxes of $<ix:nonFraction id="c81619660" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">5.0</ix:nonFraction> thousand and $<ix:nonFraction id="c81619661" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">4.0</ix:nonFraction> thousand during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:ScheduleOfDeferredTaxAssetsTableTextBlock" id="c2050931" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br /> <b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br /> <b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accruals and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619728" contextRef="i_2021-12-31" unitRef="USD" name="acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther" scale="3" format="ixt:numdotdecimal" decimals="-3">3,989</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619729" contextRef="i_2020-12-31" unitRef="USD" name="acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther" scale="3" format="ixt:numdotdecimal" decimals="-3">4,136</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619730" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:numdotdecimal" decimals="-3">7,275</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619731" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" format="ixt:numdotdecimal" decimals="-3">7,275</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619732" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:numdotdecimal" decimals="-3">75,452</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619733" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" format="ixt:numdotdecimal" decimals="-3">65,274</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Section 59(e) R&amp;D expenditures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619734" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" format="ixt:numdotdecimal" decimals="-4">5,070</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619735" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="3" format="ixt:numdotdecimal" decimals="-3">7,473</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619736" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">19,666</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619737" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="3" format="ixt:numdotdecimal" decimals="-3">20,848</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619738" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:numdotdecimal" decimals="-3">111,452</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"><ix:nonFraction id="c81619739" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsGross" scale="3" format="ixt:numdotdecimal" decimals="-3">105,006</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619740" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">111,452</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c81619741" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">105,006</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81619742">&#x2014;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81619743">&#x2014;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">34</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reconciliations of the statutory federal income tax to the Company&#x2019;s effective tax during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> are as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2050932" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax at statutory federal rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(<ix:nonFraction id="c81619744" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">7,370</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(<ix:nonFraction id="c81619745" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">8,486</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax&#x2014;net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;"><ix:nonFraction id="c81619746" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:numdotdecimal" decimals="-3">231</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(<ix:nonFraction id="c81619747" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" format="ixt:numdotdecimal" decimals="-3" sign="-">3,587</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c81619748" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" format="ixt:numdotdecimal" decimals="-3">718</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 31pt;"><ix:nonFraction id="c81619749" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" format="ixt:numdotdecimal" decimals="-3">636</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(<ix:nonFraction id="c81619750" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:numdotdecimal" decimals="-4" sign="-">20</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;"><ix:nonFraction id="c81619751" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationOtherAdjustments" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619752" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">6,446</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619753" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="3" format="ixt:numdotdecimal" decimals="-3">11,441</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619754" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">5</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619755" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" format="ixt:numdotdecimal" decimals="-3">4</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">ASC <em style="font: inherit;">740</em> requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than <em style="font: inherit;">not.&#x201d;</em> Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $<ix:nonFraction id="c81619672" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">6.4</ix:nonFraction> million and $<ix:nonFraction id="c81619673" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">11.4</ix:nonFraction> million during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had federal net operating loss carryforwards of $<ix:nonFraction id="c81619677" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">308.5</ix:nonFraction> million, of which $<ix:nonFraction id="c81619678" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-BeforeTaxYear2018Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">114.9</ix:nonFraction> million federal net operating losses generated before <em style="font: inherit;"> January 1, 2018 </em>will begin to expire in <em style="font: inherit;">2029.</em> Federal net operating losses of $<ix:nonFraction id="c81619680" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYears2018To2020Member" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">193.6</ix:nonFraction> million generated from <em style="font: inherit;">2018</em> to <em style="font: inherit;">2021</em> will carryforward indefinitely but are subject to the <em style="font: inherit;">80%</em> taxable income limitation. As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had state net operating loss carryforwards of $<ix:nonFraction id="c81619686" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">154.7</ix:nonFraction> million, which begin to expire in <em style="font: inherit;">2028.</em>&#xa0;</p>
   <p style="margin: 0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had federal research credit carryovers of $<ix:nonFraction id="c81619690" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:numdotdecimal" decimals="-5">6.5</ix:nonFraction> million, which begin to expire in <em style="font: inherit;">2026.</em> As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had state research credit carryovers of $<ix:nonFraction id="c81619694" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" format="ixt:numdotdecimal" decimals="-6">4.0</ix:nonFraction> million, which will carryforward indefinitely.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under Section&#xa0;<em style="font: inherit;">382</em> of the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended, if a corporation undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than <em style="font: inherit;">50%</em> change (by value) in its equity ownership over a <em style="font: inherit;">three</em>-year period, the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research credits, to offset its post-change income <em style="font: inherit;"> may </em>be limited. Based on an analysis performed by the Company as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2013,</em> it was determined that <em style="font: inherit;">two</em> ownership changes have occurred since inception of the Company. The <em style="font: inherit;">first</em> ownership change occurred in <em style="font: inherit;">2006</em> at the time of the Series A financing and, as a result of the change, $<ix:nonFraction id="c81619704" contextRef="i_2021-12-31_StatementScenarioAxis-SubjectToExpirationMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="6" format="ixt:numdotdecimal" decimals="-5">1.4</ix:nonFraction> million in federal and state net operating loss carryforwards will expire unutilized. In addition, $<ix:nonFraction id="c81619705" contextRef="i_2021-12-31_StatementScenarioAxis-SubjectToExpirationMember_TaxCreditCarryforwardAxis-ResearchMember" unitRef="USD" name="us-gaap:TaxCreditCarryforwardAmount" scale="3" format="ixt:numdotdecimal" decimals="-3">26</ix:nonFraction> thousand in federal and state research and development credits will expire unutilized. The <em style="font: inherit;">second</em> ownership change occurred in <em style="font: inherit;"> July 2013 </em>at the time of the underwritten public offering; however, the Company believes the resulting annual imposed limitation on use of pre-change tax attributes is sufficiently high that the limit itself will <em style="font: inherit;">not</em> result in unutilized pre-change tax attributes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Uncertain Tax Positions </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A reconciliation of the beginning and ending balances of the unrecognized tax benefits during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> is as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="c2050933" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unrecognized benefit&#x2014;beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619756" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">2,635</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"><ix:nonFraction id="c81619757" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">2,635</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross increases&#x2014;prior period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619758" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619759" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross increases&#x2014;current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619760" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c81619761" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="3" format="ixt:zerodash" decimals="-3">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unrecognized benefit&#x2014;end of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619762" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">2,635</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c81619763" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefits" scale="3" format="ixt:numdotdecimal" decimals="-3">2,635</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The entire amount of the unrecognized tax benefits would <em style="font: inherit;">not</em> impact the Company&#x2019;s effective tax rate if recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were <ix:nonFraction id="c81619712" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> accrued interest or penalties related to unrecognized tax benefits in the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em> The Company files income tax returns in the United States, California, and other states. The tax years <span style="-sec-ix-hidden:c81619715">2005</span> through <em style="font: inherit;">2014,</em> and <em style="font: inherit;">2016</em> through <em style="font: inherit;">2021,</em> remain open in all jurisdictions. The Company is <em style="font: inherit;">not</em> currently under examination by income tax authorities in federal, state or other foreign jurisdictions. The Company does <em style="font: inherit;">not</em> anticipate any significant changes within <em style="font: inherit;">12</em> months of this reporting date of its uncertain tax positions.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2020, </em>the Coronavirus Aid, Relief and Economic Security, or CARES, Act was signed into law. The CARES Act included several tax changes as part of its economic package. These changes principally related to expanded net operating loss carryback periods, increases to interest deductibility limitations, and accelerated alternative minimum tax refunds. The Company has evaluated these items and determined that the items do <em style="font: inherit;">not</em> have a material effect on the Company's financial statements as of <em style="font: inherit;"> December 31, 2021. </em>Additionally, the CARES Act enacted the Employee Retention Credit, or ERC, to incentivize companies to retain employees, which was subsequently modified by extension of the CARES Act. Under the provisions of the CARES Act and its subsequent extension, the Company was eligible for ERCs, subject to certain criteria. Accordingly, the Company has recorded a reduction in payroll taxes related to ERCs claimed for $<ix:nonFraction id="c81619723" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities" scale="6" format="ixt:numdotdecimal" decimals="-5">1.4</ix:nonFraction> million in the year ended <em style="font: inherit;"> December 31, 2021. </em>These credits are recorded in the Consolidated Statements of Operations as an offset to the related payroll expenses in the respective operating costs and expenses line item. Such claimed ERCs <em style="font: inherit;">not</em> settled prior to year-end in the amount of <em style="font: inherit;">$1.4</em> million are expected to be settled shortly thereafter and are disclosed within prepaid expenses and other current assets on the Company&#x2019;s Consolidated Balance Sheets at <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
        F-
       <em style="font: inherit;">35</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div>
     </div>
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SubsequentEventsTextBlock" id="c2050934" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">19.</em> Subsequent Events</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> January 7, 2022, </em>the Company closed the Merger Agreement with Lowell in a transaction for consideration of approximately $<ix:nonFraction id="c81619765" contextRef="d_2022-01-07_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="USD" name="acrx:BusinessCombinationConsiderationTransferredNetOfCashAcquired" scale="6" format="ixt:numdotdecimal" decimals="-5">32.5</ix:nonFraction> million plus net cash acquired and certain other adjustments. Pursuant to the terms of the Merger Agreement, all options to purchase capital stock and all shares of Lowell capital stock issued and outstanding immediately before the effective time of the merger were cancelled in exchange for the right to receive (i) <ix:nonFraction id="c81619766" contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember" unitRef="Share" name="acrx:BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">9,009,538</ix:nonFraction> shares of AcelRx common stock, and cash in the amount of $<ix:nonFraction id="c81619767" contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember" unitRef="USD" name="acrx:BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" scale="0" format="ixt:numdotdecimal" decimals="INF">3,519,129</ix:nonFraction>, (ii) <ix:nonFraction id="c81619769" contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember" unitRef="Share" name="acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" scale="0" format="ixt:numdotdecimal" decimals="INF">1,396,526</ix:nonFraction> shares of AcelRx common stock to be held back to satisfy any potential indemnification and other obligations of Lowell and its securityholders, and (iii) up to $<ix:nonFraction id="c81619770" contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember" unitRef="USD" name="us-gaap:BusinessCombinationContingentConsiderationLiability" scale="6" format="ixt:numdotdecimal" decimals="-6">26.0</ix:nonFraction> million of contingent consideration payable in cash or stock at AcelRx's option, upon the achievement of regulatory and sales-based milestones.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The <ix:nonFraction id="c81619771" contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember" unitRef="Share" name="acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" scale="0" format="ixt:numdotdecimal" decimals="INF">1,396,526</ix:nonFraction> of held back shares of AcelRx common stock issued in connection with the closing was calculated based on a fixed value of $<ix:nonFraction id="c81619772" contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember" unitRef="USDPerShare" name="acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.57284</ix:nonFraction> per share, which is the arithmetic average of the daily volume weighted average price per share of AcelRx common stock during the <em style="font: inherit;">five</em> consecutive full trading days ending on and including the last full trading day immediately prior to the date of the closing. The shares issued pursuant to the Merger Agreement were issued in private placements pursuant to the exemption from registration under Section <em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended, or the Securities Act, including Rule <em style="font: inherit;">506</em> of Regulation D promulgated under the Securities Act, or Regulation D, without general solicitation as a transaction <em style="font: inherit;">not</em> involving any public offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Merger Agreement will be accounted for in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022</em> as an acquisition of assets that does <em style="font: inherit;">not</em> meet the definition of a business. The asset acquisition does <em style="font: inherit;">not</em> constitute a business as substantially all of the fair value of the gross assets acquired was concentrated in Lowell&#x2019;s intellectual property, including NIYAD&#x2122; and LTX-<em style="font: inherit;">608.</em> The acquired assets and liabilities will be recorded at their relative fair values and the contingent consideration will be recorded when it becomes probable of achievement or the consideration becomes payable. Accordingly, the Company has classified $<ix:nonFraction id="c81619784" contextRef="i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember_BusinessAcquisitionAxis-LowellTherapeuticsMember" unitRef="USD" name="us-gaap:AcquisitionCostsCumulative" scale="6" format="ixt:numdotdecimal" decimals="-5">1.9</ix:nonFraction> million of expenses related to the Merger Agreement as Other assets in the Consolidated Balance Sheet&#xa0;at <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGNUM" style="text-align: center; width: 100%; font-size: 10pt; font-family: Times New Roman;">
      F-
     <em style="font: inherit;">36</em>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
      &#xa0;
    </div>
   </ix:exclude>
   <ix:exclude>&#xa0;</ix:exclude>
  </ix:nonNumeric>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="c2050935" escape="true">
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="acrx:ValuationAllowancesAndReservesTableTextBlock" id="c2050936" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Additions</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">&#xa0;</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Balance at</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Charged as a</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Balance at</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Beginning of</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Reduction to</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#xa0;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">End of</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Description</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Period</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Revenue</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Deductions*</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Period</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales &amp; return allowances, discounts, chargebacks and rebates:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year ended December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619788" contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" format="ixt:numdotdecimal" decimals="-3">668</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619789" contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">1,012</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81619790" contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" format="ixt:numdotdecimal" decimals="-5">900</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619791" contextRef="i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" format="ixt:numdotdecimal" decimals="-4">780</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619792" contextRef="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" format="ixt:numdotdecimal" decimals="-3">161</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c81619793" contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" scale="3" format="ixt:numdotdecimal" decimals="-3">645</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(<ix:nonFraction id="c81619794" contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" format="ixt:numdotdecimal" decimals="-3">138</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;" class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted"><ix:nonFraction id="c81619795" contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" unitRef="USD" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" format="ixt:numdotdecimal" decimals="-3">668</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">* Deductions to sales discounts and allowances relate to discounts or allowances actually taken or paid.</em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  </ix:nonNumeric>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
      &#xa0;
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>2
<FILENAME>ex_343550.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<html><head>
	<title>ex_343550.htm</title>

	<!-- Generated by ThunderDome Portal - 3/4/2022 8:07:43 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.13</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Non-Employee Director Compensation</i></b>&nbsp;<b><i>Policy</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Compensation for our non-employee directors consists of cash, restricted stock unit awards (&#8220;RSUs&#8221;) and stock options. The Compensation Committee periodically reviews the compensation paid to non-employee directors for their service on the Board and its committees and recommends any changes considered appropriate to the full Board for its approval. Each member of our Board who is not our employee receives an annual retainer of $40,000. In addition, our non-employee directors receive the following cash compensation for Board services, as applicable:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Board Chair receives an additional annual retainer of $30,000;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Audit Committee Chair receives an additional annual retainer of $20,000;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Finance and Strategic Transactions Committee (&#8220;FAST Committee&#8221;) Chair receives an additional annual retainer of $20,000;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Compensation Committee Chair receives an additional annual retainer of $15,000;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Nominating and Corporate Governance Committee Chair receives an additional annual retainer of $10,000;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">an Audit Committee member receives an additional annual retainer of $10,000;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a FAST Committee member receives an additional annual retainer of $10,000;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a Compensation Committee member receives an additional annual retainer of $7,500; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#9679;</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a Nominating and Corporate Governance Committee member receives an additional retainer of $5,000.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">Beginning in February 2022, upon election or appointment to our Board, a new non-employee director will be granted an initial stock option to purchase 46,500 shares of our common stock, which will vest as to 1/3rd of the shares subject to the option on the one-year anniversary of the date of grant and as to the remaining shares subject to the option on an equal monthly basis over the following two-year period, and 23,250 RSUs, which will vest as to 1/3rd of the RSUs on each anniversary of the date of grant over a three-year period. Each non-employee director who is then serving as a director or who is elected to our Board on the date of an annual meeting will be granted a stock option to purchase 31,000 shares of our common stock, which will vest in full on the one-year anniversary of the date of grant, and 15,500 RSUs, which will vest in full on the one-year anniversary of the date of grant.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:25pt;">All Board and committee retainers accrue and are payable on a quarterly basis at the end of each calendar quarter of service. We continue to reimburse our non-employee directors for travel, lodging and other reasonable expenses incurred in connection with their attendance at Board or committee meetings.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.31
<SEQUENCE>3
<FILENAME>ex_343559.htm
<DESCRIPTION>EXHIBIT 10.31
<TEXT>
<html><head>
	<title>ex_343559.htm</title>

	<!-- Generated by ThunderDome Portal - 3/10/2022 6:55:00 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<div contenteditable="false" data-applyto="t" data-auto-pgnum="start" data-displaynum="1" data-fontname="Times New Roman" data-fontsize="10pt" data-numstyle="a" data-prefix="" data-startnum="1" data-suffix="" data-textalign="center">&nbsp;</div>

<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.31</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECOND AMENDMENT TO</b><br>
<b>LOAN AND SECURITY AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">THIS SECOND AMENDMENT to Loan and Security Agreement (this &#8220;<b>Amendment</b>&#8221;) is entered into as of January 10, 2022, by and between <b>OXFORD FINANCE LLC</b>, a Delaware limited liability company with an office located at 115 South Union Street, Suite 300, Alexandria, Virginia 22314 (&#8220;<b>Oxford</b>&#8221;), as collateral agent (in such capacity, &#8220;<b>Collateral Agent</b>&#8221;), the Lenders listed on <u>Schedule 1.1</u> of the Loan Agreement (as defined below) or otherwise party thereto from time to time (each a &#8220;<b>Lender</b>&#8221; and collectively, the &#8220;<b>Lenders</b>&#8221;) including Oxford in its capacity as a Lender, <b>ACELRX PHARMACEUTICALS, INC.</b>, a Delaware corporation with offices located at 25821 Industrial Blvd., Suite 400, Hayward, California 94545 (&#8220;<b>Existing</b> <b>Borrower</b>&#8221;), and <b>LOWELL THERAPEUTICS, LLC</b>, a Delaware limited liability company with offices located at 25821 Industrial Blvd., Suite 400, Hayward, California 94545 (&#8220;<b>New Borrower</b>&#8221; and together with Existing Borrower, individually and collectively, jointly and severally, &#8220;<b>Borrower</b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:center;margin:0pt;"><b>Recitals</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>A.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Collateral Agent, Lenders and Borrower have entered into that certain Loan and Security Agreement dated as of May 30, 2019, as amended by that certain First Amendment to Loan and Security Agreement dated as of May 5, 2021 (as amended or modified from time to time, collectively, the &#8220;<b>Loan Agreement</b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>B.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Lenders have extended credit to Borrower for the purposes permitted in the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>C.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Existing Borrower has acquired New Borrower, and New Borrower has become a wholly owned subsidiary of Existing Borrower, pursuant to the terms of that certain Agreement and Plan of Merger dated as of November 14, 2021 by and among Existing Borrower, Lowell Therapeutics, Inc., AcelRx Intermediate Sub, Inc., AcelRx Consolidation Sub, LLC and James Wilkie, as stockholder representative.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>D.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Existing Borrower has requested that Collateral Agent and Lenders (i) add New Borrower as a Borrower under the Loan Agreement and (ii) make certain other revisions to the Loan Agreement as more fully set forth herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>E.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Collateral Agent and Lenders have agreed to modify and amend certain provisions of the Loan Agreement, but only to the extent, in accordance with the terms, subject to the conditions and in reliance upon the representations and warranties set forth below.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:center;margin:0pt;"><b>Agreement</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:justify;margin:0pt;text-indent:36pt;"><b>Now, Therefore</b><b>,</b> in consideration of the foregoing recitals and other good and valuable consideration, the receipt and adequacy of which is hereby acknowledged, and intending to be legally bound, the parties hereto agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>1.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Definitions.</b> Capitalized terms used but not defined in this Amendment shall have the meanings given to them in the Loan Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>2.</b><b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Joinder.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 72pt;"><b>2.1&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; New Borrower</b>. New Borrower hereby is added as a &#8220;Borrower&#8221; under the Loan Agreement. All references in the Loan Agreement to &#8220;Borrower&#8221; shall hereafter mean and include the Existing Borrower and New Borrower individually and collectively, jointly and severally; and New Borrower shall hereafter have all rights, duties and obligations of &#8220;Borrower&#8221; thereunder.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>2.2&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Joinder to Loan Agreement</b>. New Borrower hereby joins the Loan Agreement and each of the Loan Documents (other than the Warrants) and agrees to comply with and be bound by all of the terms, conditions and covenants of the Loan Agreement and Loan Documents (other than the Warrants), as if it were originally named a &#8220;Borrower&#8221; therein. Without limiting the generality of the preceding sentence, New Borrower agrees that it will be jointly and severally liable, together with Existing Borrower, for the payment and performance of all obligations and liabilities of Borrower under the Loan Agreement, including, without limitation, the Obligations. Each Borrower hereby appoints the other as agent for the other for all purposes hereunder. Each Borrower hereunder shall be obligated to repay all Credit Extensions made pursuant to the Loan Agreement, regardless of which Borrower actually receives said Credit Extension, as if each Borrower hereunder directly received all Credit Extensions.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="1" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">1</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>2.3&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Subrogation and Similar Rights</b>. Each Borrower waives (a) any suretyship defenses available to it under the Code or any other applicable law, including, without limitation, the benefit of California Civil Code Section 2815 permitting revocation as to future transactions and the benefit of California Civil Code Sections 1432, 2809, 2810, 2819, 2839, 2845, 2847, 2848, 2849, 2850, and 2899 and 3433, and (b) any right to require Collateral Agent or any Lender to: (i) proceed against any Borrower or any other person; (ii) proceed against or exhaust any security; or (iii) pursue any other remedy. Collateral Agent and or any Lender may exercise or not exercise any right or remedy it has against any Borrower or any security it holds (including the right to foreclose by judicial or non-judicial sale) without affecting any Borrower&#8217;s liability. Notwithstanding any other provision of this Amendment, the Loan Agreement, the Loan Documents or any other related documents, each Borrower irrevocably waives all rights that it may have at law or in equity (including, without limitation, any law subrogating Borrower to the rights of Collateral Agent and the Lenders under this Amendment and the Loan Agreement) to seek contribution, indemnification or any other form of reimbursement from any other Borrower, or any other Person now or hereafter primarily or secondarily liable for any of the Obligations, for any payment made by Borrower with respect to the Obligations in connection with this Amendment, the Loan Agreement or otherwise and all rights that it might have to benefit from, or to participate in, any security for the Obligations as a result of any payment made by Borrower with respect to the Obligations in connection with this Amendment, the Loan Agreement or otherwise. Any agreement providing for indemnification, reimbursement or any other arrangement prohibited under this Section shall be null and void. If any payment is made to a Borrower in contravention of this Section, such Borrower shall hold such payment in trust for Collateral Agent and the Lenders and such payment shall be promptly delivered to Collateral Agent for application to the Obligations, whether matured or unmatured.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>2.4&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Grant of Security Interest</b>. New Borrower hereby grants Collateral Agent, for the ratable benefit of the Lenders, to secure the payment and performance in full of all of the Obligations, a continuing security interest in, and pledges to Collateral Agent, for the ratable benefit of the Lenders, the Collateral, wherever located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. New Borrower represents, warrants, and covenants that the security interest granted herein is and shall at all times continue to be a first priority perfected security interest in the Collateral, subject only to Permitted Liens that are permitted by the terms of the Loan Agreement to have priority to Collateral Agent&#8217;s Lien. New Borrower hereby authorizes Collateral Agent to file financing statements or take any other action required to perfect Collateral Agent&#8217;s security interests in the Collateral, without notice to Borrower, with all appropriate jurisdictions to perfect or protect Collateral Agent&#8217;s interest or rights under the Loan Documents, including a notice that any disposition of the Collateral, except to the extent permitted by the terms of the Loan Agreement, by New Borrower, or any other Person, shall be deemed to violate the rights of Collateral Agent under the Code.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>2.5&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Representations and Warranties</b>. New Borrower hereby represents and warrants to Collateral Agent and each Lender that all representations and warranties in the Loan Documents made on the part of Existing Borrower are true and correct on the date hereof with respect to Existing Borrower and New Borrower, with the same force and effect as if New Borrower were named as &#8220;Borrower&#8221; in the Loan Documents in addition to Existing Borrower.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>3.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Amendment to Loan Agreement. </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>3.1&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; General</b>. Each reference to the phrase &#8220;[n]either Borrower&#8221; in the Loan Agreement hereby is replaced with &#8220;[n]o Borrower.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>4.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Limitation of Joinder and Amendment.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>4.1&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>The joinder and amendment set forth in <b>Sections 2</b> and <b>3</b> are effective for the purposes set forth herein and shall be limited precisely as written and shall not be deemed to (a) be a consent to any amendment, waiver or modification of any other term or condition of any Loan Document, or (b) otherwise prejudice any right or remedy which Collateral Agent or any Lender may now have or may have in the future under or in connection with any Loan Document.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="2" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">2</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>4.2&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>This Amendment shall be construed in connection with and as part of the Loan Documents and all terms, conditions, representations, warranties, covenants and agreements set forth in the Loan Documents, except as herein amended, are hereby ratified and confirmed and shall remain in full force and effect.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>5.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Representations and Warranties.</b> To induce Collateral Agent and Lenders to enter into this Amendment, Borrower hereby represents and warrants to Collateral Agent and Lenders as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>5.1&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Immediately after giving effect to this Amendment (a) the representations and warranties contained in the Loan Documents are true, accurate and complete in all material respects as of the date hereof (provided, however, that such materiality qualifier shall not be applicable to any representations and warranties that are already qualified or modified by materiality in the text thereof), except to the extent such representations and warranties relate to an earlier date, in which case they are true and correct in all material respects as of such date, and (b) no Event of Default has occurred and is continuing;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>5.2&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Borrower has the power and authority to execute and deliver this Amendment and to perform its obligations under the Loan Agreement, as amended by this Amendment;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>5.3&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>The organizational documents of Borrower delivered to Collateral Agent and Lenders prior to the date hereof remain true, accurate and complete and have not been amended, supplemented or restated and are and continue to be in full force and effect;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>5.4&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, have been duly authorized;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>5.5&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not and will not contravene (a) any law or regulation binding on or affecting Borrower, (b) any contractual restriction with a Person binding on Borrower, (c) any order, judgment or decree of any court or other governmental or public body or authority, or subdivision thereof, binding on Borrower, or (d) the organizational documents of Borrower;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>5.6&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>The execution and delivery by Borrower of this Amendment and the performance by Borrower of its obligations under the Loan Agreement, as amended by this Amendment, do not require any order, consent, approval, license, authorization or validation of, or filing, recording or registration with, or exemption by any governmental or public body or authority, or subdivision thereof, binding on Borrower; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;"><b>5.7&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>This Amendment has been duly executed and delivered by Borrower and is the binding obligation of Borrower, enforceable against Borrower in accordance with its terms, except as such enforceability may be limited by bankruptcy, insolvency, reorganization, liquidation, moratorium or other similar laws of general application and equitable principles relating to or affecting creditors&#8217; rights.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>6.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Counterparts.</b> This Amendment may be executed in any number of counterparts and all of such counterparts taken together shall be deemed to constitute one and the same instrument.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>7.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Effectiveness.</b> This Amendment shall be deemed effective upon the due execution and delivery to Collateral Agent and Lenders of the following (unless otherwise waived by the Collateral Agent and Lenders):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>this Amendment duly executed by each party hereto;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>a Limited Liability Company Borrowing Certificate duly executed by New Borrower;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(c)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>a Perfection Certificate duly executed by New Borrower;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="3" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">3</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(d)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Amended and Restated Secured Promissory Notes duly executed by each Borrower;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(e)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>good standing certificates for New Borrower certified by the Secretary of State (or equivalent agency) of the State of Delaware and each jurisdiction in which New Borrower is qualified to conduct business, each as of a date no earlier than thirty (30) days prior to the date of this Amendment;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(f)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>a duly filed UCC Financing Statement with the Secretary of State of the State of Delaware, identifying New Borrower as a debtor;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(g)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>the certificates and information required by Sections 2(b)(ix), 2(b)(xii) and 2(b)(xiii) of that certain Consent under Loan and Security Agreement dated as of November 14, 2021 by and among Collateral Agent, Lenders and Existing Borrower, with such modifications as approved by the Collateral Agent and Lenders; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(h)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>Borrower&#8217;s payment of all Lenders&#8217; Expenses to the extent invoiced through the date of this Amendment.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:36pt;"><b>8.&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; Conditions Subsequent.</b> Borrower agrees to provide each of the following to Collateral Agent and Lenders and Borrower acknowledges and agrees that its failure to deliver any of the following in accordance with the deadline for such item shall be an immediate Event of Default under the Loan Agreement:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(a)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>no later than (i) thirty (30) days (or such longer period as Collateral Agent shall agree in writing in its discretion), Collateral Agent and Lenders shall have received, in form and substance reasonably satisfactory to Collateral Agent, fully-executed Control Agreements in favor of Collateral Agent for all Collateral Accounts of New Borrower (other than the Collateral Account of New Borrower at Middlesex Savings Bank disclosed on the Perfection Certificate delivered pursuant to Section 7(c) of this Amendment) required by Section 6.6 of the Loan Agreement and (ii) sixty (60) days (or such longer period as Collateral Agent shall agree in writing in its discretion), Collateral Agent and Lenders shall have received, in form and substance reasonably satisfactory to Collateral Agent, (A) evidence that such Collateral Account of New Borrower at Middlesex Savings Bank has been closed or (B) a fully-executed Control Agreement in favor of Collateral Agent for such Collateral Account of New Borrower at Middlesex Savings Bank; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 0pt;text-indent:72pt;">(b)<b>&nbsp; &nbsp;&nbsp; &nbsp; &nbsp; &nbsp; </b>no later than sixty (60) days (or such longer period as Collateral Agent shall agree in writing in its discretion), Collateral Agent and Lenders shall have received, in form and substance reasonably satisfactory to Collateral Agent, (x) a fully-executed landlord waiver for New Borrower&#8217;s leased real property at 110 Canal Street, Lowell, Massachusetts 01852 or (y) evidence in form and substance reasonably satisfactory to Collateral Agent that such lease has been terminated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>[</b><b><i>Balance of Page Intentionally Left Blank</i></b><b>]</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM" data-number="4" data-prefix="" data-suffix="" style="text-align: center; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">4</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<div contenteditable="false" data-auto-pgnum="end">&nbsp;</div>

<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; margin: 0pt; text-align: left; text-indent: 36pt;"><b><font style="font-variant:small-caps;">In Witness Whereof</font></b>, the parties hereto have caused this amendment to be duly executed and delivered as of the date first written above.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:small-caps;text-align:justify;margin:0pt;text-indent:36pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr>
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>COLLATERAL AGENT AND LENDER:</b></td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">OXFORD FINANCE LLC</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">By:</p>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">/s/ Joshua Friedman</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name:</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Joshua Friedman</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title:</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Financial Officer</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;"><b>BORROWER:</b></td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">ACELRX PHARMACEUTICALS, INC.</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">/s/ Raffi Asadorian</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name:</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Raffi Asadorian</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Title:</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Financial Officer</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="2" rowspan="1" style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">LOWELL THERAPEUTICS, LLC</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">By:</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">/s/ Raffi Asadorian</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Name:</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Raffi Asadorian</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Title:</p>
			</td>
			<td style="vertical-align: top; width: 33%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Chief Financial Officer</td>
			<td style="vertical-align: top; width: 62%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>[</b><b><i>Signature Page to Second Amendment to Loan and Security Agreement</i></b><b>]</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>4
<FILENAME>ex_341620.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title></title>


</head>
<body>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 23.1 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">We hereby consent to the incorporation by reference in the Registration Statements on Form S-3 (No. 333-239156) and Form S-8 (Nos. 333-258896, 333-239213, 333-230139, 333-223535, 333-216492, 333-202709, 333-194634, 333-187206, 333-237195, 333-209998, 333-180334 and 333&#8209;172409) of AcelRx Pharmaceuticals, Inc. of our report dated March&nbsp;10, 2022, relating to the consolidated financial statements and schedule II, which appears in this Annual Report on Form 10&#8209;K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">/s/ WithumSmith+Brown, PC</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">San Francisco, California</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">March 10, 2022</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.2
<SEQUENCE>5
<FILENAME>ex_341621.htm
<DESCRIPTION>EXHIBIT 23.2
<TEXT>
<html><head>
	<title></title>


</head>
<body style="cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 23.2 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">We hereby consent to the incorporation by reference in the following Registration Statements:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(i)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Registration Statement on Form S-8 (No. 333-258896) pertaining to the Amended and Restated 2020 Equity Incentive Plan,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(ii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Registration Statement on Form S-8 (No. 333-239213) pertaining to the 2020 Equity Incentive Plan and Amended and Restated 2011 Employee Stock Purchase Plan,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Registration Statements on Form S-8 (Nos. 333-230139, 333-223535, 333-216492, 333-202709, 333-194634 and 333-187206) pertaining to the 2011 Equity Incentive Plan,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">(iii)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">Registration Statements on Form S-8 (Nos. 333-237195, 333-209998 and 333-180334) pertaining to the 2011 Equity Incentive Plan and 2011 Employee Stock Purchase Plan,</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">(iv)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">Registration Statement on Form S-8 (No. 333-172409) pertaining to the 2006 Stock Plan, 2011 Equity Incentive Plan and 2011 Employee Stock Purchase Plan, and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">&nbsp;</td>
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">(v)</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: justify; font-family: Times New Roman; font-size: 10pt;">Registration Statement on Form S-3 (No. 333-239156)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">of our report dated March 15, 2021 with respect to the consolidated financial statements and schedule of AcelRx Pharmaceuticals, Inc. as of and for the year ended December 31, 2020, which appears in this Annual Report on Form 10-K.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ OUM &amp; CO. LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">San Francisco, California</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 10, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex_341622.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title></title>


</head>
<body style="cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 31.1 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATIONS </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Vincent J. Angotti, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1. I have reviewed this annual report on Form 10-K of AcelRx Pharmaceuticals, Inc.;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March&nbsp;10, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align: top; width: 60%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Vincent J. Angotti</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 60%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Vincent J. Angotti</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Chief Executive Officer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex_341623.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title></title>


</head>
<body>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 31.2 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATIONS </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Raffi Asadorian, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1. I have reviewed this annual report on Form 10-K of AcelRx Pharmaceuticals, Inc.;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5. The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s Board of Directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Date: March&nbsp;10, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: Times New Roman; font-size: 10pt; width: 100%;">

		<tr>
			<td style="vertical-align: top; width: 60%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">/s/ Raffi Asadorian</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 60%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 40%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Raffi Asadorian</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">Chief Financial Officer</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 12pt;text-indent:-12pt;">(Principal Financial Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex_341624.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title></title>
</head>
<body style="cursor: auto;">
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: right;"><b>Exhibit 32.1 </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and Section&nbsp;1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350), Vincent J. Angotti, Chief Executive Officer of AcelRx Pharmaceuticals, Inc. (the &#8220;Company&#8221;), and Raffi Asadorian, Chief Financial Officer of the Company, each hereby certifies that, to the best of his or her knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">1.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">The Company&#8217;s Annual Report on Form 10-K for the period ended December 31, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Annual Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act, and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 27pt;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">2.</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: Times New Roman; font-size: 10pt;">The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>In Witness Whereof</b>, the undersigned have set their hands hereto as of the 10th day of March 2022.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Vincent J. Angotti</p>
			</td>
			<td style="vertical-align: top; width: 6%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Raffi Asadorian</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Vincent J. Angotti</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer</p>
			</td>
			<td style="vertical-align: top; width: 6%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 47%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Raffi Asadorian</p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of AcelRx Pharmaceuticals, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>acrx-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:13PM UTC 2022-03-10--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:acrx="http://www.acelrx.com/20211231" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.acelrx.com/20211231">
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acrx-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acrx-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acrx-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acrx-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.acelrx.com/20211231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets" roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-comprehensive-loss" roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-stockholders-deficit" roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Stockholders' Deficit</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows" roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies" roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-investments-and-fair-value-measurement" roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Investments and Fair Value Measurement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-inventories-net" roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Inventories, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-net" roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Property and Equipment, Net</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inlicense-agreement" roleURI="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - In-license Agreement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-outlicense-agreements" roleURI="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Out-license Agreements</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-revenue-from-contracts-with-customers-" roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Revenue From Contracts With Customers</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-longterm-debt-" roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Long-term Debt</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases" roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Note 9 - Leases</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-liability-related-to-sale-of-future-royalties" roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-warrants" roleURI="http://www.acelrx.com/20211231/role/statement-note-11-warrants">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 11 - Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies" roleURI="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 12 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-stockholders-equity-" roleURI="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 13 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 14 - Stock Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-net-loss-per-share-of-common-stock" roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 15 - Net Loss Per Share of Common Stock</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-accrued-liabilities" roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 16 - Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-401k-plan" roleURI="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 17 - 401(k) Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-income-taxes" roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 18 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-subsequent-events" roleURI="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 19 - Subsequent Events</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts" roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-investments-and-fair-value-measurement-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 2 - Investments and Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-inventories-net-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 3 - Inventories, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-net-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 4 - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-revenue-from-contracts-with-customers-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 7 - Revenue From Contracts With Customers (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-longterm-debt-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 8 - Long-term Debt (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 9 - Leases (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-liability-related-to-sale-of-future-royalties-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">035 - Disclosure - Note 14 - Stock Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-net-loss-per-share-of-common-stock-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">036 - Disclosure - Note 15 - Net Loss Per Share of Common Stock (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-accrued-liabilities-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">037 - Disclosure - Note 16 - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-income-taxes-tables" roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">038 - Disclosure - Note 18 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts-tables" roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">039 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">040 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">041 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-investments-and-fair-value-measurement-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">042 - Disclosure - Note 2 - Investments and Fair Value Measurement (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">043 - Disclosure - Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">044 - Disclosure - Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">045 - Disclosure - Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-inventories-net-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">046 - Disclosure - Note 3 - Inventories, Net (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-inventories-net-inventory-components-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">047 - Disclosure - Note 3 - Inventories, Net - Inventory Components (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-net-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">048 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">049 - Disclosure - Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-inlicense-agreement-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">050 - Disclosure - Note 5 - In-license Agreement (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-outlicense-agreements-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">051 - Disclosure - Note 6 - Out-license Agreements (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-revenue-from-contracts-with-customers-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">052 - Disclosure - Note 7 - Revenue From Contracts With Customers (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">053 - Disclosure - Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">054 - Disclosure - Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-longterm-debt-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">055 - Disclosure - Note 8 - Long-term Debt (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">056 - Disclosure - Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">057 - Disclosure - Note 9 - Leases (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases-operating-lease-costs-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">058 - Disclosure - Note 9 - Leases - Operating Lease Costs (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-9-leases-maturities-of-lease-liabilities-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">059 - Disclosure - Note 9 - Leases - Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">060 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">061 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-11-warrants-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">062 - Disclosure - Note 11 - Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-12-commitments-and-contingencies-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">063 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-13-stockholders-equity-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">064 - Disclosure - Note 13 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">065 - Disclosure - Note 14 - Stock Based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">066 - Disclosure - Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-restricted-stock-activity-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">067 - Disclosure - Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-option-activity-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">068 - Disclosure - Note 14 - Stock Based Compensation - Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">069 - Disclosure - Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">070 - Disclosure - Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">071 - Disclosure - Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">072 - Disclosure - Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-16-accrued-liabilities-accrued-liabilities-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">073 - Disclosure - Note 16 - Accrued Liabilities - Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-17-401k-plan-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">074 - Disclosure - Note 17 - 401(k) Plan (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-income-taxes-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">075 - Disclosure - Note 18 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-income-taxes-net-deferred-tax-assets-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">076 - Disclosure - Note 18 - Income Taxes - Net Deferred Tax Assets (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">077 - Disclosure - Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">078 - Disclosure - Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-19-subsequent-events-details-textual" roleURI="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">079 - Disclosure - Note 19 - Subsequent Events (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">080 - Disclosure - Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="acrx_ATMAgreementMember" name="ATMAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_OUMCoLLPMember" name="OUMCoLLPMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_AccruedDeferredRevenueCurrent" name="AccruedDeferredRevenueCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" name="AccruedProductReturnsAndSalesAllowancesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_AcelRXMember" name="AcelRXMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_AcelrxCommonStockMember" name="AcelrxCommonStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_AggregateOfferingPriceIncreaseDuringPeriod" name="AggregateOfferingPriceIncreaseDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_AggregateOfferingPriceMaximum" name="AggregateOfferingPriceMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_AguettantMember" name="AguettantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_AmendedLicenseAgreementMember" name="AmendedLicenseAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" name="ArmisticeCapitalAndRockSpringsCapitalMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" name="AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_BasedUponNetSalesTargetAchievementsMember" name="BasedUponNetSalesTargetAchievementsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" name="BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_BeforeTaxYear2018Member" name="BeforeTaxYear2018Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" name="BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" name="BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired" name="BusinessCombinationConsiderationTransferredNetOfCashAcquired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" name="BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" name="BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_BusinessDescriptionOfEntityPolicyTextBlock" name="BusinessDescriptionOfEntityPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" name="CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" name="CashCashEquivalentsAndShorttermInvestmentsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_CatalentPharmaSolutionsMember" name="CatalentPharmaSolutionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" name="ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_CommercialMilestonesValueMaximumAmountAvailable" name="CommercialMilestonesValueMaximumAmountAvailable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ComputerEquipmentAndSoftwareMember" name="ComputerEquipmentAndSoftwareMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement" name="ContingentGainLossOnRoyaltyMonetizationArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ContingentPutOptionLiabilityMember" name="ContingentPutOptionLiabilityMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ContingentPutOptionPolicyPolicyTextBlock" name="ContingentPutOptionPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ContractAndOtherCollaborationMember" name="ContractAndOtherCollaborationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ContractAndOtherRevenueMember" name="ContractAndOtherRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ContractWithCustomerLiabilityAdditions" name="ContractWithCustomerLiabilityAdditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ContractWithCustomerLiabilityLiabilityEliminated" name="ContractWithCustomerLiabilityLiabilityEliminated" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" name="ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ContributionsByEmployerToPostemploymentBenefitObligations" name="ContributionsByEmployerToPostemploymentBenefitObligations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_CustomerAMember" name="CustomerAMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_CustomerBMember" name="CustomerBMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_DSUVIAMember" name="DSUVIAMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_DZUVEOMember" name="DZUVEOMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" name="DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_DebtInstrumentDefaultAdditionalInterestRate" name="DebtInstrumentDefaultAdditionalInterestRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_DebtInstrumentInterestRateBasePercentage" name="DebtInstrumentInterestRateBasePercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" name="DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_DebtInstrumentUnamortizedEotFee" name="DebtInstrumentUnamortizedEotFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" name="DeferredTaxAssetsAccruedLiabilitiesAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage" name="DefinedContributionPlanEmployerDiscretionaryContributionPercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_DoDMember" name="DoDMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_EffectiveAnnualInterestRate" name="EffectiveAnnualInterestRate" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" name="EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_EmployeeStockPurchasePlanESPPMember" name="EmployeeStockPurchasePlanESPPMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" name="EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_EquityIncentivePlan2011Member" name="EquityIncentivePlan2011Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_EstimatedOfferingCosts" name="EstimatedOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_ExercisePriceRange1Member" name="ExercisePriceRange1Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ExercisePriceRange2Member" name="ExercisePriceRange2Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ExercisePriceRange3Member" name="ExercisePriceRange3Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ExercisePriceRange4Member" name="ExercisePriceRange4Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ExercisePriceRange5Member" name="ExercisePriceRange5Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ExercisePriceRange6Member" name="ExercisePriceRange6Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_FairValueOfContingentPutOptionLiability" name="FairValueOfContingentPutOptionLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_FirstFourCommercialMilestonesMember" name="FirstFourCommercialMilestonesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_GainLossOnTerminationOfSublease" name="GainLossOnTerminationOfSublease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_GainOnTerminationOfSublease" name="GainOnTerminationOfSublease" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_GrunenthalMember" name="GrunenthalMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_InlicenseAgreementTextBlock" name="InlicenseAgreementTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" name="InvestmentsAndFairValueMeasurementDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" name="LeaseForCorporateHeadquartersInHaywardCaliforniaMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LeaseholdPaidWithNotePayable" name="LeaseholdPaidWithNotePayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LesseeOperatingLeaseAbatedRentPeriod" name="LesseeOperatingLeaseAbatedRentPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments" name="LesseeOperatingLeaseAnnualOverheadFeePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LesseeOperatingLeaseMonthlyRent" name="LesseeOperatingLeaseMonthlyRent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LesseeOperatingLeaseNoticePeriod" name="LesseeOperatingLeaseNoticePeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LesseeOperatingSubleaseDeferredCosts" name="LesseeOperatingSubleaseDeferredCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LiabilityRelatedToSaleOfFutureRoyalties" name="LiabilityRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" name="LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet" name="LiabilityRelatedToSaleOfFutureRoyaltiesNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" name="LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" name="LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum" name="LicenseAgreementMilestonePaymentsToBePaidMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LicenseAgreementMinimumSalesObligationTerm" name="LicenseAgreementMinimumSalesObligationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid" name="LicenseAgreementPercentOfRevenueSharePaymentToBePaid" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" name="LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LicenseAgreementRenewalTerm" name="LicenseAgreementRenewalTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LicenseAgreementTerm" name="LicenseAgreementTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" name="LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_LoanAgreementWithOxfordFinanceLLCMember" name="LoanAgreementWithOxfordFinanceLLCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" name="LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" name="LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LongTermDebtMaturitiesRepaymentsOfInterest" name="LongTermDebtMaturitiesRepaymentsOfInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LongTermDebtTotalMinimumPayments" name="LongTermDebtTotalMinimumPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" name="LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_LowellTherapeuticsMember" name="LowellTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_LowellsIntellectualPropertyMember" name="LowellsIntellectualPropertyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_MarketableSecuritiesMember" name="MarketableSecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" name="NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_NetProceedsFromSaleOfFutureRoyalties" name="NetProceedsFromSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_NonCashRoyaltyMember" name="NonCashRoyaltyMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" name="NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_NoncashInterestExpenseRecognized" name="NoncashInterestExpenseRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" name="NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" name="NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_NotesPayableGross" name="NotesPayableGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_November2021FinancingWarrantsMember" name="November2021FinancingWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_OutlicenseAgreementTextBlock" name="OutlicenseAgreementTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_PFSProductsMember" name="PFSProductsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement" name="PercentageOfRoyaltiesAndRightsUnderAgreement" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" name="PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" name="ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" name="ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" name="ProceedsFromSaleOfRoyaltyAndMilestoneRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" name="PurchasesOfPropertyAndEquipmentInAccountsPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" name="PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" name="PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_RSUsESPPAndEmployeeStockOptionsMember" name="RSUsESPPAndEmployeeStockOptionsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_RegisteredDirectOfferingMember" name="RegisteredDirectOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" name="RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="acrx_RoyaltyArrangmentMaximumPayments" name="RoyaltyArrangmentMaximumPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" name="SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_SWKMember" name="SWKMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" name="ScheduleOfDeferredTaxAssetsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" name="ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" name="SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant"/>
  <xsd:element id="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_SiteReadinessAgreementMember" name="SiteReadinessAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" name="StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_SubjectToExpirationMember" name="SubjectToExpirationMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_TaxYears2018To2020Member" name="TaxYears2018To2020Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_The2020EquityIncentivePlanMember" name="The2020EquityIncentivePlanMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_TimebasedStockOptionMember" name="TimebasedStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ToolingMember" name="ToolingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_TotalObligationUnderLeaseholdAgreement" name="TotalObligationUnderLeaseholdAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="acrx_USGovernmentAgencySecuritiesMember" name="USGovernmentAgencySecuritiesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_ValuationAllowancesAndReservesTableTextBlock" name="ValuationAllowancesAndReservesTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" name="WarrantInConnectionWithOxfordFinanceLoanAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_WarrantsDisclosureTextBlock" name="WarrantsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_WarrantsPolicyPolicyTextBlock" name="WarrantsPolicyPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_WholesalerAMember" name="WholesalerAMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="acrx_WriteoffOfRightofuseAssetAndLeaseLiability" name="WriteoffOfRightofuseAssetAndLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_ZALVISOMember" name="ZALVISOMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" name="statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" name="statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables" name="statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" name="statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" name="statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-14-stock-based-compensation-option-activity-details" name="statement-statement-note-14-stock-based-compensation-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details" name="statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" name="statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" name="statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-14-stock-based-compensation-tables" name="statement-statement-note-14-stock-based-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" name="statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables" name="statement-statement-note-15-net-loss-per-share-of-common-stock-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details" name="statement-statement-note-16-accrued-liabilities-accrued-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-16-accrued-liabilities-tables" name="statement-statement-note-16-accrued-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details" name="statement-statement-note-18-income-taxes-net-deferred-tax-assets-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" name="statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" name="statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-18-income-taxes-tables" name="statement-statement-note-18-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" name="statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" name="statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" name="statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables" name="statement-statement-note-2-investments-and-fair-value-measurement-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-3-inventories-net-inventory-components-details" name="statement-statement-note-3-inventories-net-inventory-components-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-3-inventories-net-tables" name="statement-statement-note-3-inventories-net-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" name="statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-4-property-and-equipment-net-tables" name="statement-statement-note-4-property-and-equipment-net-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" name="statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" name="statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables" name="statement-statement-note-7-revenue-from-contracts-with-customers-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" name="statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-8-longterm-debt-tables" name="statement-statement-note-8-longterm-debt-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details" name="statement-statement-note-9-leases-maturities-of-lease-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-9-leases-operating-lease-costs-details" name="statement-statement-note-9-leases-operating-lease-costs-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-note-9-leases-tables" name="statement-statement-note-9-leases-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" name="statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" name="statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="acrx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>acrx-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:13PM UTC 2022-03-10--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:label="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtTotalMinimumPayments" xlink:label="acrx_LongTermDebtTotalMinimumPayments" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:label="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acrx_LongTermDebtTotalMinimumPayments" xlink:to="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acrx_LongTermDebtTotalMinimumPayments" xlink:to="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" xlink:href="acrx-20211231.xsd#statement-note-9-leases-operating-lease-costs-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GainLossOnTerminationOfSublease" xlink:label="acrx_GainLossOnTerminationOfSublease" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="acrx_GainLossOnTerminationOfSublease" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_GainLossOnTerminationOfLease" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:href="acrx-20211231.xsd#statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="acrx-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="acrx-20211231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="acrx-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:label="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestExpenseRecognized" xlink:label="acrx_NoncashInterestExpenseRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acrx_NoncashInterestExpenseRecognized" xlink:type="arc"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:type="arc"/>
    <link:calculationArc order="11" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="12" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net-inventory-components-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:href="acrx-20211231.xsd#statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AccruedDeferredRevenueCurrent" xlink:label="acrx_AccruedDeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:label="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="acrx_AccruedDeferredRevenueCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:label="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>acrx-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:13PM UTC 2022-03-10--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:href="acrx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities" xlink:href="acrx-20211231.xsd#statement-note-16-accrued-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock" xlink:href="acrx-20211231.xsd#statement-note-15-net-loss-per-share-of-common-stock" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-document-and-entity-information" xlink:href="acrx-20211231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
	<link:loc xlink:href="acrx-20211231.xsd#acrx_OUMCoLLPMember" xlink:label="acrx_OUMCoLLPMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
	<link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="acrx_OUMCoLLPMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
	<link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
	<link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
	<link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
	<link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="acrx-20211231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:href="acrx-20211231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:label="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DSUVIAMember" xlink:label="acrx_DSUVIAMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_AmendedLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_DSUVIAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement" xlink:href="acrx-20211231.xsd#statement-note-5-inlicense-agreement" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_InlicenseAgreementTextBlock" xlink:label="acrx_InlicenseAgreementTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PFSProductsMember" xlink:label="acrx_PFSProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_PFSProductsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_InlicenseAgreementTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements" xlink:href="acrx-20211231.xsd#statement-note-6-outlicense-agreements" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponNetSalesTargetAchievementsMember" xlink:label="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:label="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_OutlicenseAgreementTextBlock" xlink:label="acrx_OutlicenseAgreementTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_DZUVEOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_AmendedLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_OutlicenseAgreementTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ZALVISOMember" xlink:label="acrx_ZALVISOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_DZUVEOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_ZALVISOMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:label="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SiteReadinessAgreementMember" xlink:label="acrx_SiteReadinessAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acrx_SiteReadinessAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases" xlink:href="acrx-20211231.xsd#statement-note-9-leases" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CatalentPharmaSolutionsMember" xlink:label="acrx_CatalentPharmaSolutionsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:label="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_CatalentPharmaSolutionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties" xlink:href="acrx-20211231.xsd#statement-note-10-liability-related-to-sale-of-future-royalties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelRXMember" xlink:label="acrx_AcelRXMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_FirstFourCommercialMilestonesMember" xlink:label="acrx_FirstFourCommercialMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SWKMember" xlink:label="acrx_SWKMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="acrx_SWKMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acrx_FirstFourCommercialMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="acrx_AcelRXMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-11-warrants" xlink:href="acrx-20211231.xsd#statement-note-11-warrants" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-11-warrants" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantsDisclosureTextBlock" xlink:label="acrx_WarrantsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acrx_November2021FinancingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acrx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_WarrantsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies" xlink:href="acrx-20211231.xsd#statement-note-12-commitments-and-contingencies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:label="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:label="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-" xlink:href="acrx-20211231.xsd#statement-note-13-stockholders-equity-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ATMAgreementMember" xlink:label="acrx_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:label="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EmployeeStockPurchasePlanESPPMember" xlink:label="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EquityIncentivePlan2011Member" xlink:label="acrx_EquityIncentivePlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acrx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acrx_November2021FinancingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acrx_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acrx_EquityIncentivePlan2011Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acrx_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acrx_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan" xlink:href="acrx-20211231.xsd#statement-note-17-401k-plan" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BeforeTaxYear2018Member" xlink:label="acrx_BeforeTaxYear2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SubjectToExpirationMember" xlink:label="acrx_SubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TaxYears2018To2020Member" xlink:label="acrx_TaxYears2018To2020Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acrx_BeforeTaxYear2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acrx_TaxYears2018To2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="acrx_SubjectToExpirationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events" xlink:href="acrx-20211231.xsd#statement-note-19-subsequent-events" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelrxCommonStockMember" xlink:label="acrx_AcelrxCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LowellTherapeuticsMember" xlink:label="acrx_LowellTherapeuticsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acrx_LowellTherapeuticsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acrx_AcelrxCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" xlink:href="acrx-20211231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:label="acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:label="acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantsPolicyPolicyTextBlock" xlink:label="acrx_WarrantsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acrx_WarrantsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InterestExpensePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:href="acrx-20211231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-tables" xlink:href="acrx-20211231.xsd#statement-note-9-leases-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:href="acrx-20211231.xsd#statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:label="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TimebasedStockOptionMember" xlink:label="acrx_TimebasedStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acrx_TimebasedStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:href="acrx-20211231.xsd#statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables" xlink:href="acrx-20211231.xsd#statement-note-16-accrued-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:label="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:href="acrx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:label="acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:href="acrx-20211231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:label="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RoyaltyArrangmentMaximumPayments" xlink:label="acrx_RoyaltyArrangmentMaximumPayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringCharges" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_RoyaltyArrangmentMaximumPayments" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DSUVIAMember" xlink:label="acrx_DSUVIAMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_AmendedLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_DSUVIAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual" xlink:href="acrx-20211231.xsd#statement-note-5-inlicense-agreement-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum" xlink:label="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMinimumSalesObligationTerm" xlink:label="acrx_LicenseAgreementMinimumSalesObligationTerm" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid" xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementRenewalTerm" xlink:label="acrx_LicenseAgreementRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementTerm" xlink:label="acrx_LicenseAgreementTerm" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PFSProductsMember" xlink:label="acrx_PFSProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_PFSProductsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementMinimumSalesObligationTerm" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" xlink:href="acrx-20211231.xsd#statement-note-6-outlicense-agreements-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponNetSalesTargetAchievementsMember" xlink:label="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:label="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementRenewalTerm" xlink:label="acrx_LicenseAgreementRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:label="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" xlink:label="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_DZUVEOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_AmendedLicenseAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityLiabilityEliminated" xlink:label="acrx_ContractWithCustomerLiabilityLiabilityEliminated" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementRenewalTerm" xlink:label="acrx_LicenseAgreementRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementTerm" xlink:label="acrx_LicenseAgreementTerm" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:label="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ZALVISOMember" xlink:label="acrx_ZALVISOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_DZUVEOMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_ZALVISOMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContractWithCustomerLiabilityLiabilityEliminated" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" xlink:label="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentDefaultAdditionalInterestRate" xlink:label="acrx_DebtInstrumentDefaultAdditionalInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentInterestRateBasePercentage" xlink:label="acrx_DebtInstrumentInterestRateBasePercentage" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" xlink:label="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_FairValueOfContingentPutOptionLiability" xlink:label="acrx_FairValueOfContingentPutOptionLiability" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:label="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" xlink:label="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" xlink:label="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" xlink:label="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SiteReadinessAgreementMember" xlink:label="acrx_SiteReadinessAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TotalObligationUnderLeaseholdAgreement" xlink:label="acrx_TotalObligationUnderLeaseholdAgreement" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acrx_SiteReadinessAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentInterestRateBasePercentage" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentDefaultAdditionalInterestRate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_FairValueOfContingentPutOptionLiability" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_TotalObligationUnderLeaseholdAgreement" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" xlink:href="acrx-20211231.xsd#statement-note-9-leases-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CatalentPharmaSolutionsMember" xlink:label="acrx_CatalentPharmaSolutionsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:label="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseAbatedRentPeriod" xlink:label="acrx_LesseeOperatingLeaseAbatedRentPeriod" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseAnnualOverheadFeePayments" xlink:label="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseMonthlyRent" xlink:label="acrx_LesseeOperatingLeaseMonthlyRent" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseNoticePeriod" xlink:label="acrx_LesseeOperatingLeaseNoticePeriod" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingSubleaseDeferredCosts" xlink:label="acrx_LesseeOperatingSubleaseDeferredCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_CatalentPharmaSolutionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingSubleaseDeferredCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingLeaseMonthlyRent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingLeaseAbatedRentPeriod" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingLeaseNoticePeriod" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" xlink:href="acrx-20211231.xsd#statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelRXMember" xlink:label="acrx_AcelRXMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CommercialMilestonesValueMaximumAmountAvailable" xlink:label="acrx_CommercialMilestonesValueMaximumAmountAvailable" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentGainLossOnRoyaltyMonetizationArrangement" xlink:label="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EffectiveAnnualInterestRate" xlink:label="acrx_EffectiveAnnualInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_FirstFourCommercialMilestonesMember" xlink:label="acrx_FirstFourCommercialMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PercentageOfRoyaltiesAndRightsUnderAgreement" xlink:label="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:label="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RoyaltyArrangmentMaximumPayments" xlink:label="acrx_RoyaltyArrangmentMaximumPayments" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SWKMember" xlink:label="acrx_SWKMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="acrx_SWKMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acrx_FirstFourCommercialMilestonesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="acrx_AcelRXMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_CommercialMilestonesValueMaximumAmountAvailable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_RoyaltyArrangmentMaximumPayments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_EffectiveAnnualInterestRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" xlink:href="acrx-20211231.xsd#statement-note-11-warrants-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" xlink:label="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acrx_November2021FinancingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acrx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:href="acrx-20211231.xsd#statement-note-12-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:label="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:label="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="us-gaap_LossContingencyNumberOfDefendants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNumberOfDefendants" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" xlink:href="acrx-20211231.xsd#statement-note-13-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ATMAgreementMember" xlink:label="acrx_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AggregateOfferingPriceIncreaseDuringPeriod" xlink:label="acrx_AggregateOfferingPriceIncreaseDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AggregateOfferingPriceMaximum" xlink:label="acrx_AggregateOfferingPriceMaximum" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:label="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EmployeeStockPurchasePlanESPPMember" xlink:label="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" xlink:label="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EquityIncentivePlan2011Member" xlink:label="acrx_EquityIncentivePlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EstimatedOfferingCosts" xlink:label="acrx_EstimatedOfferingCosts" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" xlink:label="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acrx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="acrx_November2021FinancingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acrx_ATMAgreementMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acrx_EquityIncentivePlan2011Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acrx_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_EstimatedOfferingCosts" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_AggregateOfferingPriceMaximum" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_AggregateOfferingPriceIncreaseDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acrx_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual" xlink:href="acrx-20211231.xsd#statement-note-17-401k-plan-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContributionsByEmployerToPostemploymentBenefitObligations" xlink:label="acrx_ContributionsByEmployerToPostemploymentBenefitObligations" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage" xlink:label="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContributionsByEmployerToPostemploymentBenefitObligations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BeforeTaxYear2018Member" xlink:label="acrx_BeforeTaxYear2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SubjectToExpirationMember" xlink:label="acrx_SubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TaxYears2018To2020Member" xlink:label="acrx_TaxYears2018To2020Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acrx_BeforeTaxYear2018Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="acrx_TaxYears2018To2020Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="acrx_SubjectToExpirationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" xlink:href="acrx-20211231.xsd#statement-note-19-subsequent-events-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelrxCommonStockMember" xlink:label="acrx_AcelrxCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired" xlink:label="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LowellTherapeuticsMember" xlink:label="acrx_LowellTherapeuticsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionCostsCumulative" xlink:label="us-gaap_AcquisitionCostsCumulative" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acrx_LowellTherapeuticsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acrx_AcelrxCommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AcquisitionCostsCumulative" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityAdditions" xlink:label="acrx_ContractWithCustomerLiabilityAdditions" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" xlink:label="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContractWithCustomerLiabilityAdditions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentUnamortizedEotFee" xlink:label="acrx_DebtInstrumentUnamortizedEotFee" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:label="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtMaturitiesRepaymentsOfInterest" xlink:label="acrx_LongTermDebtMaturitiesRepaymentsOfInterest" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtTotalMinimumPayments" xlink:label="acrx_LongTermDebtTotalMinimumPayments" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:label="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesPayableGross" xlink:label="acrx_NotesPayableGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LongTermDebtTotalMinimumPayments" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LongTermDebtMaturitiesRepaymentsOfInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NotesPayableGross" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentUnamortizedEotFee" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" xlink:href="acrx-20211231.xsd#statement-note-9-leases-operating-lease-costs-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GainLossOnTerminationOfSublease" xlink:label="acrx_GainLossOnTerminationOfSublease" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubleaseIncome" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_GainLossOnTerminationOfSublease" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:href="acrx-20211231.xsd#statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:href="acrx-20211231.xsd#statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" xlink:label="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_CostOfSalesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="acrx-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="acrx-20211231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractAndOtherCollaborationMember" xlink:label="acrx_ContractAndOtherCollaborationMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_ContractAndOtherCollaborationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="acrx-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:label="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GainOnTerminationOfSublease" xlink:label="acrx_GainOnTerminationOfSublease" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LeaseholdPaidWithNotePayable" xlink:label="acrx_LeaseholdPaidWithNotePayable" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LowellsIntellectualPropertyMember" xlink:label="acrx_LowellsIntellectualPropertyMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:label="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestExpenseRecognized" xlink:label="acrx_NoncashInterestExpenseRecognized" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:label="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:label="acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="acrx_LowellsIntellectualPropertyMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acrx_NoncashInterestExpenseRecognized" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_GainOnTerminationOfSublease" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_LeaseholdPaidWithNotePayable" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange1Member" xlink:label="acrx_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange2Member" xlink:label="acrx_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange3Member" xlink:label="acrx_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange4Member" xlink:label="acrx_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange5Member" xlink:label="acrx_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange6Member" xlink:label="acrx_ExercisePriceRange6Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:label="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acrx_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acrx_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acrx_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acrx_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acrx_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="acrx_ExercisePriceRange6Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" xlink:href="acrx-20211231.xsd#statement-consolidated-statements-of-stockholders-deficit" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:label="us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:href="acrx-20211231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CustomerAMember" xlink:label="acrx_CustomerAMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CustomerBMember" xlink:label="acrx_CustomerBMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DoDMember" xlink:label="acrx_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GrunenthalMember" xlink:label="acrx_GrunenthalMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WholesalerAMember" xlink:label="acrx_WholesalerAMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="acrx_CustomerAMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="acrx_GrunenthalMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="acrx_CustomerBMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="acrx_DoDMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="acrx_WholesalerAMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net-inventory-components-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ComputerEquipmentAndSoftwareMember" xlink:label="acrx_ComputerEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LaboratoryEquipmentMember" xlink:label="acrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ToolingMember" xlink:label="acrx_ToolingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acrx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acrx_ComputerEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acrx_ToolingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TimebasedStockOptionMember" xlink:label="acrx_TimebasedStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acrx_TimebasedStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:href="acrx-20211231.xsd#statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:label="acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:href="acrx-20211231.xsd#statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AccruedDeferredRevenueCurrent" xlink:label="acrx_AccruedDeferredRevenueCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:label="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_AccruedDeferredRevenueCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:label="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:label="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_MarketableSecuritiesMember" xlink:label="acrx_MarketableSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:label="us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CashMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="acrx_MarketableSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommercialPaperAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentPutOptionLiabilityMember" xlink:label="acrx_ContingentPutOptionLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_USGovernmentAgencySecuritiesMember" xlink:label="acrx_USGovernmentAgencySecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="acrx_USGovernmentAgencySecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="acrx_ContingentPutOptionLiabilityMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractAndOtherCollaborationMember" xlink:label="acrx_ContractAndOtherCollaborationMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractAndOtherRevenueMember" xlink:label="acrx_ContractAndOtherRevenueMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DSUVIAMember" xlink:label="acrx_DSUVIAMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NonCashRoyaltyMember" xlink:label="acrx_NonCashRoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ZALVISOMember" xlink:label="acrx_ZALVISOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_DSUVIAMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_ZALVISOMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_NonCashRoyaltyMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_ContractAndOtherRevenueMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="acrx_ContractAndOtherCollaborationMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:href="acrx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:label="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>acrx-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:13PM UTC 2022-03-10--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DocumentAndEntityInformation" xlink:label="acrx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="acrx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DocumentAndEntityInformation" xlink:to="acrx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected dividend rate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="acrx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="acrx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-significant-accounting-policies-policies" xlink:label="acrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-significant-accounting-policies-policies" xlink:to="acrx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:label="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:to="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax at statutory federal rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables" xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Investments and Fair Value Measurement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables" xlink:to="acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:label="acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_RSUsESPPAndEmployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RSU's, ESPP, and Employee Stock Options [Member]</link:label>
    <link:label xlink:label="acrx_RSUsESPPAndEmployeeStockOptionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the antidilutive securities types; restricted stock units, employee stock purchase plan, and employee stock options.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:to="acrx_RSUsESPPAndEmployeeStockOptionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-3-inventories-net-tables" xlink:label="acrx_statement-statement-note-3-inventories-net-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-3-inventories-net-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Inventories, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-3-inventories-net-tables" xlink:to="acrx_statement-statement-note-3-inventories-net-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, maximum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-4-property-and-equipment-net-tables" xlink:label="acrx_statement-statement-note-4-property-and-equipment-net-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-4-property-and-equipment-net-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Property and Equipment, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-4-property-and-equipment-net-tables" xlink:to="acrx_statement-statement-note-4-property-and-equipment-net-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables" xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Revenue From Contracts With Customers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables" xlink:to="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-8-longterm-debt-tables" xlink:label="acrx_statement-statement-note-8-longterm-debt-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-8-longterm-debt-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Long-term Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-8-longterm-debt-tables" xlink:to="acrx_statement-statement-note-8-longterm-debt-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange3Member" xlink:label="acrx_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_ExercisePriceRange3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 3 [Member]</link:label>
    <link:label xlink:label="acrx_ExercisePriceRange3Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the third exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ExercisePriceRange3Member" xlink:to="acrx_ExercisePriceRange3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-9-leases-tables" xlink:label="acrx_statement-statement-note-9-leases-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-9-leases-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Leases</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-9-leases-tables" xlink:to="acrx_statement-statement-note-9-leases-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange4Member" xlink:label="acrx_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_ExercisePriceRange4Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 4 [Member]</link:label>
    <link:label xlink:label="acrx_ExercisePriceRange4Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the fourth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ExercisePriceRange4Member" xlink:to="acrx_ExercisePriceRange4Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:label="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Liability Related to Sale of Future Royalties</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:to="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange1Member" xlink:label="acrx_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_ExercisePriceRange1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 1 [Member]</link:label>
    <link:label xlink:label="acrx_ExercisePriceRange1Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the first exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ExercisePriceRange1Member" xlink:to="acrx_ExercisePriceRange1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseMonthlyRent" xlink:label="acrx_LesseeOperatingLeaseMonthlyRent" xlink:type="locator"/>
    <link:label xlink:label="acrx_LesseeOperatingLeaseMonthlyRent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LesseeOperatingLeaseMonthlyRent</link:label>
    <link:label xlink:label="acrx_LesseeOperatingLeaseMonthlyRent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Monthly Rent</link:label>
    <link:label xlink:label="acrx_LesseeOperatingLeaseMonthlyRent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of the monthly rent required for operating lease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LesseeOperatingLeaseMonthlyRent" xlink:to="acrx_LesseeOperatingLeaseMonthlyRent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-tables" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-14-stock-based-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-tables" xlink:to="acrx_statement-statement-note-14-stock-based-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange2Member" xlink:label="acrx_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_ExercisePriceRange2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 2 [Member]</link:label>
    <link:label xlink:label="acrx_ExercisePriceRange2Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the second exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ExercisePriceRange2Member" xlink:to="acrx_ExercisePriceRange2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate, minimum</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:label="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Net Loss Per Share of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:to="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax</link:label>
    <link:label xlink:label="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment, after Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-16-accrued-liabilities-tables" xlink:label="acrx_statement-statement-note-16-accrued-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-16-accrued-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Accrued Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-16-accrued-liabilities-tables" xlink:to="acrx_statement-statement-note-16-accrued-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-18-income-taxes-tables" xlink:label="acrx_statement-statement-note-18-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-18-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 18 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-18-income-taxes-tables" xlink:to="acrx_statement-statement-note-18-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:label="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)</link:label>
    <link:label xlink:label="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average exercise price of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:to="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:label="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:to="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:label="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:to="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:to="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseNoticePeriod" xlink:label="acrx_LesseeOperatingLeaseNoticePeriod" xlink:type="locator"/>
    <link:label xlink:label="acrx_LesseeOperatingLeaseNoticePeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LesseeOperatingLeaseNoticePeriod</link:label>
    <link:label xlink:label="acrx_LesseeOperatingLeaseNoticePeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Notice Period (Year)</link:label>
    <link:label xlink:label="acrx_LesseeOperatingLeaseNoticePeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Term of lessee's operating lease termination notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LesseeOperatingLeaseNoticePeriod" xlink:to="acrx_LesseeOperatingLeaseNoticePeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:to="acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:to="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derived service period (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-3-inventories-net-inventory-components-details" xlink:label="acrx_statement-statement-note-3-inventories-net-inventory-components-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-3-inventories-net-inventory-components-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Inventories, Net - Inventory Components (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-3-inventories-net-inventory-components-details" xlink:to="acrx_statement-statement-note-3-inventories-net-inventory-components-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:label="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:type="locator"/>
    <link:label xlink:label="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label xlink:label="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of minimum payments for both principal and interest on long-term debt to be paid in the third fiscal year following the latest fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:to="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:label="acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:to="acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:to="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseAnnualOverheadFeePayments" xlink:label="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments" xlink:type="locator"/>
    <link:label xlink:label="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LesseeOperatingLeaseAnnualOverheadFeePayments</link:label>
    <link:label xlink:label="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Annual Overhead Fee Payments</link:label>
    <link:label xlink:label="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of required fee payments per year for overhead, prorated based on aggregate revenues.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments" xlink:to="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:to="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:label="acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:to="acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:label="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:to="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-9-leases-operating-lease-costs-details" xlink:label="acrx_statement-statement-note-9-leases-operating-lease-costs-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-9-leases-operating-lease-costs-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Leases - Operating Lease Costs (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-9-leases-operating-lease-costs-details" xlink:to="acrx_statement-statement-note-9-leases-operating-lease-costs-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:label="acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 9 - Leases - Maturities of Lease Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:to="acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SubjectToExpirationMember" xlink:label="acrx_SubjectToExpirationMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_SubjectToExpirationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subject to Expiration [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_SubjectToExpirationMember" xlink:to="acrx_SubjectToExpirationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:label="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:to="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:to="acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</link:label>
    <link:label xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:to="acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-option-activity-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-14-stock-based-compensation-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-option-activity-details" xlink:to="acrx_statement-statement-note-14-stock-based-compensation-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:to="acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:label="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:type="locator"/>
    <link:label xlink:label="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accruals and other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:to="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:to="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:to="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, vested (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionCostsCumulative" xlink:label="us-gaap_AcquisitionCostsCumulative" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AcquisitionCostsCumulative-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AcquisitionCostsCumulative</link:label>
    <link:label xlink:label="us-gaap_AcquisitionCostsCumulative-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition Costs, Cumulative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AcquisitionCostsCumulative" xlink:to="us-gaap_AcquisitionCostsCumulative-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:label="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:to="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value, forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnTerminationOfLease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnTerminationOfLease</link:label>
    <link:label xlink:label="us-gaap_GainLossOnTerminationOfLease-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Termination of Lease</link:label>
    <link:label xlink:label="us-gaap_GainLossOnTerminationOfLease-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Gain on derecognition of operating lease</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnTerminationOfLease" xlink:to="us-gaap_GainLossOnTerminationOfLease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:label="acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 16 - Accrued Liabilities - Accrued Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:to="acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units weighted average outstanding (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units weighted average outstanding (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:label="acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 18 - Income Taxes - Net Deferred Tax Assets (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:to="acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:label="acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:to="acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:label="acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:to="acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:label="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:type="locator"/>
    <link:label xlink:label="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:to="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatements" xlink:label="acrx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="acrx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NotesToFinancialStatements" xlink:to="acrx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="acrx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="acrx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CorporateDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Subject to Stock Options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:label="acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_BusinessDescriptionOfEntityPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description of Entity [Policy Text Block]</link:label>
    <link:label xlink:label="acrx_BusinessDescriptionOfEntityPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of the accounting policy regarding the business description of entity.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:to="acrx_BusinessDescriptionOfEntityPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebtCurrent</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less current portion</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtCurrent" xlink:to="us-gaap_LongTermDebtCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and exercisable options, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and exercisable options, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage" xlink:label="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage" xlink:type="locator"/>
    <link:label xlink:label="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage</link:label>
    <link:label xlink:label="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage" xlink:to="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContributionsByEmployerToPostemploymentBenefitObligations" xlink:label="acrx_ContributionsByEmployerToPostemploymentBenefitObligations" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContributionsByEmployerToPostemploymentBenefitObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_ContributionsByEmployerToPostemploymentBenefitObligations</link:label>
    <link:label xlink:label="acrx_ContributionsByEmployerToPostemploymentBenefitObligations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contributions by Employer to Postemployment Benefit Obligations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContributionsByEmployerToPostemploymentBenefitObligations" xlink:to="acrx_ContributionsByEmployerToPostemploymentBenefitObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average Remaining Contractual LIfe (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireShortTermInvestments</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireShortTermInvestments" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiabilityCurrent</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:type="locator"/>
    <link:label xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and exercisable options (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:label xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and exercisable options, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LowellTherapeuticsMember" xlink:label="acrx_LowellTherapeuticsMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_LowellTherapeuticsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lowell Therapeutics [Member]</link:label>
    <link:label xlink:label="acrx_LowellTherapeuticsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Lowell Therapeutics.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LowellTherapeuticsMember" xlink:to="acrx_LowellTherapeuticsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:label="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options Outstanding and Exercisable Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:to="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercised, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued and other liabilities</link:label>
    <link:label xlink:label="us-gaap_AccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Stock Options Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired" xlink:label="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired" xlink:type="locator"/>
    <link:label xlink:label="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired</link:label>
    <link:label xlink:label="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Net of Cash Acquired</link:label>
    <link:label xlink:label="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, net of the cash acquired from the purchase.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired" xlink:to="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ComputerEquipmentAndSoftwareMember" xlink:label="acrx_ComputerEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_ComputerEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment and Software [Member]</link:label>
    <link:label xlink:label="acrx_ComputerEquipmentAndSoftwareMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about Computer Equipment and Software.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ComputerEquipmentAndSoftwareMember" xlink:to="acrx_ComputerEquipmentAndSoftwareMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ToolingMember" xlink:label="acrx_ToolingMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_ToolingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tooling [Member]</link:label>
    <link:label xlink:label="acrx_ToolingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about Tooling.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ToolingMember" xlink:to="acrx_ToolingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LaboratoryEquipmentMember" xlink:label="acrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label xlink:label="acrx_LaboratoryEquipmentMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about Laboratory Equipment.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LaboratoryEquipmentMember" xlink:to="acrx_LaboratoryEquipmentMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantsPolicyPolicyTextBlock" xlink:label="acrx_WarrantsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_WarrantsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="acrx_WarrantsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_WarrantsPolicyPolicyTextBlock" xlink:to="acrx_WarrantsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents and Investments [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractAndOtherRevenueMember" xlink:label="acrx_ContractAndOtherRevenueMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContractAndOtherRevenueMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract and Other Revenue [Member]</link:label>
    <link:label xlink:label="acrx_ContractAndOtherRevenueMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about Contract and Other Revenue.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContractAndOtherRevenueMember" xlink:to="acrx_ContractAndOtherRevenueMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:label="acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContingentPutOptionPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Put Option, Policy [Policy Text Block]</link:label>
    <link:label xlink:label="acrx_ContingentPutOptionPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy regarding one or more contingent put options of the Company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:to="acrx_ContingentPutOptionPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquireProductiveAssets</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Asset acquisition costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued professional services</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:label="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:type="locator"/>
    <link:label xlink:label="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label xlink:label="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of minimum payments for both principal and interest on long-term debt to be paid in the second fiscal year following the latest fiscal year.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:to="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NONCASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" xlink:label="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" xlink:type="locator"/>
    <link:label xlink:label="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue</link:label>
    <link:label xlink:label="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan, Shares Issued, Weighted Average Fair Value (in dollars per share)</link:label>
    <link:label xlink:label="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the weighted average fair value of shares issued under an ESPP.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" xlink:to="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LiabilityRelatedToSaleOfFutureRoyalties</link:label>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties &#8212; beginning balance</link:label>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents liability related to future royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LiabilityRelatedToSaleOfFutureRoyalties" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyalties-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxesPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income taxes paid (refunded)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaidNet" xlink:to="us-gaap_IncomeTaxesPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProductMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductMember" xlink:to="us-gaap_ProductMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingSubleaseDeferredCosts" xlink:label="acrx_LesseeOperatingSubleaseDeferredCosts" xlink:type="locator"/>
    <link:label xlink:label="acrx_LesseeOperatingSubleaseDeferredCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LesseeOperatingSubleaseDeferredCosts</link:label>
    <link:label xlink:label="acrx_LesseeOperatingSubleaseDeferredCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Sublease, Deferred Costs</link:label>
    <link:label xlink:label="acrx_LesseeOperatingSubleaseDeferredCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of asset related to consideration paid in advance for operating sublease deferred costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LesseeOperatingSubleaseDeferredCosts" xlink:to="acrx_LesseeOperatingSubleaseDeferredCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:label="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease for Corporate Headquarters in Hayward, California [Member]</link:label>
    <link:label xlink:label="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the lease agreement for the corporate headquarters in Hayward, California.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:to="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseAbatedRentPeriod" xlink:label="acrx_LesseeOperatingLeaseAbatedRentPeriod" xlink:type="locator"/>
    <link:label xlink:label="acrx_LesseeOperatingLeaseAbatedRentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LesseeOperatingLeaseAbatedRentPeriod</link:label>
    <link:label xlink:label="acrx_LesseeOperatingLeaseAbatedRentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Abated Rent Period (Month)</link:label>
    <link:label xlink:label="acrx_LesseeOperatingLeaseAbatedRentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The period of abated rent of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LesseeOperatingLeaseAbatedRentPeriod" xlink:to="acrx_LesseeOperatingLeaseAbatedRentPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="us-gaap_LossContingencyNumberOfDefendants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LossContingencyNumberOfDefendants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LossContingencyNumberOfDefendants</link:label>
    <link:label xlink:label="us-gaap_LossContingencyNumberOfDefendants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number of Defendants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LossContingencyNumberOfDefendants" xlink:to="us-gaap_LossContingencyNumberOfDefendants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CatalentPharmaSolutionsMember" xlink:label="acrx_CatalentPharmaSolutionsMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_CatalentPharmaSolutionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Catalent Pharma Solutions [Member]</link:label>
    <link:label xlink:label="acrx_CatalentPharmaSolutionsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to Catalent Pharma Solutions, LLC, or Catalent.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_CatalentPharmaSolutionsMember" xlink:to="acrx_CatalentPharmaSolutionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubleaseIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SubleaseIncome</link:label>
    <link:label xlink:label="us-gaap_SubleaseIncome-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less accumulated depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and Equipment, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseholdImprovementsGross</link:label>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Gross</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:label xlink:label="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties</link:label>
    <link:label xlink:label="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Interest Over Life of Liability Related to Sale of Future Royalties</link:label>
    <link:label xlink:label="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of effective interest over the life of the liability related to sale of future royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentGainLossOnRoyaltyMonetizationArrangement" xlink:label="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_ContingentGainLossOnRoyaltyMonetizationArrangement</link:label>
    <link:label xlink:label="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent Gain (Loss) on Royalty Monetization Arrangement</link:label>
    <link:label xlink:label="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of contingent gain (loss) on royalty monetization arrangement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement" xlink:to="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term investment, fair value</link:label>
    <link:label xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability related to the sale of future royalties</link:label>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of liability related to sale of future royalities classified as noncurrent.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:label xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash interest income on liability related to sale of future royalties</link:label>
    <link:label xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest (income) expense recognized</link:label>
    <link:label xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amoutn of noncash interest income expense on liability related to sale of future royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:to="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Employee Related Liabilities, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision for income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccruedLiabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesPayableGross" xlink:label="acrx_NotesPayableGross" xlink:type="locator"/>
    <link:label xlink:label="acrx_NotesPayableGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes payable, gross</link:label>
    <link:label xlink:label="acrx_NotesPayableGross-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, after subtracting the amount representing interest but before subtracting any balloon payment(s) or unamortized discount, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NotesPayableGross" xlink:to="acrx_NotesPayableGross-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtTotalMinimumPayments" xlink:label="acrx_LongTermDebtTotalMinimumPayments" xlink:type="locator"/>
    <link:label xlink:label="acrx_LongTermDebtTotalMinimumPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LongTermDebtTotalMinimumPayments</link:label>
    <link:label xlink:label="acrx_LongTermDebtTotalMinimumPayments-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total payments</link:label>
    <link:label xlink:label="acrx_LongTermDebtTotalMinimumPayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the future minimum payments on long-term debt, including both principal and interest.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LongTermDebtTotalMinimumPayments" xlink:to="acrx_LongTermDebtTotalMinimumPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtMaturitiesRepaymentsOfInterest" xlink:label="acrx_LongTermDebtMaturitiesRepaymentsOfInterest" xlink:type="locator"/>
    <link:label xlink:label="acrx_LongTermDebtMaturitiesRepaymentsOfInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LongTermDebtMaturitiesRepaymentsOfInterest</link:label>
    <link:label xlink:label="acrx_LongTermDebtMaturitiesRepaymentsOfInterest-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less amount representing interest</link:label>
    <link:label xlink:label="acrx_LongTermDebtMaturitiesRepaymentsOfInterest-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the interest portion of future minimum payments on long-term debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LongTermDebtMaturitiesRepaymentsOfInterest" xlink:to="acrx_LongTermDebtMaturitiesRepaymentsOfInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BeforeTaxYear2018Member" xlink:label="acrx_BeforeTaxYear2018Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_BeforeTaxYear2018Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Before Tax Year 2018 [Member]</link:label>
    <link:label xlink:label="acrx_BeforeTaxYear2018Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Identified as before tax year 2018.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BeforeTaxYear2018Member" xlink:to="acrx_BeforeTaxYear2018Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TaxYears2018To2020Member" xlink:label="acrx_TaxYears2018To2020Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_TaxYears2018To2020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Years 2018 to 2020 [Member]</link:label>
    <link:label xlink:label="acrx_TaxYears2018To2020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Identified as tax years 2018 to 2020.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_TaxYears2018To2020Member" xlink:to="acrx_TaxYears2018To2020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Cash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, amortized cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RoyaltyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyMember" xlink:to="us-gaap_RoyaltyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:label="us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperAtCarryingValue" xlink:to="us-gaap_CommercialPaperAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent put option associated with the Loan Agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money market funds, amortized cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
	<link:loc xlink:href="acrx-20211231.xsd#acrx_OUMCoLLPMember" xlink:label="acrx_OUMCoLLPMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_OUMCoLLPMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OUM &amp; CO. LLP [Member]</link:label>
    <link:label xlink:label="acrx_OUMCoLLPMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the auditor, OUM &amp; CO. LLP.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_OUMCoLLPMember" xlink:to="acrx_OUMCoLLPMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ComprehensiveIncomeNetOfTax</link:label>
    <link:label xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Periodic Payment, Principal</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LeaseCost</link:label>
    <link:label xlink:label="us-gaap_LeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net lease costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateEffectivePercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</link:label>
    <link:label xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain (Loss), Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average remaining discount rate &#8211; operating leases (in years)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseCostTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Establishment of right-of-use asset and lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted-average remaining lease term &#8211; operating leases (in years) (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AreaOfRealEstateProperty</link:label>
    <link:label xlink:label="us-gaap_AreaOfRealEstateProperty-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Area of Real Estate Property (Square Foot)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfRealEstateProperty" xlink:to="us-gaap_AreaOfRealEstateProperty-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value, Beginning of period</link:label>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value, End of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in fair value of contingent put option associated with the Loan Agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringCharges-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestructuringCharges</link:label>
    <link:label xlink:label="us-gaap_RestructuringCharges-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringCharges" xlink:to="us-gaap_RestructuringCharges-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentNameDomain" xlink:to="us-gaap_DebtInstrumentNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">London Interbank Offered Rate (LIBOR) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:label="us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax payments related to shares withheld for restricted stock units vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:to="us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EmployeeStockPurchasePlanESPPMember" xlink:label="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_EmployeeStockPurchasePlanESPPMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Purchase Plan (ESPP) [Member]</link:label>
    <link:label xlink:label="acrx_EmployeeStockPurchasePlanESPPMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information about the employee stock purchase plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_EmployeeStockPurchasePlanESPPMember" xlink:to="acrx_EmployeeStockPurchasePlanESPPMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:label="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment in accounts payable and accrued expenses</link:label>
    <link:label xlink:label="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents purchases of property and equipment that were acquired through accounts payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:to="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of warrants in connection with equity financings</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_VariableRateAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CapitalizedContractCostAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CapitalizedContractCostAmortization</link:label>
    <link:label xlink:label="us-gaap_CapitalizedContractCostAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedContractCostAmortization" xlink:to="us-gaap_CapitalizedContractCostAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsReceivable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</link:label>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskPercentage1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration risk</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByLiabilityClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Liability Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CustomerConcentrationRiskMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Policy Text Block]</link:label>
    <link:label xlink:label="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for cash and cash equivalents, and marketable securities including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:to="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SalesRevenueNetMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableMember" xlink:to="us-gaap_AccountsReceivableMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtTextBlock" xlink:to="us-gaap_LongTermDebtTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeCategorizationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInInventories</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInInventories-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInInventories" xlink:to="us-gaap_IncreaseDecreaseInInventories-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon ESPP purchase (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon ESPP purchase</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units vested (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted stock units vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Measurement Input</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock in connection with equity financings (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Raw materials</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:label="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_LoanAgreementWithOxfordFinanceLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loan Agreement with Oxford Finance LLC [Member]</link:label>
    <link:label xlink:label="acrx_LoanAgreementWithOxfordFinanceLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to loan agreement with Oxford Finance LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:to="acrx_LoanAgreementWithOxfordFinanceLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:label="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:type="locator"/>
    <link:label xlink:label="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization</link:label>
    <link:label xlink:label="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue related to royalty monetization</link:label>
    <link:label xlink:label="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-cash royalty revenue recognized in connection to royalty monetization.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:to="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GainLossOnTerminationOfSublease" xlink:label="acrx_GainLossOnTerminationOfSublease" xlink:type="locator"/>
    <link:label xlink:label="acrx_GainLossOnTerminationOfSublease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_GainLossOnTerminationOfSublease</link:label>
    <link:label xlink:label="acrx_GainLossOnTerminationOfSublease-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on termination of sublease</link:label>
    <link:label xlink:label="acrx_GainLossOnTerminationOfSublease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of gain (loss) on termination of sublease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_GainLossOnTerminationOfSublease" xlink:to="acrx_GainLossOnTerminationOfSublease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Liabilities and Stockholders&#8217; Deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:label="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]</link:label>
    <link:label xlink:label="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to the violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:to="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Work-in-process</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant In Connection with Oxford Finance Loan Agreement [Member]</link:label>
    <link:label xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to warrant in connection with Oxford finance loan agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingCostsAndExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating costs and expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:label="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]</link:label>
    <link:label xlink:label="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to alleged misstatements as the shareholder.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:to="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MoneyMarketFundsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementTerm" xlink:label="acrx_LicenseAgreementTerm" xlink:type="locator"/>
    <link:label xlink:label="acrx_LicenseAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LicenseAgreementTerm</link:label>
    <link:label xlink:label="acrx_LicenseAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Term (Year)</link:label>
    <link:label xlink:label="acrx_LicenseAgreementTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LicenseAgreementTerm" xlink:to="acrx_LicenseAgreementTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputSharePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Share Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputSharePriceMember" xlink:to="us-gaap_MeasurementInputSharePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_DZUVEOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DZUVEO [Member]</link:label>
    <link:label xlink:label="acrx_DZUVEOMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to DZUVEO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DZUVEOMember" xlink:to="acrx_DZUVEOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpense</link:label>
    <link:label xlink:label="us-gaap_InterestExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" xlink:label="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" xlink:type="locator"/>
    <link:label xlink:label="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments</link:label>
    <link:label xlink:label="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan Default Events, Trigger of Negative Impact of Government Approvals and Judgments</link:label>
    <link:label xlink:label="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the trigger of negative impact of government approvals and judgments for loan default events.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" xlink:to="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashMember" xlink:to="us-gaap_CashMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebt</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebt" xlink:to="us-gaap_InterestExpenseDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Price Volatility [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding</link:label>
    <link:label xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Outstanding (in shares)</link:label>
    <link:label xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the shared-based compensation arrangement by share-based payment award equity instrument other than options outstanding.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_AguettantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aguettant [Member]</link:label>
    <link:label xlink:label="acrx_AguettantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to Aguettant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AguettantMember" xlink:to="acrx_AguettantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Risk Free Interest Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" xlink:label="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" xlink:type="locator"/>
    <link:label xlink:label="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed</link:label>
    <link:label xlink:label="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Plan Option Reserve Annual Increase as Percentage of Outstanding Shares Allowed</link:label>
    <link:label xlink:label="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the stock option plan option reserve annual increase as percentage of outstanding shares allowed.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" xlink:to="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PFSProductsMember" xlink:label="acrx_PFSProductsMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_PFSProductsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PFS Products [Member]</link:label>
    <link:label xlink:label="acrx_PFSProductsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information related to PFS products.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_PFSProductsMember" xlink:to="acrx_PFSProductsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum" xlink:label="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum" xlink:type="locator"/>
    <link:label xlink:label="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum</link:label>
    <link:label xlink:label="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payments to be Paid, Maximum</link:label>
    <link:label xlink:label="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum amount of milestone payments to be paid under license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum" xlink:to="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherNoncashIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherNoncashIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_OtherNoncashIncomeExpense-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryDisclosureTextBlock" xlink:to="us-gaap_InventoryDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Dividend Rate [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExpectedTermMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Expected Term [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExpectedTermMember" xlink:to="us-gaap_MeasurementInputExpectedTermMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementRenewalTerm" xlink:label="acrx_LicenseAgreementRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="acrx_LicenseAgreementRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LicenseAgreementRenewalTerm</link:label>
    <link:label xlink:label="acrx_LicenseAgreementRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Renewal Term (Year)</link:label>
    <link:label xlink:label="acrx_LicenseAgreementRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The renewal term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LicenseAgreementRenewalTerm" xlink:to="acrx_LicenseAgreementRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:label="acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="acrx_WriteoffOfRightofuseAssetAndLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Write-off of right-of-use asset and lease liability</link:label>
    <link:label xlink:label="acrx_WriteoffOfRightofuseAssetAndLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount write-off of right-of-use asset and lease liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:to="acrx_WriteoffOfRightofuseAssetAndLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GainOnTerminationOfSublease" xlink:label="acrx_GainOnTerminationOfSublease" xlink:type="locator"/>
    <link:label xlink:label="acrx_GainOnTerminationOfSublease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain on termination of sublease</link:label>
    <link:label xlink:label="acrx_GainOnTerminationOfSublease-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of gain on termination of sublease.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_GainOnTerminationOfSublease" xlink:to="acrx_GainOnTerminationOfSublease-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsMember" xlink:to="us-gaap_CashAndCashEquivalentsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputExercisePriceMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input, Exercise Price [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputExercisePriceMember" xlink:to="us-gaap_MeasurementInputExercisePriceMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities, current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMinimumSalesObligationTerm" xlink:label="acrx_LicenseAgreementMinimumSalesObligationTerm" xlink:type="locator"/>
    <link:label xlink:label="acrx_LicenseAgreementMinimumSalesObligationTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LicenseAgreementMinimumSalesObligationTerm</link:label>
    <link:label xlink:label="acrx_LicenseAgreementMinimumSalesObligationTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Minimum Sales Obligation Term (Month)</link:label>
    <link:label xlink:label="acrx_LicenseAgreementMinimumSalesObligationTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the minimum sales obligation term under license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LicenseAgreementMinimumSalesObligationTerm" xlink:to="acrx_LicenseAgreementMinimumSalesObligationTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LowellsIntellectualPropertyMember" xlink:label="acrx_LowellsIntellectualPropertyMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_LowellsIntellectualPropertyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lowell&#8217;s Intellectual Property [Member]</link:label>
    <link:label xlink:label="acrx_LowellsIntellectualPropertyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents Lowell&#8217;s intellectual property.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LowellsIntellectualPropertyMember" xlink:to="acrx_LowellsIntellectualPropertyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:label="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:type="locator"/>
    <link:label xlink:label="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset acquisition costs in accounts payable and accrued expenses</link:label>
    <link:label xlink:label="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of asset acquisition costs in accounts payable and accrued expenses.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:to="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GrunenthalMember" xlink:label="acrx_GrunenthalMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_GrunenthalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grunenthal [Member]</link:label>
    <link:label xlink:label="acrx_GrunenthalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name or description of the counterparty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_GrunenthalMember" xlink:to="acrx_GrunenthalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total future minimum lease payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_InlicenseAgreementTextBlock" xlink:label="acrx_InlicenseAgreementTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_InlicenseAgreementTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In-license Agreement [Text Block]</link:label>
    <link:label xlink:label="acrx_InlicenseAgreementTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for in-license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_InlicenseAgreementTextBlock" xlink:to="acrx_InlicenseAgreementTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less imputed interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_OutlicenseAgreementTextBlock" xlink:label="acrx_OutlicenseAgreementTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_OutlicenseAgreementTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Out-license Agreement [Text Block]</link:label>
    <link:label xlink:label="acrx_OutlicenseAgreementTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of out-license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_OutlicenseAgreementTextBlock" xlink:to="acrx_OutlicenseAgreementTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_MeasurementInputTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Input Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelrxCommonStockMember" xlink:label="acrx_AcelrxCommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_AcelrxCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AcelRx Common Stock [Member]</link:label>
    <link:label xlink:label="acrx_AcelrxCommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents AcelRx common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AcelrxCommonStockMember" xlink:to="acrx_AcelrxCommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2021 Registered Direct Offering [Member]</link:label>
    <link:label xlink:label="acrx_RegisteredDirectOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents 2021 registered direct offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_RegisteredDirectOfferingMember" xlink:to="acrx_RegisteredDirectOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash interest expense related to debt financing</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" xlink:type="locator"/>
    <link:label xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations</link:label>
    <link:label xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)</link:label>
    <link:label xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents acquiree common stock to be held back to satisfy some obligations.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" xlink:to="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_November2021FinancingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">November 2021 Financing Warrants [Member]</link:label>
    <link:label xlink:label="acrx_November2021FinancingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">represents November 2021 Financing Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_November2021FinancingWarrantsMember" xlink:to="acrx_November2021FinancingWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ATMAgreementMember" xlink:label="acrx_ATMAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_ATMAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ATM Agreement [Member]</link:label>
    <link:label xlink:label="acrx_ATMAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information related to at the market agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ATMAgreementMember" xlink:to="acrx_ATMAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" xlink:label="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" xlink:type="locator"/>
    <link:label xlink:label="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable</link:label>
    <link:label xlink:label="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Required Percentage of Ownership to Become Exercisable</link:label>
    <link:label xlink:label="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents required percentage of ownership in order for warrants become exercisable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" xlink:to="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AggregateOfferingPriceIncreaseDuringPeriod" xlink:label="acrx_AggregateOfferingPriceIncreaseDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="acrx_AggregateOfferingPriceIncreaseDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_AggregateOfferingPriceIncreaseDuringPeriod</link:label>
    <link:label xlink:label="acrx_AggregateOfferingPriceIncreaseDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Offering Price, Increase During Period</link:label>
    <link:label xlink:label="acrx_AggregateOfferingPriceIncreaseDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the aggregate offering price increase during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AggregateOfferingPriceIncreaseDuringPeriod" xlink:to="acrx_AggregateOfferingPriceIncreaseDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseTermOfContract</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LesseeOperatingLeaseRenewalTerm</link:label>
    <link:label xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Renewal Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AggregateOfferingPriceMaximum" xlink:label="acrx_AggregateOfferingPriceMaximum" xlink:type="locator"/>
    <link:label xlink:label="acrx_AggregateOfferingPriceMaximum-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_AggregateOfferingPriceMaximum</link:label>
    <link:label xlink:label="acrx_AggregateOfferingPriceMaximum-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Offering Price, Maximum</link:label>
    <link:label xlink:label="acrx_AggregateOfferingPriceMaximum-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the maximum aggregate offering price.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AggregateOfferingPriceMaximum" xlink:to="acrx_AggregateOfferingPriceMaximum-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare</link:label>
    <link:label xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Fixed Value per Share (in dollars per share)</link:label>
    <link:label xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents acquiree common stock to be held back to satisfy some obligations, fixed value per share.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" xlink:to="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractAndOtherCollaborationMember" xlink:label="acrx_ContractAndOtherCollaborationMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContractAndOtherCollaborationMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract and Other Collaboration [Member]</link:label>
    <link:label xlink:label="acrx_ContractAndOtherCollaborationMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents contract and other collaboration.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContractAndOtherCollaborationMember" xlink:to="acrx_ContractAndOtherCollaborationMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NonCashRoyaltyMember" xlink:label="acrx_NonCashRoyaltyMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_NonCashRoyaltyMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash Royalty [Member]</link:label>
    <link:label xlink:label="acrx_NonCashRoyaltyMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information about non-cash royalty.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NonCashRoyaltyMember" xlink:to="acrx_NonCashRoyaltyMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Depreciation</link:label>
    <link:label xlink:label="us-gaap_Depreciation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Depreciation" xlink:to="us-gaap_Depreciation-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LeaseholdPaidWithNotePayable" xlink:label="acrx_LeaseholdPaidWithNotePayable" xlink:type="locator"/>
    <link:label xlink:label="acrx_LeaseholdPaidWithNotePayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold improvements paid with note payable</link:label>
    <link:label xlink:label="acrx_LeaseholdPaidWithNotePayable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents leasehold paid with note payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LeaseholdPaidWithNotePayable" xlink:to="acrx_LeaseholdPaidWithNotePayable-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" xlink:label="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" xlink:type="locator"/>
    <link:label xlink:label="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight</link:label>
    <link:label xlink:label="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Minimum Indebtedness Amount with Acceleration Right</link:label>
    <link:label xlink:label="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents minimum indebtedness amount with acceleration right under debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" xlink:to="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpensePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpensePolicyTextBlock" xlink:to="us-gaap_InterestExpensePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" xlink:label="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" xlink:type="locator"/>
    <link:label xlink:label="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash</link:label>
    <link:label xlink:label="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Covenant, Minimum Required Unrestircted Cash</link:label>
    <link:label xlink:label="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The minimum amount of unrestricted cash required to be maintained by the debt agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" xlink:to="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalent, fair value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" xlink:label="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod</link:label>
    <link:label xlink:label="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In current period</link:label>
    <link:label xlink:label="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents contract with customer liability revenue recognized during current period,</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" xlink:to="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" xlink:label="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" xlink:type="locator"/>
    <link:label xlink:label="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized</link:label>
    <link:label xlink:label="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Non-cash royalty revenue</link:label>
    <link:label xlink:label="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-cash royalty revenue recognized in connection to royalty monetization that has been realized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" xlink:to="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value&#8212;200,000,000 shares authorized as of December 31, 2021 and 2020; 136,819,647 and 98,812,008 shares issued and outstanding as of December 31, 2021 and 2020, respectively</link:label>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommercialPaperMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductOrServiceAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" xlink:type="locator"/>
    <link:label xlink:label="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived</link:label>
    <link:label xlink:label="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Milestone Payments and Revenue Share Payments to be Received</link:label>
    <link:label xlink:label="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents milestone payments and revenue share payments to be received for license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" xlink:to="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ProductsAndServicesDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" xlink:label="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" xlink:type="locator"/>
    <link:label xlink:label="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt</link:label>
    <link:label xlink:label="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Debt, Net of Issuance Costs and Repayment of Debt</link:label>
    <link:label xlink:label="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from issuance of debt, net of issuance costs paid to third parties and repayments of debt.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" xlink:to="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_LitigationCaseTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_LitigationCaseTypeDomain" xlink:to="srt_LitigationCaseTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsLiabilitiesNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentDefaultAdditionalInterestRate" xlink:label="acrx_DebtInstrumentDefaultAdditionalInterestRate" xlink:type="locator"/>
    <link:label xlink:label="acrx_DebtInstrumentDefaultAdditionalInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_DebtInstrumentDefaultAdditionalInterestRate</link:label>
    <link:label xlink:label="acrx_DebtInstrumentDefaultAdditionalInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Default Additional Interest Rate</link:label>
    <link:label xlink:label="acrx_DebtInstrumentDefaultAdditionalInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the default additional interest rate for debt instrument.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DebtInstrumentDefaultAdditionalInterestRate" xlink:to="acrx_DebtInstrumentDefaultAdditionalInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" xlink:label="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" xlink:type="locator"/>
    <link:label xlink:label="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021</link:label>
    <link:label xlink:label="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepayment Charge, Percentage of Outstanding Balance, After May 30, 2020, Before May 30, 2021</link:label>
    <link:label xlink:label="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of outstanding balance for repayment charge if prepayment occurs after May 30, 2020 and before May 30, 2021.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" xlink:to="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestPaidNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash paid for interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentInterestRateBasePercentage" xlink:label="acrx_DebtInstrumentInterestRateBasePercentage" xlink:type="locator"/>
    <link:label xlink:label="acrx_DebtInstrumentInterestRateBasePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_DebtInstrumentInterestRateBasePercentage</link:label>
    <link:label xlink:label="acrx_DebtInstrumentInterestRateBasePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Base Percentage</link:label>
    <link:label xlink:label="acrx_DebtInstrumentInterestRateBasePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual base interest rate for funds borrowed, under the debt agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DebtInstrumentInterestRateBasePercentage" xlink:to="acrx_DebtInstrumentInterestRateBasePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsGross</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsGross-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventories, net</link:label>
    <link:label xlink:label="us-gaap_InventoryNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryNet" xlink:to="us-gaap_InventoryNet-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" xlink:type="locator"/>
    <link:label xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived</link:label>
    <link:label xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Percent of Revenue Share Payments to be Received</link:label>
    <link:label xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of revenue share payments to be received under license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" xlink:to="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid" xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid" xlink:type="locator"/>
    <link:label xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid</link:label>
    <link:label xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Percent of Revenue Share Payment to be Paid</link:label>
    <link:label xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the percentage of revenue share payments to be paid under license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid" xlink:to="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Including Assessed Tax</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel3Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Section 59(e) R&amp;D expenditures</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" xlink:type="locator"/>
    <link:label xlink:label="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived</link:label>
    <link:label xlink:label="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License Agreement, Upfront and Maximum Milestone Payments to be Received</link:label>
    <link:label xlink:label="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the upfront payments and the maximum amount of milestone payments to be received under license agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" xlink:to="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_MajorCustomersAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_MajorCustomersAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_NameOfMajorCustomerDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_NameOfMajorCustomerDomain" xlink:to="srt_NameOfMajorCustomerDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel1Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueInputsLevel2Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_The2020EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The 2020 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="acrx_The2020EquityIncentivePlanMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the 2020 equity incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_The2020EquityIncentivePlanMember" xlink:to="acrx_The2020EquityIncentivePlanMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:label="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_ArmisticeCapitalAndRockSpringsCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Armistice Capital and Rock Springs Capital [Member]</link:label>
    <link:label xlink:label="acrx_ArmisticeCapitalAndRockSpringsCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to Armistice Capital and Rock Springs Capital.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:to="acrx_ArmisticeCapitalAndRockSpringsCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityLiabilityEliminated" xlink:label="acrx_ContractWithCustomerLiabilityLiabilityEliminated" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContractWithCustomerLiabilityLiabilityEliminated-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_ContractWithCustomerLiabilityLiabilityEliminated</link:label>
    <link:label xlink:label="acrx_ContractWithCustomerLiabilityLiabilityEliminated-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Liability Eliminated</link:label>
    <link:label xlink:label="acrx_ContractWithCustomerLiabilityLiabilityEliminated-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The value of the contract with customer liability eliminated.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContractWithCustomerLiabilityLiabilityEliminated" xlink:to="acrx_ContractWithCustomerLiabilityLiabilityEliminated-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConstructionInProgressMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstanding</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstanding" xlink:to="us-gaap_WarrantsAndRightsOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsReceivableNetCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FurnitureAndFixturesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and short-term investments</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenuesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShortTermInvestments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermInvestments" xlink:to="us-gaap_ShortTermInvestments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Deficit:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseholdImprovementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_AmendedLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amended License Agreement [Member]</link:label>
    <link:label xlink:label="acrx_AmendedLicenseAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amended License Agreement</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AmendedLicenseAgreementMember" xlink:to="acrx_AmendedLicenseAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NonoperatingIncomeExpense</link:label>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforward</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research credits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InvestmentIncomeNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income and other income, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNet" xlink:to="us-gaap_InvestmentIncomeNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS &#8212;Beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">CASH, CASH EQUIVALENTS &#8212;End of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryPolicyTextBlock" xlink:to="us-gaap_InventoryPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_FairValueOfContingentPutOptionLiability" xlink:label="acrx_FairValueOfContingentPutOptionLiability" xlink:type="locator"/>
    <link:label xlink:label="acrx_FairValueOfContingentPutOptionLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_FairValueOfContingentPutOptionLiability</link:label>
    <link:label xlink:label="acrx_FairValueOfContingentPutOptionLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Contingent Put Option, Liability</link:label>
    <link:label xlink:label="acrx_FairValueOfContingentPutOptionLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the fair value of contingent put option liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_FairValueOfContingentPutOptionLiability" xlink:to="acrx_FairValueOfContingentPutOptionLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrivatePlacementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrivatePlacementMember" xlink:to="us-gaap_PrivatePlacementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LicenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SiteReadinessAgreementMember" xlink:label="acrx_SiteReadinessAgreementMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_SiteReadinessAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Site Readiness Agreement [Member]</link:label>
    <link:label xlink:label="acrx_SiteReadinessAgreementMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents site readiness agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_SiteReadinessAgreementMember" xlink:to="acrx_SiteReadinessAgreementMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ExecutiveOfficerMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Officer [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ExecutiveOfficerMember" xlink:to="srt_ExecutiveOfficerMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestExpenseRecognized" xlink:label="acrx_NoncashInterestExpenseRecognized" xlink:type="locator"/>
    <link:label xlink:label="acrx_NoncashInterestExpenseRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-cash interest income on liability related to royalty monetization</link:label>
    <link:label xlink:label="acrx_NoncashInterestExpenseRecognized-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of non-cash interest expense recognized.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NoncashInterestExpenseRecognized" xlink:to="acrx_NoncashInterestExpenseRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">In prior periods(1)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfGoodsAndServicesSold-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of goods sold</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfGoodsAndServicesSold" xlink:to="us-gaap_CostOfGoodsAndServicesSold-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory impairment charge</link:label>
    <link:label xlink:label="us-gaap_InventoryWriteDown-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Write-down</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InventoryWriteDown" xlink:to="us-gaap_InventoryWriteDown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ContractWithCustomerLiability</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Total</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiability-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DSUVIAMember" xlink:label="acrx_DSUVIAMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_DSUVIAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DSUVIA [Member]</link:label>
    <link:label xlink:label="acrx_DSUVIAMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents DSUVIA.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DSUVIAMember" xlink:to="acrx_DSUVIAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants</link:label>
    <link:label xlink:label="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Proceeds from Issuance of Common Stock and Exercise of Warrants</link:label>
    <link:label xlink:label="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the issuance of common stock and exercise of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:to="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:label xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from sale of future royalties</link:label>
    <link:label xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Proceeds from Sale of Future Royalties</link:label>
    <link:label xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Net proceeds from sale of future royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:to="acrx_NetProceedsFromSaleOfFutureRoyalties-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" xlink:type="locator"/>
    <link:label xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded</link:label>
    <link:label xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares to be Added (in shares)</link:label>
    <link:label xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the number of additional shares that could be added from expired or cancelled shares already issued under another share-based payment plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RoyaltyArrangmentMaximumPayments" xlink:label="acrx_RoyaltyArrangmentMaximumPayments" xlink:type="locator"/>
    <link:label xlink:label="acrx_RoyaltyArrangmentMaximumPayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_RoyaltyArrangmentMaximumPayments</link:label>
    <link:label xlink:label="acrx_RoyaltyArrangmentMaximumPayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Arrangment Maximum Payments</link:label>
    <link:label xlink:label="acrx_RoyaltyArrangmentMaximumPayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The capped amount of payments of company required to make to PDL.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_RoyaltyArrangmentMaximumPayments" xlink:to="acrx_RoyaltyArrangmentMaximumPayments-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EstimatedOfferingCosts" xlink:label="acrx_EstimatedOfferingCosts" xlink:type="locator"/>
    <link:label xlink:label="acrx_EstimatedOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_EstimatedOfferingCosts</link:label>
    <link:label xlink:label="acrx_EstimatedOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Offering Costs</link:label>
    <link:label xlink:label="acrx_EstimatedOfferingCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of estimated offering costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_EstimatedOfferingCosts" xlink:to="acrx_EstimatedOfferingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:label="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:type="locator"/>
    <link:label xlink:label="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights</link:label>
    <link:label xlink:label="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds From Sale of Royalty and Milestone Rights</link:label>
    <link:label xlink:label="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of proceeds from the sale of royalty and milestone rights.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:to="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EffectiveAnnualInterestRate" xlink:label="acrx_EffectiveAnnualInterestRate" xlink:type="locator"/>
    <link:label xlink:label="acrx_EffectiveAnnualInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_EffectiveAnnualInterestRate</link:label>
    <link:label xlink:label="acrx_EffectiveAnnualInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Annual Interest Rate</link:label>
    <link:label xlink:label="acrx_EffectiveAnnualInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective annual rate for a liability related to sale of future royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_EffectiveAnnualInterestRate" xlink:to="acrx_EffectiveAnnualInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:label="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments and Fair Value Measurement Disclosure [Text Block]</link:label>
    <link:label xlink:label="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of investments and fair value measurement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:to="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax payments related to shares withheld for restricted stock units vested</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued compensation and employee benefits</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_MarketableSecuritiesMember" xlink:label="acrx_MarketableSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_MarketableSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Member]</link:label>
    <link:label xlink:label="acrx_MarketableSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents marketable securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_MarketableSecuritiesMember" xlink:to="acrx_MarketableSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_USGovernmentAgencySecuritiesMember" xlink:label="acrx_USGovernmentAgencySecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_USGovernmentAgencySecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. Government Agency Securities [Member]</link:label>
    <link:label xlink:label="acrx_USGovernmentAgencySecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the U.S. Government Agency Securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_USGovernmentAgencySecuritiesMember" xlink:to="acrx_USGovernmentAgencySecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:label="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:type="locator"/>
    <link:label xlink:label="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments</link:label>
    <link:label xlink:label="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds form Up-front and Sales-based Milestone License Payments</link:label>
    <link:label xlink:label="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash inflow from up-front and share-based millstone license payments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:to="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:label="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:type="locator"/>
    <link:label xlink:label="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total cash, cash equivalents and short-term investments, fair value</link:label>
    <link:label xlink:label="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents fair value of cash, cash equivalents and short-term investments.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:to="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange5Member" xlink:label="acrx_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_ExercisePriceRange5Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 5 [Member]</link:label>
    <link:label xlink:label="acrx_ExercisePriceRange5Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the fifth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ExercisePriceRange5Member" xlink:to="acrx_ExercisePriceRange5Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentPutOptionLiabilityMember" xlink:label="acrx_ContingentPutOptionLiabilityMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContingentPutOptionLiabilityMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contingent Put Option Liability [Member]</link:label>
    <link:label xlink:label="acrx_ContingentPutOptionLiabilityMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the contingent put option liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContingentPutOptionLiabilityMember" xlink:to="acrx_ContingentPutOptionLiabilityMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CostsAndExpenses</link:label>
    <link:label xlink:label="us-gaap_CostsAndExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating costs and expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostsAndExpenses" xlink:to="us-gaap_CostsAndExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfSalesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Service [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesPolicyTextBlock" xlink:to="us-gaap_CostOfSalesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of warrants in connection with equity financings</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:label xlink:label="srt_ScenarioForecastMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AccruedDeferredRevenueCurrent" xlink:label="acrx_AccruedDeferredRevenueCurrent" xlink:type="locator"/>
    <link:label xlink:label="acrx_AccruedDeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_AccruedDeferredRevenueCurrent</link:label>
    <link:label xlink:label="acrx_AccruedDeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label xlink:label="acrx_AccruedDeferredRevenueCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for deferred revenue. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AccruedDeferredRevenueCurrent" xlink:to="acrx_AccruedDeferredRevenueCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:label="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:type="locator"/>
    <link:label xlink:label="acrx_AccruedProductReturnsAndSalesAllowancesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued product returns and sales allowances</link:label>
    <link:label xlink:label="acrx_AccruedProductReturnsAndSalesAllowancesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents current accrued product returns and sales allowance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:to="acrx_AccruedProductReturnsAndSalesAllowancesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock in connection with equity financings</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" xlink:type="locator"/>
    <link:label xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber</link:label>
    <link:label xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Number (in shares)</link:label>
    <link:label xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents options to purchase capital stock and all shares of stock issued and outstanding cancelled in exchange for right to receive common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" xlink:to="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net proceeds from issuance of common stock through equity plans</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" xlink:type="locator"/>
    <link:label xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash</link:label>
    <link:label xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Cash</link:label>
    <link:label xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Value of options to purchase capital stock and all shares of capital stock issued and outstanding in exchange for cash.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" xlink:to="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponNetSalesTargetAchievementsMember" xlink:label="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_BasedUponNetSalesTargetAchievementsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Based upon Net Sales Target Achievements [Member]</link:label>
    <link:label xlink:label="acrx_BasedUponNetSalesTargetAchievementsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An amount, or portion of an amount, that is, will be, or may be based upon "net sales target achievements."</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:to="acrx_BasedUponNetSalesTargetAchievementsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TimebasedStockOptionMember" xlink:label="acrx_TimebasedStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_TimebasedStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Time-based Stock Option [Member]</link:label>
    <link:label xlink:label="acrx_TimebasedStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents time-based stock option.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_TimebasedStockOptionMember" xlink:to="acrx_TimebasedStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LongTermDebt</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Total</link:label>
    <link:label xlink:label="us-gaap_LongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ZALVISOMember" xlink:label="acrx_ZALVISOMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_ZALVISOMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ZALVISO [Member]</link:label>
    <link:label xlink:label="acrx_ZALVISOMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the product ZALVISO.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ZALVISOMember" xlink:to="acrx_ZALVISOMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:label="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Based upon Successful Regulatory and Product Development Efforts [Member]</link:label>
    <link:label xlink:label="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">An amount, or portion of an amount, that is, will be, or may be based upon "successful regulatory and product development efforts."</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:to="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" xlink:label="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" xlink:type="locator"/>
    <link:label xlink:label="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets</link:label>
    <link:label xlink:label="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets</link:label>
    <link:label xlink:label="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of additional milestone payments the Company is eligible to receive based upon successful regulatory and product development efforts and net sales target achievements.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" xlink:to="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightOutstanding</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentUnamortizedEotFee" xlink:label="acrx_DebtInstrumentUnamortizedEotFee" xlink:type="locator"/>
    <link:label xlink:label="acrx_DebtInstrumentUnamortizedEotFee-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_DebtInstrumentUnamortizedEotFee</link:label>
    <link:label xlink:label="acrx_DebtInstrumentUnamortizedEotFee-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Unamortized portion of EOT Fee</link:label>
    <link:label xlink:label="acrx_DebtInstrumentUnamortizedEotFee-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents debt instrument unamortized EOT fee.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DebtInstrumentUnamortizedEotFee" xlink:to="acrx_DebtInstrumentUnamortizedEotFee-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RepaymentsOfLongTermDebt</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt, Total</link:label>
    <link:label xlink:label="us-gaap_RepaymentsOfLongTermDebt-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of long-term debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermDebt" xlink:to="us-gaap_RepaymentsOfLongTermDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:label="acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_ValuationAllowancesAndReservesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowances and Reserves [Table Text Block]</link:label>
    <link:label xlink:label="acrx_ValuationAllowancesAndReservesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:to="acrx_ValuationAllowancesAndReservesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:label="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Allowance, Sales and Returns, Discounts, Chargebacks and Rebates [Member]</link:label>
    <link:label xlink:label="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allowance for sales and returns, discounts, chargebacks and rebates.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:to="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BalanceSheetLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentUnamortizedDiscount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: Unamortized discount on notes payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ReceivablesPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ReceivablesPolicyTextBlock" xlink:to="us-gaap_ReceivablesPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_UnrecognizedTaxBenefits</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unrecognized benefit&#8212;beginning of period</link:label>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefits-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unrecognized benefit&#8212;end of period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TotalObligationUnderLeaseholdAgreement" xlink:label="acrx_TotalObligationUnderLeaseholdAgreement" xlink:type="locator"/>
    <link:label xlink:label="acrx_TotalObligationUnderLeaseholdAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_TotalObligationUnderLeaseholdAgreement</link:label>
    <link:label xlink:label="acrx_TotalObligationUnderLeaseholdAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Obligation Under Leasehold Agreement</link:label>
    <link:label xlink:label="acrx_TotalObligationUnderLeaseholdAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents total obligation under leasehold agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_TotalObligationUnderLeaseholdAgreement" xlink:to="acrx_TotalObligationUnderLeaseholdAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross increases&#8212;prior period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross increases&#8212;current period tax positions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CostOfSalesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfSalesMember" xlink:to="us-gaap_CostOfSalesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesBalance</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ValuationAllowancesAndReservesDeductions</link:label>
    <link:label xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TypeOfArrangementAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantsDisclosureTextBlock" xlink:label="acrx_WarrantsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_WarrantsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Disclosure [Text Block]</link:label>
    <link:label xlink:label="acrx_WarrantsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The disclosure of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_WarrantsDisclosureTextBlock" xlink:to="acrx_WarrantsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability Related To Sale Of Future Royalties Disclosure [Text Block]</link:label>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for liability related to sale of future royalties.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodDomain" xlink:to="us-gaap_TaxPeriodDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxPeriodAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Period [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WholesalerAMember" xlink:label="acrx_WholesalerAMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_WholesalerAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Wholesaler A [Member]</link:label>
    <link:label xlink:label="acrx_WholesalerAMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to wholesaler A.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_WholesalerAMember" xlink:to="acrx_WholesalerAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DoDMember" xlink:label="acrx_DoDMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_DoDMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">DoD [Member]</link:label>
    <link:label xlink:label="acrx_DoDMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to DoD.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_DoDMember" xlink:to="acrx_DoDMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TaxCreditCarryforwardAmount</link:label>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing net loss per share of common stock, basic and diluted &#8211;see Note 15 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchMember" xlink:to="us-gaap_ResearchMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CustomerAMember" xlink:label="acrx_CustomerAMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_CustomerAMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer A [Member]</link:label>
    <link:label xlink:label="acrx_CustomerAMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to customer A.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_CustomerAMember" xlink:to="acrx_CustomerAMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CustomerBMember" xlink:label="acrx_CustomerBMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_CustomerBMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer B [Member]</link:label>
    <link:label xlink:label="acrx_CustomerBMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to customer B.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_CustomerBMember" xlink:to="acrx_CustomerBMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLossCarryforwards</link:label>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueByAssetClassAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Class [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PercentageOfRoyaltiesAndRightsUnderAgreement" xlink:label="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement" xlink:type="locator"/>
    <link:label xlink:label="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_PercentageOfRoyaltiesAndRightsUnderAgreement</link:label>
    <link:label xlink:label="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Royalties and Rights Under Agreement</link:label>
    <link:label xlink:label="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of royalties or milestone rights to be received under the agreement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement" xlink:to="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange6Member" xlink:label="acrx_ExercisePriceRange6Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_ExercisePriceRange6Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range 6 [Member]</link:label>
    <link:label xlink:label="acrx_ExercisePriceRange6Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the sixth exercise price range.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ExercisePriceRange6Member" xlink:to="acrx_ExercisePriceRange6Member-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_FirstFourCommercialMilestonesMember" xlink:label="acrx_FirstFourCommercialMilestonesMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_FirstFourCommercialMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Four Commercial Milestones [Member]</link:label>
    <link:label xlink:label="acrx_FirstFourCommercialMilestonesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the detail of parts of royalties and rights received.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_FirstFourCommercialMilestonesMember" xlink:to="acrx_FirstFourCommercialMilestonesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelRXMember" xlink:label="acrx_AcelRXMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_AcelRXMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AcelRX [Member]</link:label>
    <link:label xlink:label="acrx_AcelRXMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entity AcelRX.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_AcelRXMember" xlink:to="acrx_AcelRXMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CommercialMilestonesValueMaximumAmountAvailable" xlink:label="acrx_CommercialMilestonesValueMaximumAmountAvailable" xlink:type="locator"/>
    <link:label xlink:label="acrx_CommercialMilestonesValueMaximumAmountAvailable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_CommercialMilestonesValueMaximumAmountAvailable</link:label>
    <link:label xlink:label="acrx_CommercialMilestonesValueMaximumAmountAvailable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestones Value Maximum Amount Available</link:label>
    <link:label xlink:label="acrx_CommercialMilestonesValueMaximumAmountAvailable-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The maximum value of commercial milestone payments available to the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_CommercialMilestonesValueMaximumAmountAvailable" xlink:to="acrx_CommercialMilestonesValueMaximumAmountAvailable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LeaseContractualTermAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Contractual Term [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_BusinessCombinationContingentConsiderationLiability</link:label>
    <link:label xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</link:label>
    <link:label xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetAcquisitionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EquityIncentivePlan2011Member" xlink:label="acrx_EquityIncentivePlan2011Member" xlink:type="locator"/>
    <link:label xlink:label="acrx_EquityIncentivePlan2011Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2011 Equity Incentive Plan [Member]</link:label>
    <link:label xlink:label="acrx_EquityIncentivePlan2011Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The name or description of the plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_EquityIncentivePlan2011Member" xlink:to="acrx_EquityIncentivePlan2011Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetAcquisitionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetAcquisitionDomain" xlink:to="us-gaap_AssetAcquisitionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred revenue, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; deficit</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityAdditions" xlink:label="acrx_ContractWithCustomerLiabilityAdditions" xlink:type="locator"/>
    <link:label xlink:label="acrx_ContractWithCustomerLiabilityAdditions-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additions(2)</link:label>
    <link:label xlink:label="acrx_ContractWithCustomerLiabilityAdditions-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of increase (decrease) in obligation to transfer good or service to customer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_ContractWithCustomerLiabilityAdditions" xlink:to="acrx_ContractWithCustomerLiabilityAdditions-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:label xlink:label="us-gaap_LongTermDebtNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, net of current portion</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtNoncurrent" xlink:to="us-gaap_LongTermDebtNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:type="locator"/>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet</link:label>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Liability related to sale of future royalties as of December 31, 2021</link:label>
    <link:label xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of liability related to sale of future royalties less current portion.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range, Upper Range Limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term investment, amortized Cost</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SWKMember" xlink:label="acrx_SWKMember" xlink:type="locator"/>
    <link:label xlink:label="acrx_SWKMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SWK [Member]</link:label>
    <link:label xlink:label="acrx_SWKMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents SWK.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acrx_SWKMember" xlink:to="acrx_SWKMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State tax&#8212;net of federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Exercise Price Range, Lower Range Limit (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>acrx-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 05:13PM UTC 2022-03-10--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:href="acrx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:label="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities" xlink:href="acrx-20211231.xsd#statement-note-16-accrued-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock" xlink:href="acrx-20211231.xsd#statement-note-15-net-loss-per-share-of-common-stock" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-document-and-entity-information" xlink:href="acrx-20211231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
	<link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
	<link:loc xlink:href="acrx-20211231.xsd#acrx_OUMCoLLPMember" xlink:label="acrx_OUMCoLLPMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
	<link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="acrx_OUMCoLLPMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
	<link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
	<link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
	<link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
	<link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="acrx-20211231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:href="acrx-20211231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:label="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DSUVIAMember" xlink:label="acrx_DSUVIAMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="us-gaap_InventoryDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_AmendedLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_DSUVIAMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_InventoryDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement" xlink:href="acrx-20211231.xsd#statement-note-5-inlicense-agreement" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_InlicenseAgreementTextBlock" xlink:label="acrx_InlicenseAgreementTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PFSProductsMember" xlink:label="acrx_PFSProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_PFSProductsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_InlicenseAgreementTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements" xlink:href="acrx-20211231.xsd#statement-note-6-outlicense-agreements" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponNetSalesTargetAchievementsMember" xlink:label="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:label="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_OutlicenseAgreementTextBlock" xlink:label="acrx_OutlicenseAgreementTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_DZUVEOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_AmendedLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_OutlicenseAgreementTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ZALVISOMember" xlink:label="acrx_ZALVISOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_DZUVEOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_ZALVISOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:label="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SiteReadinessAgreementMember" xlink:label="acrx_SiteReadinessAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtTextBlock" xlink:label="us-gaap_LongTermDebtTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="acrx_SiteReadinessAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LongTermDebtTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases" xlink:href="acrx-20211231.xsd#statement-note-9-leases" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CatalentPharmaSolutionsMember" xlink:label="acrx_CatalentPharmaSolutionsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:label="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_CatalentPharmaSolutionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties" xlink:href="acrx-20211231.xsd#statement-note-10-liability-related-to-sale-of-future-royalties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelRXMember" xlink:label="acrx_AcelRXMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_FirstFourCommercialMilestonesMember" xlink:label="acrx_FirstFourCommercialMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SWKMember" xlink:label="acrx_SWKMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="acrx_SWKMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="acrx_FirstFourCommercialMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="acrx_AcelRXMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-11-warrants" xlink:href="acrx-20211231.xsd#statement-note-11-warrants" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-11-warrants" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantsDisclosureTextBlock" xlink:label="acrx_WarrantsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="acrx_November2021FinancingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="acrx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="acrx_WarrantsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies" xlink:href="acrx-20211231.xsd#statement-note-12-commitments-and-contingencies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:label="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:label="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-" xlink:href="acrx-20211231.xsd#statement-note-13-stockholders-equity-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ATMAgreementMember" xlink:label="acrx_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:label="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EmployeeStockPurchasePlanESPPMember" xlink:label="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EquityIncentivePlan2011Member" xlink:label="acrx_EquityIncentivePlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="acrx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="acrx_November2021FinancingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="acrx_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="acrx_EquityIncentivePlan2011Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="acrx_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="acrx_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan" xlink:href="acrx-20211231.xsd#statement-note-17-401k-plan" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BeforeTaxYear2018Member" xlink:label="acrx_BeforeTaxYear2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SubjectToExpirationMember" xlink:label="acrx_SubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TaxYears2018To2020Member" xlink:label="acrx_TaxYears2018To2020Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="acrx_BeforeTaxYear2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="acrx_TaxYears2018To2020Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="acrx_SubjectToExpirationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events" xlink:href="acrx-20211231.xsd#statement-note-19-subsequent-events" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelrxCommonStockMember" xlink:label="acrx_AcelrxCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LowellTherapeuticsMember" xlink:label="acrx_LowellTherapeuticsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesToFinancialStatementsAbstract" xlink:label="acrx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="acrx_LowellTherapeuticsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="acrx_AcelrxCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" xlink:href="acrx-20211231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:label="acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:label="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:label="acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantsPolicyPolicyTextBlock" xlink:label="acrx_WarrantsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-significant-accounting-policies-policies" xlink:label="acrx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesPolicyTextBlock" xlink:label="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpensePolicyTextBlock" xlink:label="us-gaap_InterestExpensePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="us-gaap_InventoryPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:label="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="us-gaap_ReceivablesPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acrx_BusinessDescriptionOfEntityPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ReceivablesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InventoryPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acrx_ContingentPutOptionPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostOfSalesPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acrx_WarrantsPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InterestExpensePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:href="acrx-20211231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:label="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:label="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables" xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-3-inventories-net-tables" xlink:label="acrx_statement-statement-note-3-inventories-net-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-3-inventories-net-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-4-property-and-equipment-net-tables" xlink:label="acrx_statement-statement-note-4-property-and-equipment-net-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-4-property-and-equipment-net-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables" xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:label="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-8-longterm-debt-tables" xlink:label="acrx_statement-statement-note-8-longterm-debt-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-8-longterm-debt-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-tables" xlink:href="acrx-20211231.xsd#statement-note-9-leases-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-9-leases-tables" xlink:label="acrx_statement-statement-note-9-leases-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-9-leases-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:href="acrx-20211231.xsd#statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:label="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:label="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TimebasedStockOptionMember" xlink:label="acrx_TimebasedStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-tables" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="acrx_TimebasedStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:href="acrx-20211231.xsd#statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:label="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables" xlink:href="acrx-20211231.xsd#statement-note-16-accrued-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-16-accrued-liabilities-tables" xlink:label="acrx_statement-statement-note-16-accrued-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-16-accrued-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:label="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-18-income-taxes-tables" xlink:label="acrx_statement-statement-note-18-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-18-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="acrx_ScheduleOfDeferredTaxAssetsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:href="acrx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:label="acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:label="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="acrx_ValuationAllowancesAndReservesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:href="acrx-20211231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:label="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RoyaltyArrangmentMaximumPayments" xlink:label="acrx_RoyaltyArrangmentMaximumPayments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated" xlink:label="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="us-gaap_RestructuringCharges-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestructuringCharges-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_RoyaltyArrangmentMaximumPayments-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NetProceedsFromSaleOfFutureRoyalties-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale" xlink:label="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DSUVIAMember" xlink:label="acrx_DSUVIAMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_AmendedLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_DSUVIAMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWriteDown-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Depreciation" xlink:label="us-gaap_Depreciation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Depreciation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual" xlink:href="acrx-20211231.xsd#statement-note-5-inlicense-agreement-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum" xlink:label="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMinimumSalesObligationTerm" xlink:label="acrx_LicenseAgreementMinimumSalesObligationTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid" xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementRenewalTerm" xlink:label="acrx_LicenseAgreementRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementTerm" xlink:label="acrx_LicenseAgreementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PFSProductsMember" xlink:label="acrx_PFSProductsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_PFSProductsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementMinimumSalesObligationTerm-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" xlink:href="acrx-20211231.xsd#statement-note-6-outlicense-agreements-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AmendedLicenseAgreementMember" xlink:label="acrx_AmendedLicenseAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponNetSalesTargetAchievementsMember" xlink:label="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:label="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementRenewalTerm" xlink:label="acrx_LicenseAgreementRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:label="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets" xlink:label="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_DZUVEOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_AmendedLicenseAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="acrx_BasedUponNetSalesTargetAchievementsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityLiabilityEliminated" xlink:label="acrx_ContractWithCustomerLiabilityLiabilityEliminated-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DZUVEOMember" xlink:label="acrx_DZUVEOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived" xlink:label="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementRenewalTerm" xlink:label="acrx_LicenseAgreementRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LicenseAgreementTerm" xlink:label="acrx_LicenseAgreementTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments" xlink:label="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ZALVISOMember" xlink:label="acrx_ZALVISOMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalizedContractCostAmortization" xlink:label="us-gaap_CapitalizedContractCostAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_DZUVEOMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_ZALVISOMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementTerm-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LicenseAgreementRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CapitalizedContractCostAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContractWithCustomerLiabilityLiabilityEliminated-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash" xlink:label="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentDefaultAdditionalInterestRate" xlink:label="acrx_DebtInstrumentDefaultAdditionalInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentInterestRateBasePercentage" xlink:label="acrx_DebtInstrumentInterestRateBasePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight" xlink:label="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_FairValueOfContingentPutOptionLiability" xlink:label="acrx_FairValueOfContingentPutOptionLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:label="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments" xlink:label="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021" xlink:label="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt" xlink:label="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SiteReadinessAgreementMember" xlink:label="acrx_SiteReadinessAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TotalObligationUnderLeaseholdAgreement" xlink:label="acrx_TotalObligationUnderLeaseholdAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:label="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="us-gaap_DebtInstrumentNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentPeriodicPaymentPrincipal" xlink:label="us-gaap_DebtInstrumentPeriodicPaymentPrincipal-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpenseDebt" xlink:label="us-gaap_InterestExpenseDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:label="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtInstrumentAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="acrx_LoanAgreementWithOxfordFinanceLLCMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_VariableRateAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_LondonInterbankOfferedRateLIBORMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="acrx_SiteReadinessAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RepaymentsOfLongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentInterestRateBasePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentBasisSpreadOnVariableRate1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentDefaultAdditionalInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_FairValueOfContingentPutOptionLiability-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebt-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateEffectivePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentPeriodicPaymentPrincipal-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_TotalObligationUnderLeaseholdAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseholdImprovementsGross-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" xlink:href="acrx-20211231.xsd#statement-note-9-leases-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CatalentPharmaSolutionsMember" xlink:label="acrx_CatalentPharmaSolutionsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:label="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseAbatedRentPeriod" xlink:label="acrx_LesseeOperatingLeaseAbatedRentPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseAnnualOverheadFeePayments" xlink:label="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseMonthlyRent" xlink:label="acrx_LesseeOperatingLeaseMonthlyRent-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingLeaseNoticePeriod" xlink:label="acrx_LesseeOperatingLeaseNoticePeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LesseeOperatingSubleaseDeferredCosts" xlink:label="acrx_LesseeOperatingSubleaseDeferredCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AreaOfRealEstateProperty" xlink:label="us-gaap_AreaOfRealEstateProperty-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseContractualTermAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_CatalentPharmaSolutionsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioForecastMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AreaOfRealEstateProperty-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingSubleaseDeferredCosts-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseTermOfContract-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingLeaseMonthlyRent-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingLeaseAbatedRentPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingLeaseNoticePeriod-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LesseeOperatingLeaseAnnualOverheadFeePayments-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" xlink:href="acrx-20211231.xsd#statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelRXMember" xlink:label="acrx_AcelRXMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CommercialMilestonesValueMaximumAmountAvailable" xlink:label="acrx_CommercialMilestonesValueMaximumAmountAvailable-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentGainLossOnRoyaltyMonetizationArrangement" xlink:label="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EffectiveAnnualInterestRate" xlink:label="acrx_EffectiveAnnualInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_FirstFourCommercialMilestonesMember" xlink:label="acrx_FirstFourCommercialMilestonesMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PercentageOfRoyaltiesAndRightsUnderAgreement" xlink:label="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights" xlink:label="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RoyaltyArrangmentMaximumPayments" xlink:label="acrx_RoyaltyArrangmentMaximumPayments-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SWKMember" xlink:label="acrx_SWKMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="acrx_SWKMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="acrx_FirstFourCommercialMilestonesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="acrx_AcelRXMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_PercentageOfRoyaltiesAndRightsUnderAgreement-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_CommercialMilestonesValueMaximumAmountAvailable-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_RoyaltyArrangmentMaximumPayments-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NetProceedsFromSaleOfFutureRoyalties-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContingentGainLossOnRoyaltyMonetizationArrangement-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_EffectiveAnnualInterestRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" xlink:href="acrx-20211231.xsd#statement-note-11-warrants-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable" xlink:label="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:label="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExercisePriceMember" xlink:label="us-gaap_MeasurementInputExercisePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedDividendRateMember" xlink:label="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputExpectedTermMember" xlink:label="us-gaap_MeasurementInputExpectedTermMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:label="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputSharePriceMember" xlink:label="us-gaap_MeasurementInputSharePriceMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMeasurementInput" xlink:label="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="acrx_November2021FinancingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="acrx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_MeasurementInputTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputSharePriceMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedTermMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputRiskFreeInterestRateMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExercisePriceMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputExpectedDividendRateMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingMeasurementInput-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:href="acrx-20211231.xsd#statement-note-12-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:label="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:label="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseAxis" xlink:label="srt_LitigationCaseAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="srt_LitigationCaseTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LossContingencyNumberOfDefendants" xlink:label="us-gaap_LossContingencyNumberOfDefendants-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="srt_LitigationCaseTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_LitigationCaseAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_LitigationCaseAxis" xlink:to="acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LossContingencyNumberOfDefendants-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" xlink:href="acrx-20211231.xsd#statement-note-13-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ATMAgreementMember" xlink:label="acrx_ATMAgreementMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AggregateOfferingPriceIncreaseDuringPeriod" xlink:label="acrx_AggregateOfferingPriceIncreaseDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AggregateOfferingPriceMaximum" xlink:label="acrx_AggregateOfferingPriceMaximum-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:label="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EmployeeStockPurchasePlanESPPMember" xlink:label="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue" xlink:label="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EquityIncentivePlan2011Member" xlink:label="acrx_EquityIncentivePlan2011Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_EstimatedOfferingCosts" xlink:label="acrx_EstimatedOfferingCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants" xlink:label="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_November2021FinancingWarrantsMember" xlink:label="acrx_November2021FinancingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RegisteredDirectOfferingMember" xlink:label="acrx_RegisteredDirectOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed" xlink:label="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrivatePlacementMember" xlink:label="us-gaap_PrivatePlacementMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_PrivatePlacementMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="acrx_ArmisticeCapitalAndRockSpringsCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="acrx_RegisteredDirectOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="acrx_November2021FinancingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="acrx_ATMAgreementMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="acrx_EquityIncentivePlan2011Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="acrx_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="acrx_EmployeeStockPurchasePlanESPPMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_EstimatedOfferingCosts-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_AggregateOfferingPriceMaximum-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_AggregateOfferingPriceIncreaseDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded-2" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_The2020EquityIncentivePlanMember" xlink:label="acrx_The2020EquityIncentivePlanMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ExecutiveOfficerMember" xlink:label="srt_ExecutiveOfficerMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="acrx_The2020EquityIncentivePlanMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_ExecutiveOfficerMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual" xlink:href="acrx-20211231.xsd#statement-note-17-401k-plan-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContributionsByEmployerToPostemploymentBenefitObligations" xlink:label="acrx_ContributionsByEmployerToPostemploymentBenefitObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage" xlink:label="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContributionsByEmployerToPostemploymentBenefitObligations-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BeforeTaxYear2018Member" xlink:label="acrx_BeforeTaxYear2018Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SubjectToExpirationMember" xlink:label="acrx_SubjectToExpirationMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TaxYears2018To2020Member" xlink:label="acrx_TaxYears2018To2020Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchMember" xlink:label="us-gaap_ResearchMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodAxis" xlink:label="us-gaap_TaxPeriodAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxPeriodDomain" xlink:label="us-gaap_TaxPeriodDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="us-gaap_TaxPeriodDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxPeriodAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="acrx_BeforeTaxYear2018Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxPeriodAxis" xlink:to="acrx_TaxYears2018To2020Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_ResearchMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="acrx_SubjectToExpirationMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" xlink:href="acrx-20211231.xsd#statement-note-19-subsequent-events-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AcelrxCommonStockMember" xlink:label="acrx_AcelrxCommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations" xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare" xlink:label="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired" xlink:label="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash" xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber" xlink:label="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LowellTherapeuticsMember" xlink:label="acrx_LowellTherapeuticsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoteToFinancialStatementDetailsTextual" xlink:label="acrx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AcquisitionCostsCumulative" xlink:label="us-gaap_AcquisitionCostsCumulative-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BusinessAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="acrx_LowellTherapeuticsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="acrx_AcelrxCommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_BalanceSheetLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_OtherAssetsMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AcquisitionCostsCumulative-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityAdditions" xlink:label="acrx_ContractWithCustomerLiabilityAdditions" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod" xlink:label="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ContractWithCustomerLiabilityAdditions" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiability-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:href="acrx-20211231.xsd#statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DebtInstrumentUnamortizedEotFee" xlink:label="acrx_DebtInstrumentUnamortizedEotFee-n8" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:label="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtMaturitiesRepaymentsOfInterest" xlink:label="acrx_LongTermDebtMaturitiesRepaymentsOfInterest-n8" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongTermDebtTotalMinimumPayments" xlink:label="acrx_LongTermDebtTotalMinimumPayments-3" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:label="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NotesPayableGross" xlink:label="acrx_NotesPayableGross" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:label="acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LongTermDebtTotalMinimumPayments-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LongTermDebtMaturitiesRepaymentsOfInterest-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NotesPayableGross" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DebtInstrumentUnamortizedEotFee-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebt-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LongTermDebtNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" xlink:href="acrx-20211231.xsd#statement-note-9-leases-operating-lease-costs-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GainLossOnTerminationOfSublease" xlink:label="acrx_GainLossOnTerminationOfSublease-n8" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-9-leases-operating-lease-costs-details" xlink:label="acrx_statement-statement-note-9-leases-operating-lease-costs-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnTerminationOfLease" xlink:label="us-gaap_GainLossOnTerminationOfLease-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-9-leases-operating-lease-costs-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseCost" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_GainLossOnTerminationOfLease-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SubleaseIncome-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_GainLossOnTerminationOfSublease-n8" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LeaseCost-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:href="acrx-20211231.xsd#statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:label="acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability-1" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-n8" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:href="acrx-20211231.xsd#statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyalties-4" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet-5" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:label="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties-n9" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized" xlink:label="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized-n9" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:label="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyalties-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NetProceedsFromSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized-n9" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties-n9" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="us-gaap_CostOfSalesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_CostOfSalesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" xlink:href="acrx-20211231.xsd#statement-consolidated-balance-sheets" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:label="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="us-gaap_AccountsReceivableNetCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="us-gaap_LongTermDebtCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="us-gaap_LongTermDebtNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="us-gaap_ShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_ShortTermInvestments" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InventoryNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LongTermDebtNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:href="acrx-20211231.xsd#statement-consolidated-statements-of-comprehensive-loss" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractAndOtherCollaborationMember" xlink:label="acrx_ContractAndOtherCollaborationMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:label="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="us-gaap_CostOfGoodsAndServicesSold" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="us-gaap_CostsAndExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentIncomeNet" xlink:label="us-gaap_InvestmentIncomeNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingCostsAndExpensesAbstract" xlink:label="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_ContractAndOtherCollaborationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingCostsAndExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_CostsAndExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingCostsAndExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNet" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax-3" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:href="acrx-20211231.xsd#statement-consolidated-statements-of-cash-flows" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:label="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GainOnTerminationOfSublease" xlink:label="acrx_GainOnTerminationOfSublease" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LeaseholdPaidWithNotePayable" xlink:label="acrx_LeaseholdPaidWithNotePayable" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LowellsIntellectualPropertyMember" xlink:label="acrx_LowellsIntellectualPropertyMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization" xlink:label="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization-n8" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NoncashInterestExpenseRecognized" xlink:label="acrx_NoncashInterestExpenseRecognized" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:label="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:label="acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis" xlink:label="us-gaap_AssetAcquisitionAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain" xlink:label="us-gaap_AssetAcquisitionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="us-gaap_IncomeTaxesPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:label="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown" xlink:label="us-gaap_InventoryWriteDown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="us-gaap_PaymentsToAcquireShortTermInvestments-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:label="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfWarrants" xlink:label="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="us-gaap_RepaymentsOfLongTermDebt-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="us-gaap_AssetAcquisitionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AssetAcquisitionAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetAcquisitionAxis" xlink:to="acrx_LowellsIntellectualPropertyMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acrx_NoncashInterestExpenseRecognized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_InventoryWriteDown" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInInventories-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-1" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities-1" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingLeaseLiability-1" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability-1" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireShortTermInvestments-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireProductiveAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_RepaymentsOfLongTermDebt-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfWarrants" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-4" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_InterestPaidNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaidNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_WriteoffOfRightofuseAssetAndLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_GainOnTerminationOfSublease" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="acrx_LeaseholdPaidWithNotePayable" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange1Member" xlink:label="acrx_ExercisePriceRange1Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange2Member" xlink:label="acrx_ExercisePriceRange2Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange3Member" xlink:label="acrx_ExercisePriceRange3Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange4Member" xlink:label="acrx_ExercisePriceRange4Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange5Member" xlink:label="acrx_ExercisePriceRange5Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ExercisePriceRange6Member" xlink:label="acrx_ExercisePriceRange6Member" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:label="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="acrx_ExercisePriceRange1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="acrx_ExercisePriceRange2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="acrx_ExercisePriceRange3Member" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="acrx_ExercisePriceRange4Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="acrx_ExercisePriceRange5Member" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="acrx_ExercisePriceRange6Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" xlink:href="acrx-20211231.xsd#statement-consolidated-statements-of-stockholders-deficit" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:label="us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:href="acrx-20211231.xsd#statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AguettantMember" xlink:label="acrx_AguettantMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CustomerAMember" xlink:label="acrx_CustomerAMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CustomerBMember" xlink:label="acrx_CustomerBMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DoDMember" xlink:label="acrx_DoDMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_GrunenthalMember" xlink:label="acrx_GrunenthalMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_WholesalerAMember" xlink:label="acrx_WholesalerAMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:label="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis" xlink:label="srt_MajorCustomersAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="srt_NameOfMajorCustomerDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="us-gaap_AccountsReceivableMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="us-gaap_ConcentrationRiskPercentage1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="us-gaap_CustomerConcentrationRiskMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:label="us-gaap_SalesRevenueNetMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="srt_NameOfMajorCustomerDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_SalesRevenueNetMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_CustomerConcentrationRiskMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_MajorCustomersAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="acrx_AguettantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_AccountsReceivableMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="acrx_CustomerAMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="acrx_GrunenthalMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="acrx_CustomerBMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="acrx_DoDMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_MajorCustomersAxis" xlink:to="acrx_WholesalerAMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" xlink:href="acrx-20211231.xsd#statement-note-3-inventories-net-inventory-components-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-3-inventories-net-inventory-components-details" xlink:label="acrx_statement-statement-note-3-inventories-net-inventory-components-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet" xlink:label="us-gaap_InventoryNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterialsNetOfReserves" xlink:label="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-3-inventories-net-inventory-components-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryRawMaterialsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InventoryNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:href="acrx-20211231.xsd#statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ComputerEquipmentAndSoftwareMember" xlink:label="acrx_ComputerEquipmentAndSoftwareMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_LaboratoryEquipmentMember" xlink:label="acrx_LaboratoryEquipmentMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ToolingMember" xlink:label="acrx_ToolingMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:label="acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="acrx_LaboratoryEquipmentMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_LeaseholdImprovementsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="acrx_ComputerEquipmentAndSoftwareMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_ConstructionInProgressMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="acrx_ToolingMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_FurnitureAndFixturesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-option-activity-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_TimebasedStockOptionMember" xlink:label="acrx_TimebasedStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="acrx_TimebasedStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:href="acrx-20211231.xsd#statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:label="acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:label="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="acrx_RSUsESPPAndEmployeeStockOptionsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:href="acrx-20211231.xsd#statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AccruedDeferredRevenueCurrent" xlink:label="acrx_AccruedDeferredRevenueCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:label="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:label="acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_AccruedProductReturnsAndSalesAllowancesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_AccruedDeferredRevenueCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:label="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:label="acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsGross-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:label="acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:label="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:href="acrx-20211231.xsd#statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:label="acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:label="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_MarketableSecuritiesMember" xlink:label="acrx_MarketableSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsMember" xlink:label="us-gaap_CashAndCashEquivalentsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember" xlink:label="us-gaap_CashMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperAtCarryingValue" xlink:label="us-gaap_CommercialPaperAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="us-gaap_InvestmentTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_InvestmentTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_CashAndCashEquivalentsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CashMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="acrx_MarketableSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Cash" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommercialPaperAtCarryingValue" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:href="acrx-20211231.xsd#statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContingentPutOptionLiabilityMember" xlink:label="acrx_ContingentPutOptionLiabilityMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_USGovernmentAgencySecuritiesMember" xlink:label="acrx_USGovernmentAgencySecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:label="acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByAssetClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_MoneyMarketFundsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel1Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel2Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueInputsLevel3Member" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CommercialPaperMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="acrx_USGovernmentAgencySecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_CorporateDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="acrx_ContingentPutOptionLiabilityMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:href="acrx-20211231.xsd#statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractAndOtherCollaborationMember" xlink:label="acrx_ContractAndOtherCollaborationMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ContractAndOtherRevenueMember" xlink:label="acrx_ContractAndOtherRevenueMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_DSUVIAMember" xlink:label="acrx_DSUVIAMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_NonCashRoyaltyMember" xlink:label="acrx_NonCashRoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_ZALVISOMember" xlink:label="acrx_ZALVISOMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:label="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember" xlink:label="us-gaap_ProductMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyMember" xlink:label="us-gaap_RoyaltyMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_DSUVIAMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_ZALVISOMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_ProductMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_LicenseMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_NonCashRoyaltyMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="us-gaap_RoyaltyMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_ContractAndOtherRevenueMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="acrx_ContractAndOtherCollaborationMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:href="acrx-20211231.xsd#statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:label="acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod-n9" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:href="acrx-20211231.xsd#statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:type="extended">
    <link:loc xlink:href="acrx-20211231.xsd#acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:label="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:type="locator"/>
    <link:loc xlink:href="acrx-20211231.xsd#acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:label="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance" xlink:label="us-gaap_ValuationAllowancesAndReservesBalance-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:label="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions" xlink:label="us-gaap_ValuationAllowancesAndReservesDeductions-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain" xlink:label="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:label="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesDeductions-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ValuationAllowancesAndReservesBalance-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898811896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 07, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001427925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ACELRX PHARMACEUTICALS INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-35068<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-2193603<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">25821 Industrial Boulevard, Suite 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Hayward<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94545<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">216-3500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACRX<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 161,163,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">146,949,320<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">WithumSmith+Brown, PC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=acrx_OUMCoLLPMember', window );">OUM &amp; CO. LLP [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">OUM & CO. LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">San Francisco, California<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=acrx_OUMCoLLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=acrx_OUMCoLLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670899447480">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 12,663<span></span>
</td>
<td class="nump">$ 27,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">38,967<span></span>
</td>
<td class="nump">15,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">160<span></span>
</td>
<td class="nump">635<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories, net</a></td>
<td class="nump">1,111<span></span>
</td>
<td class="nump">1,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,588<span></span>
</td>
<td class="nump">1,683<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">55,489<span></span>
</td>
<td class="nump">46,830<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">4,302<span></span>
</td>
<td class="nump">3,150<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,928<span></span>
</td>
<td class="nump">15,659<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">2,174<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total Assets</a></td>
<td class="nump">77,893<span></span>
</td>
<td class="nump">66,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">2,121<span></span>
</td>
<td class="nump">2,737<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other liabilities</a></td>
<td class="nump">6,524<span></span>
</td>
<td class="nump">5,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Long-term debt, current portion</a></td>
<td class="nump">8,796<span></span>
</td>
<td class="nump">8,735<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="nump">1,118<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,509<span></span>
</td>
<td class="nump">17,635<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">5,007<span></span>
</td>
<td class="nump">13,140<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue, net of current portion</a></td>
<td class="nump">1,151<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">3,750<span></span>
</td>
<td class="nump">2,606<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent', window );">Liability related to the sale of future royalties</a></td>
<td class="nump">85,288<span></span>
</td>
<td class="nump">88,365<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">113,786<span></span>
</td>
<td class="nump">122,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; Deficit:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value&#8212;200,000,000 shares authorized as of December 31, 2021 and 2020; 136,819,647 and 98,812,008 shares issued and outstanding as of December 31, 2021 and 2020, respectively</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">437,554<span></span>
</td>
<td class="nump">382,637<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(473,584)<span></span>
</td>
<td class="num">(438,485)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; deficit</a></td>
<td class="num">(35,893)<span></span>
</td>
<td class="num">(55,750)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total Liabilities and Stockholders&#8217; Deficit</a></td>
<td class="nump">$ 77,893<span></span>
</td>
<td class="nump">$ 66,295<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability related to sale of future royalities classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897427080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">136,819,647<span></span>
</td>
<td class="nump">98,812,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">136,819,647<span></span>
</td>
<td class="nump">98,812,008<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898528936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,818<span></span>
</td>
<td class="nump">$ 5,416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingCostsAndExpensesAbstract', window );"><strong>Operating costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">3,753<span></span>
</td>
<td class="nump">6,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,095<span></span>
</td>
<td class="nump">4,017<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">30,935<span></span>
</td>
<td class="nump">36,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating costs and expenses</a></td>
<td class="nump">38,783<span></span>
</td>
<td class="nump">46,379<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(35,965)<span></span>
</td>
<td class="num">(40,963)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(2,291)<span></span>
</td>
<td class="num">(3,305)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Interest income and other income, net</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest income on liability related to sale of future royalties</a></td>
<td class="nump">3,038<span></span>
</td>
<td class="nump">3,310<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">871<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Net loss before income taxes</a></td>
<td class="num">(35,094)<span></span>
</td>
<td class="num">(40,375)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(35,099)<span></span>
</td>
<td class="num">(40,379)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (35,099)<span></span>
</td>
<td class="num">$ (40,379)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.29)<span></span>
</td>
<td class="num">$ (0.47)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing net loss per share of common stock, basic and diluted &#8211;see Note 15 (in shares)</a></td>
<td class="nump">119,860,266<span></span>
</td>
<td class="nump">85,257,008<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,005<span></span>
</td>
<td class="nump">$ 2,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_ContractAndOtherCollaborationMember', window );">Contract and Other Collaboration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 2,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amoutn of noncash interest income expense on liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingCostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingCostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_ContractAndOtherCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_ContractAndOtherCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898983400">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Deficit - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th" colspan="2"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">79,573,101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 79<span></span>
</td>
<td class="nump">$ 356,609<span></span>
</td>
<td class="num">$ (398,106)<span></span>
</td>
<td class="num">$ (41,418)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested (in shares)</a></td>
<td class="nump">254,684<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet', window );">Tax payments related to shares withheld for restricted stock units vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(86)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock in connection with equity financings (in shares)</a></td>
<td class="nump">18,644,095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">21,318<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">21,337<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase (in shares)</a></td>
<td class="nump">340,128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">372<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(40,379)<span></span>
</td>
<td class="num">(40,379)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">98,812,008<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 98<span></span>
</td>
<td class="nump">382,637<span></span>
</td>
<td class="num">(438,485)<span></span>
</td>
<td class="num">(55,750)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">4,609<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">4,609<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested (in shares)</a></td>
<td class="nump">488,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures', window );">Restricted stock units vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet', window );">Tax payments related to shares withheld for restricted stock units vested</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Net proceeds from issuance of common stock in connection with equity financings (in shares)</a></td>
<td class="nump">37,201,562<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">44,678<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">44,716<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock upon ESPP purchase (in shares)</a></td>
<td class="nump">297,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock upon ESPP purchase</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">301<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(35,099)<span></span>
</td>
<td class="num">(35,099)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Net proceeds from issuance of warrants in connection with equity financings</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 5,562<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options (in shares)</a></td>
<td class="nump">19,403<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,403<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">136,819,647<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 137<span></span>
</td>
<td class="nump">$ 437,554<span></span>
</td>
<td class="num">$ (473,584)<span></span>
</td>
<td class="num">$ (35,893)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="6"></td></tr>
<tr><td colspan="6"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123466302&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670900310232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (35,099)<span></span>
</td>
<td class="num">$ (40,379)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization', window );">Non-cash royalty revenue related to royalty monetization</a></td>
<td class="num">(83)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NoncashInterestExpenseRecognized', window );">Non-cash interest income on liability related to royalty monetization</a></td>
<td class="num">(3,038)<span></span>
</td>
<td class="num">(3,310)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">1,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Non-cash interest expense related to debt financing</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">1,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">4,609<span></span>
</td>
<td class="nump">4,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory impairment charge</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">712<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="num">(138)<span></span>
</td>
<td class="num">(344)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">475<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(295)<span></span>
</td>
<td class="nump">957<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(908)<span></span>
</td>
<td class="nump">661<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">1,016<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="nump">79<span></span>
</td>
<td class="num">(638)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(447)<span></span>
</td>
<td class="num">(886)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">1,188<span></span>
</td>
<td class="num">(3,195)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,002)<span></span>
</td>
<td class="num">(38,505)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(1,827)<span></span>
</td>
<td class="num">(1,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchase of investments</a></td>
<td class="num">(70,459)<span></span>
</td>
<td class="num">(44,611)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of investments</a></td>
<td class="nump">2,996<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of investments</a></td>
<td class="nump">43,988<span></span>
</td>
<td class="nump">80,605<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(26,123)<span></span>
</td>
<td class="nump">34,139<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Payment of long-term debt</a></td>
<td class="num">(8,833)<span></span>
</td>
<td class="num">(4,667)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Net proceeds from issuance of common stock in connection with equity financings</a></td>
<td class="nump">44,716<span></span>
</td>
<td class="nump">21,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Net proceeds from issuance of warrants in connection with equity financings</a></td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Net proceeds from issuance of common stock through equity plans</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Tax payments related to shares withheld for restricted stock units vested</a></td>
<td class="num">(249)<span></span>
</td>
<td class="num">(86)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">41,514<span></span>
</td>
<td class="nump">16,956<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS</a></td>
<td class="num">(14,611)<span></span>
</td>
<td class="nump">12,590<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS &#8212;Beginning of year</a></td>
<td class="nump">27,274<span></span>
</td>
<td class="nump">14,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations', window );">CASH, CASH EQUIVALENTS &#8212;End of year</a></td>
<td class="nump">12,663<span></span>
</td>
<td class="nump">27,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">1,595<span></span>
</td>
<td class="nump">2,269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes paid (refunded)</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(347)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable', window );">Purchases of property and equipment in accounts payable and accrued expenses</a></td>
<td class="nump">1,095<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses', window );">Asset acquisition costs in accounts payable and accrued expenses</a></td>
<td class="nump">1,087<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Establishment of right-of-use asset and lease liability</a></td>
<td class="nump">4,669<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_WriteoffOfRightofuseAssetAndLeaseLiability', window );">Write-off of right-of-use asset and lease liability</a></td>
<td class="num">(3,128)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_GainOnTerminationOfSublease', window );">Gain on termination of sublease</a></td>
<td class="nump">522<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LeaseholdPaidWithNotePayable', window );">Leasehold improvements paid with note payable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">326<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=acrx_LowellsIntellectualPropertyMember', window );">Lowell&#8217;s Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Asset acquisition costs</a></td>
<td class="num">$ (821)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of asset acquisition costs in accounts payable and accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_GainOnTerminationOfSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gain on termination of sublease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_GainOnTerminationOfSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LeaseholdPaidWithNotePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents leasehold paid with note payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LeaseholdPaidWithNotePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash royalty revenue recognized in connection to royalty monetization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NoncashInterestExpenseRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash interest expense recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NoncashInterestExpenseRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents purchases of property and equipment that were acquired through accounts payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_WriteoffOfRightofuseAssetAndLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount write-off of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_WriteoffOfRightofuseAssetAndLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=acrx_LowellsIntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=acrx_LowellsIntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897331928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">1.</em> Organization and Summary of Significant Accounting Policies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The Company </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on <em style="font: inherit;"> July 13, 2005 </em>as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. The Company&#8217;s operations are based in Hayward, California.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA&#174;<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>(known as DZUVEO&#174; in Europe) and Zalviso&#174; are<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. On <em style="font: inherit;"> November 2, 2018, </em>the U.S. Food and Drug Administration, or FDA, approved DSUVIA for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The commercial launch of DSUVIA in the United States occurred in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2019.</em> In <em style="font: inherit;"> June 2018, </em>the European Commission, or EC, granted marketing approval of DZUVEO for the management of acute moderate to severe pain in adults in medically monitored settings. AcelRx is further developing a distribution capability and commercial organization to continue to market and sell DSUVIA in the United States. In geographies where AcelRx decides <em style="font: inherit;">not</em> to commercialize products by itself, the Company <em style="font: inherit;"> may </em>seek to out-license commercialization rights. The Company currently intends to commercialize and promote DSUVIA/DZUVEO outside the United States with <em style="font: inherit;">one</em> or more strategic partners, and, in <em style="font: inherit;"> July 2021, </em>entered into a License and Commercialization Agreement with Laboratoire Aguettant, or Aguettant, for Aguettant to commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom (see Note <em style="font: inherit;">6.</em> &#8220;Out-License Agreements&#8212;DZUVEO&#8221;<i> </i>below). The timing of the resubmission of the Zalviso new drug application, or NDA, is in part dependent upon the finalization of the FDA&#8217;s new opioid approval guidelines and process. AcelRx intends to seek regulatory approval for Zalviso in the United States and, if successful, potentially promote Zalviso either by itself or with strategic partners. Zalviso is approved in Europe and was commercialized by Gr&#252;nenthal GmbH, or Gr&#252;nenthal, through <em style="font: inherit;"> May 12, 2021 (</em>see <i>Termination of Gr</i>&#252;<i>nenthal Agreements</i> below). In <em style="font: inherit;"> July 2021, </em>the Company also entered into a separate License and Commercialization Agreement with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">3</em> mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">50</em> mcg/ml phenylephrine hydrochloride for injection (see Note <em style="font: inherit;">5.</em> &#8220;In-License Agreement&#8221; below). On <em style="font: inherit;"> January 7, 2022, </em>the Company closed the definitive merger agreement dated as of <em style="font: inherit;"> November 14, 2021, </em>or the Merger Agreement, to acquire Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note <em style="font: inherit;">19.</em> &#8220;Subsequent Events&#8221; below).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;"> December 31, 2020, </em>the Company had cash, cash equivalents and short-term investments of $51.6 million and $42.9 million, respectively. Based on the Company&#8217;s current operating plans and projections, the Company expects that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least <em style="font: inherit;">one</em> year from the date this Annual Report on Form <em style="font: inherit;">10</em>-K is filed with the United States Securities and Exchange Commission, or SEC. Although Zalviso was approved for sale in Europe on <em style="font: inherit;"> September 18, 2015, </em>the Company sold the majority of the royalty rights and certain commercial sales milestones it is entitled to receive under the Amended License Agreement (defined below) with Gr&#252;nenthal to PDL BioPharma, Inc., or PDL, in a transaction referred to as the Royalty Monetization. On <em style="font: inherit;"> August 31, 2020, </em>PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK. In consideration of the termination of the Amended License Agreement, under the Royalty Monetization, the Company must use commercially reasonable efforts to negotiate a replacement license agreement with a <em style="font: inherit;">third</em> party.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Termination of Gr</span></i>&#252;<i><span style="text-decoration: underline; ">nenthal Agreements </span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 16, 2013, </em>AcelRx and Gr&#252;nenthal entered into a Collaboration and License Agreement, or the License Agreement, which was amended effective <em style="font: inherit;"> July 17, 2015 </em>and <em style="font: inherit;"> September 20, 2016, </em>or the Amended License Agreement, which granted Gr&#252;nenthal rights to commercialize the Zalviso PCA system, or the Product, in the <em style="font: inherit;">28</em> European Union, or EU, member states, at the time of the agreement, plus Switzerland, Liechtenstein, Iceland, Norway and Australia (collectively, the Zalviso Territory) for human use in pain treatment within, or dispensed by, hospitals, hospices, nursing homes and other medically supervised settings, (collectively, the Field). In <em style="font: inherit;"> September 2015, </em>the EC granted marketing approval for the marketing authorization application, or MAA, previously submitted to the EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. On <em style="font: inherit;"> December 16, 2013, </em>AcelRx and Gr&#252;nenthal entered into a Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. Under the MSA, the Company exclusively manufactured and supplied the Product to Gr&#252;nenthal for the Field in the Zalviso Territory. On <em style="font: inherit;"> July 22, 2015, </em>the Company and Gr&#252;nenthal amended the MSA, or the Amended MSA, effective as of <em style="font: inherit;"> July 17, 2015. </em>The Amended MSA and the Amended License Agreement are referred to as the Gr&#252;nenthal Agreements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 18, 2020, </em>the Company received a notice from Gr&#252;nenthal that it had exercised its right to terminate the Gr&#252;nenthal Agreements, effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#252;nenthal Agreements were extended to <em style="font: inherit;"> May 12, 2021 </em>to enable Gr&#252;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#252;nenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on <em style="font: inherit;"> May 12, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Presentation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Reclassifications </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the amounts reported in the Consolidated Balance Sheets as deferred revenue, current portion and liability related to the sale of future royalties, current portion have been reclassified to accrued and other liabilities at <em style="font: inherit;"> December 31, 2020, </em>and the amount reported as an inventory impairment charge in the Consolidated Statements of Cash Flows was recorded as other in the year ended <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;"/></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Principles of Consolidation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiary, ARPI&#160;LLC, which was formed in <em style="font: inherit;"> September 2015 </em>for the sole purpose of facilitating the Royalty Monetization with PDL of the expected royalty stream and milestone payments due from the sales of Zalviso in the European Union by its commercial partner, Gr&#252;nenthal, pursuant to the Amended License Agreement. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note <em style="font: inherit;">10</em> &#8220;Liability Related to Sale of Future Royalties&#8221; for additional information.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management believes its most significant accounting estimates relate to revenue recognition, inventory valuation and the liability related to the sale of future royalties. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cash, Cash Equivalents and Short-Term Investments </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all highly liquid investments with an original maturity (at date of purchase) of <em style="font: inherit;">three</em> months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All marketable securities are classified as available-for-sale and consist of commercial paper, U.S. government sponsored enterprise debt securities and corporate debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. The Company&#8217;s investments are subject to a periodic impairment review for other-than-temporary declines in fair value. The Company&#8217;s review includes the consideration of the cause of the impairment including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss in the amount of such decline.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosure of fair value measurements as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level I&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level II&#8212;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level III&#8212;Unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity for the related assets or liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Segment Information </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company operates in a single segment, the development and commercialization of product candidates and products for the treatment of pain. The Company&#8217;s product sales revenue consists of sales of DSUVIA in the United States and, through <em style="font: inherit;"> May 2021, </em>sales of Zalviso in Europe by Gr&#252;nenthal. The Company&#8217;s contract and collaboration revenue consists of non-cash royalty revenue, royalty revenue, and other revenue under the Gr&#252;nenthal Agreements and license revenue under the DZUVEO Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Risk </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company invests cash that is currently <em style="font: inherit;">not</em> being used for operational purposes in accordance with its investment policy in debt securities of U.S. government sponsored agencies, commercial paper and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company relies on a single <em style="font: inherit;">third</em>-party supplier for the supply of sufentanil, the active pharmaceutical ingredient in DSUVIA and Zalviso, and various sole-source <em style="font: inherit;">third</em>-party contract manufacturer organizations to manufacture the DSUVIA SDA.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">DSUVIA&#160;sales are concentrated with the DoD and with a limited number of wholesalers in the United States. Zalviso was sold in Europe by Gr&#252;nenthal through <em style="font: inherit;"> May 2021. </em>In <em style="font: inherit;"> July 2021, </em>Aguettant was granted an exclusive license to commercialize DZUVEO in Europe. DZUVEO sales in Europe by Aguettant have <em style="font: inherit;">not</em> commenced as of <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenue and accounts receivable have been concentrated with these customers.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues from customers that accounted for <em style="font: inherit;">10%</em> or more of our total revenues during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Year Ended December 31,</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Percent of Total Revenue</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Aguettant</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">61.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gr&#252;nenthal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">DoD</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Wholesaler A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Accounts Receivable, net</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The need for a bad debt allowance is evaluated each reporting period based on the Company&#8217;s assessment of the credit worthiness of its customers or any other potential circumstances that could result in bad debt.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company believes that the entire accounts receivable balance as of <em style="font: inherit;"> December 31, 2021 </em>is collectible and there was <em style="font: inherit;">no</em> bad debt allowance provided as of <em style="font: inherit;"> December 31, 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable, net from customers that accounted for <em style="font: inherit;">10%</em> or more of our total accounts receivable balance as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Percent of Accounts Receivable, Net</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer B</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Inventories, net </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method for all inventories. Inventory includes the cost of the active pharmaceutical ingredients, or API, raw materials and <em style="font: inherit;">third</em>-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are allocated to the appropriate cost pool and then absorbed into inventory based on the units produced or distributed, assuming normal capacity, in the applicable period. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company's policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The Company periodically evaluates the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or net realizable value approach as that used to value the inventory.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Property and Equipment, net </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:c81618752">three</span> to <span style="-sec-ix-hidden:c81618753">five</span> years. Leasehold improvements are amortized over the shorter of the estimated useful life of the improvements or the remaining lease term. Expenditures for repairs and maintenance, which do <em style="font: inherit;">not</em> extend the useful life of the property and equipment, are expensed as incurred. Upon retirement, the asset cost and related accumulated depreciation are relieved from the accompanying Consolidated Balance Sheets. Gains and losses associated with dispositions are reflected as a component of interest income and other income, net in the accompanying Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Impairment of Long-Lived Assets </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. For example, if the Company is <em style="font: inherit;">not</em> successful in its commercialization of DSUVIA, and if approved, Zalviso, purchased equipment and manufacturing-related facility improvements the Company has made at its contract manufacturers could become impaired. The Company <em style="font: inherit;"> may </em>determine that it is <em style="font: inherit;">no</em> longer probable that the Company will realize the future economic benefit associated with the costs of these assets through future manufacturing activities, and if so, the Company would record an impairment charge associated with these assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contingent put option</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The contingent put option associated with the Company&#8217;s Loan Agreement with Oxford is recorded as a liability. Changes in the fair value of the contingent put option are recognized as interest income and other income (expense), net in the Consolidated Statements of Operations. For further discussion, see Note <em style="font: inherit;">8</em> &#8220;Long-Term Debt&#8221;.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"> <b><i> </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company follows the provisions of ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>. At the inception of an arrangement, the Company determines whether the arrangement is, or contains, a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically <em style="font: inherit;">not</em> readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset <em style="font: inherit;"> may </em>be required for items such as initial direct costs paid or incentives received.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the Consolidated Balance Sheets as operating lease right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Revenue from Contracts with Customers </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company follows the provisions of Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">606,</em> <i>Revenue from Contracts with Customers</i>. This guidance provides a unified model to determine how revenue is recognized. The Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company sells its products primarily through wholesale and specialty distributors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Product sales revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company sells its product primarily through distributors. Revenues from product sales are recognized when distributors obtain control of the Company&#8217;s product, which occurs at a point in time, upon delivery to such distributors. These distributors subsequently resell the product to certified medically supervised healthcare settings. In addition to distribution agreements with these customers, the Company enters into arrangements with group purchasing organizations, or GPOs, and other certified medically supervised healthcare settings that provide for privately negotiated discounts with respect to the purchase of its products. For revenue recognition under bill-and-hold arrangements, wherein the customer agrees to buy product from the Company but requests delivery at a later date, the Company deems that control passes to the customer when the product is ready for delivery. The Company recognizes revenue under these types of arrangements when a signed agreement is in place, the transaction is billable, the customer has significant risk and rewards for the product and the ability to direct the asset, the product has been set aside specifically for the customer, and the product cannot be redirected to another customer. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, government rebates, returns, distribution fees, GPO fees and product returns.&#160;Variable consideration is recorded at the time product sales are recognized resulting in a reduction in product revenue. The amount of variable consideration that is included in the transaction price <em style="font: inherit;"> may </em>be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will <em style="font: inherit;">not</em> occur in a future period. Variable consideration is estimated using the most-likely amount method, which is the single-most likely outcome under a contract and is typically at the stated contractual rate.&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method under ASC Topic <em style="font: inherit;">606</em> for relevant factors. These factors include current contractual and statutory requirements, specific known market events and trends, industry data, and/or forecasted customer buying and payment patterns. Actual amounts of consideration ultimately received <em style="font: inherit;"> may </em>differ from the Company&#8217;s estimates.&#160;If actual results vary materially from the Company&#8217;s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These estimates include:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Chargebacks</span> &#8211; The Company&#8217;s customers subsequently resell its product to qualified healthcare providers. In addition to distribution agreements with customers, the Company enters into arrangements with qualified healthcare providers that provide discounts with respect to the purchase of its product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue-related accrued liabilities on the Consolidated Balance Sheets. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by customers, and the Company issues credits for such amounts generally within a few weeks of the customer's notification to the Company of the resale. Reserves for chargebacks consists of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period end that the Company expects will be sold to the qualified healthcare providers, and chargebacks for units that the Company&#8217;s customers have sold to the qualified healthcare providers, but for which credits have <em style="font: inherit;">not</em> been issued.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Government Rebates</span> &#8211; The Company is subject to discount obligations under state Medicaid programs. The Company estimates its Medicaid rebates, and reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued liabilities on the Consolidated Balance Sheet.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Returns</span> &#8211;<i> </i>The Company allows its distributors to return product for credit <em style="font: inherit;">6</em> months prior to, and up to <em style="font: inherit;">12</em> months after, the product expiration date. As such, there <em style="font: inherit;"> may </em>be a significant period of time between the time the product is shipped and the time the credit is issued on returned product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Distribution Fees</span> &#8211;<i> </i>Distribution fees include fees paid to certain customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">GPO Fees</span><i> </i>&#8211; The Company pays administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs&#8217; members.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Trade Discounts and Allowances</span> - The Company provides its customers with discounts which include early payment incentives that are explicitly stated in its contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company believes its estimated allowances for chargebacks, government rebates and product returns require a high degree of judgment and are subject to change based on its limited experience and certain quantitative and qualitative factors. The Company believes its estimated allowances for distribution fees, GPO fees and trade discounts and allowances do <em style="font: inherit;">not</em> require a high degree of judgment because the amounts are settled within a relatively short period of time. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. Changes in product revenue allowance estimates could materially affect the Company&#8217;s results of operations and financial position.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Contract and other collaboration revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company generates revenue from collaboration agreements. These agreements typically include payments for upfront signing or license fees, cost reimbursements for development and manufacturing services, milestone payments, product sales, and royalties on licensee&#8217;s future product sales. Product sales related revenue under these collaboration agreements is classified as product sales revenue, while other revenue generated from collaboration agreements is classified as contract and other collaboration revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Performance Obligations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic <em style="font: inherit;">606.</em> The Company&#8217;s performance obligations include delivering product to its distributors, commercialization license rights, development services, services associated with the regulatory approval process, joint steering committee services, demonstration devices, manufacturing services, material rights for discounts on manufacturing services, and product supply.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s or the Company&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. If the Company is entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Transaction Price</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has both fixed and variable consideration. Variable consideration for product revenue is described as Net product sales in the Consolidated Statements of Operations. For collaboration agreements, non-refundable upfront fees and product supply selling prices are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would <em style="font: inherit;">not</em> occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are <em style="font: inherit;">not</em> within the control of the Company, such as approvals from regulators, are <em style="font: inherit;">not</em> considered probable of being achieved until those approvals are received.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Allocation of Consideration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights and material rights for discounts on manufacturing services are calculated using an income approach model and can include the following key assumptions: the development timeline, sales forecasts, costs of product sales, commercialization expenses, discount rate, the time which the manufacturing services are expected to be performed, and probabilities of technical and regulatory success. For all other performance obligations, the Company uses a cost-plus margin approach.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Timing of Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant management judgment is required to determine the level of effort required under collaboration arrangements and the period over which the Company expects to complete its performance obligations under the arrangement. The Company estimates the performance period or measure of progress at the inception of the arrangement and re-evaluates it each reporting period. This re-evaluation <em style="font: inherit;"> may </em>shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer, and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cost of Goods Sold </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cost of goods sold for product revenue includes <em style="font: inherit;">third</em> party manufacturing costs, shipping and handling costs, and indirect overhead costs associated with production and distribution which are allocated to the appropriate cost pool and recognized when revenue is recognized. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Gr&#252;nenthal Agreements, the Company sold Zalviso to Gr&#252;nenthal at predetermined, contractual transfer prices that were less than the direct costs of manufacturing and recognized indirect costs as period costs where they were in excess of normal capacity and <em style="font: inherit;">not</em> recoverable on a lower of cost or net realizable value basis. Cost of goods sold for Zalviso shipped to Gr&#252;nenthal included the inventory costs of API, <em style="font: inherit;">third</em>-party contract manufacturing costs, packaging and distribution costs, shipping, handling and storage costs, depreciation and costs of the employees involved with production.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research and Development Expenses </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock-Based Compensation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compensation expense for all stock-based payment awards made to employees and directors, including employee stock options and restricted stock units related to the <em style="font: inherit;">2020</em> Equity Incentive Plan, or <em style="font: inherit;">2020</em> EIP, the <em style="font: inherit;">2011</em> Equity Incentive Plan, or <em style="font: inherit;">2011</em> EIP, and employee share purchases related to the Amended and Restated <em style="font: inherit;">2011</em> Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. The Company applies the graded-vesting attribution method to awards with market conditions that include graded-vesting features. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. The expected term, which represents the period of time that options granted are expected to be outstanding, is derived by analyzing the historical experience of similar awards, giving consideration to the contractual terms of the stock&#8209;based awards, vesting schedules and expectations of future employee behavior. Expected volatilities are estimated using the historical stock price performance over the expected term of the option, which are adjusted as necessary for any other factors which <em style="font: inherit;"> may </em>reasonably affect the volatility of AcelRx&#8217;s stock in the future. The risk&#8209;free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company recognizes forfeitures when they occur and does <em style="font: inherit;">not</em> anticipate paying dividends in the near future.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Warrants Issued in Connection with Financings</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company <em style="font: inherit;"> may </em>need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Restructuring Costs</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> March 16, 2020, </em>in connection with entering into the Co-Promotion Agreement, the Company initiated a reduction in headcount, designed to eliminate the overlap with the Tetraphase commercial team in order to more efficiently commercialize DSUVIA alongside the Tetraphase commercial team and reduce operating expenses. The Company eliminated 30 positions, primarily within the commercial organization. For the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company incurred and paid $0.5 million in employee termination benefits related to this restructuring. The headcount reduction was completed in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> There were <em style="font: inherit;">no</em> such restructuring costs for the year ended <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;"/></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i/></b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Non-Cash Interest Income (Expense) on Liability Related to Sale of Future Royalties</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> September 2015, </em>the Company sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Gr&#252;nenthal to PDL for gross proceeds of $65.0 million. Gr&#252;nenthal terminated the Gr&#252;nenthal Agreements effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#252;nenthal Agreements were extended to <em style="font: inherit;"> May 2021 </em>to enable Gr&#252;nenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Territory reverted back to the Company in <em style="font: inherit;"> May 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Royalty Monetization, the Company has a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Under the relevant accounting guidance, because of the Company&#8217;s significant continuing involvement, the Royalty Monetization is accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and payments made to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $61.2 million of net proceeds the Company received, are amortized as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense, or interest income, as these estimates are updated.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are a number of factors that could materially affect the amount and timing of royalty and milestone payments from Zalviso in Europe, most of which are <em style="font: inherit;">not</em> within the Company&#8217;s control. Such factors include, but are <em style="font: inherit;">not</em> limited to, the success of any future sales and promotion of Zalviso under any New Arrangement, if achieved; changing standards of care; the introduction of competing products; manufacturing or other delays; intellectual property matters; adverse events that result in governmental health authority imposed restrictions on the use of Zalviso; significant changes in foreign exchange rates as the royalties remitted to ARPI LLC are made in U.S. dollars; and other events or circumstances that could result in reduced royalty payments from European sales of Zalviso, all of which <em style="font: inherit;"> may </em>result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Monetization. Conversely, if sales of Zalviso in Europe are greater than expected, the non-cash royalty revenues and the non-cash interest expense recorded by the Company would be greater over the term of the Royalty Monetization. The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. Because estimated sales forecasts and payments <em style="font: inherit;"> may </em>vary over the life of the Royalty Monetization, the Company <em style="font: inherit;"> may </em>be required to recognize interest income as the imputed interest rate is adjusted prospectively to reflect the revised effective interest rate over the term of the Royalty Monetization.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company records non-cash royalty revenues and non-cash interest income (expense), net, within its Consolidated Statements of Operations over the term of the Royalty Monetization.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When the expected payments under the Royalty Monetization are lower than the gross proceeds of <em style="font: inherit;">$65.0</em> million received, the Company defers recognition of any probable contingent gain until the Royalty Monetization liability expires.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Comprehensive Loss </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss is comprised of net loss and other comprehensive income (loss) and is disclosed in the Consolidated Statements of Operations. For the Company, other comprehensive income (loss) consists of changes in unrealized gains and losses on the Company&#8217;s investments.</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Income Taxes </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than <em style="font: inherit;">not.</em></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><em style="font: inherit;"/></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Net Loss per Share of Common Stock </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, options to purchase common stock, restricted stock subject to repurchase, restricted stock units, warrants to purchase convertible preferred stock and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. For additional information regarding the net loss per share, see Note <em style="font: inherit;">15</em> &#8220;Net Loss per Share of Common Stock&#8221;.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Recently Adopted Accounting Standards</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> December 2019, </em>the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> &#8220;<i>Simplifying the Accounting for Income Taxes</i>&#8221;. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020, </em>and interim periods within those fiscal years. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> on <em style="font: inherit;"> January 1, 2021, </em>which did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s Consolidated Financial Statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> August 2020, </em>the FASB issued ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em> &#8220;<i>Debt - Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</i>&#8221;. The standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with <em style="font: inherit;">no</em> separate accounting for embedded conversion features. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within those fiscal years for smaller reporting companies, with early adoption permitted. The Company early adopted ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> on <em style="font: inherit;"> January 1, 2021, </em>which did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s Consolidated Financial Statements on the date of adoption.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Recently Issued Accounting Pronouncements </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> &#8220;<i>Financial Instruments </i>&#8211;<i> Credit Losses: Measurement of Credit Losses on Financial Instruments,</i>&#8221; or ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> replaces the incurred loss impairment model in current GAAP with a model that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for the Company beginning <em style="font: inherit;"> January 1, 2023, </em>with early adoption allowed beginning <em style="font: inherit;"> January 1, 2020. </em>In <em style="font: inherit;"> May 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> &#8220;<i>Financial Instruments </i>&#8211;<i> Credit Losses,</i>&#8221; or ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost upon adoption of the new credit losses standard. The new effective dates and transition align with those of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> Management is currently assessing the date of adoption and the impact ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05</em> will have on the Company, but it does <em style="font: inherit;">not</em> anticipate adoption of these new standards to have a material impact on the Company&#8217;s financial position, results of operations or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2020, </em>the FASB issued ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> &#8220;<i>Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,</i>&#8221; which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments are effective immediately and <em style="font: inherit;"> may </em>be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before <em style="font: inherit;"> December 31, 2022. </em>In <em style="font: inherit;"> January 2021, </em>the FASB issued ASU <em style="font: inherit;">2021</em>-<em style="font: inherit;">01,</em> &#8220;<i>Reference Rate Reform (Topic <em style="font: inherit;">848</em>),</i>&#8221; to expand and clarify the scope of Topic <em style="font: inherit;">848</em> to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">04.</em> The Company is currently evaluating the impact this guidance will have on its Consolidated Financial Statements.</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"/>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670987544504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Investments and Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock', window );">Investments and Fair Value Measurement Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">2.</em> Investments and Fair Value Measurement </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Investments </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond <em style="font: inherit;">one</em> year as of the end of the reporting period are classified as non-current.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The table below summarizes the Company&#8217;s cash, cash equivalents and investments (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized</b> <b>Cost</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br/> <b>Gains</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br/> <b>Losses</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b><br/> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,443</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,443</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,398</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,398</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">12,663</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">12,663</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 40%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">29,504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">29,504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">38,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">38,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash, cash equivalents and short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">51,630</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">51,630</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized</b> <b>Cost</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br/> <b>Gains</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br/> <b>Losses</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b><br/> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">18,097</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">18,097</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 40%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">U.S. government agency securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,794</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,794</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">15,612</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">15,612</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash, cash equivalents and short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">42,886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">42,886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><em style="font: inherit;">None</em> of the available-for-sale securities held by the Company had material unrealized losses and there were no realized losses for the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020.</em> There were no other-than-temporary impairments for these securities as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> or <em style="font: inherit;">2020.</em> <em style="font: inherit;"><span style="-sec-ix-hidden:c81618861">No</span></em> gross realized gains or losses were recognized on the available-for-sale securities and, accordingly, there were no amounts reclassified out of accumulated other comprehensive income (loss) to earnings during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> the contractual maturity of all investments held was less than <em style="font: inherit;">one</em> year.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value Measurement </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company&#8217;s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level <em style="font: inherit;">1</em> of the fair value hierarchy. For Level II instruments, the Company estimates fair value by utilizing <em style="font: inherit;">third</em> party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. Such Level II instruments typically include U.S. treasury, U.S. government agency securities and commercial paper. As of <em style="font: inherit;"> December 31, 2021, </em>and <em style="font: inherit;"> December 31, 2020, </em>the Company held, in addition to Level II assets, a contingent put option liability associated with the Loan Agreement with Oxford. See Note <em style="font: inherit;">8</em> &#8220;Long-Term Debt&#8221; for further description. The Company&#8217;s estimate of fair value of the contingent put option liability was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated both with and without the presence of the default provisions, holding all other assumptions constant. The resulting difference between the <em style="font: inherit;">two</em> estimated fair values is the estimated fair value of the default provisions, or the contingent put option, which is included under other long-term liabilities on the Consolidated Balance Sheets. Changes to the estimated fair value of this liability is recorded in interest income and other income (expense), net in the Consolidated Statements of Operations. The fair value of the underlying debt facility is estimated by calculating the expected cash flows in consideration of an estimated probability of default and expected recovery rate in default and discounting such cash flows back to the reporting date using a risk-free rate.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth the fair value of the Company&#8217;s financial assets and liabilities by level within the fair value hierarchy (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>I</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>II</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>III</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><b>Assets</b></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">37,902</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">37,902</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">50,187</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">47,365</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><span style="text-decoration: underline; ">Liabilities</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingent put option liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>



    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>I</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>II</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>III</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><b>Assets</b></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. government agency securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27,891</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27,891</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">37,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">33,709</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><span style="text-decoration: underline; ">Liabilities</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingent put option liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table sets forth a summary of the changes in the fair value of the Company&#8217;s Level III financial liabilities for the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> (in thousands):</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended</b><br/> <b>December</b> <b>31,</b><br/> <b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#8212;beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change in fair value of contingent put option associated with the Loan Agreement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#8212;end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended</b><br/> <b>December</b> <b>31,</b><br/> <b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#8212;beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;">437</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change in fair value of contingent put option associated with the Loan Agreement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#8212;end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of investments and fair value measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897354696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Inventories, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventory Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">3.</em> Inventories, net </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inventories consist of finished goods, raw materials and work in process and are stated at the lower of cost or net realizable value and consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As</b> <b>of</b> <b>December</b> <b>31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">722</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Work-in-process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,339</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,626</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company recorded inventory impairment charges of approximately $0.8 million, primarily as a result of DSUVIA inventory that <em style="font: inherit;"> may </em>expire before being sold. During the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company recorded inventory impairment charges of approximately $0.7 million, of which $0.3 million related to the termination of the Amended Agreements, while $0.4 million related to DSUVIA inventory, primarily inventory that <em style="font: inherit;"> may </em>expire before being sold.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897286984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">4.</em> Property and Equipment, net </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment, net consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As</b> <b>of</b> <b>December</b> <b>31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">4,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">4,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">5,838</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">4,616</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">1,589</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">1,724</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Construction in process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">13,805</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">14,101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tooling</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">826</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">1,109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">292</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">26,714</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">26,248</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(10,786</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(10,589</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">15,928</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">15,659</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Depreciation and amortization expense was <span style="-sec-ix-hidden:c81619034">$1.1</span> million for each of the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670901231480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - In-license Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_InlicenseAgreementTextBlock', window );">In-license Agreement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">5.</em> In-License Agreement</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> July 14, 2021, </em>the Company entered into a License and Commercialization Agreement, or the PFS Agreement, with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">3</em> mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">50</em> mcg/ml phenylephrine hydrochloride for injection. Aguettant will supply the Company with the products for use in commercialization, if they are approved in the U.S.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The PFS Agreement has an initial term of <em style="font: inherit;">ten</em> (<span style="-sec-ix-hidden:c81619063">10</span>) marketing years, with the <em style="font: inherit;">first</em> marketing year ending on <em style="font: inherit;"> December 31 </em>of the calendar year after the <em style="font: inherit;">first</em> launch of a product (or <em style="font: inherit;"> December 31 </em>of the same calendar year if the <em style="font: inherit;">first</em> launch of a product occurs between <em style="font: inherit;"> January 1 </em>and <em style="font: inherit;"> April 30 </em>of a calendar year). The term will automatically renew for successive <span style="-sec-ix-hidden:c81619067">five</span> marketing year periods unless a party notifies the other party of its intention <em style="font: inherit;">not</em> to renew at least <em style="font: inherit;">six</em> (<em style="font: inherit;">6</em>) months prior to the expiration of the then-current term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Aguettant is entitled to receive up to $24.0 million in sales-based milestone payments. The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from 40% to 45% of net sales in the United States.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company and Aguettant will agree on minimum sales obligations <em style="font: inherit;">twelve</em> (<span style="-sec-ix-hidden:c81619075">12</span>) months prior to the launch of each product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has the right to grant sublicenses to its affiliates or, with the prior approval of Aguettant, <em style="font: inherit;">third</em> parties, subject to certain limitations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2021, </em>there have been <em style="font: inherit;">no</em> payments by the Company to Aguettant under the PFS Agreement.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_InlicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for in-license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_InlicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897610152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Out-license Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_OutlicenseAgreementTextBlock', window );">Out-license Agreement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">6.</em> Out-license Agreements</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>DZUVEO</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> July 14, 2021, </em>the Company entered into a License and Commercialization Agreement, or the DZUVEO Agreement, with Aguettant, pursuant to which Aguettant obtained the exclusive right to develop and commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom, or the DZUVEO Territory, for the management of acute moderate to severe pain in adults in medically monitored settings. The Company will supply Aguettant with product.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The DZUVEO Agreement has an initial term of <em style="font: inherit;">ten</em> (<em style="font: inherit;">10</em>) marketing years, with the <em style="font: inherit;">first</em> marketing year ending on <em style="font: inherit;"> December 31 </em>of the calendar year after the launch of DZUVEO (or <em style="font: inherit;"> December 31, 2022, </em>if the launch occurs between <em style="font: inherit;"> January 1, 2022 </em>and <em style="font: inherit;"> April 30, 2022). </em>The term will automatically renew for successive <span style="-sec-ix-hidden:c81619082">five</span> marketing year periods unless a party notifies the other party of its intention <em style="font: inherit;">not</em> to renew at least <em style="font: inherit;">six</em> (<em style="font: inherit;">6</em>) months prior to the expiration of the then-current term. The DZUVEO Agreement <em style="font: inherit;"> may </em>be terminated for cause by either party based on uncured material breach by the other party, insolvency of the other party, or force majeure event. Upon early termination, all ongoing activities under the agreement and all rights and commercialization licenses and sublicenses with respect to DZUVEO will terminate. Additionally, if terminated early by either party, any accrued liability at the time of such termination will <em style="font: inherit;">not</em> be released.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is entitled to receive up to <span style="-sec-ix-hidden:c81619087">&#8364;47.0</span> million in a combination of up-front and sales-based milestone payments, of which the Company received <span style="-sec-ix-hidden:c81619088">&#8364;2.5</span> million, or approximately $2.9 million, in the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021,</em> for which it recognized revenue of $1.7 million in the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021.</em> Aguettant will purchase product from the Company at an agreed price, or the DZUVEO Purchase Price, subject to adjustment. Aguettant will also make revenue share payments that, combined with the DZUVEO Purchase Price, range from 35% to 45% of net sales in the DZUVEO Territory.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Beginning in the <em style="font: inherit;">third</em> marketing year, the parties will establish binding annual minimums for purchase orders to be submitted by Aguettant. Aguettant has the right to grant sublicenses to its affiliates or, with the prior approval of the Company, <em style="font: inherit;">third</em> parties, subject to certain limitations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The DZUVEO Agreement also provides Aguettant with a right of <em style="font: inherit;">first</em> negotiation for <em style="font: inherit;">eighteen</em> (<em style="font: inherit;">18</em>) months before the Company can enter into a collaboration regarding Zalviso&#160;in Europe.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Zalviso</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 18, 2020, </em>the Company received a notice from Gr&#252;nenthal that it had exercised its right to terminate the Gr&#252;nenthal Agreements, effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#252;nenthal Agreements were extended to <em style="font: inherit;"> May 12, 2021 </em>to enable Gr&#252;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#252;nenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on <em style="font: inherit;"> May 12, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Amended License Agreement </span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Amended License Agreement with Gr&#252;nenthal, the Company was eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). A portion of the tiered royalty payments earned were paid to PDL in connection with the Royalty Monetization. For additional information on the Royalty Monetization with PDL, see Note <em style="font: inherit;">10</em> &#8220;Liability Related to Sale of Future Royalties&#8221;. On <em style="font: inherit;"> August 31, 2020, </em>PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Amended MSA </span></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the terms of the Amended MSA with Gr&#252;nenthal, the Company manufactured and supplied the Product for use in the Field for the Territory exclusively for Gr&#252;nenthal. The Product was supplied at prices approximating the Company&#8217;s manufacturing cost, subject to certain caps, as defined in the MSA Amendment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Gr&#252;nenthal Agreements entitled the Company to receive additional payments upon the achievement of certain development milestones which related to post approval product enhancements, expanded market opportunities and manufacturing efficiencies for Zalviso and required future research, development and regulatory activities. These payments were excluded from the transaction price as they were considered payments for optional additional services elected by Gr&#252;nenthal.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Gr&#252;nenthal Agreements also included milestone payments related to specified net sales targets, totaling $166.0 million. These payments were considered sales-based license royalties under ASC Topic <em style="font: inherit;">606</em> and would have been recognized apart from the other contract consideration when the related sales occurred. These net sales targets were <em style="font: inherit;">not</em> achieved prior to the termination of the Gr&#252;nenthal Agreements.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_OutlicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of out-license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_OutlicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670900939144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Revenue From Contracts With Customers<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue from Contract with Customer [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">7</em></b>. <b>Revenue from Contracts with Customers</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes revenue from contracts with customers for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">DSUVIA</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,409</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Zalviso</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total product sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contract and other collaboration:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">License revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Non-cash royalty revenue related to Royalty Monetization (See Note 10)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total revenues from contract and other collaboration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,895</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,416</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For additional detail on the Company&#8217;s accounting policy regarding revenue recognition, refer to Note <em style="font: inherit;">1</em> &#8220;Organization and Summary of Significant Accounting Policies - Revenue from Contracts with Customers.&#8221;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Product Sales</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s commercial launch of DSUVIA in the United States occurred in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2019.</em> Zalviso was sold in Europe by Gr&#252;nenthal through <em style="font: inherit;"> May 12, 2021. </em>DZUVEO sales in Europe by the Company&#8217;s collaboration partner, Aguettant, have <em style="font: inherit;">not</em> commenced as of <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contract and Other Collaboration</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Contract and other collaboration revenue includes revenue under the Gr&#252;nenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe and license revenue recognized under the DZUVEO Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company concluded that Aguettant is a customer and therefore revenue recognition for the DZUVEO Agreement in Europe should be accounted for in accordance with FASB Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">606,</em> &#8220;<i>Revenue from Contracts with Customers</i>&#8221;, because the Company granted to Aguettant licenses and will provide the supply of product, as defined below, all of which are outputs of the Company&#8217;s ongoing activities, in exchange for consideration.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company identified the following promises under the DZUVEO Agreement at inception, namely: (a) granting of the licenses, (b) manufacturing services inclusive of quality control testing and stability testing which are options in the initial arrangement, and (c) a material right associated with the discounted price for future optional orders of DZUVEO commercial product supply.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The licenses are considered to be functional intellectual property. The Company determined that the licenses are capable of being distinct because Aguettant can benefit from the license on its own by commercializing the underlying product using its own resources. The Company manufacturing services are <em style="font: inherit;">not</em> highly specialized in nature and can be performed by <em style="font: inherit;">third</em> party contract manufacturing organizations. There are <em style="font: inherit;">no</em> binding commitments for manufacturing purchase orders at inception of the arrangement. Therefore, the manufacturing services are considered to be an option and <em style="font: inherit;">not</em> a performance obligation in the initial arrangement. However, the Company has determined that the discounted price per unit on future optional product orders constitutes a material right and is a performance obligation. The right to purchase at a discount is capable of being used by the customer on a standalone basis, because this relates to future product purchases and occur after the licenses&#8217; performance obligations are transferred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company evaluated if there is an interdependence between the performance obligations and determined that the licenses are a combined solution and the predominant performance obligation. The material right is separately identifiable in the context of the contract and is <em style="font: inherit;">not</em> modified by, and does <em style="font: inherit;">not</em> modify, the license performance obligation and is <em style="font: inherit;">not</em> highly interdependent or interrelated with the material right performance obligations in the contract.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The transaction price at the inception of the DZUVEO Agreement consisted of the upfront fee of <span style="-sec-ix-hidden:c81619125">&#8364;2.5</span> million, or approximately $2.9 million. The variable consideration related to product supply and reimbursables has been constrained as of <em style="font: inherit;"> December 31, 2021 </em>as there has been <em style="font: inherit;">no</em> forecast provided by Aguettant. The Company will re-evaluate the transaction price each reporting period and as uncertain events are resolved or other changes in circumstances occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The Company determined that the $52.2 million<i> </i>sales-based milestone payments and revenue share payments were probable of significant revenue reversal, as their achievement was highly dependent on factors outside the Company&#8217;s control. As a result, these payments were fully constrained and were <em style="font: inherit;">not</em> included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the licenses granted to Aguettant and the optional manufacturing services provided by the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The transaction price is allocated to the performance obligations based on relative standalone selling price which were determined for the licenses using the adjusted market approach, and for the manufacturing services and the material right associated with discounted DZUVEO product supply using the cost-plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in <em style="font: inherit;"> July 2021 </em>and ends after an initial term of <span style="-sec-ix-hidden:c81619131">10</span> marketing years, unless it automatically renews for a successive <span style="-sec-ix-hidden:c81619132">five</span> marketing years. The Company also analyzed the impact if Aguettant terminated the agreement prior to the end of the term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Aguettant for doing so.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Revenue for the granting of the licenses was recognized on the effective date of the DZUVEO Agreement at the point in time that the licenses are effective. The manufacturing services inclusive of quality control testing and stability testing will be recognized at a point in time when, or as, the Company transfers the associated promised goods and services to Aguettant. The material right for the discounted price per unit on future optional orders will be recognized over time with the measure of progress being straight-line over the period in which the Company stands ready to provide the discounted price per unit on the manufacturing services.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company recorded $1.7 million in contract and other collaboration revenue as a result of satisfying its licenses performance obligation by transferring the license rights to Aguettant.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contract Liabilities</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;">A contract liability of $1.2 million was recorded on the Consolidated Balance Sheets as deferred revenue as of <em style="font: inherit;"> December 31, 2021, </em>$0.1 million of which represented the current portion, for the portion of the upfront fee received under the DZUVEO Agreement allocated to the material right for discounted price on future optional product supply which has <em style="font: inherit;">not</em> yet been satisfied. The material right contract liability will be recognized over the period the discount on future product supply is made available. There was <em style="font: inherit;">no</em> contract asset as of <em style="font: inherit;"> December 31, 2021 </em>associated with the DZUVEO Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">As of <em style="font: inherit;"> December 31, 2021, </em>deferred contract acquisition costs were negligible and deferred contract acquisition costs amortized during the year ended <em style="font: inherit;"> December 31, 2021 </em>were <span style="-sec-ix-hidden:c81619138">$0.3</span> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table presents changes in the Company&#8217;s contract liability for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 36pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deductions for performance obligations satisfied:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In current period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c81619166">( 623</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In prior periods<span style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(2,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions<span style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deductions for performance obligations satisfied:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In current period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="font-size:10pt;"><span style="font-family: &quot;Times New Roman&quot;;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>)</sup></span></span> In <em style="font: inherit;"> May 2020, </em>upon notification of early termination by Gr&#252;nenthal, the Company recognized approximately $2.6 million of deferred revenue under the Gr&#252;nenthal Agreements.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">2</em>)</sup><sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>Deferred revenue under the DZUVEO Agreement with Aguettant.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897215992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Long-term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtTextBlock', window );">Long-term Debt [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">8.</em> Long-Term Debt </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Loan Agreement with Oxford</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 30, 2019, </em>the Company entered into the Loan Agreement with Oxford as the Lender. Under the Loan Agreement, the Lender made a term loan to the Company in an aggregate principal amount of $25.0 million, or the Loan, which was funded on <em style="font: inherit;"> May 30, 2019. </em>The Company used approximately $8.9 million of the proceeds from the Loan to repay its outstanding obligations under its prior debt agreement. After deducting all loan initiation costs and outstanding interest on the prior debt agreement, the Company received $15.9 million in net proceeds.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The interest rate is calculated at a rate equal to the sum of (a) the greater of (i) the <em style="font: inherit;">30</em>-day U.S. LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 2.50%, plus (b) 6.75%. On <em style="font: inherit;"> July 27, 2017, </em>the Financial Conduct Authority, or FCA, in the U.K. announced that it would phase out LIBOR as a benchmark by the end of <em style="font: inherit;">2021.</em> It is unclear whether new methods of calculating LIBOR will be established such that it continues to exist after <em style="font: inherit;">2021</em> or if LIBOR will be replaced with an alternative reference rate; however, the Company does <em style="font: inherit;">not</em> believe such changes would have a material adverse effect on its financing costs. Payments on the Loan were interest-only until <em style="font: inherit;"> July 1, 2020 </em>followed by equal principal payments and monthly accrued interest payments through the scheduled maturity date of <em style="font: inherit;"> June 1, 2023. </em>The Company&#8217;s obligations under the Loan Agreement are secured by a security interest in all the assets of the Company, other than the Company&#8217;s intellectual property which is subject to a negative pledge.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company <em style="font: inherit;"> may </em>prepay the Loan at any time. If the Loan is paid prior to the maturity date, the Company will pay the Lender a prepayment charge, based on a percentage of the then outstanding principal balance, equal to 1%. Upon voluntary or mandatory prepayment, in addition to the prepayment charge, the Company is required to pay the EOT Fee, Lender&#8217;s expenses and all outstanding principal and accrued interest through the prepayment date.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Loan Agreement includes customary representations and covenants that, subject to exceptions, will restrict the Company&#8217;s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are <em style="font: inherit;">not</em> related to its existing business. The Loan Agreement requires that the Company always maintain unrestricted cash of <em style="font: inherit;">not</em> less than $5.0 million in accounts subject to control agreements in favor of Lender, tested monthly as of the last day of the month.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Loan Agreement also includes standard events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of the Lender&#8217;s security interest or in the value of the collateral, a material adverse change in business, operations or the prospect of repayment, events relating to bankruptcy or insolvency. The Loan also contains a cross default provision, under which if a <em style="font: inherit;">third</em> party (under any agreement) has the right to accelerate indebtedness greater than $250,000, the Loan would also be considered in default. In addition, the Loan defines events which negatively impact government approvals, judgments in excess of $500,000 and the delisting of the Company&#8217;s shares of common stock on the Nasdaq Global Market, or Nasdaq, as events of default. Upon the occurrence of an event of default, a default interest rate of an additional 5% <em style="font: inherit;"> may </em>be applied to the outstanding loan balances, and the Lender <em style="font: inherit;"> may </em>declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. Acceleration would result in the payment of any applicable prepayment charges and application of the default interest rate to the outstanding balance until payment is made in full. The Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to the Lender. The bifurcated embedded derivative must be valued and separately accounted for in the Company&#8217;s Consolidated Financial Statements. The contingent put option liability is classified as a component of other long-term liabilities. As of <em style="font: inherit;"> December 31, 2021, </em>the estimated fair value of the contingent put option liability was $0.1 million which was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated, both with and without the presence of the default provisions, holding all other assumptions constant. See Note <em style="font: inherit;">2</em> &#8220;Investments and Fair Value Measurement&#8221; for further description.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Loan Agreement, on <em style="font: inherit;"> May 30, 2019, </em>the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of 176,679 shares of the Company&#8217;s common stock with a per share exercise price of $2.83, or the Warrants. The Warrants have been classified within stockholders&#8217; (deficit) equity and accounted for as a discount to the loan by allocating the gross proceeds on a relative fair value basis. For further discussion, see Note <em style="font: inherit;">11</em> &#8220;Warrants&#8221;.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The outstanding balance due under the Loan Agreement was $13.3 million and $21.0 million at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively. Interest expense related to the Loan Agreement was $2.2 million, of which $0.7 million represented amortization of the debt discount, and $3.2 million, $0.9 million of which represented amortization of the debt discount, for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively, and the effective interest rate was 13.15% in both periods.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Non-Interest Bearing Payments for the Construction of Leasehold Improvements </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> August 2019, </em>the Company entered into a Site Readiness Agreement, or SRA, with a potential Contract Manufacturing Organization, or CMO, in contemplation of entering into a commercial supply agreement for its product DSUVIA&#174; at a future date. Under the SRA, the Company is building out a suite within the CMO&#8217;s production facility. If additional equipment and facility modifications are required to meet the Company&#8217;s product needs, the Company <em style="font: inherit;"> may </em>be required to contribute to the cost of such additional equipment and facility modifications. The Company has determined that it is the owner of the leasehold improvements related to the build-out which will be paid for in <em style="font: inherit;">four</em> annual installments of $0.5 million through <em style="font: inherit;"> July 2022. </em>As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> the accrued balance under the SRA is $0.5 million and $0.8 million, respectively, and $1.7 million of these leasehold improvements have been capitalized. The effective interest rate related to the payments at <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was 14.35%. The leasehold improvements are recorded as property and equipment, net, in the Consolidated Balance Sheets.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Future Payments on Long-Term Debt </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes the outstanding future payments associated with the Company&#8217;s long-term debt as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,530</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less amount representing interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(927</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Unamortized portion of EOT Fee</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Unamortized discount on notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(247</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,803</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,796</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,007</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670978034312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Lessee, Operating Leases [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">9.</em> Leases </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Office Lease </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company leased office and laboratory space for its former corporate headquarters, located at <em style="font: inherit;">301</em> &#8211; <em style="font: inherit;">351</em> Galveston Drive, Redwood City, California, and entered into an agreement to sublease approximately 12,106 square feet of this office and laboratory space.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 26, 2021, </em>the Company entered into a Lease Termination Agreement with its landlord and a Sublease Termination Agreement with its sublessee, to terminate the lease and sublease agreements at its former corporate headquarters. The termination of both the lease and sublease was effective on <em style="font: inherit;"> April 30, 2021. </em>As of the date of the Lease Termination Agreement, the Company remeasured its lease liability and recorded a gain of $0.5 million upon derecognition of the lease liability and right of use asset for the master lease, which was included in operating expenses for the year ended <em style="font: inherit;"> December 31, 2021. </em>In connection with the Sublease Termination, the remaining deferred costs of $0.3 million were fully amortized through <em style="font: inherit;"> April 30, 2021, </em>the effective date of the Sublease Termination, and included in operating expenses for the year ended <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">On <em style="font: inherit;"> March 26, 2021, </em>the Company entered into a Sublease Agreement to sublet space for its new corporate headquarters, located at <em style="font: inherit;">25821</em> Industrial Boulevard, Hayward, California. The Sublease Agreement commencement date was <em style="font: inherit;"> April 1, 2021. </em>The Sublease Agreement is for a period of <span style="-sec-ix-hidden:c81619236">two</span> years and <em style="font: inherit;">three</em> months with monthly rental payments of $17,000, including <span style="-sec-ix-hidden:c81619239">one</span> month of abated rent. On the lease commencement date, the Company recognized an operating lease right-of-use asset in the amount of $0.4 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contract Manufacturing Leases</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 12, 2012, </em>the Company entered into an agreement for commercial supply manufacturing services related to the Company&#8217;s Zalviso drug product with a contract manufacturing organization. The initial term of the agreement was through <em style="font: inherit;"> December 31, 2017, </em>which term automatically renews in <span style="-sec-ix-hidden:c81619241">two</span>-year increments unless earlier terminated by either party by giving <span style="-sec-ix-hidden:c81619242">eighteen</span> months&#8217; notice. Commencing in <em style="font: inherit;">2013,</em> the Company is required to make overhead fee payments each year of $0.2 million, prorated based on aggregate revenues. The Company has determined that this fee is an in-substance fixed lease payment as it represents the minimum annual payment under the contract. The Company concluded that this agreement contains an embedded lease as the clean rooms have been built specifically for production of the Company&#8217;s product and their use is effectively controlled by the Company as it has priority over the space during the term of the agreement. The Company accounts for the agreement as an operating lease and has evaluated the non-cancelable term to be through the binding commitment date of <em style="font: inherit;"> June 30, 2023.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> April 21, 2021, </em>the Company entered into a Commercial Supply Agreement, or the CSA, with Catalent Pharma Solutions, LLC, or Catalent, effective <em style="font: inherit;"> March 31, 2021, </em>under which Catalent provides certain services to the Company in connection with the processing and packaging of a packaged single dose applicator containing the sublingual tablet <em style="font: inherit;">30</em> mcg sufentanil dosage form contained in the pharmaceutical product, DSUVIA (sufentanil), intended for commercialization.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The term of the CSA is for a period of <span style="-sec-ix-hidden:c81619247">five</span> years from the <em style="font: inherit;">first</em> date upon which the FDA approves Catalent as a manufacturer of DSUVIA in the United States, or the Commencement Date. The term shall automatically be extended for successive <span style="-sec-ix-hidden:c81619249">two</span>-year periods, unless and until <em style="font: inherit;">one</em> party gives the other party at least <em style="font: inherit;">24</em> months&#8217; prior written notice of its desire to terminate as of the end of the then-current term.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company will pay Catalent an annual fee of $1.0 million beginning <em style="font: inherit;"> January 1, 2022. </em>Pursuant to the CSA, the Company will purchase each <em style="font: inherit;">10</em>-pack carton of DSUVIA from Catalent at an agreed price through <em style="font: inherit;"> December 31, 2022, </em>and pay other fees set forth in the CSA. All pricing and fees, with the exception of raw materials, <em style="font: inherit;"> may </em>be adjusted on an annual basis, effective on <em style="font: inherit;"> January 1 </em>of each calendar year, beginning with <em style="font: inherit;"> January 1, 2023, </em>subject to certain limitations. Price increases for raw materials will be passed through to the Company.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has determined that the fixed fees in the CSA are in-substance lease payments. The Company concluded that this agreement contains an embedded lease as the clean rooms have been built specifically for production of the Company&#8217;s product and their use is effectively controlled by the Company as it has sole use over the space during the term of the agreement. The Company accounts for the agreement as an operating lease and has evaluated the non-cancelable lease term to be through the binding commitment date of <em style="font: inherit;"> May 15, 2027.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The components of lease expense are presented in the following table (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br/> <b>December</b> <b>31,</b><br/> <b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br/> <b>December</b> <b>31,</b><br/> <b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gain on derecognition of operating lease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(522</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(598</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss on termination of sublease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net lease costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,077</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term &#8211; operating leases (in years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.97</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.1</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining discount rate &#8211; operating leases&#160;(in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Maturities of lease liabilities as of <em style="font: inherit;"> December 31, 2021 </em>are presented in the following table (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,040</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,040</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,040</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;">6,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">4,818</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">Reported as:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;">4,818</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating lease liabilities, current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI http://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897338072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Liability Related to Sale of Future Royalties<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock', window );">Liability Related To Sale Of Future Royalties Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">10.</em> Liability Related to Sale of Future Royalties </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> September 18, 2015, </em>the Company entered into the Royalty Monetization with PDL for which it received gross proceeds of $65.0 million. Under the Royalty Monetization, PDL was to receive 75% of the European royalties under the Amended License Agreement with Gr&#252;nenthal, as well as 80% of the <em style="font: inherit;">first</em> <em style="font: inherit;">four</em> commercial milestones worth $35.6 million (or <em style="font: inherit;">80%</em> of $44.5 million), up to a capped amount of <em style="font: inherit;">$195.0</em> million over the life of the arrangement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the relevant accounting guidance, because of the Company&#8217;s significant continuing involvement, the Royalty Monetization has been accounted for as a liability that will be amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and paid to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $61.2 million of net proceeds the Company received will be recorded as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense relating to the Royalty Monetization accordingly.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. During the <em style="font: inherit;">three</em> months ended <em style="font: inherit;"> June 30, 2020, </em>Gr&#252;nenthal notified the Company that it was terminating the Amended License Agreement, effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#252;nenthal Agreements were extended to <em style="font: inherit;"> May 12, 2021 </em>to enable Gr&#252;nenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on <em style="font: inherit;"> May 12, 2021. </em>There is a continuing obligation on the Company&#8217;s part, through the term of the Royalty Monetization with SWK (assignee of PDL), to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. If the Company is unable to find a New Arrangement, a contingent gain of up to approximately $64 million <em style="font: inherit;"> may </em>be recognized when it is realized upon expiration of the liability at the end of the Royalty Monetization term. Due to the significant judgments and factors related to the estimates of future payments under the Royalty Monetization, there are significant uncertainties surrounding the amount and timing of future payments and the probability of realization of the estimated contingent gain.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The effective interest rate over the life of the liability will be 0% as the Company records interest income over the remaining term of the arrangement as an offset to the interest expense that was recognized in prior periods. The effective interest income rate for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> was approximately 3.5% and 3.6%, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table shows the activity within the liability account during the year ended <em style="font: inherit;"> December 31, 2021 (</em>in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br/> <b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Period from</b><br/> <b>inception to </b><br/> <b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liability related to sale of future royalties &#8212; beginning balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">88,471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from sale of future royalties</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,184</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-cash royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,083</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-cash interest (income) expense recognized</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,038</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,187</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liability related to sale of future royalties as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">85,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">85,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As royalties are remitted to PDL from ARPI LLC, as described in Note&#160;<em style="font: inherit;">1</em> &#8220;Organization and Summary of Significant Accounting Policies,&#8221; the balance of the liability will be effectively repaid over the life of the agreement. The Company will record non-cash royalty revenues and non-cash interest (income) expense within its Consolidated Statements of Operations over the term of the Royalty Monetization. The liability related to the sale of future royalties, current portion, is recorded as accrued liabilities in the Company&#8217;s Consolidated Balance Sheets.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670900952376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_WarrantsDisclosureTextBlock', window );">Warrants Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">11.</em> Warrants </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i><em style="font: inherit;"> November 2021 </em>Financing Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> November 15, 2021, </em>the Company entered into a securities purchase agreement with certain investors pursuant to which the Company, in a registered direct offering, sold (i) an aggregate of 17,500,000 shares of the Company's common stock, and (ii) warrants to purchase up to an aggregate of 17,500,000 shares of common stock, for an aggregate purchase price of $14.0 million (see Note <em style="font: inherit;">13</em> &#8220;Stockholders&#8217; Equity&#8221;). The <em style="font: inherit;"> November 2021 </em>Financing Warrants have an exercise price of $1.00 per share and become exercisable, if the holder&#8217;s post-exercise beneficial ownership is less than or equal to 9.99%, <em style="font: inherit;">6</em> months after their issuance date and have a <em style="font: inherit;">five</em>-year term (<em style="font: inherit;"> November 15, 2026). </em>All common stock issuable under the issued warrants, were added to the Company&#8217;s effective registration statement on <em style="font: inherit;"> November 15, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The <em style="font: inherit;"> November 2021 </em>Financing warrants were valued at approximately $8.6 million using the Black-Scholes option pricing model as follows: exercise price of $1.00 per share, stock price of $0.7461 per share, expected life of <span style="-sec-ix-hidden:c81619332">five</span> years, volatility of 91.77%, and a risk-free rate of 1.26%. The common stock and warrants were issued in a unit structure; therefore, in accordance with ASC Topic <em style="font: inherit;">815,</em> the aggregate gross proceeds of $14.0 million were allocated to the <em style="font: inherit;">two</em> securities using the relative fair value method, resulting in the common stock and warrants being allocated values of $8.4 million and $5.6 million, respectively, and recorded to stockholders' equity.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Loan Agreement Warrants </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Loan Agreement, on <em style="font: inherit;"> May 30, 2019, </em>the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of 176,679 shares of the Company&#8217;s common stock with a per share exercise price of $2.83, or the Loan Agreement Warrants. The Loan Agreement Warrants <em style="font: inherit;"> may </em>be exercised on a cashless basis. The Loan Agreement Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of <span style="-sec-ix-hidden:c81619342">ten</span> years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Loan Agreement Warrants. The number of shares for which the Loan Agreement Warrants are exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Loan Agreement Warrants.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company estimated the fair value of these Loan Agreement Warrants as of the issuance date to be $0.4 million, which was used in estimating the fair value of the debt instrument and was recorded as equity. The fair value of the Loan Agreement Warrants was calculated using the Black-Scholes option-valuation model, and was based on the strike price of $2.83, the stock price at issuance of $2.66, the <span style="-sec-ix-hidden:c81619346">ten</span>-year contractual term of the warrants, a risk-free interest rate of 2.22%, expected volatility of 80.22% and 0% expected dividend yield.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2021, </em>Loan Agreement Warrants to purchase 176,679 shares of common stock issued to the Lender and its affiliates had <em style="font: inherit;">not</em> been exercised and were still outstanding. These warrants expire in <em style="font: inherit;"> May 2029.</em></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_WarrantsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The disclosure of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_WarrantsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897162008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">12.</em> Commitments and Contingencies </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Litigation </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> June 8, 2021, </em>a securities class action complaint was filed in the U.S. District Court for the Northern District of California against the Company and <span style="-sec-ix-hidden:c81619353">two</span> of its officers. The plaintiff is a purported stockholder of the Company. The complaint alleges that defendants violated Sections <em style="font: inherit;">10</em>(b) and <em style="font: inherit;">20</em>(a) of the Exchange Act and SEC Rule <em style="font: inherit;">10b</em>-<em style="font: inherit;">5</em> by making false and misleading statements and omissions of material fact about the Company&#8217;s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint seeks unspecified damages, interest, attorneys&#8217; fees, and other costs. On <em style="font: inherit;"> December 16, 2021, </em>the Court appointed co-lead plaintiffs. Plaintiffs&#8217; amended complaint was filed on <em style="font: inherit;"> March 7, 2022. </em>The amended complaint names the Company and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">three</em> of its officers and continues to allege that defendants violated Sections <span style="-sec-ix-hidden:c81619358">10</span>(b) and <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">20</em>(a) of the Exchange Act and SEC Rule <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">10b</em>-<em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">5</em> by making false and misleading statements and omissions of material fact about the Company&#8217;s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint also alleges a violation of Section <em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;">20A</em> of the Exchange Act against the individual defendants for alleged insider trading. Defendants&#8217; motion to dismiss the amended complaint is due <em style="font: inherit;"> May 6, 2022.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> July 6, 2021, </em>a purported shareholder derivative complaint was filed in the U.S. District Court for the Northern District of California. The complaint names <em style="font: inherit;">ten</em> of the Company&#8217;s officers and directors and asserts state and federal claims based on the same alleged misstatements as the shareholder class action complaint. On <em style="font: inherit;"> September 30, 2021, </em><em style="font: inherit;"> October 26, 2021, </em>and <em style="font: inherit;"> November 17, 2021, </em><em style="font: inherit;">three</em> additional purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California. The complaints name <em style="font: inherit;">nine</em> of the Company&#8217;s officers and directors and also assert state and federal claims based on the same alleged misstatements as the shareholder class action complaint. All <em style="font: inherit;">four</em> complaints seek unspecified damages, attorneys&#8217; fees, and other costs. On <em style="font: inherit;"> December 6, 2021, </em>the Court entered an order consolidating all <em style="font: inherit;">four</em> actions and staying the consolidated action pending the outcome of any motion to dismiss the securities class action. Please see &#8220;Part II., Item <em style="font: inherit;">1A.</em> Risk Factors&#8212;Risks of a General Nature&#8212;Litigation <em style="font: inherit;"> may </em>substantially increase our costs and harm our business<i>.</i>&#8221;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that <em style="font: inherit;"> may </em>result from these actions.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897138344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">13.</em> Stockholders</b>&#8217;<b> Equity </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Common Stock </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Underwritten Public Offering</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> January 22, 2021, </em>the Company completed an underwritten public offering in which the Company issued and sold 14,500,000 shares of its common stock to the underwriter at a price of $1.7625 per share. On <em style="font: inherit;"> January 27, 2021, </em>the underwriters exercised their option in full and purchased an additional 2,175,000 shares at a price of $1.7625 per share. The total net proceeds from this offering of an aggregate 16,675,000 shares were approximately $28.9 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2021</em> Registered Direct Offering</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> November 17, 2021, </em>the Company completed a registered direct offering in which the Company issued and sold 17,500,000 shares of its common stock at a price of $0.80 per share and warrants exercisable for an aggregate of 17,500,000 shares of its common stock at a price of $1.00 per share. The total net proceeds from this offering were approximately $13.9 million. The <em style="font: inherit;"> November 2021 </em>issued shares were valued at approximately $13.1 million based on the closing stock price of $0.7491 per share on <em style="font: inherit;"> November 15, 2021. </em>The common stock and warrants were issued in a unit structure; therefore, in accordance with ASC Topic <em style="font: inherit;">815,</em> the aggregate gross proceeds of $14.0 million were allocated to the <em style="font: inherit;">two</em> securities using the relative fair value method, resulting in the common stock and warrants being allocated values of $8.4 million and $5.6 million, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2020</em> Registered Direct Offerings</i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> July 23, 2020, </em>the Company completed a registered direct offering in which it issued and sold 9,433,962 shares of its common stock at a price of $1.06 per share. The total net proceeds from this offering were approximately $10.0 million, after deducting estimated expenses payable by the Company of $49,000. <em style="font: inherit;">No</em> underwriter or placement agent participated in the offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 11, 2020, </em>the Company completed a registered direct offering in which it issued and sold 8,333,333 shares of its common stock at a price of $1.20 per share. The total net proceeds from this offering were approximately $9.9 million, after deducting estimated expenses payable by the Company of $51,000. <em style="font: inherit;">No</em> underwriter or placement agent participated in the offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>ATM Agreement </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> June 21, 2016, </em>the Company entered into a Controlled Equity Offering<sup style="vertical-align:top;line-height:120%;font-size:pt">SM</sup> Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald &amp; Co., or Cantor, as agent, pursuant to which the Company <em style="font: inherit;"> may </em>offer and sell, from time to time through Cantor, shares of the Company&#8217;s common stock, or the Common Stock having an aggregate offering price of up to $40.0 million, or the Shares. On <em style="font: inherit;"> May 9, 2019, </em>the Company increased the aggregate offering price of shares of the Company&#8217;s common stock which <em style="font: inherit;"> may </em>be offered and sold under the ATM Agreement by $40.0 million, for a total of $80.0 million, or the Shares. The offering of Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the ATM Agreement or (b) the termination of the ATM Agreement by Cantor or the Company, as permitted therein. The Company will pay Cantor a commission rate in the low single digits on the aggregate gross proceeds from each sale of Shares and have agreed to provide Cantor with customary indemnification and contribution rights.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company issued and sold approximately 3.0 million shares of common stock pursuant to the ATM Agreement, and received net proceeds of approximately $7.5 million, after deducting fees and expenses. During the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company issued and sold 876,800 shares of common stock pursuant to the ATM Agreement, for which the Company received net proceeds of approximately $1.4 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December 31, 2021, </em>the Company had the ability to offer and sell shares of the Company&#8217;s common stock having an aggregate offering price of up to $36.1 million under the ATM Agreement.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock Plans </i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><em style="font: inherit;">2011</em> Equity Incentive Plan </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> January 2011, </em>the Board of Directors adopted, and the Company&#8217;s stockholders approved, the <em style="font: inherit;">2011</em> Equity Incentive Plan, or <em style="font: inherit;">2011</em> EIP. The initial aggregate number of shares of the Company&#8217;s common stock that were issuable pursuant to stock awards under the <em style="font: inherit;">2011</em> EIP was approximately 1.9 million shares. The number of shares of common stock reserved for issuance under the <em style="font: inherit;">2011</em> EIP automatically increased on <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">1</em> of each year, starting on <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2012</em> and continuing through <em style="font: inherit;"> January&#160;</em><em style="font: inherit;">1,</em> <em style="font: inherit;">2020,</em> by 4% of the total number of shares of the Company&#8217;s common stock outstanding on <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31</em> of the preceding calendar year, or such lesser number of shares of common stock as determined by the Board of Directors.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> June 16, 2020, </em><em style="font: inherit;">no</em> more awards <em style="font: inherit;"> may </em>be granted under the <em style="font: inherit;">2011</em> Equity Incentive Plan, or the <em style="font: inherit;">2011</em> EIP, although all outstanding stock options and other stock awards previously granted under the <em style="font: inherit;">2011</em> EIP will continue to remain subject to the terms of the <em style="font: inherit;">2011</em> EIP.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Amended <em style="font: inherit;">2020</em> Plan </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> June 16, 2020, </em>at the <em style="font: inherit;">2020</em> Annual Meeting of Stockholders of the Company, the Company&#8217;s stockholders, upon the recommendation of the Company&#8217;s Board of Directors, approved the Company&#8217;s <em style="font: inherit;">2020</em> Equity Incentive Plan, or the <em style="font: inherit;">2020</em> EIP.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The initial aggregate number of shares of the Company&#8217;s common stock issuable pursuant to stock awards under the <em style="font: inherit;">2020</em> EIP was 5,500,000 shares. In addition, the share reserve will be increased by the number of returning shares, if any, as such shares become available from time to time under the <em style="font: inherit;">2011</em> EIP, for an additional number of shares <em style="font: inherit;">not</em> to exceed 14,892,170 shares. The term of any option granted under the <em style="font: inherit;">2020</em> EIP is determined on the date of grant but shall <em style="font: inherit;">not</em> be longer than <em style="font: inherit;">10</em> years. The Company issues new shares for settlement of vested restricted stock units and exercises of stock options. The Company does <em style="font: inherit;">not</em> have a policy of purchasing its shares relating to its stock-based programs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> June 17, 2021, </em>at the <em style="font: inherit;">2021</em> Annual Meeting of Stockholders of the Company, upon the recommendation of the Company&#8217;s Board of Directors, the Company&#8217;s stockholders approved an amendment and restatement of the Company&#8217;s <em style="font: inherit;">2020</em> Equity Incentive Plan, or <em style="font: inherit;">2020</em> Plan, or as amended and restated, the Amended <em style="font: inherit;">2020</em> Plan, to increase the number of authorized shares reserved for issuance thereunder by 4,300,000 shares, subject to adjustment for certain changes in the Company&#8217;s capitalization. The aggregate number of shares of the Company&#8217;s common stock that <em style="font: inherit;"> may </em>be issued under the Amended <em style="font: inherit;">2020</em> Plan will <em style="font: inherit;">not</em> exceed the sum of: (i) 4,300,000 shares approved in connection with the adoption of the Amended <em style="font: inherit;">2020</em> Plan, (ii) 5,500,000 shares approved in connection with the original adoption of the <em style="font: inherit;">2020</em> Plan, and (iii) certain shares subject to outstanding awards granted under the <em style="font: inherit;">2011</em> Equity Incentive Plan that <em style="font: inherit;"> may </em>become available for issuance under the <em style="font: inherit;">2020</em> Plan and Amended <em style="font: inherit;">2020</em> Plan, as such shares become available from time to time.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Amended and Restated <em style="font: inherit;">2011</em> Employee Stock Purchase Plan </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additionally, on <em style="font: inherit;"> June 16, 2020, </em>the Company&#8217;s stockholders, upon the recommendation of the Company&#8217;s Board of Directors, approved the Amended and Restated <em style="font: inherit;">2011</em> Employee Stock Purchase Plan, or the Amended ESPP, which increased the aggregate number of shares of the Company&#8217;s common stock reserved for issuance under the <em style="font: inherit;">2011</em> Employee Stock Purchase Plan, or ESPP, to 4,900,000 shares, subject to adjustment for certain changes in the Company&#8217;s capitalization, and removed the &#8220;evergreen&#8221; provision from the ESPP.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the year ended <em style="font: inherit;"> December 31, 2021, </em>there were 297,959 shares issued under the Amended ESPP. The weighted average fair value of shares issued under the Amended ESPP in <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $1.01 and $1.09 per share, respectively. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were 4,456,364 shares available for future grant under the Amended ESPP.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897187096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">14.</em> Stock-Based Compensation </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company recorded total stock-based compensation expense for stock options, stock awards and the Amended ESPP as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br/> <b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br/> <b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">123</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">813</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,704</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,537</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,609</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes restricted stock unit activity under the Company&#8217;s Equity Incentive Plans:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b> <b>of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Average</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Restricted</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Grant</b> <b>Date</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stock</b> <b>Units</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, January 1, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">988,645</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">908,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(304,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(194,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,397,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,149,632</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.68</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(587,214</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(186,025</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.58</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,774,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following table summarizes stock&#160;option activity under the Company&#8217;s Equity Incentive Plans:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b><br/> <b>of</b> <b>Stock</b> <b>Options</b><br/> <b>Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;"><b><b>Weighted-</b><br/> <b>Average</b><br/> <b>Exercise</b><br/> <b>Price</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-</b><br/> <b>Average</b><br/> <b>Remaining</b><br/> <b>Contractual</b><br/> <b>Life (Years)</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Aggregate</b><br/> <b>Intrinsic</b><br/> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in</b> <b>thousands)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">12,813,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">3.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,667,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">(375,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">1.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">(801,749</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">3.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 1px solid rgb(0, 0, 0);">(19,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">0.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">14,284,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">2.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">5.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and exercisable options&#8212;December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">10,496,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">3.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">4.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest&#8212;December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">14,284,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">2.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">5.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were 7,858,933 shares available for future grant under the <em style="font: inherit;">2020</em> EIP.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Additional information regarding the Company&#8217;s stock options outstanding and vested and exercisable as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em>&#160;is summarized below:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b> <b>Vested</b> <b>and</b> <b>Exercisable</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Exercise Prices</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b><br/> <b>Stock</b> <b>Options</b><br/> <b>Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br/> <b>Remaining</b><br/> <b>Contractual</b> <b>Life</b><br/> <b>(Years)</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br/> <b>Exercise</b> <b>Price</b> <b>per</b><br/> <b>Share</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b> <b>Subject</b><br/> <b>to Stock</b><br/> <b>Options</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br/> <b>Exercise</b> <b>Price</b> <b>per</b><br/> <b>Share</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$0.72</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619560">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$1.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">695,482</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">8.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">0.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">280,047</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">0.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$1.26</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619567">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$1.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">3,402,418</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">8.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">1.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">496,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">1.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.00</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619574">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$3.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">5,310,550</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">6.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">2.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">4,856,618</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">2.43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$3.10</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619581">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$4.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">3,066,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">3.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">3.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">3,054,619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">3.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$4.73</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619588">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$7.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">1,295,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">1.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">5.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">1,295,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">5.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$8.18</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619595">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$12.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">513,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">2.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">10.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);">513,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">10.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 7pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">14,284,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">5.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">2.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">10,496,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">3.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The weighted average grant-date fair value of options granted during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $1.24 and $0.92 per share, respectively. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> total stock-based compensation expense related to unvested options to be recognized in future periods was $3.8 million which is expected to be recognized over a weighted-average period of 2.1 years. The grant date fair value of shares vested during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $2.4 million and $3.6 million, respectively. The total intrinsic value of options exercised during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was $5.7 thousand and $0.0 million, respectively.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> March 3, 2021, </em>the Company granted 1.27 million performance-based stock options to certain of its executive officers, which are included in the stock option tables and associated disclosures above. The awards were granted under the <em style="font: inherit;">2020</em> EIP with an exercise price of $1.88 per share, the closing sales price as reported on the Nasdaq on the date of grant. The performance-based stock options are eligible to vest subject to the satisfaction of the service-based vesting requirements and attainment of share price target goals, a market-based condition. No performance-based stock options vested during the year ended <em style="font: inherit;"> December 31, 2021, </em>and there were no performance-based stock options granted for the year ended <em style="font: inherit;"> December 31, 2020.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company used the following assumptions to calculate the fair value of each performance-based stock option: &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 15%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Year</b> <b>Ended</b> <b>December</b> <b>31,</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Derived service period (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">2.3</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#8211;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">1.5%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">90%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">0%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company used the following assumptions to calculate the fair value of each time-based stock option:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="10" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year</b> <b>Ended</b> <b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="5" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b style="font-size: 10pt;">2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b style="font-size: 10pt;">2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">6.0</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">6.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: center;">6.2</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">0.9%</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">1.3%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">0.4%</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">1.5%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;">90%</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;">83%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;">0%</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;">0%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898780744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Net Loss Per Share of Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Share [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">15.</em> Net Loss per Share of Common Stock </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock units and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: &#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ESPP, RSUs and stock options to purchase common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">16,328,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">14,541,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">17,676,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">176,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898413464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">16.</em> Accrued Liabilities </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accrued liabilities consist of the following (in thousands): &#160;&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation and employee benefits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">2,974</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">3,323</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">1,523</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">179</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Accrued product returns and sales allowances</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">656</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Deferred revenue</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">49</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,166</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">6,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">5,045</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897376072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - 401(k) Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Retirement Benefits [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">17.</em> <em style="font: inherit;">401</em>(k) Plan </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company sponsors a <em style="font: inherit;">401</em>(k) plan that stipulates that eligible employees can elect to contribute to the <em style="font: inherit;">401</em>(k) plan, subject to certain limitations. Pursuant to the <em style="font: inherit;">401</em>(k) plan, the Company makes a matching contribution of up to 4% of the related compensation. Under the vesting schedule, employees have ownership in the matching employer contributions based on the number of years of vesting service completed. Company contributions were $0.4 million and $0.5 million for the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139671028691032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">18.</em> Income Taxes </b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company recorded a provision for income taxes of $5.0 thousand and $4.0 thousand during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Net deferred tax assets as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> consist of the following (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br/> <b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br/> <b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accruals and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">3,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">4,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">7,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">7,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">75,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">65,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Section 59(e) R&amp;D expenditures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">5,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">7,473</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">19,666</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">20,848</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">111,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">105,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(111,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(105,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81619742">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81619743">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reconciliations of the statutory federal income tax to the Company&#8217;s effective tax during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> are as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax at statutory federal rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(7,370</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(8,486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax&#8212;net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(3,587</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">718</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 31pt;">636</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);">6,446</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);">11,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">ASC <em style="font: inherit;">740</em> requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than <em style="font: inherit;">not.&#8221;</em> Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $6.4 million and $11.4 million during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had federal net operating loss carryforwards of $308.5 million, of which $114.9 million federal net operating losses generated before <em style="font: inherit;"> January 1, 2018 </em>will begin to expire in <em style="font: inherit;">2029.</em> Federal net operating losses of $193.6 million generated from <em style="font: inherit;">2018</em> to <em style="font: inherit;">2021</em> will carryforward indefinitely but are subject to the <em style="font: inherit;">80%</em> taxable income limitation. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had state net operating loss carryforwards of $154.7 million, which begin to expire in <em style="font: inherit;">2028.</em>&#160;</p>
   <p style="margin: 0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had federal research credit carryovers of $6.5 million, which begin to expire in <em style="font: inherit;">2026.</em> As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had state research credit carryovers of $4.0 million, which will carryforward indefinitely.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under Section&#160;<em style="font: inherit;">382</em> of the Internal Revenue Code of <em style="font: inherit;">1986,</em> as amended, if a corporation undergoes an &#8220;ownership change,&#8221; generally defined as a greater than <em style="font: inherit;">50%</em> change (by value) in its equity ownership over a <em style="font: inherit;">three</em>-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research credits, to offset its post-change income <em style="font: inherit;"> may </em>be limited. Based on an analysis performed by the Company as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2013,</em> it was determined that <em style="font: inherit;">two</em> ownership changes have occurred since inception of the Company. The <em style="font: inherit;">first</em> ownership change occurred in <em style="font: inherit;">2006</em> at the time of the Series A financing and, as a result of the change, $1.4 million in federal and state net operating loss carryforwards will expire unutilized. In addition, $26 thousand in federal and state research and development credits will expire unutilized. The <em style="font: inherit;">second</em> ownership change occurred in <em style="font: inherit;"> July 2013 </em>at the time of the underwritten public offering; however, the Company believes the resulting annual imposed limitation on use of pre-change tax attributes is sufficiently high that the limit itself will <em style="font: inherit;">not</em> result in unutilized pre-change tax attributes.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Uncertain Tax Positions </i></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A reconciliation of the beginning and ending balances of the unrecognized tax benefits during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> is as follows (in thousands):</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unrecognized benefit&#8212;beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">2,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">2,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross increases&#8212;prior period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross increases&#8212;current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unrecognized benefit&#8212;end of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">2,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">2,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The entire amount of the unrecognized tax benefits would <em style="font: inherit;">not</em> impact the Company&#8217;s effective tax rate if recognized.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There were no accrued interest or penalties related to unrecognized tax benefits in the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020.</em> The Company files income tax returns in the United States, California, and other states. The tax years <span style="-sec-ix-hidden:c81619715">2005</span> through <em style="font: inherit;">2014,</em> and <em style="font: inherit;">2016</em> through <em style="font: inherit;">2021,</em> remain open in all jurisdictions. The Company is <em style="font: inherit;">not</em> currently under examination by income tax authorities in federal, state or other foreign jurisdictions. The Company does <em style="font: inherit;">not</em> anticipate any significant changes within <em style="font: inherit;">12</em> months of this reporting date of its uncertain tax positions.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2020, </em>the Coronavirus Aid, Relief and Economic Security, or CARES, Act was signed into law. The CARES Act included several tax changes as part of its economic package. These changes principally related to expanded net operating loss carryback periods, increases to interest deductibility limitations, and accelerated alternative minimum tax refunds. The Company has evaluated these items and determined that the items do <em style="font: inherit;">not</em> have a material effect on the Company's financial statements as of <em style="font: inherit;"> December 31, 2021. </em>Additionally, the CARES Act enacted the Employee Retention Credit, or ERC, to incentivize companies to retain employees, which was subsequently modified by extension of the CARES Act. Under the provisions of the CARES Act and its subsequent extension, the Company was eligible for ERCs, subject to certain criteria. Accordingly, the Company has recorded a reduction in payroll taxes related to ERCs claimed for $1.4 million in the year ended <em style="font: inherit;"> December 31, 2021. </em>These credits are recorded in the Consolidated Statements of Operations as an offset to the related payroll expenses in the respective operating costs and expenses line item. Such claimed ERCs <em style="font: inherit;">not</em> settled prior to year-end in the amount of <em style="font: inherit;">$1.4</em> million are expected to be settled shortly thereafter and are disclosed within prepaid expenses and other current assets on the Company&#8217;s Consolidated Balance Sheets at <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897360968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 19 - Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><em style="font: inherit;">19.</em> Subsequent Events</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> January 7, 2022, </em>the Company closed the Merger Agreement with Lowell in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments. Pursuant to the terms of the Merger Agreement, all options to purchase capital stock and all shares of Lowell capital stock issued and outstanding immediately before the effective time of the merger were cancelled in exchange for the right to receive (i) 9,009,538 shares of AcelRx common stock, and cash in the amount of $3,519,129, (ii) 1,396,526 shares of AcelRx common stock to be held back to satisfy any potential indemnification and other obligations of Lowell and its securityholders, and (iii) up to $26.0 million of contingent consideration payable in cash or stock at AcelRx's option, upon the achievement of regulatory and sales-based milestones.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The 1,396,526 of held back shares of AcelRx common stock issued in connection with the closing was calculated based on a fixed value of $0.57284 per share, which is the arithmetic average of the daily volume weighted average price per share of AcelRx common stock during the <em style="font: inherit;">five</em> consecutive full trading days ending on and including the last full trading day immediately prior to the date of the closing. The shares issued pursuant to the Merger Agreement were issued in private placements pursuant to the exemption from registration under Section <em style="font: inherit;">4</em>(a)(<em style="font: inherit;">2</em>) of the Securities Act of <em style="font: inherit;">1933,</em> as amended, or the Securities Act, including Rule <em style="font: inherit;">506</em> of Regulation D promulgated under the Securities Act, or Regulation D, without general solicitation as a transaction <em style="font: inherit;">not</em> involving any public offering.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Merger Agreement will be accounted for in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2022</em> as an acquisition of assets that does <em style="font: inherit;">not</em> meet the definition of a business. The asset acquisition does <em style="font: inherit;">not</em> constitute a business as substantially all of the fair value of the gross assets acquired was concentrated in Lowell&#8217;s intellectual property, including NIYAD&#8482; and LTX-<em style="font: inherit;">608.</em> The acquired assets and liabilities will be recorded at their relative fair values and the contingent consideration will be recorded when it becomes probable of achievement or the consideration becomes payable. Accordingly, the Company has classified $1.9 million of expenses related to the Merger Agreement as Other assets in the Consolidated Balance Sheet&#160;at <em style="font: inherit;"> December 31, 2021.</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>


  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897380200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</a></td>
<td class="text">

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Additions</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Balance at</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Charged as a</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Balance at</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Beginning of</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Reduction to</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">End of</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Description</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Period</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Revenue</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Deductions*</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Period</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales &amp; return allowances, discounts, chargebacks and rebates:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year ended December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">668</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,012</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">780</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">645</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">668</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">* Deductions to sales discounts and allowances relate to discounts or allowances actually taken or paid.</em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897528968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_BusinessDescriptionOfEntityPolicyTextBlock', window );">Business Description of Entity [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>The Company </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on <em style="font: inherit;"> July 13, 2005 </em>as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. The Company&#8217;s operations are based in Hayward, California.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA&#174;<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>(known as DZUVEO&#174; in Europe) and Zalviso&#174; are<sup style="vertical-align:top;line-height:120%;font-size:pt"> </sup>both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. On <em style="font: inherit;"> November 2, 2018, </em>the U.S. Food and Drug Administration, or FDA, approved DSUVIA for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The commercial launch of DSUVIA in the United States occurred in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2019.</em> In <em style="font: inherit;"> June 2018, </em>the European Commission, or EC, granted marketing approval of DZUVEO for the management of acute moderate to severe pain in adults in medically monitored settings. AcelRx is further developing a distribution capability and commercial organization to continue to market and sell DSUVIA in the United States. In geographies where AcelRx decides <em style="font: inherit;">not</em> to commercialize products by itself, the Company <em style="font: inherit;"> may </em>seek to out-license commercialization rights. The Company currently intends to commercialize and promote DSUVIA/DZUVEO outside the United States with <em style="font: inherit;">one</em> or more strategic partners, and, in <em style="font: inherit;"> July 2021, </em>entered into a License and Commercialization Agreement with Laboratoire Aguettant, or Aguettant, for Aguettant to commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom (see Note <em style="font: inherit;">6.</em> &#8220;Out-License Agreements&#8212;DZUVEO&#8221;<i> </i>below). The timing of the resubmission of the Zalviso new drug application, or NDA, is in part dependent upon the finalization of the FDA&#8217;s new opioid approval guidelines and process. AcelRx intends to seek regulatory approval for Zalviso in the United States and, if successful, potentially promote Zalviso either by itself or with strategic partners. Zalviso is approved in Europe and was commercialized by Gr&#252;nenthal GmbH, or Gr&#252;nenthal, through <em style="font: inherit;"> May 12, 2021 (</em>see <i>Termination of Gr</i>&#252;<i>nenthal Agreements</i> below). In <em style="font: inherit;"> July 2021, </em>the Company also entered into a separate License and Commercialization Agreement with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">3</em> mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing <em style="font: inherit;">10</em> ml of a solution of <em style="font: inherit;">50</em> mcg/ml phenylephrine hydrochloride for injection (see Note <em style="font: inherit;">5.</em> &#8220;In-License Agreement&#8221; below). On <em style="font: inherit;"> January 7, 2022, </em>the Company closed the definitive merger agreement dated as of <em style="font: inherit;"> November 14, 2021, </em>or the Merger Agreement, to acquire Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note <em style="font: inherit;">19.</em> &#8220;Subsequent Events&#8221; below).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;"> December 31, 2020, </em>the Company had cash, cash equivalents and short-term investments of $51.6 million and $42.9 million, respectively. Based on the Company&#8217;s current operating plans and projections, the Company expects that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least <em style="font: inherit;">one</em> year from the date this Annual Report on Form <em style="font: inherit;">10</em>-K is filed with the United States Securities and Exchange Commission, or SEC. Although Zalviso was approved for sale in Europe on <em style="font: inherit;"> September 18, 2015, </em>the Company sold the majority of the royalty rights and certain commercial sales milestones it is entitled to receive under the Amended License Agreement (defined below) with Gr&#252;nenthal to PDL BioPharma, Inc., or PDL, in a transaction referred to as the Royalty Monetization. On <em style="font: inherit;"> August 31, 2020, </em>PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK. In consideration of the termination of the Amended License Agreement, under the Royalty Monetization, the Company must use commercially reasonable efforts to negotiate a replacement license agreement with a <em style="font: inherit;">third</em> party.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i><span style="text-decoration: underline; ">Termination of Gr</span></i>&#252;<i><span style="text-decoration: underline; ">nenthal Agreements </span></i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> December 16, 2013, </em>AcelRx and Gr&#252;nenthal entered into a Collaboration and License Agreement, or the License Agreement, which was amended effective <em style="font: inherit;"> July 17, 2015 </em>and <em style="font: inherit;"> September 20, 2016, </em>or the Amended License Agreement, which granted Gr&#252;nenthal rights to commercialize the Zalviso PCA system, or the Product, in the <em style="font: inherit;">28</em> European Union, or EU, member states, at the time of the agreement, plus Switzerland, Liechtenstein, Iceland, Norway and Australia (collectively, the Zalviso Territory) for human use in pain treatment within, or dispensed by, hospitals, hospices, nursing homes and other medically supervised settings, (collectively, the Field). In <em style="font: inherit;"> September 2015, </em>the EC granted marketing approval for the marketing authorization application, or MAA, previously submitted to the EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. On <em style="font: inherit;"> December 16, 2013, </em>AcelRx and Gr&#252;nenthal entered into a Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. Under the MSA, the Company exclusively manufactured and supplied the Product to Gr&#252;nenthal for the Field in the Zalviso Territory. On <em style="font: inherit;"> July 22, 2015, </em>the Company and Gr&#252;nenthal amended the MSA, or the Amended MSA, effective as of <em style="font: inherit;"> July 17, 2015. </em>The Amended MSA and the Amended License Agreement are referred to as the Gr&#252;nenthal Agreements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On <em style="font: inherit;"> May 18, 2020, </em>the Company received a notice from Gr&#252;nenthal that it had exercised its right to terminate the Gr&#252;nenthal Agreements, effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#252;nenthal Agreements were extended to <em style="font: inherit;"> May 12, 2021 </em>to enable Gr&#252;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#252;nenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on <em style="font: inherit;"> May 12, 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Basis of Presentation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassification, Comparability Adjustment [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Reclassifications </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the amounts reported in the Consolidated Balance Sheets as deferred revenue, current portion and liability related to the sale of future royalties, current portion have been reclassified to accrued and other liabilities at <em style="font: inherit;"> December 31, 2020, </em>and the amount reported as an inventory impairment charge in the Consolidated Statements of Cash Flows was recorded as other in the year ended <em style="font: inherit;"> December 31, 2020.</em></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Principles of Consolidation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiary, ARPI&#160;LLC, which was formed in <em style="font: inherit;"> September 2015 </em>for the sole purpose of facilitating the Royalty Monetization with PDL of the expected royalty stream and milestone payments due from the sales of Zalviso in the European Union by its commercial partner, Gr&#252;nenthal, pursuant to the Amended License Agreement. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note <em style="font: inherit;">10</em> &#8220;Liability Related to Sale of Future Royalties&#8221; for additional information.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Use of Estimates </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management believes its most significant accounting estimates relate to revenue recognition, inventory valuation and the liability related to the sale of future royalties. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are <em style="font: inherit;">not</em> readily apparent from other sources. Actual results could differ from those estimates.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock', window );">Cash, Cash Equivalents, and Marketable Securities [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cash, Cash Equivalents and Short-Term Investments </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company considers all highly liquid investments with an original maturity (at date of purchase) of <em style="font: inherit;">three</em> months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All marketable securities are classified as available-for-sale and consist of commercial paper, U.S. government sponsored enterprise debt securities and corporate debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. The Company&#8217;s investments are subject to a periodic impairment review for other-than-temporary declines in fair value. The Company&#8217;s review includes the consideration of the cause of the impairment including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss in the amount of such decline.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurement, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Fair Value of Financial Instruments </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a <em style="font: inherit;">three</em>-level valuation hierarchy for disclosure of fair value measurements as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level I&#8212;Unadjusted quoted prices in active markets for identical assets or liabilities;</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level II&#8212;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are <em style="font: inherit;">not</em> active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;">Level III&#8212;Unobservable inputs that are supported by little or <em style="font: inherit;">no</em> market activity for the related assets or liabilities.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Reporting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Segment Information </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company operates in a single segment, the development and commercialization of product candidates and products for the treatment of pain. The Company&#8217;s product sales revenue consists of sales of DSUVIA in the United States and, through <em style="font: inherit;"> May 2021, </em>sales of Zalviso in Europe by Gr&#252;nenthal. The Company&#8217;s contract and collaboration revenue consists of non-cash royalty revenue, royalty revenue, and other revenue under the Gr&#252;nenthal Agreements and license revenue under the DZUVEO Agreement.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Concentration of Risk </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company invests cash that is currently <em style="font: inherit;">not</em> being used for operational purposes in accordance with its investment policy in debt securities of U.S. government sponsored agencies, commercial paper and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the Consolidated Balance Sheets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company relies on a single <em style="font: inherit;">third</em>-party supplier for the supply of sufentanil, the active pharmaceutical ingredient in DSUVIA and Zalviso, and various sole-source <em style="font: inherit;">third</em>-party contract manufacturer organizations to manufacture the DSUVIA SDA.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">DSUVIA&#160;sales are concentrated with the DoD and with a limited number of wholesalers in the United States. Zalviso was sold in Europe by Gr&#252;nenthal through <em style="font: inherit;"> May 2021. </em>In <em style="font: inherit;"> July 2021, </em>Aguettant was granted an exclusive license to commercialize DZUVEO in Europe. DZUVEO sales in Europe by Aguettant have <em style="font: inherit;">not</em> commenced as of <em style="font: inherit;"> December 31, 2021.</em></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Revenue and accounts receivable have been concentrated with these customers.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Revenues from customers that accounted for <em style="font: inherit;">10%</em> or more of our total revenues during the years ended <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Year Ended December 31,</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Percent of Total Revenue</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Aguettant</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">61.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gr&#252;nenthal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">DoD</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Wholesaler A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Receivable [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Accounts Receivable, net</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The need for a bad debt allowance is evaluated each reporting period based on the Company&#8217;s assessment of the credit worthiness of its customers or any other potential circumstances that could result in bad debt.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company believes that the entire accounts receivable balance as of <em style="font: inherit;"> December 31, 2021 </em>is collectible and there was <em style="font: inherit;">no</em> bad debt allowance provided as of <em style="font: inherit;"> December 31, 2020.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Accounts receivable, net from customers that accounted for <em style="font: inherit;">10%</em> or more of our total accounts receivable balance as of <em style="font: inherit;"> December 31, 2021 </em>and <em style="font: inherit;">2020</em> are as follows:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Percent of Accounts Receivable, Net</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer B</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
     <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventory, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Inventories, net </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Inventories are valued at the lower of cost or net realizable value. Cost is determined using the <em style="font: inherit;">first</em>-in, <em style="font: inherit;">first</em>-out method for all inventories. Inventory includes the cost of the active pharmaceutical ingredients, or API, raw materials and <em style="font: inherit;">third</em>-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are allocated to the appropriate cost pool and then absorbed into inventory based on the units produced or distributed, assuming normal capacity, in the applicable period. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company's policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The Company periodically evaluates the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or net realizable value approach as that used to value the inventory.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Property and Equipment, net </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally <span style="-sec-ix-hidden:c81618752">three</span> to <span style="-sec-ix-hidden:c81618753">five</span> years. Leasehold improvements are amortized over the shorter of the estimated useful life of the improvements or the remaining lease term. Expenditures for repairs and maintenance, which do <em style="font: inherit;">not</em> extend the useful life of the property and equipment, are expensed as incurred. Upon retirement, the asset cost and related accumulated depreciation are relieved from the accompanying Consolidated Balance Sheets. Gains and losses associated with dispositions are reflected as a component of interest income and other income, net in the accompanying Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Impairment of Long-Lived Assets </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. For example, if the Company is <em style="font: inherit;">not</em> successful in its commercialization of DSUVIA, and if approved, Zalviso, purchased equipment and manufacturing-related facility improvements the Company has made at its contract manufacturers could become impaired. The Company <em style="font: inherit;"> may </em>determine that it is <em style="font: inherit;">no</em> longer probable that the Company will realize the future economic benefit associated with the costs of these assets through future manufacturing activities, and if so, the Company would record an impairment charge associated with these assets.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ContingentPutOptionPolicyPolicyTextBlock', window );">Contingent Put Option, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Contingent put option</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The contingent put option associated with the Company&#8217;s Loan Agreement with Oxford is recorded as a liability. Changes in the fair value of the contingent put option are recognized as interest income and other income (expense), net in the Consolidated Statements of Operations. For further discussion, see Note <em style="font: inherit;">8</em> &#8220;Long-Term Debt&#8221;.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lessee, Leases [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b><i>Leases</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company follows the provisions of ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2016</em>-<em style="font: inherit;">02,</em> <i>Leases (Topic <em style="font: inherit;">842</em>)</i>. At the inception of an arrangement, the Company determines whether the arrangement is, or contains, a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically <em style="font: inherit;">not</em> readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset <em style="font: inherit;"> may </em>be required for items such as initial direct costs paid or incentives received.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the Consolidated Balance Sheets as operating lease right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Revenue from Contracts with Customers </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company follows the provisions of Accounting Standards Codification, or ASC, Topic <em style="font: inherit;">606,</em> <i>Revenue from Contracts with Customers</i>. This guidance provides a unified model to determine how revenue is recognized. The Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company sells its products primarily through wholesale and specialty distributors.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Product sales revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company sells its product primarily through distributors. Revenues from product sales are recognized when distributors obtain control of the Company&#8217;s product, which occurs at a point in time, upon delivery to such distributors. These distributors subsequently resell the product to certified medically supervised healthcare settings. In addition to distribution agreements with these customers, the Company enters into arrangements with group purchasing organizations, or GPOs, and other certified medically supervised healthcare settings that provide for privately negotiated discounts with respect to the purchase of its products. For revenue recognition under bill-and-hold arrangements, wherein the customer agrees to buy product from the Company but requests delivery at a later date, the Company deems that control passes to the customer when the product is ready for delivery. The Company recognizes revenue under these types of arrangements when a signed agreement is in place, the transaction is billable, the customer has significant risk and rewards for the product and the ability to direct the asset, the product has been set aside specifically for the customer, and the product cannot be redirected to another customer. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, government rebates, returns, distribution fees, GPO fees and product returns.&#160;Variable consideration is recorded at the time product sales are recognized resulting in a reduction in product revenue. The amount of variable consideration that is included in the transaction price <em style="font: inherit;"> may </em>be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will <em style="font: inherit;">not</em> occur in a future period. Variable consideration is estimated using the most-likely amount method, which is the single-most likely outcome under a contract and is typically at the stated contractual rate.&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method under ASC Topic <em style="font: inherit;">606</em> for relevant factors. These factors include current contractual and statutory requirements, specific known market events and trends, industry data, and/or forecasted customer buying and payment patterns. Actual amounts of consideration ultimately received <em style="font: inherit;"> may </em>differ from the Company&#8217;s estimates.&#160;If actual results vary materially from the Company&#8217;s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These estimates include:</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Chargebacks</span> &#8211; The Company&#8217;s customers subsequently resell its product to qualified healthcare providers. In addition to distribution agreements with customers, the Company enters into arrangements with qualified healthcare providers that provide discounts with respect to the purchase of its product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue-related accrued liabilities on the Consolidated Balance Sheets. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by customers, and the Company issues credits for such amounts generally within a few weeks of the customer's notification to the Company of the resale. Reserves for chargebacks consists of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period end that the Company expects will be sold to the qualified healthcare providers, and chargebacks for units that the Company&#8217;s customers have sold to the qualified healthcare providers, but for which credits have <em style="font: inherit;">not</em> been issued.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Government Rebates</span> &#8211; The Company is subject to discount obligations under state Medicaid programs. The Company estimates its Medicaid rebates, and reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued liabilities on the Consolidated Balance Sheet.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Returns</span> &#8211;<i> </i>The Company allows its distributors to return product for credit <em style="font: inherit;">6</em> months prior to, and up to <em style="font: inherit;">12</em> months after, the product expiration date. As such, there <em style="font: inherit;"> may </em>be a significant period of time between the time the product is shipped and the time the credit is issued on returned product.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Distribution Fees</span> &#8211;<i> </i>Distribution fees include fees paid to certain customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">GPO Fees</span><i> </i>&#8211; The Company pays administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs&#8217; members.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"><span style="text-decoration: underline; ">Trade Discounts and Allowances</span> - The Company provides its customers with discounts which include early payment incentives that are explicitly stated in its contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company believes its estimated allowances for chargebacks, government rebates and product returns require a high degree of judgment and are subject to change based on its limited experience and certain quantitative and qualitative factors. The Company believes its estimated allowances for distribution fees, GPO fees and trade discounts and allowances do <em style="font: inherit;">not</em> require a high degree of judgment because the amounts are settled within a relatively short period of time. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. Changes in product revenue allowance estimates could materially affect the Company&#8217;s results of operations and financial position.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><span style="text-decoration: underline; ">Contract and other collaboration revenue</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company generates revenue from collaboration agreements. These agreements typically include payments for upfront signing or license fees, cost reimbursements for development and manufacturing services, milestone payments, product sales, and royalties on licensee&#8217;s future product sales. Product sales related revenue under these collaboration agreements is classified as product sales revenue, while other revenue generated from collaboration agreements is classified as contract and other collaboration revenue.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Performance Obligations</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic <em style="font: inherit;">606.</em> The Company&#8217;s performance obligations include delivering product to its distributors, commercialization license rights, development services, services associated with the regulatory approval process, joint steering committee services, demonstration devices, manufacturing services, material rights for discounts on manufacturing services, and product supply.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#8217;s or the Company&#8217;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. If the Company is entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Transaction Price</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company has both fixed and variable consideration. Variable consideration for product revenue is described as Net product sales in the Consolidated Statements of Operations. For collaboration agreements, non-refundable upfront fees and product supply selling prices are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would <em style="font: inherit;">not</em> occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are <em style="font: inherit;">not</em> within the control of the Company, such as approvals from regulators, are <em style="font: inherit;">not</em> considered probable of being achieved until those approvals are received.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Allocation of Consideration</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights and material rights for discounts on manufacturing services are calculated using an income approach model and can include the following key assumptions: the development timeline, sales forecasts, costs of product sales, commercialization expenses, discount rate, the time which the manufacturing services are expected to be performed, and probabilities of technical and regulatory success. For all other performance obligations, the Company uses a cost-plus margin approach.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>Timing of Recognition</i></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Significant management judgment is required to determine the level of effort required under collaboration arrangements and the period over which the Company expects to complete its performance obligations under the arrangement. The Company estimates the performance period or measure of progress at the inception of the arrangement and re-evaluates it each reporting period. This re-evaluation <em style="font: inherit;"> may </em>shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer, and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfSalesPolicyTextBlock', window );">Cost of Goods and Service [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Cost of Goods Sold </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cost of goods sold for product revenue includes <em style="font: inherit;">third</em> party manufacturing costs, shipping and handling costs, and indirect overhead costs associated with production and distribution which are allocated to the appropriate cost pool and recognized when revenue is recognized. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Gr&#252;nenthal Agreements, the Company sold Zalviso to Gr&#252;nenthal at predetermined, contractual transfer prices that were less than the direct costs of manufacturing and recognized indirect costs as period costs where they were in excess of normal capacity and <em style="font: inherit;">not</em> recoverable on a lower of cost or net realizable value basis. Cost of goods sold for Zalviso shipped to Gr&#252;nenthal included the inventory costs of API, <em style="font: inherit;">third</em>-party contract manufacturing costs, packaging and distribution costs, shipping, handling and storage costs, depreciation and costs of the employees involved with production.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Research and Development Expenses </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Stock-Based Compensation </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Compensation expense for all stock-based payment awards made to employees and directors, including employee stock options and restricted stock units related to the <em style="font: inherit;">2020</em> Equity Incentive Plan, or <em style="font: inherit;">2020</em> EIP, the <em style="font: inherit;">2011</em> Equity Incentive Plan, or <em style="font: inherit;">2011</em> EIP, and employee share purchases related to the Amended and Restated <em style="font: inherit;">2011</em> Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. The Company applies the graded-vesting attribution method to awards with market conditions that include graded-vesting features. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. The expected term, which represents the period of time that options granted are expected to be outstanding, is derived by analyzing the historical experience of similar awards, giving consideration to the contractual terms of the stock&#8209;based awards, vesting schedules and expectations of future employee behavior. Expected volatilities are estimated using the historical stock price performance over the expected term of the option, which are adjusted as necessary for any other factors which <em style="font: inherit;"> may </em>reasonably affect the volatility of AcelRx&#8217;s stock in the future. The risk&#8209;free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company recognizes forfeitures when they occur and does <em style="font: inherit;">not</em> anticipate paying dividends in the near future.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_WarrantsPolicyPolicyTextBlock', window );">Warrants, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Warrants Issued in Connection with Financings</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company <em style="font: inherit;"> may </em>need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Operations.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Restructuring Costs</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">On <em style="font: inherit;"> March 16, 2020, </em>in connection with entering into the Co-Promotion Agreement, the Company initiated a reduction in headcount, designed to eliminate the overlap with the Tetraphase commercial team in order to more efficiently commercialize DSUVIA alongside the Tetraphase commercial team and reduce operating expenses. The Company eliminated 30 positions, primarily within the commercial organization. For the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company incurred and paid $0.5 million in employee termination benefits related to this restructuring. The headcount reduction was completed in the <em style="font: inherit;">first</em> quarter of <em style="font: inherit;">2020.</em> There were <em style="font: inherit;">no</em> such restructuring costs for the year ended <em style="font: inherit;"> December 31, 2021.</em></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpensePolicyTextBlock', window );">Interest Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Non-Cash Interest Income (Expense) on Liability Related to Sale of Future Royalties</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> September 2015, </em>the Company sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Gr&#252;nenthal to PDL for gross proceeds of $65.0 million. Gr&#252;nenthal terminated the Gr&#252;nenthal Agreements effective <em style="font: inherit;"> November 13, 2020. </em>The terms of the Gr&#252;nenthal Agreements were extended to <em style="font: inherit;"> May 2021 </em>to enable Gr&#252;nenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Territory reverted back to the Company in <em style="font: inherit;"> May 2021.</em></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Under the Royalty Monetization, the Company has a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Under the relevant accounting guidance, because of the Company&#8217;s significant continuing involvement, the Royalty Monetization is accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and payments made to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $61.2 million of net proceeds the Company received, are amortized as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense, or interest income, as these estimates are updated.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">There are a number of factors that could materially affect the amount and timing of royalty and milestone payments from Zalviso in Europe, most of which are <em style="font: inherit;">not</em> within the Company&#8217;s control. Such factors include, but are <em style="font: inherit;">not</em> limited to, the success of any future sales and promotion of Zalviso under any New Arrangement, if achieved; changing standards of care; the introduction of competing products; manufacturing or other delays; intellectual property matters; adverse events that result in governmental health authority imposed restrictions on the use of Zalviso; significant changes in foreign exchange rates as the royalties remitted to ARPI LLC are made in U.S. dollars; and other events or circumstances that could result in reduced royalty payments from European sales of Zalviso, all of which <em style="font: inherit;"> may </em>result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Monetization. Conversely, if sales of Zalviso in Europe are greater than expected, the non-cash royalty revenues and the non-cash interest expense recorded by the Company would be greater over the term of the Royalty Monetization. The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company&#8217;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. Because estimated sales forecasts and payments <em style="font: inherit;"> may </em>vary over the life of the Royalty Monetization, the Company <em style="font: inherit;"> may </em>be required to recognize interest income as the imputed interest rate is adjusted prospectively to reflect the revised effective interest rate over the term of the Royalty Monetization.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">The Company records non-cash royalty revenues and non-cash interest income (expense), net, within its Consolidated Statements of Operations over the term of the Royalty Monetization.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">When the expected payments under the Royalty Monetization are lower than the gross proceeds of <em style="font: inherit;">$65.0</em> million received, the Company defers recognition of any probable contingent gain until the Royalty Monetization liability expires.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Comprehensive Loss </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Comprehensive loss is comprised of net loss and other comprehensive income (loss) and is disclosed in the Consolidated Statements of Operations. For the Company, other comprehensive income (loss) consists of changes in unrealized gains and losses on the Company&#8217;s investments.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Income Taxes </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than <em style="font: inherit;">not.</em></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Net Loss per Share of Common Stock </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company&#8217;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, options to purchase common stock, restricted stock subject to repurchase, restricted stock units, warrants to purchase convertible preferred stock and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. For additional information regarding the net loss per share, see Note <em style="font: inherit;">15</em> &#8220;Net Loss per Share of Common Stock&#8221;.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Recently Adopted Accounting Standards</i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> December 2019, </em>the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> &#8220;<i>Simplifying the Accounting for Income Taxes</i>&#8221;. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020, </em>and interim periods within those fiscal years. The Company adopted ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">12</em> on <em style="font: inherit;"> January 1, 2021, </em>which did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s Consolidated Financial Statements.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> August 2020, </em>the FASB issued ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06,</em> &#8220;<i>Debt - Debt with Conversion and Other Options (Subtopic <em style="font: inherit;">470</em>-<em style="font: inherit;">20</em>) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em>): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity</i>&#8221;. The standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with <em style="font: inherit;">no</em> separate accounting for embedded conversion features. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2023, </em>and interim periods within those fiscal years for smaller reporting companies, with early adoption permitted. The Company early adopted ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">06</em> on <em style="font: inherit;"> January 1, 2021, </em>which did <em style="font: inherit;">not</em> have a material impact on the Company&#8217;s Consolidated Financial Statements on the date of adoption.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>Recently Issued Accounting Pronouncements </i></b></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> &#8220;<i>Financial Instruments </i>&#8211;<i> Credit Losses: Measurement of Credit Losses on Financial Instruments,</i>&#8221; or ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> replaces the incurred loss impairment model in current GAAP with a model that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> is effective for the Company beginning <em style="font: inherit;"> January 1, 2023, </em>with early adoption allowed beginning <em style="font: inherit;"> January 1, 2020. </em>In <em style="font: inherit;"> May 2019, </em>the FASB issued ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> &#8220;<i>Financial Instruments </i>&#8211;<i> Credit Losses,</i>&#8221; or ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05,</em> to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost upon adoption of the new credit losses standard. The new effective dates and transition align with those of ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13.</em> Management is currently assessing the date of adoption and the impact ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13</em> and ASU <em style="font: inherit;">2019</em>-<em style="font: inherit;">05</em> will have on the Company, but it does <em style="font: inherit;">not</em> anticipate adoption of these new standards to have a material impact on the Company&#8217;s financial position, results of operations or cash flows.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
      <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">In <em style="font: inherit;"> March 2020, </em>the FASB issued ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">04,</em> &#8220;<i>Reference Rate Reform (Topic <em style="font: inherit;">848</em>): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,</i>&#8221; which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments are effective immediately and <em style="font: inherit;"> may </em>be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before <em style="font: inherit;"> December 31, 2022. </em>In <em style="font: inherit;"> January 2021, </em>the FASB issued ASU <em style="font: inherit;">2021</em>-<em style="font: inherit;">01,</em> &#8220;<i>Reference Rate Reform (Topic <em style="font: inherit;">848</em>),</i>&#8221; to expand and clarify the scope of Topic <em style="font: inherit;">848</em> to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU <em style="font: inherit;">2020</em>-<em style="font: inherit;">04.</em> The Company is currently evaluating the impact this guidance will have on its Consolidated Financial Statements.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_BusinessDescriptionOfEntityPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the accounting policy regarding the business description of entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_BusinessDescriptionOfEntityPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, and marketable securities including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ContingentPutOptionPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding one or more contingent put options of the Company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ContingentPutOptionPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_WarrantsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_WarrantsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfSalesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cost of product sold and service rendered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 705<br> -URI http://asc.fasb.org/topic&amp;trid=2122478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfSalesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpensePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 10<br> -Section 05<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=28365394&amp;loc=d3e23770-108382<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpensePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 330<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6471895&amp;loc=d3e55923-109411<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124437754&amp;loc=d3e543-108305<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123577603&amp;loc=d3e5033-111524<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897373576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</a></td>
<td class="text">
     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Year Ended December 31,</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Percent of Total Revenue</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b></b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Aguettant</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">61.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gr&#252;nenthal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">11.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">74.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">DoD</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.3</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Wholesaler A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>

     <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Percent of Accounts Receivable, Net</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer A</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">73</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Customer B</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">79</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td></tr>
</tbody></table>
    <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670901574392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Investments and Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock', window );">Cash, Cash Equivalents and Investments [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized</b> <b>Cost</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br/> <b>Gains</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br/> <b>Losses</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b><br/> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,443</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,443</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,398</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">8,398</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">12,663</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">12,663</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 40%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">29,504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">29,504</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">38,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">38,967</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash, cash equivalents and short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">51,630</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">51,630</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="14" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amortized</b> <b>Cost</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br/> <b>Gains</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Gross</b> <b>Unrealized</b><br/> <b>Losses</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b><br/> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5,181</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">18,097</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">18,097</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27,274</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="width: 40%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 1%;">&#160;</td><td style="width: 12%;">&#160;</td><td style="width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Short-term investments:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 12%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">U.S. government agency securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">5,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,794</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,794</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">15,612</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">15,612</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total cash, cash equivalents and short-term investments</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">42,886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">42,886</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>I</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>II</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>III</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><b>Assets</b></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">37,902</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">37,902</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Corporate debt securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">9,463</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">50,187</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">2,822</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">47,365</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><span style="text-decoration: underline; ">Liabilities</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingent put option liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As of December 31, 2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>I</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>II</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Level</b> <b>III</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><span style="text-decoration: underline; "><b>Assets</b></span></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Money market funds</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">U.S. government agency securities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commercial paper</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27,891</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">27,891</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total assets measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">37,705</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">3,996</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">33,709</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><span style="text-decoration: underline; ">Liabilities</span></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contingent put option liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities measured at fair value</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended</b><br/> <b>December</b> <b>31,</b><br/> <b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#8212;beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change in fair value of contingent put option associated with the Loan Agreement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(165</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#8212;end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended</b><br/> <b>December</b> <b>31,</b><br/> <b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#8212;beginning of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;">437</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Change in fair value of contingent put option associated with the Loan Agreement</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(191</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Fair value&#8212;end of period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">246</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=SL7498348-110258<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash, cash equivalents, and investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897329000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Inventories, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory, Current [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As</b> <b>of</b> <b>December</b> <b>31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Raw materials</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">722</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">257</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Work-in-process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">159</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">30</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Finished goods</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">230</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,339</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Inventories</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,111</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">1,626</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897235944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Property, Plant and Equipment [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>As</b> <b>of</b> <b>December</b> <b>31,</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2021</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"><b><b>2020</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Laboratory equipment</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">4,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">4,406</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Leasehold improvements</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">5,838</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">4,616</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Computer equipment and software</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">1,589</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">1,724</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Construction in process</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">13,805</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">14,101</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tooling</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">826</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">1,109</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Furniture and fixtures</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">250</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">292</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">26,714</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;">26,248</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less accumulated depreciation and amortization</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(10,786</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(10,589</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">15,928</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">15,659</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670896470408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Revenue From Contracts With Customers (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Disaggregation of Revenue [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Product sales:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">DSUVIA</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">735</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,409</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Zalviso</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">270</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total product sales</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,005</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,521</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Contract and other collaboration:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">License revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,696</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Non-cash royalty revenue related to Royalty Monetization (See Note 10)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">83</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">242</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Royalty revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">81</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Other revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">6</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total revenues from contract and other collaboration</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,813</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,895</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total revenue</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,818</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,416</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 36pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,244</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deductions for performance obligations satisfied:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In current period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><span style="-sec-ix-hidden:c81619166">( 623</span></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In prior periods<span style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(2,572</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Additions<span style="font-family:Times New Roman;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(2)</sup></span></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">1,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Deductions for performance obligations satisfied:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">In current period</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(49</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,237</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897235944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Long-term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Maturities of Long-term Debt [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 85%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">9,647</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">5,530</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">15,177</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less amount representing interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(927</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Notes payable, gross</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">14,250</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Unamortized portion of EOT Fee</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(200</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less: Unamortized discount on notes payable</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(247</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">13,803</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Less current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(8,796</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Long-term debt, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5,007</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123465755&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670901231480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Lease, Cost [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br/> <b>December</b> <b>31,</b><br/> <b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br/> <b>December</b> <b>31,</b><br/> <b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,467</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,360</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gain on derecognition of operating lease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(522</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sublease income</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(199</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(598</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss on termination of sublease</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">331</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net lease costs</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,077</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">762</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 64%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining lease term &#8211; operating leases (in years)</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">4.97</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">3.1</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted-average remaining discount rate &#8211; operating leases&#160;(in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">12.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 15%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">11.7</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">%</p> </td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2022</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,608</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2023</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,244</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2024</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,040</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2025</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,040</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">2026</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,040</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Thereafter</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">415</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total future minimum lease payments</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;">6,387</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Less imputed interest</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,569</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">4,818</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 81%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating lease liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt;">4,818</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Operating lease liabilities, current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,068</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating lease liabilities, net of current portion</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,750</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897271832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Liability Related to Sale of Future Royalties (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesTableTextBlock', window );">Other Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b><br/> <b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Period from</b><br/> <b>inception to </b><br/> <b>December 31,</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liability related to sale of future royalties &#8212; beginning balance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">88,471</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from sale of future royalties</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,184</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-cash royalty revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(145</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(1,083</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Non-cash interest (income) expense recognized</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(3,038</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">25,187</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Liability related to sale of future royalties as of December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">85,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">85,288</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898840552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br/> <b>2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br/> <b>2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cost of goods sold</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">92</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">123</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">813</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">764</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Selling, general and administrative</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,704</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">3,537</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,609</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,424</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px; margin-left: 36pt;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b> <b>of</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Average</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Restricted</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Grant</b> <b>Date</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stock</b> <b>Units</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Fair</b> <b>Value</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 66%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, January 1, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">988,645</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">908,300</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.30</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(304,810</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.53</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(194,152</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.16</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,397,983</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1,149,632</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.68</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Vested</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">(587,214</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(186,025</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.58</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Restricted stock units outstanding, December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,774,376</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 14%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">1.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number</b><br/> <b>of</b> <b>Stock</b> <b>Options</b><br/> <b>Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;"><b><b>Weighted-</b><br/> <b>Average</b><br/> <b>Exercise</b><br/> <b>Price</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-</b><br/> <b>Average</b><br/> <b>Remaining</b><br/> <b>Contractual</b><br/> <b>Life (Years)</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Aggregate</b><br/> <b>Intrinsic</b><br/> <b>Value</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in</b> <b>thousands)</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 52%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">12,813,022</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">3.20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Granted</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">2,667,612</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1.82</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Forfeited</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">(375,432</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">1.79</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Expired</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">(801,749</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">3.03</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;">Exercised</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 1px solid rgb(0, 0, 0);">(19,403</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">0.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">14,284,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">2.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">5.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and exercisable options&#8212;December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">10,496,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">3.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">4.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest&#8212;December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">14,284,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 14pt; text-align: right;">2.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">5.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt;">$</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 19pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options Outstanding and Exercisable Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="10" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b> <b>Vested</b> <b>and</b> <b>Exercisable</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="3" rowspan="1" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Exercise Prices</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b><br/> <b>Stock</b> <b>Options</b><br/> <b>Outstanding</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br/> <b>Remaining</b><br/> <b>Contractual</b> <b>Life</b><br/> <b>(Years)</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br/> <b>Exercise</b> <b>Price</b> <b>per</b><br/> <b>Share</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b> <b>Subject</b><br/> <b>to Stock</b><br/> <b>Options</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b>Weighted-Average</b><br/> <b>Exercise</b> <b>Price</b> <b>per</b><br/> <b>Share</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$0.72</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619560">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$1.12</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">695,482</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">8.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">0.85</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">280,047</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">0.84</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$1.26</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619567">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$1.89</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">3,402,418</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">8.9</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">1.80</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">496,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">1.67</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$2.00</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619574">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$3.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">5,310,550</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">6.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">2.44</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">4,856,618</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">2.43</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$3.10</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619581">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$4.65</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">3,066,819</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">3.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">3.37</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">3,054,619</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">3.38</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$4.73</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619588">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$7.10</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right;">1,295,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">1.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">5.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt;">1,295,781</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">5.71</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;">$8.18</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center; width: 4%;"><span style="-sec-ix-hidden:c81619595">-</span></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">$12.27</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">513,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">2.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">10.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 13%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);">513,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">10.28</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 4%;"></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 7pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">14,284,050</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: right;">5.8</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">2.99</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">10,496,744</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt;">$</td><td style="width: 13%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 26pt; text-align: right;">3.42</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=acrx_TimebasedStockOptionMember', window );">Time-based Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="10" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year</b> <b>Ended</b> <b>December</b> <b>31,</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="5" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b style="font-size: 10pt;">2021</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="4" rowspan="1" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"><b><b style="font-size: 10pt;">2020</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">6.0</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">6.2</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt; text-align: center;">6.2</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 5pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">0.9%</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">1.3%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">0.4%</td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"><em style="font: inherit;">-</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;">1.5%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;">90%</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;">83%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 76%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;">0%</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt; text-align: center;">0%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 8pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td><td colspan="7" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 15%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Year</b> <b>Ended</b> <b>December</b> <b>31,</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2021</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>2020</b> </b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Derived service period (in years)</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;">2.3</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;"><em style="font: inherit;">&#8211;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">2.6</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">1.5%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">90%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 71%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected dividend rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: center;">0%</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=acrx_TimebasedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=acrx_TimebasedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897271832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Net Loss Per Share of Common Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">ESPP, RSUs and stock options to purchase common stock</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">16,328,426</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">14,541,005</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">17,676,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">176,679</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897256296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 16 - Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued compensation and employee benefits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">2,974</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">3,323</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional services</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">1,523</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">179</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Accrued product returns and sales allowances</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">775</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">656</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">Deferred revenue</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">86</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">49</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">1,166</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">838</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total accrued liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">6,524</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">5,045</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898393240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ScheduleOfDeferredTaxAssetsTableTextBlock', window );">Schedule of Deferred Tax Assets [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br/> <b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December</b> <b>31,</b><br/> <b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accruals and other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">3,989</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">4,136</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Research credits</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">7,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">7,275</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Net operating loss carryforward</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">75,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">65,274</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Section 59(e) R&amp;D expenditures</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">5,070</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">7,473</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Deferred revenue</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">19,666</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">20,848</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;">Total deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">111,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right;">105,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(111,452</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">(105,006</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81619742">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"><span style="-sec-ix-hidden:c81619743">&#8212;</span></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax at statutory federal rate</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(7,370</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(8,486</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax&#8212;net of federal benefit</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">231</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(3,587</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">718</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 31pt;">636</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">(20</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);">6,446</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);">11,441</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Provision for income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);">5</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">4</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="6" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December</b> <b>31,</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b><b>2021</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"><b><b>2020</b> </b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 62%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unrecognized benefit&#8212;beginning of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">2,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt;">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right;">2,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross increases&#8212;prior period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Gross increases&#8212;current period tax positions</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unrecognized benefit&#8212;end of period</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">2,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);">2,635</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ScheduleOfDeferredTaxAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ScheduleOfDeferredTaxAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897235944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ValuationAllowancesAndReservesTableTextBlock', window );">Valuation Allowances and Reserves [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>(in thousands)</b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Additions</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 48%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">&#160;</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Balance at</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Charged as a</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Balance at</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Beginning of</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Reduction to</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b><em style="font: inherit;">&#160;</em></b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">End of</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"><b>Description</b></td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Period</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Revenue</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Deductions*</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><em style="font: inherit;">Period</em></b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Sales &amp; return allowances, discounts, chargebacks and rebates:</p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year ended December 31, 2021</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">668</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">1,012</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(900</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">780</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Year ended December 31, 2020</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">161</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">645</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">(138</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">)</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td><td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">668</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom;"><td colspan="16" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;"><em style="font: inherit;">* Deductions to sales discounts and allowances relate to discounts or allowances actually taken or paid.</em></em></em></em></p> </td><td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ValuationAllowancesAndReservesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ValuationAllowancesAndReservesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670899017064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">75 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 16, 2020</div></th>
<th class="th">
<div>Sep. 18, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, Cash Equivalents, and Short-term Investments, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,630<span></span>
</td>
<td class="nump">$ 42,886<span></span>
</td>
<td class="nump">$ 51,630<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated', window );">Restructuring and Related Cost, Number of Positions Eliminated</a></td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring Charges, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights', window );">Proceeds From Sale of Royalty and Milestone Rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_RoyaltyArrangmentMaximumPayments', window );">Royalty Arrangment Maximum Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">195,000<span></span>
</td>
<td class="nump">195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NetProceedsFromSaleOfFutureRoyalties', window );">Net Proceeds from Sale of Future Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,200<span></span>
</td>
<td class="nump">$ 61,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,184<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NetProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NetProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from the sale of royalty and milestone rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_RoyaltyArrangmentMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capped amount of payments of company required to make to PDL.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_RoyaltyArrangmentMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a result of restructuring activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237686&amp;loc=d3e17752-110868<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670900270216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details) - Customer Concentration Risk [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Aguettant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">61.90%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Grunenthal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">11.70%<span></span>
</td>
<td class="nump">74.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | DoD [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">0.30%<span></span>
</td>
<td class="nump">16.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember', window );">Revenue Benchmark [Member] | Wholesaler A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">15.90%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer A [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">73.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember', window );">Accounts Receivable [Member] | Customer B [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">79.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=acrx_AguettantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=acrx_AguettantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=acrx_GrunenthalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=acrx_GrunenthalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=acrx_DoDMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=acrx_DoDMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=acrx_WholesalerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=acrx_WholesalerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=acrx_CustomerAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=acrx_CustomerAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=acrx_CustomerBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=acrx_CustomerBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895623400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Investments and Fair Value Measurement (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Debt Securities, Available-for-sale, Realized Gain (Loss), Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Debt Securities, Available-for-sale, Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax', window );">OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment, after Tax</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale', window );">Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8A<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=SL6284422-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895228216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investment, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">12,663<span></span>
</td>
<td class="nump">27,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Total cash, cash equivalents and short-term investments</a></td>
<td class="nump">51,630<span></span>
</td>
<td class="nump">42,886<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue', window );">Total cash, cash equivalents and short-term investments, fair value</a></td>
<td class="nump">51,630<span></span>
</td>
<td class="nump">42,886<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="nump">12,663<span></span>
</td>
<td class="nump">27,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">12,663<span></span>
</td>
<td class="nump">27,274<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member] | Cash [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash, amortized cost</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="nump">1,443<span></span>
</td>
<td class="nump">5,181<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member] | Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market funds, amortized cost</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalent, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investment, amortized Cost</a></td>
<td class="nump">8,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investment, fair value</a></td>
<td class="nump">8,398<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaperAtCarryingValue', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,097<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=acrx_MarketableSecuritiesMember', window );">Marketable Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investment, amortized Cost</a></td>
<td class="nump">38,967<span></span>
</td>
<td class="nump">15,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investment, fair value</a></td>
<td class="nump">38,967<span></span>
</td>
<td class="nump">15,612<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=acrx_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investment, amortized Cost</a></td>
<td class="nump">29,504<span></span>
</td>
<td class="nump">9,794<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investment, fair value</a></td>
<td class="nump">29,504<span></span>
</td>
<td class="nump">9,794<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=acrx_MarketableSecuritiesMember', window );">Marketable Securities [Member] | US Government Agencies Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investment, amortized Cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investment, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,818<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=acrx_MarketableSecuritiesMember', window );">Marketable Securities [Member] | Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Short-term investment, amortized Cost</a></td>
<td class="nump">9,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Short-term investment, fair value</a></td>
<td class="nump">$ 9,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents fair value of cash, cash equivalents and short-term investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631418-115840<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=118262064&amp;loc=SL116631419-115840<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaperAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaperAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=acrx_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=acrx_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895080424">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 50,187<span></span>
</td>
<td class="nump">$ 37,705<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByLiabilityClassAxis=acrx_ContingentPutOptionLiabilityMember', window );">Contingent Put Option Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Fair Value, Inputs, Level 1 [Member] | Contingent Put Option Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">47,365<span></span>
</td>
<td class="nump">33,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Fair Value, Inputs, Level 2 [Member] | Contingent Put Option Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Fair Value, Inputs, Level 3 [Member] | Contingent Put Option Liability [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Liabilities, fair value</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">246<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">2,822<span></span>
</td>
<td class="nump">3,996<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember', window );">Money Market Funds [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">37,902<span></span>
</td>
<td class="nump">27,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">37,902<span></span>
</td>
<td class="nump">27,891<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=acrx_USGovernmentAgencySecuritiesMember', window );">U.S. Government Agency Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=acrx_USGovernmentAgencySecuritiesMember', window );">U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=acrx_USGovernmentAgencySecuritiesMember', window );">U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,818<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=acrx_USGovernmentAgencySecuritiesMember', window );">U.S. Government Agency Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">9,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Fair Value, Inputs, Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Fair Value, Inputs, Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">9,463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities [Member] | Fair Value, Inputs, Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Assets, fair value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=acrx_ContingentPutOptionLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=acrx_ContingentPutOptionLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=acrx_USGovernmentAgencySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=acrx_USGovernmentAgencySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897533512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details) - Fair Value, Inputs, Level 3 [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, Beginning of period</a></td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 437<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings', window );">Change in fair value of contingent put option associated with the Loan Agreement</a></td>
<td class="num">(165)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements', window );">Change in fair value of contingent put option associated with the Loan Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Fair value, End of period</a></td>
<td class="nump">$ 81<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897444536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Inventories, Net (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="nump">$ 810<span></span>
</td>
<td class="nump">$ 712<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_AmendedLicenseAgreementMember', window );">Amended License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_DSUVIAMember', window );">DSUVIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory Write-down</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_AmendedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_AmendedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_DSUVIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_DSUVIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898370872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 3 - Inventories, Net - Inventory Components (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsNetOfReserves', window );">Raw materials</a></td>
<td class="nump">$ 722<span></span>
</td>
<td class="nump">$ 257<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work-in-process</a></td>
<td class="nump">159<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">1,339<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 1,111<span></span>
</td>
<td class="nump">$ 1,626<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897255464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation, Total</a></td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895054472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 26,714<span></span>
</td>
<td class="nump">$ 26,248<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(10,786)<span></span>
</td>
<td class="num">(10,589)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">15,928<span></span>
</td>
<td class="nump">15,659<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_LaboratoryEquipmentMember', window );">Laboratory Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">4,406<span></span>
</td>
<td class="nump">4,406<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">5,838<span></span>
</td>
<td class="nump">4,616<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_ComputerEquipmentAndSoftwareMember', window );">Computer Equipment and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">1,589<span></span>
</td>
<td class="nump">1,724<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">13,805<span></span>
</td>
<td class="nump">14,101<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_ToolingMember', window );">Tooling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">826<span></span>
</td>
<td class="nump">1,109<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and Equipment, Gross</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 292<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_ComputerEquipmentAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_ComputerEquipmentAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_ToolingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=acrx_ToolingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898966360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 5 - In-license Agreement (Details Textual) - Aguettant [Member] - PFS Products [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 14, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementTerm', window );">License Agreement, Term (Year)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementRenewalTerm', window );">License Agreement, Renewal Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum', window );">License Agreement, Milestone Payments to be Paid, Maximum</a></td>
<td class="nump">$ 24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementMinimumSalesObligationTerm', window );">License Agreement, Minimum Sales Obligation Term (Month)</a></td>
<td class="text">12 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acrx_AguettantMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid', window );">License Agreement, Percent of Revenue Share Payment to be Paid</a></td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acrx_AguettantMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid', window );">License Agreement, Percent of Revenue Share Payment to be Paid</a></td>
<td class="nump">45.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum amount of milestone payments to be paid under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementMinimumSalesObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the minimum sales obligation term under license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementMinimumSalesObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of revenue share payments to be paid under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The renewal term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=acrx_AguettantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=acrx_AguettantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_PFSProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_PFSProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898550744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Out-license Agreements (Details Textual)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 14, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 17, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_AmendedLicenseAgreementMember', window );">Amended License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets', window );">Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 194,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_AmendedLicenseAgreementMember', window );">Amended License Agreement [Member] | Based upon Successful Regulatory and Product Development Efforts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets', window );">Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_AmendedLicenseAgreementMember', window );">Amended License Agreement [Member] | Based upon Net Sales Target Achievements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets', window );">Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 166,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acrx_AguettantMember', window );">Aguettant [Member] | DZUVEO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementRenewalTerm', window );">License Agreement, Renewal Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived', window );">License Agreement, Upfront and Maximum Milestone Payments to be Received | &#8364;</a></td>
<td class="nump">&#8364; 47.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments', window );">Proceeds form Up-front and Sales-based Milestone License Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">&#8364; 2.5<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">&#8364; 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acrx_AguettantMember', window );">Aguettant [Member] | DZUVEO [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived', window );">License Agreement, Percent of Revenue Share Payments to be Received</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acrx_AguettantMember', window );">Aguettant [Member] | DZUVEO [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived', window );">License Agreement, Percent of Revenue Share Payments to be Received</a></td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of revenue share payments to be received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The renewal term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the upfront payments and the maximum amount of milestone payments to be received under license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from up-front and share-based millstone license payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of additional milestone payments the Company is eligible to receive based upon successful regulatory and product development efforts and net sales target achievements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_AmendedLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_AmendedLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=acrx_BasedUponNetSalesTargetAchievementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=acrx_BasedUponNetSalesTargetAchievementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=acrx_AguettantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=acrx_AguettantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_DZUVEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_DZUVEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898599352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Revenue From Contracts With Customers (Details Textual)<br> $ in Thousands, &#8364; in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 14, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,818<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="nump">$ 3,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_DZUVEOMember', window );">DZUVEO [Member] | Aguettant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments', window );">Proceeds form Up-front and Sales-based Milestone License Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">&#8364; 2.5<span></span>
</td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">&#8364; 2.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived', window );">License Agreement, Milestone Payments and Revenue Share Payments to be Received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementTerm', window );">License Agreement, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LicenseAgreementRenewalTerm', window );">License Agreement, Renewal Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with Customer, Liability, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract with Customer, Liability, Current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Capitalized Contract Cost, Amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_ZALVISOMember', window );">ZALVISO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue from Contract with Customer, Including Assessed Tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 270<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ContractWithCustomerLiabilityLiabilityEliminated', window );">Contract with Customer, Liability, Liability Eliminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ContractWithCustomerLiabilityLiabilityEliminated">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the contract with customer liability eliminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ContractWithCustomerLiabilityLiabilityEliminated</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents milestone payments and revenue share payments to be received for license agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The renewal term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LicenseAgreementTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LicenseAgreementTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash inflow from up-front and share-based millstone license payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123353750&amp;loc=SL49131252-203054<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_DZUVEOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_DZUVEOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=acrx_AguettantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=acrx_AguettantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_ZALVISOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_ZALVISOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895005032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 2,818<span></span>
</td>
<td class="nump">$ 5,416<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_DSUVIAMember', window );">DSUVIA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">735<span></span>
</td>
<td class="nump">1,409<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_ZALVISOMember', window );">ZALVISO [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">270<span></span>
</td>
<td class="nump">1,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,005<span></span>
</td>
<td class="nump">2,521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">1,696<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_NonCashRoyaltyMember', window );">Non-cash Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">242<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember', window );">Royalty [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">81<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_ContractAndOtherRevenueMember', window );">Contract and Other Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">2,572<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=acrx_ContractAndOtherCollaborationMember', window );">Contract and Other Collaboration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax', window );">Revenue</a></td>
<td class="nump">$ 1,813<span></span>
</td>
<td class="nump">$ 2,895<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_DSUVIAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_DSUVIAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_ZALVISOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_ZALVISOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_NonCashRoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_NonCashRoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_RoyaltyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_RoyaltyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_ContractAndOtherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_ContractAndOtherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=acrx_ContractAndOtherCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=acrx_ContractAndOtherCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898674104">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Revenue From Contracts With Customers - Contract Liability (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 3,244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod', window );">In current period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(49)<span></span>
</td>
<td class="num">(623)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">In prior periods(1)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,572)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ContractWithCustomerLiabilityAdditions', window );">Additions(2)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="nump">1,237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,237<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">In May 2020, upon notification of early termination by Gr&#252;nenthal, the Company recognized approximately $2.6 million of deferred revenue under the Gr&#252;nenthal Agreements.</td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top">Deferred revenue under the DZUVEO Agreement with Aguettant.</td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ContractWithCustomerLiabilityAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ContractWithCustomerLiabilityAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents contract with customer liability revenue recognized during current period,</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895539064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Long-term Debt (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 01, 2019</div></th>
<th class="th"><div>May 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,833,000<span></span>
</td>
<td class="nump">$ 4,667,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,803,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">761,000<span></span>
</td>
<td class="nump">$ 1,069,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold Improvements, Gross</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=acrx_SiteReadinessAgreementMember', window );">Site Readiness Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.35%<span></span>
</td>
<td class="nump">14.35%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal', window );">Debt Instrument, Periodic Payment, Principal</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_TotalObligationUnderLeaseholdAgreement', window );">Total Obligation Under Leasehold Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember', window );">Warrant In Connection with Oxford Finance Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=acrx_LoanAgreementWithOxfordFinanceLLCMember', window );">Loan Agreement with Oxford Finance LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt', window );">Proceeds from Debt, Net of Issuance Costs and Repayment of Debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_DebtInstrumentInterestRateBasePercentage', window );">Debt Instrument, Interest Rate, Base Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021', window );">Prepayment Charge, Percentage of Outstanding Balance, After May 30, 2020, Before May 30, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash', window );">Debt Instrument, Covenant, Minimum Required Unrestircted Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight', window );">Debt Instrument, Minimum Indebtedness Amount with Acceleration Right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments', window );">Loan Default Events, Trigger of Negative Impact of Government Approvals and Judgments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_DebtInstrumentDefaultAdditionalInterestRate', window );">Debt Instrument, Default Additional Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_FairValueOfContingentPutOptionLiability', window );">Fair Value of Contingent Put Option, Liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,300,000<span></span>
</td>
<td class="nump">21,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest Expense, Debt, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,200,000<span></span>
</td>
<td class="nump">3,200,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Debt Instrument, Interest Rate, Effective Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.15%<span></span>
</td>
<td class="nump">13.15%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=acrx_LoanAgreementWithOxfordFinanceLLCMember', window );">Loan Agreement with Oxford Finance LLC [Member] | London Interbank Offered Rate (LIBOR) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Debt Instrument, Basis Spread on Variable Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount of unrestricted cash required to be maintained by the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_DebtInstrumentDefaultAdditionalInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the default additional interest rate for debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_DebtInstrumentDefaultAdditionalInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_DebtInstrumentInterestRateBasePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual base interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_DebtInstrumentInterestRateBasePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents minimum indebtedness amount with acceleration right under debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_FairValueOfContingentPutOptionLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the fair value of contingent put option liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_FairValueOfContingentPutOptionLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the trigger of negative impact of government approvals and judgments for loan default events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of outstanding balance for repayment charge if prepayment occurs after May 30, 2020 and before May 30, 2021.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of debt, net of issuance costs paid to third parties and repayments of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_TotalObligationUnderLeaseholdAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents total obligation under leasehold agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_TotalObligationUnderLeaseholdAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPaymentPrincipal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments applied to principal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPaymentPrincipal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6036836-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69F<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495745-112612<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69E<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495743-112612<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495355-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=acrx_SiteReadinessAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=acrx_SiteReadinessAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=acrx_LoanAgreementWithOxfordFinanceLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=acrx_LoanAgreementWithOxfordFinanceLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_LondonInterbankOfferedRateLIBORMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670899365016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo', window );">2022</a></td>
<td class="nump">$ 9,647<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree', window );">2023</a></td>
<td class="nump">5,530<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LongTermDebtTotalMinimumPayments', window );">Total payments</a></td>
<td class="nump">15,177<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LongTermDebtMaturitiesRepaymentsOfInterest', window );">Less amount representing interest</a></td>
<td class="num">(927)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NotesPayableGross', window );">Notes payable, gross</a></td>
<td class="nump">14,250<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_DebtInstrumentUnamortizedEotFee', window );">Less: Unamortized portion of EOT Fee</a></td>
<td class="num">(200)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Less: Unamortized discount on notes payable</a></td>
<td class="num">(247)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Long-term debt</a></td>
<td class="nump">13,803<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less current portion</a></td>
<td class="num">(8,796)<span></span>
</td>
<td colspan="2" class="num">$ (8,735)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt, net of current portion</a></td>
<td class="nump">$ 5,007<span></span>
</td>
<td colspan="2" class="nump">$ 13,140<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_DebtInstrumentUnamortizedEotFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents debt instrument unamortized EOT fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_DebtInstrumentUnamortizedEotFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum payments for both principal and interest on long-term debt to be paid in the second fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LongTermDebtMaturitiesRepaymentsOfInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the interest portion of future minimum payments on long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LongTermDebtMaturitiesRepaymentsOfInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LongTermDebtTotalMinimumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the future minimum payments on long-term debt, including both principal and interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LongTermDebtTotalMinimumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum payments for both principal and interest on long-term debt to be paid in the third fiscal year following the latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NotesPayableGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, after subtracting the amount representing interest but before subtracting any balloon payment(s) or unamortized discount, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NotesPayableGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28541-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670894871768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Leases (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 26, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 12, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th" colspan="2">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 21, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain (Loss) on Termination of Lease</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 522,000<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,302,000<span></span>
</td>
<td class="nump">$ 3,150,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LesseeOperatingLeaseNoticePeriod', window );">Lessee, Operating Lease, Notice Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LesseeOperatingLeaseAnnualOverheadFeePayments', window );">Lessee, Operating Lease, Annual Overhead Fee Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acrx_CatalentPharmaSolutionsMember', window );">Catalent Pharma Solutions [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, Operating Lease, Renewal Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acrx_CatalentPharmaSolutionsMember', window );">Catalent Pharma Solutions [Member] | Forecast [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LesseeOperatingSubleaseDeferredCosts', window );">Lessee, Operating Sublease, Deferred Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember', window );">Lease for Corporate Headquarters in Hayward, California [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfRealEstateProperty', window );">Area of Real Estate Property (Square Foot) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Lessee, Operating Lease, Term of Contract (Year)</a></td>
<td class="text">2 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LesseeOperatingLeaseMonthlyRent', window );">Lessee, Operating Lease, Monthly Rent</a></td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LesseeOperatingLeaseAbatedRentPeriod', window );">Lessee, Operating Lease, Abated Rent Period (Month)</a></td>
<td class="text">1 month<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating Lease, Right-of-Use Asset</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="9"></td></tr>
<tr><td colspan="9"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LesseeOperatingLeaseAbatedRentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The period of abated rent of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LesseeOperatingLeaseAbatedRentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LesseeOperatingLeaseAnnualOverheadFeePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required fee payments per year for overhead, prorated based on aggregate revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LesseeOperatingLeaseAnnualOverheadFeePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LesseeOperatingLeaseMonthlyRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the monthly rent required for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LesseeOperatingLeaseMonthlyRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LesseeOperatingLeaseNoticePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease termination notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LesseeOperatingLeaseNoticePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LesseeOperatingSubleaseDeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for operating sublease deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LesseeOperatingSubleaseDeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfRealEstateProperty">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of a real estate property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfRealEstateProperty</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=acrx_CatalentPharmaSolutionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=acrx_CatalentPharmaSolutionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670899007224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 9 - Leases - Operating Lease Costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 26, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,467<span></span>
</td>
<td class="nump">$ 1,360<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnTerminationOfLease', window );">Gain on derecognition of operating lease</a></td>
<td class="num">$ (500)<span></span>
</td>
<td class="num">(522)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(199)<span></span>
</td>
<td class="num">(598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_GainLossOnTerminationOfSublease', window );">Loss on termination of sublease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Net lease costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,077<span></span>
</td>
<td class="nump">$ 762<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted-average remaining lease term &#8211; operating leases (in years) (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 11 months 19 days<span></span>
</td>
<td class="text">3 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted-average remaining discount rate &#8211; operating leases (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.80%<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_GainLossOnTerminationOfSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of sublease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_GainLossOnTerminationOfSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 40<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123386189&amp;loc=SL77918607-209975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898687912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 9 - Leases - Maturities of Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><sup>[1]</sup></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">$ 1,608<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">1,244<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">1,040<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">1,040<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2026</a></td>
<td class="nump">1,040<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">415<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum lease payments</a></td>
<td class="nump">6,387<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less imputed interest</a></td>
<td class="num">(1,569)<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">4,818<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="nump">4,818<span></span>
</td>
<td colspan="2" class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current portion</a></td>
<td class="num">(1,068)<span></span>
</td>
<td colspan="2" class="num">$ (1,118)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, net of current portion</a></td>
<td class="nump">$ 3,750<span></span>
</td>
<td colspan="2" class="nump">$ 2,606<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895068952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Liability Related to Sale of Future Royalties (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">75 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 18, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights', window );">Proceeds From Sale of Royalty and Milestone Rights</a></td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="nump">$ 65,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_RoyaltyArrangmentMaximumPayments', window );">Royalty Arrangment Maximum Payments</a></td>
<td class="nump">195,000<span></span>
</td>
<td class="nump">195,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NetProceedsFromSaleOfFutureRoyalties', window );">Net Proceeds from Sale of Future Royalties</a></td>
<td class="nump">$ 61,200<span></span>
</td>
<td class="nump">$ 61,200<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 61,184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ContingentGainLossOnRoyaltyMonetizationArrangement', window );">Contingent Gain (Loss) on Royalty Monetization Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 64,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties', window );">Effective Interest Over Life of Liability Related to Sale of Future Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_EffectiveAnnualInterestRate', window );">Effective Annual Interest Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.60%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=acrx_SWKMember', window );">SWK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_PercentageOfRoyaltiesAndRightsUnderAgreement', window );">Percentage of Royalties and Rights Under Agreement</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=acrx_SWKMember', window );">SWK [Member] | First Four Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_PercentageOfRoyaltiesAndRightsUnderAgreement', window );">Percentage of Royalties and Rights Under Agreement</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_CommercialMilestonesValueMaximumAmountAvailable', window );">Commercial Milestones Value Maximum Amount Available</a></td>
<td class="nump">$ 35,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=acrx_AcelRXMember', window );">AcelRX [Member] | First Four Commercial Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_CommercialMilestonesValueMaximumAmountAvailable', window );">Commercial Milestones Value Maximum Amount Available</a></td>
<td class="nump">$ 44,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_CommercialMilestonesValueMaximumAmountAvailable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum value of commercial milestone payments available to the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_CommercialMilestonesValueMaximumAmountAvailable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ContingentGainLossOnRoyaltyMonetizationArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of contingent gain (loss) on royalty monetization arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ContingentGainLossOnRoyaltyMonetizationArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_EffectiveAnnualInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective annual rate for a liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_EffectiveAnnualInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of effective interest over the life of the liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NetProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NetProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_PercentageOfRoyaltiesAndRightsUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties or milestone rights to be received under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_PercentageOfRoyaltiesAndRightsUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of proceeds from the sale of royalty and milestone rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_RoyaltyArrangmentMaximumPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capped amount of payments of company required to make to PDL.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_RoyaltyArrangmentMaximumPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=acrx_SWKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=acrx_SWKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=acrx_FirstFourCommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=acrx_FirstFourCommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=acrx_AcelRXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=acrx_AcelRXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670899006264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1">75 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 18, 2015</div></th>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LiabilityRelatedToSaleOfFutureRoyalties', window );">Liability related to sale of future royalties &#8212; beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 88,471<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NetProceedsFromSaleOfFutureRoyalties', window );">Proceeds from sale of future royalties</a></td>
<td class="nump">$ 61,200<span></span>
</td>
<td class="nump">$ 61,200<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,184<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized', window );">Non-cash royalty revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,083)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties', window );">Non-cash interest (income) expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,038)<span></span>
</td>
<td class="num">$ (3,310)<span></span>
</td>
<td class="nump">25,187<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet', window );">Liability related to sale of future royalties as of December 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 85,288<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents liability related to future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liability related to sale of future royalties less current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NetProceedsFromSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NetProceedsFromSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amoutn of noncash interest income expense on liability related to sale of future royalties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of non-cash royalty revenue recognized in connection to royalty monetization that has been realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670894339464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 11 - Warrants (Details Textual)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 17, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 15, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>May 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>yr </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,716,000<span></span>
</td>
<td class="nump">$ 21,337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,716,000<span></span>
</td>
<td class="nump">21,337,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,562,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_RegisteredDirectOfferingMember', window );">2021 Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">$ 13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="nump">$ 14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_RegisteredDirectOfferingMember', window );">2021 Registered Direct Offering [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember', window );">November 2021 Financing Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfWarrants', window );">Proceeds from Issuance of Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember', window );">November 2021 Financing Warrants [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember', window );">November 2021 Financing Warrants [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember', window );">November 2021 Financing Warrants [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember', window );">November 2021 Financing Warrants [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember', window );">November 2021 Financing Warrants [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable', window );">Class of Warrant or Right, Required Percentage of Ownership to Become Exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember', window );">November 2021 Financing Warrants [Member] | 2021 Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember', window );">Warrant In Connection with Oxford Finance Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,679<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Class of Warrant or Right, Outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">176,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember', window );">Warrant In Connection with Oxford Finance Loan Agreement [Member] | Measurement Input, Share Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember', window );">Warrant In Connection with Oxford Finance Loan Agreement [Member] | Measurement Input, Expected Term [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input | yr</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember', window );">Warrant In Connection with Oxford Finance Loan Agreement [Member] | Measurement Input, Price Volatility [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.8022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember', window );">Warrant In Connection with Oxford Finance Loan Agreement [Member] | Measurement Input, Risk Free Interest Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.0222<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember', window );">Warrant In Connection with Oxford Finance Loan Agreement [Member] | Measurement Input, Exercise Price [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember', window );">Warrant In Connection with Oxford Finance Loan Agreement [Member] | Measurement Input, Expected Dividend Rate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput', window );">Warrants and Rights Outstanding, Measurement Input</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents required percentage of ownership in order for warrants become exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acrx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputRiskFreeInterestRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputSharePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedTermMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputPriceVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExercisePriceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputExpectedDividendRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898816584">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 12 - Commitments and Contingencies (Details Textual)<br></strong></div></th>
<th class="th"><div>Jul. 06, 2021</div></th>
<th class="th"><div>Jun. 08, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member', window );">Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Loss Contingency, Number of Defendants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember', window );">Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyNumberOfDefendants', window );">Loss Contingency, Number of Defendants</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyNumberOfDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of defendants named in a legal action.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyNumberOfDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670892552552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 13 - Stockholders' Equity (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 17, 2021</div></th>
<th class="th"><div>Nov. 15, 2021</div></th>
<th class="th"><div>Jun. 17, 2021</div></th>
<th class="th"><div>Jan. 27, 2021</div></th>
<th class="th"><div>Jan. 27, 2021</div></th>
<th class="th"><div>Jan. 22, 2021</div></th>
<th class="th"><div>Dec. 11, 2020</div></th>
<th class="th"><div>Jul. 23, 2020</div></th>
<th class="th"><div>May 09, 2019</div></th>
<th class="th"><div>Jun. 21, 2016</div></th>
<th class="th"><div>Jan. 31, 2011</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jun. 16, 2020</div></th>
<th class="th"><div>Dec. 31, 2011</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,716,000<span></span>
</td>
<td class="nump">$ 21,337,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44,716,000<span></span>
</td>
<td class="nump">21,337,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price (in dollars per share)</a></td>
<td class="nump">$ 0.7491<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued, Ending Balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 137,000<span></span>
</td>
<td class="nump">$ 98,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue', window );">Employee Stock Purchase Plan, Shares Issued, Weighted Average Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.01<span></span>
</td>
<td class="nump">$ 1.09<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acrx_EquityIncentivePlan2011Member', window );">2011 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding', window );">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed', window );">Stock Option Plan Option Reserve Annual Increase as Percentage of Outstanding Shares Allowed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">5,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,858,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares to be Added (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">14,892,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acrx_EmployeeStockPurchasePlanESPPMember', window );">Employee Stock Purchase Plan (ESPP) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,959<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">4,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,456,364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember', window );">November 2021 Financing Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Warrants and Rights Outstanding</a></td>
<td class="nump">$ 5,600,000<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement [Member] | Armistice Capital and Rock Springs Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,675,000<span></span>
</td>
<td class="nump">2,175,000<span></span>
</td>
<td class="nump">14,500,000<span></span>
</td>
<td class="nump">8,333,333<span></span>
</td>
<td class="nump">9,433,962<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.7625<span></span>
</td>
<td class="nump">$ 1.7625<span></span>
</td>
<td class="nump">$ 1.7625<span></span>
</td>
<td class="nump">$ 1.20<span></span>
</td>
<td class="nump">$ 1.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,900,000<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_EstimatedOfferingCosts', window );">Estimated Offering Costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,000<span></span>
</td>
<td class="nump">$ 49,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_RegisteredDirectOfferingMember', window );">2021 Registered Direct Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants', window );">Net Proceeds from Issuance of Common Stock and Exercise of Warrants</a></td>
<td class="nump">$ 13,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="nump">13,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity, Total</a></td>
<td class="nump">14,000,000.0<span></span>
</td>
<td class="nump">14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common Stock, Value, Issued, Ending Balance</a></td>
<td class="nump">$ 8,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_RegisteredDirectOfferingMember', window );">2021 Registered Direct Offering [Member] | November 2021 Financing Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_ATMAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000.0<span></span>
</td>
<td class="nump">876,800<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,000<span></span>
</td>
<td class="nump">$ 1,400,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_AggregateOfferingPriceMaximum', window );">Aggregate Offering Price, Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_AggregateOfferingPriceIncreaseDuringPeriod', window );">Aggregate Offering Price, Increase During Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="17"></td></tr>
<tr><td colspan="17"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_AggregateOfferingPriceIncreaseDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the aggregate offering price increase during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_AggregateOfferingPriceIncreaseDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_AggregateOfferingPriceMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the maximum aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_AggregateOfferingPriceMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the weighted average fair value of shares issued under an ESPP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_EstimatedOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of estimated offering costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_EstimatedOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock and exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the shared-based compensation arrangement by share-based payment award equity instrument other than options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of additional shares that could be added from expired or cancelled shares already issued under another share-based payment plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the stock option plan option reserve annual increase as percentage of outstanding shares allowed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acrx_EquityIncentivePlan2011Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acrx_EquityIncentivePlan2011Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acrx_EmployeeStockPurchasePlanESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acrx_EmployeeStockPurchasePlanESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=acrx_November2021FinancingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=acrx_ArmisticeCapitalAndRockSpringsCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=acrx_ArmisticeCapitalAndRockSpringsCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_RegisteredDirectOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acrx_RegisteredDirectOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_ATMAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acrx_ATMAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670894779480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation (Details Textual) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 03, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.24<span></span>
</td>
<td class="nump">$ 0.92<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 3,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,667,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,858,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member] | Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember', window );">The 2020 Equity Incentive Plan [Member] | Executive Officer [Member] | Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="nump">$ 1.88<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="nump">1,270,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acrx_The2020EquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670900167480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 4,609<span></span>
</td>
<td class="nump">$ 4,424<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">92<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">813<span></span>
</td>
<td class="nump">764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 3,704<span></span>
</td>
<td class="nump">$ 3,537<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898570888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Restricted Stock Activity (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="nump">1,397,983<span></span>
</td>
<td class="nump">988,645<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock units weighted average outstanding (in dollars per share)</a></td>
<td class="nump">$ 1.79<span></span>
</td>
<td class="nump">$ 2.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">1,149,632<span></span>
</td>
<td class="nump">908,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, granted (in dollars per share)</a></td>
<td class="nump">$ 1.68<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(587,214)<span></span>
</td>
<td class="num">(304,810)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, vested (in dollars per share)</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="nump">$ 2.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(186,025)<span></span>
</td>
<td class="num">(194,152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, forfeited (in dollars per share)</a></td>
<td class="nump">$ 1.58<span></span>
</td>
<td class="nump">$ 2.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Restricted stock units outstanding (in shares)</a></td>
<td class="nump">1,774,376<span></span>
</td>
<td class="nump">1,397,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Restricted stock units weighted average outstanding (in dollars per share)</a></td>
<td class="nump">$ 1.71<span></span>
</td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670898876344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Option Activity (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">12,813,022<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,667,612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.82<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(375,432)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 1.79<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(801,749)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(19,403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding (in shares) | shares</a></td>
<td class="nump">14,284,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, weighted-average remaining contractual life (Year)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, aggregate intrinsic value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber', window );">Vested and exercisable options (in shares) | shares</a></td>
<td class="nump">10,496,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable options, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 3.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm', window );">Vested and exercisable options, weighted-average remaining contractual life (Year)</a></td>
<td class="text">4 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Vested and exercisable options, aggregate intrinsic value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares) | shares</a></td>
<td class="nump">14,284,050<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted-average exercise price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 2.99<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted-average remaining contractual life (Year)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, aggregate intrinsic value | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670889984840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding (in shares)</a></td>
<td class="nump">14,284,050<span></span>
</td>
<td class="nump">12,813,022<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual LIfe (Year)</a></td>
<td class="text">5 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 2.99<span></span>
</td>
<td class="nump">$ 3.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares Subject to Stock Options (in shares)</a></td>
<td class="nump">10,496,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice', window );">Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 3.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange1Member', window );">Exercise Price Range 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">0.72<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 1.12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding (in shares)</a></td>
<td class="nump">695,482<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual LIfe (Year)</a></td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares Subject to Stock Options (in shares)</a></td>
<td class="nump">280,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice', window );">Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 0.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange2Member', window );">Exercise Price Range 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">1.26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 1.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding (in shares)</a></td>
<td class="nump">3,402,418<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual LIfe (Year)</a></td>
<td class="text">8 years 10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 1.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares Subject to Stock Options (in shares)</a></td>
<td class="nump">496,679<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice', window );">Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 1.67<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange3Member', window );">Exercise Price Range 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 3.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding (in shares)</a></td>
<td class="nump">5,310,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual LIfe (Year)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 2.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares Subject to Stock Options (in shares)</a></td>
<td class="nump">4,856,618<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice', window );">Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 2.43<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange4Member', window );">Exercise Price Range 4 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">3.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 4.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding (in shares)</a></td>
<td class="nump">3,066,819<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual LIfe (Year)</a></td>
<td class="text">3 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 3.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares Subject to Stock Options (in shares)</a></td>
<td class="nump">3,054,619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice', window );">Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 3.38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange5Member', window );">Exercise Price Range 5 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">4.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 7.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding (in shares)</a></td>
<td class="nump">1,295,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual LIfe (Year)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 5.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares Subject to Stock Options (in shares)</a></td>
<td class="nump">1,295,781<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice', window );">Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 5.71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange6Member', window );">Exercise Price Range 6 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Exercise Price Range, Lower Range Limit (in dollars per share)</a></td>
<td class="nump">8.18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Exercise Price Range, Upper Range Limit (in dollars per share)</a></td>
<td class="nump">$ 12.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Stock Options Outstanding (in shares)</a></td>
<td class="nump">513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-average Remaining Contractual LIfe (Year)</a></td>
<td class="text">2 years 1 month 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Shares Subject to Stock Options (in shares)</a></td>
<td class="nump">513,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice', window );">Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 10.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange4Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange4Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange5Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange5Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange6Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=acrx_ExercisePriceRange6Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670889968376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details) - Performance Shares [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.50%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Derived service period (in years) (Year)</a></td>
<td class="text">2 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Derived service period (in years) (Year)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895512008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details) - Time-based Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">90.00%<span></span>
</td>
<td class="nump">83.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend rate</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=acrx_TimebasedStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=acrx_TimebasedStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670894793448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=acrx_RSUsESPPAndEmployeeStockOptionsMember', window );">RSU's, ESPP, and Employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">16,328,426<span></span>
</td>
<td class="nump">14,541,005<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities (in shares)</a></td>
<td class="nump">17,676,679<span></span>
</td>
<td class="nump">176,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=acrx_RSUsESPPAndEmployeeStockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=acrx_RSUsESPPAndEmployeeStockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670901511368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 16 - Accrued Liabilities - Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">$ 2,974<span></span>
</td>
<td class="nump">$ 3,323<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional services</a></td>
<td class="nump">1,523<span></span>
</td>
<td class="nump">179<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_AccruedProductReturnsAndSalesAllowancesCurrent', window );">Accrued product returns and sales allowances</a></td>
<td class="nump">775<span></span>
</td>
<td class="nump">656<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_AccruedDeferredRevenueCurrent', window );">Deferred revenue</a></td>
<td class="nump">86<span></span>
</td>
<td class="nump">49<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">1,166<span></span>
</td>
<td class="nump">838<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 6,524<span></span>
</td>
<td class="nump">$ 5,045<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_AccruedDeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for deferred revenue. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_AccruedDeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_AccruedProductReturnsAndSalesAllowancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents current accrued product returns and sales allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_AccruedProductReturnsAndSalesAllowancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897338968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 17 - 401(k) Plan (Details Textual) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage', window );">Defined Contribution Plan, Employer Discretionary Contribution Percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_ContributionsByEmployerToPostemploymentBenefitObligations', window );">Contributions by Employer to Postemployment Benefit Obligations</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_ContributionsByEmployerToPostemploymentBenefitObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_ContributionsByEmployerToPostemploymentBenefitObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670895116968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Income Taxes (Details Textual) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</a></td>
<td class="nump">6,400<span></span>
</td>
<td class="nump">11,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2016 2017 2018 2019 2020 2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Increase (Decrease) in Employee Related Liabilities, Total</a></td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=acrx_SubjectToExpirationMember', window );">Subject to Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research Tax Credit Carryforward [Member] | Subject to Expiration [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">26<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">308,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">6,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Before Tax Year 2018 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">114,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member] | Tax Years 2018 to 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">193,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating Loss Carryforwards, Total</a></td>
<td class="nump">154,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member] | Research Tax Credit Carryforward [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax Credit Carryforward, Amount</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=acrx_SubjectToExpirationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=acrx_SubjectToExpirationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acrx_BeforeTaxYear2018Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acrx_BeforeTaxYear2018Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxPeriodAxis=acrx_TaxYears2018To2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxPeriodAxis=acrx_TaxYears2018To2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670901515688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 18 - Income Taxes - Net Deferred Tax Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther', window );">Accruals and other</a></td>
<td class="nump">$ 3,989<span></span>
</td>
<td class="nump">$ 4,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research credits</a></td>
<td class="nump">7,275<span></span>
</td>
<td class="nump">7,275<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforward</a></td>
<td class="nump">75,452<span></span>
</td>
<td class="nump">65,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Section 59(e) R&amp;D expenditures</a></td>
<td class="nump">5,070<span></span>
</td>
<td class="nump">7,473<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">19,666<span></span>
</td>
<td class="nump">20,848<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax assets</a></td>
<td class="nump">111,452<span></span>
</td>
<td class="nump">105,006<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(111,452)<span></span>
</td>
<td class="num">(105,006)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670899354040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at statutory federal rate</a></td>
<td class="num">$ (7,370)<span></span>
</td>
<td class="num">$ (8,486)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State tax&#8212;net of federal benefit</a></td>
<td class="nump">231<span></span>
</td>
<td class="num">(3,587)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="num">(20)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">6,446<span></span>
</td>
<td class="nump">11,441<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897145128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized benefit&#8212;beginning of period</a></td>
<td class="nump">$ 2,635<span></span>
</td>
<td class="nump">$ 2,635<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Gross increases&#8212;prior period tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Gross increases&#8212;current period tax positions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized benefit&#8212;end of period</a></td>
<td class="nump">$ 2,635<span></span>
</td>
<td class="nump">$ 2,635<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670899368392">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 19 - Subsequent Events (Details Textual) - Lowell Therapeutics [Member] - USD ($)<br></strong></div></th>
<th class="th"><div>Jan. 07, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=acrx_LowellTherapeuticsMember', window );">Other Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquisitionCostsCumulative', window );">Acquisition Costs, Cumulative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired', window );">Business Combination, Consideration Transferred, Net of Cash Acquired</a></td>
<td class="nump">$ 32,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | AcelRx Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber', window );">Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Number (in shares)</a></td>
<td class="nump">9,009,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash', window );">Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Cash</a></td>
<td class="nump">$ 3,519,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations', window );">Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)</a></td>
<td class="nump">1,396,526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Business Combination, Contingent Consideration, Liability, Total</a></td>
<td class="nump">$ 26,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare', window );">Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Fixed Value per Share (in dollars per share)</a></td>
<td class="nump">$ 0.57284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents acquiree common stock to be held back to satisfy some obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents acquiree common stock to be held back to satisfy some obligations, fixed value per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of options to purchase capital stock and all shares of capital stock issued and outstanding in exchange for cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents options to purchase capital stock and all shares of stock issued and outstanding cancelled in exchange for right to receive common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acrx_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquisitionCostsCumulative">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The capitalized costs incurred (excluded from amortization), as of the date of the balance sheet, to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 932<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-10.(c)(7)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=123726172&amp;loc=d3e511914-122862<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquisitionCostsCumulative</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=acrx_LowellTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=acrx_LowellTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acrx_AcelrxCommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acrx_AcelrxCommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139670897406392">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details) - SEC Schedule, 12-09, Allowance, Sales and Returns, Discounts, Chargebacks and Rebates [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 668<span></span>
</td>
<td class="nump">$ 161<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,012<span></span>
</td>
<td class="nump">645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="num">(900)<span></span>
</td>
<td class="num">(138)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 780<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top">Deductions to sales discounts and allowances relate to discounts or allowances actually taken or paid.</td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>acrx20211231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:acrx="http://www.acelrx.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="acrx-20211231.xsd" xlink:type="simple"/>
    <context id="d_2021-01-01_2021-12-31_LegalEntityAxis-OUMCoLLPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">acrx:OUMCoLLPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2022-03-07">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <instant>2022-03-07</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ContractAndOtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ContractAndOtherCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AssetAcquisitionAxis-LowellsIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">acrx:LowellsIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AssetAcquisitionAxis-LowellsIntellectualPropertyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">acrx:LowellsIntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-GrunenthalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:GrunenthalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-GrunenthalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:GrunenthalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DoDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DoDMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:DoDMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-WholesalerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:WholesalerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-WholesalerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:WholesalerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:CustomerAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">acrx:CustomerBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-03-16_2020-03-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2020-03-16</startDate>
            <endDate>2020-03-16</endDate>
        </period>
    </context>
    <context id="d_2015-09-01_2015-09-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-09-30</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CashMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashAndCashEquivalentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">acrx:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2019-01-01_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acrx:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acrx:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acrx:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">acrx:USGovernmentAgencySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">acrx:ContingentPutOptionLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-AmendedLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:AmendedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-DSUVIAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DSUVIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:ComputerEquipmentAndSoftwareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:ToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acrx:ToolingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:PFSProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:PFSProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-14</instant>
        </period>
    </context>
    <context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:PFSProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:PFSProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-14</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-09-30_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-14</startDate>
            <endDate>2021-07-14</endDate>
        </period>
    </context>
    <context id="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:AmendedLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-17</instant>
        </period>
    </context>
    <context id="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:AmendedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">acrx:BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-17</instant>
        </period>
    </context>
    <context id="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponNetSalesTargetAchievementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:AmendedLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">acrx:BasedUponNetSalesTargetAchievementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-07-17</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-DSUVIAMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DSUVIAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ZALVISOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ZALVISOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ZALVISOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ZALVISOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-LicenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-NonCashRoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:NonCashRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NonCashRoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:NonCashRoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:RoyaltyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ContractAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ContractAndOtherRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-07-01_2021-07-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:AguettantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:DZUVEOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="d_2020-05-01_2020-05-31_ProductOrServiceAxis-ZALVISOMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">acrx:ZALVISOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-30</startDate>
            <endDate>2019-05-30</endDate>
        </period>
    </context>
    <context id="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:LondonInterbankOfferedRateLIBORMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-30</startDate>
            <endDate>2019-05-30</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">acrx:LoanAgreementWithOxfordFinanceLLCMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2019-08-01_2019-08-01_LongtermDebtTypeAxis-SiteReadinessAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acrx:SiteReadinessAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-01</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acrx:SiteReadinessAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acrx:SiteReadinessAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acrx:LeaseForCorporateHeadquartersInHaywardCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-03-26_2021-03-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="i_2021-04-30_BalanceSheetLocationAxis-PrepaidExpensesAndOtherCurrentAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-30</instant>
        </period>
    </context>
    <context id="i_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acrx:LeaseForCorporateHeadquartersInHaywardCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-26</instant>
        </period>
    </context>
    <context id="d_2021-03-26_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acrx:LeaseForCorporateHeadquartersInHaywardCaliforniaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-26</startDate>
            <endDate>2021-03-26</endDate>
        </period>
    </context>
    <context id="i_2012-12-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <instant>2012-12-12</instant>
        </period>
    </context>
    <context id="d_2012-12-12_2012-12-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2012-12-12</startDate>
            <endDate>2012-12-12</endDate>
        </period>
    </context>
    <context id="i_2021-04-21_CounterpartyNameAxis-CatalentPharmaSolutionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:CatalentPharmaSolutionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-21</instant>
        </period>
    </context>
    <context id="d_2022-01-01_2022-12-31_CounterpartyNameAxis-CatalentPharmaSolutionsMember_StatementScenarioAxis-ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:CatalentPharmaSolutionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="d_2015-09-18_2015-09-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2015-09-18</startDate>
            <endDate>2015-09-18</endDate>
        </period>
    </context>
    <context id="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">acrx:SWKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-18</startDate>
            <endDate>2015-09-18</endDate>
        </period>
    </context>
    <context id="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acrx:FirstFourCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">acrx:SWKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-18</startDate>
            <endDate>2015-09-18</endDate>
        </period>
    </context>
    <context id="d_2015-09-18_2015-09-18_LegalEntityAxis-AcelRXMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acrx:FirstFourCommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">acrx:AcelRXMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-18</startDate>
            <endDate>2015-09-18</endDate>
        </period>
    </context>
    <context id="i_2015-09-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <instant>2015-09-18</instant>
        </period>
    </context>
    <context id="d_2015-09-19_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <startDate>2015-09-19</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="d_2021-11-15_2021-11-15_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-15</instant>
        </period>
    </context>
    <context id="d_2021-11-15_2021-11-15_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-15</startDate>
            <endDate>2021-11-15</endDate>
        </period>
    </context>
    <context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExercisePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputSharePriceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedTermMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputRiskFreeInterestRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputPriceVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputExpectedDividendRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-30</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:WarrantInConnectionWithOxfordFinanceLoanAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-06-08_2021-06-08_LitigationCaseAxis-PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">acrx:PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-08</startDate>
            <endDate>2021-06-08</endDate>
        </period>
    </context>
    <context id="d_2021-07-06_2021-07-06_LitigationCaseAxis-PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">acrx:PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-06</startDate>
            <endDate>2021-07-06</endDate>
        </period>
    </context>
    <context id="d_2021-01-22_2021-01-22_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-22</startDate>
            <endDate>2021-01-22</endDate>
        </period>
    </context>
    <context id="i_2021-01-22_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-22</instant>
        </period>
    </context>
    <context id="d_2021-01-27_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-27</startDate>
            <endDate>2021-01-27</endDate>
        </period>
    </context>
    <context id="i_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-27</instant>
        </period>
    </context>
    <context id="d_2021-01-22_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-22</startDate>
            <endDate>2021-01-27</endDate>
        </period>
    </context>
    <context id="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-17</startDate>
            <endDate>2021-11-17</endDate>
        </period>
    </context>
    <context id="i_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:RegisteredDirectOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">acrx:November2021FinancingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="i_2021-11-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
        </entity>
        <period>
            <instant>2021-11-17</instant>
        </period>
    </context>
    <context id="d_2020-07-23_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-23</startDate>
            <endDate>2020-07-23</endDate>
        </period>
    </context>
    <context id="i_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-23</instant>
        </period>
    </context>
    <context id="d_2020-12-11_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-11</startDate>
            <endDate>2020-12-11</endDate>
        </period>
    </context>
    <context id="i_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acrx:ArmisticeCapitalAndRockSpringsCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-11</instant>
        </period>
    </context>
    <context id="d_2016-06-21_2016-06-21_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-06-21</startDate>
            <endDate>2016-06-21</endDate>
        </period>
    </context>
    <context id="d_2019-05-09_2019-05-09_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-09</startDate>
            <endDate>2019-05-09</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:ATMAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2011-01-01_2011-01-31_PlanNameAxis-EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-01-01</startDate>
            <endDate>2011-01-31</endDate>
        </period>
    </context>
    <context id="i_2011-12-31_PlanNameAxis-EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-12-31</instant>
        </period>
    </context>
    <context id="i_2020-06-16_PlanNameAxis-EquityIncentivePlan2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EquityIncentivePlan2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-16</instant>
        </period>
    </context>
    <context id="i_2020-06-16_PlanNameAxis-The2020EquityIncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-16</instant>
        </period>
    </context>
    <context id="d_2021-06-17_2021-06-17_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-17</startDate>
            <endDate>2021-06-17</endDate>
        </period>
    </context>
    <context id="i_2021-06-17_PlanNameAxis-The2020EquityIncentivePlanMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-17</instant>
        </period>
    </context>
    <context id="i_2020-06-16_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-16</instant>
        </period>
    </context>
    <context id="i_2020-06-16_PlanNameAxis-EmployeeStockPurchasePlanESPPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-16</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-EmployeeStockPurchasePlanESPPMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:EmployeeStockPurchasePlanESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange4Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange5Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">acrx:ExercisePriceRange6Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-03-03_2021-03-03_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ExecutiveOfficerMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-03</startDate>
            <endDate>2021-03-03</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acrx:The2020EquityIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acrx:TimebasedStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">acrx:RSUsESPPAndEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">acrx:RSUsESPPAndEmployeeStockOptionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-BeforeTaxYear2018Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acrx:BeforeTaxYear2018Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYears2018To2020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxPeriodAxis">acrx:TaxYears2018To2020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementScenarioAxis-SubjectToExpirationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">acrx:SubjectToExpirationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementScenarioAxis-SubjectToExpirationMember_TaxCreditCarryforwardAxis-ResearchMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">acrx:SubjectToExpirationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2022-01-07_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acrx:LowellTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-07</startDate>
            <endDate>2022-01-07</endDate>
        </period>
    </context>
    <context id="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acrx:LowellTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acrx:AcelrxCommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-01-07</instant>
        </period>
    </context>
    <context id="i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember_BusinessAcquisitionAxis-LowellTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acrx:LowellTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001427925</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">acrx:SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <unit id="EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="SquareFoot">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2021-01-01_2021-12-31"
      id="thunderdome-EntityCentralIndexKey">0001427925</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2021-01-01_2021-12-31"
      id="thunderdome-EntityRegistrantName">ACELRX PHARMACEUTICALS INC</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2021-01-01_2021-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2021-01-01_2021-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2021-01-01_2021-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2021-01-01_2021-12-31">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-12-31"
      id="c81618454"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2020-12-31"
      id="c81618455"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81618459"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81618460"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81618461"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81618462"
      unitRef="Share">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81618463"
      unitRef="Share">136819647</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81618465"
      unitRef="Share">136819647</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81618464"
      unitRef="Share">98812008</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81618466"
      unitRef="Share">98812008</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      id="c81618752">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      id="c81618753">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618855"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="d_2019-01-01_2019-12-31"
      decimals="-3"
      id="c81618856"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618861"
      unitRef="USD">0</us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale>
    <us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618867"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax>
    <us-gaap:Depreciation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-5"
      id="c81619034"
      unitRef="USD">1100000</us-gaap:Depreciation>
    <acrx:LicenseAgreementTerm
      contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember"
      id="c81619063">P10Y</acrx:LicenseAgreementTerm>
    <acrx:LicenseAgreementRenewalTerm
      contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember"
      id="c81619067">P5Y</acrx:LicenseAgreementRenewalTerm>
    <acrx:LicenseAgreementMinimumSalesObligationTerm
      contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember"
      id="c81619075">P12M</acrx:LicenseAgreementMinimumSalesObligationTerm>
    <acrx:LicenseAgreementRenewalTerm
      contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      id="c81619082">P5Y</acrx:LicenseAgreementRenewalTerm>
    <acrx:LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived
      contextRef="i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-6"
      id="c81619087"
      unitRef="EUR">47000000.0</acrx:LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived>
    <acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments
      contextRef="d_2021-07-01_2021-09-30_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619088"
      unitRef="EUR">2500000</acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments>
    <acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619125"
      unitRef="EUR">2500000</acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments>
    <acrx:LicenseAgreementTerm
      contextRef="d_2021-07-01_2021-07-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      id="c81619131">P10Y</acrx:LicenseAgreementTerm>
    <acrx:LicenseAgreementRenewalTerm
      contextRef="d_2021-07-01_2021-07-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      id="c81619132">P5Y</acrx:LicenseAgreementRenewalTerm>
    <us-gaap:CapitalizedContractCostAmortization
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619138"
      unitRef="USD">300000</us-gaap:CapitalizedContractCostAmortization>
    <acrx:ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619166"
      unitRef="USD">623000</acrx:ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="4"
      id="c81619206"
      unitRef="Pure">0.1315</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2020-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember"
      decimals="4"
      id="c81619215"
      unitRef="Pure">0.1435</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember"
      id="c81619236">P2Y3M</us-gaap:LesseeOperatingLeaseTermOfContract>
    <acrx:LesseeOperatingLeaseAbatedRentPeriod
      contextRef="d_2021-03-26_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember"
      id="c81619239">P1M</acrx:LesseeOperatingLeaseAbatedRentPeriod>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="i_2012-12-12" id="c81619241">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <acrx:LesseeOperatingLeaseNoticePeriod contextRef="d_2012-12-12_2012-12-12" id="c81619242">P18Y</acrx:LesseeOperatingLeaseNoticePeriod>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="i_2021-04-21_CounterpartyNameAxis-CatalentPharmaSolutionsMember"
      id="c81619247">P5Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="i_2021-04-21_CounterpartyNameAxis-CatalentPharmaSolutionsMember"
      id="c81619249">P2Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c81619332"
      unitRef="Pure">5</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"
      id="c81619342">P10Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExpectedTermMember"
      decimals="INF"
      id="c81619346"
      unitRef="Year">10</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="d_2021-06-08_2021-06-08_LitigationCaseAxis-PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member"
      decimals="INF"
      id="c81619353"
      unitRef="Pure">2</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:LossContingencyNumberOfDefendants
      contextRef="d_2021-07-06_2021-07-06_LitigationCaseAxis-PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember"
      decimals="INF"
      id="c81619358"
      unitRef="Pure">10</us-gaap:LossContingencyNumberOfDefendants>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c81619560"
      unitRef="USDPerShare">0.72</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c81619567"
      unitRef="USDPerShare">1.26</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c81619574"
      unitRef="USDPerShare">2.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c81619581"
      unitRef="USDPerShare">3.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c81619588"
      unitRef="USDPerShare">4.73</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c81619595"
      unitRef="USDPerShare">8.18</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619742"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619743"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619713"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:OpenTaxYear contextRef="d_2021-01-01_2021-12-31" id="c81619715">2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2016 2017 2018 2019 2020 2021</us-gaap:OpenTaxYear>
    <dei:DocumentType contextRef="d_2021-01-01_2021-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2021-01-01_2021-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2021-01-01_2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2021-01-01_2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2021-01-01_2021-12-31">001-35068</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2021-01-01_2021-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2021-01-01_2021-12-31">41-2193603</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2021-01-01_2021-12-31">25821 Industrial Boulevard, Suite 400</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2021-01-01_2021-12-31">Hayward</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2021-01-01_2021-12-31">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2021-01-01_2021-12-31">94545</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2021-01-01_2021-12-31">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2021-01-01_2021-12-31">216-3500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2021-01-01_2021-12-31">Common Stock, $0.001 par value</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2021-01-01_2021-12-31">ACRX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2021-01-01_2021-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2021-01-01_2021-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2021-01-01_2021-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2021-01-01_2021-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2021-01-01_2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2021-01-01_2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2021-01-01_2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2021-01-01_2021-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2021-01-01_2021-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="d_2021-01-01_2021-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="i_2021-06-30" decimals="INF" unitRef="USD">161163094</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2022-03-07" decimals="INF" unitRef="Share">146949320</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="d_2021-01-01_2021-12-31">WithumSmith+Brown, PC</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2021-01-01_2021-12-31">San Francisco, California</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="d_2021-01-01_2021-12-31">100</dei:AuditorFirmId>
    <dei:AuditorName contextRef="d_2021-01-01_2021-12-31_LegalEntityAxis-OUMCoLLPMember">OUM &amp; CO. LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2021-01-01_2021-12-31_LegalEntityAxis-OUMCoLLPMember">San Francisco, California</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="d_2021-01-01_2021-12-31_LegalEntityAxis-OUMCoLLPMember">252</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618409"
      unitRef="USD">12663000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618410"
      unitRef="USD">27274000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618411"
      unitRef="USD">38967000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618412"
      unitRef="USD">15612000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81618413"
      unitRef="USD">160000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618414"
      unitRef="USD">635000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618415"
      unitRef="USD">1111000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618416"
      unitRef="USD">1626000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618417"
      unitRef="USD">2588000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618418"
      unitRef="USD">1683000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618419"
      unitRef="USD">55489000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c81618420"
      unitRef="USD">46830000</us-gaap:AssetsCurrent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618421"
      unitRef="USD">4302000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c81618422"
      unitRef="USD">3150000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618423"
      unitRef="USD">15928000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618424"
      unitRef="USD">15659000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618425"
      unitRef="USD">2174000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618426"
      unitRef="USD">656000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618427"
      unitRef="USD">77893000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618428"
      unitRef="USD">66295000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618431"
      unitRef="USD">2121000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618432"
      unitRef="USD">2737000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618433"
      unitRef="USD">6524000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618434"
      unitRef="USD">5045000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618435"
      unitRef="USD">8796000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618436"
      unitRef="USD">8735000</us-gaap:LongTermDebtCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618437"
      unitRef="USD">1068000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618438"
      unitRef="USD">1118000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618439"
      unitRef="USD">18509000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618440"
      unitRef="USD">17635000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618441"
      unitRef="USD">5007000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c81618442"
      unitRef="USD">13140000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618443"
      unitRef="USD">1151000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618444"
      unitRef="USD">0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81618445"
      unitRef="USD">3750000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618446"
      unitRef="USD">2606000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618447"
      unitRef="USD">85288000</acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618448"
      unitRef="USD">88365000</acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618449"
      unitRef="USD">81000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618450"
      unitRef="USD">299000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618451"
      unitRef="USD">113786000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618452"
      unitRef="USD">122045000</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618457"
      unitRef="USD">137000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618458"
      unitRef="USD">98000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618467"
      unitRef="USD">437554000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618468"
      unitRef="USD">382637000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618469"
      unitRef="USD">-473584000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618470"
      unitRef="USD">-438485000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618471"
      unitRef="USD">-35893000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c81618472"
      unitRef="USD">-55750000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618473"
      unitRef="USD">77893000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618474"
      unitRef="USD">66295000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c81618476"
      unitRef="USD">1005000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c81618477"
      unitRef="USD">2521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember"
      decimals="-3"
      id="c81618478"
      unitRef="USD">1813000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember"
      decimals="-3"
      id="c81618479"
      unitRef="USD">2895000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618480"
      unitRef="USD">2818000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618481"
      unitRef="USD">5416000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618483"
      unitRef="USD">3753000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618484"
      unitRef="USD">6032000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618485"
      unitRef="USD">4095000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618486"
      unitRef="USD">4017000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618487"
      unitRef="USD">30935000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c81618488"
      unitRef="USD">36330000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618489"
      unitRef="USD">38783000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618490"
      unitRef="USD">46379000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618491"
      unitRef="USD">-35965000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618492"
      unitRef="USD">-40963000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618494"
      unitRef="USD">2291000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618495"
      unitRef="USD">3305000</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618496"
      unitRef="USD">124000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618497"
      unitRef="USD">583000</us-gaap:InvestmentIncomeNet>
    <acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618498"
      unitRef="USD">3038000</acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties>
    <acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c81618499"
      unitRef="USD">3310000</acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618500"
      unitRef="USD">871000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618501"
      unitRef="USD">588000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618502"
      unitRef="USD">-35094000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618503"
      unitRef="USD">-40375000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618504"
      unitRef="USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618505"
      unitRef="USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618506"
      unitRef="USD">-35099000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618507"
      unitRef="USD">-40379000</us-gaap:NetIncomeLoss>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618508"
      unitRef="USD">-35099000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618509"
      unitRef="USD">-40379000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81618510"
      unitRef="USDPerShare">-0.29</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81618511"
      unitRef="USDPerShare">-0.47</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81618512"
      unitRef="Share">119860266</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81618513"
      unitRef="Share">85257008</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618514"
      unitRef="Share">79573101</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618515"
      unitRef="USD">79000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618516"
      unitRef="USD">356609000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618517"
      unitRef="USD">-398106000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c81618518"
      unitRef="USD">-41418000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618520"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618521"
      unitRef="USD">4424000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618522"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618523"
      unitRef="USD">4424000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618524"
      unitRef="Share">254684</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618525"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618526"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618527"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618528"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618530"
      unitRef="USD">0</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618531"
      unitRef="USD">-86000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618532"
      unitRef="USD">0</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618533"
      unitRef="USD">-86000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618534"
      unitRef="Share">18644095</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618535"
      unitRef="USD">19000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618536"
      unitRef="USD">21318000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618537"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618538"
      unitRef="USD">21337000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618539"
      unitRef="Share">340128</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618540"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618541"
      unitRef="USD">372000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618542"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618543"
      unitRef="USD">372000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618545"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618546"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618547"
      unitRef="USD">-40379000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618548"
      unitRef="USD">-40379000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618549"
      unitRef="Share">98812008</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618550"
      unitRef="USD">98000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618551"
      unitRef="USD">382637000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618552"
      unitRef="USD">-438485000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c81618553"
      unitRef="USD">-55750000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618555"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618556"
      unitRef="USD">4609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618557"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618558"
      unitRef="USD">4609000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618559"
      unitRef="Share">488715</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618560"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618561"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618562"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618563"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618565"
      unitRef="USD">0</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618566"
      unitRef="USD">-249000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618567"
      unitRef="USD">0</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618568"
      unitRef="USD">-249000</us-gaap:AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618569"
      unitRef="Share">37201562</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618570"
      unitRef="USD">38000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618571"
      unitRef="USD">44678000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618572"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618573"
      unitRef="USD">44716000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618575"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618576"
      unitRef="USD">5562000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618577"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618578"
      unitRef="USD">5562000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618579"
      unitRef="Share">19403</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618580"
      unitRef="USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618581"
      unitRef="USD">16000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618582"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618583"
      unitRef="USD">17000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618584"
      unitRef="Share">297959</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618585"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618586"
      unitRef="USD">301000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618587"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618588"
      unitRef="USD">301000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618590"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618591"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618592"
      unitRef="USD">-35099000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618593"
      unitRef="USD">-35099000</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c81618594"
      unitRef="Share">136819647</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="-3"
      id="c81618595"
      unitRef="USD">137000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="-3"
      id="c81618596"
      unitRef="USD">437554000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="-3"
      id="c81618597"
      unitRef="USD">-473584000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618598"
      unitRef="USD">-35893000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618600"
      unitRef="USD">-35099000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618601"
      unitRef="USD">-40379000</us-gaap:NetIncomeLoss>
    <acrx:NonCashRoyaltyRevenueRelatedToRoyaltyMonetization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618603"
      unitRef="USD">83000</acrx:NonCashRoyaltyRevenueRelatedToRoyaltyMonetization>
    <acrx:NonCashRoyaltyRevenueRelatedToRoyaltyMonetization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618604"
      unitRef="USD">242000</acrx:NonCashRoyaltyRevenueRelatedToRoyaltyMonetization>
    <acrx:NoncashInterestExpenseRecognized
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618605"
      unitRef="USD">-3038000</acrx:NoncashInterestExpenseRecognized>
    <acrx:NoncashInterestExpenseRecognized
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c81618606"
      unitRef="USD">-3310000</acrx:NoncashInterestExpenseRecognized>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618607"
      unitRef="USD">1973000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618608"
      unitRef="USD">1853000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618609"
      unitRef="USD">761000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618610"
      unitRef="USD">1069000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618611"
      unitRef="USD">4609000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618612"
      unitRef="USD">4424000</us-gaap:ShareBasedCompensation>
    <us-gaap:InventoryWriteDown
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-4"
      id="c81618613"
      unitRef="USD">810000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618614"
      unitRef="USD">712000</us-gaap:InventoryWriteDown>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618615"
      unitRef="USD">138000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618616"
      unitRef="USD">344000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618618"
      unitRef="USD">-475000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618619"
      unitRef="USD">203000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618620"
      unitRef="USD">295000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618621"
      unitRef="USD">-957000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618622"
      unitRef="USD">908000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618623"
      unitRef="USD">-661000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618624"
      unitRef="USD">111000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618625"
      unitRef="USD">1016000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618626"
      unitRef="USD">79000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618627"
      unitRef="USD">-638000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618628"
      unitRef="USD">-447000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618629"
      unitRef="USD">-886000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618630"
      unitRef="USD">1188000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618631"
      unitRef="USD">-3195000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618632"
      unitRef="USD">-30002000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618633"
      unitRef="USD">-38505000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618635"
      unitRef="USD">1827000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618636"
      unitRef="USD">1855000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618637"
      unitRef="USD">70459000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618638"
      unitRef="USD">44611000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2021-01-01_2021-12-31_AssetAcquisitionAxis-LowellsIntellectualPropertyMember"
      decimals="-3"
      id="c81618639"
      unitRef="USD">821000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="d_2020-01-01_2020-12-31_AssetAcquisitionAxis-LowellsIntellectualPropertyMember"
      decimals="-3"
      id="c81618640"
      unitRef="USD">-0</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618641"
      unitRef="USD">2996000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618642"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618643"
      unitRef="USD">43988000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618644"
      unitRef="USD">80605000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618645"
      unitRef="USD">-26123000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618646"
      unitRef="USD">34139000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618648"
      unitRef="USD">8833000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618649"
      unitRef="USD">4667000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618650"
      unitRef="USD">44716000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618651"
      unitRef="USD">21337000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618652"
      unitRef="USD">5562000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618653"
      unitRef="USD">0</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618654"
      unitRef="USD">318000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618655"
      unitRef="USD">372000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618656"
      unitRef="USD">249000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618657"
      unitRef="USD">86000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618658"
      unitRef="USD">41514000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618659"
      unitRef="USD">16956000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618660"
      unitRef="USD">-14611000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c81618661"
      unitRef="USD">12590000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618662"
      unitRef="USD">27274000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c81618663"
      unitRef="USD">14684000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618664"
      unitRef="USD">12663000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618665"
      unitRef="USD">27274000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations>
    <us-gaap:InterestPaidNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618667"
      unitRef="USD">1595000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618668"
      unitRef="USD">2269000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618669"
      unitRef="USD">5000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618670"
      unitRef="USD">-347000</us-gaap:IncomeTaxesPaidNet>
    <acrx:PurchasesOfPropertyAndEquipmentInAccountsPayable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618672"
      unitRef="USD">1095000</acrx:PurchasesOfPropertyAndEquipmentInAccountsPayable>
    <acrx:PurchasesOfPropertyAndEquipmentInAccountsPayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618673"
      unitRef="USD">0</acrx:PurchasesOfPropertyAndEquipmentInAccountsPayable>
    <acrx:AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618674"
      unitRef="USD">1087000</acrx:AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses>
    <acrx:AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618675"
      unitRef="USD">0</acrx:AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618676"
      unitRef="USD">4669000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618677"
      unitRef="USD">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <acrx:WriteoffOfRightofuseAssetAndLeaseLiability
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618678"
      unitRef="USD">-3128000</acrx:WriteoffOfRightofuseAssetAndLeaseLiability>
    <acrx:WriteoffOfRightofuseAssetAndLeaseLiability
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618679"
      unitRef="USD">0</acrx:WriteoffOfRightofuseAssetAndLeaseLiability>
    <acrx:GainOnTerminationOfSublease
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618680"
      unitRef="USD">522000</acrx:GainOnTerminationOfSublease>
    <acrx:GainOnTerminationOfSublease
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618681"
      unitRef="USD">0</acrx:GainOnTerminationOfSublease>
    <acrx:LeaseholdPaidWithNotePayable
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618682"
      unitRef="USD">0</acrx:LeaseholdPaidWithNotePayable>
    <acrx:LeaseholdPaidWithNotePayable
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81618683"
      unitRef="USD">326000</acrx:LeaseholdPaidWithNotePayable>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050888">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt; Organization and Summary of Significant Accounting Policies &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;The Company &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on &lt;em style="font: inherit;"&gt; July 13, 2005 &lt;/em&gt;as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. The Company&#x2019;s operations are based in Hayward, California.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA&#xae;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt; &lt;/sup&gt;(known as DZUVEO&#xae; in Europe) and Zalviso&#xae; are&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt; &lt;/sup&gt;both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. On &lt;em style="font: inherit;"&gt; November 2, 2018, &lt;/em&gt;the U.S. Food and Drug Administration, or FDA, approved DSUVIA for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The commercial launch of DSUVIA in the United States occurred in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt; In &lt;em style="font: inherit;"&gt; June 2018, &lt;/em&gt;the European Commission, or EC, granted marketing approval of DZUVEO for the management of acute moderate to severe pain in adults in medically monitored settings. AcelRx is further developing a distribution capability and commercial organization to continue to market and sell DSUVIA in the United States. In geographies where AcelRx decides &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to commercialize products by itself, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek to out-license commercialization rights. The Company currently intends to commercialize and promote DSUVIA/DZUVEO outside the United States with &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more strategic partners, and, in &lt;em style="font: inherit;"&gt; July 2021, &lt;/em&gt;entered into a License and Commercialization Agreement with Laboratoire Aguettant, or Aguettant, for Aguettant to commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom (see Note &lt;em style="font: inherit;"&gt;6.&lt;/em&gt; &#x201c;Out-License Agreements&#x2014;DZUVEO&#x201d;&lt;i&gt; &lt;/i&gt;below). The timing of the resubmission of the Zalviso new drug application, or NDA, is in part dependent upon the finalization of the FDA&#x2019;s new opioid approval guidelines and process. AcelRx intends to seek regulatory approval for Zalviso in the United States and, if successful, potentially promote Zalviso either by itself or with strategic partners. Zalviso is approved in Europe and was commercialized by Gr&#xfc;nenthal GmbH, or Gr&#xfc;nenthal, through &lt;em style="font: inherit;"&gt; May 12, 2021 (&lt;/em&gt;see &lt;i&gt;Termination of Gr&lt;/i&gt;&#xfc;&lt;i&gt;nenthal Agreements&lt;/i&gt; below). In &lt;em style="font: inherit;"&gt; July 2021, &lt;/em&gt;the Company also entered into a separate License and Commercialization Agreement with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing &lt;em style="font: inherit;"&gt;10&lt;/em&gt; ml of a solution of &lt;em style="font: inherit;"&gt;3&lt;/em&gt; mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing &lt;em style="font: inherit;"&gt;10&lt;/em&gt; ml of a solution of &lt;em style="font: inherit;"&gt;50&lt;/em&gt; mcg/ml phenylephrine hydrochloride for injection (see Note &lt;em style="font: inherit;"&gt;5.&lt;/em&gt; &#x201c;In-License Agreement&#x201d; below). On &lt;em style="font: inherit;"&gt; January 7, 2022, &lt;/em&gt;the Company closed the definitive merger agreement dated as of &lt;em style="font: inherit;"&gt; November 14, 2021, &lt;/em&gt;or the Merger Agreement, to acquire Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note &lt;em style="font: inherit;"&gt;19.&lt;/em&gt; &#x201c;Subsequent Events&#x201d; below).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company had cash, cash equivalents and short-term investments of $51.6 million and $42.9 million, respectively. Based on the Company&#x2019;s current operating plans and projections, the Company expects that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year from the date this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K is filed with the United States Securities and Exchange Commission, or SEC. Although Zalviso was approved for sale in Europe on &lt;em style="font: inherit;"&gt; September 18, 2015, &lt;/em&gt;the Company sold the majority of the royalty rights and certain commercial sales milestones it is entitled to receive under the Amended License Agreement (defined below) with Gr&#xfc;nenthal to PDL BioPharma, Inc., or PDL, in a transaction referred to as the Royalty Monetization. On &lt;em style="font: inherit;"&gt; August 31, 2020, &lt;/em&gt;PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK. In consideration of the termination of the Amended License Agreement, under the Royalty Monetization, the Company must use commercially reasonable efforts to negotiate a replacement license agreement with a &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Termination of Gr&lt;/span&gt;&lt;/i&gt;&#xfc;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;nenthal Agreements &lt;/span&gt;&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; December 16, 2013, &lt;/em&gt;AcelRx and Gr&#xfc;nenthal entered into a Collaboration and License Agreement, or the License Agreement, which was amended effective &lt;em style="font: inherit;"&gt; July 17, 2015 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 20, 2016, &lt;/em&gt;or the Amended License Agreement, which granted Gr&#xfc;nenthal rights to commercialize the Zalviso PCA system, or the Product, in the &lt;em style="font: inherit;"&gt;28&lt;/em&gt; European Union, or EU, member states, at the time of the agreement, plus Switzerland, Liechtenstein, Iceland, Norway and Australia (collectively, the Zalviso Territory) for human use in pain treatment within, or dispensed by, hospitals, hospices, nursing homes and other medically supervised settings, (collectively, the Field). In &lt;em style="font: inherit;"&gt; September 2015, &lt;/em&gt;the EC granted marketing approval for the marketing authorization application, or MAA, previously submitted to the EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. On &lt;em style="font: inherit;"&gt; December 16, 2013, &lt;/em&gt;AcelRx and Gr&#xfc;nenthal entered into a Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. Under the MSA, the Company exclusively manufactured and supplied the Product to Gr&#xfc;nenthal for the Field in the Zalviso Territory. On &lt;em style="font: inherit;"&gt; July 22, 2015, &lt;/em&gt;the Company and Gr&#xfc;nenthal amended the MSA, or the Amended MSA, effective as of &lt;em style="font: inherit;"&gt; July 17, 2015. &lt;/em&gt;The Amended MSA and the Amended License Agreement are referred to as the Gr&#xfc;nenthal Agreements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; May 18, 2020, &lt;/em&gt;the Company received a notice from Gr&#xfc;nenthal that it had exercised its right to terminate the Gr&#xfc;nenthal Agreements, effective &lt;em style="font: inherit;"&gt; November 13, 2020. &lt;/em&gt;The terms of the Gr&#xfc;nenthal Agreements were extended to &lt;em style="font: inherit;"&gt; May 12, 2021 &lt;/em&gt;to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on &lt;em style="font: inherit;"&gt; May 12, 2021.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Reclassifications &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the amounts reported in the Consolidated Balance Sheets as deferred revenue, current portion and liability related to the sale of future royalties, current portion have been reclassified to accrued and other liabilities at &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;and the amount reported as an inventory impairment charge in the Consolidated Statements of Cash Flows was recorded as other in the year ended &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;em style="font: inherit;"/&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiary, ARPI&#160;LLC, which was formed in &lt;em style="font: inherit;"&gt; September 2015 &lt;/em&gt;for the sole purpose of facilitating the Royalty Monetization with PDL of the expected royalty stream and milestone payments due from the sales of Zalviso in the European Union by its commercial partner, Gr&#xfc;nenthal, pursuant to the Amended License Agreement. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; &#x201c;Liability Related to Sale of Future Royalties&#x201d; for additional information.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management believes its most significant accounting estimates relate to revenue recognition, inventory valuation and the liability related to the sale of future royalties. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results could differ from those estimates.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents and Short-Term Investments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company considers all highly liquid investments with an original maturity (at date of purchase) of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;All marketable securities are classified as available-for-sale and consist of commercial paper, U.S. government sponsored enterprise debt securities and corporate debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. The Company&#x2019;s investments are subject to a periodic impairment review for other-than-temporary declines in fair value. The Company&#x2019;s review includes the consideration of the cause of the impairment including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss in the amount of such decline.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"&gt;Level I&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"&gt;Level II&#x2014;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"&gt;Level III&#x2014;Unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity for the related assets or liabilities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Segment Information &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company operates in a single segment, the development and commercialization of product candidates and products for the treatment of pain. The Company&#x2019;s product sales revenue consists of sales of DSUVIA in the United States and, through &lt;em style="font: inherit;"&gt; May 2021, &lt;/em&gt;sales of Zalviso in Europe by Gr&#xfc;nenthal. The Company&#x2019;s contract and collaboration revenue consists of non-cash royalty revenue, royalty revenue, and other revenue under the Gr&#xfc;nenthal Agreements and license revenue under the DZUVEO Agreement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Risk &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company invests cash that is currently &lt;em style="font: inherit;"&gt;not&lt;/em&gt; being used for operational purposes in accordance with its investment policy in debt securities of U.S. government sponsored agencies, commercial paper and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the Consolidated Balance Sheets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company relies on a single &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party supplier for the supply of sufentanil, the active pharmaceutical ingredient in DSUVIA and Zalviso, and various sole-source &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract manufacturer organizations to manufacture the DSUVIA SDA.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;DSUVIA&#160;sales are concentrated with the DoD and with a limited number of wholesalers in the United States. Zalviso was sold in Europe by Gr&#xfc;nenthal through &lt;em style="font: inherit;"&gt; May 2021. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; July 2021, &lt;/em&gt;Aguettant was granted an exclusive license to commercialize DZUVEO in Europe. DZUVEO sales in Europe by Aguettant have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; commenced as of &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Revenue and accounts receivable have been concentrated with these customers.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Revenues from customers that accounted for &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; or more of our total revenues during the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; are as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Percent of Total Revenue&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Aguettant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;61.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gr&#xfc;nenthal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;74.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;DoD&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Wholesaler A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The need for a bad debt allowance is evaluated each reporting period based on the Company&#x2019;s assessment of the credit worthiness of its customers or any other potential circumstances that could result in bad debt.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company believes that the entire accounts receivable balance as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;is collectible and there was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; bad debt allowance provided as of &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accounts receivable, net from customers that accounted for &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; or more of our total accounts receivable balance as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; are as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Percent of Accounts Receivable, Net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Customer A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Customer B&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;79&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Inventories, net &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost is determined using the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out method for all inventories. Inventory includes the cost of the active pharmaceutical ingredients, or API, raw materials and &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are allocated to the appropriate cost pool and then absorbed into inventory based on the units produced or distributed, assuming normal capacity, in the applicable period. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company's policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The Company periodically evaluates the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or net realizable value approach as that used to value the inventory.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment, net &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:c81618752"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c81618753"&gt;five&lt;/span&gt; years. Leasehold improvements are amortized over the shorter of the estimated useful life of the improvements or the remaining lease term. Expenditures for repairs and maintenance, which do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; extend the useful life of the property and equipment, are expensed as incurred. Upon retirement, the asset cost and related accumulated depreciation are relieved from the accompanying Consolidated Balance Sheets. Gains and losses associated with dispositions are reflected as a component of interest income and other income, net in the accompanying Consolidated Statements of Operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. For example, if the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; successful in its commercialization of DSUVIA, and if approved, Zalviso, purchased equipment and manufacturing-related facility improvements the Company has made at its contract manufacturers could become impaired. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;determine that it is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer probable that the Company will realize the future economic benefit associated with the costs of these assets through future manufacturing activities, and if so, the Company would record an impairment charge associated with these assets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Contingent put option&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The contingent put option associated with the Company&#x2019;s Loan Agreement with Oxford is recorded as a liability. Changes in the fair value of the contingent put option are recognized as interest income and other income (expense), net in the Consolidated Statements of Operations. For further discussion, see Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &#x201c;Long-Term Debt&#x201d;.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt; &lt;b&gt;&lt;i&gt; &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company follows the provisions of ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02,&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;. At the inception of an arrangement, the Company determines whether the arrangement is, or contains, a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required for items such as initial direct costs paid or incentives received.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the Consolidated Balance Sheets as operating lease right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue from Contracts with Customers &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company follows the provisions of Accounting Standards Codification, or ASC, Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. This guidance provides a unified model to determine how revenue is recognized. The Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company sells its products primarily through wholesale and specialty distributors.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Product sales revenue&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company sells its product primarily through distributors. Revenues from product sales are recognized when distributors obtain control of the Company&#x2019;s product, which occurs at a point in time, upon delivery to such distributors. These distributors subsequently resell the product to certified medically supervised healthcare settings. In addition to distribution agreements with these customers, the Company enters into arrangements with group purchasing organizations, or GPOs, and other certified medically supervised healthcare settings that provide for privately negotiated discounts with respect to the purchase of its products. For revenue recognition under bill-and-hold arrangements, wherein the customer agrees to buy product from the Company but requests delivery at a later date, the Company deems that control passes to the customer when the product is ready for delivery. The Company recognizes revenue under these types of arrangements when a signed agreement is in place, the transaction is billable, the customer has significant risk and rewards for the product and the ability to direct the asset, the product has been set aside specifically for the customer, and the product cannot be redirected to another customer. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, government rebates, returns, distribution fees, GPO fees and product returns.&#160;Variable consideration is recorded at the time product sales are recognized resulting in a reduction in product revenue. The amount of variable consideration that is included in the transaction price &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur in a future period. Variable consideration is estimated using the most-likely amount method, which is the single-most likely outcome under a contract and is typically at the stated contractual rate.&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method under ASC Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; for relevant factors. These factors include current contractual and statutory requirements, specific known market events and trends, industry data, and/or forecasted customer buying and payment patterns. Actual amounts of consideration ultimately received &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from the Company&#x2019;s estimates.&#160;If actual results vary materially from the Company&#x2019;s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These estimates include:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Chargebacks&lt;/span&gt; &#x2013; The Company&#x2019;s customers subsequently resell its product to qualified healthcare providers. In addition to distribution agreements with customers, the Company enters into arrangements with qualified healthcare providers that provide discounts with respect to the purchase of its product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue-related accrued liabilities on the Consolidated Balance Sheets. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by customers, and the Company issues credits for such amounts generally within a few weeks of the customer's notification to the Company of the resale. Reserves for chargebacks consists of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period end that the Company expects will be sold to the qualified healthcare providers, and chargebacks for units that the Company&#x2019;s customers have sold to the qualified healthcare providers, but for which credits have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been issued.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Government Rebates&lt;/span&gt; &#x2013; The Company is subject to discount obligations under state Medicaid programs. The Company estimates its Medicaid rebates, and reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued liabilities on the Consolidated Balance Sheet.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Returns&lt;/span&gt; &#x2013;&lt;i&gt; &lt;/i&gt;The Company allows its distributors to return product for credit &lt;em style="font: inherit;"&gt;6&lt;/em&gt; months prior to, and up to &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months after, the product expiration date. As such, there &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be a significant period of time between the time the product is shipped and the time the credit is issued on returned product.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Distribution Fees&lt;/span&gt; &#x2013;&lt;i&gt; &lt;/i&gt;Distribution fees include fees paid to certain customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;GPO Fees&lt;/span&gt;&lt;i&gt; &lt;/i&gt;&#x2013; The Company pays administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs&#x2019; members.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Trade Discounts and Allowances&lt;/span&gt; - The Company provides its customers with discounts which include early payment incentives that are explicitly stated in its contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company believes its estimated allowances for chargebacks, government rebates and product returns require a high degree of judgment and are subject to change based on its limited experience and certain quantitative and qualitative factors. The Company believes its estimated allowances for distribution fees, GPO fees and trade discounts and allowances do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; require a high degree of judgment because the amounts are settled within a relatively short period of time. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. Changes in product revenue allowance estimates could materially affect the Company&#x2019;s results of operations and financial position.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Contract and other collaboration revenue&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company generates revenue from collaboration agreements. These agreements typically include payments for upfront signing or license fees, cost reimbursements for development and manufacturing services, milestone payments, product sales, and royalties on licensee&#x2019;s future product sales. Product sales related revenue under these collaboration agreements is classified as product sales revenue, while other revenue generated from collaboration agreements is classified as contract and other collaboration revenue.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Performance Obligations&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; The Company&#x2019;s performance obligations include delivering product to its distributors, commercialization license rights, development services, services associated with the regulatory approval process, joint steering committee services, demonstration devices, manufacturing services, material rights for discounts on manufacturing services, and product supply.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#x2019;s or the Company&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. If the Company is entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Transaction Price&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company has both fixed and variable consideration. Variable consideration for product revenue is described as Net product sales in the Consolidated Statements of Operations. For collaboration agreements, non-refundable upfront fees and product supply selling prices are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; within the control of the Company, such as approvals from regulators, are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; considered probable of being achieved until those approvals are received.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Allocation of Consideration&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights and material rights for discounts on manufacturing services are calculated using an income approach model and can include the following key assumptions: the development timeline, sales forecasts, costs of product sales, commercialization expenses, discount rate, the time which the manufacturing services are expected to be performed, and probabilities of technical and regulatory success. For all other performance obligations, the Company uses a cost-plus margin approach.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Timing of Recognition&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Significant management judgment is required to determine the level of effort required under collaboration arrangements and the period over which the Company expects to complete its performance obligations under the arrangement. The Company estimates the performance period or measure of progress at the inception of the arrangement and re-evaluates it each reporting period. This re-evaluation &lt;em style="font: inherit;"&gt; may &lt;/em&gt;shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer, and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cost of Goods Sold &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Cost of goods sold for product revenue includes &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party manufacturing costs, shipping and handling costs, and indirect overhead costs associated with production and distribution which are allocated to the appropriate cost pool and recognized when revenue is recognized. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Gr&#xfc;nenthal Agreements, the Company sold Zalviso to Gr&#xfc;nenthal at predetermined, contractual transfer prices that were less than the direct costs of manufacturing and recognized indirect costs as period costs where they were in excess of normal capacity and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recoverable on a lower of cost or net realizable value basis. Cost of goods sold for Zalviso shipped to Gr&#xfc;nenthal included the inventory costs of API, &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract manufacturing costs, packaging and distribution costs, shipping, handling and storage costs, depreciation and costs of the employees involved with production.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Compensation expense for all stock-based payment awards made to employees and directors, including employee stock options and restricted stock units related to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan, or &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; EIP, the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Equity Incentive Plan, or &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP, and employee share purchases related to the Amended and Restated &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. The Company applies the graded-vesting attribution method to awards with market conditions that include graded-vesting features. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. The expected term, which represents the period of time that options granted are expected to be outstanding, is derived by analyzing the historical experience of similar awards, giving consideration to the contractual terms of the stock&#x2011;based awards, vesting schedules and expectations of future employee behavior. Expected volatilities are estimated using the historical stock price performance over the expected term of the option, which are adjusted as necessary for any other factors which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;reasonably affect the volatility of AcelRx&#x2019;s stock in the future. The risk&#x2011;free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company recognizes forfeitures when they occur and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate paying dividends in the near future.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Warrants Issued in Connection with Financings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Restructuring Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 16, 2020, &lt;/em&gt;in connection with entering into the Co-Promotion Agreement, the Company initiated a reduction in headcount, designed to eliminate the overlap with the Tetraphase commercial team in order to more efficiently commercialize DSUVIA alongside the Tetraphase commercial team and reduce operating expenses. The Company eliminated 30 positions, primarily within the commercial organization. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company incurred and paid $0.5 million in employee termination benefits related to this restructuring. The headcount reduction was completed in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; such restructuring costs for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"/&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Non-Cash Interest Income (Expense) on Liability Related to Sale of Future Royalties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; September 2015, &lt;/em&gt;the Company sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Gr&#xfc;nenthal to PDL for gross proceeds of $65.0 million. Gr&#xfc;nenthal terminated the Gr&#xfc;nenthal Agreements effective &lt;em style="font: inherit;"&gt; November 13, 2020. &lt;/em&gt;The terms of the Gr&#xfc;nenthal Agreements were extended to &lt;em style="font: inherit;"&gt; May 2021 &lt;/em&gt;to enable Gr&#xfc;nenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Territory reverted back to the Company in &lt;em style="font: inherit;"&gt; May 2021.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Royalty Monetization, the Company has a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Under the relevant accounting guidance, because of the Company&#x2019;s significant continuing involvement, the Royalty Monetization is accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and payments made to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $61.2 million of net proceeds the Company received, are amortized as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense, or interest income, as these estimates are updated.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There are a number of factors that could materially affect the amount and timing of royalty and milestone payments from Zalviso in Europe, most of which are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; within the Company&#x2019;s control. Such factors include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, the success of any future sales and promotion of Zalviso under any New Arrangement, if achieved; changing standards of care; the introduction of competing products; manufacturing or other delays; intellectual property matters; adverse events that result in governmental health authority imposed restrictions on the use of Zalviso; significant changes in foreign exchange rates as the royalties remitted to ARPI LLC are made in U.S. dollars; and other events or circumstances that could result in reduced royalty payments from European sales of Zalviso, all of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Monetization. Conversely, if sales of Zalviso in Europe are greater than expected, the non-cash royalty revenues and the non-cash interest expense recorded by the Company would be greater over the term of the Royalty Monetization. The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. Because estimated sales forecasts and payments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;vary over the life of the Royalty Monetization, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required to recognize interest income as the imputed interest rate is adjusted prospectively to reflect the revised effective interest rate over the term of the Royalty Monetization.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company records non-cash royalty revenues and non-cash interest income (expense), net, within its Consolidated Statements of Operations over the term of the Royalty Monetization.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;When the expected payments under the Royalty Monetization are lower than the gross proceeds of &lt;em style="font: inherit;"&gt;$65.0&lt;/em&gt; million received, the Company defers recognition of any probable contingent gain until the Royalty Monetization liability expires.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Loss &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Comprehensive loss is comprised of net loss and other comprehensive income (loss) and is disclosed in the Consolidated Statements of Operations. For the Company, other comprehensive income (loss) consists of changes in unrealized gains and losses on the Company&#x2019;s investments.&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"/&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than &lt;em style="font: inherit;"&gt;not.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;em style="font: inherit;"/&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share of Common Stock &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, options to purchase common stock, restricted stock subject to repurchase, restricted stock units, warrants to purchase convertible preferred stock and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. For additional information regarding the net loss per share, see Note &lt;em style="font: inherit;"&gt;15&lt;/em&gt; &#x201c;Net Loss per Share of Common Stock&#x201d;.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2019, &lt;/em&gt;the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12,&lt;/em&gt; &#x201c;&lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;&#x201d;. ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2020, &lt;/em&gt;and interim periods within those fiscal years. The Company adopted ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; on &lt;em style="font: inherit;"&gt; January 1, 2021, &lt;/em&gt;which did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06,&lt;/em&gt; &#x201c;&lt;i&gt;Debt - Debt with Conversion and Other Options (Subtopic &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20&lt;/em&gt;) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/i&gt;&#x201d;. The standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; separate accounting for embedded conversion features. ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06&lt;/em&gt; removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;and interim periods within those fiscal years for smaller reporting companies, with early adoption permitted. The Company early adopted ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06&lt;/em&gt; on &lt;em style="font: inherit;"&gt; January 1, 2021, &lt;/em&gt;which did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on the Company&#x2019;s Consolidated Financial Statements on the date of adoption.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &#x201c;&lt;i&gt;Financial Instruments &lt;/i&gt;&#x2013;&lt;i&gt; Credit Losses: Measurement of Credit Losses on Financial Instruments,&lt;/i&gt;&#x201d; or ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; replaces the incurred loss impairment model in current GAAP with a model that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is effective for the Company beginning &lt;em style="font: inherit;"&gt; January 1, 2023, &lt;/em&gt;with early adoption allowed beginning &lt;em style="font: inherit;"&gt; January 1, 2020. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; May 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05,&lt;/em&gt; &#x201c;&lt;i&gt;Financial Instruments &lt;/i&gt;&#x2013;&lt;i&gt; Credit Losses,&lt;/i&gt;&#x201d; or ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05,&lt;/em&gt; to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost upon adoption of the new credit losses standard. The new effective dates and transition align with those of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; Management is currently assessing the date of adoption and the impact ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; and ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05&lt;/em&gt; will have on the Company, but it does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate adoption of these new standards to have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; March 2020, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;04,&lt;/em&gt; &#x201c;&lt;i&gt;Reference Rate Reform (Topic &lt;em style="font: inherit;"&gt;848&lt;/em&gt;): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,&lt;/i&gt;&#x201d; which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments are effective immediately and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before &lt;em style="font: inherit;"&gt; December 31, 2022. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; January 2021, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;-&lt;em style="font: inherit;"&gt;01,&lt;/em&gt; &#x201c;&lt;i&gt;Reference Rate Reform (Topic &lt;em style="font: inherit;"&gt;848&lt;/em&gt;),&lt;/i&gt;&#x201d; to expand and clarify the scope of Topic &lt;em style="font: inherit;"&gt;848&lt;/em&gt; to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;04.&lt;/em&gt; The Company is currently evaluating the impact this guidance will have on its Consolidated Financial Statements.&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"/&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <acrx:BusinessDescriptionOfEntityPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624726">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;The Company &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;AcelRx Pharmaceuticals, Inc., or the Company, or AcelRx, was incorporated in Delaware on &lt;em style="font: inherit;"&gt; July 13, 2005 &lt;/em&gt;as SuRx, Inc. The Company subsequently changed its name to AcelRx Pharmaceuticals, Inc. The Company&#x2019;s operations are based in Hayward, California.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. DSUVIA&#xae;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt; &lt;/sup&gt;(known as DZUVEO&#xae; in Europe) and Zalviso&#xae; are&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt; &lt;/sup&gt;both focused on the treatment of acute pain, and each utilize sufentanil, delivered via a non-invasive route of sublingual administration, exclusively for use in medically supervised settings. On &lt;em style="font: inherit;"&gt; November 2, 2018, &lt;/em&gt;the U.S. Food and Drug Administration, or FDA, approved DSUVIA for use in adults in a certified medically supervised healthcare setting, such as hospitals, surgical centers, and emergency departments, for the management of acute pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The commercial launch of DSUVIA in the United States occurred in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt; In &lt;em style="font: inherit;"&gt; June 2018, &lt;/em&gt;the European Commission, or EC, granted marketing approval of DZUVEO for the management of acute moderate to severe pain in adults in medically monitored settings. AcelRx is further developing a distribution capability and commercial organization to continue to market and sell DSUVIA in the United States. In geographies where AcelRx decides &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to commercialize products by itself, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;seek to out-license commercialization rights. The Company currently intends to commercialize and promote DSUVIA/DZUVEO outside the United States with &lt;em style="font: inherit;"&gt;one&lt;/em&gt; or more strategic partners, and, in &lt;em style="font: inherit;"&gt; July 2021, &lt;/em&gt;entered into a License and Commercialization Agreement with Laboratoire Aguettant, or Aguettant, for Aguettant to commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom (see Note &lt;em style="font: inherit;"&gt;6.&lt;/em&gt; &#x201c;Out-License Agreements&#x2014;DZUVEO&#x201d;&lt;i&gt; &lt;/i&gt;below). The timing of the resubmission of the Zalviso new drug application, or NDA, is in part dependent upon the finalization of the FDA&#x2019;s new opioid approval guidelines and process. AcelRx intends to seek regulatory approval for Zalviso in the United States and, if successful, potentially promote Zalviso either by itself or with strategic partners. Zalviso is approved in Europe and was commercialized by Gr&#xfc;nenthal GmbH, or Gr&#xfc;nenthal, through &lt;em style="font: inherit;"&gt; May 12, 2021 (&lt;/em&gt;see &lt;i&gt;Termination of Gr&lt;/i&gt;&#xfc;&lt;i&gt;nenthal Agreements&lt;/i&gt; below). In &lt;em style="font: inherit;"&gt; July 2021, &lt;/em&gt;the Company also entered into a separate License and Commercialization Agreement with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing &lt;em style="font: inherit;"&gt;10&lt;/em&gt; ml of a solution of &lt;em style="font: inherit;"&gt;3&lt;/em&gt; mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing &lt;em style="font: inherit;"&gt;10&lt;/em&gt; ml of a solution of &lt;em style="font: inherit;"&gt;50&lt;/em&gt; mcg/ml phenylephrine hydrochloride for injection (see Note &lt;em style="font: inherit;"&gt;5.&lt;/em&gt; &#x201c;In-License Agreement&#x201d; below). On &lt;em style="font: inherit;"&gt; January 7, 2022, &lt;/em&gt;the Company closed the definitive merger agreement dated as of &lt;em style="font: inherit;"&gt; November 14, 2021, &lt;/em&gt;or the Merger Agreement, to acquire Lowell Therapeutics, Inc., or Lowell, a privately held company (see Note &lt;em style="font: inherit;"&gt;19.&lt;/em&gt; &#x201c;Subsequent Events&#x201d; below).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has incurred recurring operating losses and negative cash flows from operating activities since inception. As of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company had cash, cash equivalents and short-term investments of $51.6 million and $42.9 million, respectively. Based on the Company&#x2019;s current operating plans and projections, the Company expects that its existing cash, cash equivalents and short-term investments will be sufficient to fund operations for at least &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year from the date this Annual Report on Form &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-K is filed with the United States Securities and Exchange Commission, or SEC. Although Zalviso was approved for sale in Europe on &lt;em style="font: inherit;"&gt; September 18, 2015, &lt;/em&gt;the Company sold the majority of the royalty rights and certain commercial sales milestones it is entitled to receive under the Amended License Agreement (defined below) with Gr&#xfc;nenthal to PDL BioPharma, Inc., or PDL, in a transaction referred to as the Royalty Monetization. On &lt;em style="font: inherit;"&gt; August 31, 2020, &lt;/em&gt;PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC, or SWK. In consideration of the termination of the Amended License Agreement, under the Royalty Monetization, the Company must use commercially reasonable efforts to negotiate a replacement license agreement with a &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;Termination of Gr&lt;/span&gt;&lt;/i&gt;&#xfc;&lt;i&gt;&lt;span style="text-decoration: underline; "&gt;nenthal Agreements &lt;/span&gt;&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; December 16, 2013, &lt;/em&gt;AcelRx and Gr&#xfc;nenthal entered into a Collaboration and License Agreement, or the License Agreement, which was amended effective &lt;em style="font: inherit;"&gt; July 17, 2015 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; September 20, 2016, &lt;/em&gt;or the Amended License Agreement, which granted Gr&#xfc;nenthal rights to commercialize the Zalviso PCA system, or the Product, in the &lt;em style="font: inherit;"&gt;28&lt;/em&gt; European Union, or EU, member states, at the time of the agreement, plus Switzerland, Liechtenstein, Iceland, Norway and Australia (collectively, the Zalviso Territory) for human use in pain treatment within, or dispensed by, hospitals, hospices, nursing homes and other medically supervised settings, (collectively, the Field). In &lt;em style="font: inherit;"&gt; September 2015, &lt;/em&gt;the EC granted marketing approval for the marketing authorization application, or MAA, previously submitted to the EMA, for Zalviso for the management of acute moderate-to-severe post-operative pain in adult patients. On &lt;em style="font: inherit;"&gt; December 16, 2013, &lt;/em&gt;AcelRx and Gr&#xfc;nenthal entered into a Manufacture and Supply Agreement, or the MSA, and together with the License Agreement, the Agreements. Under the MSA, the Company exclusively manufactured and supplied the Product to Gr&#xfc;nenthal for the Field in the Zalviso Territory. On &lt;em style="font: inherit;"&gt; July 22, 2015, &lt;/em&gt;the Company and Gr&#xfc;nenthal amended the MSA, or the Amended MSA, effective as of &lt;em style="font: inherit;"&gt; July 17, 2015. &lt;/em&gt;The Amended MSA and the Amended License Agreement are referred to as the Gr&#xfc;nenthal Agreements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; May 18, 2020, &lt;/em&gt;the Company received a notice from Gr&#xfc;nenthal that it had exercised its right to terminate the Gr&#xfc;nenthal Agreements, effective &lt;em style="font: inherit;"&gt; November 13, 2020. &lt;/em&gt;The terms of the Gr&#xfc;nenthal Agreements were extended to &lt;em style="font: inherit;"&gt; May 12, 2021 &lt;/em&gt;to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on &lt;em style="font: inherit;"&gt; May 12, 2021.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</acrx:BusinessDescriptionOfEntityPolicyTextBlock>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2021-12-31"
      decimals="-5"
      id="c81618708"
      unitRef="USD">51600000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2020-12-31"
      decimals="-5"
      id="c81618710"
      unitRef="USD">42900000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624727">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and the accompanying notes. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="d_2021-01-01_2021-12-31" id="c81624728">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Reclassifications &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Certain prior year amounts in the Consolidated Financial Statements have been reclassified to conform to the current year's presentation. In particular, the amounts reported in the Consolidated Balance Sheets as deferred revenue, current portion and liability related to the sale of future royalties, current portion have been reclassified to accrued and other liabilities at &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;and the amount reported as an inventory impairment charge in the Consolidated Statements of Cash Flows was recorded as other in the year ended &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/p&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624729">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Principles of Consolidation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Consolidated Financial Statements include the accounts of the Company and its wholly owned subsidiary, ARPI&#160;LLC, which was formed in &lt;em style="font: inherit;"&gt; September 2015 &lt;/em&gt;for the sole purpose of facilitating the Royalty Monetization with PDL of the expected royalty stream and milestone payments due from the sales of Zalviso in the European Union by its commercial partner, Gr&#xfc;nenthal, pursuant to the Amended License Agreement. All intercompany accounts and transactions have been eliminated in consolidation. Refer to Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; &#x201c;Liability Related to Sale of Future Royalties&#x201d; for additional information.&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2021-01-01_2021-12-31" id="c81624730">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the amounts reported in the Consolidated Financial Statements and accompanying notes. Management believes its most significant accounting estimates relate to revenue recognition, inventory valuation and the liability related to the sale of future royalties. Management evaluates its estimates on an ongoing basis including critical accounting policies. Estimates are based on historical experience and on various other market-specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily apparent from other sources. Actual results could differ from those estimates.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <acrx:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624731">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cash, Cash Equivalents and Short-Term Investments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company considers all highly liquid investments with an original maturity (at date of purchase) of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with banks.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;All marketable securities are classified as available-for-sale and consist of commercial paper, U.S. government sponsored enterprise debt securities and corporate debt securities. These securities are carried at estimated fair value, which is based on quoted market prices or observable market inputs of almost identical assets, with unrealized gains and losses included in accumulated other comprehensive income (loss). The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and accretion is included in interest income or expense. The cost of securities sold is based on specific identification. The Company&#x2019;s investments are subject to a periodic impairment review for other-than-temporary declines in fair value. The Company&#x2019;s review includes the consideration of the cause of the impairment including the creditworthiness of the security issuers, the number of securities in an unrealized loss position, the severity and duration of the unrealized losses and the Company&#x2019;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. When the Company determines that the decline in fair value of an investment is below its accounting basis and this decline is other-than-temporary, it reduces the carrying value of the security it holds and records a loss in the amount of such decline.&lt;/p&gt;</acrx:CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624764">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company measures and reports its cash equivalents, investments and financial liabilities at fair value. Fair value is defined as the exchange price that would be received for an asset or an exit price paid to transfer a liability in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. The fair value hierarchy defines a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-level valuation hierarchy for disclosure of fair value measurements as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"&gt;Level I&#x2014;Unadjusted quoted prices in active markets for identical assets or liabilities;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"&gt;Level II&#x2014;Inputs other than quoted prices included within Level I that are observable, unadjusted quoted prices in markets that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities; and&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 25pt;"&gt;Level III&#x2014;Unobservable inputs that are supported by little or &lt;em style="font: inherit;"&gt;no&lt;/em&gt; market activity for the related assets or liabilities.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The categorization of a financial instrument within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624765">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Segment Information &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company operates in a single segment, the development and commercialization of product candidates and products for the treatment of pain. The Company&#x2019;s product sales revenue consists of sales of DSUVIA in the United States and, through &lt;em style="font: inherit;"&gt; May 2021, &lt;/em&gt;sales of Zalviso in Europe by Gr&#xfc;nenthal. The Company&#x2019;s contract and collaboration revenue consists of non-cash royalty revenue, royalty revenue, and other revenue under the Gr&#xfc;nenthal Agreements and license revenue under the DZUVEO Agreement.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2021-01-01_2021-12-31" id="c81624837">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Risk &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company invests cash that is currently &lt;em style="font: inherit;"&gt;not&lt;/em&gt; being used for operational purposes in accordance with its investment policy in debt securities of U.S. government sponsored agencies, commercial paper and overnight deposits. The Company is exposed to credit risk in the event of default by the institutions holding the cash equivalents and available-for-sale securities to the extent recorded on the Consolidated Balance Sheets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company relies on a single &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party supplier for the supply of sufentanil, the active pharmaceutical ingredient in DSUVIA and Zalviso, and various sole-source &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract manufacturer organizations to manufacture the DSUVIA SDA.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;DSUVIA&#160;sales are concentrated with the DoD and with a limited number of wholesalers in the United States. Zalviso was sold in Europe by Gr&#xfc;nenthal through &lt;em style="font: inherit;"&gt; May 2021. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; July 2021, &lt;/em&gt;Aguettant was granted an exclusive license to commercialize DZUVEO in Europe. DZUVEO sales in Europe by Aguettant have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; commenced as of &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Revenue and accounts receivable have been concentrated with these customers.&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Revenues from customers that accounted for &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; or more of our total revenues during the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; are as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Percent of Total Revenue&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Aguettant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;61.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gr&#xfc;nenthal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;74.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;DoD&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Wholesaler A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="d_2021-01-01_2021-12-31"
      id="c31D4AAC7-3711-4B48-98BE-2E21463C76B6">
     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Year Ended December 31,&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Percent of Total Revenue&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Aguettant&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;61.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gr&#xfc;nenthal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;11.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;74.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;DoD&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.3&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;16.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Wholesaler A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Percent of Accounts Receivable, Net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Customer A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Customer B&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;79&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
    </us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember"
      decimals="3"
      id="c81618834"
      unitRef="Pure">0.619</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember"
      decimals="-3"
      id="c81618835"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-GrunenthalMember"
      decimals="3"
      id="c81618836"
      unitRef="Pure">0.117</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-GrunenthalMember"
      decimals="2"
      id="c81618837"
      unitRef="Pure">0.740</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DoDMember"
      decimals="3"
      id="c81618838"
      unitRef="Pure">0.003</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-DoDMember"
      decimals="3"
      id="c81618839"
      unitRef="Pure">0.169</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-WholesalerAMember"
      decimals="3"
      id="c81618840"
      unitRef="Pure">0.159</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-WholesalerAMember"
      decimals="3"
      id="c81618841"
      unitRef="Pure">0.039</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ReceivablesPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624838">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Accounts Receivable, net&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The need for a bad debt allowance is evaluated each reporting period based on the Company&#x2019;s assessment of the credit worthiness of its customers or any other potential circumstances that could result in bad debt.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company believes that the entire accounts receivable balance as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;is collectible and there was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; bad debt allowance provided as of &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Accounts receivable, net from customers that accounted for &lt;em style="font: inherit;"&gt;10%&lt;/em&gt; or more of our total accounts receivable balance as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; are as follows:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

     &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Percent of Accounts Receivable, Net&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Customer A&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;73&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Customer B&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;79&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
     &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"
      decimals="2"
      id="c81618844"
      unitRef="Pure">0.73</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerAMember"
      decimals="2"
      id="c81618845"
      unitRef="Pure">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"
      decimals="-3"
      id="c81618846"
      unitRef="Pure">0</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="d_2020-01-01_2020-12-31_ConcentrationRiskByBenchmarkAxis-AccountsReceivableMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-CustomerBMember"
      decimals="2"
      id="c81618847"
      unitRef="Pure">0.79</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:InventoryPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624839">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Inventories, net &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Inventories are valued at the lower of cost or net realizable value. Cost is determined using the &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-in, &lt;em style="font: inherit;"&gt;first&lt;/em&gt;-out method for all inventories. Inventory includes the cost of the active pharmaceutical ingredients, or API, raw materials and &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract manufacturing and packaging services. Indirect overhead costs associated with production and distribution are allocated to the appropriate cost pool and then absorbed into inventory based on the units produced or distributed, assuming normal capacity, in the applicable period. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company's policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value and inventory in excess of expected requirements. The Company periodically evaluates the carrying value of inventory on hand for potential excess amount over demand using the same lower of cost or net realizable value approach as that used to value the inventory.&lt;/p&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624840">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment, net &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method over the estimated useful lives of the assets, generally &lt;span style="-sec-ix-hidden:c81618752"&gt;three&lt;/span&gt; to &lt;span style="-sec-ix-hidden:c81618753"&gt;five&lt;/span&gt; years. Leasehold improvements are amortized over the shorter of the estimated useful life of the improvements or the remaining lease term. Expenditures for repairs and maintenance, which do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; extend the useful life of the property and equipment, are expensed as incurred. Upon retirement, the asset cost and related accumulated depreciation are relieved from the accompanying Consolidated Balance Sheets. Gains and losses associated with dispositions are reflected as a component of interest income and other income, net in the accompanying Consolidated Statements of Operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624841">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-Lived Assets &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company periodically assesses the impairment of long-lived assets and, if indicators of asset impairment exist, the Company assesses the recoverability of the affected long-lived assets by determining whether the carrying value of such assets can be recovered through an analysis of the undiscounted future expected operating cash flows. If impairment is indicated, the Company records the amount of such impairment for the excess of the carrying value of the asset over its estimated fair value. For example, if the Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; successful in its commercialization of DSUVIA, and if approved, Zalviso, purchased equipment and manufacturing-related facility improvements the Company has made at its contract manufacturers could become impaired. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;determine that it is &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer probable that the Company will realize the future economic benefit associated with the costs of these assets through future manufacturing activities, and if so, the Company would record an impairment charge associated with these assets.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <acrx:ContingentPutOptionPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624842">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Contingent put option&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The contingent put option associated with the Company&#x2019;s Loan Agreement with Oxford is recorded as a liability. Changes in the fair value of the contingent put option are recognized as interest income and other income (expense), net in the Consolidated Statements of Operations. For further discussion, see Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &#x201c;Long-Term Debt&#x201d;.&lt;/p&gt;</acrx:ContingentPutOptionPolicyPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624843">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company follows the provisions of ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;02,&lt;/em&gt; &lt;i&gt;Leases (Topic &lt;em style="font: inherit;"&gt;842&lt;/em&gt;)&lt;/i&gt;. At the inception of an arrangement, the Company determines whether the arrangement is, or contains, a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically &lt;em style="font: inherit;"&gt;not&lt;/em&gt; readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow on a collateralized basis over a similar term an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use asset &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required for items such as initial direct costs paid or incentives received.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized on the Consolidated Balance Sheets as operating lease right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624852">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Revenue from Contracts with Customers &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company follows the provisions of Accounting Standards Codification, or ASC, Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; &lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;. This guidance provides a unified model to determine how revenue is recognized. The Company recognizes revenue upon transfer of control of promised products or services to customers in an amount that reflects the consideration the Company expects to receive in exchange for those products or services. The Company sells its products primarily through wholesale and specialty distributors.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In determining the appropriate amount of revenue to be recognized as it fulfills its obligations under its agreements, the Company performs the following steps: (i)&#160;identification of the promised goods or services in the contract; (ii)&#160;determination of whether the promised goods or services are performance obligations, including whether they are distinct in the context of the contract; (iii)&#160;measurement of the transaction price, including the constraint on variable consideration; (iv)&#160;allocation of the transaction price to the performance obligations based on estimated selling prices; and (v)&#160;recognition of revenue when (or as) the Company satisfies each performance obligation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Product sales revenue&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company sells its product primarily through distributors. Revenues from product sales are recognized when distributors obtain control of the Company&#x2019;s product, which occurs at a point in time, upon delivery to such distributors. These distributors subsequently resell the product to certified medically supervised healthcare settings. In addition to distribution agreements with these customers, the Company enters into arrangements with group purchasing organizations, or GPOs, and other certified medically supervised healthcare settings that provide for privately negotiated discounts with respect to the purchase of its products. For revenue recognition under bill-and-hold arrangements, wherein the customer agrees to buy product from the Company but requests delivery at a later date, the Company deems that control passes to the customer when the product is ready for delivery. The Company recognizes revenue under these types of arrangements when a signed agreement is in place, the transaction is billable, the customer has significant risk and rewards for the product and the ability to direct the asset, the product has been set aside specifically for the customer, and the product cannot be redirected to another customer. Revenue from product sales is recorded at the transaction price, net of estimates for variable consideration consisting of chargebacks, government rebates, returns, distribution fees, GPO fees and product returns.&#160;Variable consideration is recorded at the time product sales are recognized resulting in a reduction in product revenue. The amount of variable consideration that is included in the transaction price &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be constrained and is included in the net sales price only to the extent that it is probable that a significant reversal in the amount of the cumulative revenue recognized will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur in a future period. Variable consideration is estimated using the most-likely amount method, which is the single-most likely outcome under a contract and is typically at the stated contractual rate.&#160;Where appropriate, these estimates take into consideration a range of possible outcomes that are probability-weighted in accordance with the expected value method under ASC Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; for relevant factors. These factors include current contractual and statutory requirements, specific known market events and trends, industry data, and/or forecasted customer buying and payment patterns. Actual amounts of consideration ultimately received &lt;em style="font: inherit;"&gt; may &lt;/em&gt;differ from the Company&#x2019;s estimates.&#160;If actual results vary materially from the Company&#x2019;s estimates, the Company will adjust these estimates, which will affect revenue from product sales and earnings in the period such estimates are adjusted. These estimates include:&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Chargebacks&lt;/span&gt; &#x2013; The Company&#x2019;s customers subsequently resell its product to qualified healthcare providers. In addition to distribution agreements with customers, the Company enters into arrangements with qualified healthcare providers that provide discounts with respect to the purchase of its product. Chargebacks represent the estimated obligations resulting from contractual commitments to sell product to qualified healthcare providers at prices lower than the list prices charged to customers who directly purchase the product from the Company. Customers charge the Company for the difference between what they pay for the product and the ultimate selling price to the qualified healthcare providers. These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of product revenue-related accrued liabilities on the Consolidated Balance Sheets. Chargeback amounts are determined at the time of resale to the qualified healthcare providers by customers, and the Company issues credits for such amounts generally within a few weeks of the customer's notification to the Company of the resale. Reserves for chargebacks consists of credits that the Company expects to issue for units that remain in the distribution channel inventories at each reporting period end that the Company expects will be sold to the qualified healthcare providers, and chargebacks for units that the Company&#x2019;s customers have sold to the qualified healthcare providers, but for which credits have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been issued.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Government Rebates&lt;/span&gt; &#x2013; The Company is subject to discount obligations under state Medicaid programs. The Company estimates its Medicaid rebates, and reserves are recorded in the same period the related product revenue is recognized, resulting in a reduction of product revenue and the establishment of a current liability that is included in accrued liabilities on the Consolidated Balance Sheet.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Returns&lt;/span&gt; &#x2013;&lt;i&gt; &lt;/i&gt;The Company allows its distributors to return product for credit &lt;em style="font: inherit;"&gt;6&lt;/em&gt; months prior to, and up to &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months after, the product expiration date. As such, there &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be a significant period of time between the time the product is shipped and the time the credit is issued on returned product.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Distribution Fees&lt;/span&gt; &#x2013;&lt;i&gt; &lt;/i&gt;Distribution fees include fees paid to certain customers for sales order management, data and distribution services. Distribution fees are recorded as a reduction of revenue in the period the related product revenue is recognized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;GPO Fees&lt;/span&gt;&lt;i&gt; &lt;/i&gt;&#x2013; The Company pays administrative fees to GPOs for services and access to data. These fees are based on contracted terms and are paid after the quarter in which the product was purchased by the GPOs&#x2019; members.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Trade Discounts and Allowances&lt;/span&gt; - The Company provides its customers with discounts which include early payment incentives that are explicitly stated in its contracts and are recorded as a reduction of revenue in the period the related product revenue is recognized.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company believes its estimated allowances for chargebacks, government rebates and product returns require a high degree of judgment and are subject to change based on its limited experience and certain quantitative and qualitative factors. The Company believes its estimated allowances for distribution fees, GPO fees and trade discounts and allowances do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; require a high degree of judgment because the amounts are settled within a relatively short period of time. The Company will continue to assess its estimates of variable consideration as it accumulates additional historical data and will adjust these estimates accordingly. Changes in product revenue allowance estimates could materially affect the Company&#x2019;s results of operations and financial position.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Contract and other collaboration revenue&lt;/span&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company generates revenue from collaboration agreements. These agreements typically include payments for upfront signing or license fees, cost reimbursements for development and manufacturing services, milestone payments, product sales, and royalties on licensee&#x2019;s future product sales. Product sales related revenue under these collaboration agreements is classified as product sales revenue, while other revenue generated from collaboration agreements is classified as contract and other collaboration revenue.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Performance Obligations&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;A performance obligation is a promise in a contract to transfer a distinct good or service to the customer and is the unit of account in ASC Topic &lt;em style="font: inherit;"&gt;606.&lt;/em&gt; The Company&#x2019;s performance obligations include delivering product to its distributors, commercialization license rights, development services, services associated with the regulatory approval process, joint steering committee services, demonstration devices, manufacturing services, material rights for discounts on manufacturing services, and product supply.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has optional additional items in contracts, which are considered marketing offers and are accounted for as separate contracts when the customer elects such options. Arrangements that include a promise for future commercial product supply and optional research and development services at the customer&#x2019;s or the Company&#x2019;s discretion are generally considered as options. The Company assesses if these options provide a material right to the licensee and if so, such material rights are accounted for as separate performance obligations. If the Company is entitled to additional payments when the customer exercises these options, any additional payments are recorded in revenue when the customer obtains control of the goods or services.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Transaction Price&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company has both fixed and variable consideration. Variable consideration for product revenue is described as Net product sales in the Consolidated Statements of Operations. For collaboration agreements, non-refundable upfront fees and product supply selling prices are considered fixed, while milestone payments are identified as variable consideration when determining the transaction price. Funding of research and development activities is considered variable until such costs are reimbursed at which point, they are considered fixed. The Company allocates the total transaction price to each performance obligation based on the relative estimated standalone selling prices of the promised goods or services for each performance obligation.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;At the inception of each arrangement that includes milestone payments, the Company evaluates whether the milestones are considered probable of being achieved and estimates the amount to be included in the transaction price using the most likely amount method. If it is probable that a significant revenue reversal would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; occur, the value of the associated milestone (such as a regulatory submission by the Company) is included in the transaction price. Milestone payments that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; within the control of the Company, such as approvals from regulators, are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; considered probable of being achieved until those approvals are received.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (a) when the related sales occur, or (b) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied).&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Allocation of Consideration&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As part of the accounting for collaboration arrangements, the Company must develop assumptions that require judgment to determine the stand-alone selling price of each performance obligation identified in the contract. Estimated selling prices for license rights and material rights for discounts on manufacturing services are calculated using an income approach model and can include the following key assumptions: the development timeline, sales forecasts, costs of product sales, commercialization expenses, discount rate, the time which the manufacturing services are expected to be performed, and probabilities of technical and regulatory success. For all other performance obligations, the Company uses a cost-plus margin approach.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Timing of Recognition&lt;/i&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Significant management judgment is required to determine the level of effort required under collaboration arrangements and the period over which the Company expects to complete its performance obligations under the arrangement. The Company estimates the performance period or measure of progress at the inception of the arrangement and re-evaluates it each reporting period. This re-evaluation &lt;em style="font: inherit;"&gt; may &lt;/em&gt;shorten or lengthen the period over which revenue is recognized. Changes to these estimates are recorded on a cumulative catch-up basis. If the Company cannot reasonably estimate when its performance obligations either are completed or become inconsequential, then revenue recognition is deferred until the Company can reasonably make such estimates. Revenue is then recognized over the remaining estimated period of performance using the cumulative catch-up method. Revenue is recognized for products at a point in time when control of the product is transferred to the customer in an amount that reflects the consideration the Company expects to be entitled to in exchange for those product sales, which is typically once the product physically arrives at the customer, and for licenses of functional intellectual property at the point in time the customer can use and benefit from the license. For performance obligations that are services, revenue is recognized over time proportionate to the costs that the Company has incurred to perform the services using the cost-to-cost input method.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:CostOfSalesPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624861">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Cost of Goods Sold &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Cost of goods sold for product revenue includes &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party manufacturing costs, shipping and handling costs, and indirect overhead costs associated with production and distribution which are allocated to the appropriate cost pool and recognized when revenue is recognized. Indirect overhead costs in excess of normal capacity are recorded as period costs in the period incurred.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Gr&#xfc;nenthal Agreements, the Company sold Zalviso to Gr&#xfc;nenthal at predetermined, contractual transfer prices that were less than the direct costs of manufacturing and recognized indirect costs as period costs where they were in excess of normal capacity and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; recoverable on a lower of cost or net realizable value basis. Cost of goods sold for Zalviso shipped to Gr&#xfc;nenthal included the inventory costs of API, &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party contract manufacturing costs, packaging and distribution costs, shipping, handling and storage costs, depreciation and costs of the employees involved with production.&lt;/p&gt;</us-gaap:CostOfSalesPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2021-01-01_2021-12-31" id="c81624862">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Research and development costs are charged to expense when incurred. Research and development expenses include salaries, employee benefits, including stock-based compensation, consultant fees, laboratory supplies, costs associated with clinical trials and manufacturing, including contract research organization fees, other professional services and allocations of corporate costs. The Company reviews and accrues clinical trial expenses based on work performed, which relies on estimates of total costs incurred based on patient enrollment, completion of patient studies and other events.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2021-01-01_2021-12-31" id="c81624871">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-Based Compensation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Compensation expense for all stock-based payment awards made to employees and directors, including employee stock options and restricted stock units related to the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan, or &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; EIP, the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Equity Incentive Plan, or &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP, and employee share purchases related to the Amended and Restated &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Employee Stock Purchase Plan, or ESPP, is based on estimated fair values at grant date. The Company determines the grant date fair value of the awards using the Black-Scholes option-pricing model and generally recognizes the fair value as stock-based compensation expense on a straight-line basis over the vesting period of the respective awards. The Company applies the graded-vesting attribution method to awards with market conditions that include graded-vesting features. Additionally, the Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Black-Scholes option pricing model requires inputs such as expected term, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. The expected term, which represents the period of time that options granted are expected to be outstanding, is derived by analyzing the historical experience of similar awards, giving consideration to the contractual terms of the stock&#x2011;based awards, vesting schedules and expectations of future employee behavior. Expected volatilities are estimated using the historical stock price performance over the expected term of the option, which are adjusted as necessary for any other factors which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;reasonably affect the volatility of AcelRx&#x2019;s stock in the future. The risk&#x2011;free interest rate is based on the U.S. Treasury yield in effect at the time of the grant for the expected term of the award. The Company recognizes forfeitures when they occur and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate paying dividends in the near future.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <acrx:WarrantsPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624872">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Warrants Issued in Connection with Financings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company generally accounts for warrants issued in connection with debt and equity financings as a component of equity, unless the warrants include a conditional obligation to issue a variable number of shares or there is a deemed possibility that the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;need to settle the warrants in cash. For warrants issued with a conditional obligation to issue a variable number of shares or the deemed possibility of a cash settlement, the Company records the fair value of the warrants as a liability at each balance sheet date and records changes in fair value in other (income) expense in the Consolidated Statements of Operations.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</acrx:WarrantsPolicyPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624873">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Restructuring Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company's restructuring costs consist of employee termination benefit costs. Liabilities for costs associated with the cost reduction plan are recognized when the liability is incurred and are measured at fair value. One-time termination benefits are expensed at the date the Company notifies the employee, unless the employee must provide future service, in which case the benefits are expensed ratably over the future service period.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 16, 2020, &lt;/em&gt;in connection with entering into the Co-Promotion Agreement, the Company initiated a reduction in headcount, designed to eliminate the overlap with the Tetraphase commercial team in order to more efficiently commercialize DSUVIA alongside the Tetraphase commercial team and reduce operating expenses. The Company eliminated 30 positions, primarily within the commercial organization. For the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company incurred and paid $0.5 million in employee termination benefits related to this restructuring. The headcount reduction was completed in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; There were &lt;em style="font: inherit;"&gt;no&lt;/em&gt; such restructuring costs for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;</us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated
      contextRef="d_2020-03-16_2020-03-16"
      decimals="INF"
      id="c81618787"
      unitRef="Pure">30</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated>
    <us-gaap:RestructuringCharges
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-5"
      id="c81618788"
      unitRef="USD">500000</us-gaap:RestructuringCharges>
    <us-gaap:InterestExpensePolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81630872">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Non-Cash Interest Income (Expense) on Liability Related to Sale of Future Royalties&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; September 2015, &lt;/em&gt;the Company sold certain royalty and milestone payment rights from the sales of Zalviso in the European Union by Gr&#xfc;nenthal to PDL for gross proceeds of $65.0 million. Gr&#xfc;nenthal terminated the Gr&#xfc;nenthal Agreements effective &lt;em style="font: inherit;"&gt; November 13, 2020. &lt;/em&gt;The terms of the Gr&#xfc;nenthal Agreements were extended to &lt;em style="font: inherit;"&gt; May 2021 &lt;/em&gt;to enable Gr&#xfc;nenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Territory reverted back to the Company in &lt;em style="font: inherit;"&gt; May 2021.&lt;/em&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Royalty Monetization, the Company has a continuing obligation to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. Under the relevant accounting guidance, because of the Company&#x2019;s significant continuing involvement, the Royalty Monetization is accounted for as a liability that is being amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and payments made to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $61.2 million of net proceeds the Company received, are amortized as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense, or interest income, as these estimates are updated.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There are a number of factors that could materially affect the amount and timing of royalty and milestone payments from Zalviso in Europe, most of which are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; within the Company&#x2019;s control. Such factors include, but are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; limited to, the success of any future sales and promotion of Zalviso under any New Arrangement, if achieved; changing standards of care; the introduction of competing products; manufacturing or other delays; intellectual property matters; adverse events that result in governmental health authority imposed restrictions on the use of Zalviso; significant changes in foreign exchange rates as the royalties remitted to ARPI LLC are made in U.S. dollars; and other events or circumstances that could result in reduced royalty payments from European sales of Zalviso, all of which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result in a reduction of non-cash royalty revenues and the non-cash interest expense over the life of the Royalty Monetization. Conversely, if sales of Zalviso in Europe are greater than expected, the non-cash royalty revenues and the non-cash interest expense recorded by the Company would be greater over the term of the Royalty Monetization. The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. Because estimated sales forecasts and payments &lt;em style="font: inherit;"&gt; may &lt;/em&gt;vary over the life of the Royalty Monetization, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required to recognize interest income as the imputed interest rate is adjusted prospectively to reflect the revised effective interest rate over the term of the Royalty Monetization.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company records non-cash royalty revenues and non-cash interest income (expense), net, within its Consolidated Statements of Operations over the term of the Royalty Monetization.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;When the expected payments under the Royalty Monetization are lower than the gross proceeds of &lt;em style="font: inherit;"&gt;$65.0&lt;/em&gt; million received, the Company defers recognition of any probable contingent gain until the Royalty Monetization liability expires.&lt;/p&gt;</us-gaap:InterestExpensePolicyTextBlock>
    <acrx:ProceedsFromSaleOfRoyaltyAndMilestoneRights
      contextRef="d_2015-09-01_2015-09-30"
      decimals="-6"
      id="c81618791"
      unitRef="USD">65000000.0</acrx:ProceedsFromSaleOfRoyaltyAndMilestoneRights>
    <acrx:RoyaltyArrangmentMaximumPayments
      contextRef="d_2015-09-01_2015-09-30"
      decimals="-6"
      id="c81618792"
      unitRef="USD">195000000.0</acrx:RoyaltyArrangmentMaximumPayments>
    <acrx:NetProceedsFromSaleOfFutureRoyalties
      contextRef="d_2015-09-01_2015-09-30"
      decimals="-5"
      id="c81618793"
      unitRef="USD">61200000</acrx:NetProceedsFromSaleOfFutureRoyalties>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624874">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Comprehensive Loss &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;Comprehensive loss is comprised of net loss and other comprehensive income (loss) and is disclosed in the Consolidated Statements of Operations. For the Company, other comprehensive income (loss) consists of changes in unrealized gains and losses on the Company&#x2019;s investments.&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624875">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Deferred tax assets and liabilities are measured based on differences between the financial reporting and tax basis of assets and liabilities using enacted rates and laws that are expected to be in effect when the differences are expected to reverse. The Company records a valuation allowance for the full amount of deferred assets, which would otherwise be recorded for tax benefits relating to operating loss and tax credit carryforwards, as realization of such deferred tax assets cannot be determined to be more likely than &lt;em style="font: inherit;"&gt;not.&lt;/em&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624876">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss per Share of Common Stock &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, convertible preferred stock, options to purchase common stock, restricted stock subject to repurchase, restricted stock units, warrants to purchase convertible preferred stock and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, such common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive. For additional information regarding the net loss per share, see Note &lt;em style="font: inherit;"&gt;15&lt;/em&gt; &#x201c;Net Loss per Share of Common Stock&#x201d;.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c81624877">&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Standards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2019, &lt;/em&gt;the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12,&lt;/em&gt; &#x201c;&lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;&#x201d;. ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; eliminates certain exceptions related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. It also clarifies and simplifies other aspects of the accounting for income taxes. ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2020, &lt;/em&gt;and interim periods within those fiscal years. The Company adopted ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12&lt;/em&gt; on &lt;em style="font: inherit;"&gt; January 1, 2021, &lt;/em&gt;which did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on the Company&#x2019;s Consolidated Financial Statements.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2020, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06,&lt;/em&gt; &#x201c;&lt;i&gt;Debt - Debt with Conversion and Other Options (Subtopic &lt;em style="font: inherit;"&gt;470&lt;/em&gt;-&lt;em style="font: inherit;"&gt;20&lt;/em&gt;) and Derivatives and Hedging - Contracts in Entity's Own Equity (Subtopic &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt;): Accounting for Convertible Instruments and Contracts in an Entity's Own Equity&lt;/i&gt;&#x201d;. The standard simplifies accounting for convertible instruments by removing major separation models required under current GAAP. Consequently, more convertible debt instruments will be reported as a single liability instrument with &lt;em style="font: inherit;"&gt;no&lt;/em&gt; separate accounting for embedded conversion features. ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06&lt;/em&gt; removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception, which will permit more equity contracts to qualify for it. The standard also simplifies the diluted net income per share calculation in certain areas. ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06&lt;/em&gt; is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2023, &lt;/em&gt;and interim periods within those fiscal years for smaller reporting companies, with early adoption permitted. The Company early adopted ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;06&lt;/em&gt; on &lt;em style="font: inherit;"&gt; January 1, 2021, &lt;/em&gt;which did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on the Company&#x2019;s Consolidated Financial Statements on the date of adoption.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Issued Accounting Pronouncements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; &#x201c;&lt;i&gt;Financial Instruments &lt;/i&gt;&#x2013;&lt;i&gt; Credit Losses: Measurement of Credit Losses on Financial Instruments,&lt;/i&gt;&#x201d; or ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; replaces the incurred loss impairment model in current GAAP with a model that reflects expected credit losses and requires consideration of a broader range of reasonable and supportable information to determine credit loss estimates. ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; is effective for the Company beginning &lt;em style="font: inherit;"&gt; January 1, 2023, &lt;/em&gt;with early adoption allowed beginning &lt;em style="font: inherit;"&gt; January 1, 2020. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; May 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05,&lt;/em&gt; &#x201c;&lt;i&gt;Financial Instruments &lt;/i&gt;&#x2013;&lt;i&gt; Credit Losses,&lt;/i&gt;&#x201d; or ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05,&lt;/em&gt; to allow entities to irrevocably elect the fair value option for certain financial assets previously measured at amortized cost upon adoption of the new credit losses standard. The new effective dates and transition align with those of ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; Management is currently assessing the date of adoption and the impact ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13&lt;/em&gt; and ASU &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;05&lt;/em&gt; will have on the Company, but it does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate adoption of these new standards to have a material impact on the Company&#x2019;s financial position, results of operations or cash flows.&lt;/p&gt; &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
      &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; March 2020, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;04,&lt;/em&gt; &#x201c;&lt;i&gt;Reference Rate Reform (Topic &lt;em style="font: inherit;"&gt;848&lt;/em&gt;): Facilitation of the Effects of Reference Rate Reform on Financial Reporting,&lt;/i&gt;&#x201d; which provides elective amendments for entities that have contracts, hedging relationships and other transactions that reference LIBOR or another reference rate expected to be discontinued because of reference rate reform. These amendments are effective immediately and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be applied prospectively to contract modifications made and hedging relationships entered into or evaluated on or before &lt;em style="font: inherit;"&gt; December 31, 2022. &lt;/em&gt;In &lt;em style="font: inherit;"&gt; January 2021, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;-&lt;em style="font: inherit;"&gt;01,&lt;/em&gt; &#x201c;&lt;i&gt;Reference Rate Reform (Topic &lt;em style="font: inherit;"&gt;848&lt;/em&gt;),&lt;/i&gt;&#x201d; to expand and clarify the scope of Topic &lt;em style="font: inherit;"&gt;848&lt;/em&gt; to include derivative instruments on discounting transactions. The amendments in this ASU are effective in the same timeframe as ASU &lt;em style="font: inherit;"&gt;2020&lt;/em&gt;-&lt;em style="font: inherit;"&gt;04.&lt;/em&gt; The Company is currently evaluating the impact this guidance will have on its Consolidated Financial Statements.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050891">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt; Investments and Fair Value Measurement &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Investments &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company classifies its marketable securities as available-for-sale and records its investments at fair value. Available-for-sale securities are carried at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income (loss). Marketable securities which have maturities beyond &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year as of the end of the reporting period are classified as non-current.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The table below summarizes the Company&#x2019;s cash, cash equivalents and investments (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt; &lt;b&gt;Cost&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt; &lt;b&gt;Unrealized&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Gains&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt; &lt;b&gt;Unrealized&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Losses&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,398&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,398&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total cash and cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,663&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,663&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Short-term investments:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;29,504&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;29,504&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total short-term investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38,967&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38,967&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total cash, cash equivalents and short-term investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;51,630&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;51,630&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt; &lt;b&gt;Cost&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt; &lt;b&gt;Unrealized&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Gains&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt; &lt;b&gt;Unrealized&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Losses&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,181&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,181&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,097&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,097&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total cash and cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,274&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,274&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Short-term investments:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;U.S. government agency securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,794&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,794&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total short-term investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,612&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,612&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total cash, cash equivalents and short-term investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;42,886&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;42,886&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;None&lt;/em&gt; of the available-for-sale securities held by the Company had material unrealized losses and there were no realized losses for the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; There were no other-than-temporary impairments for these securities as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; or &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; &lt;em style="font: inherit;"&gt;&lt;span style="-sec-ix-hidden:c81618861"&gt;No&lt;/span&gt;&lt;/em&gt; gross realized gains or losses were recognized on the available-for-sale securities and, accordingly, there were no amounts reclassified out of accumulated other comprehensive income (loss) to earnings during the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the contractual maturity of all investments held was less than &lt;em style="font: inherit;"&gt;one&lt;/em&gt; year.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value Measurement &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company&#x2019;s financial instruments consist of Level I and II assets and Level III liabilities. Money market funds are highly liquid investments and are actively traded. The pricing information on these investment instruments are readily available and can be independently validated as of the measurement date. This approach results in the classification of these securities as Level &lt;em style="font: inherit;"&gt;1&lt;/em&gt; of the fair value hierarchy. For Level II instruments, the Company estimates fair value by utilizing &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party pricing services in developing fair value measurements where fair value is based on valuation methodologies such as models using observable market inputs, including benchmark yields, reported trades, broker/dealer quotes, bids, offers and other reference data. Such Level II instruments typically include U.S. treasury, U.S. government agency securities and commercial paper. As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;and &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company held, in addition to Level II assets, a contingent put option liability associated with the Loan Agreement with Oxford. See Note &lt;em style="font: inherit;"&gt;8&lt;/em&gt; &#x201c;Long-Term Debt&#x201d; for further description. The Company&#x2019;s estimate of fair value of the contingent put option liability was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated both with and without the presence of the default provisions, holding all other assumptions constant. The resulting difference between the &lt;em style="font: inherit;"&gt;two&lt;/em&gt; estimated fair values is the estimated fair value of the default provisions, or the contingent put option, which is included under other long-term liabilities on the Consolidated Balance Sheets. Changes to the estimated fair value of this liability is recorded in interest income and other income (expense), net in the Consolidated Statements of Operations. The fair value of the underlying debt facility is estimated by calculating the expected cash flows in consideration of an estimated probability of default and expected recovery rate in default and discounting such cash flows back to the reporting date using a risk-free rate.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table sets forth the fair value of the Company&#x2019;s financial assets and liabilities by level within the fair value hierarchy (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;I&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;II&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;III&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;37,902&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;37,902&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total assets measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;50,187&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;47,365&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Contingent put option liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total liabilities measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;



    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;I&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;II&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;III&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. government agency securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,891&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,891&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total assets measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;37,705&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;33,709&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Contingent put option liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total liabilities measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table sets forth a summary of the changes in the fair value of the Company&#x2019;s Level III financial liabilities for the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value&#x2014;beginning of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;"&gt;Change in fair value of contingent put option associated with the Loan Agreement&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(165&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value&#x2014;end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value&#x2014;beginning of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;437&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;"&gt;Change in fair value of contingent put option associated with the Loan Agreement&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(191&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value&#x2014;end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock>
    <us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock
      contextRef="d_2021-01-01_2021-12-31"
      id="D01D4045-1EF5-4D25-B758-332A294EFAD1">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt; &lt;b&gt;Cost&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt; &lt;b&gt;Unrealized&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Gains&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt; &lt;b&gt;Unrealized&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Losses&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,443&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,398&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;8,398&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total cash and cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,663&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;12,663&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Short-term investments:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;29,504&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;29,504&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total short-term investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38,967&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;38,967&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total cash, cash equivalents and short-term investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;51,630&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;51,630&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 46%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Amortized&lt;/b&gt; &lt;b&gt;Cost&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt; &lt;b&gt;Unrealized&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Gains&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Gross&lt;/b&gt; &lt;b&gt;Unrealized&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Losses&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cash and cash equivalents:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Cash&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,181&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,181&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,097&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18,097&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total cash and cash equivalents&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,274&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,274&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="width: 40%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Short-term investments:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 12%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;U.S. government agency securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,794&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,794&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total short-term investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,612&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;15,612&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 40%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total cash, cash equivalents and short-term investments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;42,886&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;42,886&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock>
    <us-gaap:Cash
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618894"
      unitRef="USD">1443000</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618897"
      unitRef="USD">1443000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618898"
      unitRef="USD">2822000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618901"
      unitRef="USD">2822000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618902"
      unitRef="USD">8398000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618903"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618904"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618905"
      unitRef="USD">8398000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618906"
      unitRef="USD">12663000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2021-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618909"
      unitRef="USD">12663000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618911"
      unitRef="USD">29504000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618912"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618913"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618914"
      unitRef="USD">29504000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618915"
      unitRef="USD">9463000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618916"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618917"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618918"
      unitRef="USD">9463000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618919"
      unitRef="USD">38967000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618920"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618921"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618922"
      unitRef="USD">38967000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81618923"
      unitRef="USD">51630000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618924"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618925"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <acrx:CashCashEquivalentsAndShorttermInvestmentsFairValue
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81618926"
      unitRef="USD">51630000</acrx:CashCashEquivalentsAndShorttermInvestmentsFairValue>
    <us-gaap:Cash
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618928"
      unitRef="USD">5181000</us-gaap:Cash>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CashMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618931"
      unitRef="USD">5181000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:MoneyMarketFundsAtCarryingValue
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618932"
      unitRef="USD">3996000</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618935"
      unitRef="USD">3996000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CommercialPaperAtCarryingValue
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618936"
      unitRef="USD">18097000</us-gaap:CommercialPaperAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618939"
      unitRef="USD">18097000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618940"
      unitRef="USD">27274000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i_2020-12-31_InvestmentTypeAxis-CashAndCashEquivalentsMember"
      decimals="-3"
      id="c81618943"
      unitRef="USD">27274000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618945"
      unitRef="USD">5818000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618946"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618947"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgenciesDebtSecuritiesMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618948"
      unitRef="USD">5818000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618949"
      unitRef="USD">9794000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618950"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618951"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618952"
      unitRef="USD">9794000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618953"
      unitRef="USD">15612000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618954"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618955"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2020-12-31_InvestmentTypeAxis-MarketableSecuritiesMember"
      decimals="-3"
      id="c81618956"
      unitRef="USD">15612000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618957"
      unitRef="USD">42886000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618958"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618959"
      unitRef="USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <acrx:CashCashEquivalentsAndShorttermInvestmentsFairValue
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81618960"
      unitRef="USD">42886000</acrx:CashCashEquivalentsAndShorttermInvestmentsFairValue>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618854"
      unitRef="USD">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618860"
      unitRef="USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81618866"
      unitRef="USD">0</us-gaap:OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock
      contextRef="d_2021-01-01_2021-12-31"
      id="C6739F65-1FE0-4DD0-B522-F6084C90642A">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;I&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;II&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;III&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;37,902&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;37,902&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Corporate debt securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;9,463&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total assets measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;50,187&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,822&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;47,365&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Contingent put option liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total liabilities measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="14" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As of December 31, 2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;I&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;II&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Level&lt;/b&gt; &lt;b&gt;III&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;&lt;b&gt;Assets&lt;/b&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Money market funds&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;U.S. government agency securities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;5,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Commercial paper&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,891&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;27,891&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total assets measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;37,705&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,996&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;33,709&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;&lt;span style="text-decoration: underline; "&gt;Liabilities&lt;/span&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Contingent put option liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total liabilities measured at fair value&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c81618962"
      unitRef="USD">2822000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81618963"
      unitRef="USD">2822000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81618964"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81618965"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember"
      decimals="-3"
      id="c81618966"
      unitRef="USD">37902000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81618967"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81618968"
      unitRef="USD">37902000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81618969"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember"
      decimals="-3"
      id="c81618970"
      unitRef="USD">9463000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81618971"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81618972"
      unitRef="USD">9463000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByAssetClassAxis-CorporateDebtSecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81618973"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618974"
      unitRef="USD">50187000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81618975"
      unitRef="USD">2822000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81618976"
      unitRef="USD">47365000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81618977"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"
      decimals="-3"
      id="c81618979"
      unitRef="USD">81000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"
      decimals="-3"
      id="c81618980"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"
      decimals="-3"
      id="c81618981"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"
      decimals="-3"
      id="c81618982"
      unitRef="USD">81000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81618983"
      unitRef="USD">81000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81618984"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81618985"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81618986"
      unitRef="USD">81000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember"
      decimals="-3"
      id="c81618988"
      unitRef="USD">3996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81618989"
      unitRef="USD">3996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81618990"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-MoneyMarketFundsMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81618991"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember"
      decimals="-3"
      id="c81618992"
      unitRef="USD">5818000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81618993"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81618994"
      unitRef="USD">5818000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-USGovernmentAgencySecuritiesMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81618995"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember"
      decimals="-3"
      id="c81618996"
      unitRef="USD">27891000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81618997"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81618998"
      unitRef="USD">27891000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByAssetClassAxis-CommercialPaperMember_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81618999"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619000"
      unitRef="USD">37705000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81619001"
      unitRef="USD">3996000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81619002"
      unitRef="USD">33709000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81619003"
      unitRef="USD">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"
      decimals="-3"
      id="c81619005"
      unitRef="USD">246000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"
      decimals="-3"
      id="c81619006"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"
      decimals="-3"
      id="c81619007"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member_FairValueByLiabilityClassAxis-ContingentPutOptionLiabilityMember"
      decimals="-3"
      id="c81619008"
      unitRef="USD">246000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619009"
      unitRef="USD">246000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel1Member"
      decimals="-3"
      id="c81619010"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel2Member"
      decimals="-3"
      id="c81619011"
      unitRef="USD">0</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81619012"
      unitRef="USD">246000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="d_2021-01-01_2021-12-31"
      id="c0974F29A-90CE-4F5E-A9C4-FF390B4918BC">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value&#x2014;beginning of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;"&gt;Change in fair value of contingent put option associated with the Loan Agreement&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(165&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value&#x2014;end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value&#x2014;beginning of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;437&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;"&gt;Change in fair value of contingent put option associated with the Loan Agreement&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(191&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Fair value&#x2014;end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;246&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81619013"
      unitRef="USD">246000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings
      contextRef="d_2021-01-01_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81619014"
      unitRef="USD">165000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2021-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81619015"
      unitRef="USD">81000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2019-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81619016"
      unitRef="USD">437000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
      contextRef="d_2020-01-01_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81619017"
      unitRef="USD">-191000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member"
      decimals="-3"
      id="c81619018"
      unitRef="USD">246000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:InventoryDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050898">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt; Inventories, net &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Inventories consist of finished goods, raw materials and work in process and are stated at the lower of cost or net realizable value and consist of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As&lt;/b&gt; &lt;b&gt;of&lt;/b&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Raw materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;722&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;257&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Work-in-process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;159&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;30&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,339&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Inventories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,111&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,626&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company recorded inventory impairment charges of approximately $0.8 million, primarily as a result of DSUVIA inventory that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;expire before being sold. During the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company recorded inventory impairment charges of approximately $0.7 million, of which $0.3 million related to the termination of the Amended Agreements, while $0.4 million related to DSUVIA inventory, primarily inventory that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;expire before being sold.&lt;/p&gt;
  </us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050899">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As&lt;/b&gt; &lt;b&gt;of&lt;/b&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Raw materials&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;722&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;257&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Work-in-process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;159&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;30&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Finished goods&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;230&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,339&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Inventories&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,111&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,626&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619024"
      unitRef="USD">722000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryRawMaterialsNetOfReserves
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619025"
      unitRef="USD">257000</us-gaap:InventoryRawMaterialsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619026"
      unitRef="USD">159000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="i_2020-12-31"
      decimals="-4"
      id="c81619027"
      unitRef="USD">30000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81619028"
      unitRef="USD">230000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619029"
      unitRef="USD">1339000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619030"
      unitRef="USD">1111000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619031"
      unitRef="USD">1626000</us-gaap:InventoryNet>
    <us-gaap:InventoryWriteDown
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c81619020"
      unitRef="USD">800000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-5"
      id="c81619021"
      unitRef="USD">700000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-AmendedLicenseAgreementMember"
      decimals="-5"
      id="c81619022"
      unitRef="USD">300000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-DSUVIAMember"
      decimals="-5"
      id="c81619023"
      unitRef="USD">400000</us-gaap:InventoryWriteDown>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050900">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt; Property and Equipment, net &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Property and equipment, net consist of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As&lt;/b&gt; &lt;b&gt;of&lt;/b&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;4,406&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;4,406&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;5,838&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;4,616&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Computer equipment and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;1,589&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;1,724&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Construction in process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;13,805&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;14,101&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tooling&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;826&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;1,109&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and fixtures&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;250&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;292&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;26,714&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;26,248&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(10,786&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(10,589&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,928&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,659&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Depreciation and amortization expense was &lt;span style="-sec-ix-hidden:c81619034"&gt;$1.1&lt;/span&gt; million for each of the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively.&lt;/p&gt;
  </us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050901">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 18pt; width: 95%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;As&lt;/b&gt; &lt;b&gt;of&lt;/b&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 13pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 68%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Laboratory equipment&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;4,406&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;4,406&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Leasehold improvements&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;5,838&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;4,616&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Computer equipment and software&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;1,589&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;1,724&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Construction in process&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;13,805&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;14,101&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tooling&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;826&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;1,109&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Furniture and fixtures&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;250&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;292&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;26,714&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right;"&gt;26,248&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less accumulated depreciation and amortization&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(10,786&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(10,589&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Property and equipment, net&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,928&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: Times New Roman; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;15,659&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c81619039"
      unitRef="USD">4406000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LaboratoryEquipmentMember"
      decimals="-3"
      id="c81619040"
      unitRef="USD">4406000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c81619041"
      unitRef="USD">5838000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-LeaseholdImprovementsMember"
      decimals="-3"
      id="c81619042"
      unitRef="USD">4616000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember"
      decimals="-3"
      id="c81619043"
      unitRef="USD">1589000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ComputerEquipmentAndSoftwareMember"
      decimals="-3"
      id="c81619044"
      unitRef="USD">1724000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"
      decimals="-3"
      id="c81619045"
      unitRef="USD">13805000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ConstructionInProgressMember"
      decimals="-3"
      id="c81619046"
      unitRef="USD">14101000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingMember"
      decimals="-3"
      id="c81619047"
      unitRef="USD">826000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-ToolingMember"
      decimals="-3"
      id="c81619048"
      unitRef="USD">1109000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-4"
      id="c81619049"
      unitRef="USD">250000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31_PropertyPlantAndEquipmentByTypeAxis-FurnitureAndFixturesMember"
      decimals="-3"
      id="c81619050"
      unitRef="USD">292000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619051"
      unitRef="USD">26714000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619052"
      unitRef="USD">26248000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619053"
      unitRef="USD">10786000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619054"
      unitRef="USD">10589000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619055"
      unitRef="USD">15928000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619056"
      unitRef="USD">15659000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c81619035"
      unitRef="USD">1100000</us-gaap:Depreciation>
    <acrx:InlicenseAgreementTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050902">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt; In-License Agreement&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 14, 2021, &lt;/em&gt;the Company entered into a License and Commercialization Agreement, or the PFS Agreement, with Aguettant pursuant to which the Company obtained the exclusive right to develop and, subject to FDA approval, commercialize in the United States (i) an ephedrine pre-filled syringe containing &lt;em style="font: inherit;"&gt;10&lt;/em&gt; ml of a solution of &lt;em style="font: inherit;"&gt;3&lt;/em&gt; mg/ml ephedrine hydrochloride for injection, and (ii) a phenylephrine pre-filled syringe containing &lt;em style="font: inherit;"&gt;10&lt;/em&gt; ml of a solution of &lt;em style="font: inherit;"&gt;50&lt;/em&gt; mcg/ml phenylephrine hydrochloride for injection. Aguettant will supply the Company with the products for use in commercialization, if they are approved in the U.S.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The PFS Agreement has an initial term of &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; (&lt;span style="-sec-ix-hidden:c81619063"&gt;10&lt;/span&gt;) marketing years, with the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; marketing year ending on &lt;em style="font: inherit;"&gt; December 31 &lt;/em&gt;of the calendar year after the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; launch of a product (or &lt;em style="font: inherit;"&gt; December 31 &lt;/em&gt;of the same calendar year if the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; launch of a product occurs between &lt;em style="font: inherit;"&gt; January 1 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; April 30 &lt;/em&gt;of a calendar year). The term will automatically renew for successive &lt;span style="-sec-ix-hidden:c81619067"&gt;five&lt;/span&gt; marketing year periods unless a party notifies the other party of its intention &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to renew at least &lt;em style="font: inherit;"&gt;six&lt;/em&gt; (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;) months prior to the expiration of the then-current term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Aguettant is entitled to receive up to $24.0 million in sales-based milestone payments. The Company will purchase each product from Aguettant at an agreed price, or the PFS Purchase Price, subject to adjustment. The Company will also make revenue share payments that, combined with the PFS Purchase Price, will range from 40% to 45% of net sales in the United States.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company and Aguettant will agree on minimum sales obligations &lt;em style="font: inherit;"&gt;twelve&lt;/em&gt; (&lt;span style="-sec-ix-hidden:c81619075"&gt;12&lt;/span&gt;) months prior to the launch of each product.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has the right to grant sublicenses to its affiliates or, with the prior approval of Aguettant, &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, subject to certain limitations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;there have been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; payments by the Company to Aguettant under the PFS Agreement.&lt;/p&gt;
  </acrx:InlicenseAgreementTextBlock>
    <acrx:LicenseAgreementMilestonePaymentsToBePaidMaximum
      contextRef="i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember"
      decimals="-6"
      id="c81619071"
      unitRef="USD">24000000.0</acrx:LicenseAgreementMilestonePaymentsToBePaidMaximum>
    <acrx:LicenseAgreementPercentOfRevenueSharePaymentToBePaid
      contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember_RangeAxis-MinimumMember"
      decimals="1"
      id="c81619072"
      unitRef="Pure">0.40</acrx:LicenseAgreementPercentOfRevenueSharePaymentToBePaid>
    <acrx:LicenseAgreementPercentOfRevenueSharePaymentToBePaid
      contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c81619073"
      unitRef="Pure">0.45</acrx:LicenseAgreementPercentOfRevenueSharePaymentToBePaid>
    <acrx:OutlicenseAgreementTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050903">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt; Out-license Agreements&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;DZUVEO&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 14, 2021, &lt;/em&gt;the Company entered into a License and Commercialization Agreement, or the DZUVEO Agreement, with Aguettant, pursuant to which Aguettant obtained the exclusive right to develop and commercialize DZUVEO in the European Union, Norway, Iceland, Liechtenstein, Andorra, Vatican City, Monaco, Switzerland and the United Kingdom, or the DZUVEO Territory, for the management of acute moderate to severe pain in adults in medically monitored settings. The Company will supply Aguettant with product.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The DZUVEO Agreement has an initial term of &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; (&lt;em style="font: inherit;"&gt;10&lt;/em&gt;) marketing years, with the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; marketing year ending on &lt;em style="font: inherit;"&gt; December 31 &lt;/em&gt;of the calendar year after the launch of DZUVEO (or &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;if the launch occurs between &lt;em style="font: inherit;"&gt; January 1, 2022 &lt;/em&gt;and &lt;em style="font: inherit;"&gt; April 30, 2022). &lt;/em&gt;The term will automatically renew for successive &lt;span style="-sec-ix-hidden:c81619082"&gt;five&lt;/span&gt; marketing year periods unless a party notifies the other party of its intention &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to renew at least &lt;em style="font: inherit;"&gt;six&lt;/em&gt; (&lt;em style="font: inherit;"&gt;6&lt;/em&gt;) months prior to the expiration of the then-current term. The DZUVEO Agreement &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be terminated for cause by either party based on uncured material breach by the other party, insolvency of the other party, or force majeure event. Upon early termination, all ongoing activities under the agreement and all rights and commercialization licenses and sublicenses with respect to DZUVEO will terminate. Additionally, if terminated early by either party, any accrued liability at the time of such termination will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be released.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company is entitled to receive up to &lt;span style="-sec-ix-hidden:c81619087"&gt;&#x20ac;47.0&lt;/span&gt; million in a combination of up-front and sales-based milestone payments, of which the Company received &lt;span style="-sec-ix-hidden:c81619088"&gt;&#x20ac;2.5&lt;/span&gt; million, or approximately $2.9 million, in the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; for which it recognized revenue of $1.7 million in the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; Aguettant will purchase product from the Company at an agreed price, or the DZUVEO Purchase Price, subject to adjustment. Aguettant will also make revenue share payments that, combined with the DZUVEO Purchase Price, range from 35% to 45% of net sales in the DZUVEO Territory.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Beginning in the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; marketing year, the parties will establish binding annual minimums for purchase orders to be submitted by Aguettant. Aguettant has the right to grant sublicenses to its affiliates or, with the prior approval of the Company, &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties, subject to certain limitations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The DZUVEO Agreement also provides Aguettant with a right of &lt;em style="font: inherit;"&gt;first&lt;/em&gt; negotiation for &lt;em style="font: inherit;"&gt;eighteen&lt;/em&gt; (&lt;em style="font: inherit;"&gt;18&lt;/em&gt;) months before the Company can enter into a collaboration regarding Zalviso&#160;in Europe.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Zalviso&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; May 18, 2020, &lt;/em&gt;the Company received a notice from Gr&#xfc;nenthal that it had exercised its right to terminate the Gr&#xfc;nenthal Agreements, effective &lt;em style="font: inherit;"&gt; November 13, 2020. &lt;/em&gt;The terms of the Gr&#xfc;nenthal Agreements were extended to &lt;em style="font: inherit;"&gt; May 12, 2021 &lt;/em&gt;to enable Gr&#xfc;nenthal to sell down its Zalviso inventory, a right it had under the Gr&#xfc;nenthal Agreements. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on &lt;em style="font: inherit;"&gt; May 12, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Amended License Agreement &lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the Amended License Agreement with Gr&#xfc;nenthal, the Company was eligible to receive approximately $194.5 million in additional milestone payments, based upon successful regulatory and product development efforts ($28.5 million) and net sales target achievements ($166.0 million). A portion of the tiered royalty payments earned were paid to PDL in connection with the Royalty Monetization. For additional information on the Royalty Monetization with PDL, see Note &lt;em style="font: inherit;"&gt;10&lt;/em&gt; &#x201c;Liability Related to Sale of Future Royalties&#x201d;. On &lt;em style="font: inherit;"&gt; August 31, 2020, &lt;/em&gt;PDL announced it sold its royalty interest for Zalviso to SWK Funding, LLC.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="text-decoration: underline; "&gt;Amended MSA &lt;/span&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the terms of the Amended MSA with Gr&#xfc;nenthal, the Company manufactured and supplied the Product for use in the Field for the Territory exclusively for Gr&#xfc;nenthal. The Product was supplied at prices approximating the Company&#x2019;s manufacturing cost, subject to certain caps, as defined in the MSA Amendment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Gr&#xfc;nenthal Agreements entitled the Company to receive additional payments upon the achievement of certain development milestones which related to post approval product enhancements, expanded market opportunities and manufacturing efficiencies for Zalviso and required future research, development and regulatory activities. These payments were excluded from the transaction price as they were considered payments for optional additional services elected by Gr&#xfc;nenthal.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Gr&#xfc;nenthal Agreements also included milestone payments related to specified net sales targets, totaling $166.0 million. These payments were considered sales-based license royalties under ASC Topic &lt;em style="font: inherit;"&gt;606&lt;/em&gt; and would have been recognized apart from the other contract consideration when the related sales occurred. These net sales targets were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; achieved prior to the termination of the Gr&#xfc;nenthal Agreements.&lt;/p&gt;
  </acrx:OutlicenseAgreementTextBlock>
    <acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments
      contextRef="d_2021-07-01_2021-09-30_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619089"
      unitRef="USD">2900000</acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-07-01_2021-09-30_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619092"
      unitRef="USD">1700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <acrx:LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived
      contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember_RangeAxis-MinimumMember"
      decimals="2"
      id="c81619095"
      unitRef="Pure">0.35</acrx:LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived>
    <acrx:LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived
      contextRef="d_2021-07-14_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember_RangeAxis-MaximumMember"
      decimals="2"
      id="c81619096"
      unitRef="Pure">0.45</acrx:LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived>
    <acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets
      contextRef="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember"
      decimals="-5"
      id="c81619103"
      unitRef="USD">194500000</acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets>
    <acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets
      contextRef="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember"
      decimals="-5"
      id="c81619104"
      unitRef="USD">28500000</acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets>
    <acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets
      contextRef="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponNetSalesTargetAchievementsMember"
      decimals="-6"
      id="c81619105"
      unitRef="USD">166000000.0</acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets>
    <acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets
      contextRef="i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember_StatementScenarioAxis-BasedUponNetSalesTargetAchievementsMember"
      decimals="-6"
      id="c81619107"
      unitRef="USD">166000000.0</acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050904">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7&lt;/em&gt;&lt;/b&gt;. &lt;b&gt;Revenue from Contracts with Customers&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes revenue from contracts with customers for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Product sales:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;DSUVIA&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;735&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,409&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Zalviso&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Total product sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,005&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,521&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Contract and other collaboration:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;License revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,696&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Non-cash royalty revenue related to Royalty Monetization (See Note 10)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;242&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Other revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,572&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Total revenues from contract and other collaboration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,895&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,416&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For additional detail on the Company&#x2019;s accounting policy regarding revenue recognition, refer to Note &lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x201c;Organization and Summary of Significant Accounting Policies - Revenue from Contracts with Customers.&#x201d;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Product Sales&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s commercial launch of DSUVIA in the United States occurred in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2019.&lt;/em&gt; Zalviso was sold in Europe by Gr&#xfc;nenthal through &lt;em style="font: inherit;"&gt; May 12, 2021. &lt;/em&gt;DZUVEO sales in Europe by the Company&#x2019;s collaboration partner, Aguettant, have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; commenced as of &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Contract and Other Collaboration&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Contract and other collaboration revenue includes revenue under the Gr&#xfc;nenthal Agreements related to research and development services, non-cash royalty revenue related to the Royalty Monetization and royalty revenue for sales of Zalviso in Europe and license revenue recognized under the DZUVEO Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company concluded that Aguettant is a customer and therefore revenue recognition for the DZUVEO Agreement in Europe should be accounted for in accordance with FASB Accounting Standards Codification, or ASC, Topic &lt;em style="font: inherit;"&gt;606,&lt;/em&gt; &#x201c;&lt;i&gt;Revenue from Contracts with Customers&lt;/i&gt;&#x201d;, because the Company granted to Aguettant licenses and will provide the supply of product, as defined below, all of which are outputs of the Company&#x2019;s ongoing activities, in exchange for consideration.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company identified the following promises under the DZUVEO Agreement at inception, namely: (a) granting of the licenses, (b) manufacturing services inclusive of quality control testing and stability testing which are options in the initial arrangement, and (c) a material right associated with the discounted price for future optional orders of DZUVEO commercial product supply.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The licenses are considered to be functional intellectual property. The Company determined that the licenses are capable of being distinct because Aguettant can benefit from the license on its own by commercializing the underlying product using its own resources. The Company manufacturing services are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; highly specialized in nature and can be performed by &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party contract manufacturing organizations. There are &lt;em style="font: inherit;"&gt;no&lt;/em&gt; binding commitments for manufacturing purchase orders at inception of the arrangement. Therefore, the manufacturing services are considered to be an option and &lt;em style="font: inherit;"&gt;not&lt;/em&gt; a performance obligation in the initial arrangement. However, the Company has determined that the discounted price per unit on future optional product orders constitutes a material right and is a performance obligation. The right to purchase at a discount is capable of being used by the customer on a standalone basis, because this relates to future product purchases and occur after the licenses&#x2019; performance obligations are transferred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company evaluated if there is an interdependence between the performance obligations and determined that the licenses are a combined solution and the predominant performance obligation. The material right is separately identifiable in the context of the contract and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; modified by, and does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; modify, the license performance obligation and is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; highly interdependent or interrelated with the material right performance obligations in the contract.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The transaction price at the inception of the DZUVEO Agreement consisted of the upfront fee of &lt;span style="-sec-ix-hidden:c81619125"&gt;&#x20ac;2.5&lt;/span&gt; million, or approximately $2.9 million. The variable consideration related to product supply and reimbursables has been constrained as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;as there has been &lt;em style="font: inherit;"&gt;no&lt;/em&gt; forecast provided by Aguettant. The Company will re-evaluate the transaction price each reporting period and as uncertain events are resolved or other changes in circumstances occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The Company determined that the $52.2 million&lt;i&gt; &lt;/i&gt;sales-based milestone payments and revenue share payments were probable of significant revenue reversal, as their achievement was highly dependent on factors outside the Company&#x2019;s control. As a result, these payments were fully constrained and were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the transaction price. Any variable consideration related to sales-based milestones (including royalties) will be recognized when the related sales occur, as they were determined to relate predominantly to the licenses granted to Aguettant and the optional manufacturing services provided by the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;The transaction price is allocated to the performance obligations based on relative standalone selling price which were determined for the licenses using the adjusted market approach, and for the manufacturing services and the material right associated with discounted DZUVEO product supply using the cost-plus reasonable margin approach. Variable consideration is allocated to the specific performance obligations to which it relates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;For revenue recognition purposes, the Company determined that the duration of the contract began on the effective date in &lt;em style="font: inherit;"&gt; July 2021 &lt;/em&gt;and ends after an initial term of &lt;span style="-sec-ix-hidden:c81619131"&gt;10&lt;/span&gt; marketing years, unless it automatically renews for a successive &lt;span style="-sec-ix-hidden:c81619132"&gt;five&lt;/span&gt; marketing years. The Company also analyzed the impact if Aguettant terminated the agreement prior to the end of the term and determined, considering both quantitative and qualitative factors, that there were substantive non-monetary penalties to Aguettant for doing so.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;Revenue for the granting of the licenses was recognized on the effective date of the DZUVEO Agreement at the point in time that the licenses are effective. The manufacturing services inclusive of quality control testing and stability testing will be recognized at a point in time when, or as, the Company transfers the associated promised goods and services to Aguettant. The material right for the discounted price per unit on future optional orders will be recognized over time with the measure of progress being straight-line over the period in which the Company stands ready to provide the discounted price per unit on the manufacturing services.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;For the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company recorded $1.7 million in contract and other collaboration revenue as a result of satisfying its licenses performance obligation by transferring the license rights to Aguettant.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Contract Liabilities&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"&gt;A contract liability of $1.2 million was recorded on the Consolidated Balance Sheets as deferred revenue as of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;$0.1 million of which represented the current portion, for the portion of the upfront fee received under the DZUVEO Agreement allocated to the material right for discounted price on future optional product supply which has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; yet been satisfied. The material right contract liability will be recognized over the period the discount on future product supply is made available. There was &lt;em style="font: inherit;"&gt;no&lt;/em&gt; contract asset as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;associated with the DZUVEO Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;deferred contract acquisition costs were negligible and deferred contract acquisition costs amortized during the year ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;were &lt;span style="-sec-ix-hidden:c81619138"&gt;$0.3&lt;/span&gt; million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table presents changes in the Company&#x2019;s contract liability for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 36pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,244&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Deductions for performance obligations satisfied:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;In current period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c81619166"&gt;( 623&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;In prior periods&lt;span style="font-family:Times New Roman;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,572&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;49&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Additions&lt;span style="font-family:Times New Roman;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,237&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Deductions for performance obligations satisfied:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;In current period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(49&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,237&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;span style="font-size:10pt;"&gt;&lt;span style="font-family: &amp;quot;Times New Roman&amp;quot;;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;)&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt; In &lt;em style="font: inherit;"&gt; May 2020, &lt;/em&gt;upon notification of early termination by Gr&#xfc;nenthal, the Company recognized approximately $2.6 million of deferred revenue under the Gr&#xfc;nenthal Agreements.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;)&lt;/sup&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt; &lt;/sup&gt;Deferred revenue under the DZUVEO Agreement with Aguettant.&lt;/p&gt;
  </us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050905">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Product sales:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;DSUVIA&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;735&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,409&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Zalviso&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;270&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Total product sales&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,005&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,521&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Contract and other collaboration:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;License revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,696&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Non-cash royalty revenue related to Royalty Monetization (See Note 10)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;83&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;242&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;81&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Other revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,572&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Total revenues from contract and other collaboration&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,813&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;2,895&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,818&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,416&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-DSUVIAMember"
      decimals="-3"
      id="c81619145"
      unitRef="USD">735000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-DSUVIAMember"
      decimals="-3"
      id="c81619146"
      unitRef="USD">1409000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ZALVISOMember"
      decimals="-4"
      id="c81619147"
      unitRef="USD">270000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ZALVISOMember"
      decimals="-3"
      id="c81619148"
      unitRef="USD">1112000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c81619149"
      unitRef="USD">1005000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ProductMember"
      decimals="-3"
      id="c81619150"
      unitRef="USD">2521000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-LicenseMember"
      decimals="-3"
      id="c81619152"
      unitRef="USD">1696000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-LicenseMember"
      decimals="-3"
      id="c81619153"
      unitRef="USD">0</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-NonCashRoyaltyMember"
      decimals="-3"
      id="c81619154"
      unitRef="USD">83000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-NonCashRoyaltyMember"
      decimals="-3"
      id="c81619155"
      unitRef="USD">242000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c81619156"
      unitRef="USD">28000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-RoyaltyMember"
      decimals="-3"
      id="c81619157"
      unitRef="USD">81000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherRevenueMember"
      decimals="-3"
      id="c81619158"
      unitRef="USD">6000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherRevenueMember"
      decimals="-3"
      id="c81619159"
      unitRef="USD">2572000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember"
      decimals="-3"
      id="c81619160"
      unitRef="USD">1813000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31_ProductOrServiceAxis-ContractAndOtherCollaborationMember"
      decimals="-3"
      id="c81619161"
      unitRef="USD">2895000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619162"
      unitRef="USD">2818000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619163"
      unitRef="USD">5416000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619126"
      unitRef="USD">2900000</acrx:ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments>
    <acrx:LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived
      contextRef="i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619128"
      unitRef="USD">52200000</acrx:LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived>
    <us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
      contextRef="d_2021-01-01_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619133"
      unitRef="USD">1700000</us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619134"
      unitRef="USD">1200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember"
      decimals="-5"
      id="c81619135"
      unitRef="USD">100000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050906">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; margin-left: 36pt; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,244&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Deductions for performance obligations satisfied:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;In current period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;span style="-sec-ix-hidden:c81619166"&gt;( 623&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;In prior periods&lt;span style="font-family:Times New Roman;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,572&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;49&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Additions&lt;span style="font-family:Times New Roman;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,237&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Deductions for performance obligations satisfied:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;In current period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(49&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,237&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c81619164"
      unitRef="USD">3244000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619167"
      unitRef="USD">2572000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619168"
      unitRef="USD">49000</us-gaap:ContractWithCustomerLiability>
    <acrx:ContractWithCustomerLiabilityAdditions
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619169"
      unitRef="USD">1237000</acrx:ContractWithCustomerLiabilityAdditions>
    <acrx:ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619171"
      unitRef="USD">49000</acrx:ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619172"
      unitRef="USD">1237000</us-gaap:ContractWithCustomerLiability>
    <acrx:ContractWithCustomerLiabilityLiabilityEliminated
      contextRef="d_2020-05-01_2020-05-31_ProductOrServiceAxis-ZALVISOMember"
      decimals="-5"
      id="c81619141"
      unitRef="USD">2600000</acrx:ContractWithCustomerLiabilityLiabilityEliminated>
    <us-gaap:LongTermDebtTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050907">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt; Long-Term Debt &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Loan Agreement with Oxford&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; May 30, 2019, &lt;/em&gt;the Company entered into the Loan Agreement with Oxford as the Lender. Under the Loan Agreement, the Lender made a term loan to the Company in an aggregate principal amount of $25.0 million, or the Loan, which was funded on &lt;em style="font: inherit;"&gt; May 30, 2019. &lt;/em&gt;The Company used approximately $8.9 million of the proceeds from the Loan to repay its outstanding obligations under its prior debt agreement. After deducting all loan initiation costs and outstanding interest on the prior debt agreement, the Company received $15.9 million in net proceeds.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The interest rate is calculated at a rate equal to the sum of (a) the greater of (i) the &lt;em style="font: inherit;"&gt;30&lt;/em&gt;-day U.S. LIBOR rate reported in The Wall Street Journal on the last business day of the month that immediately precedes the month in which the interest will accrue and (ii) 2.50%, plus (b) 6.75%. On &lt;em style="font: inherit;"&gt; July 27, 2017, &lt;/em&gt;the Financial Conduct Authority, or FCA, in the U.K. announced that it would phase out LIBOR as a benchmark by the end of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; It is unclear whether new methods of calculating LIBOR will be established such that it continues to exist after &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; or if LIBOR will be replaced with an alternative reference rate; however, the Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; believe such changes would have a material adverse effect on its financing costs. Payments on the Loan were interest-only until &lt;em style="font: inherit;"&gt; July 1, 2020 &lt;/em&gt;followed by equal principal payments and monthly accrued interest payments through the scheduled maturity date of &lt;em style="font: inherit;"&gt; June 1, 2023. &lt;/em&gt;The Company&#x2019;s obligations under the Loan Agreement are secured by a security interest in all the assets of the Company, other than the Company&#x2019;s intellectual property which is subject to a negative pledge.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;prepay the Loan at any time. If the Loan is paid prior to the maturity date, the Company will pay the Lender a prepayment charge, based on a percentage of the then outstanding principal balance, equal to 1%. Upon voluntary or mandatory prepayment, in addition to the prepayment charge, the Company is required to pay the EOT Fee, Lender&#x2019;s expenses and all outstanding principal and accrued interest through the prepayment date.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Loan Agreement includes customary representations and covenants that, subject to exceptions, will restrict the Company&#x2019;s ability to do the following things: declare dividends or redeem or repurchase equity interests; incur additional liens; make loans and investments; incur additional indebtedness; engage in mergers, acquisitions, and asset sales; transact with affiliates; undergo a change in control; add or change business locations; and engage in businesses that are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; related to its existing business. The Loan Agreement requires that the Company always maintain unrestricted cash of &lt;em style="font: inherit;"&gt;not&lt;/em&gt; less than $5.0 million in accounts subject to control agreements in favor of Lender, tested monthly as of the last day of the month.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Loan Agreement also includes standard events of default, including payment defaults, breaches of covenants following any applicable cure period, a material impairment in the perfection or priority of the Lender&#x2019;s security interest or in the value of the collateral, a material adverse change in business, operations or the prospect of repayment, events relating to bankruptcy or insolvency. The Loan also contains a cross default provision, under which if a &lt;em style="font: inherit;"&gt;third&lt;/em&gt; party (under any agreement) has the right to accelerate indebtedness greater than $250,000, the Loan would also be considered in default. In addition, the Loan defines events which negatively impact government approvals, judgments in excess of $500,000 and the delisting of the Company&#x2019;s shares of common stock on the Nasdaq Global Market, or Nasdaq, as events of default. Upon the occurrence of an event of default, a default interest rate of an additional 5% &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be applied to the outstanding loan balances, and the Lender &lt;em style="font: inherit;"&gt; may &lt;/em&gt;declare all outstanding obligations immediately due and payable and take such other actions as set forth in the Loan Agreement. Acceleration would result in the payment of any applicable prepayment charges and application of the default interest rate to the outstanding balance until payment is made in full. The Company bifurcated a compound derivative liability related to a contingent interest feature and acceleration upon default provision (contingent put option) provided to the Lender. The bifurcated embedded derivative must be valued and separately accounted for in the Company&#x2019;s Consolidated Financial Statements. The contingent put option liability is classified as a component of other long-term liabilities. As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the estimated fair value of the contingent put option liability was $0.1 million which was determined by using a risk-neutral valuation model, wherein the fair value of the underlying debt facility is estimated, both with and without the presence of the default provisions, holding all other assumptions constant. See Note &lt;em style="font: inherit;"&gt;2&lt;/em&gt; &#x201c;Investments and Fair Value Measurement&#x201d; for further description.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In connection with the Loan Agreement, on &lt;em style="font: inherit;"&gt; May 30, 2019, &lt;/em&gt;the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of 176,679 shares of the Company&#x2019;s common stock with a per share exercise price of $2.83, or the Warrants. The Warrants have been classified within stockholders&#x2019; (deficit) equity and accounted for as a discount to the loan by allocating the gross proceeds on a relative fair value basis. For further discussion, see Note &lt;em style="font: inherit;"&gt;11&lt;/em&gt; &#x201c;Warrants&#x201d;.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The outstanding balance due under the Loan Agreement was $13.3 million and $21.0 million at &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively. Interest expense related to the Loan Agreement was $2.2 million, of which $0.7 million represented amortization of the debt discount, and $3.2 million, $0.9 million of which represented amortization of the debt discount, for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively, and the effective interest rate was 13.15% in both periods.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Non-Interest Bearing Payments for the Construction of Leasehold Improvements &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; August 2019, &lt;/em&gt;the Company entered into a Site Readiness Agreement, or SRA, with a potential Contract Manufacturing Organization, or CMO, in contemplation of entering into a commercial supply agreement for its product DSUVIA&#xae; at a future date. Under the SRA, the Company is building out a suite within the CMO&#x2019;s production facility. If additional equipment and facility modifications are required to meet the Company&#x2019;s product needs, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be required to contribute to the cost of such additional equipment and facility modifications. The Company has determined that it is the owner of the leasehold improvements related to the build-out which will be paid for in &lt;em style="font: inherit;"&gt;four&lt;/em&gt; annual installments of $0.5 million through &lt;em style="font: inherit;"&gt; July 2022. &lt;/em&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; the accrued balance under the SRA is $0.5 million and $0.8 million, respectively, and $1.7 million of these leasehold improvements have been capitalized. The effective interest rate related to the payments at &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was 14.35%. The leasehold improvements are recorded as property and equipment, net, in the Consolidated Balance Sheets.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Future Payments on Long-Term Debt &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes the outstanding future payments associated with the Company&#x2019;s long-term debt as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;9,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,530&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;15,177&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less amount representing interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(927&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Notes payable, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;14,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: Unamortized portion of EOT Fee&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: Unamortized discount on notes payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Long-term debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;13,803&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,796&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Long-term debt, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,007&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:LongTermDebtTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-6"
      id="c81619174"
      unitRef="USD">25000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-5"
      id="c81619175"
      unitRef="USD">8900000</us-gaap:RepaymentsOfLongTermDebt>
    <acrx:ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt
      contextRef="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-5"
      id="c81619176"
      unitRef="USD">15900000</acrx:ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt>
    <acrx:DebtInstrumentInterestRateBasePercentage
      contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="3"
      id="c81619179"
      unitRef="Pure">0.0250</acrx:DebtInstrumentInterestRateBasePercentage>
    <us-gaap:DebtInstrumentBasisSpreadOnVariableRate1
      contextRef="d_2019-05-30_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember_VariableRateAxis-LondonInterbankOfferedRateLIBORMember"
      decimals="4"
      id="c81619180"
      unitRef="Pure">0.0675</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
    <acrx:PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021
      contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="2"
      id="c81619184"
      unitRef="Pure">0.01</acrx:PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021>
    <acrx:DebtInstrumentCovenantMinimumRequiredUnrestirctedCash
      contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-6"
      id="c81619187"
      unitRef="USD">5000000.0</acrx:DebtInstrumentCovenantMinimumRequiredUnrestirctedCash>
    <acrx:DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight
      contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="INF"
      id="c81619189"
      unitRef="USD">250000</acrx:DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight>
    <acrx:LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments
      contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="INF"
      id="c81619190"
      unitRef="USD">500000</acrx:LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments>
    <acrx:DebtInstrumentDefaultAdditionalInterestRate
      contextRef="i_2019-05-30_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="2"
      id="c81619191"
      unitRef="Pure">0.05</acrx:DebtInstrumentDefaultAdditionalInterestRate>
    <acrx:FairValueOfContingentPutOptionLiability
      contextRef="i_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-5"
      id="c81619192"
      unitRef="USD">100000</acrx:FairValueOfContingentPutOptionLiability>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"
      decimals="INF"
      id="c81619194"
      unitRef="Share">176679</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"
      decimals="INF"
      id="c81619195"
      unitRef="USDPerShare">2.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:LongTermDebt
      contextRef="i_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-5"
      id="c81619197"
      unitRef="USD">13300000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="i_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-6"
      id="c81619198"
      unitRef="USD">21000000.0</us-gaap:LongTermDebt>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2021-01-01_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-5"
      id="c81619200"
      unitRef="USD">2200000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2021-01-01_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-5"
      id="c81619201"
      unitRef="USD">700000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:InterestExpenseDebt
      contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-5"
      id="c81619202"
      unitRef="USD">3200000</us-gaap:InterestExpenseDebt>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="d_2020-01-01_2020-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="-5"
      id="c81619203"
      unitRef="USD">900000</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2021-12-31_DebtInstrumentAxis-LoanAgreementWithOxfordFinanceLLCMember"
      decimals="4"
      id="c81619205"
      unitRef="Pure">0.1315</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentPeriodicPaymentPrincipal
      contextRef="d_2019-08-01_2019-08-01_LongtermDebtTypeAxis-SiteReadinessAgreementMember"
      decimals="-5"
      id="c81619208"
      unitRef="USD">500000</us-gaap:DebtInstrumentPeriodicPaymentPrincipal>
    <acrx:TotalObligationUnderLeaseholdAgreement
      contextRef="i_2021-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember"
      decimals="-5"
      id="c81619210"
      unitRef="USD">500000</acrx:TotalObligationUnderLeaseholdAgreement>
    <acrx:TotalObligationUnderLeaseholdAgreement
      contextRef="i_2020-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember"
      decimals="-5"
      id="c81619211"
      unitRef="USD">800000</acrx:TotalObligationUnderLeaseholdAgreement>
    <us-gaap:LeaseholdImprovementsGross
      contextRef="i_2021-12-31"
      decimals="-5"
      id="c81619212"
      unitRef="USD">1700000</us-gaap:LeaseholdImprovementsGross>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage
      contextRef="i_2021-12-31_LongtermDebtTypeAxis-SiteReadinessAgreementMember"
      decimals="4"
      id="c81619214"
      unitRef="Pure">0.1435</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050908">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 85%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;9,647&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;5,530&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;15,177&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less amount representing interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(927&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Notes payable, gross&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;14,250&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: Unamortized portion of EOT Fee&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(200&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less: Unamortized discount on notes payable&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(247&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Long-term debt&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;13,803&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Less current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(8,796&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Long-term debt, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,007&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <acrx:LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619219"
      unitRef="USD">9647000</acrx:LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo>
    <acrx:LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81619220"
      unitRef="USD">5530000</acrx:LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree>
    <acrx:LongTermDebtTotalMinimumPayments
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619221"
      unitRef="USD">15177000</acrx:LongTermDebtTotalMinimumPayments>
    <acrx:LongTermDebtMaturitiesRepaymentsOfInterest
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619222"
      unitRef="USD">927000</acrx:LongTermDebtMaturitiesRepaymentsOfInterest>
    <acrx:NotesPayableGross
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81619223"
      unitRef="USD">14250000</acrx:NotesPayableGross>
    <acrx:DebtInstrumentUnamortizedEotFee
      contextRef="i_2021-12-31"
      decimals="-5"
      id="c81619224"
      unitRef="USD">200000</acrx:DebtInstrumentUnamortizedEotFee>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619225"
      unitRef="USD">247000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:LongTermDebt
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619226"
      unitRef="USD">13803000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619227"
      unitRef="USD">8796000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619228"
      unitRef="USD">5007000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050909">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;9.&lt;/em&gt; Leases &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Office Lease &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company leased office and laboratory space for its former corporate headquarters, located at &lt;em style="font: inherit;"&gt;301&lt;/em&gt; &#x2013; &lt;em style="font: inherit;"&gt;351&lt;/em&gt; Galveston Drive, Redwood City, California, and entered into an agreement to sublease approximately 12,106 square feet of this office and laboratory space.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 26, 2021, &lt;/em&gt;the Company entered into a Lease Termination Agreement with its landlord and a Sublease Termination Agreement with its sublessee, to terminate the lease and sublease agreements at its former corporate headquarters. The termination of both the lease and sublease was effective on &lt;em style="font: inherit;"&gt; April 30, 2021. &lt;/em&gt;As of the date of the Lease Termination Agreement, the Company remeasured its lease liability and recorded a gain of $0.5 million upon derecognition of the lease liability and right of use asset for the master lease, which was included in operating expenses for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021. &lt;/em&gt;In connection with the Sublease Termination, the remaining deferred costs of $0.3 million were fully amortized through &lt;em style="font: inherit;"&gt; April 30, 2021, &lt;/em&gt;the effective date of the Sublease Termination, and included in operating expenses for the year ended &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 26, 2021, &lt;/em&gt;the Company entered into a Sublease Agreement to sublet space for its new corporate headquarters, located at &lt;em style="font: inherit;"&gt;25821&lt;/em&gt; Industrial Boulevard, Hayward, California. The Sublease Agreement commencement date was &lt;em style="font: inherit;"&gt; April 1, 2021. &lt;/em&gt;The Sublease Agreement is for a period of &lt;span style="-sec-ix-hidden:c81619236"&gt;two&lt;/span&gt; years and &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months with monthly rental payments of $17,000, including &lt;span style="-sec-ix-hidden:c81619239"&gt;one&lt;/span&gt; month of abated rent. On the lease commencement date, the Company recognized an operating lease right-of-use asset in the amount of $0.4 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Contract Manufacturing Leases&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; December 12, 2012, &lt;/em&gt;the Company entered into an agreement for commercial supply manufacturing services related to the Company&#x2019;s Zalviso drug product with a contract manufacturing organization. The initial term of the agreement was through &lt;em style="font: inherit;"&gt; December 31, 2017, &lt;/em&gt;which term automatically renews in &lt;span style="-sec-ix-hidden:c81619241"&gt;two&lt;/span&gt;-year increments unless earlier terminated by either party by giving &lt;span style="-sec-ix-hidden:c81619242"&gt;eighteen&lt;/span&gt; months&#x2019; notice. Commencing in &lt;em style="font: inherit;"&gt;2013,&lt;/em&gt; the Company is required to make overhead fee payments each year of $0.2 million, prorated based on aggregate revenues. The Company has determined that this fee is an in-substance fixed lease payment as it represents the minimum annual payment under the contract. The Company concluded that this agreement contains an embedded lease as the clean rooms have been built specifically for production of the Company&#x2019;s product and their use is effectively controlled by the Company as it has priority over the space during the term of the agreement. The Company accounts for the agreement as an operating lease and has evaluated the non-cancelable term to be through the binding commitment date of &lt;em style="font: inherit;"&gt; June 30, 2023.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; April 21, 2021, &lt;/em&gt;the Company entered into a Commercial Supply Agreement, or the CSA, with Catalent Pharma Solutions, LLC, or Catalent, effective &lt;em style="font: inherit;"&gt; March 31, 2021, &lt;/em&gt;under which Catalent provides certain services to the Company in connection with the processing and packaging of a packaged single dose applicator containing the sublingual tablet &lt;em style="font: inherit;"&gt;30&lt;/em&gt; mcg sufentanil dosage form contained in the pharmaceutical product, DSUVIA (sufentanil), intended for commercialization.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The term of the CSA is for a period of &lt;span style="-sec-ix-hidden:c81619247"&gt;five&lt;/span&gt; years from the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; date upon which the FDA approves Catalent as a manufacturer of DSUVIA in the United States, or the Commencement Date. The term shall automatically be extended for successive &lt;span style="-sec-ix-hidden:c81619249"&gt;two&lt;/span&gt;-year periods, unless and until &lt;em style="font: inherit;"&gt;one&lt;/em&gt; party gives the other party at least &lt;em style="font: inherit;"&gt;24&lt;/em&gt; months&#x2019; prior written notice of its desire to terminate as of the end of the then-current term.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company will pay Catalent an annual fee of $1.0 million beginning &lt;em style="font: inherit;"&gt; January 1, 2022. &lt;/em&gt;Pursuant to the CSA, the Company will purchase each &lt;em style="font: inherit;"&gt;10&lt;/em&gt;-pack carton of DSUVIA from Catalent at an agreed price through &lt;em style="font: inherit;"&gt; December 31, 2022, &lt;/em&gt;and pay other fees set forth in the CSA. All pricing and fees, with the exception of raw materials, &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be adjusted on an annual basis, effective on &lt;em style="font: inherit;"&gt; January 1 &lt;/em&gt;of each calendar year, beginning with &lt;em style="font: inherit;"&gt; January 1, 2023, &lt;/em&gt;subject to certain limitations. Price increases for raw materials will be passed through to the Company.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company has determined that the fixed fees in the CSA are in-substance lease payments. The Company concluded that this agreement contains an embedded lease as the clean rooms have been built specifically for production of the Company&#x2019;s product and their use is effectively controlled by the Company as it has sole use over the space during the term of the agreement. The Company accounts for the agreement as an operating lease and has evaluated the non-cancelable lease term to be through the binding commitment date of &lt;em style="font: inherit;"&gt; May 15, 2027.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The components of lease expense are presented in the following table (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 36pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Operating lease costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,467&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,360&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gain on derecognition of operating lease&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(522&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Sublease income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(199&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(598&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Loss on termination of sublease&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;331&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net lease costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,077&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The weighted average remaining lease term and discount rate related to the operating leases are presented in the following table:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 36pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 64%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-average remaining lease term &#x2013; operating leases (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;4.97&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;3.1&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-average remaining discount rate &#x2013; operating leases&#160;(in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;12.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Maturities of lease liabilities as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;are presented in the following table (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,608&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,244&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,040&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,040&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,040&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;415&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total future minimum lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt;"&gt;6,387&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Less imputed interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,569&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,818&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;"&gt;Reported as:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt;"&gt;4,818&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Operating lease liabilities, current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,068&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Operating lease liabilities, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="margin: 0pt; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:AreaOfRealEstateProperty
      contextRef="i_2021-12-31_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember"
      decimals="INF"
      id="c81619232"
      unitRef="SquareFoot">12106</us-gaap:AreaOfRealEstateProperty>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="d_2021-03-26_2021-03-26"
      decimals="-5"
      id="c81619233"
      unitRef="USD">500000</us-gaap:GainLossOnTerminationOfLease>
    <acrx:LesseeOperatingSubleaseDeferredCosts
      contextRef="i_2021-04-30_BalanceSheetLocationAxis-PrepaidExpensesAndOtherCurrentAssetsMember"
      decimals="-5"
      id="c81619234"
      unitRef="USD">300000</acrx:LesseeOperatingSubleaseDeferredCosts>
    <acrx:LesseeOperatingLeaseMonthlyRent
      contextRef="d_2021-03-26_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember"
      decimals="INF"
      id="c81619238"
      unitRef="USD">17000</acrx:LesseeOperatingLeaseMonthlyRent>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-03-26_LeaseContractualTermAxis-LeaseForCorporateHeadquartersInHaywardCaliforniaMember"
      decimals="-5"
      id="c81619240"
      unitRef="USD">400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <acrx:LesseeOperatingLeaseAnnualOverheadFeePayments
      contextRef="d_2012-12-12_2012-12-12"
      decimals="-5"
      id="c81619244"
      unitRef="USD">200000</acrx:LesseeOperatingLeaseAnnualOverheadFeePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2022-01-01_2022-12-31_CounterpartyNameAxis-CatalentPharmaSolutionsMember_StatementScenarioAxis-ScenarioForecastMember"
      decimals="-6"
      id="c81619252"
      unitRef="USD">1000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="d_2021-01-01_2021-12-31"
      id="BB990736-8B2D-4097-8022-1CBABFCCD006">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 20%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 36pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Operating lease costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,467&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,360&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gain on derecognition of operating lease&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(522&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Sublease income&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(199&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(598&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Loss on termination of sublease&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;331&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net lease costs&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,077&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;762&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 15%; width: 85%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 36pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 64%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-average remaining lease term &#x2013; operating leases (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;4.97&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"&gt;3.1&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Weighted-average remaining discount rate &#x2013; operating leases&#160;(in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;12.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;11.7&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;%&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619255"
      unitRef="USD">1467000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-4"
      id="c81619256"
      unitRef="USD">1360000</us-gaap:OperatingLeaseCost>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619257"
      unitRef="USD">522000</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:GainLossOnTerminationOfLease
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619258"
      unitRef="USD">-0</us-gaap:GainLossOnTerminationOfLease>
    <us-gaap:SubleaseIncome
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619259"
      unitRef="USD">199000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619260"
      unitRef="USD">598000</us-gaap:SubleaseIncome>
    <acrx:GainLossOnTerminationOfSublease
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619261"
      unitRef="USD">-331000</acrx:GainLossOnTerminationOfSublease>
    <acrx:GainLossOnTerminationOfSublease
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619262"
      unitRef="USD">-0</acrx:GainLossOnTerminationOfSublease>
    <us-gaap:LeaseCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619263"
      unitRef="USD">1077000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619264"
      unitRef="USD">762000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2021-12-31" id="c81619265">P4Y11M19D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="i_2020-12-31" id="c81619266">P3Y1M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2021-12-31"
      decimals="3"
      id="c81619267"
      unitRef="Pure">0.128</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="i_2020-12-31"
      decimals="3"
      id="c81619268"
      unitRef="Pure">0.117</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="d_2021-01-01_2021-12-31"
      id="c82EBC742-6455-4E52-8F8A-94168F119E13">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2022&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,608&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2023&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,244&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2024&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,040&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2025&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,040&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;2026&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,040&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Thereafter&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;415&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total future minimum lease payments&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt;"&gt;6,387&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Less imputed interest&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,569&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,818&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 81%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Operating lease liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt;"&gt;4,818&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Operating lease liabilities, current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(1,068&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Operating lease liabilities, net of current portion&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,750&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619269"
      unitRef="USD">1608000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619270"
      unitRef="USD">1244000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81619271"
      unitRef="USD">1040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81619272"
      unitRef="USD">1040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81619273"
      unitRef="USD">1040000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619274"
      unitRef="USD">415000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619275"
      unitRef="USD">6387000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619276"
      unitRef="USD">1569000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619277"
      unitRef="USD">4818000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619278"
      unitRef="USD">4818000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619279"
      unitRef="USD">1068000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81619280"
      unitRef="USD">3750000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050914">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;10.&lt;/em&gt; Liability Related to Sale of Future Royalties &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; September 18, 2015, &lt;/em&gt;the Company entered into the Royalty Monetization with PDL for which it received gross proceeds of $65.0 million. Under the Royalty Monetization, PDL was to receive 75% of the European royalties under the Amended License Agreement with Gr&#xfc;nenthal, as well as 80% of the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; &lt;em style="font: inherit;"&gt;four&lt;/em&gt; commercial milestones worth $35.6 million (or &lt;em style="font: inherit;"&gt;80%&lt;/em&gt; of $44.5 million), up to a capped amount of &lt;em style="font: inherit;"&gt;$195.0&lt;/em&gt; million over the life of the arrangement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under the relevant accounting guidance, because of the Company&#x2019;s significant continuing involvement, the Royalty Monetization has been accounted for as a liability that will be amortized using the effective interest method over the life of the arrangement. In order to determine the amortization of the liability, the Company is required to estimate the total amount of future royalty and milestone payments to be received by ARPI LLC and paid to PDL, up to a capped amount of $195.0 million, over the life of the arrangement. The aggregate future estimated royalty and milestone payments (subject to the capped amount), less the $61.2 million of net proceeds the Company received will be recorded as interest expense over the life of the liability. Consequently, the Company imputes interest on the unamortized portion of the liability and records interest expense relating to the Royalty Monetization accordingly.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company periodically assesses the expected royalty and milestone payments using a combination of historical results, internal projections and forecasts from external sources. To the extent such payments are greater or less than the Company&#x2019;s initial estimates or the timing of such payments is materially different than its original estimates, the Company will prospectively adjust the amortization of the liability and the effective interest rate. During the &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months ended &lt;em style="font: inherit;"&gt; June 30, 2020, &lt;/em&gt;Gr&#xfc;nenthal notified the Company that it was terminating the Amended License Agreement, effective &lt;em style="font: inherit;"&gt; November 13, 2020. &lt;/em&gt;The terms of the Gr&#xfc;nenthal Agreements were extended to &lt;em style="font: inherit;"&gt; May 12, 2021 &lt;/em&gt;to enable Gr&#xfc;nenthal to sell down its Zalviso inventory. The rights to market and sell Zalviso in the Zalviso Territory reverted back to the Company on &lt;em style="font: inherit;"&gt; May 12, 2021. &lt;/em&gt;There is a continuing obligation on the Company&#x2019;s part, through the term of the Royalty Monetization with SWK (assignee of PDL), to use commercially reasonable efforts to negotiate a replacement license agreement, or New Arrangement. If the Company is unable to find a New Arrangement, a contingent gain of up to approximately $64 million &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be recognized when it is realized upon expiration of the liability at the end of the Royalty Monetization term. Due to the significant judgments and factors related to the estimates of future payments under the Royalty Monetization, there are significant uncertainties surrounding the amount and timing of future payments and the probability of realization of the estimated contingent gain.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The effective interest rate over the life of the liability will be 0% as the Company records interest income over the remaining term of the arrangement as an offset to the interest expense that was recognized in prior periods. The effective interest income rate for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was approximately 3.5% and 3.6%, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table shows the activity within the liability account during the year ended &lt;em style="font: inherit;"&gt; December 31, 2021 (&lt;/em&gt;in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Period from&lt;/b&gt;&lt;br/&gt; &lt;b&gt;inception to &lt;/b&gt;&lt;br/&gt; &lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liability related to sale of future royalties &#x2014; beginning balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;88,471&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Proceeds from sale of future royalties&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;61,184&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Non-cash royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(145&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(1,083&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Non-cash interest (income) expense recognized&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,038&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;25,187&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liability related to sale of future royalties as of December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;85,288&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;85,288&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;As royalties are remitted to PDL from ARPI LLC, as described in Note&#160;&lt;em style="font: inherit;"&gt;1&lt;/em&gt; &#x201c;Organization and Summary of Significant Accounting Policies,&#x201d; the balance of the liability will be effectively repaid over the life of the agreement. The Company will record non-cash royalty revenues and non-cash interest (income) expense within its Consolidated Statements of Operations over the term of the Royalty Monetization. The liability related to the sale of future royalties, current portion, is recorded as accrued liabilities in the Company&#x2019;s Consolidated Balance Sheets.&lt;/p&gt;
  </acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock>
    <acrx:ProceedsFromSaleOfRoyaltyAndMilestoneRights
      contextRef="d_2015-09-18_2015-09-18"
      decimals="-6"
      id="c81619282"
      unitRef="USD">65000000.0</acrx:ProceedsFromSaleOfRoyaltyAndMilestoneRights>
    <acrx:PercentageOfRoyaltiesAndRightsUnderAgreement
      contextRef="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember"
      decimals="2"
      id="c81619283"
      unitRef="Pure">0.75</acrx:PercentageOfRoyaltiesAndRightsUnderAgreement>
    <acrx:PercentageOfRoyaltiesAndRightsUnderAgreement
      contextRef="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember"
      decimals="1"
      id="c81619284"
      unitRef="Pure">0.80</acrx:PercentageOfRoyaltiesAndRightsUnderAgreement>
    <acrx:CommercialMilestonesValueMaximumAmountAvailable
      contextRef="d_2015-09-18_2015-09-18_LegalEntityAxis-SWKMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember"
      decimals="-5"
      id="c81619287"
      unitRef="USD">35600000</acrx:CommercialMilestonesValueMaximumAmountAvailable>
    <acrx:CommercialMilestonesValueMaximumAmountAvailable
      contextRef="d_2015-09-18_2015-09-18_LegalEntityAxis-AcelRXMember_TypeOfArrangementAxis-FirstFourCommercialMilestonesMember"
      decimals="-5"
      id="c81619289"
      unitRef="USD">44500000</acrx:CommercialMilestonesValueMaximumAmountAvailable>
    <acrx:RoyaltyArrangmentMaximumPayments
      contextRef="d_2015-09-18_2015-09-18"
      decimals="-6"
      id="c81619291"
      unitRef="USD">195000000.0</acrx:RoyaltyArrangmentMaximumPayments>
    <acrx:NetProceedsFromSaleOfFutureRoyalties
      contextRef="d_2015-09-18_2015-09-18"
      decimals="-5"
      id="c81619292"
      unitRef="USD">61200000</acrx:NetProceedsFromSaleOfFutureRoyalties>
    <acrx:ContingentGainLossOnRoyaltyMonetizationArrangement
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-6"
      id="c81619294"
      unitRef="USD">64000000</acrx:ContingentGainLossOnRoyaltyMonetizationArrangement>
    <acrx:EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619295"
      unitRef="Pure">0</acrx:EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties>
    <acrx:EffectiveAnnualInterestRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c81619297"
      unitRef="Pure">0.035</acrx:EffectiveAnnualInterestRate>
    <acrx:EffectiveAnnualInterestRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="3"
      id="c81619298"
      unitRef="Pure">0.036</acrx:EffectiveAnnualInterestRate>
    <us-gaap:OtherLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050915">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year ended&lt;/b&gt;&lt;br/&gt; &lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Period from&lt;/b&gt;&lt;br/&gt; &lt;b&gt;inception to &lt;/b&gt;&lt;br/&gt; &lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liability related to sale of future royalties &#x2014; beginning balance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;88,471&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Proceeds from sale of future royalties&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;61,184&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Non-cash royalty revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(145&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(1,083&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;"&gt;Non-cash interest (income) expense recognized&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(3,038&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;25,187&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Liability related to sale of future royalties as of December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;85,288&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;85,288&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:OtherLiabilitiesTableTextBlock>
    <acrx:LiabilityRelatedToSaleOfFutureRoyalties
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619309"
      unitRef="USD">88471000</acrx:LiabilityRelatedToSaleOfFutureRoyalties>
    <acrx:LiabilityRelatedToSaleOfFutureRoyalties
      contextRef="i_2015-09-18"
      decimals="-3"
      id="c81619310"
      unitRef="USD">0</acrx:LiabilityRelatedToSaleOfFutureRoyalties>
    <acrx:NetProceedsFromSaleOfFutureRoyalties
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619311"
      unitRef="USD">0</acrx:NetProceedsFromSaleOfFutureRoyalties>
    <acrx:NetProceedsFromSaleOfFutureRoyalties
      contextRef="d_2015-09-19_2021-12-31"
      decimals="-3"
      id="c81619312"
      unitRef="USD">61184000</acrx:NetProceedsFromSaleOfFutureRoyalties>
    <acrx:NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619313"
      unitRef="USD">145000</acrx:NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized>
    <acrx:NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized
      contextRef="d_2015-09-19_2021-12-31"
      decimals="-3"
      id="c81619314"
      unitRef="USD">1083000</acrx:NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized>
    <acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619315"
      unitRef="USD">3038000</acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties>
    <acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties
      contextRef="d_2015-09-19_2021-12-31"
      decimals="-3"
      id="c81619316"
      unitRef="USD">-25187000</acrx:NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties>
    <acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619317"
      unitRef="USD">85288000</acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNet>
    <acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNet
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619318"
      unitRef="USD">85288000</acrx:LiabilityRelatedToSaleOfFutureRoyaltiesNet>
    <acrx:WarrantsDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050916">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;11.&lt;/em&gt; Warrants &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt; November 2021 &lt;/em&gt;Financing Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; November 15, 2021, &lt;/em&gt;the Company entered into a securities purchase agreement with certain investors pursuant to which the Company, in a registered direct offering, sold (i) an aggregate of 17,500,000 shares of the Company's common stock, and (ii) warrants to purchase up to an aggregate of 17,500,000 shares of common stock, for an aggregate purchase price of $14.0 million (see Note &lt;em style="font: inherit;"&gt;13&lt;/em&gt; &#x201c;Stockholders&#x2019; Equity&#x201d;). The &lt;em style="font: inherit;"&gt; November 2021 &lt;/em&gt;Financing Warrants have an exercise price of $1.00 per share and become exercisable, if the holder&#x2019;s post-exercise beneficial ownership is less than or equal to 9.99%, &lt;em style="font: inherit;"&gt;6&lt;/em&gt; months after their issuance date and have a &lt;em style="font: inherit;"&gt;five&lt;/em&gt;-year term (&lt;em style="font: inherit;"&gt; November 15, 2026). &lt;/em&gt;All common stock issuable under the issued warrants, were added to the Company&#x2019;s effective registration statement on &lt;em style="font: inherit;"&gt; November 15, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The &lt;em style="font: inherit;"&gt; November 2021 &lt;/em&gt;Financing warrants were valued at approximately $8.6 million using the Black-Scholes option pricing model as follows: exercise price of $1.00 per share, stock price of $0.7461 per share, expected life of &lt;span style="-sec-ix-hidden:c81619332"&gt;five&lt;/span&gt; years, volatility of 91.77%, and a risk-free rate of 1.26%. The common stock and warrants were issued in a unit structure; therefore, in accordance with ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; the aggregate gross proceeds of $14.0 million were allocated to the &lt;em style="font: inherit;"&gt;two&lt;/em&gt; securities using the relative fair value method, resulting in the common stock and warrants being allocated values of $8.4 million and $5.6 million, respectively, and recorded to stockholders' equity.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Loan Agreement Warrants &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In connection with the Loan Agreement, on &lt;em style="font: inherit;"&gt; May 30, 2019, &lt;/em&gt;the Company issued warrants to the Lender and its affiliates, which are exercisable for an aggregate of 176,679 shares of the Company&#x2019;s common stock with a per share exercise price of $2.83, or the Loan Agreement Warrants. The Loan Agreement Warrants &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be exercised on a cashless basis. The Loan Agreement Warrants are exercisable for a term beginning on the date of issuance and ending on the earlier to occur of &lt;span style="-sec-ix-hidden:c81619342"&gt;ten&lt;/span&gt; years from the date of issuance or the consummation of certain acquisitions of the Company as set forth in the Loan Agreement Warrants. The number of shares for which the Loan Agreement Warrants are exercisable and the associated exercise price are subject to certain proportional adjustments as set forth in the Loan Agreement Warrants.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company estimated the fair value of these Loan Agreement Warrants as of the issuance date to be $0.4 million, which was used in estimating the fair value of the debt instrument and was recorded as equity. The fair value of the Loan Agreement Warrants was calculated using the Black-Scholes option-valuation model, and was based on the strike price of $2.83, the stock price at issuance of $2.66, the &lt;span style="-sec-ix-hidden:c81619346"&gt;ten&lt;/span&gt;-year contractual term of the warrants, a risk-free interest rate of 2.22%, expected volatility of 80.22% and 0% expected dividend yield.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;Loan Agreement Warrants to purchase 176,679 shares of common stock issued to the Lender and its affiliates had &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been exercised and were still outstanding. These warrants expire in &lt;em style="font: inherit;"&gt; May 2029.&lt;/em&gt;&lt;/p&gt;
  </acrx:WarrantsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c81619320"
      unitRef="USD">17500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"
      decimals="INF"
      id="c81619321"
      unitRef="Share">17500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2021-11-15_2021-11-15_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-6"
      id="c81619322"
      unitRef="USD">14000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"
      decimals="INF"
      id="c81619324"
      unitRef="USDPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acrx:ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable
      contextRef="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_RangeAxis-MaximumMember"
      decimals="4"
      id="c81619325"
      unitRef="Pure">0.0999</acrx:ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"
      decimals="-5"
      id="c81619329"
      unitRef="USD">8600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"
      decimals="INF"
      id="c81619330"
      unitRef="USDPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c81619331"
      unitRef="Pure">0.7461</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="4"
      id="c81619333"
      unitRef="Pure">0.9177</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c81619334"
      unitRef="Pure">0.0126</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2021-11-15_2021-11-15_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-6"
      id="c81619336"
      unitRef="USD">14000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-11-15_2021-11-15_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-5"
      id="c81619338"
      unitRef="USD">8400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfWarrants
      contextRef="d_2021-11-15_2021-11-15_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"
      decimals="-5"
      id="c81619339"
      unitRef="USD">5600000</us-gaap:ProceedsFromIssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"
      decimals="INF"
      id="c81619340"
      unitRef="Share">176679</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"
      decimals="INF"
      id="c81619341"
      unitRef="USDPerShare">2.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"
      decimals="-5"
      id="c81619343"
      unitRef="USD">400000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExercisePriceMember"
      decimals="INF"
      id="c81619344"
      unitRef="USDPerShare">2.83</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputSharePriceMember"
      decimals="INF"
      id="c81619345"
      unitRef="USDPerShare">2.66</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember"
      decimals="4"
      id="c81619347"
      unitRef="Pure">0.0222</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputPriceVolatilityMember"
      decimals="4"
      id="c81619348"
      unitRef="Pure">0.8022</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:WarrantsAndRightsOutstandingMeasurementInput
      contextRef="i_2019-05-30_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember_MeasurementInputTypeAxis-MeasurementInputExpectedDividendRateMember"
      decimals="-3"
      id="c81619349"
      unitRef="Pure">0</us-gaap:WarrantsAndRightsOutstandingMeasurementInput>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2020-12-31_ClassOfWarrantOrRightAxis-WarrantInConnectionWithOxfordFinanceLoanAgreementMember"
      decimals="INF"
      id="c81619350"
      unitRef="Share">176679</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050917">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;12.&lt;/em&gt; Commitments and Contingencies &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Litigation &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; June 8, 2021, &lt;/em&gt;a securities class action complaint was filed in the U.S. District Court for the Northern District of California against the Company and &lt;span style="-sec-ix-hidden:c81619353"&gt;two&lt;/span&gt; of its officers. The plaintiff is a purported stockholder of the Company. The complaint alleges that defendants violated Sections &lt;em style="font: inherit;"&gt;10&lt;/em&gt;(b) and &lt;em style="font: inherit;"&gt;20&lt;/em&gt;(a) of the Exchange Act and SEC Rule &lt;em style="font: inherit;"&gt;10b&lt;/em&gt;-&lt;em style="font: inherit;"&gt;5&lt;/em&gt; by making false and misleading statements and omissions of material fact about the Company&#x2019;s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint seeks unspecified damages, interest, attorneys&#x2019; fees, and other costs. On &lt;em style="font: inherit;"&gt; December 16, 2021, &lt;/em&gt;the Court appointed co-lead plaintiffs. Plaintiffs&#x2019; amended complaint was filed on &lt;em style="font: inherit;"&gt; March 7, 2022. &lt;/em&gt;The amended complaint names the Company and &lt;em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;"&gt;three&lt;/em&gt; of its officers and continues to allege that defendants violated Sections &lt;span style="-sec-ix-hidden:c81619358"&gt;10&lt;/span&gt;(b) and &lt;em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;"&gt;20&lt;/em&gt;(a) of the Exchange Act and SEC Rule &lt;em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;"&gt;10b&lt;/em&gt;-&lt;em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;"&gt;5&lt;/em&gt; by making false and misleading statements and omissions of material fact about the Company&#x2019;s disclosure controls and procedures with respect to its marketing of DSUVIA. The complaint also alleges a violation of Section &lt;em class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="font: inherit;"&gt;20A&lt;/em&gt; of the Exchange Act against the individual defendants for alleged insider trading. Defendants&#x2019; motion to dismiss the amended complaint is due &lt;em style="font: inherit;"&gt; May 6, 2022.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 6, 2021, &lt;/em&gt;a purported shareholder derivative complaint was filed in the U.S. District Court for the Northern District of California. The complaint names &lt;em style="font: inherit;"&gt;ten&lt;/em&gt; of the Company&#x2019;s officers and directors and asserts state and federal claims based on the same alleged misstatements as the shareholder class action complaint. On &lt;em style="font: inherit;"&gt; September 30, 2021, &lt;/em&gt;&lt;em style="font: inherit;"&gt; October 26, 2021, &lt;/em&gt;and &lt;em style="font: inherit;"&gt; November 17, 2021, &lt;/em&gt;&lt;em style="font: inherit;"&gt;three&lt;/em&gt; additional purported shareholder derivative complaints were filed in the U.S. District Court for the Northern District of California. The complaints name &lt;em style="font: inherit;"&gt;nine&lt;/em&gt; of the Company&#x2019;s officers and directors and also assert state and federal claims based on the same alleged misstatements as the shareholder class action complaint. All &lt;em style="font: inherit;"&gt;four&lt;/em&gt; complaints seek unspecified damages, attorneys&#x2019; fees, and other costs. On &lt;em style="font: inherit;"&gt; December 6, 2021, &lt;/em&gt;the Court entered an order consolidating all &lt;em style="font: inherit;"&gt;four&lt;/em&gt; actions and staying the consolidated action pending the outcome of any motion to dismiss the securities class action. Please see &#x201c;Part II., Item &lt;em style="font: inherit;"&gt;1A.&lt;/em&gt; Risk Factors&#x2014;Risks of a General Nature&#x2014;Litigation &lt;em style="font: inherit;"&gt; may &lt;/em&gt;substantially increase our costs and harm our business&lt;i&gt;.&lt;/i&gt;&#x201d;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company believes that these lawsuits are without merit and intends to vigorously defend against them. Given the uncertainty of litigation, the preliminary stage of the cases, and the legal standards that must be met for, among other things, class certification and success on the merits, the Company cannot estimate the reasonably possible loss or range of loss that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;result from these actions.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050918">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;13.&lt;/em&gt; Stockholders&lt;/b&gt;&#x2019;&lt;b&gt; Equity &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Common Stock &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Underwritten Public Offering&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 22, 2021, &lt;/em&gt;the Company completed an underwritten public offering in which the Company issued and sold 14,500,000 shares of its common stock to the underwriter at a price of $1.7625 per share. On &lt;em style="font: inherit;"&gt; January 27, 2021, &lt;/em&gt;the underwriters exercised their option in full and purchased an additional 2,175,000 shares at a price of $1.7625 per share. The total net proceeds from this offering of an aggregate 16,675,000 shares were approximately $28.9 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Registered Direct Offering&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; November 17, 2021, &lt;/em&gt;the Company completed a registered direct offering in which the Company issued and sold 17,500,000 shares of its common stock at a price of $0.80 per share and warrants exercisable for an aggregate of 17,500,000 shares of its common stock at a price of $1.00 per share. The total net proceeds from this offering were approximately $13.9 million. The &lt;em style="font: inherit;"&gt; November 2021 &lt;/em&gt;issued shares were valued at approximately $13.1 million based on the closing stock price of $0.7491 per share on &lt;em style="font: inherit;"&gt; November 15, 2021. &lt;/em&gt;The common stock and warrants were issued in a unit structure; therefore, in accordance with ASC Topic &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; the aggregate gross proceeds of $14.0 million were allocated to the &lt;em style="font: inherit;"&gt;two&lt;/em&gt; securities using the relative fair value method, resulting in the common stock and warrants being allocated values of $8.4 million and $5.6 million, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Registered Direct Offerings&lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; July 23, 2020, &lt;/em&gt;the Company completed a registered direct offering in which it issued and sold 9,433,962 shares of its common stock at a price of $1.06 per share. The total net proceeds from this offering were approximately $10.0 million, after deducting estimated expenses payable by the Company of $49,000. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; underwriter or placement agent participated in the offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; December 11, 2020, &lt;/em&gt;the Company completed a registered direct offering in which it issued and sold 8,333,333 shares of its common stock at a price of $1.20 per share. The total net proceeds from this offering were approximately $9.9 million, after deducting estimated expenses payable by the Company of $51,000. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; underwriter or placement agent participated in the offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;ATM Agreement &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; June 21, 2016, &lt;/em&gt;the Company entered into a Controlled Equity Offering&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;SM&lt;/sup&gt; Sales Agreement, or the ATM Agreement, with Cantor Fitzgerald &amp;amp; Co., or Cantor, as agent, pursuant to which the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;offer and sell, from time to time through Cantor, shares of the Company&#x2019;s common stock, or the Common Stock having an aggregate offering price of up to $40.0 million, or the Shares. On &lt;em style="font: inherit;"&gt; May 9, 2019, &lt;/em&gt;the Company increased the aggregate offering price of shares of the Company&#x2019;s common stock which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be offered and sold under the ATM Agreement by $40.0 million, for a total of $80.0 million, or the Shares. The offering of Shares pursuant to the ATM Agreement will terminate upon the earlier of (a) the sale of all of the Shares subject to the ATM Agreement or (b) the termination of the ATM Agreement by Cantor or the Company, as permitted therein. The Company will pay Cantor a commission rate in the low single digits on the aggregate gross proceeds from each sale of Shares and have agreed to provide Cantor with customary indemnification and contribution rights.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company issued and sold approximately 3.0 million shares of common stock pursuant to the ATM Agreement, and received net proceeds of approximately $7.5 million, after deducting fees and expenses. During the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company issued and sold 876,800 shares of common stock pursuant to the ATM Agreement, for which the Company received net proceeds of approximately $1.4 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company had the ability to offer and sell shares of the Company&#x2019;s common stock having an aggregate offering price of up to $36.1 million under the ATM Agreement.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;i&gt;Stock Plans &lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Equity Incentive Plan &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In &lt;em style="font: inherit;"&gt; January 2011, &lt;/em&gt;the Board of Directors adopted, and the Company&#x2019;s stockholders approved, the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Equity Incentive Plan, or &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP. The initial aggregate number of shares of the Company&#x2019;s common stock that were issuable pursuant to stock awards under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP was approximately 1.9 million shares. The number of shares of common stock reserved for issuance under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP automatically increased on &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1&lt;/em&gt; of each year, starting on &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2012&lt;/em&gt; and continuing through &lt;em style="font: inherit;"&gt; January&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;1,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; by 4% of the total number of shares of the Company&#x2019;s common stock outstanding on &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31&lt;/em&gt; of the preceding calendar year, or such lesser number of shares of common stock as determined by the Board of Directors.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; June 16, 2020, &lt;/em&gt;&lt;em style="font: inherit;"&gt;no&lt;/em&gt; more awards &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be granted under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Equity Incentive Plan, or the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP, although all outstanding stock options and other stock awards previously granted under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP will continue to remain subject to the terms of the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Amended &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; June 16, 2020, &lt;/em&gt;at the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Annual Meeting of Stockholders of the Company, the Company&#x2019;s stockholders, upon the recommendation of the Company&#x2019;s Board of Directors, approved the Company&#x2019;s &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan, or the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; EIP.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The initial aggregate number of shares of the Company&#x2019;s common stock issuable pursuant to stock awards under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; EIP was 5,500,000 shares. In addition, the share reserve will be increased by the number of returning shares, if any, as such shares become available from time to time under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; EIP, for an additional number of shares &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to exceed 14,892,170 shares. The term of any option granted under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; EIP is determined on the date of grant but shall &lt;em style="font: inherit;"&gt;not&lt;/em&gt; be longer than &lt;em style="font: inherit;"&gt;10&lt;/em&gt; years. The Company issues new shares for settlement of vested restricted stock units and exercises of stock options. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a policy of purchasing its shares relating to its stock-based programs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;On &lt;em style="font: inherit;"&gt; June 17, 2021, &lt;/em&gt;at the &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Annual Meeting of Stockholders of the Company, upon the recommendation of the Company&#x2019;s Board of Directors, the Company&#x2019;s stockholders approved an amendment and restatement of the Company&#x2019;s &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Equity Incentive Plan, or &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, or as amended and restated, the Amended &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, to increase the number of authorized shares reserved for issuance thereunder by 4,300,000 shares, subject to adjustment for certain changes in the Company&#x2019;s capitalization. The aggregate number of shares of the Company&#x2019;s common stock that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be issued under the Amended &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; exceed the sum of: (i) 4,300,000 shares approved in connection with the adoption of the Amended &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, (ii) 5,500,000 shares approved in connection with the original adoption of the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, and (iii) certain shares subject to outstanding awards granted under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Equity Incentive Plan that &lt;em style="font: inherit;"&gt; may &lt;/em&gt;become available for issuance under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan and Amended &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Plan, as such shares become available from time to time.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Amended and Restated &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Employee Stock Purchase Plan &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Additionally, on &lt;em style="font: inherit;"&gt; June 16, 2020, &lt;/em&gt;the Company&#x2019;s stockholders, upon the recommendation of the Company&#x2019;s Board of Directors, approved the Amended and Restated &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Employee Stock Purchase Plan, or the Amended ESPP, which increased the aggregate number of shares of the Company&#x2019;s common stock reserved for issuance under the &lt;em style="font: inherit;"&gt;2011&lt;/em&gt; Employee Stock Purchase Plan, or ESPP, to 4,900,000 shares, subject to adjustment for certain changes in the Company&#x2019;s capitalization, and removed the &#x201c;evergreen&#x201d; provision from the ESPP.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;In the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;there were 297,959 shares issued under the Amended ESPP. The weighted average fair value of shares issued under the Amended ESPP in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $1.01 and $1.09 per share, respectively. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there were 4,456,364 shares available for future grant under the Amended ESPP.&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-22_2021-01-22_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619369"
      unitRef="Share">14500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-01-22_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619370"
      unitRef="USDPerShare">1.7625</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-27_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619371"
      unitRef="Share">2175000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619372"
      unitRef="USDPerShare">1.7625</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-22_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619373"
      unitRef="Share">16675000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-22_2021-01-27_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c81619374"
      unitRef="USD">28900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c81619376"
      unitRef="Share">17500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c81619377"
      unitRef="USDPerShare">0.80</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="INF"
      id="c81619378"
      unitRef="Share">17500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"
      decimals="INF"
      id="c81619379"
      unitRef="USDPerShare">1.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acrx:NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants
      contextRef="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-5"
      id="c81619380"
      unitRef="USD">13900000</acrx:NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-5"
      id="c81619381"
      unitRef="USD">13100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:SharePrice
      contextRef="i_2021-11-17"
      decimals="INF"
      id="c81619382"
      unitRef="USDPerShare">0.7491</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOrSaleOfEquity
      contextRef="d_2021-11-17_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-6"
      id="c81619384"
      unitRef="USD">14000000.0</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
    <us-gaap:CommonStockValue
      contextRef="i_2021-11-17_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember"
      decimals="-5"
      id="c81619386"
      unitRef="USD">8400000</us-gaap:CommonStockValue>
    <us-gaap:WarrantsAndRightsOutstanding
      contextRef="i_2021-11-17_ClassOfWarrantOrRightAxis-November2021FinancingWarrantsMember"
      decimals="-5"
      id="c81619387"
      unitRef="USD">5600000</us-gaap:WarrantsAndRightsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-07-23_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619389"
      unitRef="Share">9433962</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619390"
      unitRef="USDPerShare">1.06</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-07-23_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-7"
      id="c81619391"
      unitRef="USD">10000000.0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <acrx:EstimatedOfferingCosts
      contextRef="i_2020-07-23_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619392"
      unitRef="USD">49000</acrx:EstimatedOfferingCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-12-11_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619394"
      unitRef="Share">8333333</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619395"
      unitRef="USDPerShare">1.20</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-12-11_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="-5"
      id="c81619396"
      unitRef="USD">9900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <acrx:EstimatedOfferingCosts
      contextRef="i_2020-12-11_CounterpartyNameAxis-ArmisticeCapitalAndRockSpringsCapitalMember_SubsidiarySaleOfStockAxis-PrivatePlacementMember"
      decimals="INF"
      id="c81619397"
      unitRef="USD">51000</acrx:EstimatedOfferingCosts>
    <acrx:AggregateOfferingPriceMaximum
      contextRef="d_2016-06-21_2016-06-21_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-7"
      id="c81619399"
      unitRef="USD">40000000.0</acrx:AggregateOfferingPriceMaximum>
    <acrx:AggregateOfferingPriceIncreaseDuringPeriod
      contextRef="d_2019-05-09_2019-05-09_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-7"
      id="c81619400"
      unitRef="USD">40000000.0</acrx:AggregateOfferingPriceIncreaseDuringPeriod>
    <acrx:AggregateOfferingPriceMaximum
      contextRef="d_2019-05-09_2019-05-09_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-7"
      id="c81619401"
      unitRef="USD">80000000.0</acrx:AggregateOfferingPriceMaximum>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-6"
      id="c81619402"
      unitRef="Share">3000000.0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c81619403"
      unitRef="USD">7500000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-01-01_2020-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="INF"
      id="c81619404"
      unitRef="Share">876800</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-01-01_2020-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c81619405"
      unitRef="USD">1400000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <acrx:AggregateOfferingPriceMaximum
      contextRef="d_2021-01-01_2021-12-31_SubsidiarySaleOfStockAxis-ATMAgreementMember"
      decimals="-5"
      id="c81619406"
      unitRef="USD">36100000</acrx:AggregateOfferingPriceMaximum>
    <acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding
      contextRef="d_2011-01-01_2011-01-31_PlanNameAxis-EquityIncentivePlan2011Member"
      decimals="-5"
      id="c81619411"
      unitRef="Share">1900000</acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding>
    <acrx:StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed
      contextRef="i_2011-12-31_PlanNameAxis-EquityIncentivePlan2011Member"
      decimals="2"
      id="c81619418"
      unitRef="Pure">0.04</acrx:StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-06-16_PlanNameAxis-EquityIncentivePlan2011Member"
      decimals="INF"
      id="c81619431"
      unitRef="Share">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded
      contextRef="i_2020-06-16_PlanNameAxis-The2020EquityIncentivePlanMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c81619434"
      unitRef="Share">14892170</acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2021-06-17_2021-06-17_PlanNameAxis-The2020EquityIncentivePlanMember"
      decimals="INF"
      id="c81619443"
      unitRef="Share">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2021-06-17_PlanNameAxis-The2020EquityIncentivePlanMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c81619446"
      unitRef="Share">4300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-06-16_PlanNameAxis-The2020EquityIncentivePlanMember"
      decimals="INF"
      id="c81619448"
      unitRef="Share">5500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2020-06-16_PlanNameAxis-EmployeeStockPurchasePlanESPPMember"
      decimals="INF"
      id="c81619456"
      unitRef="Share">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="i_2021-12-31_PlanNameAxis-EmployeeStockPurchasePlanESPPMember"
      decimals="INF"
      id="c81619457"
      unitRef="Share">297959</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <acrx:EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619460"
      unitRef="USDPerShare">1.01</acrx:EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue>
    <acrx:EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81619461"
      unitRef="USDPerShare">1.09</acrx:EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-12-31_PlanNameAxis-EmployeeStockPurchasePlanESPPMember"
      decimals="INF"
      id="c81619464"
      unitRef="Share">4456364</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050919">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;14.&lt;/em&gt; Stock-Based Compensation &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company recorded total stock-based compensation expense for stock options, stock awards and the Amended ESPP as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 36pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cost of goods sold&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;92&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;123&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;813&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;764&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Selling, general and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,704&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,537&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,609&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,424&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes restricted stock unit activity under the Company&#x2019;s Equity Incentive Plans:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 36pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number&lt;/b&gt; &lt;b&gt;of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Restricted&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Grant&lt;/b&gt; &lt;b&gt;Date&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Stock&lt;/b&gt; &lt;b&gt;Units&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Restricted stock units outstanding, January 1, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;988,645&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;908,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(304,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(194,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2.16&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Restricted stock units outstanding, December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,397,983&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,149,632&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.68&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(587,214&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.89&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(186,025&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.58&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Restricted stock units outstanding, December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,774,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following table summarizes stock&#160;option activity under the Company&#x2019;s Equity Incentive Plans:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number&lt;/b&gt;&lt;br/&gt; &lt;b&gt;of&lt;/b&gt; &lt;b&gt;Stock&lt;/b&gt; &lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Outstanding&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Price&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Remaining&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Contractual&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Life (Years)&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(in&lt;/b&gt; &lt;b&gt;thousands)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;12,813,022&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;3.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,667,612&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1.82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt;"&gt;(375,432&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;1.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt;"&gt;(801,749&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;3.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(19,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;0.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,284,050&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;2.99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;5.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and exercisable options&#x2014;December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;10,496,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;3.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and expected to vest&#x2014;December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;14,284,050&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;2.99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;5.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there were 7,858,933 shares available for future grant under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; EIP.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Additional information regarding the Company&#x2019;s stock options outstanding and vested and exercisable as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt;&#160;is summarized below:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options Outstanding&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt; &lt;b&gt;Vested&lt;/b&gt; &lt;b&gt;and&lt;/b&gt; &lt;b&gt;Exercisable&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="3" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Exercise Prices&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Stock&lt;/b&gt; &lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Outstanding&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Remaining&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Contractual&lt;/b&gt; &lt;b&gt;Life&lt;/b&gt;&lt;br/&gt; &lt;b&gt;(Years)&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise&lt;/b&gt; &lt;b&gt;Price&lt;/b&gt; &lt;b&gt;per&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Share&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Shares&lt;/b&gt; &lt;b&gt;Subject&lt;/b&gt;&lt;br/&gt; &lt;b&gt;to Stock&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Options&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise&lt;/b&gt; &lt;b&gt;Price&lt;/b&gt; &lt;b&gt;per&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Share&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$0.72&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619560"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$1.12&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;695,482&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;8.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;0.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;280,047&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;0.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$1.26&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619567"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$1.89&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;3,402,418&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;8.9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;496,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;1.67&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$2.00&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619574"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$3.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;5,310,550&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;6.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;2.44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;4,856,618&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;2.43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$3.10&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619581"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$4.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;3,066,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;3.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;3.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;3,054,619&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;3.38&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$4.73&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619588"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$7.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;1,295,781&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;1.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;5.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;1,295,781&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;5.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$8.18&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619595"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$12.27&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;513,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;2.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;10.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;513,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;10.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 7pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,284,050&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;5.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;2.99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,496,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;3.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The weighted average grant-date fair value of options granted during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $1.24 and $0.92 per share, respectively. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; total stock-based compensation expense related to unvested options to be recognized in future periods was $3.8 million which is expected to be recognized over a weighted-average period of 2.1 years. The grant date fair value of shares vested during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $2.4 million and $3.6 million, respectively. The total intrinsic value of options exercised during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was $5.7 thousand and $0.0 million, respectively.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; March 3, 2021, &lt;/em&gt;the Company granted 1.27 million performance-based stock options to certain of its executive officers, which are included in the stock option tables and associated disclosures above. The awards were granted under the &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; EIP with an exercise price of $1.88 per share, the closing sales price as reported on the Nasdaq on the date of grant. The performance-based stock options are eligible to vest subject to the satisfaction of the service-based vesting requirements and attainment of share price target goals, a market-based condition. No performance-based stock options vested during the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;and there were no performance-based stock options granted for the year ended &lt;em style="font: inherit;"&gt; December 31, 2020.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company uses the Monte Carlo Simulation model to evaluate the derived service period and fair value of awards with market conditions, including assumptions of historical volatility and risk-free interest rate commensurate with the vesting term.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company used the following assumptions to calculate the fair value of each performance-based stock option: &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 15%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Year&lt;/b&gt; &lt;b&gt;Ended&lt;/b&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Derived service period (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;2.3&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2013;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2.6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;1.5%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;90%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company used the following assumptions to calculate the fair value of each time-based stock option:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year&lt;/b&gt; &lt;b&gt;Ended&lt;/b&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b style="font-size: 10pt;"&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b style="font-size: 10pt;"&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;6.0&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;6.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 5pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;6.2&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 5pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;0.9%&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;1.3%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;0.4%&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;1.5%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;90%&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;83%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050920">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 36pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Cost of goods sold&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;92&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;123&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;813&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;764&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Selling, general and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,704&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;3,537&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,609&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4,424&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-CostOfSalesMember"
      decimals="-3"
      id="c81619496"
      unitRef="USD">92000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-CostOfSalesMember"
      decimals="-3"
      id="c81619497"
      unitRef="USD">123000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c81619498"
      unitRef="USD">813000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="-3"
      id="c81619499"
      unitRef="USD">764000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c81619500"
      unitRef="USD">3704000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-SellingGeneralAndAdministrativeExpensesMember"
      decimals="-3"
      id="c81619501"
      unitRef="USD">3537000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619502"
      unitRef="USD">4609000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619503"
      unitRef="USD">4424000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050921">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px; margin-left: 36pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number&lt;/b&gt; &lt;b&gt;of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Average&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Restricted&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Grant&lt;/b&gt; &lt;b&gt;Date&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Stock&lt;/b&gt; &lt;b&gt;Units&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Fair&lt;/b&gt; &lt;b&gt;Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 66%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Restricted stock units outstanding, January 1, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;988,645&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;908,300&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.30&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(304,810&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2.53&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(194,152&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2.16&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Restricted stock units outstanding, December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,397,983&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1,149,632&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.68&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Vested&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;(587,214&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.89&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(186,025&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.58&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Restricted stock units outstanding, December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,774,376&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 14%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;1.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2019-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619510"
      unitRef="Share">988645</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2019-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619511"
      unitRef="USDPerShare">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619512"
      unitRef="Share">908300</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619513"
      unitRef="USDPerShare">1.30</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619514"
      unitRef="Share">304810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619515"
      unitRef="USDPerShare">2.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619516"
      unitRef="Share">194152</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619517"
      unitRef="USDPerShare">2.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619518"
      unitRef="Share">1397983</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619519"
      unitRef="USDPerShare">1.79</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619520"
      unitRef="Share">1149632</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619521"
      unitRef="USDPerShare">1.68</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619522"
      unitRef="Share">587214</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619523"
      unitRef="USDPerShare">1.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619524"
      unitRef="Share">186025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619525"
      unitRef="USDPerShare">1.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619526"
      unitRef="Share">1774376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c81619527"
      unitRef="USDPerShare">1.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050922">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number&lt;/b&gt;&lt;br/&gt; &lt;b&gt;of&lt;/b&gt; &lt;b&gt;Stock&lt;/b&gt; &lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Outstanding&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 6pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 6pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Price&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Remaining&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Contractual&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Life (Years)&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Intrinsic&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(in&lt;/b&gt; &lt;b&gt;thousands)&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;12,813,022&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;3.20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;2,667,612&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1.82&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt;"&gt;(375,432&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;1.79&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt;"&gt;(801,749&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;3.03&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 36pt;"&gt;Exercised&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(19,403&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;0.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,284,050&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;2.99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;5.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and exercisable options&#x2014;December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;10,496,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;3.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;4.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and expected to vest&#x2014;December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;14,284,050&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 14pt; text-align: right;"&gt;2.99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;5.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 19pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81619528"
      unitRef="Share">12813022</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c81619529"
      unitRef="USDPerShare">3.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619532"
      unitRef="Share">2667612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619533"
      unitRef="USDPerShare">1.82</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619536"
      unitRef="Share">375432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619537"
      unitRef="USDPerShare">1.79</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619540"
      unitRef="Share">801749</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619541"
      unitRef="USDPerShare">3.03</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619544"
      unitRef="Share">19403</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619545"
      unitRef="USDPerShare">0.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619548"
      unitRef="Share">14284050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619549"
      unitRef="USDPerShare">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2021-01-01_2021-12-31" id="c81619550">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619551"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619552"
      unitRef="Share">10496744</acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619553"
      unitRef="USDPerShare">3.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm contextRef="d_2021-01-01_2021-12-31" id="c81619554">P4Y9M18D</acrx:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619555"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619556"
      unitRef="Share">14284050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619557"
      unitRef="USDPerShare">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2021-01-01_2021-12-31" id="c81619558">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619559"
      unitRef="USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-12-31_PlanNameAxis-The2020EquityIncentivePlanMember"
      decimals="INF"
      id="c81619472"
      unitRef="Share">7858933</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <acrx:ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050923">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 33%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options Outstanding&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 17%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt; &lt;b&gt;Vested&lt;/b&gt; &lt;b&gt;and&lt;/b&gt; &lt;b&gt;Exercisable&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="3" rowspan="1" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Exercise Prices&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Stock&lt;/b&gt; &lt;b&gt;Options&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Outstanding&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Remaining&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Contractual&lt;/b&gt; &lt;b&gt;Life&lt;/b&gt;&lt;br/&gt; &lt;b&gt;(Years)&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise&lt;/b&gt; &lt;b&gt;Price&lt;/b&gt; &lt;b&gt;per&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Share&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Shares&lt;/b&gt; &lt;b&gt;Subject&lt;/b&gt;&lt;br/&gt; &lt;b&gt;to Stock&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Options&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted-Average&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Exercise&lt;/b&gt; &lt;b&gt;Price&lt;/b&gt; &lt;b&gt;per&lt;/b&gt;&lt;br/&gt; &lt;b&gt;Share&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$0.72&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619560"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$1.12&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;695,482&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;8.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;0.85&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;280,047&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;0.84&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$1.26&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619567"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$1.89&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;3,402,418&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;8.9&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;1.80&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;496,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;1.67&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$2.00&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619574"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$3.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;5,310,550&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;6.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;2.44&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;4,856,618&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;2.43&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$3.10&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619581"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$4.65&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;3,066,819&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;3.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;3.37&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;3,054,619&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;3.38&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$4.73&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619588"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$7.10&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right;"&gt;1,295,781&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;1.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;5.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt;"&gt;1,295,781&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;5.71&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; text-align: right;"&gt;$8.18&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center; width: 4%;"&gt;&lt;span style="-sec-ix-hidden:c81619595"&gt;-&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;$12.27&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;513,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;2.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;10.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;513,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;10.28&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 4%;"&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 7pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;14,284,050&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: right;"&gt;5.8&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;2.99&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,496,744&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt;"&gt;$&lt;/td&gt;&lt;td style="width: 13%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 26pt; text-align: right;"&gt;3.42&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </acrx:ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c81619561"
      unitRef="USDPerShare">1.12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c81619562"
      unitRef="Share">695482</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      id="c81619563">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c81619564"
      unitRef="USDPerShare">0.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c81619565"
      unitRef="Share">280047</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange1Member"
      decimals="INF"
      id="c81619566"
      unitRef="USDPerShare">0.84</acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c81619568"
      unitRef="USDPerShare">1.89</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c81619569"
      unitRef="Share">3402418</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      id="c81619570">P8Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c81619571"
      unitRef="USDPerShare">1.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c81619572"
      unitRef="Share">496679</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange2Member"
      decimals="INF"
      id="c81619573"
      unitRef="USDPerShare">1.67</acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c81619575"
      unitRef="USDPerShare">3.00</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c81619576"
      unitRef="Share">5310550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      id="c81619577">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c81619578"
      unitRef="USDPerShare">2.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c81619579"
      unitRef="Share">4856618</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange3Member"
      decimals="INF"
      id="c81619580"
      unitRef="USDPerShare">2.43</acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c81619582"
      unitRef="USDPerShare">4.65</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c81619583"
      unitRef="Share">3066819</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      id="c81619584">P3Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c81619585"
      unitRef="USDPerShare">3.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c81619586"
      unitRef="Share">3054619</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange4Member"
      decimals="INF"
      id="c81619587"
      unitRef="USDPerShare">3.38</acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c81619589"
      unitRef="USDPerShare">7.10</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c81619590"
      unitRef="Share">1295781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      id="c81619591">P1Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c81619592"
      unitRef="USDPerShare">5.71</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c81619593"
      unitRef="Share">1295781</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange5Member"
      decimals="INF"
      id="c81619594"
      unitRef="USDPerShare">5.71</acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c81619596"
      unitRef="USDPerShare">12.27</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c81619597"
      unitRef="Share">513000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="d_2021-01-01_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      id="c81619598">P2Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c81619599"
      unitRef="USDPerShare">10.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c81619600"
      unitRef="Share">513000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice
      contextRef="i_2021-12-31_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis-ExercisePriceRange6Member"
      decimals="INF"
      id="c81619601"
      unitRef="USDPerShare">10.28</acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="d_2021-01-01_2021-12-31"
      id="c81619603"
      unitRef="USDPerShare"
      xsi:nil="true"/>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619604"
      unitRef="Share">14284050</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2021-01-01_2021-12-31" id="c81619605">P5Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619606"
      unitRef="USDPerShare">2.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619607"
      unitRef="Share">10496744</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c81619608"
      unitRef="USDPerShare">3.42</acrx:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c81619479"
      unitRef="USDPerShare">1.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c81619480"
      unitRef="USDPerShare">0.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2021-12-31"
      decimals="-5"
      id="c81619483"
      unitRef="USD">3800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2021-01-01_2021-12-31" id="c81619484">P2Y1M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c81619488"
      unitRef="USD">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-5"
      id="c81619489"
      unitRef="USD">3600000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c81619493"
      unitRef="USD">5700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619494"
      unitRef="USD">0.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-03-03_2021-03-03_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="-4"
      id="c81621094"
      unitRef="Share">1270000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-03-03_2021-03-03_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember_TitleOfIndividualAxis-ExecutiveOfficerMember"
      decimals="INF"
      id="c81621096"
      unitRef="USDPerShare">1.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember"
      decimals="-3"
      id="c81621097"
      unitRef="Share">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember_PlanNameAxis-The2020EquityIncentivePlanMember"
      decimals="-3"
      id="c81621098"
      unitRef="Share">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember"
      id="c2050991">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="7" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 15%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;Year&lt;/b&gt; &lt;b&gt;Ended&lt;/b&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 8%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Derived service period (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;2.3&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2013;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;2.6&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;1.5%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;90%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 71%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 4%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_RangeAxis-MinimumMember"
      id="c81620442">P2Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember_RangeAxis-MaximumMember"
      id="c81620444">P2Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="3"
      id="c81620447"
      unitRef="Pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="0"
      id="c81620449"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="1"
      id="c81620451"
      unitRef="Pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="0"
      id="c81620453"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="-3"
      id="c81620455"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="0"
      id="c81620457"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      id="c2050924">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="10" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; width: 13%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year&lt;/b&gt; &lt;b&gt;Ended&lt;/b&gt; &lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="5" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b style="font-size: 10pt;"&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="4" rowspan="1" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; width: 1%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;"&gt;&lt;b&gt;&lt;b style="font-size: 10pt;"&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 1%; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;6.0&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;6.2&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 5pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 5pt; text-align: center;"&gt;6.2&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 5pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;0.9%&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;1.3%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;0.4%&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;1.5%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;90%&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;83%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 76%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected dividend rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 3%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 8pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MinimumMember"
      id="c81619609">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      id="c81619611">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      id="c81619613">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      decimals="3"
      id="c81619615"
      unitRef="Pure">0.009</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      decimals="3"
      id="c81619617"
      unitRef="Pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c81619618"
      unitRef="Pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c81619620"
      unitRef="Pure">0.015</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      decimals="1"
      id="c81619622"
      unitRef="Pure">0.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      decimals="2"
      id="c81619625"
      unitRef="Pure">0.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      decimals="-3"
      id="c81619628"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-TimebasedStockOptionMember"
      decimals="-3"
      id="c81619631"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:EarningsPerShareTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050925">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;15.&lt;/em&gt; Net Loss per Share of Common Stock &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company&#x2019;s basic net loss per share of common stock is calculated by dividing the net loss by the weighted average number of shares of common stock outstanding for the period. The diluted net loss per share of common stock is computed by giving effect to all potential common stock equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, options to purchase common stock, restricted stock units and warrants to purchase common stock were considered to be common stock equivalents. In periods with a reported net loss, common stock equivalents are excluded from the calculation of diluted net loss per share of common stock if their effect is antidilutive.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The following outstanding shares of common stock equivalents were excluded from the computation of diluted net loss per share of common stock for the periods presented because including them would have been antidilutive: &#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;ESPP, RSUs and stock options to purchase common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;16,328,426&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;14,541,005&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;17,676,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;176,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050926">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;ESPP, RSUs and stock options to purchase common stock&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;16,328,426&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;14,541,005&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;17,676,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;176,679&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember"
      decimals="INF"
      id="c81619635"
      unitRef="Share">16328426</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember"
      decimals="INF"
      id="c81619636"
      unitRef="Share">14541005</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c81619637"
      unitRef="Share">17676679</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c81619638"
      unitRef="Share">176679</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050927">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;16.&lt;/em&gt; Accrued Liabilities &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Accrued liabilities consist of the following (in thousands): &#160;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued compensation and employee benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;2,974&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;3,323&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued professional services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;1,523&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;179&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Accrued product returns and sales allowances&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;775&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;656&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Deferred revenue&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;86&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;49&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other accrued liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,166&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;838&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total accrued liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,524&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,045&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050928">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued compensation and employee benefits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;2,974&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;3,323&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued professional services&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;1,523&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;179&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Accrued product returns and sales allowances&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;775&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;656&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;Deferred revenue&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;86&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;49&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other accrued liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,166&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;838&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total accrued liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,524&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;5,045&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619640"
      unitRef="USD">2974000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619641"
      unitRef="USD">3323000</us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619642"
      unitRef="USD">1523000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619643"
      unitRef="USD">179000</us-gaap:AccruedProfessionalFeesCurrent>
    <acrx:AccruedProductReturnsAndSalesAllowancesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619644"
      unitRef="USD">775000</acrx:AccruedProductReturnsAndSalesAllowancesCurrent>
    <acrx:AccruedProductReturnsAndSalesAllowancesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619645"
      unitRef="USD">656000</acrx:AccruedProductReturnsAndSalesAllowancesCurrent>
    <acrx:AccruedDeferredRevenueCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619646"
      unitRef="USD">86000</acrx:AccruedDeferredRevenueCurrent>
    <acrx:AccruedDeferredRevenueCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619647"
      unitRef="USD">49000</acrx:AccruedDeferredRevenueCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81620494"
      unitRef="USD">1166000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81620495"
      unitRef="USD">838000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619648"
      unitRef="USD">6524000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619649"
      unitRef="USD">5045000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050929">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;17.&lt;/em&gt; &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The Company sponsors a &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) plan that stipulates that eligible employees can elect to contribute to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) plan, subject to certain limitations. Pursuant to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) plan, the Company makes a matching contribution of up to 4% of the related compensation. Under the vesting schedule, employees have ownership in the matching employer contributions based on the number of years of vesting service completed. Company contributions were $0.4 million and $0.5 million for the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively.&lt;/p&gt;
  </us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <acrx:DefinedContributionPlanEmployerDiscretionaryContributionPercentage
      contextRef="d_2019-01-01_2019-12-31"
      decimals="2"
      id="c81619655"
      unitRef="Pure">0.04</acrx:DefinedContributionPlanEmployerDiscretionaryContributionPercentage>
    <acrx:ContributionsByEmployerToPostemploymentBenefitObligations
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c81619656"
      unitRef="USD">400000</acrx:ContributionsByEmployerToPostemploymentBenefitObligations>
    <acrx:ContributionsByEmployerToPostemploymentBenefitObligations
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-5"
      id="c81619657"
      unitRef="USD">500000</acrx:ContributionsByEmployerToPostemploymentBenefitObligations>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050930">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;18.&lt;/em&gt; Income Taxes &lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Company recorded a provision for income taxes of $5.0 thousand and $4.0 thousand during the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Net deferred tax assets as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; consist of the following (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Accruals and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;3,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;4,136&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Research credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;7,275&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;7,275&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Net operating loss carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;75,452&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;65,274&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Section 59(e) R&amp;amp;D expenditures&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;5,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;7,473&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Deferred revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;19,666&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,848&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;111,452&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;105,006&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(111,452&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(105,006&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c81619742"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c81619743"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Reconciliations of the statutory federal income tax to the Company&#x2019;s effective tax during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; are as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tax at statutory federal rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;(7,370&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;(8,486&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State tax&#x2014;net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;(3,587&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;718&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 31pt;"&gt;636&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;(20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,446&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,441&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Provision for income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt; requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than &lt;em style="font: inherit;"&gt;not.&#x201d;&lt;/em&gt; Realization of deferred tax assets is dependent on future taxable income, if any, the timing and the amount of which are uncertain. Accordingly, the deferred tax assets have been fully offset by a valuation allowance. The valuation allowance increased by $6.4 million and $11.4 million during the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company had federal net operating loss carryforwards of $308.5 million, of which $114.9 million federal net operating losses generated before &lt;em style="font: inherit;"&gt; January 1, 2018 &lt;/em&gt;will begin to expire in &lt;em style="font: inherit;"&gt;2029.&lt;/em&gt; Federal net operating losses of $193.6 million generated from &lt;em style="font: inherit;"&gt;2018&lt;/em&gt; to &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; will carryforward indefinitely but are subject to the &lt;em style="font: inherit;"&gt;80%&lt;/em&gt; taxable income limitation. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company had state net operating loss carryforwards of $154.7 million, which begin to expire in &lt;em style="font: inherit;"&gt;2028.&lt;/em&gt;&#160;&lt;/p&gt;
   &lt;p style="margin: 0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company had federal research credit carryovers of $6.5 million, which begin to expire in &lt;em style="font: inherit;"&gt;2026.&lt;/em&gt; As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company had state research credit carryovers of $4.0 million, which will carryforward indefinitely.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;Under Section&#160;&lt;em style="font: inherit;"&gt;382&lt;/em&gt; of the Internal Revenue Code of &lt;em style="font: inherit;"&gt;1986,&lt;/em&gt; as amended, if a corporation undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; change (by value) in its equity ownership over a &lt;em style="font: inherit;"&gt;three&lt;/em&gt;-year period, the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes, such as research credits, to offset its post-change income &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be limited. Based on an analysis performed by the Company as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2013,&lt;/em&gt; it was determined that &lt;em style="font: inherit;"&gt;two&lt;/em&gt; ownership changes have occurred since inception of the Company. The &lt;em style="font: inherit;"&gt;first&lt;/em&gt; ownership change occurred in &lt;em style="font: inherit;"&gt;2006&lt;/em&gt; at the time of the Series A financing and, as a result of the change, $1.4 million in federal and state net operating loss carryforwards will expire unutilized. In addition, $26 thousand in federal and state research and development credits will expire unutilized. The &lt;em style="font: inherit;"&gt;second&lt;/em&gt; ownership change occurred in &lt;em style="font: inherit;"&gt; July 2013 &lt;/em&gt;at the time of the underwritten public offering; however, the Company believes the resulting annual imposed limitation on use of pre-change tax attributes is sufficiently high that the limit itself will &lt;em style="font: inherit;"&gt;not&lt;/em&gt; result in unutilized pre-change tax attributes.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;i&gt;Uncertain Tax Positions &lt;/i&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;A reconciliation of the beginning and ending balances of the unrecognized tax benefits during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; is as follows (in thousands):&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unrecognized benefit&#x2014;beginning of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gross increases&#x2014;prior period tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gross increases&#x2014;current period tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unrecognized benefit&#x2014;end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The entire amount of the unrecognized tax benefits would &lt;em style="font: inherit;"&gt;not&lt;/em&gt; impact the Company&#x2019;s effective tax rate if recognized.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;There were no accrued interest or penalties related to unrecognized tax benefits in the years ended &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;and &lt;em style="font: inherit;"&gt;2020.&lt;/em&gt; The Company files income tax returns in the United States, California, and other states. The tax years &lt;span style="-sec-ix-hidden:c81619715"&gt;2005&lt;/span&gt; through &lt;em style="font: inherit;"&gt;2014,&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2016&lt;/em&gt; through &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; remain open in all jurisdictions. The Company is &lt;em style="font: inherit;"&gt;not&lt;/em&gt; currently under examination by income tax authorities in federal, state or other foreign jurisdictions. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; anticipate any significant changes within &lt;em style="font: inherit;"&gt;12&lt;/em&gt; months of this reporting date of its uncertain tax positions.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;In &lt;em style="font: inherit;"&gt; March 2020, &lt;/em&gt;the Coronavirus Aid, Relief and Economic Security, or CARES, Act was signed into law. The CARES Act included several tax changes as part of its economic package. These changes principally related to expanded net operating loss carryback periods, increases to interest deductibility limitations, and accelerated alternative minimum tax refunds. The Company has evaluated these items and determined that the items do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material effect on the Company's financial statements as of &lt;em style="font: inherit;"&gt; December 31, 2021. &lt;/em&gt;Additionally, the CARES Act enacted the Employee Retention Credit, or ERC, to incentivize companies to retain employees, which was subsequently modified by extension of the CARES Act. Under the provisions of the CARES Act and its subsequent extension, the Company was eligible for ERCs, subject to certain criteria. Accordingly, the Company has recorded a reduction in payroll taxes related to ERCs claimed for $1.4 million in the year ended &lt;em style="font: inherit;"&gt; December 31, 2021. &lt;/em&gt;These credits are recorded in the Consolidated Statements of Operations as an offset to the related payroll expenses in the respective operating costs and expenses line item. Such claimed ERCs &lt;em style="font: inherit;"&gt;not&lt;/em&gt; settled prior to year-end in the amount of &lt;em style="font: inherit;"&gt;$1.4&lt;/em&gt; million are expected to be settled shortly thereafter and are disclosed within prepaid expenses and other current assets on the Company&#x2019;s Consolidated Balance Sheets at &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619660"
      unitRef="USD">5000.0</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619661"
      unitRef="USD">4000.0</us-gaap:IncomeTaxExpenseBenefit>
    <acrx:ScheduleOfDeferredTaxAssetsTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050931">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt;&lt;br/&gt; &lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Accruals and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;3,989&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;4,136&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Research credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;7,275&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;7,275&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Net operating loss carryforward&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;75,452&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;65,274&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Section 59(e) R&amp;amp;D expenditures&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;5,070&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;7,473&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Deferred revenue&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;19,666&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;20,848&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 54pt;"&gt;Total deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;111,452&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right;"&gt;105,006&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(111,452&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(105,006&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c81619742"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 16pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;&lt;span style="-sec-ix-hidden:c81619743"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </acrx:ScheduleOfDeferredTaxAssetsTableTextBlock>
    <acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619728"
      unitRef="USD">3989000</acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther>
    <acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619729"
      unitRef="USD">4136000</acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619730"
      unitRef="USD">7275000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619731"
      unitRef="USD">7275000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619732"
      unitRef="USD">75452000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619733"
      unitRef="USD">65274000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i_2021-12-31"
      decimals="-4"
      id="c81619734"
      unitRef="USD">5070000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619735"
      unitRef="USD">7473000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619736"
      unitRef="USD">19666000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619737"
      unitRef="USD">20848000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619738"
      unitRef="USD">111452000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619739"
      unitRef="USD">105006000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619740"
      unitRef="USD">111452000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619741"
      unitRef="USD">105006000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050932">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Tax at statutory federal rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;(7,370&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;(8,486&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State tax&#x2014;net of federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;231&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;(3,587&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;718&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 31pt;"&gt;636&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;(20&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;6,446&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;11,441&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Provision for income taxes&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 11pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;4&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-4"
      id="c81619744"
      unitRef="USD">-7370000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619745"
      unitRef="USD">-8486000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619746"
      unitRef="USD">231000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619747"
      unitRef="USD">-3587000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619748"
      unitRef="USD">718000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619749"
      unitRef="USD">636000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-4"
      id="c81619750"
      unitRef="USD">-20000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationOtherAdjustments
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619751"
      unitRef="USD">0</us-gaap:IncomeTaxReconciliationOtherAdjustments>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619752"
      unitRef="USD">6446000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619753"
      unitRef="USD">11441000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619754"
      unitRef="USD">5000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619755"
      unitRef="USD">4000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c81619672"
      unitRef="USD">6400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-5"
      id="c81619673"
      unitRef="USD">11400000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="-5"
      id="c81619677"
      unitRef="USD">308500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-BeforeTaxYear2018Member"
      decimals="-5"
      id="c81619678"
      unitRef="USD">114900000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxPeriodAxis-TaxYears2018To2020Member"
      decimals="-5"
      id="c81619680"
      unitRef="USD">193600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="-5"
      id="c81619686"
      unitRef="USD">154700000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-5"
      id="c81619690"
      unitRef="USD">6500000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-6"
      id="c81619694"
      unitRef="USD">4000000.0</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_StatementScenarioAxis-SubjectToExpirationMember"
      decimals="-5"
      id="c81619704"
      unitRef="USD">1400000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="i_2021-12-31_StatementScenarioAxis-SubjectToExpirationMember_TaxCreditCarryforwardAxis-ResearchMember"
      decimals="-3"
      id="c81619705"
      unitRef="USD">26000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050933">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year Ended December&lt;/b&gt; &lt;b&gt;31,&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 15pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 62%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unrecognized benefit&#x2014;beginning of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt;"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right;"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gross increases&#x2014;prior period tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Gross increases&#x2014;current period tax positions&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unrecognized benefit&#x2014;end of period&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 15pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 13pt; text-align: right; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,635&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619756"
      unitRef="USD">2635000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2019-12-31"
      decimals="-3"
      id="c81619757"
      unitRef="USD">2635000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619758"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619759"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c81619760"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c81619761"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619762"
      unitRef="USD">2635000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="i_2020-12-31"
      decimals="-3"
      id="c81619763"
      unitRef="USD">2635000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
      contextRef="i_2021-12-31"
      decimals="-3"
      id="c81619712"
      unitRef="USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c81619723"
      unitRef="USD">1400000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
    <us-gaap:SubsequentEventsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050934">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;19.&lt;/em&gt; Subsequent Events&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;On &lt;em style="font: inherit;"&gt; January 7, 2022, &lt;/em&gt;the Company closed the Merger Agreement with Lowell in a transaction for consideration of approximately $32.5 million plus net cash acquired and certain other adjustments. Pursuant to the terms of the Merger Agreement, all options to purchase capital stock and all shares of Lowell capital stock issued and outstanding immediately before the effective time of the merger were cancelled in exchange for the right to receive (i) 9,009,538 shares of AcelRx common stock, and cash in the amount of $3,519,129, (ii) 1,396,526 shares of AcelRx common stock to be held back to satisfy any potential indemnification and other obligations of Lowell and its securityholders, and (iii) up to $26.0 million of contingent consideration payable in cash or stock at AcelRx's option, upon the achievement of regulatory and sales-based milestones.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;The 1,396,526 of held back shares of AcelRx common stock issued in connection with the closing was calculated based on a fixed value of $0.57284 per share, which is the arithmetic average of the daily volume weighted average price per share of AcelRx common stock during the &lt;em style="font: inherit;"&gt;five&lt;/em&gt; consecutive full trading days ending on and including the last full trading day immediately prior to the date of the closing. The shares issued pursuant to the Merger Agreement were issued in private placements pursuant to the exemption from registration under Section &lt;em style="font: inherit;"&gt;4&lt;/em&gt;(a)(&lt;em style="font: inherit;"&gt;2&lt;/em&gt;) of the Securities Act of &lt;em style="font: inherit;"&gt;1933,&lt;/em&gt; as amended, or the Securities Act, including Rule &lt;em style="font: inherit;"&gt;506&lt;/em&gt; of Regulation D promulgated under the Securities Act, or Regulation D, without general solicitation as a transaction &lt;em style="font: inherit;"&gt;not&lt;/em&gt; involving any public offering.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"&gt;The Merger Agreement will be accounted for in the &lt;em style="font: inherit;"&gt;first&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2022&lt;/em&gt; as an acquisition of assets that does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; meet the definition of a business. The asset acquisition does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; constitute a business as substantially all of the fair value of the gross assets acquired was concentrated in Lowell&#x2019;s intellectual property, including NIYAD&#x2122; and LTX-&lt;em style="font: inherit;"&gt;608.&lt;/em&gt; The acquired assets and liabilities will be recorded at their relative fair values and the contingent consideration will be recorded when it becomes probable of achievement or the consideration becomes payable. Accordingly, the Company has classified $1.9 million of expenses related to the Merger Agreement as Other assets in the Consolidated Balance Sheet&#160;at &lt;em style="font: inherit;"&gt; December 31, 2021.&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;


  </us-gaap:SubsequentEventsTextBlock>
    <acrx:BusinessCombinationConsiderationTransferredNetOfCashAcquired
      contextRef="d_2022-01-07_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="-5"
      id="c81619765"
      unitRef="USD">32500000</acrx:BusinessCombinationConsiderationTransferredNetOfCashAcquired>
    <acrx:BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber
      contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember"
      decimals="INF"
      id="c81619766"
      unitRef="Share">9009538</acrx:BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber>
    <acrx:BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash
      contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember"
      decimals="INF"
      id="c81619767"
      unitRef="USD">3519129</acrx:BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash>
    <acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations
      contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember"
      decimals="INF"
      id="c81619769"
      unitRef="Share">1396526</acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember"
      decimals="-6"
      id="c81619770"
      unitRef="USD">26000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations
      contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember"
      decimals="INF"
      id="c81619771"
      unitRef="Share">1396526</acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations>
    <acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare
      contextRef="i_2022-01-07_BusinessAcquisitionAxis-LowellTherapeuticsMember_SubsequentEventTypeAxis-SubsequentEventMember_SubsidiarySaleOfStockAxis-AcelrxCommonStockMember"
      decimals="INF"
      id="c81619772"
      unitRef="USDPerShare">0.57284</acrx:BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare>
    <us-gaap:AcquisitionCostsCumulative
      contextRef="i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember_BusinessAcquisitionAxis-LowellTherapeuticsMember"
      decimals="-5"
      id="c81619784"
      unitRef="USD">1900000</us-gaap:AcquisitionCostsCumulative>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050935">

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="16" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="16" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Additions&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance at&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Charged as a&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance at&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Beginning of&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Reduction to&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;End of&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Period&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Revenue&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Deductions*&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Period&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Sales &amp;amp; return allowances, discounts, chargebacks and rebates:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year ended December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;668&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,012&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(900&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;780&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year ended December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;645&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(138&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;668&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="16" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;* Deductions to sales discounts and allowances relate to discounts or allowances actually taken or paid.&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
  </srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <acrx:ValuationAllowancesAndReservesTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2050936">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 2.5%; margin-left: 2.5%; width: 95%; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="16" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;SCHEDULE II: VALUATION AND QUALIFYING ACCOUNTS&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="16" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;(in thousands)&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Additions&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; width: 48%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&#160;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance at&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Charged as a&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Balance at&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Beginning of&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Reduction to&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;End of&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition" style="vertical-align: bottom;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&lt;b&gt;Description&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Period&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Revenue&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Deductions*&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;Period&lt;/em&gt;&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Sales &amp;amp; return allowances, discounts, chargebacks and rebates:&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year ended December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;668&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;1,012&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(900&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;780&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Year ended December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;161&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;645&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;(138&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td class="GFJY4-DIN-com-rdg-thunderdome-client-resources-CssResource-html-element-highlighted" style="width: 10%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;668&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td colspan="16" style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;&lt;em style="font: inherit;"&gt;* Deductions to sales discounts and allowances relate to discounts or allowances actually taken or paid.&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </acrx:ValuationAllowancesAndReservesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"
      decimals="-3"
      id="c81619788"
      unitRef="USD">668000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"
      decimals="-3"
      id="c81619789"
      unitRef="USD">1012000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="d_2021-01-01_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"
      decimals="-5"
      id="c81619790"
      unitRef="USD">900000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2021-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"
      decimals="-4"
      id="c81619791"
      unitRef="USD">780000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"
      decimals="-3"
      id="c81619792"
      unitRef="USD">161000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense
      contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"
      decimals="-3"
      id="c81619793"
      unitRef="USD">645000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="d_2020-01-01_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"
      decimals="-3"
      id="c81619794"
      unitRef="USD">138000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember"
      decimals="-3"
      id="c81619795"
      unitRef="USD">668000</us-gaap:ValuationAllowancesAndReservesBalance>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#c81619167"
          xlink:label="c81619167"
          xlink:type="locator"/>
        <link:footnote id="f885b942b-4d82-4328-906f-3d3734a0164b" xlink:label="f885b942b-4d82-4328-906f-3d3734a0164b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">In May 2020, upon notification of early termination by Gr&#xfc;nenthal, the Company recognized approximately $2.6 million of deferred revenue under the Gr&#xfc;nenthal Agreements.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81619167"
          xlink:to="f885b942b-4d82-4328-906f-3d3734a0164b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c81618468"
          xlink:label="c81618468"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618416"
          xlink:label="c81618416"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618410"
          xlink:label="c81618410"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618442"
          xlink:label="c81618442"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618446"
          xlink:label="c81618446"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618424"
          xlink:label="c81618424"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618412"
          xlink:label="c81618412"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618448"
          xlink:label="c81618448"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618418"
          xlink:label="c81618418"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618474"
          xlink:label="c81618474"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618458"
          xlink:label="c81618458"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618428"
          xlink:label="c81618428"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618420"
          xlink:label="c81618420"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618438"
          xlink:label="c81618438"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618414"
          xlink:label="c81618414"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618440"
          xlink:label="c81618440"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618432"
          xlink:label="c81618432"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618470"
          xlink:label="c81618470"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618426"
          xlink:label="c81618426"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618422"
          xlink:label="c81618422"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618472"
          xlink:label="c81618472"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618434"
          xlink:label="c81618434"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618436"
          xlink:label="c81618436"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618452"
          xlink:label="c81618452"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81618450"
          xlink:label="c81618450"
          xlink:type="locator"/>
        <link:footnote id="f40de3ee5-5f1e-4028-af76-e4a0b0310e24" xlink:label="f40de3ee5-5f1e-4028-af76-e4a0b0310e24" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">The condensed consolidated balance sheet as of December 31, 2020 has been derived from the audited financial statements as of that date
included in the Company&#x2019;s Annual Report on Form 10-K for the year ended December 31, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618468"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618416"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618410"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618442"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618446"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618424"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618412"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618448"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618418"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618474"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618458"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618428"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618420"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618438"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618414"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618440"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618432"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618470"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618426"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618422"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618472"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618434"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618436"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618452"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81618450"
          xlink:to="f40de3ee5-5f1e-4028-af76-e4a0b0310e24"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c81619790"
          xlink:label="c81619790"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#c81619794"
          xlink:label="c81619794"
          xlink:type="locator"/>
        <link:footnote id="ff222100c-5872-47bd-9e81-c9770f715bf5" xlink:label="ff222100c-5872-47bd-9e81-c9770f715bf5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Deductions to sales discounts and allowances relate to discounts or allowances actually taken or paid.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81619790"
          xlink:to="ff222100c-5872-47bd-9e81-c9770f715bf5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81619794"
          xlink:to="ff222100c-5872-47bd-9e81-c9770f715bf5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#c81619169"
          xlink:label="c81619169"
          xlink:type="locator"/>
        <link:footnote id="fb2165eae-cac4-48dd-b222-f940250826c6" xlink:label="fb2165eae-cac4-48dd-b222-f940250826c6" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-us">Deferred revenue under the DZUVEO Agreement with Aguettant.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="c81619169"
          xlink:to="fb2165eae-cac4-48dd-b222-f940250826c6"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>96
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( 'V+:E0'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " !]BVI4RK_-S>T    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+!
M2L0P$(9?17)O)TU%(71S43PI""XHWD(RNQMLTI",M/OVMG&WB^@#>,S,GV^^
M@>E,E&9(^)R&B(D<YJO)]R%+$S?L0!0E0#8']#K7<R+,S=V0O*;YF?80M?G0
M>P3!^0UX)&TU:5B 55R)3'762)-0TY!.>&M6?/Q,?8%9 ]BCQT 9FKH!II:)
M\3CU'5P "XPP^?Q=0+L22_5/;.D .R6G[-;4.([UV);<O$,#;T^/+V7=RH5,
M.AB<?V4GZ1AQP\Z37]N[^^T#4X(+4?&V:OA6""ENY35_7UQ_^%V$_6#=SOUC
MX[.@ZN#77:@O4$L#!!0    ( 'V+:E297)PC$ 8  )PG   3    >&PO=&AE
M;64O=&AE;64Q+GAM;.U:6W/:.!1^[Z_0>&?V;0O&-H&VM!-S:7;;M)F$[4X?
MA1%8C6QY9)&$?[]'-A#+E@WMDDVZFSP$+.G[SD5'Y^@X>?/N+F+HAHB4\GA@
MV2_;UKNW+][@5S(D$4$P&:>O\, *I4Q>M5II ,,X?<D3$L/<@HL(2W@4R]9<
MX%L:+R/6ZK3;W5:$:6RA&$=D8'U>+&A T%116F]?(+3E'S/X%<M4C66C 1-7
M02:YB+3R^6S%_-K>/F7/Z3H=,H%N,!M8('_.;Z?D3EJ(X53"Q,!J9S]6:\?1
MTDB @LE]E 6Z2?:CTQ4(,@T[.IU8SG9\]L3MGXS*VG0T;1K@X_%X.+;+THMP
M' 3@4;N>PIWT;+^D00FTHVG09-CVVJZ1IJJ-4T_3]WW?ZYMHG J-6T_3:W?=
MTXZ)QJW0> V^\4^'PZZ)QJO0=.MI)B?]KFNDZ19H0D;CZWH2%;7E0-,@ %AP
M=M;,T@.67BGZ=90:V1V[W4%<\%CN.8D1_L;%!-9ITAF6-$9RG9 %#@ WQ-%,
M4'RO0;:*X,*2TER0UL\IM5 :")K(@?5'@B'%W*_]]9>[R:0S>IU].LYKE']I
MJP&G[;N;SY/\<^CDGZ>3UTU"SG"\+ GQ^R-;88<G;CL3<CH<9T)\S_;VD:4E
M,L_O^0KK3CQG'U:6L%W/S^2>C'(CN]WV6'WV3T=N(]>IP+,BUY1&)$6?R"VZ
MY!$XM4D-,A,_")V&F&I0' *D"3&6H8;XM,:L$> 3?;>^",C?C8CWJV^:/5>A
M6$G:A/@01AKBG'/F<]%L^P>E1M'V5;S<HY=8%0&7&-\TJC4LQ=9XE<#QK9P\
M'1,2S90+!D&&ER0F$JDY?DU($_XKI=K^G-- \)0O)/I*D8]ILR.G=";-Z#,:
MP4:O&W6':-(\>OX%^9PU"AR1&QT"9QNS1B&$:;OP'J\DCIJMPA$K0CYB&38:
M<K46@;9QJ81@6A+&T7A.TK01_%FL-9,^8,CLS9%USM:1#A&27C="/F+.BY 1
MOQZ&.$J:[:)Q6 3]GE[#2<'H@LMF_;A^AM4S;"R.]T?4%TKD#R:G/^DR- >C
MFED)O816:I^JAS0^J!XR"@7QN1X^Y7IX"C>6QKQ0KH)[ ?_1VC?"J_B"P#E_
M+GW/I>^Y]#VATK<W(WUGP=.+6]Y&;EO$^ZXQVM<T+BAC5W+-R,=4KY,IV#F?
MP.S]:#Z>\>WZV22$KYI9+2,6D$N!LT$DN/R+RO JQ GH9%LE"<M4TV4WBA*>
M0AMNZ5/U2I77Y:^Y*+@\6^3IKZ%T/BS/^3Q?Y[3-"S-#MW)+ZK:4OK4F.$KT
ML<QP3A[+##MG/)(=MG>@'37[]EUVY".E,%.70[@:0KX#;;J=W#HXGIB1N0K3
M4I!OP_GIQ7@:XCG9!+E]F%=MY]C1T?OGP5&PH^\\EAW'B/*B(>ZAAIC/PT.'
M>7M?F&>5QE T%&ULK"0L1K=@N-?Q+!3@9& MH >#KU$"\E)58#%;Q@,KD*)\
M3(Q%Z'#GEUQ?X]&2X]NF9;5NKREW&6TB4CG":9@39ZO*WF6QP54=SU5;\K"^
M:CVT%4[/_EFMR)\,$4X6"Q)(8Y07IDJB\QE3ON<K2<15.+]%,[82EQB\X^;'
M<4Y3N!)VM@\",KF[.:EZ93%GIO+?+0P)+%N(61+B35WMU>>;G*YZ(G;ZEW?!
M8/+]<,E'#^4[YU_T74.N?O;=X_INDSM(3)QYQ1$!=$4"(Y4<!A87,N10[I*0
M!A,!S93)1/ "@F2F'("8^@N]\@RY*17.K3XY?T4L@X9.7M(E$A2*L P%(1=R
MX^_ODVIWC-?Z+(%MA%0R9-47RD.)P3TS<D/85"7SKMHF"X7;XE3-NQJ^)F!+
MPWING2TG_]M>U#VT%SU&\Z.9X!ZSAW.;>KC"1:S_6-8>^3+?.7#;.MX#7N83
M+$.D?L%]BHJ $:MBOKJO3_DEG#NT>_&!()O\UMND]MW@#'S4JUJE9"L1/TL'
M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M64*LO8I++(M3,RX#'@>0#S2#^$\9>C98[:,SD'MVUHZ<MY:F+4-F)MD-N!6
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MF8EP=/XK6G/1J3PQJ!RLT48L-R]<@SX^N VLF;CO;E4EZDYL^ANM?6M_<[O
ME\ON@M-HOXG)Y3(FCB\P_,^7O>.AB_ZJ^#<J[LM& O]?0W?1Q126ENAO7_L7
MQ;?=?>2**\7K[G'#*(RS%H#O:\[5\XON8'\'/O\/4$L#!!0    ( 'V+:E09
M;(*/4@(  &0&   8    >&PO=V]R:W-H965T<R]S:&5E=#,N>&ULE95;C]HP
M$(7_BA7U85?:DANW74&DPJIJ'RJA16V?33(0"\=.;8=L^^L[=D($"PC@@=C.
MG./SY3*9U%)M=0Y@R'O!A9YZN3'EB^_K-(>"ZIXL0>"9M50%-3A5&U^7"FCF
M1 7WHR 8^@5EPDLF;FVADHFL#&<"%HKHJBBH^CL#+NNI%WK[A3>VR8U=\)-)
M23>P!/.S7"B<^9U+Q@H0FDE!%*RGWI?P93ZP]:[@%X-:'XR))5E)N;63[]G4
M"VP@X) :ZT#QL(,Y<&Z-,,:?UM/KMK3"P_'>_:MC1Y85U3"7_#?+3#[UQA[)
M8$TK;MYD_0U:'A<PE5R[?U(WM0,L3BMM9-&*,4'!1'.D[^UU.!"$_0N"J!5$
MMPKB5A [T":9PWJEAB83)6NB;#6ZV8&[-DZ--$S8N[@T"L\RU)ED+H66G&74
M0$9FE%.1 EE:.TT>%E2!,#D8EE*N'\EG\HGX1.>XK">^P>VMB9^V6\V:K:(+
M6[U"VB-Q^$2B( K/R.>WRX-CN8_0'7G4D4?.KW^1O"CP.<(KG&Z?2$D5V5%>
M 7E@@F22<ZHT*4$UN(_G<!O_D?.W;\LN"7I!@&B[0ZIK54?AXRY\?$?XYHX0
M6IE<*O8/[Z2%:%;/)F_,AP>9\*UO?A_2WU)Y1-#O"/KW$S"MJ^OI^R>9PG@X
M#I^'_=&']*>5S^-QB 3C\^$'7?C!_>&Q1VI#1<;$YAK!X&:"T\H+!/Y!#[#]
M]P=5&R8TX;!&:= ;H9-J>EHS,;)T;6$E#389-\SQ,P#*%N#YM91F/[&=IONP
M)/\!4$L#!!0    ( 'V+:E29"D<M%04  -D2   8    >&PO=V]R:W-H965T
M<R]S:&5E=#0N>&ULI5AM;]LV$/XKA%<,+9#&(F7)4N88:)P-*[!T0=-N'X9]
MH"7:$B*)'DDYR;_?D5(D1Z+8H/UB6_+=\7F.]T:N'KBXEQEC"CV6124O9YE2
MAXOY7"89*ZD\YP=6P3\[+DJJX%'LY_(@&$V-4EG,B>>%\Y+FU6R],N]NQ7K%
M:U7D%;L52-9E2<73%2OXP^4,SYY??,[WF=(OYNO5@>[9'5-?#[<"GN:=E30O
M625S7B'!=I>S#_AB0Y9:P4C\E;,'>?(;:2I;SN_UP\?T<N9I1*Q@B=(F*'P=
MV885A;8$./YKC<ZZ-;7BZ>]GZ[\9\D!F2R7;\.+O/%79Y2R:H93M:%VHS_SA
M=]82"K2]A!?2?**'5M:;H:26BI>M,B H\ZKYIH^M(TX4<#BA0%H%,E183"CX
MK8)OB#;(#*UKJNAZ)?@#$EH:K.D?QC=&&]CDE=[&.R7@WQSTU'K#*\F+/*6*
MI>A.P1?LD9*([]"&EQ 9F=ZR(T-_<"G1>_3U[AJ]??,.O4%YA;YDO):T2N5J
MK@"+MCA/VG6OFG7)Q+J8H!M>J4RB7ZN4I2\-S(%$QX0\,[DB3HO7+#E'/CY#
MQ"/8 FCS>G7/ <?O'.L;>_Z$O<_LR*J:73A,+3I3"V-JX39E<W*C&!A%G;''
M-8EPM)H?3XF/A8(%#CNA%YB"#E/@I/?G@0FJ\FJ/$BXA7B *$'N$XB*9='$.
M._NAD_,&K.H@W'.>2@0AFMKH-S;"$V;^,O '],="H><3._UE!V_YC2V1C(HD
M,[Q3V)^"'W3BV$ N1^LOO#@8@+0)X:4=9-2!C)P@[Z XP@Z=H3VK8+<* Y:F
M4$5RJ?3N':TQ%8V=ZL7^$+!%*O1]SXXX[A#'3L1?N *8W!%;-L#Q&$JTC(9A
M,)9:A/XRM@/&7E\_/2=D4Q=W@I?/L*&@6LNA-UK_O1_$X="O-CF(E]"? 'I2
MZ+$[8U7&!%3MA)?.JH1);Y$XJ7^L%!,,\K3='"MM,J9#2(R'K"UB$$W!!.F^
M"&/_=1 ;WB:4^(DCSE#%K$G;VCT%A,EBB'HL%$13&]57>^PN]Y]X]3ZA,@.(
M+\'#U%/D=)L7N7J"$:HP/5MQ)&G!=*W<U:H6# G^1 N5VW.E7?ME=OO#CF&3
M\O%$<N.^9^#@->E]XG\KQ&"T>+0<!<Q8*(BB"8!]T\'NKO,)YN9")_26P83,
MGAVOZ..$-\>]!9+:BT>!8I%;>-"K)@#W;0B[^]"MX,?<C-2 ]]MPQUUF5'XL
MC6@"9-^&L+L//7O5"FG<1XP'XR$NBYSVX%3][CL.=K><EU/N),QX-$/985KD
M'#!)WV:(N\UTD0E-!LF,"I/QL-TE[#V<$I+[,WV<R9-F(LF+6A>'MS"DI[PH
MJ#A1?&<CV"X?G0+WSLF0GUUL,3&HD+XY$>P>530PB6H)H $S\#K49@*HOHOW
MSS]%!.-?)&/H$U<,X<"XPNA+.W\\KO<XCD*/A.'0!V/1*"#!TO,FZ@_I.RIQ
M=U1(Y[1.%/KGAI5;)OYU'8OZ'DA^^"1"^N9$OOLL0L;G#.QYPP)CD2(!P1.>
MZUL+<;<6.,?"2 NNTV'0C#H;'?A;WLQDKW)IWR=(^,,N[6LX^=998MJER[%+
M(SR<;"U2)(J'O65^<DE0,K$W=R<24JFN5'/*[MYV]S,?S*W$X/T5OM@TMRR]
MF>;2YX:*?5Y)5+ =F/3.EP!)-/<HS8/B!W,5L>5*\=+\S!A-F= "\/^.0[:V
M#WJ![C9K_3]02P,$%     @ ?8MJ5-!22L&K!@  '1X  !@   !X;"]W;W)K
M<VAE971S+W-H965T-2YX;6R]F5MOG#@4@-_W5UBSU6XK=3+8W+-)I#8ST5:K
M5E'2=A^J?7# DT$%/ 63R[_?8Z P8&/2R^Y+,L YQ^=B'S[CDWM>?"YWC GT
MD*5Y>;K8";$_7JW*:,<R6A[Q/<OAR987&15P6=RNRGW!:%PK9>F*6):WRFB2
M+\Y.ZGN7Q=D)KT2:Y.RR0&659;1X?,U2?G^ZP(NO-ZZ2VYV0-U9G)WMZRZZ9
M^+"_+.!JU5F)DXSE9<)S5+#MZ>(5/KZP+:E02WQ,V'UY\!O)4&XX_RPOWL2G
M"TMZQ%(6"6F"PK\[=L[25%H"/[ZT1A?=F%+Q\/=7ZQ=U\!#,#2W9.4__3F*Q
M.UT$"Q2S+:U2<<7O_V1M0*ZT%_&TK/^B^U;66J"H*@7/6F7P($ORYC]]:!/Q
M% 72*I"1@NU-*-BM@CU2(/Z$@M,J.",%;$\HN*V"^U0%KU7PZMPWR:HSO::"
MGIT4_!X54AJLR1]UN6IM2'"2RYEU+0IXFH">.#OG><G3)*:"Q>A:P#^8-J)$
M? M7//J\XVG,BO)WM&;;)$H$6J(/UVOT_-D+] PE.7J_XU5)\[@\60EP1QI=
M1>W0KYNAR>30609SJQX&?7K+LAM6_*,Q<VXV\RJ.$SE):8HN:1(OP:ESND\$
M7!N,KLU&KYB 50DIV= B3_+;TF1K8[;UGH,O0[455*DK%>E*16H[SH2=US2E
M><30<XBPW-&"E2\0%5"8Z C9^"4B%@YU56BL>K55V6CNSOS0]6ULX9/5G<8?
MN_/'?I(_3_&AL>0.?.A&;ZJLBMBNYUDCL;4JMK3# %O>4&ZCD7.P@P-]S$X7
MLV.,N9ZL2]G*8A3Q#/I[2>7DT\7L*!Y8HY =I3*.0YQ1P*K0R,QFQLP@4+<+
MU#4&>L5*4221[ IEO4"K/(&V< >WX=;!%-1%[BH.$=?Q@@F7O,XE[_M=TKGA
MS1; F\OM>E9B8Y(8Q.EW<?K&.-_3![2GCTT?+EA:MV;!VX3#^T'L=BR-$6 %
M//[&G/BS.?&5>);!:'&M59EQ5LQ6!GD)NKP$QKR\ \[:%SQB+"[1MN 92LJR
MJEL0O*VBYFW29 &F9\3SO*47F3'$OE2)>$3;) >-NJ//3.) B0 'GN-8H:L/
M(^S"".=;"'H#KD/1UE4!OJ!+5B0\?HD^TK1B+]$[ +):0/M6#942XG$O#=4%
MB.V#WM=4494:5U%KQ_;U"<!6SQR6,05OINI6[>'GYOKR$NVK(MI!FYVK4CO2
MH8NV8V$RT>?Q 1?AG^6CUB\\N]!:D8'K/AG52",T+M*,G6'\/6Q@,VW(U9;R
M4L]U9#XXE3K&K54CLG0L>PP&FWFY88@]O^"G <PT4!%+&[ZM.!0& 8;-W-2L
MZ_$"F_E"SU03;JB $0;C,JAL8 ?$.UC";2U4N:5C!T[@CHNA$71=WQT5]V(F
MSD_X'P,1XYY2L!E3OH7'6E/&6:N2BZ,BJ$9*69,SAH;A]@2$?P"!9ENE2BI.
M$/AXXGV&>U[!9F#Y9C##\Q2"9Q%C/2^R,8H,H^TI!)LQY#_%LW9L8V94,%D2
M1YFCJI22G!E#P_ST>(/-?/,_8QI6&07>?A9VO8E7(.DQA9@QY8=)K;4_V-..
M.S11 <9Q/'_,:AJQ<3VUEGP\0=VD)R'RTTAHKEA$1142^J$[,>G(P:<1,ZW\
M(*V1>: A*H78!U]0VBK-4L]FQLXP_AYEB!EE3+1&5%Q1@IL566M$EK9KA6-:
MFY<;AMBC$3$C@[FOW-.BH+(C/Z6G:+,T_[F&J.SC'K:9-E'S'VPT8[G3_:J'
M(6*&(?,B8 ^LB)*R?MK<YGN9H]D.2U26P2$ ^#BH.;%A5#WS$#/S?&=4VDC4
M+T)X7&,5DO#XZX=&1JFP9J2);3/I.8N8.>L)^Q6L#5NE(&Q[ 0X]9\JGGH:(
MF88F-BQZ/U2XP>.=R+E&R+%]UQU_%M7(+1W?=@-G7 J-((B%4Q-3@L[P>W@/
M#+89&)1=3?OQVZSU?L=DRXIA[U+O8@X.9&[:[#:'C+0^EH$TUR<1W=X0P5L-
MW3"6HQC@Y [4ZNXHP"RMXD3::5L?36&-=$<\C3FQ@]+)T7Y)\BBM8I"&Z265
MSV$_1?/'WWX-"/;_*-&K/*_ PA7;\T(@6'OR: ]A:_E7S;I2Y9'1 K%<&E'<
M/-)M^%8')U<9*V[K,\82DE#EHCF)Z.XVYY@;?'Q1'_>-[K\BX?$%U$Y] NG_
M>O2YZH=H#D[?TN(V@0Z8LBT,9QWY,$N*YBRRN1!\7Y^=W7 A>%;_W#$*>98"
M\'S+N?AZ(0?H3H3/_@502P,$%     @ ?8MJ5)A),[^P"   ]",  !@   !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6RU6FUSXC@2_BLJ=NMJIFH9+,DV,)ND
MBA"R2U4"7$AF/ES=!P4$>,>V6,GD97_]2K9!8+TDV:O[$@QIR4^WNOOI;OOL
MF?$?8D-I 5ZR-!?GK4U1;+]V.F*QH1D17]B6YO(_*\8S4LBO?-T16T[)LER4
MI1T4!'$G(TG>NC@K?YOQBS.V*](DIS,.Q"[+"'^]I"E[/F_!UOZ'NV2]*=0/
MG8NS+5G3.2T>MC,NOW4.NRR3C.8B83G@='7>&L"OPRA0"TJ);PE]%D?70*GR
MR-@/]66\/&\%"A%-Z:)06Q#Y\42'-$W53A+'G_6FK<,]U<+CZ_WNUZ7R4IE'
M(NB0I=^39;$Y;_5:8$E79)<6=^SY=UHK%*G]%BP5Y5_P7,L&+;#8B8)E]6*)
M($ORZI.\U(8X6@!CQP)4+T#-!:%C :X7X%+1"EFIUA4IR,499\^ *VFYF[HH
M;5.NEMHDN3K&><'E?Q.YKK@8LERP-%F2@B[!O) ?\HP* =@*#(G8@&MYS@*T
MP</\"GSZ^3/X&20YN-^PG2#Y4IQU"HE![=19U/>[K.Z''/>#"-RRO-@(,,J7
M='FZ04>"/VB ]AI<(N^.5W3Q!6#X"T !@A9 P_<O#SQP\,&@N-P/NPPZF/\.
MKF^FW^?@^FYZ"Z:ST=W@?CSY#0R&]^-OX_OQ:/[5<Y_P<)^PO$_HN,]$AGC*
MA/4(JI51N5+%\=-%&T=!OW_6>3HVC$4L#'!7BYT BP[ (J\!!LL_I-M67E0P
M&>H+EB^2E(*\1JQ^5=<+Y5\[(?U.NI3,2YP42;ZN CLI$BI\9HH/:&*_F5C>
M+F_$V2M)BU>)YXGF.RH_T]+G%<3Z7QF3L)*_B,HO-K-6=XJ/[=7##9M:9%"(
M[!;M'G3HOD^')"\HIZ*0%PN642#38)J0QR1-2L4^K%#7!(L#W&NH9)/",+#K
MU#OHU//J=$4EZRP24N7R? E(QK@/:\]  ?O=IO4M0KT(VY'V#TC['[0^?9$D
M*DY<:$D?"[!*<B)=/5_;\/<-:-T8-N";,C"('>$( YWA Z\"\X(M?K05URV!
M=!N%W6GE>JMC"&$<-!.'32I$H0/H$15!+]!Q+D.S8/P5)-F6)%SE$+#8$+ZF
M5JS00-$[<LL:JBG4A8YXA$@C15ZDTV)#N143,H,%&A%ED\*ARWZ:>> ;U+,A
M^9J*1CH5@LI,K$)LGRO>2*U04Q#T<]!@L6 [E>=E*-/DB3RF]H,*37?I1DV;
MF$)M%#AB%VHR@M&[?$KJ;(466>[:-["94OVHZX"FF0GZJ6G&J?3RY3Z=5&?$
ME&?5AV8%;"&8?F XF"D5'V6;4\":AJ"?AP['O26OSK,VV0+"9IZS"04P=N#3
ME +]G"+Q\1T]\7,K1),END:&,V7:\5$<GR+45 +]7#(]A&5*93Y^$ZE)".TP
M[#:Q6J1Z/8<UD:8-Y*>-*[JBG$MSUA63#2 RB0#"7M,;+5)M#(^B[!2AY@OD
MYXO)>XI(*VR3%&3A$P2H"=PFUXL"%W+-'PA]J$D83[Z-YA]H$I#F!(3]26;'
M)8-*5Y,-W98K \FZ4"4:^N<NV2J&M1H(6VBLAYJ>9Q>+7.;1O(+\O'(,.I$)
MO&XGK$@MM-$-PJ@9T#:Y,(RA(RDB33#(3S SSA:4+@58<98!0=)WH38)!?7[
M<1.S*>6HNI$F'?06Z1S#S4BQXV68O >T22HA[IO1;HKU@M@9,YI]T!M=T#[:
M/]7A_EDY]%.RE%\>7VOP[XA]2SN#8HB:K81%#H<0.ZIQI$D*]3X4^M?CR6 R
M_$#H:[)!?K*9D=>R@I8GF[)\W9;=2U8V*E:S6$D$&U:Q,5(<.VHAK,D&^\E&
M'>[VQ#43(7:RFRJC278MLI4%0C4R*L\O6)[78\#GI-B4N4RFM4/_93UX;&M:
MNK 9=!8Q!#%V::C)"K]-5FX-GPGG1)56_U@[DZJB*&X2FD7*D5&PYC+L[X4^
M<'3%AK/=^J#1-B6Y71FS/\*PF6=L0EU'9X>/IG=^OKPG+ZJ\K<971PV^D&VH
MS)+J0#8T78(5XT - WBR4!*5?KL\D:M4'FI.-FN]+'R)PB95V:1<Y1S6G(K?
MGA>6Z?,X:1Y\ZHVDB2T='(Q@V$1NBL&X'[FP:X[%?HZ=C.[!IZO1\&XTF(\^
MRVJINI(70*737\J_8/3OA_&WP<UH<C^WZF!I]>!)!5 K8<I!%/5=<:*9%_N9
MUXX4_.NG'H+HUTNZ3O)<G80,FE=*K-,%;%(KZJ*N<0RFF%2TYY@O8,W V,_
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M&X2"S+KM.68(Q30B#7C925&*^"G55\U\%!ICISO1&2#V#YQ$?034'U&1)>8
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M!U2YF%H_-T)H-2L .D45)?&,%&^R':.4?!9PG/'21_K)N(K4#WJJ44\B*W<
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MH@V*)B!_(?'3N1K0!KO+OZM_ %!+ P04    " !]BVI4I8<M^,0"  #J!0
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MUCOP^=SP)]]N_ 7[]C[^!U!+ P04    " !]BVI4C5[ $0L#  !M!@  &0
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M+T$DGWR*5T62,YTU)) !U6=HA\=];EJFDZ0R!L_UVTP:ZT"EZ&+ /O UB^+
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MDTLM2YFS?FY8N65]J6^,N@E)38)>#'G%[$ O_Q&A62OA"!]U;YF210,(:%>
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M!0J3&/!^UN&>.2QH@_&GEK/_ %!+ P04    " !]BVI4Q$S![+8#  #-"
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M(<09?( +SDV#.=P(MA%2.(%V'CI*X1U#OH=;=7#)&W!Q K=:N=+"1Y5C_B]
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M>O/\)/$:>1?ZO0[D6=X[P>L?RNU'7O]$N0Z\@5NAF>:"27CTS*-Z6_ K_N#
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MMT<<EG1=HPT&M+\T)(+=) 0X_ %,_P-02P,$%     @ ?8MJ5&N)=NPK P
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M=_/V<+1D@J[N+U:4'VE"V$J3A(+FC$MG.I"1;%[ #J2>T)JE.^-5UK2F:Q_
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M^XZ*Q733PP<4;V"S#R:U]Z^93D\ZKNIDA5"CK>N2>B0YAUI#Y$JE;O1;K[_
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M%O0 JYSMB^#&1%)8OFNQ\,&E^5NRG1K,Z+Y<X[YO%LF+UK68HB\SBP9P.@N
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M<+4!UY<,;SOE1!FH_@:8_@502P,$%     @ ?8MJ5"NR5V9= @  ^00  !D
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ME*7!T(IKFL2HG0+=+Q6]YMW&.>AG^_0_4$L#!!0    ( 'V+:E3C$]_\@P,
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M:AJ, BAPR1IA;]3Z"V[JZ3N^7 GCO[!N8P=Q 'ECK*HV8%)0<=G^V=.F#UN
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MR92J*[N'J!MHT=CFOQ::GA)K[NCM1FDVT/I&4%/L!^: X=_ \CM02P,$%
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M(%;T[J'Q"G2_T=0SW<8[Z%_2^1]02P,$%     @ ?8MJ5'Z?!1^9 @  CP4
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MW]9T8Z)V"?2^4O3S#8$K,-[!J[]02P,$%     @ ?8MJ5 Z30#SS P  J0D
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MD%2S8QJ4.(@G+P3QI *[R=8'F5U_'':3Y\)NTAB8B0-F\FS 3!JC+G&H2UX
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M$_DYX\(;#=S:G1H-9&DR+O!.@2[SG*F_8\SD=N@%WLO"/5^GQB[XHT'!UKA
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MG%^0(E5U[VIB9.$:X%(::J=NF-*#A\H:T/Y*4A.L)_: Y@D=_0-02P,$%
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M#V "<C6?+Z(D^T\VQM9N$#]-E(@-&#V(0Y[_LD<CQ!Z@18\ 6@;0^@I G2.
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M8FLWT"R2B@<)6"L(:+CY)4])(#( [)8 G 3@U 4T$T#S!< ID^0F /<E )<
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M-<#-K*KW0M4PLG 5="D-UD'WF>(;"Y1UP/Z5Q"I:-^P S:MM^AU02P,$%
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M ^#[@D.E*SNZ<%87J\D_4$L#!!0    ( 'V+:E0FB53 _0,  .P,   9
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M8%T!E J@(P'H5@AXJ8!W+% U0SL5:!^;U*T0\%.!9#%;NV ED1YAB0=]SM:
MZ]%*F_Z0+%<BK0),(YU9$\G5MU3)R<%7)@EP7? '^(DYQY$4X,.(2$P# ;Z1
MC8QQ\+'?DFHF/;XU3;5>[;3"2JU/3>!V+@!TH/M],@(??OOX&V@!L<2<B-UK
MB=9A':WMEVH=V;6.R+0)D'N@M43+=7TM3JJETJ*Q7=<-W@+D:%5NK^#FEI>I
M;:EES]8>9FL/DWF\BGDFDDT?P1<A8C(#HYC3: 'N"*=L=@%^X" F%^"K*@W)
M@-+ [M2W$_6ZA#T-/*_C^H[C]%M/^=@5!T(7H4Y^X($'*/, 63VXXVQ*R$R
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MIS0)@Y5H9Q]R^@#Y94HD:N<4+_.27=Z) %OVPP/&K$=B;GAD,+&@*1L69:N
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MD,ANA]F+XBMS7YIR1;<O\[BD&S4*;4#S<TYWIOQ%7\&*.WK_+U!+ P04
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M1U,255>J)HHO;6&?<:7;A!WFNI&C, %Z?\YU<:\GY@#W:3#\!U!+ P04
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M3=OG7E>F,P=I 69](4RSU@[L!EVO/_T/4$L#!!0    ( 'V+:E3;K*J^(P0
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M4VZJ/83V\6HKYBL5"PV%4ICKH=X@U'E%M;M1G2A>E#L*SUPIGI6'2Z )"/.
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M*F:F&]+O!LIL <VO!96@(LA>4/[ C'\#4$L#!!0    ( 'V+:E2XL#JE#@,
M (0*   9    >&PO=V]R:W-H965T<R]S:&5E=#<R+GAM;*U676_:,!3]*U:D
M2:W4D@\^"A4@%4JU/;!5[=9IFO9@D@M8V'%FFP+_?M=.FD('*9MX26S'Y_B<
MZ^OX=E=2+?0<P)"UX*GN>7-CLFO?U_$<!-4UF4&*7Z92"6JPJV:^SA30Q($$
M]Z,@:/F"LM3K=]W8O>IWY=)PEL*](GHI!%6; 7"YZGFA]S+PP&9S8P?\?C>C
M,W@$\RV[5]CS2Y:$"4@UDRE1,.UY-^'U,(PLP,UX8K#26VUBK4RD7-C.IZ3G
M!581<(B-I:#X>H8A<&Z94,?O@M0KU[3 [?8+^YTSCV8F5,-0\N\L,?.>U_9(
M E.ZY.9!KCY"8:AI^6+)M7N253$W\$B\U$:* HP*!$OS-UT7@=@"1,T#@*@
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MV&*!L@:X7TBLHMW$'M W;:O_ %!+ P04    " !]BVI4'CW8JW0"   .!@
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MS/NY,/U=<6,G*/\>&/X+4$L#!!0    ( 'V+:E2%3'SV[@(  *8(   9
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M90Y4"#\*@I%?,%YZ\ZD;NU+SJ:R-X"5>*=!U43#UL$ A=S,O]'X,7/-M;NR
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M)<$U<[K'H;(+:'XCZ6AO.O:FT-X,Y_\ 4$L#!!0    ( 'V+:E3S<*"[# ,
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MU N[4BSERZJ_3!L!&'N L].B$*L/@L]DQNS@#PXX&M"UGS?/%;\WT:!4IL;
M%/'NF-)\NFGYH6AQPY9Z74[+%-?</4+-_S;/,R:9HF)3M*G]EYSE)RNN]P7/
MH;FZK>PJ=HH,>R]?8[T7>NDBHV,0>133W3\&D?$1B.P]VUWS$7>@HTAD< PB
MNR]2I%_O*3<VKEO;UL;JP>O!D'R%%Q+1!O4F"RXTEW5OSI.$R0>[5T.OZ<2\
M^F_QF^L3EM*%T#<-."1M^PM+^"*+FZNN(!'U56W[,PS/;(77[R8F%I<)6[)D
M7'?5;%(U/=,P4>L#'':1R^IP(YB/Q=P(8%@<3 'F8[VP./_3>/KH>"R&:>L[
MD3[JTT=]K)<+&5<?+([;)S:'>Z1Q'(91A&5T/'8J&&-YBR+XNMDP;>"!Q8%(
MC\LU/MMXA>RO VQ.]U4(-E*\$K&1XKD&Q)TW\(AC]VQC<< #FP6L=B"^.P[4
ME-LG#&%6,6W8"L:1.,80J$5WC481DIT(/N[YP59)&,:Q&P',K2 ,,016(XY@
M"D #AH1A]1S<>1[YZ^>4W_X?/OH#4$L#!!0    ( 'V+:E27BKL<P    !,"
M   +    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8
M$@6*19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*N
MU"P>-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I
M2$LS#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3
MZ:]C(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ ?8MJ5 QK
M;BK[!0  "C8   \   !X;"]W;W)K8F]O:RYX;6S%FUMOVS84@/\*X9>EP#);
M=Z=H"G1-NP7HVJP.LL>"EFF;B"1Z))5>?OU(J48.$_-@+SY^2G2Q_.E(Y'<.
M2;_ZJO3]4JE[]JUM.G,YV5J[>SF=FGHK6FY^4SO1N2-KI5MNW:;>3,U."[XR
M6R%LVTS3V:R<MEQVD]>O]M>ZT5.XH:RHK52=V^EWW$GQU3P>]YOL01JYE(VT
MWR\GP_^-F+!6=K*5/\3J<C*;,+-57_]46OY0G>7-HM:J:2XGR7C@3F@KZV>[
M%Q[REB_-L,?RY6?N0"XGY<Q=<"VUL<,9P_6Y8WP0[N1QJ[?JO6RLT%?<BC^T
MZG>RV_C+N+N8@ML8XK#_.P;QI?X_853KM:S%E:K[5G1VC*,6C0?LS%;NS(1U
MO!67D_TI[$VW8N\ZZX+$KKOQ4NY<?Z?NJZ]7XUU;APMBJ%]*=T!?KP;PXT&^
M==NJD2OW[2OV.V]X5PLV!-< P!0!3$\&R,YN.(#,$,B,$'+A(?P'#%-K]E:U
M.P"9(Y#YR2 75M4 LD @B]-%DILM@"P1R/*XD!]=S\@2=LX^Z0WOY(_A#,9=
M,U_T;0O?R0J!K @@4P=YW3T(8\<P>L;W7&IV!R#G".2< #+["=E9IPEA?F4?
MA05X%PC>!0%>[O"<#'=.5=^' +[[MY<[_TG8A<^P/GQ&@%D,43QOW$<Z(]B;
MC1;B*20JFB.;9H L?:/I[7-*:)L$TTUR9-\,F)7#_"S<&]D+]EZKUO7BG=4N
MTP@P,>$D1S;.@#EWF!]4MSEWZ4[+KL0R>-B8:I(CNV; N_!X@AL11 V32W)D
MNXP=]\QS23[FK>XY-X-LK&(0$]-+0N(7+YA_N-;\2>O G))02"7Q5G%Y32N!
M57P+D1 3LTI"H97$>\5G-O=;U:R$-K\,/;?]#BDQN204=DGR/:7+;HU8#0FC
MZQLY;,LI9I>4PBZ)UXOSLNMOC&$W0KL<G&OA\C*(B?DEI?!+X@7SIJYU[R*Y
M;^,RZ(!2M)BAL$OB]9+/DK/[%^S&%300#G-*2N&49#[D$;5J!;OEW\+084I)
M*922>*<L^J41__:^M'[W\"1W2#&]I$?6R\)=8]4W@EU?.\P[WO2/E<'?/:P+
M4DPOZ9'ULI";3KISN1^;J&O5NYZ[V[ ;5W?53]H*YIJ4Q#61*NM+"C$QUZ04
MKHG562$F)IN40C:'*BUV=LN7#1Q'P6234<@F5G$%T<PPV604LHE5"2$FIIN,
M0C?/JX3QD0<M/4-'SRC$\U@M[/%>0#Y,/1F)>B)E0_BT,?UD)-5-))\,,3']
M9"35322?##$Q_60D^HGDD^P,8F+ZR4A*G:=)V\$FA.DG.[)^T-0H>.@YII^<
MI-:)Y1P9Q,3TDY/4.C','&)B^LDI]!--C8)H8OK)*?03Q0RBB4[?4%@HBEE
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M;W!S+V%P<"YX;6Q02P$"% ,4    " !]BVI4RK_-S>T    K @  $0
M        @ &O    9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    " !]BVI4
MF5R<(Q &  "<)P  $P              @ '+ 0  >&PO=&AE;64O=&AE;64Q
M+GAM;%!+ 0(4 Q0    ( 'V+:E3T'MH=?@8  )8<   8              "
M@0P(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    " !]BVI4
ME(:YOB$'   /'P  &               @(' #@  >&PO=V]R:W-H965T<R]S
M:&5E=#(N>&UL4$L! A0#%     @ ?8MJ5!EL@H]2 @  9 8  !@
M     ("!%Q8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (
M 'V+:E29"D<M%04  -D2   8              " @9\8  !X;"]W;W)K<VAE
M971S+W-H965T-"YX;6Q02P$"% ,4    " !]BVI4T%)*P:L&   ='@  &
M            @('J'0  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#
M%     @ ?8MJ5)A),[^P"   ]",  !@              ("!RR0  'AL+W=O
M<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( 'V+:E1Z=HX3+1\  &M?
M   8              " @;$M  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q0
M2P$"% ,4    " !]BVI4VKNA>G4&   (%   &               @($430
M>&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ ?8MJ5*6'+?C$
M @  Z@4  !@              ("!OU,  'AL+W=O<FMS:&5E=',O<VAE970Y
M+GAM;%!+ 0(4 Q0    ( 'V+:E2-7L 1"P,  &T&   9              "
M@;E6  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ ?8MJ
M5'#>4CI< P  00<  !D              ("!^UD  'AL+W=O<FMS:&5E=',O
M<VAE970Q,2YX;6Q02P$"% ,4    " !]BVI4U?W&&58%   I#   &0
M        @(&.70  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0
M   ( 'V+:E20<1>]8P@  "P6   9              " @1MC  !X;"]W;W)K
M<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ ?8MJ5.M!)9*@!0  <@P
M !D              ("!M6L  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q0
M2P$"% ,4    " !]BVI44&R20J0%   2#0  &0              @(&,<0
M>&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( 'V+:E38[[U0
MP 4    .   9              " @6=W  !X;"]W;W)K<VAE971S+W-H965T
M,38N>&UL4$L! A0#%     @ ?8MJ5$)-WXD= P  [@8  !D
M ("!7GT  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " !]
MBVI4#$=;[TL#  #[!@  &0              @(&R@   >&PO=V]R:W-H965T
M<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( 'V+:E3^SB)X2 ,  .P'   9
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M970R,RYX;6Q02P$"% ,4    " !]BVI4:_+\L_P$   B#   &0
M    @($4F   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (
M 'V+:E1I'8 EZ0(   P&   9              " @4>=  !X;"]W;W)K<VAE
M971S+W-H965T,C4N>&UL4$L! A0#%     @ ?8MJ5&N)=NPK P  E08  !D
M             ("!9Z   'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"
M% ,4    " !]BVI4RWT?Y(4A  ""<   &0              @(')HP  >&PO
M=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( 'V+:E3_!*;:J@(
M *(%   9              " @87%  !X;"]W;W)K<VAE971S+W-H965T,C@N
M>&UL4$L! A0#%     @ ?8MJ5-KRSNK$!   $A   !D              ("!
M9L@  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " !]BVI4
M*[)79ET"  #Y!   &0              @(%AS0  >&PO=V]R:W-H965T<R]S
M:&5E=#,P+GAM;%!+ 0(4 Q0    ( 'V+:E1+7H&[W (  .<%   9
M      " @?7/  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%
M  @ ?8MJ5.,3W_R# P  )0@  !D              ("!"-,  'AL+W=O<FMS
M:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !]BVI4FXS)Y:P"  "S!0
M&0              @('"U@  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+
M 0(4 Q0    ( 'V+:E2%BNY6; ,  !D(   9              " @:79  !X
M;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ ?8MJ5":_X,C)
M @  'P8  !D              ("!2-T  'AL+W=O<FMS:&5E=',O<VAE970S
M-2YX;6Q02P$"% ,4    " !]BVI4M$]@Q$ &  #$$@  &0
M@(%(X   >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    ( 'V+
M:E0NI-W@C@(  %4%   9              " @;_F  !X;"]W;W)K<VAE971S
M+W-H965T,S<N>&UL4$L! A0#%     @ ?8MJ5'Z?!1^9 @  CP4  !D
M         ("!A.D  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
M    " !]BVI4#I- //,#  "I"0  &0              @(%4[   >&PO=V]R
M:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( 'V+:E0ZO9,U%P,  &<&
M   9              " @7[P  !X;"]W;W)K<VAE971S+W-H965T-# N>&UL
M4$L! A0#%     @ ?8MJ5*CR6#&K P  !@P  !D              ("!S/,
M 'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    " !]BVI4X$6I
MHAH#  #5"P  &0              @(&N]P  >&PO=V]R:W-H965T<R]S:&5E
M=#0R+GAM;%!+ 0(4 Q0    ( 'V+:E1,3>60TP(  ,,'   9
M  " @?_Z  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @
M?8MJ5!VA"JX*!@  MAX  !D              ("!"?X  'AL+W=O<FMS:&5E
M=',O<VAE970T-"YX;6Q02P$"% ,4    " !]BVI4E2$C^2\%  #*'P  &0
M            @(%*! $ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4
M Q0    ( 'V+:E3D^XM9UP(  $X'   9              " @; ) 0!X;"]W
M;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ ?8MJ5(\6#(-V @
M8@8  !D              ("!O@P! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX
M;6Q02P$"% ,4    " !]BVI4B$:_>R$#   E"   &0              @(%K
M#P$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( 'V+:E2>
MZ=AN)P(  +X$   9              " @<,2 0!X;"]W;W)K<VAE971S+W-H
M965T-#DN>&UL4$L! A0#%     @ ?8MJ5(9_I.DS!   4@X  !D
M     ("!(14! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( 'V+:E0'F:\^;0,  ,$)   9              "
M@44I 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ ?8MJ
M5*!NR(#Y!0  Y!8  !D              ("!Z2P! 'AL+W=O<FMS:&5E=',O
M<VAE970U-BYX;6Q02P$"% ,4    " !]BVI4XG7._0($   )#   &0
M        @($9,P$ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0
M   ( 'V+:E2V-X^4*@4  /$2   9              " @5(W 0!X;"]W;W)K
M<VAE971S+W-H965T-3@N>&UL4$L! A0#%     @ ?8MJ5()BGS(1 P  9 D
M !D              ("!LSP! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q0
M2P$"% ,4    " !]BVI4)HE4P/T#  #L#   &0              @('[/P$
M>&PO=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    ( 'V+:E2H(C>R
MQ0,  '@-   9              " @2]$ 0!X;"]W;W)K<VAE971S+W-H965T
M-C$N>&UL4$L! A0#%     @ ?8MJ5!Q.K,C[ @  /@D  !D
M ("!*T@! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    " !]
MBVI4M>LNLS<&  "I(@  &0              @(%=2P$ >&PO=V]R:W-H965T
M<R]S:&5E=#8S+GAM;%!+ 0(4 Q0    ( 'V+:E14VH[K:0(  ,\%   9
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M970V."YX;6Q02P$"% ,4    " !]BVI4VZRJOB,$  !O$@  &0
M    @(%%: $ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (
M 'V+:E3=GIS@, 8  /PG   9              " @9]L 0!X;"]W;W)K<VAE
M971S+W-H965T-S N>&UL4$L! A0#%     @ ?8MJ5,YSA?WK @  S @  !D
M             ("!!G,! 'AL+W=O<FMS:&5E=',O<VAE970W,2YX;6Q02P$"
M% ,4    " !]BVI4N+ ZI0X#  "$"@  &0              @($H=@$ >&PO
M=V]R:W-H965T<R]S:&5E=#<R+GAM;%!+ 0(4 Q0    ( 'V+:E0J!_2UH (
M (P&   9              " @6UY 0!X;"]W;W)K<VAE971S+W-H965T-S,N
M>&UL4$L! A0#%     @ ?8MJ5%LU_6V  P  P D  !D              ("!
M1'P! 'AL+W=O<FMS:&5E=',O<VAE970W-"YX;6Q02P$"% ,4    " !]BVI4
M'CW8JW0"   .!@  &0              @('[?P$ >&PO=V]R:W-H965T<R]S
M:&5E=#<U+GAM;%!+ 0(4 Q0    ( 'V+:E3]8$"G3P0  "H0   9
M      " @::" 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%
M  @ ?8MJ5(5,?/;N @  I@@  !D              ("!+(<! 'AL+W=O<FMS
M:&5E=',O<VAE970W-RYX;6Q02P$"% ,4    " !]BVI4FFQ)MNT"   -"
M&0              @(%1B@$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+
M 0(4 Q0    ( 'V+:E3X:["^JP(  #D'   9              " @76- 0!X
M;"]W;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ ?8MJ5$PD'H]\
M P  )0H  !D              ("!5Y ! 'AL+W=O<FMS:&5E=',O<VAE970X
M,"YX;6Q02P$"% ,4    " !]BVI4\W"@NPP#  !^"   &0
M@($*E $ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    ( 'V+
M:E1G"-HM:@,  !P7   -              "  4V7 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ ?8MJ5)>*NQS     $P(   L              ( !XIH!
M %]R96QS+RYR96QS4$L! A0#%     @ ?8MJ5 QK;BK[!0  "C8   \
M         ( !RYL! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( 'V+:E2K
MG#%+;@(  -HO   :              "  ?.A 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( 'V+:E1$Y-]8'@(  )<N   3
M      "  9FD 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !9 %D 9A@
' .BF 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>270</ContextCount>
  <ElementCount>497</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>101</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Stockholders' Deficit</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit</Role>
      <ShortName>Consolidated Statements of Stockholders' Deficit</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Investments and Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement</Role>
      <ShortName>Note 2 - Investments and Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Inventories, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-3-inventories-net</Role>
      <ShortName>Note 3 - Inventories, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net</Role>
      <ShortName>Note 4 - Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - In-license Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement</Role>
      <ShortName>Note 5 - In-license Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Out-license Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements</Role>
      <ShortName>Note 6 - Out-license Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Revenue From Contracts With Customers</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-</Role>
      <ShortName>Note 7 - Revenue From Contracts With Customers</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Long-term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-</Role>
      <ShortName>Note 8 - Long-term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Note 9 - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-9-leases</Role>
      <ShortName>Note 9 - Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties</Role>
      <ShortName>Note 10 - Liability Related to Sale of Future Royalties</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 11 - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-11-warrants</Role>
      <ShortName>Note 11 - Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 12 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies</Role>
      <ShortName>Note 12 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 13 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-</Role>
      <ShortName>Note 13 - Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 14 - Stock Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation</Role>
      <ShortName>Note 14 - Stock Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 15 - Net Loss Per Share of Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock</Role>
      <ShortName>Note 15 - Net Loss Per Share of Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 16 - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities</Role>
      <ShortName>Note 16 - Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 17 - 401(k) Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-17-401k-plan</Role>
      <ShortName>Note 17 - 401(k) Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 18 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-18-income-taxes</Role>
      <ShortName>Note 18 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 19 - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events</Role>
      <ShortName>Note 19 - Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 2 - Investments and Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables</Role>
      <ShortName>Note 2 - Investments and Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 3 - Inventories, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables</Role>
      <ShortName>Note 3 - Inventories, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-3-inventories-net</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 4 - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables</Role>
      <ShortName>Note 4 - Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 7 - Revenue From Contracts With Customers (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables</Role>
      <ShortName>Note 7 - Revenue From Contracts With Customers (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 8 - Long-term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables</Role>
      <ShortName>Note 8 - Long-term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 9 - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-9-leases-tables</Role>
      <ShortName>Note 9 - Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-9-leases</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables</Role>
      <ShortName>Note 10 - Liability Related to Sale of Future Royalties (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>035 - Disclosure - Note 14 - Stock Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables</Role>
      <ShortName>Note 14 - Stock Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>036 - Disclosure - Note 15 - Net Loss Per Share of Common Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables</Role>
      <ShortName>Note 15 - Net Loss Per Share of Common Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>037 - Disclosure - Note 16 - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables</Role>
      <ShortName>Note 16 - Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>038 - Disclosure - Note 18 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables</Role>
      <ShortName>Note 18 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-18-income-taxes</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>039 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>040 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>041 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details</Role>
      <ShortName>Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>042 - Disclosure - Note 2 - Investments and Fair Value Measurement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual</Role>
      <ShortName>Note 2 - Investments and Fair Value Measurement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>043 - Disclosure - Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details</Role>
      <ShortName>Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>044 - Disclosure - Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details</Role>
      <ShortName>Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>045 - Disclosure - Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details</Role>
      <ShortName>Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>046 - Disclosure - Note 3 - Inventories, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual</Role>
      <ShortName>Note 3 - Inventories, Net (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>047 - Disclosure - Note 3 - Inventories, Net - Inventory Components (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details</Role>
      <ShortName>Note 3 - Inventories, Net - Inventory Components (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>048 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual</Role>
      <ShortName>Note 4 - Property and Equipment, Net (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>049 - Disclosure - Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details</Role>
      <ShortName>Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>050 - Disclosure - Note 5 - In-license Agreement (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual</Role>
      <ShortName>Note 5 - In-license Agreement (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>051 - Disclosure - Note 6 - Out-license Agreements (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual</Role>
      <ShortName>Note 6 - Out-license Agreements (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>052 - Disclosure - Note 7 - Revenue From Contracts With Customers (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual</Role>
      <ShortName>Note 7 - Revenue From Contracts With Customers (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>053 - Disclosure - Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details</Role>
      <ShortName>Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>054 - Disclosure - Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details</Role>
      <ShortName>Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>055 - Disclosure - Note 8 - Long-term Debt (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual</Role>
      <ShortName>Note 8 - Long-term Debt (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>056 - Disclosure - Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details</Role>
      <ShortName>Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>057 - Disclosure - Note 9 - Leases (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual</Role>
      <ShortName>Note 9 - Leases (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-9-leases-tables</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>058 - Disclosure - Note 9 - Leases - Operating Lease Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details</Role>
      <ShortName>Note 9 - Leases - Operating Lease Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>059 - Disclosure - Note 9 - Leases - Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details</Role>
      <ShortName>Note 9 - Leases - Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>060 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual</Role>
      <ShortName>Note 10 - Liability Related to Sale of Future Royalties (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>061 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details</Role>
      <ShortName>Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>062 - Disclosure - Note 11 - Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual</Role>
      <ShortName>Note 11 - Warrants (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-11-warrants</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>063 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 12 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>064 - Disclosure - Note 13 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual</Role>
      <ShortName>Note 13 - Stockholders' Equity (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>065 - Disclosure - Note 14 - Stock Based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual</Role>
      <ShortName>Note 14 - Stock Based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>066 - Disclosure - Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>067 - Disclosure - Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>068 - Disclosure - Note 14 - Stock Based Compensation - Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>069 - Disclosure - Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>070 - Disclosure - Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>071 - Disclosure - Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details</Role>
      <ShortName>Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>072 - Disclosure - Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details</Role>
      <ShortName>Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>073 - Disclosure - Note 16 - Accrued Liabilities - Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details</Role>
      <ShortName>Note 16 - Accrued Liabilities - Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>074 - Disclosure - Note 17 - 401(k) Plan (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual</Role>
      <ShortName>Note 17 - 401(k) Plan (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-17-401k-plan</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>075 - Disclosure - Note 18 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual</Role>
      <ShortName>Note 18 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables</ParentRole>
      <Position>76</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>076 - Disclosure - Note 18 - Income Taxes - Net Deferred Tax Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details</Role>
      <ShortName>Note 18 - Income Taxes - Net Deferred Tax Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>077 - Disclosure - Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details</Role>
      <ShortName>Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>078 - Disclosure - Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details</Role>
      <ShortName>Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>079 - Disclosure - Note 19 - Subsequent Events (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual</Role>
      <ShortName>Note 19 - Subsequent Events (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events</ParentRole>
      <Position>80</Position>
    </Report>
    <Report instance="acrx20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>080 - Disclosure - Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="acrx20211231_10k.htm">acrx20211231_10k.htm</File>
    <File>acrx-20211231.xsd</File>
    <File>acrx-20211231_cal.xml</File>
    <File>acrx-20211231_def.xml</File>
    <File>acrx-20211231_lab.xml</File>
    <File>acrx-20211231_pre.xml</File>
    <File>ex_341620.htm</File>
    <File>ex_341621.htm</File>
    <File>ex_341622.htm</File>
    <File>ex_341623.htm</File>
    <File>ex_341624.htm</File>
    <File>ex_343550.htm</File>
    <File>ex_343559.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="781">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>102
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "acrx20211231_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 37,
   "contextCount": 270,
   "dts": {
    "calculationLink": {
     "local": [
      "acrx-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "acrx-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "acrx20211231_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acrx-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acrx-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "acrx-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 650,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 39,
    "http://www.acelrx.com/20211231": 12,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 57
   },
   "keyCustom": 89,
   "keyStandard": 408,
   "memberCustom": 55,
   "memberStandard": 45,
   "nsprefix": "acrx",
   "nsuri": "http://www.acelrx.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.acelrx.com/20211231/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "span",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 4 - Property and Equipment, Net",
     "role": "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net",
     "shortName": "Note 4 - Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:InlicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 5 - In-license Agreement",
     "role": "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
     "shortName": "Note 5 - In-license Agreement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:InlicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:OutlicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 6 - Out-license Agreements",
     "role": "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
     "shortName": "Note 6 - Out-license Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:OutlicenseAgreementTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 7 - Revenue From Contracts With Customers",
     "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
     "shortName": "Note 7 - Revenue From Contracts With Customers",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 8 - Long-term Debt",
     "role": "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
     "shortName": "Note 8 - Long-term Debt",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LongTermDebtTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Note 9 - Leases",
     "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases",
     "shortName": "Note 9 - Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties",
     "role": "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
     "shortName": "Note 10 - Liability Related to Sale of Future Royalties",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 11 - Warrants",
     "role": "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
     "shortName": "Note 11 - Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:WarrantsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 12 - Commitments and Contingencies",
     "role": "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
     "shortName": "Note 12 - Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 13 - Stockholders' Equity",
     "role": "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
     "shortName": "Note 13 - Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 14 - Stock Based Compensation",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
     "shortName": "Note 14 - Stock Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 15 - Net Loss Per Share of Common Stock",
     "role": "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock",
     "shortName": "Note 15 - Net Loss Per Share of Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 16 - Accrued Liabilities",
     "role": "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities",
     "shortName": "Note 16 - Accrued Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 17 - 401(k) Plan",
     "role": "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan",
     "shortName": "Note 17 - 401(k) Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 18 - Income Taxes",
     "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
     "shortName": "Note 18 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 19 - Subsequent Events",
     "role": "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
     "shortName": "Note 19 - Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "role": "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:BusinessDescriptionOfEntityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:BusinessDescriptionOfEntityPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 2 - Investments and Fair Value Measurement (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables",
     "shortName": "Note 2 - Investments and Fair Value Measurement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 3 - Inventories, Net (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables",
     "shortName": "Note 3 - Inventories, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 4 - Property and Equipment, Net (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables",
     "shortName": "Note 4 - Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 7 - Revenue From Contracts With Customers (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables",
     "shortName": "Note 7 - Revenue From Contracts With Customers (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 8 - Long-term Debt (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables",
     "shortName": "Note 8 - Long-term Debt (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 9 - Leases (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables",
     "shortName": "Note 9 - Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables",
     "shortName": "Note 10 - Liability Related to Sale of Future Royalties (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "035 - Disclosure - Note 14 - Stock Based Compensation (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables",
     "shortName": "Note 14 - Stock Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "036 - Disclosure - Note 15 - Net Loss Per Share of Common Stock (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables",
     "shortName": "Note 15 - Net Loss Per Share of Common Stock (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "037 - Disclosure - Note 16 - Accrued Liabilities (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables",
     "shortName": "Note 16 - Accrued Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:ScheduleOfDeferredTaxAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "038 - Disclosure - Note 18 - Income Taxes (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables",
     "shortName": "Note 18 - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:ScheduleOfDeferredTaxAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Comprehensive Loss",
     "role": "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:ValuationAllowancesAndReservesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "039 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Tables)",
     "role": "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:ValuationAllowancesAndReservesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "040 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2020-03-16_2020-03-16",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminated",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "041 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "us-gaap:ConcentrationRiskCreditRisk",
       "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_ConcentrationRiskByBenchmarkAxis-SalesRevenueNetMember_ConcentrationRiskByTypeAxis-CustomerConcentrationRiskMember_MajorCustomersAxis-AguettantMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "042 - Disclosure - Note 2 - Investments and Fair Value Measurement (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual",
     "shortName": "Note 2 - Investments and Fair Value Measurement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "043 - Disclosure - Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details",
     "shortName": "Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "044 - Disclosure - Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
     "shortName": "Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2020-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "045 - Disclosure - Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details",
     "shortName": "Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "ix:continuation",
       "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2019-12-31_FairValueByFairValueHierarchyLevelAxis-FairValueInputsLevel3Member",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "046 - Disclosure - Note 3 - Inventories, Net (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
     "shortName": "Note 3 - Inventories, Net (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2020-01-01_2020-12-31_ProductOrServiceAxis-AmendedLicenseAgreementMember",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:InventoryWriteDown",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "047 - Disclosure - Note 3 - Inventories, Net - Inventory Components (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details",
     "shortName": "Note 3 - Inventories, Net - Inventory Components (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "us-gaap:InventoryDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryRawMaterialsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "048 - Disclosure - Note 4 - Property and Equipment, Net (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual",
     "shortName": "Note 4 - Property and Equipment, Net (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:Depreciation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Stockholders' Deficit",
     "role": "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit",
     "shortName": "Consolidated Statements of Stockholders' Deficit",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "049 - Disclosure - Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details",
     "shortName": "Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "acrx:InlicenseAgreementTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "acrx:LicenseAgreementMilestonePaymentsToBePaidMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "050 - Disclosure - Note 5 - In-license Agreement (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
     "shortName": "Note 5 - In-license Agreement (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "acrx:InlicenseAgreementTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-07-14_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-PFSProductsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "acrx:LicenseAgreementMilestonePaymentsToBePaidMaximum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "051 - Disclosure - Note 6 - Out-license Agreements (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
     "shortName": "Note 6 - Out-license Agreements (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "acrx:OutlicenseAgreementTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2015-07-17_ProductOrServiceAxis-AmendedLicenseAgreementMember",
      "decimals": "-5",
      "lang": null,
      "name": "acrx:RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "052 - Disclosure - Note 7 - Revenue From Contracts With Customers (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
     "shortName": "Note 7 - Revenue From Contracts With Customers (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31_CounterpartyNameAxis-AguettantMember_ProductOrServiceAxis-DZUVEOMember",
      "decimals": "-5",
      "lang": null,
      "name": "acrx:LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "053 - Disclosure - Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details",
     "shortName": "Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_ProductOrServiceAxis-DSUVIAMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ContractWithCustomerLiability",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "054 - Disclosure - Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details",
     "shortName": "Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "us-gaap:RevenueFromContractWithCustomerTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "acrx:ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RepaymentsOfLongTermDebt",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "055 - Disclosure - Note 8 - Long-term Debt (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual",
     "shortName": "Note 8 - Long-term Debt (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:LeaseholdImprovementsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acrx:LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "056 - Disclosure - Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details",
     "shortName": "Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "us-gaap:LongTermDebtTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acrx:LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-03-26_2021-03-26",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossOnTerminationOfLease",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "057 - Disclosure - Note 9 - Leases (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual",
     "shortName": "Note 9 - Leases (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2012-12-12_2012-12-12",
      "decimals": "-5",
      "lang": null,
      "name": "acrx:LesseeOperatingLeaseAnnualOverheadFeePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "058 - Disclosure - Note 9 - Leases - Operating Lease Costs (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details",
     "shortName": "Note 9 - Leases - Operating Lease Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "acrx:NonCashRoyaltyRevenueRelatedToRoyaltyMonetization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "059 - Disclosure - Note 9 - Leases - Maturities of Lease Liabilities (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details",
     "shortName": "Note 9 - Leases - Maturities of Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2015-09-18_2015-09-18",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "acrx:ProceedsFromSaleOfRoyaltyAndMilestoneRights",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "060 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual",
     "shortName": "Note 10 - Liability Related to Sale of Future Royalties (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-6",
      "lang": null,
      "name": "acrx:ContingentGainLossOnRoyaltyMonetizationArrangement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acrx:LiabilityRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "061 - Disclosure - Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details",
     "shortName": "Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherLiabilitiesTableTextBlock",
       "acrx:LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acrx:LiabilityRelatedToSaleOfFutureRoyalties",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodValueNewIssues",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "062 - Disclosure - Note 11 - Warrants (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
     "shortName": "Note 11 - Warrants (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "acrx:WarrantsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-11-15_2021-11-15_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_SubsidiarySaleOfStockAxis-RegisteredDirectOfferingMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOrSaleOfEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": null,
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "063 - Disclosure - Note 12 - Commitments and Contingencies (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
     "shortName": "Note 12 - Commitments and Contingencies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "064 - Disclosure - Note 13 - Stockholders' Equity (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
     "shortName": "Note 13 - Stockholders' Equity (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-11-17",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "065 - Disclosure - Note 14 - Stock Based Compensation (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
     "shortName": "Note 14 - Stock Based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "066 - Disclosure - Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details",
     "shortName": "Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "067 - Disclosure - Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details",
     "shortName": "Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2019-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "068 - Disclosure - Note 14 - Stock Based Compensation - Option Activity (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details",
     "shortName": "Note 14 - Stock Based Compensation - Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 1 - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
     "shortName": "Note 1 - Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "acrx:ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "true"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "069 - Disclosure - Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details",
     "shortName": "Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "acrx:ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "true"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "070 - Disclosure - Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
     "shortName": "Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "071 - Disclosure - Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
     "shortName": "Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-TimebasedStockOptionMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "072 - Disclosure - Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details",
     "shortName": "Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-RSUsESPPAndEmployeeStockOptionsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "073 - Disclosure - Note 16 - Accrued Liabilities - Accrued Liabilities (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details",
     "shortName": "Note 16 - Accrued Liabilities - Accrued Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2019-01-01_2019-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "acrx:DefinedContributionPlanEmployerDiscretionaryContributionPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "074 - Disclosure - Note 17 - 401(k) Plan (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual",
     "shortName": "Note 17 - 401(k) Plan (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2019-01-01_2019-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "acrx:DefinedContributionPlanEmployerDiscretionaryContributionPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "075 - Disclosure - Note 18 - Income Taxes (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual",
     "shortName": "Note 18 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "acrx:ScheduleOfDeferredTaxAssetsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "076 - Disclosure - Note 18 - Income Taxes - Net Deferred Tax Assets (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details",
     "shortName": "Note 18 - Income Taxes - Net Deferred Tax Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "acrx:ScheduleOfDeferredTaxAssetsTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acrx:DeferredTaxAssetsAccruedLiabilitiesAndOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "077 - Disclosure - Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details",
     "shortName": "Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "-4",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "078 - Disclosure - Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details",
     "shortName": "Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2019-12-31",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 2 - Investments and Fair Value Measurement",
     "role": "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement",
     "shortName": "Note 2 - Investments and Fair Value Measurement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acrx:InvestmentsAndFairValueMeasurementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember_BusinessAcquisitionAxis-LowellTherapeuticsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AcquisitionCostsCumulative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "079 - Disclosure - Note 19 - Subsequent Events (Details Textual)",
     "role": "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual",
     "shortName": "Note 19 - Subsequent Events (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2021-12-31_BalanceSheetLocationAxis-OtherAssetsMember_BusinessAcquisitionAxis-LowellTherapeuticsMember",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:AcquisitionCostsCumulative",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "acrx:ValuationAllowancesAndReservesTableTextBlock",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2020-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "080 - Disclosure - Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)",
     "role": "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details",
     "shortName": "Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "acrx:ValuationAllowancesAndReservesTableTextBlock",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "i_2019-12-31_ValuationAllowancesAndReservesTypeAxis-SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 3 - Inventories, Net",
     "role": "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
     "shortName": "Note 3 - Inventories, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "acrx20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 101,
   "tag": {
    "acrx_ATMAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to at the market agreement.",
        "label": "ATM Agreement [Member]"
       }
      }
     },
     "localname": "ATMAgreementMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_AccruedDeferredRevenueCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for deferred revenue. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "acrx_AccruedDeferredRevenueCurrent",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "AccruedDeferredRevenueCurrent",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_AccruedProductReturnsAndSalesAllowancesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents current accrued product returns and sales allowance.",
        "label": "Accrued product returns and sales allowances"
       }
      }
     },
     "localname": "AccruedProductReturnsAndSalesAllowancesCurrent",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_AcelRXMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entity AcelRX.",
        "label": "AcelRX [Member]"
       }
      }
     },
     "localname": "AcelRXMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_AcelrxCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents AcelRx common stock.",
        "label": "AcelRx Common Stock [Member]"
       }
      }
     },
     "localname": "AcelrxCommonStockMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_AggregateOfferingPriceIncreaseDuringPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the aggregate offering price increase during period.",
        "label": "acrx_AggregateOfferingPriceIncreaseDuringPeriod",
        "terseLabel": "Aggregate Offering Price, Increase During Period"
       }
      }
     },
     "localname": "AggregateOfferingPriceIncreaseDuringPeriod",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_AggregateOfferingPriceMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum aggregate offering price.",
        "label": "acrx_AggregateOfferingPriceMaximum",
        "terseLabel": "Aggregate Offering Price, Maximum"
       }
      }
     },
     "localname": "AggregateOfferingPriceMaximum",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_AguettantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to Aguettant.",
        "label": "Aguettant [Member]"
       }
      }
     },
     "localname": "AguettantMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_AmendedLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended License Agreement",
        "label": "Amended License Agreement [Member]"
       }
      }
     },
     "localname": "AmendedLicenseAgreementMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ArmisticeCapitalAndRockSpringsCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Armistice Capital and Rock Springs Capital.",
        "label": "Armistice Capital and Rock Springs Capital [Member]"
       }
      }
     },
     "localname": "ArmisticeCapitalAndRockSpringsCapitalMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of asset acquisition costs in accounts payable and accrued expenses.",
        "label": "Asset acquisition costs in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "AssetAcquisitionCostsInAccountsPayableAndAccruedExpenses",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_BasedUponNetSalesTargetAchievementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount, or portion of an amount, that is, will be, or may be based upon \"net sales target achievements.\"",
        "label": "Based upon Net Sales Target Achievements [Member]"
       }
      }
     },
     "localname": "BasedUponNetSalesTargetAchievementsMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An amount, or portion of an amount, that is, will be, or may be based upon \"successful regulatory and product development efforts.\"",
        "label": "Based upon Successful Regulatory and Product Development Efforts [Member]"
       }
      }
     },
     "localname": "BasedUponSuccessfulRegulatoryAndProductDevelopmentEffortsMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_BeforeTaxYear2018Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as before tax year 2018.",
        "label": "Before Tax Year 2018 [Member]"
       }
      }
     },
     "localname": "BeforeTaxYear2018Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents acquiree common stock to be held back to satisfy some obligations.",
        "label": "acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations",
        "terseLabel": "Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligations",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents acquiree common stock to be held back to satisfy some obligations, fixed value per share.",
        "label": "acrx_BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare",
        "terseLabel": "Business Combination, Acquiree Common Stock to Be Held Back to Satisfy Some Obligations, Fixed Value per Share (in dollars per share)"
       }
      }
     },
     "localname": "BusinessCombinationAcquireeCommonStockToBeHeldBackToSatisfySomeObligationsFixedValuePerShare",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer, net of the cash acquired from the purchase.",
        "label": "acrx_BusinessCombinationConsiderationTransferredNetOfCashAcquired",
        "terseLabel": "Business Combination, Consideration Transferred, Net of Cash Acquired"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredNetOfCashAcquired",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of options to purchase capital stock and all shares of capital stock issued and outstanding in exchange for cash.",
        "label": "acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash",
        "terseLabel": "Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Cash"
       }
      }
     },
     "localname": "BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCash",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents options to purchase capital stock and all shares of stock issued and outstanding cancelled in exchange for right to receive common stock.",
        "label": "acrx_BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber",
        "terseLabel": "Business Combination, Options To Purchase Capital Stock Issued and Outstanding Cancelled, Exchange for Common Stock, Number (in shares)"
       }
      }
     },
     "localname": "BusinessCombinationOptionsToPurchaseCapitalStockIssuedAndOutstandingCancelledExchangeForCommonStockNumber",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "acrx_BusinessDescriptionOfEntityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the accounting policy regarding the business description of entity.",
        "label": "Business Description of Entity [Policy Text Block]"
       }
      }
     },
     "localname": "BusinessDescriptionOfEntityPolicyTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, and marketable securities including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Policy Text Block]"
       }
      }
     },
     "localname": "CashCashEquivalentsAndMarketableSecuritiesPolicyTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_CashCashEquivalentsAndShorttermInvestmentsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents fair value of cash, cash equivalents and short-term investments.",
        "label": "Total cash, cash equivalents and short-term investments, fair value"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShorttermInvestmentsFairValue",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_CatalentPharmaSolutionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to Catalent Pharma Solutions, LLC, or Catalent.",
        "label": "Catalent Pharma Solutions [Member]"
       }
      }
     },
     "localname": "CatalentPharmaSolutionsMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents required percentage of ownership in order for warrants become exercisable.",
        "label": "acrx_ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable",
        "terseLabel": "Class of Warrant or Right, Required Percentage of Ownership to Become Exercisable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightRequiredPercentageOfOwnershipToBecomeExercisable",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_CommercialMilestonesValueMaximumAmountAvailable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum value of commercial milestone payments available to the company.",
        "label": "acrx_CommercialMilestonesValueMaximumAmountAvailable",
        "terseLabel": "Commercial Milestones Value Maximum Amount Available"
       }
      }
     },
     "localname": "CommercialMilestonesValueMaximumAmountAvailable",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ComputerEquipmentAndSoftwareMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about Computer Equipment and Software.",
        "label": "Computer Equipment and Software [Member]"
       }
      }
     },
     "localname": "ComputerEquipmentAndSoftwareMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ContingentGainLossOnRoyaltyMonetizationArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of contingent gain (loss) on royalty monetization arrangement.",
        "label": "acrx_ContingentGainLossOnRoyaltyMonetizationArrangement",
        "terseLabel": "Contingent Gain (Loss) on Royalty Monetization Arrangement"
       }
      }
     },
     "localname": "ContingentGainLossOnRoyaltyMonetizationArrangement",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ContingentPutOptionLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the contingent put option liability.",
        "label": "Contingent Put Option Liability [Member]"
       }
      }
     },
     "localname": "ContingentPutOptionLiabilityMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ContingentPutOptionPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding one or more contingent put options of the Company.",
        "label": "Contingent Put Option, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ContingentPutOptionPolicyPolicyTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_ContractAndOtherCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents contract and other collaboration.",
        "label": "Contract and Other Collaboration [Member]"
       }
      }
     },
     "localname": "ContractAndOtherCollaborationMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ContractAndOtherRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about Contract and Other Revenue.",
        "label": "Contract and Other Revenue [Member]"
       }
      }
     },
     "localname": "ContractAndOtherRevenueMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ContractWithCustomerLiabilityAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer.",
        "label": "Additions(2)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityAdditions",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ContractWithCustomerLiabilityLiabilityEliminated": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the contract with customer liability eliminated.",
        "label": "acrx_ContractWithCustomerLiabilityLiabilityEliminated",
        "terseLabel": "Contract with Customer, Liability, Liability Eliminated"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityLiabilityEliminated",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents contract with customer liability revenue recognized during current period,",
        "label": "acrx_ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod",
        "negatedLabel": "In current period"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedDuringCurrentPeriod",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ContributionsByEmployerToPostemploymentBenefitObligations": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "acrx_ContributionsByEmployerToPostemploymentBenefitObligations",
        "terseLabel": "Contributions by Employer to Postemployment Benefit Obligations"
       }
      }
     },
     "localname": "ContributionsByEmployerToPostemploymentBenefitObligations",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_CustomerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to customer A.",
        "label": "Customer A [Member]"
       }
      }
     },
     "localname": "CustomerAMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_CustomerBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to customer B.",
        "label": "Customer B [Member]"
       }
      }
     },
     "localname": "CustomerBMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_DSUVIAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents DSUVIA.",
        "label": "DSUVIA [Member]"
       }
      }
     },
     "localname": "DSUVIAMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_DZUVEOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to DZUVEO.",
        "label": "DZUVEO [Member]"
       }
      }
     },
     "localname": "DZUVEOMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum amount of unrestricted cash required to be maintained by the debt agreement.",
        "label": "acrx_DebtInstrumentCovenantMinimumRequiredUnrestirctedCash",
        "terseLabel": "Debt Instrument, Covenant, Minimum Required Unrestircted Cash"
       }
      }
     },
     "localname": "DebtInstrumentCovenantMinimumRequiredUnrestirctedCash",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_DebtInstrumentDefaultAdditionalInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the default additional interest rate for debt instrument.",
        "label": "acrx_DebtInstrumentDefaultAdditionalInterestRate",
        "terseLabel": "Debt Instrument, Default Additional Interest Rate"
       }
      }
     },
     "localname": "DebtInstrumentDefaultAdditionalInterestRate",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_DebtInstrumentInterestRateBasePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual base interest rate for funds borrowed, under the debt agreement.",
        "label": "acrx_DebtInstrumentInterestRateBasePercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Base Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateBasePercentage",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents minimum indebtedness amount with acceleration right under debt instrument.",
        "label": "acrx_DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight",
        "terseLabel": "Debt Instrument, Minimum Indebtedness Amount with Acceleration Right"
       }
      }
     },
     "localname": "DebtInstrumentMinimumIndebtednessAmountWithAccelerationRight",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_DebtInstrumentUnamortizedEotFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents debt instrument unamortized EOT fee.",
        "label": "acrx_DebtInstrumentUnamortizedEotFee",
        "negatedLabel": "Less: Unamortized portion of EOT Fee"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedEotFee",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_DeferredTaxAssetsAccruedLiabilitiesAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "label": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsAccruedLiabilitiesAndOther",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "acrx_DefinedContributionPlanEmployerDiscretionaryContributionPercentage",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Percentage"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionPercentage",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_DoDMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to DoD.",
        "label": "DoD [Member]"
       }
      }
     },
     "localname": "DoDMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_EffectiveAnnualInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective annual rate for a liability related to sale of future royalties.",
        "label": "acrx_EffectiveAnnualInterestRate",
        "terseLabel": "Effective Annual Interest Rate"
       }
      }
     },
     "localname": "EffectiveAnnualInterestRate",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of effective interest over the life of the liability related to sale of future royalties.",
        "label": "acrx_EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties",
        "terseLabel": "Effective Interest Over Life of Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "EffectiveInterestOverLifeOfLiabilityRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_EmployeeStockPurchasePlanESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the employee stock purchase plan.",
        "label": "Employee Stock Purchase Plan (ESPP) [Member]"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanESPPMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the weighted average fair value of shares issued under an ESPP.",
        "label": "acrx_EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue",
        "terseLabel": "Employee Stock Purchase Plan, Shares Issued, Weighted Average Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanSharesIssuedWeightedAverageFairValue",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "acrx_EquityIncentivePlan2011Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name or description of the plan.",
        "label": "2011 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2011Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_EstimatedOfferingCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of estimated offering costs.",
        "label": "acrx_EstimatedOfferingCosts",
        "terseLabel": "Estimated Offering Costs"
       }
      }
     },
     "localname": "EstimatedOfferingCosts",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ExercisePriceRange1Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the first exercise price range.",
        "label": "Exercise Price Range 1 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange1Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ExercisePriceRange2Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the second exercise price range.",
        "label": "Exercise Price Range 2 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange2Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ExercisePriceRange3Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the third exercise price range.",
        "label": "Exercise Price Range 3 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange3Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ExercisePriceRange4Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the fourth exercise price range.",
        "label": "Exercise Price Range 4 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange4Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ExercisePriceRange5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the fifth exercise price range.",
        "label": "Exercise Price Range 5 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange5Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ExercisePriceRange6Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the sixth exercise price range.",
        "label": "Exercise Price Range 6 [Member]"
       }
      }
     },
     "localname": "ExercisePriceRange6Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_FairValueOfContingentPutOptionLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the fair value of contingent put option liability.",
        "label": "acrx_FairValueOfContingentPutOptionLiability",
        "terseLabel": "Fair Value of Contingent Put Option, Liability"
       }
      }
     },
     "localname": "FairValueOfContingentPutOptionLiability",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_FirstFourCommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the detail of parts of royalties and rights received.",
        "label": "First Four Commercial Milestones [Member]"
       }
      }
     },
     "localname": "FirstFourCommercialMilestonesMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_GainLossOnTerminationOfSublease": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of sublease.",
        "label": "acrx_GainLossOnTerminationOfSublease",
        "negatedLabel": "Loss on termination of sublease"
       }
      }
     },
     "localname": "GainLossOnTerminationOfSublease",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_GainOnTerminationOfSublease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of gain on termination of sublease.",
        "label": "Gain on termination of sublease"
       }
      }
     },
     "localname": "GainOnTerminationOfSublease",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_GrunenthalMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name or description of the counterparty.",
        "label": "Grunenthal [Member]"
       }
      }
     },
     "localname": "GrunenthalMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_InlicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for in-license agreement.",
        "label": "In-license Agreement [Text Block]"
       }
      }
     },
     "localname": "InlicenseAgreementTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_InvestmentsAndFairValueMeasurementDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of investments and fair value measurement.",
        "label": "Investments and Fair Value Measurement Disclosure [Text Block]"
       }
      }
     },
     "localname": "InvestmentsAndFairValueMeasurementDisclosureTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about Laboratory Equipment.",
        "label": "Laboratory Equipment [Member]"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_LeaseForCorporateHeadquartersInHaywardCaliforniaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the lease agreement for the corporate headquarters in Hayward, California.",
        "label": "Lease for Corporate Headquarters in Hayward, California [Member]"
       }
      }
     },
     "localname": "LeaseForCorporateHeadquartersInHaywardCaliforniaMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_LeaseholdPaidWithNotePayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents leasehold paid with note payable.",
        "label": "Leasehold improvements paid with note payable"
       }
      }
     },
     "localname": "LeaseholdPaidWithNotePayable",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LesseeOperatingLeaseAbatedRentPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The period of abated rent of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "acrx_LesseeOperatingLeaseAbatedRentPeriod",
        "terseLabel": "Lessee, Operating Lease, Abated Rent Period (Month)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAbatedRentPeriod",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "acrx_LesseeOperatingLeaseAnnualOverheadFeePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required fee payments per year for overhead, prorated based on aggregate revenues.",
        "label": "acrx_LesseeOperatingLeaseAnnualOverheadFeePayments",
        "terseLabel": "Lessee, Operating Lease, Annual Overhead Fee Payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseAnnualOverheadFeePayments",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LesseeOperatingLeaseMonthlyRent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the monthly rent required for operating lease.",
        "label": "acrx_LesseeOperatingLeaseMonthlyRent",
        "terseLabel": "Lessee, Operating Lease, Monthly Rent"
       }
      }
     },
     "localname": "LesseeOperatingLeaseMonthlyRent",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LesseeOperatingLeaseNoticePeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease termination notice, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "acrx_LesseeOperatingLeaseNoticePeriod",
        "terseLabel": "Lessee, Operating Lease, Notice Period (Year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseNoticePeriod",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "acrx_LesseeOperatingSubleaseDeferredCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for operating sublease deferred costs.",
        "label": "acrx_LesseeOperatingSubleaseDeferredCosts",
        "terseLabel": "Lessee, Operating Sublease, Deferred Costs"
       }
      }
     },
     "localname": "LesseeOperatingSubleaseDeferredCosts",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LiabilityRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents liability related to future royalties.",
        "label": "acrx_LiabilityRelatedToSaleOfFutureRoyalties",
        "periodStartLabel": "Liability related to sale of future royalties \u2014 beginning balance"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for liability related to sale of future royalties.",
        "label": "Liability Related To Sale Of Future Royalties Disclosure [Text Block]"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesDisclosureTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of liability related to sale of future royalties less current portion.",
        "label": "acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNet",
        "periodEndLabel": "Liability related to sale of future royalties as of December 31, 2021"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNet",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability related to sale of future royalities classified as noncurrent.",
        "label": "Liability related to the sale of future royalties"
       }
      }
     },
     "localname": "LiabilityRelatedToSaleOfFutureRoyaltiesNoncurrent",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents milestone payments and revenue share payments to be received for license agreement.",
        "label": "acrx_LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived",
        "terseLabel": "License Agreement, Milestone Payments and Revenue Share Payments to be Received"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsAndRevenueSharePaymentsToBeReceived",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the maximum amount of milestone payments to be paid under license agreement.",
        "label": "acrx_LicenseAgreementMilestonePaymentsToBePaidMaximum",
        "terseLabel": "License Agreement, Milestone Payments to be Paid, Maximum"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsToBePaidMaximum",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LicenseAgreementMinimumSalesObligationTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the minimum sales obligation term under license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "acrx_LicenseAgreementMinimumSalesObligationTerm",
        "terseLabel": "License Agreement, Minimum Sales Obligation Term (Month)"
       }
      }
     },
     "localname": "LicenseAgreementMinimumSalesObligationTerm",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of revenue share payments to be paid under license agreement.",
        "label": "acrx_LicenseAgreementPercentOfRevenueSharePaymentToBePaid",
        "terseLabel": "License Agreement, Percent of Revenue Share Payment to be Paid"
       }
      }
     },
     "localname": "LicenseAgreementPercentOfRevenueSharePaymentToBePaid",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of revenue share payments to be received under license agreement.",
        "label": "acrx_LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived",
        "terseLabel": "License Agreement, Percent of Revenue Share Payments to be Received"
       }
      }
     },
     "localname": "LicenseAgreementPercentOfRevenueSharePaymentsToBeReceived",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_LicenseAgreementRenewalTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The renewal term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "acrx_LicenseAgreementRenewalTerm",
        "terseLabel": "License Agreement, Renewal Term (Year)"
       }
      }
     },
     "localname": "LicenseAgreementRenewalTerm",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "acrx_LicenseAgreementTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The term of the license agreement, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "acrx_LicenseAgreementTerm",
        "terseLabel": "License Agreement, Term (Year)"
       }
      }
     },
     "localname": "LicenseAgreementTerm",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the upfront payments and the maximum amount of milestone payments to be received under license agreement.",
        "label": "acrx_LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived",
        "terseLabel": "License Agreement, Upfront and Maximum Milestone Payments to be Received"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontAndMaximumMilestonePaymentsToBeReceived",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LoanAgreementWithOxfordFinanceLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to loan agreement with Oxford Finance LLC.",
        "label": "Loan Agreement with Oxford Finance LLC [Member]"
       }
      }
     },
     "localname": "LoanAgreementWithOxfordFinanceLLCMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the trigger of negative impact of government approvals and judgments for loan default events.",
        "label": "acrx_LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments",
        "terseLabel": "Loan Default Events, Trigger of Negative Impact of Government Approvals and Judgments"
       }
      }
     },
     "localname": "LoanDefaultEventsTriggerOfNegativeImpactOfGovernmentApprovalsAndJudgments",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": {
       "order": 1.0,
       "parentTag": "acrx_LongTermDebtTotalMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum payments for both principal and interest on long-term debt to be paid in the second fiscal year following the latest fiscal year.",
        "label": "2022"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearTwo",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LongTermDebtMaturitiesRepaymentsOfInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the interest portion of future minimum payments on long-term debt.",
        "label": "acrx_LongTermDebtMaturitiesRepaymentsOfInterest",
        "negatedLabel": "Less amount representing interest"
       }
      }
     },
     "localname": "LongTermDebtMaturitiesRepaymentsOfInterest",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LongTermDebtTotalMinimumPayments": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the future minimum payments on long-term debt, including both principal and interest.",
        "label": "acrx_LongTermDebtTotalMinimumPayments",
        "totalLabel": "Total payments"
       }
      }
     },
     "localname": "LongTermDebtTotalMinimumPayments",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": {
       "order": 0.0,
       "parentTag": "acrx_LongTermDebtTotalMinimumPayments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of minimum payments for both principal and interest on long-term debt to be paid in the third fiscal year following the latest fiscal year.",
        "label": "2023"
       }
      }
     },
     "localname": "LongtermDebtMaturitiesPaymentsOfPrincipalAndInterestInYearThree",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_LowellTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to Lowell Therapeutics.",
        "label": "Lowell Therapeutics [Member]"
       }
      }
     },
     "localname": "LowellTherapeuticsMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_LowellsIntellectualPropertyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents Lowell\u2019s intellectual property.",
        "label": "Lowell\u2019s Intellectual Property [Member]"
       }
      }
     },
     "localname": "LowellsIntellectualPropertyMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents marketable securities.",
        "label": "Marketable Securities [Member]"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock and exercise of warrants.",
        "label": "acrx_NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants",
        "terseLabel": "Net Proceeds from Issuance of Common Stock and Exercise of Warrants"
       }
      }
     },
     "localname": "NetProceedsFromIssuanceOfCommonStockAndExerciseOfWarrants",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_NetProceedsFromSaleOfFutureRoyalties": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net proceeds from sale of future royalties.",
        "label": "Proceeds from sale of future royalties",
        "terseLabel": "Net Proceeds from Sale of Future Royalties"
       }
      }
     },
     "localname": "NetProceedsFromSaleOfFutureRoyalties",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_NonCashRoyaltyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about non-cash royalty.",
        "label": "Non-cash Royalty [Member]"
       }
      }
     },
     "localname": "NonCashRoyaltyMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash royalty revenue recognized in connection to royalty monetization.",
        "label": "acrx_NonCashRoyaltyRevenueRelatedToRoyaltyMonetization",
        "negatedLabel": "Non-cash royalty revenue related to royalty monetization"
       }
      }
     },
     "localname": "NonCashRoyaltyRevenueRelatedToRoyaltyMonetization",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_NoncashInterestExpenseRecognized": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash interest expense recognized.",
        "label": "Non-cash interest income on liability related to royalty monetization"
       }
      }
     },
     "localname": "NoncashInterestExpenseRecognized",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 2.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amoutn of noncash interest income expense on liability related to sale of future royalties.",
        "label": "Non-cash interest income on liability related to sale of future royalties",
        "negatedTerseLabel": "Non-cash interest (income) expense recognized"
       }
      }
     },
     "localname": "NoncashInterestIncomeExpenseOnLiabilityRelatedToSaleOfFutureRoyalties",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of non-cash royalty revenue recognized in connection to royalty monetization that has been realized.",
        "label": "acrx_NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized",
        "negatedTerseLabel": "Non-cash royalty revenue"
       }
      }
     },
     "localname": "NoncashRoyaltyRevenueRelatedToRoyaltyMonetizationRealized",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_NotesPayableGross": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, after subtracting the amount representing interest but before subtracting any balloon payment(s) or unamortized discount, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.",
        "label": "Notes payable, gross"
       }
      }
     },
     "localname": "NotesPayableGross",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_November2021FinancingWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "represents November 2021 Financing Warrants.",
        "label": "November 2021 Financing Warrants [Member]"
       }
      }
     },
     "localname": "November2021FinancingWarrantsMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_OUMCoLLPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the auditor, OUM &amp; CO. LLP.",
        "label": "OUM &amp; CO. LLP [Member]"
       }
      }
     },
     "localname": "OUMCoLLPMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_OutlicenseAgreementTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of out-license agreement.",
        "label": "Out-license Agreement [Text Block]"
       }
      }
     },
     "localname": "OutlicenseAgreementTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_PFSProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to PFS products.",
        "label": "PFS Products [Member]"
       }
      }
     },
     "localname": "PFSProductsMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_PercentageOfRoyaltiesAndRightsUnderAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of royalties or milestone rights to be received under the agreement.",
        "label": "acrx_PercentageOfRoyaltiesAndRightsUnderAgreement",
        "terseLabel": "Percentage of Royalties and Rights Under Agreement"
       }
      }
     },
     "localname": "PercentageOfRoyaltiesAndRightsUnderAgreement",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the percentage of outstanding balance for repayment charge if prepayment occurs after May 30, 2020 and before May 30, 2021.",
        "label": "acrx_PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021",
        "terseLabel": "Prepayment Charge, Percentage of Outstanding Balance, After May 30, 2020, Before May 30, 2021"
       }
      }
     },
     "localname": "PrepaymentChargePercentageOfOutstandingBalanceAfterMay302020BeforeMay302021",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash inflow from up-front and share-based millstone license payments.",
        "label": "acrx_ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments",
        "terseLabel": "Proceeds form Up-front and Sales-based Milestone License Payments"
       }
      }
     },
     "localname": "ProceedsFormUpfrontAndSalesbasedMilestoneLicensePayments",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of debt, net of issuance costs paid to third parties and repayments of debt.",
        "label": "acrx_ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt",
        "terseLabel": "Proceeds from Debt, Net of Issuance Costs and Repayment of Debt"
       }
      }
     },
     "localname": "ProceedsFromDebtNetOfIssuanceCostsAndRepaymentOfDebt",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of proceeds from the sale of royalty and milestone rights.",
        "label": "acrx_ProceedsFromSaleOfRoyaltyAndMilestoneRights",
        "terseLabel": "Proceeds From Sale of Royalty and Milestone Rights"
       }
      }
     },
     "localname": "ProceedsFromSaleOfRoyaltyAndMilestoneRights",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_PurchasesOfPropertyAndEquipmentInAccountsPayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents purchases of property and equipment that were acquired through accounts payable.",
        "label": "Purchases of property and equipment in accounts payable and accrued expenses"
       }
      }
     },
     "localname": "PurchasesOfPropertyAndEquipmentInAccountsPayable",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to alleged misstatements as the shareholder.",
        "label": "Purported Shareholder v. Company - Alleged Misstatements as the Shareholder [Member]"
       }
      }
     },
     "localname": "PurportedShareholderVCompanyAllegedMisstatementsAsTheShareholderMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information related to the violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5.",
        "label": "Purported Shareholder v. Company - Violation of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b-5 [Member]"
       }
      }
     },
     "localname": "PurportedShareholderVCompanyViolationOfSections10bAnd20aOfTheExchangeActAndSecRule10b5Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_RSUsESPPAndEmployeeStockOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the antidilutive securities types; restricted stock units, employee stock purchase plan, and employee stock options.",
        "label": "RSU's, ESPP, and Employee Stock Options [Member]"
       }
      }
     },
     "localname": "RSUsESPPAndEmployeeStockOptionsMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_RegisteredDirectOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents 2021 registered direct offering.",
        "label": "2021 Registered Direct Offering [Member]"
       }
      }
     },
     "localname": "RegisteredDirectOfferingMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of additional milestone payments the Company is eligible to receive based upon successful regulatory and product development efforts and net sales target achievements.",
        "label": "acrx_RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets",
        "terseLabel": "Revenue Recognition Milestone Method Agreed, Additional Amount, Based On Efforts And Targets"
       }
      }
     },
     "localname": "RevenueRecognitionMilestoneMethodAgreedAdditionalAmountBasedOnEffortsAndTargets",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_RoyaltyArrangmentMaximumPayments": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capped amount of payments of company required to make to PDL.",
        "label": "acrx_RoyaltyArrangmentMaximumPayments",
        "terseLabel": "Royalty Arrangment Maximum Payments"
       }
      }
     },
     "localname": "RoyaltyArrangmentMaximumPayments",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance for sales and returns, discounts, chargebacks and rebates.",
        "label": "SEC Schedule, 12-09, Allowance, Sales and Returns, Discounts, Chargebacks and Rebates [Member]"
       }
      }
     },
     "localname": "SECSchedule1209AllowanceSalesAndReturnsDiscountsChargebacksAndRebatesMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_SWKMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents SWK.",
        "label": "SWK [Member]"
       }
      }
     },
     "localname": "SWKMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ScheduleOfDeferredTaxAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Deferred Tax Assets [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsTableTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule of Share-based Compensation, Stock Options Outstanding and Exercisable Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationStockOptionsOutstandingAndExercisableActivityTableTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average exercise price of exercisable share options (fully vested and expected to vest) that may be converted as of the balance sheet date.",
        "label": "Options Vested and Exercisable, Weighted-average Exercise Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableAndVestedWeightedAverageExercisePrice",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the shared-based compensation arrangement by share-based payment award equity instrument other than options outstanding.",
        "label": "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Outstanding (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstanding",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of additional shares that could be added from expired or cancelled shares already issued under another share-based payment plan.",
        "label": "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares to be Added (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardNumberOfAdditionalSharesToBeAdded",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and exercisable options (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableAndVestedNumber",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "acrx_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Vested and exercisable options, weighted-average remaining contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "acrx_SiteReadinessAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents site readiness agreement.",
        "label": "Site Readiness Agreement [Member]"
       }
      }
     },
     "localname": "SiteReadinessAgreementMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the stock option plan option reserve annual increase as percentage of outstanding shares allowed.",
        "label": "acrx_StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed",
        "terseLabel": "Stock Option Plan Option Reserve Annual Increase as Percentage of Outstanding Shares Allowed"
       }
      }
     },
     "localname": "StockOptionPlanOptionReserveAnnualIncreaseAsPercentageOfOutstandingSharesAllowed",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "acrx_SubjectToExpirationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subject to Expiration [Member]"
       }
      }
     },
     "localname": "SubjectToExpirationMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_TaxYears2018To2020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified as tax years 2018 to 2020.",
        "label": "Tax Years 2018 to 2020 [Member]"
       }
      }
     },
     "localname": "TaxYears2018To2020Member",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_The2020EquityIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the 2020 equity incentive plan.",
        "label": "The 2020 Equity Incentive Plan [Member]"
       }
      }
     },
     "localname": "The2020EquityIncentivePlanMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_TimebasedStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents time-based stock option.",
        "label": "Time-based Stock Option [Member]"
       }
      }
     },
     "localname": "TimebasedStockOptionMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ToolingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information about Tooling.",
        "label": "Tooling [Member]"
       }
      }
     },
     "localname": "ToolingMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_TotalObligationUnderLeaseholdAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents total obligation under leasehold agreement.",
        "label": "acrx_TotalObligationUnderLeaseholdAgreement",
        "terseLabel": "Total Obligation Under Leasehold Agreement"
       }
      }
     },
     "localname": "TotalObligationUnderLeaseholdAgreement",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_USGovernmentAgencySecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the U.S. Government Agency Securities.",
        "label": "U.S. Government Agency Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgencySecuritiesMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_ValuationAllowancesAndReservesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a schedule of allowance and reserve accounts where the valuation and qualifying accounts are either netted against the cost of an asset (in order to value it at its carrying value) or that reflect a liability established to represent expected future costs.",
        "label": "Valuation Allowances and Reserves [Table Text Block]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTableTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_WarrantInConnectionWithOxfordFinanceLoanAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information related to warrant in connection with Oxford finance loan agreement.",
        "label": "Warrant In Connection with Oxford Finance Loan Agreement [Member]"
       }
      }
     },
     "localname": "WarrantInConnectionWithOxfordFinanceLoanAgreementMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_WarrantsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The disclosure of warrants.",
        "label": "Warrants Disclosure [Text Block]"
       }
      }
     },
     "localname": "WarrantsDisclosureTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_WarrantsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for warrants.",
        "label": "Warrants, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "WarrantsPolicyPolicyTextBlock",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acrx_WholesalerAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to wholesaler A.",
        "label": "Wholesaler A [Member]"
       }
      }
     },
     "localname": "WholesalerAMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_WriteoffOfRightofuseAssetAndLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount write-off of right-of-use asset and lease liability.",
        "label": "Write-off of right-of-use asset and lease liability"
       }
      }
     },
     "localname": "WriteoffOfRightofuseAssetAndLeaseLiability",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acrx_ZALVISOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the product ZALVISO.",
        "label": "ZALVISO [Member]"
       }
      }
     },
     "localname": "ZALVISOMember",
     "nsuri": "http://www.acelrx.com/20211231",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies - Concentration of Revenue and Accounts Receivable (Details)"
       }
      }
     },
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 1 - Organization and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Liability Related to Sale of Future Royalties - Activity of Liability Related to Sale of Future Royalties (Details)"
       }
      }
     },
     "localname": "statement-statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 10 - Liability Related to Sale of Future Royalties"
       }
      }
     },
     "localname": "statement-statement-note-10-liability-related-to-sale-of-future-royalties-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Employee Stock Option (Details)"
       }
      }
     },
     "localname": "statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Stock Based Compensation - Assumptions to Calculate Fair Value of Each Performance-based Stock Option (Details)"
       }
      }
     },
     "localname": "statement-statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-14-stock-based-compensation-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Stock Based Compensation - Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-14-stock-based-compensation-option-activity-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Stock Based Compensation - Restricted Stock Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-14-stock-based-compensation-restricted-stock-activity-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Stock Based Compensation - Stock Options Outstanding, Vested and Exercisable (Details)"
       }
      }
     },
     "localname": "statement-statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Stock Based Compensation - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "localname": "statement-statement-note-14-stock-based-compensation-stockbased-compensation-expense-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-14-stock-based-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 14 - Stock Based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-14-stock-based-compensation-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Net Loss Per Share of Common Stock - Common Stock Excluded From Computation of Diluted Net Loss Per Share (Details)"
       }
      }
     },
     "localname": "statement-statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-15-net-loss-per-share-of-common-stock-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 15 - Net Loss Per Share of Common Stock"
       }
      }
     },
     "localname": "statement-statement-note-15-net-loss-per-share-of-common-stock-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-16-accrued-liabilities-accrued-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Accrued Liabilities - Accrued Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-16-accrued-liabilities-accrued-liabilities-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-16-accrued-liabilities-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 16 - Accrued Liabilities"
       }
      }
     },
     "localname": "statement-statement-note-16-accrued-liabilities-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-18-income-taxes-net-deferred-tax-assets-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 18 - Income Taxes - Net Deferred Tax Assets (Details)"
       }
      }
     },
     "localname": "statement-statement-note-18-income-taxes-net-deferred-tax-assets-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 18 - Income Taxes - Reconciliation of Beginning and Ending Balance of Unrecognized Tax Benefits (Details)"
       }
      }
     },
     "localname": "statement-statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 18 - Income Taxes - Reconciliation of Statutory Federal Income Tax (Details)"
       }
      }
     },
     "localname": "statement-statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-18-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 18 - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-18-income-taxes-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Investments and Fair Value Measurement - Fair Value of Financial Assets and Liabilities by Level Within Fair Value Hierarchy (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Investments and Fair Value Measurement - Summary of Cash, Cash Equivalents and Investments (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Investments and Fair Value Measurement - Summary of Changes in Fair Value of Level III Financial Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-2-investments-and-fair-value-measurement-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 2 - Investments and Fair Value Measurement"
       }
      }
     },
     "localname": "statement-statement-note-2-investments-and-fair-value-measurement-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-3-inventories-net-inventory-components-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Inventories, Net - Inventory Components (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-inventories-net-inventory-components-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-3-inventories-net-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Inventories, Net"
       }
      }
     },
     "localname": "statement-statement-note-3-inventories-net-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Property and Equipment, Net - Components of Property and Equipment (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-4-property-and-equipment-net-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Property and Equipment, Net"
       }
      }
     },
     "localname": "statement-statement-note-4-property-and-equipment-net-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Revenue From Contracts With Customers - Contract Liability (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-revenue-from-contracts-with-customers-contract-liability-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Revenue From Contracts With Customers - Disaggregation of Revenue (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-7-revenue-from-contracts-with-customers-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Revenue From Contracts With Customers"
       }
      }
     },
     "localname": "statement-statement-note-7-revenue-from-contracts-with-customers-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Long-term Debt - Outstanding Future Payments of Long-term Debt (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-8-longterm-debt-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Long-term Debt"
       }
      }
     },
     "localname": "statement-statement-note-8-longterm-debt-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-9-leases-maturities-of-lease-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Leases - Maturities of Lease Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-leases-maturities-of-lease-liabilities-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-9-leases-operating-lease-costs-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Leases - Operating Lease Costs (Details)"
       }
      }
     },
     "localname": "statement-statement-note-9-leases-operating-lease-costs-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-note-9-leases-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 9 - Leases"
       }
      }
     },
     "localname": "statement-statement-note-9-leases-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule II - Valuation and Qualifying Accounts"
       }
      }
     },
     "localname": "statement-statement-schedule-ii-valuation-and-qualifying-accounts-tables",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Schedule II - Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Details)"
       }
      }
     },
     "localname": "statement-statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acrx_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.acelrx.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r567"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details",
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r568"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r562"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r564",
      "r565",
      "r566"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details",
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r55",
      "r57",
      "r105",
      "r106",
      "r239",
      "r262",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ExecutiveOfficerMember": {
     "auth_ref": [
      "r175"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Person with designation of executive officer.",
        "label": "Executive Officer [Member]"
       }
      }
     },
     "localname": "ExecutiveOfficerMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim.",
        "label": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information.",
        "label": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r174",
      "r290",
      "r295",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name or description of a single external customer or a group of external customers.",
        "label": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r238",
      "r261",
      "r318",
      "r321",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r525",
      "r528",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r238",
      "r261",
      "r318",
      "r321",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r525",
      "r528",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r174",
      "r290",
      "r295",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Single external customer or group of external customers.",
        "label": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r172",
      "r290",
      "r294",
      "r491",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by product and service, or group of similar products and similar services.",
        "label": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r172",
      "r290",
      "r294",
      "r491",
      "r524",
      "r526"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product or service, or a group of similar products or similar services.",
        "label": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r238",
      "r261",
      "r298",
      "r318",
      "r321",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r525",
      "r528",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r238",
      "r261",
      "r298",
      "r318",
      "r321",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r487",
      "r525",
      "r528",
      "r558",
      "r559"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r56",
      "r57",
      "r105",
      "r106",
      "r239",
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r124",
      "r319",
      "r569"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r124",
      "r128",
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]"
       }
      }
     },
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts"
     ],
     "xbrltype": "textBlockItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r124",
      "r128",
      "r218",
      "r319",
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r175",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by title of individual or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of individual, or nature of relationship to individual or group of individuals.",
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r41",
      "r473"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r5",
      "r22",
      "r176",
      "r177"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts receivable, net"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued and other liabilities",
        "totalLabel": "Total accrued liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r45"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r39",
      "r203"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
        "negatedLabel": "Less accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AcquisitionCostsCumulative": {
     "auth_ref": [
      "r492"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The capitalized costs incurred (excluded from amortization), as of the date of the balance sheet, to purchase, lease or otherwise acquire an unproved property, including costs of lease bonuses and options to purchase or lease properties, the portion of costs applicable to minerals when land including mineral rights is purchased in fee, brokers' fees, recording fees, legal costs, and other costs incurred in acquiring properties.",
        "label": "us-gaap_AcquisitionCostsCumulative",
        "terseLabel": "Acquisition Costs, Cumulative"
       }
      }
     },
     "localname": "AcquisitionCostsCumulative",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r23",
      "r362",
      "r473"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r359",
      "r360",
      "r361",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in additional paid in capital (APIC) resulting from a tax benefit (deficiency) associated with an share-based compensation plan other than an employee stock ownership plan (ESOP).",
        "label": "Tax payments related to shares withheld for restricted stock units vested"
       }
      }
     },
     "localname": "AdjustmentToAdditionalPaidInCapitalIncomeTaxEffectFromShareBasedCompensationNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r323",
      "r325",
      "r365",
      "r366"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued": {
     "auth_ref": [
      "r234",
      "r274",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.",
        "label": "us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
        "terseLabel": "Net proceeds from issuance of warrants in connection with equity financings"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalWarrantIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r325",
      "r355",
      "r364"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfDebtDiscountPremium": {
     "auth_ref": [
      "r77",
      "r90",
      "r251",
      "r448"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.",
        "label": "Non-cash interest expense related to debt financing",
        "terseLabel": "Amortization of Debt Discount (Premium)"
       }
      }
     },
     "localname": "AmortizationOfDebtDiscountPremium",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AreaOfRealEstateProperty": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of a real estate property.",
        "label": "us-gaap_AreaOfRealEstateProperty",
        "terseLabel": "Area of Real Estate Property (Square Foot)"
       }
      }
     },
     "localname": "AreaOfRealEstateProperty",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r101",
      "r155",
      "r164",
      "r170",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r413",
      "r416",
      "r437",
      "r471",
      "r473",
      "r494",
      "r513"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total Assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r54",
      "r101",
      "r191",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r413",
      "r416",
      "r437",
      "r471",
      "r473"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r188"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r189"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r186",
      "r193"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Short-term investment, amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r183",
      "r187",
      "r193",
      "r500"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Short-term investment, fair value",
        "terseLabel": "Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r326",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r418",
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r317",
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r317",
      "r320",
      "r403",
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r405",
      "r406",
      "r407"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "us-gaap_BusinessCombinationContingentConsiderationLiability",
        "terseLabel": "Business Combination, Contingent Consideration, Liability, Total"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.",
        "label": "us-gaap_CapitalizedContractCostAmortization",
        "terseLabel": "Capitalized Contract Cost, Amortization"
       }
      }
     },
     "localname": "CapitalizedContractCostAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r36",
      "r473",
      "r536",
      "r537"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash, amortized cost"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r36",
      "r92"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and cash equivalent, fair value"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Member]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r36"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Total cash, cash equivalents and short-term investments",
        "terseLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations": {
     "auth_ref": [
      "r86",
      "r92",
      "r94"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including, but not limited to, disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
        "periodEndLabel": "CASH, CASH EQUIVALENTS \u2014End of year",
        "periodStartLabel": "CASH, CASH EQUIVALENTS \u2014Beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r86",
      "r438"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r277",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "us-gaap_ClassOfWarrantOrRightOutstanding",
        "terseLabel": "Class of Warrant or Right, Outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommercialPaperAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured short-term debt instrument issued by corporations which are highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r220"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r50",
      "r217",
      "r502",
      "r518"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r214",
      "r215",
      "r216",
      "r219",
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r116",
      "r117",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r21"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r21",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r21",
      "r473"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value\u2014200,000,000 shares authorized as of December 31, 2021 and 2020; 136,819,647 and 98,812,008 shares issued and outstanding as of December 31, 2021 and 2020, respectively",
        "terseLabel": "Common Stock, Value, Issued, Ending Balance"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r60",
      "r62",
      "r63",
      "r71",
      "r505",
      "r521"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "us-gaap_ComprehensiveIncomeNetOfTax",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r144",
      "r145",
      "r174",
      "r434",
      "r435",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r174",
      "r434",
      "r435",
      "r535",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r144",
      "r145",
      "r174",
      "r434",
      "r435",
      "r535",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r139",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r144",
      "r145",
      "r174",
      "r434",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration risk"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r144",
      "r145",
      "r174",
      "r434",
      "r435",
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r95",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r279",
      "r280",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "us-gaap_ContractWithCustomerLiability",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "terseLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r279",
      "r280",
      "r291"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "us-gaap_ContractWithCustomerLiabilityCurrent",
        "terseLabel": "Contract with Customer, Liability, Current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r279",
      "r280",
      "r291"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred revenue, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.",
        "label": "us-gaap_ContractWithCustomerLiabilityRevenueRecognized",
        "negatedLabel": "In prior periods(1)"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r299",
      "r313",
      "r534"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r73",
      "r491"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfSalesPolicyTextBlock": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cost of product sold and service rendered.",
        "label": "Cost of Goods and Service [Policy Text Block]"
       }
      }
     },
     "localname": "CostOfSalesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "us-gaap_CostsAndExpenses",
        "totalLabel": "Total operating costs and expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r210",
      "r211",
      "r213"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r143",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r16",
      "r18",
      "r19",
      "r100",
      "r107",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r451",
      "r495",
      "r496",
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument.",
        "label": "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1",
        "terseLabel": "Debt Instrument, Basis Spread on Variable Rate"
       }
      }
     },
     "localname": "DebtInstrumentBasisSpreadOnVariableRate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r235",
      "r255",
      "r256",
      "r449",
      "r451",
      "r452"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "us-gaap_DebtInstrumentFaceAmount",
        "terseLabel": "Debt Instrument, Face Amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "auth_ref": [
      "r47",
      "r253",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.",
        "label": "us-gaap_DebtInstrumentInterestRateEffectivePercentage",
        "terseLabel": "Debt Instrument, Interest Rate, Effective Percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r48",
      "r100",
      "r107",
      "r235",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r255",
      "r256",
      "r257",
      "r258",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentPeriodicPaymentPrincipal": {
     "auth_ref": [
      "r48"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the required periodic payments applied to principal.",
        "label": "us-gaap_DebtInstrumentPeriodicPaymentPrincipal",
        "terseLabel": "Debt Instrument, Periodic Payment, Principal"
       }
      }
     },
     "localname": "DebtInstrumentPeriodicPaymentPrincipal",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscount": {
     "auth_ref": [
      "r242",
      "r448",
      "r452"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after accumulated amortization, of debt discount.",
        "label": "us-gaap_DebtInstrumentUnamortizedDiscount",
        "negatedLabel": "Less: Unamortized discount on notes payable"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "auth_ref": [
      "r190"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss",
        "terseLabel": "Debt Securities, Available-for-sale, Realized Gain (Loss), Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r383"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsGross",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Section 59(e) R&amp;D expenditures"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r385"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforward"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r388",
      "r390",
      "r391"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Research credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r384"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Depreciation": {
     "auth_ref": [
      "r90",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.",
        "label": "us-gaap_Depreciation",
        "terseLabel": "Depreciation, Total"
       }
      }
     },
     "localname": "Depreciation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r90",
      "r153"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r130"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Net loss per share of common stock, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r131",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r131",
      "r132",
      "r133",
      "r134"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrentAndNoncurrent": {
     "auth_ref": [
      "r501",
      "r519"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "Accrued compensation and employee benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r356"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r65",
      "r66",
      "r67",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r136",
      "r192",
      "r274",
      "r276",
      "r359",
      "r360",
      "r361",
      "r394",
      "r395",
      "r421",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r529",
      "r530",
      "r531",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": {
     "auth_ref": [
      "r423",
      "r424",
      "r425",
      "r432",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.",
        "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Asset Class [Domain]"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r423",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Asset Class [Axis]"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r313",
      "r424",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r431",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Liability Class [Axis]"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r244",
      "r299",
      "r301",
      "r306",
      "r313",
      "r424",
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r299",
      "r301",
      "r306",
      "r313",
      "r424",
      "r479"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r313",
      "r424",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value by Liability Class [Domain]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r428",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r429"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
        "negatedLabel": "Change in fair value of contingent put option associated with the Loan Agreement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements": {
     "auth_ref": [
      "r430"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of purchases, (sales), issuances and (settlements) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Change in fair value of contingent put option associated with the Loan Agreement"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
        "periodEndLabel": "Fair value, End of period",
        "periodStartLabel": "Fair value, Beginning of period"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r244",
      "r255",
      "r256",
      "r299",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r313",
      "r478",
      "r479",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnTerminationOfLease": {
     "auth_ref": [
      "r453"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "us-gaap_GainLossOnTerminationOfLease",
        "negatedLabel": "Gain on derecognition of operating lease",
        "terseLabel": "Gain (Loss) on Termination of Lease"
       }
      }
     },
     "localname": "GainLossOnTerminationOfLease",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r200",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r69",
      "r155",
      "r163",
      "r166",
      "r169",
      "r171",
      "r493",
      "r503",
      "r507",
      "r522"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Net loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r205",
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r102",
      "r374",
      "r381",
      "r387",
      "r396",
      "r398",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r103",
      "r126",
      "r127",
      "r154",
      "r372",
      "r397",
      "r399",
      "r523"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      },
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Provision for income taxes",
        "terseLabel": "Income Tax Expense (Benefit), Total",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r370",
      "r371",
      "r381",
      "r382",
      "r386",
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.",
        "label": "Change in valuation allowance"
       }
      }
     },
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Tax at statutory federal rate"
       }
      }
     },
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Stock options"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationOtherAdjustments": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Other"
       }
      }
     },
     "localname": "IncomeTaxReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).",
        "label": "State tax\u2014net of federal benefit"
       }
      }
     },
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income taxes paid (refunded)"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "us-gaap_IncreaseDecreaseInAccountsPayable",
        "verboseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "us-gaap_IncreaseDecreaseInAccountsReceivable",
        "negatedLabel": "Accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.",
        "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities",
        "verboseLabel": "Accrued liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r89",
      "r488"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "us-gaap_IncreaseDecreaseInContractWithCustomerLiability",
        "verboseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities": {
     "auth_ref": [
      "r89"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.",
        "label": "us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities",
        "terseLabel": "Increase (Decrease) in Employee Related Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInEmployeeRelatedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "us-gaap_IncreaseDecreaseInInventories",
        "negatedLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "auth_ref": [
      "r89",
      "r462"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation for operating lease.",
        "label": "us-gaap_IncreaseDecreaseInOperatingLeaseLiability",
        "verboseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r68",
      "r152",
      "r447",
      "r450",
      "r506"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "us-gaap_InterestExpense",
        "negatedLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpenseDebt": {
     "auth_ref": [
      "r77",
      "r249",
      "r254",
      "r257",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt.",
        "label": "us-gaap_InterestExpenseDebt",
        "terseLabel": "Interest Expense, Debt, Total"
       }
      }
     },
     "localname": "InterestExpenseDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpensePolicyTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing interest expense, including the method of amortizing debt issuance costs.",
        "label": "Interest Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InterestExpensePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r85",
      "r87",
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r28",
      "r197"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details": {
       "order": 0.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r4",
      "r52",
      "r473"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventories, net",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r12",
      "r53",
      "r96",
      "r135",
      "r194",
      "r196",
      "r198",
      "r489"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsNetOfReserves": {
     "auth_ref": [
      "r30",
      "r197"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of unprocessed items to be consumed in the manufacturing or production process.",
        "label": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterialsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r29",
      "r197"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Work-in-process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory impairment charge",
        "terseLabel": "Inventory Write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNet": {
     "auth_ref": [
      "r75",
      "r77"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.",
        "label": "Interest income and other income, net"
       }
      }
     },
     "localname": "InvestmentIncomeNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r538",
      "r539",
      "r540",
      "r541",
      "r542",
      "r543",
      "r544",
      "r545",
      "r546",
      "r547",
      "r548",
      "r549",
      "r550",
      "r551",
      "r552"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r466",
      "r468"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "us-gaap_LeaseCost",
        "totalLabel": "Net lease costs"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r466"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseholdImprovementsGross": {
     "auth_ref": [
      "r8",
      "r202"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.",
        "label": "us-gaap_LeaseholdImprovementsGross",
        "terseLabel": "Leasehold Improvements, Gross"
       }
      }
     },
     "localname": "LeaseholdImprovementsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
        "totalLabel": "Total future minimum lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r467"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
        "negatedLabel": "Less imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseRenewalTerm",
        "terseLabel": "Lessee, Operating Lease, Renewal Term (Year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_LesseeOperatingLeaseTermOfContract",
        "terseLabel": "Lessee, Operating Lease, Term of Contract (Year)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r44",
      "r101",
      "r165",
      "r191",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r414",
      "r416",
      "r417",
      "r437",
      "r471",
      "r472"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r27",
      "r101",
      "r191",
      "r437",
      "r473",
      "r497",
      "r516"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total Liabilities and Stockholders\u2019 Deficit"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r46",
      "r101",
      "r191",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r414",
      "r416",
      "r417",
      "r437",
      "r471",
      "r472",
      "r473"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Liabilities, fair value"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LondonInterbankOfferedRateLIBORMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate at which a bank borrows funds from other banks in the London interbank market.",
        "label": "London Interbank Offered Rate (LIBOR) [Member]"
       }
      }
     },
     "localname": "LondonInterbankOfferedRateLIBORMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r19",
      "r243",
      "r252",
      "r255",
      "r256",
      "r496",
      "r514"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "us-gaap_LongTermDebt",
        "terseLabel": "Long-term Debt, Total",
        "totalLabel": "Long-term debt"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "us-gaap_LongTermDebtCurrent",
        "negatedLabel": "Less current portion",
        "terseLabel": "Long-term debt, current portion"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details": {
       "order": 0.0,
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term debt, net of current portion",
        "terseLabel": "Long-term debt, net of current portion"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-term debt.",
        "label": "Long-term Debt [Text Block]"
       }
      }
     },
     "localname": "LongTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r48"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r48",
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyNumberOfDefendants": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of defendants named in a legal action.",
        "label": "us-gaap_LossContingencyNumberOfDefendants",
        "terseLabel": "Loss Contingency, Number of Defendants"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MeasurementInputExercisePriceMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using agreed upon price for exchange of underlying asset.",
        "label": "Measurement Input, Exercise Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputExercisePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedDividendRateMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using expected dividend rate to be paid to holder of share per year.",
        "label": "Measurement Input, Expected Dividend Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedDividendRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputExpectedTermMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.",
        "label": "Measurement Input, Expected Term [Member]"
       }
      }
     },
     "localname": "MeasurementInputExpectedTermMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input, Price Volatility [Member]"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputRiskFreeInterestRateMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.",
        "label": "Measurement Input, Risk Free Interest Rate [Member]"
       }
      }
     },
     "localname": "MeasurementInputRiskFreeInterestRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputSharePriceMember": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using share price of saleable stock.",
        "label": "Measurement Input, Share Price [Member]"
       }
      }
     },
     "localname": "MeasurementInputSharePriceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r426"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsAtCarryingValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.",
        "label": "Money market funds, amortized cost"
       }
      }
     },
     "localname": "MoneyMarketFundsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r86",
      "r88",
      "r91"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r59",
      "r61",
      "r67",
      "r70",
      "r91",
      "r101",
      "r119",
      "r121",
      "r122",
      "r123",
      "r124",
      "r126",
      "r127",
      "r129",
      "r155",
      "r163",
      "r166",
      "r169",
      "r171",
      "r191",
      "r223",
      "r224",
      "r225",
      "r227",
      "r228",
      "r229",
      "r230",
      "r231",
      "r232",
      "r233",
      "r422",
      "r437",
      "r504",
      "r520"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "NONCASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "us-gaap_NonoperatingIncomeExpense",
        "totalLabel": "Total other income"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "us-gaap_OpenTaxYear",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingCostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating costs and expenses:"
       }
      }
     },
     "localname": "OperatingCostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r155",
      "r163",
      "r166",
      "r169",
      "r171"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r460",
      "r468"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating lease costs"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r456"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r455"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating lease liabilities",
        "verboseLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating lease liabilities, current portion",
        "negatedLabel": "Operating lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r455"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating lease liabilities, net of current portion",
        "terseLabel": "Operating lease liabilities, net of current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r454"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating lease right-of-use assets",
        "terseLabel": "Operating Lease, Right-of-Use Asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r465",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Weighted-average remaining discount rate \u2013 operating leases (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r464",
      "r468"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average remaining lease term \u2013 operating leases (in years) (Year)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_OperatingLossCarryforwards",
        "terseLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r45"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other accrued liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r418",
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax": {
     "auth_ref": [
      "r58"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "us-gaap_OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax",
        "terseLabel": "OCI, Debt Securities, Available-for-Sale, Transfer from Held-to-Maturity, Gain (Loss), before Adjustment, after Tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTransfersFromHeldToMaturityToAvailableForSaleSecuritiesNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other liabilities.",
        "label": "Other Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "OtherLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "us-gaap_OtherNoncashIncomeExpense",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale": {
     "auth_ref": [
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other-than-temporary impairment (OTTI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), recognized in earnings and other comprehensive loss (OCI).",
        "label": "us-gaap_OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
        "terseLabel": "Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale, Total"
       }
      }
     },
     "localname": "OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
        "negatedLabel": "Tax payments related to shares withheld for restricted stock units vested"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r80",
      "r409",
      "r410",
      "r411"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "us-gaap_PaymentsToAcquireProductiveAssets",
        "negatedLabel": "Asset acquisition costs"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment",
        "negatedLabel": "Purchase of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "us-gaap_PaymentsToAcquireShortTermInvestments",
        "negatedLabel": "Purchase of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r298",
      "r300",
      "r306",
      "r307",
      "r308",
      "r309",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Retirement Benefits [Text Block]"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r326",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r34",
      "r35"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses and Other Current Assets [Member]"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PrivatePlacementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts.",
        "label": "Private Placement [Member]"
       }
      }
     },
     "localname": "PrivatePlacementMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Net proceeds from issuance of common stock in connection with equity financings",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r82",
      "r358"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Net proceeds from issuance of common stock through equity plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfWarrants": {
     "auth_ref": [
      "r82"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).",
        "label": "Net proceeds from issuance of warrants in connection with equity financings",
        "terseLabel": "Proceeds from Issuance of Warrants"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOrSaleOfEquity": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.",
        "label": "us-gaap_ProceedsFromIssuanceOrSaleOfEquity",
        "terseLabel": "Proceeds from Issuance or Sale of Equity, Total"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOrSaleOfEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from maturities of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r78",
      "r79",
      "r184"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from sale of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r39",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r207",
      "r555",
      "r556",
      "r557"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r38",
      "r202"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and Equipment, Gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r204",
      "r473",
      "r509",
      "r517"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r204",
      "r555",
      "r556"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r14",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r14",
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r178",
      "r180",
      "r181",
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "us-gaap_RepaymentsOfLongTermDebt",
        "negatedLabel": "Payment of long-term debt",
        "terseLabel": "Repayments of Long-term Debt, Total"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r368",
      "r490",
      "r560"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 0.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchMember": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes.",
        "label": "Research Tax Credit Carryforward [Member]"
       }
      }
     },
     "localname": "ResearchMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of positions eliminated during the period as a result of restructuring activities.",
        "label": "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminated",
        "terseLabel": "Restructuring and Related Cost, Number of Positions Eliminated"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminated",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r90",
      "r208",
      "r210",
      "r212"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "us-gaap_RestructuringCharges",
        "terseLabel": "Restructuring Charges, Total"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r24",
      "r276",
      "r362",
      "r473",
      "r515",
      "r532",
      "r533"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r192",
      "r359",
      "r360",
      "r361",
      "r394",
      "r395",
      "r421",
      "r529",
      "r531"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerIncludingAssessedTax": {
     "auth_ref": [
      "r150",
      "r151",
      "r162",
      "r167",
      "r168",
      "r172",
      "r173",
      "r174",
      "r289",
      "r290",
      "r491"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, including tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value-added and excise.",
        "label": "Revenue",
        "terseLabel": "Revenue from Contract with Customer, Including Assessed Tax"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerIncludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r293",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r97",
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r463",
      "r468"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Establishment of right-of-use asset and lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyMember": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Money for usage-based right to asset.",
        "label": "Royalty [Member]"
       }
      }
     },
     "localname": "RoyaltyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueNetMember": {
     "auth_ref": [
      "r144",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue Benchmark [Member]"
       }
      }
     },
     "localname": "SalesRevenueNetMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r131"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r325",
      "r354",
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r31",
      "r32",
      "r33"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "auth_ref": [
      "r221"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt.",
        "label": "Schedule of Maturities of Long-term Debt [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r331",
      "r341",
      "r344"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of the number and weighted-average grant date fair value for restricted stock and restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock and restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock and Restricted Stock Unit, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfSharebasedCompensationRestrictedStockAndRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r380",
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r142",
      "r144",
      "r145",
      "r146",
      "r434",
      "r436"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r156",
      "r157",
      "r158",
      "r159",
      "r160",
      "r161",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
        "negatedTerseLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
        "terseLabel": "Weighted average grant date fair value, forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r338"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Weighted average grant date fair value, granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodEndLabel": "Restricted stock units outstanding (in shares)",
        "periodStartLabel": "Restricted stock units outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Restricted stock units weighted average outstanding (in dollars per share)",
        "periodStartLabel": "Restricted stock units weighted average outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedTerseLabel": "Vested (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Weighted average grant date fair value, vested (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Expected dividend rate",
        "terseLabel": "Expected dividend rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r343"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r336"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r333",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Number of Stock Options Outstanding (in shares)",
        "periodEndLabel": "Outstanding (in shares)",
        "periodStartLabel": "Outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Options Outstanding, Weighted-average Exercise Price Per Share (in dollars per share)",
        "periodEndLabel": "Outstanding, weighted-average exercise price (in dollars per share)",
        "periodStartLabel": "Outstanding (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r346"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and exercisable options, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Shares Subject to Stock Options (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and exercisable options, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r344"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r324",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Exercised, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Expired, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Forfeited, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r326",
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis": {
     "auth_ref": [
      "r347"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by range of option prices pertaining to options granted.",
        "label": "Exercise Price Range [Axis]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplementary information on outstanding and exercisable share awards as of the balance sheet date which stratifies outstanding options by ranges of exercise prices.",
        "label": "Exercise Price Range [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Exercise Price Range, Lower Range Limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.",
        "label": "Exercise Price Range, Upper Range Limit (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "us-gaap_SharePrice",
        "terseLabel": "Share Price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r349",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (Year)",
        "terseLabel": "Derived service period (in years) (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Weighted-average Remaining Contractual LIfe (Year)",
        "terseLabel": "Outstanding, weighted-average remaining contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest, weighted-average remaining contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r330"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares (in shares)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r498",
      "r499",
      "r512"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r51",
      "r65",
      "r66",
      "r67",
      "r116",
      "r117",
      "r118",
      "r120",
      "r125",
      "r127",
      "r136",
      "r192",
      "r274",
      "r276",
      "r359",
      "r360",
      "r361",
      "r394",
      "r395",
      "r421",
      "r439",
      "r440",
      "r441",
      "r442",
      "r443",
      "r444",
      "r529",
      "r530",
      "r531",
      "r573"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details",
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r116",
      "r117",
      "r118",
      "r136",
      "r491"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-concentration-of-revenue-and-accounts-receivable-details",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-activity-of-liability-related-to-sale-of-future-royalties-details",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies",
      "http://www.acelrx.com/20211231/role/statement-note-12-commitments-and-contingencies-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-employee-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-assumptions-to-calculate-fair-value-of-each-performancebased-stock-option-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-restricted-stock-activity-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stock-options-outstanding-vested-and-exercisable-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-stockbased-compensation-expense-details",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-accrued-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan",
      "http://www.acelrx.com/20211231/role/statement-note-17-401k-plan-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-net-deferred-tax-assets-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-statutory-federal-income-tax-details",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-fair-value-of-financial-assets-and-liabilities-by-level-within-fair-value-hierarchy-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-changes-in-fair-value-of-level-iii-financial-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-inventory-components-details",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-components-of-property-and-equipment-details",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement",
      "http://www.acelrx.com/20211231/role/statement-note-5-inlicense-agreement-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements",
      "http://www.acelrx.com/20211231/role/statement-note-6-outlicense-agreements-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-contract-liability-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-disaggregation-of-revenue-details",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-outstanding-future-payments-of-longterm-debt-details",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-maturities-of-lease-liabilities-details",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details",
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r20",
      "r21",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Issuance of common stock upon ESPP purchase (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Net proceeds from issuance of common stock in connection with equity financings (in shares)",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r20",
      "r21",
      "r274",
      "r276"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.",
        "label": "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
        "terseLabel": "Restricted stock units vested (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r21",
      "r274",
      "r276",
      "r334"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Issuance of common stock upon exercise of stock options (in shares)",
        "negatedLabel": "Exercised (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r20",
      "r21",
      "r274",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Issuance of common stock upon ESPP purchase"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r20",
      "r21",
      "r274",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "us-gaap_StockIssuedDuringPeriodValueNewIssues",
        "terseLabel": "Stock Issued During Period, Value, New Issues"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures": {
     "auth_ref": [
      "r274",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.",
        "label": "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
        "terseLabel": "Restricted stock units vested"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r274",
      "r276"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r21",
      "r25",
      "r26",
      "r101",
      "r179",
      "r191",
      "r437",
      "r473"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders\u2019 deficit"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets",
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-stockholders-deficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Deficit:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-balance-sheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r99",
      "r260",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r269",
      "r270",
      "r271",
      "r272",
      "r273",
      "r276",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r461",
      "r468"
     ],
     "calculation": {
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "us-gaap_SubleaseIncome",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-operating-lease-costs-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r445",
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r474",
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants",
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events",
      "http://www.acelrx.com/20211231/role/statement-note-19-subsequent-events-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-cash-flows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-1-organization-and-summary-of-significant-accounting-policies-tables",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-tables",
      "http://www.acelrx.com/20211231/role/statement-note-14-stock-based-compensation-tables",
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-tables",
      "http://www.acelrx.com/20211231/role/statement-note-16-accrued-liabilities-tables",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-tables",
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-tables",
      "http://www.acelrx.com/20211231/role/statement-note-3-inventories-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-4-property-and-equipment-net-tables",
      "http://www.acelrx.com/20211231/role/statement-note-7-revenue-from-contracts-with-customers-tables",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-tables",
      "http://www.acelrx.com/20211231/role/statement-note-9-leases-tables",
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "us-gaap_TaxCreditCarryforwardAmount",
        "terseLabel": "Tax Credit Carryforward, Amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r389"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxPeriodAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information about the period subject to enacted tax laws.",
        "label": "Tax Period [Axis]"
       }
      }
     },
     "localname": "TaxPeriodAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxPeriodDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identified tax period.",
        "label": "Tax Period [Domain]"
       }
      }
     },
     "localname": "TaxPeriodDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes",
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties",
      "http://www.acelrx.com/20211231/role/statement-note-10-liability-related-to-sale-of-future-royalties-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r104",
      "r299",
      "r508"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-2-investments-and-fair-value-measurement-summary-of-cash-cash-equivalents-and-investments-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r369",
      "r377"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "us-gaap_UnrecognizedTaxBenefits",
        "periodEndLabel": "Unrecognized benefit\u2014end of period",
        "periodStartLabel": "Unrecognized benefit\u2014beginning of period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "auth_ref": [
      "r375"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
        "terseLabel": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued, Total"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Gross increases\u2014current period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r378"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Gross increases\u2014prior period tax positions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-reconciliation-of-beginning-and-ending-balance-of-unrecognized-tax-benefits-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r137",
      "r138",
      "r140",
      "r141",
      "r147",
      "r148",
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r385"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount",
        "terseLabel": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-18-income-taxes-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r108",
      "r113"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "us-gaap_ValuationAllowancesAndReservesBalance",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "auth_ref": [
      "r111"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.",
        "label": "Additions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r112"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "us-gaap_ValuationAllowancesAndReservesDeductions",
        "negatedLabel": "Deductions"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r108",
      "r109",
      "r110",
      "r112",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-schedule-ii-valuation-and-qualifying-accounts-valuation-and-qualifying-accounts-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-",
      "http://www.acelrx.com/20211231/role/statement-note-8-longterm-debt-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-15-net-loss-per-share-of-common-stock-common-stock-excluded-from-computation-of-diluted-net-loss-per-share-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstanding": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.",
        "label": "us-gaap_WarrantsAndRightsOutstanding",
        "terseLabel": "Warrants and Rights Outstanding"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual",
      "http://www.acelrx.com/20211231/role/statement-note-13-stockholders-equity-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.",
        "label": "us-gaap_WarrantsAndRightsOutstandingMeasurementInput",
        "terseLabel": "Warrants and Rights Outstanding, Measurement Input"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-note-11-warrants-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Shares used in computing net loss per share of common stock, basic and diluted \u2013see Note 15 (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.acelrx.com/20211231/role/statement-consolidated-statements-of-comprehensive-loss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24072-122690"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=124437754&loc=d3e543-108305"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=123577603&loc=d3e5033-111524"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=SL6284422-111562"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27357-111563"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123353750&loc=SL49131252-203054"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=109237686&loc=d3e17752-110868"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=d3e1835-112601"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466302&loc=d3e4724-112606"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1F",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495355-112611"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466204&loc=SL6036836-161870"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495743-112612"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495745-112612"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "705",
   "URI": "http://asc.fasb.org/topic&trid=2122478"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123421605&loc=SL5629052-113961"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL7498348-110258"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=28365394&loc=d3e23770-108382"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28541-108399"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123386189&loc=SL77918607-209975"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/subtopic&trid=77888251"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "330",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6471895&loc=d3e55923-109411"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-10.(c)(7)(ii))",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123726172&loc=d3e511914-122862"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column B)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 6))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12B(Column D)(Footnote 7))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611197-123010"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column B)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13D(Column C)(Footnote 2))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=SL120429264-123010"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column B))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column C))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column D))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=122147990&loc=d3e611379-123010"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r561": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r562": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r563": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r564": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r565": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r566": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r567": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r568": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r569": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r570": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "09"
  },
  "r571": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r572": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a),(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3151-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3367-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>103
<FILENAME>0001437749-22-005888-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-005888-xbrl.zip
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M-QQN\('TT,4R"Y?^*YIGYL0%9I]J6GL* F6AM6WH^S*TGL9<"%NQN,)S*KC
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M^17+2#()\_BQ5$^F_)8*.5:$N=!7TKD!UW8G&&"5S@E/2XHH+Y]J@;$.[#4
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MF'5&9Y1S&MV3I[(LMEYU:M<9CSJ-CR*OX$.R9F8S*H.5]+(\%6*[W8KS(@$
M:2C$4&G9&ZK\[8<<="4^IWP'>Q TG]!4")X\NV5)<L%XB6\R6X>V WI3R)M"
MWA3RII WA;PI]!9,H2Z:[ZC1AUT5I5&C"[MI1\[,WVQ#<!#'P>,6TA:0- K^
M*$@2S]9Q.I>!&%:DN;E=W&7T_@WF[M1ULJ3W",(D8=]DLD!607$I?VR(0[3N
MC\=ZQ4>1MZ>]_>3M)V\_>?O)VT_>?D)F/[57=AQ'D@+!/Q%:_UZ9S(KEDO"U
MS$/(8F$0S.*0B.8;Q5+JF"N6Q*%$-T4T)W$B=$W!BE!!30-0?<SM*F[5'^V=
ME/1KFM]P%E(:91(/>$>D;7=1E@N_W58+KU/.3?I9J SX>JYJEK4X))]B8;?D
M+*6W\7R1UU+;HKL%HK=SE/G7<BM\(D_QLEAN4JYJ*87VP6-6X*/H[1@Z&<\/
M%'#Q7R^5;_&G?VUV4&UA0.7OKF@3(E9+6]WOCFB[E543:KYH[6\N:5*N5LVO
MV.A"4"3KE&0+^;_G?Q3QH[@,A%05U\#=@O%<OMEXF0J%*Z\3T.T'&*(P*&?"
M0,K7LIJ'?-%=$KN21'W.Z*Q(KN*9RF-@T', OLI4_B*4K]&46=NWU6LGLL3!
M=2%WV'1VP[)2;\O.DW@9I_)G!:O=!AN:^],%X?-7ZAFDJ7>Q#>MB\QZ>SHS4
MW\*LX2(<G8]*HVR@<7&H5IPUZG"H'&S0'86\&%C3UU!K^VY9\ [<'AVXRD-_
M; Y<A\7U0"RUM0W084%@[!K;"D ^W963@O%IPU  LNZN8%0+UFOM""!C/R-A
MK)M'&,CL7S$Q:^94!G+X"R8.S<,1;L-F'X)X+_G+Z,^,Q+Q$95'!.\D$H67K
M;A&RKM,X"H;9(=.717C;P0]C9\[D46PFJ6E>,"XEQ+XDRAE]R/?_I7#SF'8?
M@,/GA+PD^):21,)U/XIM<L4R%9_M!AF V_*Q1%G!AM.%-+RV0&Q)UKVXZK(9
MY>5U\ ^:1/=L]X0Y4W])<8],9_?D2;$T#F8<:AWO%R2]I\L5XX2O+Y<K(9#+
M*U=PIM\0NJ7J/*AW5'M'-7I'M?=D>4_6\7FRNJ@!(_5FM=/P1NK2<J;+C-3O
M95.!<>ML^+$TKU-QFTOLJ*P8WLVK ![/D?O D)Y.^-C)LNQ[%8?BC-#)G-.2
M$/6KU* .%L"E9W>?OUQ.U'34_8['2X&/HK?C-P$!^FXXBXHPG_+-HS,*'*2N
MF5M*RS!;1416^\%!;<=$,P(HY>5&#J^_BEN0GK%OJO=6U0V]A>\M?/06?C,4
M32L(F9'T&9WS G81H(*K-7\*9J[/H?+1=-Z4(X"YP;^B6AOVH#?O*O2NPFZN
MDB;MSJW[XZ=@M4&EE= "NH6D6?"$M!G:D5.D/6D>1_&V_0$M4 8K3L.JOIG"
M#JEKXBT];^FAM_2\@N85M.-3T-3BV*UJ]G,0ITEE20=D:TIWU,F,QG2DC+6@
MJ5N4:E[0/"?:N%1]$PN1J%>ND2U\?@LOOV<GXM]QM$&=UU'7=HQ>R"_3%640
M-YL^)/&\JN-*.9#PIMX]D'PCKBSQ_Z:S6RH,L8*6K_=M5FZ[<!#B3<;I@8U;
MFM)O)($N=4WS'HB"4F.9C)N+NZUW2WVFE8WPF%'X*'H[AATH%'DJBXU1OB(\
M7U^3I2K0JVOFZQBAKF/D0_GH:;8?RO<5KH:B:ZAO25<%#Q?D0"5Y*;.5^]*X
M[S'QA !&X]V4WDUIDY$QU$8Z8DA-,VM:;9IU$LJC<Y?#K M4Z"'S3\,@7CA4
M<0'KVQ0#GLB#W?0PJ0:'$KH-.AS S5+JFJ\0Z"L$'E^%0$NICCX6[V/QQQ.+
M!T:-W-X__7"EC,RYE1_],&<6F@9RC"7YV5)8&,@UJHJ ;2/Y;A$T?PU8D;^"
MEG1]6<EP5$<HFE94C1='@S;5_$08]]'G%4NO:5X>AWM9!#2?A(M8"(3RFZB)
M-.YLD^"[(A3F7C8KDELZ+Q(YHBSPN3$)SP0!"2M1\N>S&>,@-KH-:2/Q_Y^?
MOYQ/-8G_-;\[QAR55^(M#6G\^.KI#3N#O17TT>>5N,?*RLI;JZQ.^S!9ZG8C
MVD T;>NS,K[<$U&*A =YN'9T;"C6O9+6=2P+[&QVZFWU"+J\\G:3?J+Y@D7E
MBD>3*"I_),ED*=VBI1R9IAOA((BNQ&']6W#]3($'BH6/(@\.\^ P#PY[3:('
MAWEPF >'>7"8!X<YX>U.:*V$Q^QSFJUH&,]B&BEY:6P[)IJ'6N^MXVE+F$+N
M:=L- ,';6 BR2N>IL($X"?.O<;XX+821L*3\,@V3(I(OUF09%?\3J2N;=QC)
M R8]8-(#)A%PX &3^ &3S:SJ[QAF=.E[,*@'@WHPJ >#MJN9IPPDH=N;'@?J
M<: >!XH.!XJM"JC]6JYXD*Y ]P0J4="LQ6Z_G%7X!3I9TDWE'X&4:?&AS>!"
M;F&6'ICN@>E'#DSO"N%&C4_O@H$:(X3=#EQJ9%!V:Y&-8P"SMP18 EG']=A]
MGZ@YMV#_7P)>,1/(50C"S?;-@F]B P?A9@=W!?]WG,51,H 5*L>;'% GNJYB
M\A G0NO:_>,\B9=Q*M:M%@K<=HSC :V_NN?%.;>!7^\R[EN!L@]52/.X8.?_
MG%Q]N;S3G*3:!G@ UO@H\I#OD4*^/709/<T>[CHNGA#40CPEJSBOWI;?ZJNG
M+,N%D<;S^$_=FS,&/8?@2Z=\JSB"],'&RVG!^8%#UH2E%UT]H-8#:CV@5A-G
M&32TZ^&H1P!']1@XCX'#@B'P\&$/'QX1?-B:C-%X[$8'0O6P%F-IXF$MQX)\
M0(UYZ1ZB&B/RQ5J]32RHEE[ 6EB@*ZXA.UAP*RW\?4 .?QD3A[7N/R"COV)C
MU-09#>3S-R1\6@"4N,52_1HD+)T+4V(IU+B'KH\. T=SA(TRHJ83!NI,#'^9
M9F+/5<:9D--D5RKWEOY1Q)Q&GU,N5(V8A^*3GY)L\<(QVWT@&X"D9_.?58K]
M'A-X*8U.,?>M6.=F\D'=K1-].(E$+VXPGF0.H+BYKW5R-]_V,I5;E$:IN+DK
MY*64'I-0;'7*2[EX&\\7+\-'UL:SP-8%B?D7DA1T.I,"4.@A$F!;Y--5=9[K
M8WIMNMI 83&2[O1$N3+3IYFX2BZ$0$Y#>G5UJD82&7:U1.SF+)T_EL8(C^=S
MRJ>S:RK+;S_2R^5*W#?3V4<A,'@J"9NL5IP]DD3:,_]91',E>,OZX%; :715
MV5VG"PDWWA_#Z6Q:Y$+,IU+//2&)7/+)3!S:3V3]XSLQTKL3*KX&W?[G^SJ6
M>QC>)B)/J!OR2%]3L>:7659((J225)FF&\JG,]FFGKOVXUA@XR[.A5)"Q )*
MR=-<K1O2W@)9]TRHG?MZ]9^%>.175(CX!4NBW;1U!)KUM$#J5\(YD7>1D(4I
M#>6DK\7,H1!2+V['H?"@$?%1]';PD<;X@T-KKI(O9W$62AU$2-YE7+S$.QOW
M&P+;DY LF\XV!VK*2^VIYDN VV/AH7:S&_08.Q\8L'UUU)T_":TD%B8(CT.Z
M^S';_)J]5&RLC(6%]^M"WD+3V1T-"RYL1YJ=DB2AT<GZ)>DFJV ^Z@#K\=R8
MTP@8=</!J1:6<YS=K;C0ZJ;I%\)C&323)K5JTYIV'YS#"R+L@M*J!G'TNOG@
M'!QZ.LYG,ZD;/JI=)9W&&)Q7)0@<VGR\'""XW9Z3)K9'S*(XW,15Q8V4AO%J
M[XS5\M74>0#NMF?@_&DE8X\U1CF@Y0!T[RS8RZ7TY50E9#YREJGNF^8.0W#!
MTHBEY<H^D/3WJ1!"G$92'EU=GDQO:PWC5GV'X6TN0]>:+5779"!*\PT9]V)Z
MC=:B:XJ <JV,U3<>)_4([H>=*U(H[( ]W]3<9XD,FR72$[6'=H!&OJB:#4RQ
M]F2J&XZ+:A-9XG.).C,"< 0P4Q,'(W_-GE36PF&)D5.M<L3,%!&,_"F%,X,+
MP]'E@4']=6BR;\ 2@W4!1*!*>+ C2C%DWUC<L'I5"MUVU0@.ULGH1[E3VXG2
M(RGI;QAC1;=5(4H*LXG@0+F%;>EUG38UGD+U< \9NOW<H(\R8Z07ROW:33OO
MM$M]?7:?R.H3614LP4+M(\M5-?-VCS$%M3M,>8PIJNW234::K]H.UC.R)-5^
M,PI&EL]J*X=M9-FMEM.PQICSVE,:$50G<6?L&.\$@RQ(*+=85+#VR7M03K'I
M8U:!Q=!%P**W:1?!#&,.91V+\M:,N()RA$U):X0E0AG#HI!M6QEF$T'9Q*)J
M68!D0UG&HF9U 05#>46E5+5)/84Z.K!H3*;XXCU_+LJC_!8DDJZN;TDU#>.H
M( J,C$Z54$Z)V++R& H[>$GN6%)(XC-UBC*H@XTB"I+S"\9/&5\Q87K1?U 2
M_5$0+@1F=IG^@ZR_$2Y,T206YG@:$TT!B$XC66$ERRB=KDH+,IV7]$P>9"6A
MVYT\K"<<WJ\O,M-4[+>IL  78M$NJ/9=H58#]$3X)V':+)+UK:)( +!+3\1=
MLUPHW68?OJZ/??+NBH=2Y @CF'(NBWYEH&^M[8>G"  ^BMY.68(C>[;)/\[3
MDJ>!'E/:OMTN% $:DJR^"$MS0\?4*E^:KR%8_2K]B&@>:G=L%>\M80K!HVTW
M1.D63HE\#5F([-)VN.%,7,G*EYB:F@_ P2;&=K>@-+^2$TN[5YTPU-0<"0?:
M5)SF#N/F D&2XD=!QA7+LFDJO;^R;&OI52PU:04_D"Y#)7YO*]06575L7<)N
M0W,D'.A37QL[C)L+!.>CSL)4/[=LV L)/Y*D*L8IOX !2_4=!^#J.5F;B(^"
M$6W;P6DO@XK3V6=A'8CU5GT,4)\!>"GA0G&T650)?YCF"\HWA=Y+ZNH]INT'
M\&GQ_O'$D2<\']4+@[",V4;KA)E; 9CX;#:!F9%/ A-O8 WZ91 4H*FZY=-F
M=A/(G,"7X=3\79C%Z""J)!J[^_C(DJ1A[B-T^QEP5[#NVB;*;6SG2CV23.HW
M]3"L =($U<[%]4PLGHQI8/P$U>YMUF,9/&J(;I=V4^5]BK1/D?8ITKU X4%A
M6K?:BS7FX'$VMS><I;PZ8UR<6X%I$?]M%C@!LHDEW<8<)0ID$$O:34N$,9!+
M;%DW!I$E((?8DFR,8K- 'E$EUYB!HJ$W/Y:TFJX >BB_V%0=0-C:;0;1^W=!
MLLV!#CA-I# ,<A9D)*$!FP6S(B\X#3A;DT2F#G?,-+(UG:.,)+OD=LI<F@B2
M;_];G?93][N%A(E3MES*S&F2?(H3FN4LI5F93O^)/,D*$E75B,FCX+HF(-UE
M""O$;Q/^]UKX;?FMUD*OH=OTVXG,!9\K7]AL/XH%%G99LI5@;'KA&M#<)E';
M\:6\OHIG5-@UV^-R6YV6>W8GSLIT=E&>E-OM0='2WGE4"RQ>Q#S++UC!ZW:O
M^A0:=+- Y#7-#^M4@5?:I)\%,@_+#>W&E^6SRM(+9=JP]HG;-OUMD/UJB3:G
M7DR]^ZBU[_RU[6Z!Z.T<I3 J*_U40E:7R CM8X&\NZ__I7EK^>6/>/+6\%'T
M=C+I6F2)[&YB*2:N64KV?[D7_\I(J$[[[CC*6^$7 :K;(SC[IU:6")[.#O:&
M)AE#V]:C3YW ^?3?@%D2;Z,#^-F*>O;O/U-N.:;7DMYLV!8?Z@X@!]%LMZ[B
M@+4U?%'MU[ZE)X8-WD7FJ)V+'EN!$UO1S04Q,JQ%1R_1&($7G9SJ(\-@M'!2
MC1%^8>Z5'2,&HVLT962(C%XB&R/#;)A%IAS'O]\'WS:UH+N&MIM'<A6UAE+2
MK91F79GM[?L)SUZ8^)92GBWBU3T[H8)XNJG%K8P7VQS81I1-EGL56U_^4CUI
M)^37MH"X.IIAT,U&W(?.XTP>J>A,+)-\R&!&N9A031^LAP72.KX1>$BSE><&
M,41O\%'T=N))H II&^U263:O]G=7=0NE9J2HV/;J-Y<T*5>KYE=L="&(9S4^
M.?HBW@)\8'9X'K2%HR#/S8Z<#ZQ["_HH"H13LP=6AN?=_%4<R"JT?6MG^/4X
M> ?.A.&:;@-P](F23)C+4N.[3%?%\\VH13T8]$3!UXK*)^G.XL<X$J:;M)X-
MV6L: !&7,I&C%7>O.R+@JMQ17UA"\M+?8\28MB\"WF[C[/<+87(=>G6,&&P>
M  &7=PO"6X@453<$',EXIT;!;&J.A .M6M;<8=Q<(- M#Z,6VR>295[L<LG2
MNYR%ORN8 O=#P]-6B3-BZ&4G+-SP*M)P_D<1*RNHPSL.@:0LR2AWBJP>,YT=
M "^TIPG>\;BX0B K/&;7!;5B"\C3*O3\0KKTJXSA$AYP3;^5OZB7W:#O$+P5
M#UD<Q82O#[:[1H5I;#\ #]L+80=.:;:](5V0<?)296G!F6H(9)QJ2LA#NWET
M?.^%?%]'1EA#< (3!W"??]-+V-B_%=CX9.9&'D8^FV\HUEYS'5VBAF%L"QV.
M'G+D6%N$"$K,O"V)A $C;W$# Q5/=!O80,*P%D@BE%O8L@@^HNK+"C@)FEVK
MTM]8(TH'U4:$ZJ='4AK9++Z 9K,9:)L:)O7A(%3;TJXJCN&"[_WK-H6@T656
M=6,7$)A&EUW5C6-HI!K=OC:Q3*S@K-%EF74]V0W(('0Y9W8D61-4R.UG1E0+
MXOA**?@L;?OF-) EXZ@;.D4"QJE5U"PZU0*V!J:@"G07:8=/;0831W>E0A*<
M[:<O I<!2YZW>= :R""6I.[NL6L@PU@RN%LB]H!<8JF[WP;&!U4XL!3>;P=,
M@'*)3:\R2UG9<^FD\L"'0+19QGE9OB00! 7AMC9&:*'2?LOA7=4HZ$1>I\(%
M-X5\^E98MJ4G=L$2L7>_"!FV(NEZ(M3..8T^Q=F.WFR2W2_H05MU>KK=D2VD
MWNL(^A*7;COY&-5=Y>+)WK][$/+@PSLRG0G"SI_"11F3"'/Q5]'FMDBH:/)S
MNP6P-1^>E'E\%/DD_F?)WU="7,W+/7<JGY:ISYA7-QJ$2F4J"*3I>"A& $67
MM:=VU:C"]=8)(=^N2R--E@>XGX?7#PNO]\!9*\!9C8!D)F+)+5^6 #!-MP,:
M< +H.S#G>AJJ6$JWW8P<OV!M [2U5-RNA \$^D#@\04"#75+QQZK'X-,.GDK
M$9 %M(Q5=?53&0WJRCO5@JANKSO>?P*4/U2WLN KFLS%T.+RH%OX=AFBNTQ#
M7K[H?1"6KB7-N'=O)&] OW J7W2P01A?QIE\J_>4K.*<)-+++K;3W4K.F6W^
MJ/G.YMTM$'TN#A5;4UH&<H2"(+2\C-XD)#V_N[E1$VO0K4\B2^4DJS 47ZGT
M\]-H\D@YF=,+$O,22F%$OLF -A@K18PX,.)LQX\E!1_>O7^O67=(!QN$B9VX
ME*6IMV?FE&7U[PCJ6UH@Y46%]-H(I#@K6XR!LEZ'G<%L,.1+"W<BK3RC#^+
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MZN?X:D!H[JWGM-W*6K'3V>>,EEHIB!]%GR%XR1>45^IT\S?1M1V*]@/)"6-
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M9+ !,[>;KN_:5@-E;I</*I2>KS/V3:4YJ1L.D[==YYBXB%.2AL\<$PINS =
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MM 7;JV"0<(2NF%BWM6B+[T4G&3HY'L'@;73*40>&#A^F:(GO0Z<J];0<S6A
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MU2NGS1J28 7OA2>M"1]%/M%*G3Y2GF,XK+^QO8<H>XCRN &V?@4]1!D%1/F
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MA8)"YQ6H$8F^XD@.S@*=X;$U(7Z8)B1]I+O+>AKA!Z4UO;\)HP+>3LJ)(/]
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M81PDM\$&9X*[I=!+&MFINQMWD8V:4T<;(.\MT;0 ?XD:TQQ+V%409PS%!QQ
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MG0PRR'ED!-W5<#YP%M'QE'+$PT%KKDZ7C\BJU;Y61:Y7[9I3K;Q6GN(SVD6
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M-*OV$8_[U^TVQAF_[Y)"//H]587SQ4,2/S(#3/3L:_AM,W=<NJAXNMW2!<?
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MHT#:4'\]J PR0D94F:L;G[G\L"^TUAV:V?F44E3F26O6U\_EAV86/^503 /
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M\*A3.GG(XR0[WX@.UYV?Z-!=MH!\DV%WE(K8P\KG-FV-VH^!8E113=9O'-X
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MWQH0BW""%9S/# AI>5I/#6&ML"C2G[.<TXP5]"Y[>AX_PHC/,>?: $R0PVZ
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MD$)'.;VU>;J%5 >$&=(Q="LHZ47D/")NQ8Q69X^5,-Q-" 3U!]@F4),3>^\
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M?ZOI;(8C08D7=<.!J'W .;=+K].85QPKPD2 ,)6V,T4K+\17/D_,,R 7>/5
M),NUQ0@&\!B3[R&-7U>.>X7!J&UC%#DXG9T?'/*;EZ//299G92+E&;\';L-U
M><ZJ4#,=C3IV)*4K?)A%A"(Z(W3):W662Z8^10?8VB-:G4&T[L^/PQ-FPOW2
M\TH;/%L?G3'EL;L_>],8Q'.?4WG<J2_BX_&,'L_H\8S]KHIZA9L,><B[(LI3
MQKFI[6G2@;DZ=BGY@+'9 *GE(I$'2 'NJK$+ GR*0/R,KB )U(>%Q&DV]A4!
M5E- #@Y7@NI#A(]'"R;QX6-I^+A3'_3@0>5?@P]OWOX1K)@FH!M%KNDZ7-A8
M.+DS<6(?B!US*,,5/@R'9-*,7QUI/,T7B-ZRHY2B'%=O89VA%,VP]'6?HYA-
MN^&\"]V[T+T+W;O0O0M]_-:8Y>:YM\8:6F/=W/&#FV&_!3AEK5"0A\_Z[__5
M]Q[.&)/-W\H>.T,SPCY2^/S?**3OWKS]38R%530]C9+#]\7COU"4/Y#+YQ6F
MY0<62TS9N M4<_4],OY!'@@/04C0S(JVWG@>SG@&86WO(Y2&%),O:;9"$9YA
M% M1M<JV0]&\W7Y;@@189FF[L1OUKO!AU#G!EB_BE2#*LA%T+46+2ML:H/VZ
MO*[9@3LI\@6A]0<,K+$5U$M1E:KF)CF .Z\@70QP<L=42:8M+Z3+O[Z1*<<4
MLPUNV*3)?Q049S&.A%J29B_O'G2RLBO;<N?,-,;Y>4CIFAD9)11/?%PJV]O"
M@Q*.#NQEAI];Q)0RQ7<X;F.25I6LZUIY=[AWAWMW^&F[PQ7Z-]'5=%V12_T!
M3X!GJD-24*@;I.&-/G8)J=TX1,LW-79YP&-+$(O?E4@;_'0%.'%<$8IZB4BT
M:U>$(+Q?X/$F5R#S<E'  C>NR )^8&CYC5P1#^CH@#A('#I&X J:S%/J?K(%
M,/ V]I4!4DQU0O3NYZ!T!_P:;2%+#_R2 K_@\;'!P5T?@ZQXS-"?!?\3>N+N
MSBU%4(279(CA8%Y*(EIAO28E&>=DN21I69)3C!12-.T MW1#OJ,D>5@@&JY0
MP8P^R8/MJK:.0<\\M&K@ -)9F%19N CEW)0HCW%QW$O5W!(.I-$P=0<37!09
MNW&S;!+]6> ,EW+E_Z1('D8%][.$)\G2DK<>.YS,%3Z,PN)*V/TDR]#K1UM>
MT2]L9P*0XI]]]N"@9M3N%.)+K@_+862RMN9I5Q025K2V@W[Y9E6U-\^#LN"Q
MLKTA'ORSX![TY$%/'O34V:I06K%$WUIT1C8*,XPTMCU=D9!*62':6H%+DO'O
M9K</PD"TX;''*=OOIM/&2('<9:Z( W I:41+3@<- [2&7%DF&H\=0X)\[F-B
M],(ZKBP3'?5?X4GVX!@/CG%.0]5]XA3F-AP0&9/A>8IG. K9O\,HXI!ZG,Z#
M%4EPA%&V^\>60#501G?$(7 SS6AJ5S)IHX==H"RB>,69F,ZJ@^&6S[86N9@;
M]NX W7(>9@O^O_QU@B>F%7#/:!I_"ND?*.<;_1Y%!64:)<H '+0>K N&2/F=
MV=RW13XMI5A-!J%?LV\'Y'X+^>,S>0:F$=2A \(.-E+C+75(=Q?C>:C4$5'V
M0*4FNP]XN_EL"A2%NH,1N%2&L^GL%6V*C=FLLP'N>(U\BA:\3N,3JE"[.OSI
M=C?"8?G 3H77O\/9'U7^!_^7D"EE#S-\9$RH<;B_A-1?1]W%""=9/IUQCX-"
MA8!W,,1%Q@Q=$F'^L@1_Z.OR&>=3RJR!%<G"9!+E^*G4;:;T#K%SK(ARINRD
M<PVNNYW @)0N0YJ6%"%:/KL!8QW8RP _5R&F7\.D0)]0R T^KK7H')C:_4W4
M0UNN&)6<LOU:F\YN2#J_8:=\7#EW8.RV&<ID)3@@=XKF1CC($;.8\\MG_O0-
M<+O!.AGAACM(" 5N+E5S QS<,/,=H1NVV:&7':"' 3X^H^\'2BPE*?MG5.&F
M=(Z_IL.8>.[D)24*TT71>JSTFWUPAF)"JTH'=RA*PBPK70.E;SC^5Y'E?-T<
M^,9$K#4<Q@C'9(5HON9/@>:3-.9NL]5>15 ^J:/9W4B%T@CA)^[Z QZ'Z@X&
MZZPR&5^@)Y204LHOKD\A.^">1OAB%VB!F,S)/,5P0Q/<SP0@&LVYB._0BE!=
M]XU67Q.\U;Y>7OFIV0I[\;1P)EV7+4;RR31.)M-\R=!T=IGE>,D($LFWOI%C
M*0.=!"I\,H$HF0"H>HX=+. 3"0:"S5@.IO*P&:C-?/@&/# RZ(IH /R2EB 1
M5_833%1M K*NP)_U)-7.;>(*%%A/9O" JRLX6#WYR,P%5V"Q&D=W1^@XL.1^
M<4%R+2.I8&']ZI*P&CBRP(+ZS25!@;$_8/%\=$D\4&\\7+ET0A'7"T##A>.4
MZMTL.@47EE/:=WO@#%QP3JC@+>#Z<$DYI8R#@29P^3BAFC<,:L*EY)0:#L7F
MPL7CE.*M'>^'R\DIO;MU_!DN-R<4<MW,+[@/TRF%O"\,/5R<3JGP.D!AN(B<
M4MR;943!A>6$LJX'H(<+QRG]7"L)!BXCIW3T=GCRO= &>GLD8 ()4_Q7.4$0
MIG&0%<ME2-<!F2DA165(0/NMD@ZG'.YMD\Z);E7$H0[_U3F=JLSXG@3C4^>M
M3)V_CQ8H+MC7FLY>1"2F,QZ).%OS_WO%SD1"E1#FYB-Y8*^3P-YR?M6RJ6\T
M#FIA24OC H8->"]XI+((J2Q?9F/''GJ L@<H>X#RR\>":R]!TJ%V-;0)^B[
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MM4Y  G.\N2(#7X_=U];N>=5 /,'."$::_J3&!(Q=#I![N1V:V)F<%%^>WK^
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MDQ["W.;U*/XH$HI;".G%.$:Y/GA,3'IR"-L9H)E72\_7?'F1E(E9&I&3MC5
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M[.!(4947T,,&/IC5S?\0SI&HRB*DBPV<<.GJ;9CC'B;XV!RD1]3)$RQAO4R
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MODYO$<4D%DAF0 J"]*/+HB[84?@-X?F"L3QY0C2<H]_9X/D%.TN/JB0._15
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M1Z,O>QT-^+!1[\*JFW5^V;L9B)-[9T"G1@[9M\*YCCT!0W87VH7HX$Y#.<9
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M;99<I'29M@-+#HDH33FF.^%Y(6:;>)Z@T'-;0GF]<5BT&G,<_N":MDLPSO(
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MMV2)S.W9F4=J"-J]"))K,*ZC>M$=#\06X-0XHQY:X_9MTA*OV[I?X64!:/\
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M#FRZ$VZ#%K\2U*1%=@QD10 FT"@.PA@-(Y@;C$"YF7.Z-IKONQ\0&^BP:#L
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M\B@*9#=&9^7$H6?J@?8D'A2&RHOUL9(^*%"^*8-3,0YG/&/09XJ43384PV[
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M3?MW3+2K:CR-"Q]%[ Y_0:-2)W-@D4LBD,F5;@4KN43/!&R!QHXNAT[H(^M
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M["Q'?$R4B#57<")8["]2S@]L2:R;\:85=92)ED^:=7-G@/4T"+KPDDQ1(*J
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M"L_5G3DS$@*%*%3A/X#[*NL_&25;F7%$I)E,/>&X8J K)N*)'-7*H9@&7M@
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M493OXL(7BDYPSI1-X-<RV<18GWSQC'WZ)8DGJUI)=I><U1.7C.5WD[^AAW1
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M>,6D2:CO4CRQ6 T?=[K\9T .TY<8K@6CRQ82]UIQ\3R?J^V:I&)*-SYN5V]
M,-/ZVZUE6%P:,$8J)3Q']^:B7I?U@]BTGX(_JKM6MFF\&AD=>/6\+].FSLGH
MQ54;3_KD>?U<VS!,1\]6'.*<BR%TWFQVD^]+DOB.K8>+J$9XN9DA*I_/X]7_
M9[0O/R^8!@-;\XV$L9N=)-C.'@^KQ2?U(.YP0-RL_')>*,4&?53^S9/;</R2
MW](U=;TE89F3Q\[$]*H\[.^9_Z09BS'FC4G]K>B89*Z=G*=1_/@QS %,,+#8
M<J44AZ_"%Y'395V1;_Q!D=6U9J-Z^G<Y(FW<$CY8;E<?C*BJ>^!D%=<C>YR(
M'4(8UGE?,4'V8M#;-.C><0OZC@)T]=EC\6Z]J2TGX^[L R7Z@ZC\6/+FYCM*
MR4-YKP])QX/98!+=QN^OVZ1K3MY<%R!KGV@C&QUW,:+"+J$W8[?5[5QS^MLJ
M6**20&:*F4^Q#<NB7C;Y=N6HX[E36+V@7-RFE,+$$XV3M" ;PV$>5_I2-X.=
M/YUX-BLU"X;3"/Q23+'T$7?;1J:E;+2I36O+83FM<U97]GEHF$C^QH@Y#<<S
MG'OEQ,CQJX4VQ 9=1MS8V*YH/> ,5E!Q:V3?Y/7L!?>DVC=%XRT>GAJ)M<V,
MKH&*;EBL0*" 9]<8M[MIK;CSN&L=YQN&]+^<M6LF7Y?T,KXBL#Q\,8^MEOK^
M?+W049Q+1.V;8MKTK+JYQ]<%9CG_6;REM6>@/#'^@V)%C5(=3<I%*7ZL2_G9
M2"V,P,N+Z)GM<!DRQ1RTCR>:X>MU^Y8UJ9$'<Y+9%*0YVH965_6:KZB2=ZE<
M[*R)?DW26[6(M+)+ ;<,/XEIS#J4=\MWU(I63VP ,M?U$F5OH/".B1Y^X8>3
M"[96YFXM3BM9:E=%8XGT:&7REZ9]N9;=CJ9?:A?"/>!HBEB1C!"PY) *W+KX
M."9E'!R!F3A$L3QF< QRY?[@I*2M$Y3'=7US1EYC6;"^S,MT?C,+'I:Z+4V;
M?5?S'[&H&J5%I&G;-RW]BW-[B0X9>%N 0W#&=%DM&M)%#8V&0]4,01WW/?,\
MOS#KWQ:S7E+L;#/9LO#A;*R[UATU/TOG5B<^)@Q+SI_[R4R=H0A%25,?]040
MXQ-C#O"9XA[>5\?@F-L^E-O^^)C;_H_);?_:.^LR>KEP:<5U<#K.ARE="1-J
M'O5/V3!^J63)JF-92T##E>8]<+^FU%EN24;R)1(\I)>WL;59-"T;GC.  /2,
M;RZPYW6S)'-,XQ^P@N:2?0QJ6O,#9/\5LU5%LK<$C8[BBL0),"/ @[ \DG@R
MUJ\!Z 5N9FMY%G/N4?YA<CNP21RW&V@=>5M7Z/FE.YQD U^KBF7-5BLY[QCG
M.3>U*[)#WAK%[%RR@Q""U_4.)O[W-<-CR'8)T>FCZ8>3?JNRPFEV@1Y!#1U;
M3_2 95^BSI9+V\EAJ>B-"AT2@BC\D8(KL=MPLQ9(-TVU6-FBWS;_'^A-7!97
M%&\2YFA[X)B_S.-%L1I9-1PZ7O3K3#WA^&!D7Z1L]H2K=J,59@WZ=9, HF (
M^8@;\B"$\<OI5Y=($O!>?Q]2&0\I=^,#O@=TI5.)JI<L<C46S? Z3<.U=&>N
M2?K5\S9/*Q-^W!@&+KQC@/B]]UWW#4(U^&PP<P[2,6XQ]&&^-8 ?5&6,CV_\
MH(SX'#?$H4XG+ZL8@2@4:8?C''-R'.?"_[XW4VZ=*=B? A((YH6C1!\D+:'.
M0C$2)8>U)R^-L8<<52"ACIG?.&/?7^.QKJ!BCY Z1K6X"N/R0OXQ(,>.D;1'
MQ>GR-!L$*FC6'P[FL3_PX&!CF/))N;&Y[X84DE[<;1$"#@_AC&F,.#BA3A*=
MC([*(6G?9<,+@VH%UO>Z7K>.D>I*XD QZ1MM#5Q/E,6T@_B1.G%BU]BKXF7!
MASW:&S>_]_?&];B;&$@]D7*4:]%&1S#T(T+JK3ECM>-0PBJ:J\K#3=HB.H7@
M:CC3G"*B@[?,837F]+4N+]=FAZ(F5(-''+PD([.'H1=")AK$29DD%P7L1_H;
M]SVTB8^A'6=VCD.B=GTD4CX>BKL82T37RZ])/BNM7X&;;?5PAL;(=2T1VW'0
M284_!K1'JQ;8\N=GN??5PV-)D>='J3Y*]1V,I:B69$RI-[]M$%@XG[,W3<;U
MUS7J^&'R6F(P]/I*XBPR(OM2R)Q.!QO#)8=\2/)=?QB*MT$7SN4P@MRYL\YB
M<D(*N@YF8L:_^J]\LWWV4R9]SUU7<&T;A[^U+ Q735.L<5=Q&;B&2(S)N==$
M8EEM^PZ%"VZ2WN>O)2)F2 %ZI? _T7$;TJ5O"AHIE^)RX_'Q0!X/Y!V,A5VM
M#M"_%KEQ1:C>^0_-I/-BP4WH7KC;8KF1(ZI=H%[$-3ABI4(=9YMFK9/\HV0?
M)?LNKAH7#E,52]*9P! >#/!8*[G K[A,,HI>B[FK>44[N',RX@VES=F0=XD?
MN+]I$ER<E%&LK2Q6=L;:0*DDP>6#:V$>7"'ZW3JW3@6SY**/,^%2LGI#/E0D
M+(MQB2.D__$8WM%8Q$5'K^>ZN.*BD1NEDWV/I&H&X;N2[+$(1A')*U+#3!X?
MBE3ECGDG'"\GPM G^I]&#_ #[:W@-%A-QT@<>BU [VR+'T-ZQU-_:X[>%C$T
M[C'1#!3.<BVA?;T9?<!>[CBN*"V7JY-_].C5RT*EY8D% Z6 *EY_VI;TSC35
M'!6DUK?+]012:F7P-QE>3 -!A6+:P%2O^U"B%;%2MOG.7,,TC,C.8'/TUXX'
MZR[&XLL)I($G7)+YM%AK 1]")UL _C3,4!*P\%LN3M0F7O2F,@%*J(0(-S-]
M"[9M]-&.!N)1HN\H^Y/<#\%K<_VO.3I#A(U@59.O=#O#[AW\%($@Y_Z*]=W0
M8B\,(*"OC(XHKKI+88^%A$(6OL2M.Q%O&47F.=WFQ29".VAO"[>WCI>)>/0O
MY(V5^20.:UE4A;;SAYIXZW([Y3XY$@T%W-ILFV+%)>-7C"W7DK'@2\$8YZ0-
ML5N4C8Q8NURI@<IGSOP+1,'LV6N&2/F&G/BZ:>5W'S^;O,;S7L?G7=S0H,D3
MUI(Q><#\&<</BAQ5C<6Z+0PZ0:KAN?]/!.')XY._/(BZCB^G7SWW!4?G)BOW
MI3CL#N"1?JPF?^X9W/>S#%V<PF*D_7MR8M(JK'" D(U 5>[HFF6'FX/PS?_]
M.OR$?@9MU)#^H/#'&,L2I"7M!9*2*4UK<+5C%OOVZ=!*.U\N1:#\J3"#XL;2
MFH#B(:D;^/=M:!>T%@;QY+6<*\0&]LC4-$6D(;2)-D(]BOF@6.LE?_LP0\O4
MR29_6Z[7-7>E\NK,:!9EG?Z6%[!N8E]5$I #3F@L$V@#1&W96.&M='<-6C-<
MMVPH.]LJ1L_<BG&MG"_L4 1)2<1$:MHF\QJ5:W3]:L.;"V9BQ0(LH@-J064\
ME&*3H^LNQ4%@& C7,_;D$TCN&237FLJ OV2BJ)(89 I@5YM:VY1-J)0XD/TB
MC-0):%5?3W+#G>U;5=8W2:!RD1Z0.FW#*^:Q#^\GH&94%O/=%X2PU=:4B&I*
M(TN=K7(6/7(X6^0MM$JP5N"PT=#M'A1/1""%'QMZ_O._UPVOCF7@77V9E& ?
MFVON2W/-)\?FFF-SS>W-G9<D;NLU70B<$WK%</$-G?/[8N[\!G6Z*%Q6:"O2
M?%TQ.QQ\$P(#5+]+\=UZ%X#.?&&$M1A:^X2BNCL#6F DUFW]F[U_!(-9L/[X
M2XJMIFC--5DF.VVGD4Y1OIKHP8:X/B\6!2!],"J[J!V.LS0 , 1"$S&9^ K7
M7PO?KLU' -I"*U,&]*8JFA4.#LWC<ONFGJ15=X ?9;>.]81*-RQ $=D-:_M&
M"21D/I'Y8<F\E@88X!J.V$O39]Z$?49S'_OFV$<7J.F<[M@TT)U=]-QCRY9#
M@W*$ZR(=K!M$\9;O[# *O#F^J0WS@ &6/C_,-5E-,M.DMCM(G'93Q$V* MIP
M6)L+)V!JM<RN&^J%L+N'I%^#XP.IW$/H4D]=7C8O>,5; =%L4'T$%,&Z.N'F
MY-):MM0?=@LB51P%VLY58O$AY[S_>E>[]-IPJ]KPUN[VGK?-*S&J8/]3_6OT
M :H\0')%'CR0N@@C6N&UC:*KCQF]8YCVMF.1<(&& _7.,Y4=7'>O3-RE_,ON
M^@3#X8;KNMBNBCF==>9M(+U$D]^NY,>]B_R8E#N>C3L8B]I]@N&#F_4H:$=!
MNXOL+]?"-QI>F]750BJE!-@X0BY$>_.8MSW*XET9!%O)S7D7$HX= S>HTR%5
MY)--V<9R<>^01<L!#L<).QR[$9?D/RU'>ZBE/X%W0B558G%IU7W["PTN_#MX
M;B[N\)O;88?#-#DP5Q^$4W8N!=;%#$U$\L:G3Y!2>9)99@"YA.M*,+88PY[<
M;OK7&2U1V_8&*:OGQ4#^NGI9F+V-UB- WS,"S@(XC*';SW4%XF!T,67%D2 N
MI0#+5271@$4B"4-\B343?,Q)R<4.)3\XV],?)3?X=5V_<05$R,.T,?(@XOUV
M6Y+<JO@@DZ5E('DWX=A QXOU68RIK.HU2V9EBQ.(.,,"H8/JBA3;/+04F[NB
M3&KV9$39:?I]U:',G_XFC\M CECY>?TY!TV+?(5^OEB55:Z5#%<@K)C\A3EJ
M-#WJ8--$NR7!QU^T!I),TVZWG6,I41^,*3\F^?SO?:NUSUR<P4]K!82<]Z8&
M1H;.-P#R8F$1SA38OSAV[*ZRBA0,XS@2HE. ]9'87:< IIBE!/)0*\D_<HAQ
M5W0".6YA."[_8+:7E#)'=WH@9*GB0!XSC-)-\04V)XUYS6M7Y,(ATA:!W+1<
MA<<R6^7K=5$IA*A^_4%HI@'JH< 226%MGO@Q0R=^6G,^GC6&W33,#<GTJ(T&
MP(%IOE/ETB97QX9T5CW7]+,!20\"A3=<3B-W&8!=(H!^4*I1FCUDZ=B$WO%.
MSR@IF/OV%YF@0N&/_#X^6'2I//N2R1D\HT,]OBJ2(@:BYKSIEP8X&?2UKC[.
M,.)],242@=T=2B6 M ZOP*UR(/=!\.^@3.?G1$.!Z&%/:,+U.@ZM+==&(NK(
M0D#UFU;Z>]^4[;Q4L,]0JY+9W8(K)2.!GI?TOXN\RN=RP^!B(4E?J"H4F5.E
MYKLP<<\5E7!1,F+ M;!"53V\PT8'M.3)5!NIB%@4A?#\;/-R+A5*;R4IH^3$
M[LJ&H.&ZXI1+=\VZ&U<3C^?L\=-/L\$EY182UY.R3AVZKOR?AE?7'HS4S[A$
MBC!.^_8ZO\99VKL,E!]!^O7D+J0G#W8RVD9<X:*PIW9:<B[)F$L^*KT16RM=
MC!P,^IK"/P#DIO)];SC=BY/U:Z^4;P3 #R(D>HC#$%Q1\XNRLY*QR:_('$"(
M 'AFS-GD!#Y:IDPCJ'2VK,[.+UY\]_K_92/UERCQ@4A=H!+JDRPDGEX)-@#P
M '#%,*A]'MTI*&?Q74ORA[>W_7A>O27W;)?%U!0-1][^Y'%\_7-6\^'Z;'<T
MG4W[+ "?V[52Y9N"Z5]R^@O3?(0^NH)384U=<0N=7!1*@.BY^>1I>IM9^1Q3
MT<S=G\(H,I>.AI?1%K,>5=;(,W5U>N6S)>">'^:;[+F(HA[B^R#W=U'X>1L1
M#):WDUU=J>#4T))Q4;+O/X8&=P8NOTMM"YRULKW=4X]U9?>EKNS38UW9L:[L
M]G5E%V3^%U((_6"JR;XLO_J2>7 3>9IS+ QWR1\%U(TA?Y]-&+DZA+<N8W@K
M\BWSDVA9R@>Q-#^B>&9.9G*#RC-M4IV9%"A36-N#O .1DWQ;BN/FBC]B-%=8
M]E8<HK.J-HLDV4/K)O*R"*/,P-@!3T19.Y#M0)62N=K[D6^AH8=-%+9VW)<0
MIE-39^RQ>PQ8#(WD%V$A%4,.+C4'0M]>S=L W]:*9JQL+=1@:6BVS1=LO D5
M6T".JM?D#FH5C6*P9>:$!":-0]B"+7VF70CK@Q3"B;>?O)\N;41&##@]&L)K
M-92O#$\'/(_K4L>#?NNKHBJ-;W=>"]T(V<RS0B/\Y6;*B%B^"- 105XID/>6
M8X_,O!M /2<;,C!IG9D<!R(4O+/!7D>1K5#F5U< 63 L[\BH/73K!E9XI. Q
MX##]6MHX4TD?..8BP!"95<))9&B<[G:V$H.9+?H,6]X4OCZ_; (2NH>"-!!*
MG5C)VQ(G1J*Z B;?4)SF!1](C3'LC>7F;D9'0_X.\JXFUW1:?H#CUT^:O6Z)
M 04*Y[X54<;+=!-MK\GN7,^5'-+P_D<.D@,_#Y4\Y6(2F;]'M_X^:.L[< 8B
ML0+I*E-U8\L25N7T\C0S[&Y\*3-FKAB9#Y6MB,Y+Q6IZ!$4YS!.O4H.RL2(Y
M<PP+(5G"/3 2I("WL1]DU2DA1"XCM %>LY?("U)(.<([2EH=@M^C\D,F.">-
MG;OC%+M#C3-V4S?;%7**8@3LUMEDM9MSHQ#]@>D6Y2IA@(@Y#(9')3T:'5V&
M&6//JM_N9O7<OH.GR,_X$GW+;BLWL'4M5QGP!@4YT!XW[;?E53[C1!.+_K3)
MT2_E0\C '"SJ!;_@ZD-4Y[*31J/"0[N2BW77^68C;5R\>])U]L/E^<OGEQ[R
MD#:I;NIU/D..A/DRJKR5]C4;]LN_X>4B<O3#AC;]+<G&1MD8: 2@Y]CTL[I%
M+%!6U-T%[Q;4$2EPR2^LN+9'.2VTU1!$G X-[]7%^63;;[:M-.OAYYA&X)N.
M!TM:<A/VDC]S/S3'[VL"OXID6)=*AO5 [=]OK3/1M=!M^X9NI%9([)A&)$@F
M6/KX!L4M=B-E&(=GD4KI)=\:6S1QX%@O*CWBNN\*SX##:NMD5>.J_W$\>1+I
ME'WS!QT-/T &1B2KAH\,M&,8+%HR=<1MQ%V<,K_-!I@>W%D0PWH2YHO - 7#
M955YX/9A(!Y<\Z2Z9D$5(4,4 _28IQE3/!"!;BRV0]L[[P:W>6+HX-Y"G#MQ
M/Z:DDA:EM#^$9M,(TAJ)%2:U69^ZWV&3"G\=1,6QKFF5Z&6K8KTX69<+I#X<
M[K[?XZ)I:N9N6 )OG(,II">%]:*E<4CB)-"5SMBV:Y%48(MOO<-%:$MF\SXD
M8EX<8H8NT93A$C>%35-O+:F:L!)?"<5WLVG=K9JETB2">N"S]VLTF1452)>P
ME0VY/T>N6#K?)^%\CRRWWCDN\1+O6RN9<D2FL(M'4Y[WXAJY P/T_6Z6'W(:
M2=V227Y?;Y0[6"+)=2O/F1!)5W$=]B3%J@P<HXZP+0I 60OQ71K) !F)=<ZD
M4R*;:DQ*,DQ[\FA'FIPV9,N97C+[RV;6EQTJ:YIA_WA5.ZO:S@79ZD:I99XB
M#Z,:O%X-MT.ODV6XAI,W+=QBH,:A6D<(EO!B.<-@%+7,3W([2'60J7+0,@#B
MFU4*B%X*Z?O'%3;/P<TS67$J35M-9B64SNGD6_UE"3@@I,<8RS29'[X0^A?Q
M5&E2*:78M$-S&K^<3/F"KX33R86\0(C@F;WN[2!G)A$3M&JVR9VVZDGN. A
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M;<Q1A/B29 TMVBIV(^<:MG,D'MZ1'G7QK@ OD7,P12^WI.PH'>L 4<1N7L?
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M?:YEN[%,_M^+>LL5-O\LXFE-BDOR6</I>4DY6<@R%(4X:7I8L$G[41X[X*_
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MV CB)3"DEBO7@"JQ$-Z/ !["?AI JPLKC=#H8U+1.2\V7(S86%YO7%NGM$+
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MI"( ?R0=6#"*<^/XC)-):"QL8ZT>EQ5"]*34R]68YC?/SQ_$"?WN-O@)T9X
M-A+?U9R-GPO*:L#-&N+LNKM-6PHCB#I]95-W\9HV1F@.>!QJ/OM9X(PX$ \
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MF=U0XR5I.Q#BJD5_I=C0!8@3;1P#$)3P_3)6I^W!]C QHY8G^0RCS< !.Y#
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M:CS8*W @(J&BQJ?EF!/,'J6BF.\J.J8S839,"0A\!#A&RSGZV',0C"RMHI+
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M-A ,X8Z+^5'^C_+_>YA_ZN0<;E51WX6I0TD\%>GGZ)T<Q?/.Q_U#WL[S?T
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M4SDS)=K8<L=)O-B73M[(=_]<O'YV3B]=;ZMZ5U\<YSTY[\D[&(O'I#.YW5E
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M5$[2"9?);>,443S>F@\B"I-R\H].9'",[PZJ;88W5J4JR>!,\;_1!&W+51E
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MHS)'+Z\"WSY]9>UPM!X9*$"3S0[.!*6FB \^-&6->JEB9NM*P6@).B;T\94
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M$Q ";AV&73V0>:_6B(N3CY($$NYOK_,N69M!5\&^Z+9U3F?CPBJL*KIYGNK
M0XI-+LX?FWY_&&8@T-5MDT1>0V6./N"9'$U:&CT=JXPS+3*+^VQO7O7Y1='I
MHZ#"-,BQM3'/=+2T(OWC4.^N5@*7)W]2/YU_*[9#/7ZZU.ZDZ#_JEX8&-/N^
MT0"2JWRLM%!JGQQGD$7O%U=JF!%[KC4X)%,;'<8P!9&&F]'"P=^D40B[>*9^
M.Z<'\9FA3:U,.\#X<\,PL'46S.?AT%OL_C1:^ACF-L6;P#$2K@790+%'9M67
MNUP92]$/[9^&_O6XXR0:>99569[1RDG$@%7[@?:PCM>6Z-MOWUJC5"%L^R%9
M@ZX/4"AD&XB"KD13P&#:VB2_3@)5D;)/W;8!*6LM39':]V5EG]=<P7@>,CQY
MR23_HNUN^U@?>PS]>0+)9 ]0@[[0RN-#MS8Z;BP$;06C<34*?B$O=+"5QFZB
MM9S)C"&^. T2$ "F?_5T ;\+'RTU[NJB%B$BZVJ78<E.0UB!#&^KC7=^$29G
M/@J :$KR0,_OSNK-&?,. CQ_A798?N+P:>89;LI?8%V9[1&M6.(@KXKN"@F/
M4RN@K(9NG9<G2G[BXJ)=2J@!W#2SDL1N.'$W;F'D >!FM0Y+1J;]_R%[Y2!A
M"H.4E-RSEV^7KK""VZ[<^].>G.:!)8N6Y"7WV7^=73+=_>*'+!"(O/SZAY%Y
M35-LY//'H6+W_S5&\7Y-@J+)F>T\AV76/,BNON*[6C;%@;^6F3APDKC^4>_E
M-N:\GF"!G#[<B;HGUV&<CAK:SL->#1EW"Q[H>UF&A&\V^M?0P/4D% Z?,2]J
M#\;0H5W5.FQ+MCUOP]->\M,F%D:[B7='5Y&</)C1B(\,[C(4#%^+R@!]Q3,C
MJX[:0B')\0)S>%S&8B+(IBUU$$K*-%WDPN$$CALH,7!O C#JN)5&8ZS]%?,7
MFTBVV.Y^>I:4Y)&&X<USGN=PJ.C#OBV9/45:@-'EJ.HTG;2YTIZIUOP9\0H9
M^!1R[Q0<*#-_%J>\RD+H^@(X,_$ETTI5R)<HMP!SMVG2'9N1IUJ4V70<P64R
MSPX.D[T 51,^,]&19=;@K$U=6NTC2DZQ5P]S/F+H!!W<6Z"X*N'1N>R#38[W
MM%2C,>@8+8:*W]KFTXF\BN"UEZ'SU?(?X<1;#[Z4[L2V6H\HF#WX(;NZ-:7Q
MQ(FU3-,R\.BCJ5U)]$/AR4\ _5[=(X7F_0K',QRU*C$I_>Z=8[H/%EIDMB=$
M&F5^KE$07/J;S/CCE> @5F2F%*A- I-&=W%1Z"4?3B9?1W6:  44(E&]MVYA
M.+] SH?;*H+KX0*43;[PPMRH.3FIEF!TO7ISU+#7K](16P[7<KJ,=<ZX9%?L
MQFS1X5]HJ?-B\4GYJ'A$"]RLR@[K9C<T701G>(UXBTQF;W\.8_H4!3*5N)'#
M![H/^AQFUURFW&V!2]XZ[_FY(YWKJPF.>)-$?W2;V/>_(_'Y_6GBE1!3N%@7
MNG%\OA@FG _(3I(4I-#\6')?&^(C8;17VAF0I)S(D:)P:]5%&(JK;8''N_SK
M5'G+2O8::L.;L5\UC@MG2)<Q) *K&1U[NH^,Y]4>ICI ^C!U4"/5B17Q,8"D
M>ST1SIW0*L0^7FH!_4'DU@?@@E%!81)%$*@OM0BI/?]"<2_D/..BY !F,*%Y
M-=:<3>K 2 LP+D=JT^4$,,0-/T7KI 6Y870T6=N3 ,EI!$LO;@!TQ!<L$Y +
MC;R"IWNZA<]A-<RRIUVX&CN8MP"N>RO#J?IS^AM .0RKZ$BS%WMCV.,93R0D
M4WHBV)' :JMR(LI9-%'Q'_$]HFJF=Z\IA@4AQ):AAHT7<]0C-90UD_==(],]
MK:(\>I"I$D==$53-(RPA0!\&N 1#]."^QUH#+6I?-*K,9!^=,_]N14F@3/,+
MP_C@M2CW!@>D=O!4;1P;4EDER6%!@  VG,E#Z%,][P_$X?C4.V:I)NDQ-HU;
MA4DYC"(NR01X-FP0*HK[6Y<V?G",<S-_V,P?]I_G#_MQIMB:*\XW59R_G"O.
M<\7Y]C<; _:XQX;O\\4K.>NOY?9_VQ6"BHI,@X ZFG246FE)52J(\K+T>%9$
M@VI 0+[&%BQ]&KDAS86&/ MA([.T$W!U?.W\#S0;R$ C\1Z"6*&>ED81]EV*
MP!X$RK=$OSBHA4O]X-MGKW%!A#(E!5]J9K\2G8;!VW"!V[U-P35"<EPF@=4U
M/"FW3\YQ[T!2EX7O&>M+P03+Z-;J[2)25CKYR*;\E<E%T#C*-HR!;[*BV1T3
MQ)I=P0#6P5= OK%LX39L@N.F1./<]:)(/;OO8;[#K6$M8UK9T22CP),J><,9
MM I"XTSO\[7RRUVVIY&>F9/;):6(Y>A=*"%>U.Q0%'+3@IHN?8BJ>.$3;0#K
MAY$S"$7L3(MI2^UB 8%O-<G?"_)T46J [*3+D<[43'-W]^V[N\>>L/4<K*)4
M+V,^N.;,.!*K-\Z<'/..O(.Q2/+8*?O8'24]0O37G%@JA>0>.3:Z504Y81N7
M178LI.)R$&\&GZZ?V3+FW7M'8W%9->E7C5&]5=61E1NVG\7*-F]B\VU=Y@])
M#^T#Y'C^]T9S\=J)]4[URUG2)% %./77L@+\U5JQ4NOB#$KT[+-\JU5FCG"\
M%8D+97A"288H_&N42>7EO*U/=TI <>ET$U)(#RIO[O.X;+C4/L6*^R:Z(:Q+
MT_&T,R^+*D=Q'>RK4(0+7;X4RR2=B&GIT\\G%XGH:SI:7IL"'EP;B]/^IZ4N
MY8I1XU+%2*#1%:X'RLY#@:RLK]9;S4N?;(^UQTW+0B=-A.Y3D+"\Y8>$2DCR
M*4&Y>KDPZ6KW.UIBEK&W6K.Q88\$X2?'_A BH?-*3PMX@G#=ESN$VC&!ZFI-
MR^F=,MG#F4JCF&RSEK6 )R\R[ABC/1-K7!#?FA9V#F]S[G)0=0.(1OJ&0\FN
M$]BD5,QR)</( ?,4[?-4+^V1%Y8U=H0A"1G4 VOC1LA$&J*5@GI>MADK<$KP
MSOL-#]:@/FS"8<V?83-!IIS^_C;:;I-CQ2"4:B@!2Z#0:.OFX$;9X+$VTH#G
MM>F-L._B%SXA+5IT+RJ4GRJ!5]$'X8*]5-Q#JMQ#9VM55H'9P> (R=RZIV#W
MR97<%J"K.J$CUIJDK"19A$L)[)U!; MKG4V-(&ZI(']G0CNY&/ZD92SR[?P@
MR2%!FWF0:=3/]$AY$89TX($I?R.=KW#_.%F?^/Z!(*+#4UI1P;CR0#CPW*;F
M6=WNH7<"LFYH"C\[!_)ESX0B0Y'[_\M<.F0NWRK@ZTT8(G[Y_[Y]8S4?H!T9
M7+ =US2L:?B"QC(*-*0)1NJCW[Q\O1QOW/1;]4(5Z('S$R;KM%:Q:P0J8?1E
MT*OB#%>.<F! <?( 6B-#,&*AP9RTB4ORWI+V@=0;D :A &,F#QX<,.WWX4ZY
M ZJ *6L%/#M@'V)E%E.I$5Z<37'%"5_5+E0%S40+KR.CAYW#?>$!^@%ICFCX
MG+<%N'_1H 45><Z-.%S1Q)B931IYS!E(A%W(2!A9U. 9;BMK>TJ?'\T0L(IH
MQK U^JU#R.AR)//%V>,O110$6=R U=!?U$$DKLZNZ#ITKBKNF[M.ZG5M>MMH
MA^5]INI"HKIH$R&>EI$*:6L.>T/5S^3>*<N+-LO2&:S[ELY#?#V8O3#S(AJ]
M"3A6LV7Q4^U&D\8%9_S<S"'OQ=UR?"?2R .@AZUXSFYX$-3L 6&6"1EYDM/7
M(Z@]=+\!)&,E][7PB2K9%M>LC28(\4-;-IDQ2 -J'?S=L6#S:5WVP7ZZ*A01
M,%9H=?A1>Z6@L?9*&,/- WPMGG7U&;JX"E4M/2CQUF"NAJJE9+%YDSK=&00Q
M W^ UX WC8&1\B@4OCM&?1LLGS(,(C]T8<,46$38X1&=9)JX ;P)<7?[?(Z(
MTF>&#V%^MK0S1%%E6!;P\<@=Z-SY&F+1#-MX2%BG'^,^]/NE8?\7SA7R%NB+
MB/164Z'\=&3VD!!%MYTJ(#4&D:+JL!H[6B%4CN-9#+M]=(E-AD=W>JP?+5@-
M_O6624&?A@;<-&0KC9R42PYR;VZT(&R_.(HZ?@*+)9TEN>U*',VN/IQQ2L:%
M,05%73$AH7K4L1VSDRXCD[ZS,:474@+X>;J,4F92']ZJ:@SPNW 31!*Y].U4
M](N^_^GQGT9H*.D(VC%*[(T!:K_7ZY3[WMY\OPR@S\%X+1 ,XZ<?%K??_87!
M7^,UJ?%8O/P\%X8"A>P!XGF[/)F4I!=::Q9\+/O%E@K2-Q@U7@I6POHXECVT
MW2:D/4#$T6V9%^H6F=IWTR#,=>JL!D,@AX-=71"9Y76+3A_?0UYRZ+",BQ]&
MXV8  P.C$@RUF/)ML>,6NDWXTA"U)>TSI?'PT/)^CCLUZ(]'SQ^?D\B-<Z]4
MZ(TNH^M@FW!5<&K+RN.XM:[JQ;>0M?M:NF2".X.Z2&X>I;@J0W0VMEL;>4:"
M/^?VRG(<D?/E6Q5%;E2DK;7M&@0AF7X1:K$! X+,9)SZH^Z?-<M#)_JO@+WJ
MMG/Y-][O/QX/Q>(9JCNET4"?.J R]6L]2[DMF+BABGU('B"T0D;%*<Q.[" O
M%]^=OW[Z^,ER](HO_C.-,3/R[13R[<\S\FU&OMT6^89##7N6!?\B1,2GG/VD
MZ9*<K!Z*E]MB0%C/"4:]F:R%3))M$K]*%HL-3M^:8S? [NH]IU*G )^!D8T\
M#&X#E& "*2E_B:C9E,\P:R=7L7ZO_!-_M?\4M'%+<_#G?[!W6^:=W3]YAORR
M)F5#'B!;<,)QW^_Y&YX^_CS,%CR=;O!NVA1EA[;E.E/]OL6NKM^ITX1:91>Z
M0YK"J7UI,M-Z=%<T7AZC?,*J,/74F);LZ-;OZ4I^5]573)^^R,E;.?#/RUMB
M3A1-I:WPQR0_PK\U?:4QZ\TUUWE_<0'/QT#G1V/&AQ^$RXWWSC4W9I0ZB&Y5
MN"B1"LQV:U%A9V>%O6VX16[!DD6W_9JCUJ=>E5RNY 7IY.EGNS#\H)-IVTD\
MUOBF, PTRM>%(/IN_Z%(<,9;7(NW=SY!2^=@H!<M?I"R^?:5N/-&[1H2Z8'/
M0J+ZVVX"(W,M9,-29,7*&/RS;UXPN<)$4.3<VLFMJ^MK;I+P>3*1G\1O. -)
M &61SZXILOSHW*.!\_<#SD3TC^?6@X^0$6@*@<_29V90<7;DW$,@R%7AW'O7
M,A-"P;24I1L%R[\T2GQ@"$K)+R3U\IB=&1:P78$U0\F?LVY9NT4JC4OS'1N7
M1XOS7;<%YX^K?PYO F;<TN0J70JT$=I-%@5D]3C'"U*::JW.T9V8KO13TY-A
M1\F%/TU6NIM%3K?/B/K,X$>SW2$G^0'6*>0 ;-04+]*GHQK$[6=%4PUY(P>%
MASC@Y40LO?AD8(@^Q1LUM,:D@OZ#LZ=:6T2!&P:&]DN<TK7F2J7PV+>AN,6I
M#VNEM^ASF4:ZRT'7/.?7U1C 0-F -"!>)DW1 B\ !5,A*\J#'5J\A:]1Z[3\
MH&'BU- 5O.*KT.[,JEB1E#8=7$ 7+^@DX8V'II0^VST*%5)1JFW+!I,0,M:\
MAY=#OG !1O:;#6/.^"Z@R0>>(A3YZ&M!F6M-T4@2ZIHYC@*4OF4DUQV;G\:U
M Z4YC86QY&Z[XWSCMP^EC"!8K@=;.OC' 51/U[H2J1WFUDFTH@C81>!=TD]D
MF2'?]V[_EK1::DT/E)1\1)@3+5YOCSC39/R7X]?H=6(4PI99:P.[)CTP]BY1
M!/$N.2O#NSD\-_H^R$ZE7:%IF A\@ 0ZDLMB-O#1=+BV7242694J1L[!D\PA
M4 'VDXO@;HSGEJ=>0 5&*Q'@;Y:M"T4(3;#Y*4W9RM52K;=U+3G)HKH ?U%E
MT)M##QO8UKO>,#(HE_BDW8,X :^D-"LDJ4(/5&7[PKM;(P"4;:<7+\^M[2JR
M7PIR"#RD@> '&BPI:U\ >0BSW.#)V*@JZ<9U^ "*V"EQ=1RII-\OV5,7<(QP
M9")%;\UHJR;3&S 89G^F>5'S)KL2P^H+@7IS9ZU<TW@."+ OJM(X#AC)@R-I
M<5;H4(R[!5-J\QGDG<:U<G6OKA@[M'LHP85'5<;9C2L]:7-K(*<[(> ,=;*E
M!K%3Q#)M5Z_?.;(P]M%2F)%>?  J)X,*(8<(KE0C6' *H;!/N)K$=/I5Y:-P
M'2QTZ1&@";6)%RX^B0&]GHCK*KCK(&;.I7RK[F>VHK=H>5=KNG OC!4GJ>QY
MQ^#]H%T/8@,+P."U57B#/Q<*1 ;*X0DVG);'YZ["G0*C*#D_OJ.6%-C@:HQ1
MY"DU'N>XA_=YYI51=?HA(19^TEZK]RJW\S[<\/^QI3A1R/=U.EG A.^V#MB!
M)Z/?= OM[I8)^'6(FS#,= &'#Q4:K%)T.LU&T@"66B74;+ZL.I_)I70D*R>*
M?Y&0,!KVNM4"JOI/,'4<EDOL =2I^OX\@QGMV0W8#L%!B9\2%:Z*ORPOM5":
M<1YE+R]\1&M\XNFNFCJJZS*H3-^UMK;Q"D2Q&$]4:@36H1X$O]!EU'RC/<XB
M2A<%#Z<Y7,-.[<[#^4>W<XBS3J7*W,MLOD4/2VFJPJ8-<]&D ;4DBE+4? J0
M]^G/7=<FZ6L4+-SL(/@[_?TI=N/$-1"8&2TGHFS+O^I.P.6+WB';M_)MSB6X
M<LF2+DG^IA&I.4X'HZ[U/)/7ZI!Y;^ AF$BYI)X+F=>XGP-!F"BZJG=T64@'
M/TZ7&I<L>$5F"2Q-:ZK*N?+5L4B5>"H_%_6!$WK_+@0<"@=CLK?JU-4FY<1U
MP+1(P]'#O,$B%UL>KO74I#NVMOSD:EX#JA419NM.CG?;IG8@N-'NJ**LPBTN
MN^4)K\-Y*1>EX+>0=A4#43FV<*GC+E5KEDGE8[;0D9J$!%4C? #V,?3D=KTM
M\I[SY"[U/T04<\*+&U]R+4UK&Z>!:NJFO"@E!&4+4ED=&"6BA@+/?Y&%[V0L
MRKU6#V$X*$[9>V \4>!6ENH89(C97A?E0?C-#$U%CQ:<>FQUXB*:,;1&P/J
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M;\F:MYUV5(<C&$4,K#O 72Q19N1AF3;'^AH*DR;7'F[V&.E!M,F1J \D(-*
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MIF+:+NB@TL*,MFW@75:B<90O \^?1Y9L&4<. ^[Q6-3R%-AR1;220!S&'31
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M%?W(IM]M^*;EU!8T%R:E.QF_?-[LCXNW!>-,_QZHZE_UW09_H!]Z^_=7O,C
M6O)N*_(_RG]@NS9U?:"]]TRNIL"T2P>.?L^& 8\CM*BV::T=&3P:1"KM[!_&
MG9P1"AWDTE3&K7"GA[W?IH^8=?]^>#R-1I=R+FDNZ,^XE4TY;#'(F?)ZCOD!
M/)@_=Y(SO$!_J^GD,])'3R;W#3$>3?@8U@SOV94"U)KVTYQIR0N^ \7LA 4
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M=_[ZZ>,GL;>-:5Q4))0S/K)CE#,IN1"^T#[\TV!1]^UCY6C;BJ<.PKC%+/;
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M@&6^T?J3\$N/R+X-\#]..-?P,5,S_-J(6W2-32U[;/KC*CEWGJ6+2#3-Y7G
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M=[V8W-@X%+'<Q[#-0H-0*%?&L#9$?]ZH(2X,?)H;(%368I36F^96<<=Z+1<
MZ-[YL)*G#]!#<"G"1D99_.1"&+(SP3JJULQ;8.YIM?[AXLGYDZ!5#Q<Z&@!,
M]6$#-G.H7 /$;R(H['%S-PUM@4(-%:@J9$A/Y.#N)%TB>;-<Z=4#>9ZF4IP8
M?366.8#9TH 41B"+S,<,ZM_Y_KOYC)*T5+ [IF:D(]_['=KGF3*@(4<W'647
M'%&!JZ]D;Z\/C*!B?D'YU4H8^QEP3*,XBDW^W'2C('K#GIM04"M0,;*4,M21
M]G:V*"M)>?1A"0GVOI<C;:4H3%H&)JFFV<YB)$H:>(,\Q5;3&CL07:+9"*-"
M# WT8"\WP72(*\LK+6 ]XSZAGS97)<8K'N%JU0[:>#+4N[PJPKK(7/; GCI[
M]YF94(('Z/N!MH)#^%.=/L:?.C$OH?TV#&HX.M&II8Q%[+[F7++G@U ;9VRZ
M9:8V)9_&@^8S58B,[E<W@(FCFT-';4F@Z)O.@F%U(-B2,N/)"XHN@%D,<#F%
M\$AV\8Y,$--X'C9ASP5!OI&K=M>2#.[[<KO#FV>6^]6F$8Q"T&OHN5Z2Z88=
M:LM?*:EYZ[#S2L!1(CNW-7GW-0/WXQQ6M4RW.7]F#U/WA4ENWN54NLRL-FQC
M]$,8TOT$I0[E?*=)\5DIM8>U6!ZZ\^4)'_$^^(C/3_B($S[B_G[Y*RBROXK)
M!>9/HG]6TGQ3DP/(C70OI9%N\:'XU+]:1-*R58?=MW[!A":J31I*O2#0@*C;
M"XS.4SD>^,U,VV'"]W'@NS,W0)E-B!?>XU'F:+O$_H](VM[Q[/]PU["$%LKH
MIB*Z;7%V>-BHK)K[$;K;W+#FYV^2OWG7P7B<")P?#RZ*F1=\<"6ZMYT2:_@&
M+&\]#J]%)O:L-IQ8J;G:SU;H)(UQ@AN_]U@D!^@\U@ NL+7)]#N!#U:6+=D.
M?#U1".>V8Y:KXMZH4YO'[V.QOE=J[3=<N.\YKLDBYF02"!?RVW!>=4FK]YJB
M=0A)2Y8T$.%<4_!?6JF:KWNU:99FQO?\>56?5O?O8W7_SDQQKCRES92!%8NY
M:0W$YFHZ*2'3*N=7VY_L[VF%/L18INQ?YB281Z!<^Z[:CB[I,Y'*3'Y_6J.G
M-?H 8Q$:*P 7Z3I%:+UG4#&[JY$<5%F3*JQ7+;-P0&\K]K1 3POT08YYR]H
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MR;T&$XB5R[%+"X(XNL$Z6%WH&(S""YOB$%TRL(MFL]F705.Q-&B$G2"WUR(
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M*"];+<2OHYK\$#("EE:8<Y;&:U1TBY178N3[3G*59]92&+";XE!YR-0T,:*
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MLP-=;*AGB!#*08# ::C/6W>4K'0B?%@3XL*.JE="JQLJ5LHQ,ZE8*3Y.,FT
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M286!TP <N:V3ZE"87'4XZ_*6VRPXEG"!Y/_,(C]A0 YA0#X[84!.&)#[UR=
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MR3T.X"TB[\U!*OG8?+?NS5XXFV#5ZEKQ@-BGO'V2#'XL<6)6NE2M4Z>[8XO
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MQ_&*.LFE^<N<#9:%:!DRK3S3MV_R:N,85 XNPO/%)3OJZYB_Z\:&@S[J45A
MJJT=5<:P%.=V4!:*"/1IQ\'%*N_*$)UK@@P^>!ZG:,O"L;)A^<)I,+BV^C\=
M71>??.(L\.MHQ!!P!G,0@)<'3FA-++)!8K+X("F3EO+?*>A^%-EN<4A^#D4F
M%,]@*7:TP,@AI&5>%PC*)QN!B:+I_&E+.K>9 RTD1421REZZS\7H^CLFC\<
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MZ?SUN<5<*)"4Y!;W38M(Y[*#! (O0=DS,V\$D7X;2X;YF)DP$@V''X7=RP_
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MEU.'C7'AL&5:<^*4_Y9@R]^W0E.6OE=>"Y^[H^ !)LMK6H-K'*/U]DB@+24
M9J8:QS]%XX..D"(.B:<[Q980N')(X(",OP/D*IV0.PG]*>'\:Y$.0[Y]6NP
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M'7F4.OTCID>3.S>KT<E:<_OZ*^:8='=GY"4D)TY@K\&AO!B/D5(TSDL;S3+
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M4%(&_"QB\DC-C5A:_U%RS7YN%9#$*!3BR9M[CF-<I)2EJL=#SD"9Q"0=7"G
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MV?"'&,T8(@NDY&PFJCAJF!';)*KH[K>/F[$@"E4<'V/V5:,69)VHHONJN^\
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M?)D()>6))_-D09OOR3Q^_N'TY"/_\/;=>_[AX\D;G^E#&!KONC*L9__B*\7
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MSXB^ 0N-9D8VHL.8R06G\(FPA,]D=M=$K]V$Y"-'C&2S#.A]! J2%'5%-O6
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MD3&0D0&,&KB(%%*XR \ZL!S#Z5MD ,(;E'A[O.WI36T*G(%,E[[_^N7O1].
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M5V^G!&EJ3^6X 9.1,R6HML TUD[7B(X4LU:Q=O0M'.%!Q,,5Z#8%NK43,XJ
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M >O+]3Q#U_XP4,X!<0*F=>V[ZQA]5]<>89K_9IY-=UO@W\2^_QW(PG1'V@>
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M1Y4!Q<Y*9!]3\SCTL <VD377#9)/=$6N*;T9:7&<J^(OA'SB<  2^"?KT_N
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ML-7QS7IZ?VD\8$67JC7P/T4.4;16%!SW/,IW_<A1>R51X!W'36G30NG1:6A
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MLQ[CCNU(F0XL"/E V6V\_F[C9EJ=?8[0<_/<T5./6 L![&FEUBU:5W()X%+
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MXN*[Z3*<1JU=.T48Z42ES2:+E##PSJC#.N;"*3ETQPXJAFN'<9R]\Y3::R=
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M%WK"/'&.!A\7/X5N)']5_B8%6CY9'' Y9*I5U?_GD!3Q_AQ*'L8&2>2GR!*
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MZ45L#%I.D%3D?Q;? ^ON17Y?D*6DD DE)-W,R9$P!*D$54C$'C@<=O49?5U
MJN-K&3![F$=C+/7\+,PO\1E^<J">%K'R&^'S%@V:;RR9JW$:G3"F>4D^89K#
M6E<E4FEH>U:, 2TLLS5E3.R,V,$<\48U%H#@Q]P4<D;)ZGJ/(/3L9,W7*L?&
MW[QGY$--LDD-R73-"O*,5H$'4IH5A7%:NTB1$W.%+Q@Z880AX*P*@U<D_R3]
M#33.5Z(BDLL PS+5H/ &,YLK"EB\</3*]\$Y174,#L@(:6D>S< )=$_ D3XP
M,<R*%Y/O(Y_.C@!%LX8Y"(6YD7M=VO Y;\2+3MQ# YNX20Y:PTK!LG^8HX@L
ME3-@]Y.6W67>.\N>(%,$SM2C'3[;@LQE[@Q22+) W2*9]_B1+@B\4:0V%!/#
MVY:'Q"T@/%F"-R6L,.+ !DW$Y*W2%R&Y$SM-'$](E9"H.8)OY]G,8_**27C9
M]%N>O<0W7RH)6S%',2PQ'J'4$^N$>YO_(D,]Y7],3=F\)=3F"R?HL#=!"M-8
M*!3SE V9\5G).@0XP^**: +^ 'PPL$G9)7@4JX'=KSH_JT/'@D7Z(([-&FW1
M0VSV/S:0@I4H%"7O$P5>^5F)&SD;:L[)6OADMK^!I\WL6]*_$7Q;Z2"I- 4+
M&;7@NWW;MH(K6(;O/"<]UZ+<*W%4?97\6J*9^U;P6JU&77L\"Y*:(,XR2"I0
M$21YJ70:O81?+>CKG/%CY ?XQ8!L+W%@D<'T35)=*^3X!(%.(-2LNFT.9P@=
MEKX9A#+ )0NJ5BWI*U(@[-M5J=GG<.K9)K$)$ILL.E+P1(^)*LT@9M\Q,'P/
M67&C;SI"IBTDV^,4%\6\I#3ZCM^/QFC"^S*C?-BZ(RN\R-RHI[/<>-O;G3,$
M>W(WRFT(>U6D;.Z'L.CRSP_>&9+D(:>EM=).;3>.9^NSY5;]S<'Z)>>33F4W
MGN4HY*W)^:0 1S=%B@>;XU$ZFX%V(!;GTL"O#I"HE3>AXR<H./%<0AA5S9ZZ
MBDO*B\) )I=2#A(HOW!L]-!IAJT2C4*R^#/4?8-H-'I)ZA+7RL]WIT@<A:6>
MV=DP!!#+Q7HO=;*),4M46L0L@N]9J3PFTKI9U'Z5)&6GOD<\<;WNZXU>9$I:
M>8JI"3_I)JJ(9D[XIFM);;4.6R'-JGATY$<CKZ_G_.?Y?2P'4D(P>::%8X$]
M&G'. F_+2;+IA97):;6"G-B@ -S"0<<DM.35F,@;BPLJOS@O%!=KOB#%I@7"
MPE>;LNOQ<)#7N#H911A2F@'($6X3GDXUM&/CC_0-E#:G@C"U/W=RX3J>-">4
M8>SV9;&LYD$<A;*:YPU4\RQ2EUC@DW; -HG\B4?'"^$"#\^*A#Z83B@\VD^8
M)V3+:!,U)2I3"RV>D^GK&W^/0$TEF3;!"0E$*HM2,IPNQ.'DC#&;]:-/]9H*
M+4G_HAXD%M *^(E@L@-42V84>D@-#Y[=" ]^7?N9\ZTF*- ^*&(Z4,GSQ 96
MB?RPYSPS&:L0+;4)EOSE+W%RY, ',(W.0#/[DLQ77&*J(#Q!^6N[*A:G"4HF
MHRI*C^-0'B%^P:,A9&]G:X=7\UD1_RZ<OHI:<K!V9/*"Z!$M(UV$!^UC/#S'
M*BSP& 7G<L)GP3FTZ,@P\ [7 ;G3*@5P!>8=W)&3K3F1Z1ME7M)%;+X)3"<=
M>H?P(G.RC.J.,F&X]J/"68^8DM_)P:&3S)F<*:4B$\T!BW3LS8@#4\MX\CR+
MW1\U7%VP4A.A<OJ7.A80QP$I+^3]P!PZO8=*(X++1-^F8W58F2 0B7T*9V 0
M57 5;?%5=C@QL>"XP@72)X%<3'+#K!>1BE'']YFO,-]?W-\M-F.A)%OS*F3-
M%;8A^F3CNOIXHZSL1#.ME'_+:<1U= 0LDYJH'Y_,S4Q0:BMO;9<9A_Z4@H!/
M@\&+/-Y5ZFE.ZO\Q5@J^#%54515NK*G]?QB"/E4L^,5A/>L4K5)W2;#.Q$-5
M;Y_NL$LS*B)/V=C7B\5MY$B; \*4N6E;.THIRIV:MCWE2KZLN"?G9PN5#T':
M3)7EN]2]2S;TS!S1[KH?VC;F#:GLBPYU];VZ;/Y>Z-3,E6@7>27.L<K;#5=:
MD-KQ+-J46A!50>?;$ZQ/=:6KWN<G&G3*@&=:TD$1?T@[//-%FCFS8FPZ!9/B
M!\TX$!D5$2)'Q"^!!S-Y,K$O=L@'.*SH'=M*]<E2]O-<5ROVEW072!OYU("=
M )X&#I/YPW1&F*V213;/B]Y!UJQ+TP8&-'S-H=9LP=O;*?;MK:Q+E%J*%Z+_
MG\@).!V!B4IQ:.#:3_!\!_.1'-<N_IXYQCV&LF5%RJ%8U9_DX?(A18X<P.G1
MI_^N'3>GCK3W5P)FDNUQ@2LU:QI"[07ZD>C\<Z*D-AAHOGZP^N(L*$IC G?<
M].]H;%X48/#U_L,N$M%Q1VN^GOC%1@Z# "PT4,;N =?E >Y\!J;BSR.VTHU:
MN]:M@=VSP01.,(7J1[9,A_[&2\FIW-^/$.#&'HU$]Z[Z'22ZKW[GS.G <>EI
M*C$K>H!]D?C%+'"B+;C9F<3)VM/:+\OFO=F1=.B$$AW'GP1AP=W#N\?$4"]6
M_V5G^!C2 S1#X^^F&V%^CC=+K>!@O4L1+7=V@*+:20DVZMT\'?[YHH1E>OF;
ME4:KM;<@J <%\,8@J!<V>J=TYHE6;=YYJ'*82^*LC1-$[3G442J,X+4;1Y84
M+A5<J2^Z86<=,".I1#R+??5.Y^C3.Z/3D,[Z1K7G^U)QSA=I/LUD@0X2*Y<O
M>N$;_19$DSGS"J/ZB(<S55&24$?/-/[^) 1)J,,2P1T^*6EXL^";&]J4N4?W
M+LL)RP=E_PI_3!R^W*D,U5[#\JY'[^RY*4U$1=-)A#7'15O:Z:NC>FX[IEH+
MW&A:Z?CKM_I*.[LUVWBQUXB@!^53<##6$Q!6._,E&IOT)0[(2<_8\6FP_7E!
M0ZGA(W/G*PE9$1R[T9RMG-B7[,N>&_,R^[(7V9>#,BO;R;Z40>*:@L23-'3Z
M]1F/F0CQ@HZ919')+4G&_KJ69<2X*&*LE[#SVPT95\+F/FG,KTC;=LRX=8=Q
M?Z&W][D^9C;<C+^<]FF>"MM7QZ(+89:G8U6N7+K.;ME" %K,P8ARKF@"F\_U
M0H6>B'5AMNEC?[/H81*5WE-8G\G>$+VE)#< 2&L.%TU;I83AQWE<-/_7^_+'
M]?UB^(!,G:!^N!PYHE]K15"/67Q^O=1TII8W#X3J@=2>;6X7-!*[X%6/,?@F
M%_/7:::@EZI&9WL;TG3P=M8/.V.Y S;N?HT;7%]?P_;%<Y\>0"=<V(]A>I7:
M26J5VN:Z,.:+QJD \,8Q5W'0!H[:*$YSQGJ:4+YX8)BF1/+F)Z@MJUBM**]]
MVYO%-JU90Q>_WDUI(Z-&?8(?$:7W\Z=-@( 87["FU3\VOJO]G_Q.1;M*U+-S
M"^\(+Q./44BS"))FF$]/R+) ,"*.VW<FB*(XYF+Y[&:9D_3Z-32.M7^A7%\C
M,$N$XR+3B$-5(T6[Q^]VA< E??O+E_,\;1G)^UZ98'9IL,O;QPYHZO9Q;:Z!
MI&93.<45B=4!"S&(7-$NDW?Q!:*^WJ]-X(WY?9*3]JQ/HN9Z"]-^9TOHG9N!
MKG!7<DM.,[#&9!_+1("?Q=BP7X0(^S@4AGF-0NI[I>YH+2W+UA&OX$(0"W6L
MZG4_-GH$ V!QCA?;DD<CWB ,"Z!7_F.?HO84 @2T ]4YFW;_&0^4>W R5S<%
M<FX;JYN$F8.)Q@=\L\.;P7401'B#<YP&0K(2ZW\S6'G9Z^VL=4<873M4ZUZB
MNNP$U:5=HKJ\ 527F28<I==\0E=!L.%1/V(P,L)BH+_;B.N@H)HB0DY!;'F&
MJ;!-P6'SSGF_B/RFR0TT50LT^??C^V/CR_79S1T_A9$4&98-Q_9/5,_W(:BX
MT/B[%_D$M,#J=X1 CH^(1X7@"7@S83W&\+PAXUDXX[%M.6QA)ZB-D3(DOB:!
MIJ"F@=H*S7[?C[A+[)T#[Y2EP+N;=H5N(]].J.WD7:_%R._@1<_,P+ZU?509
MYI.M5'6UD5-78[79<7O6,?JE8A#6%Q(&9,S%:0J?]7J-V;\DHAB^K?BB:WDN
M3<*CZ?YY,QB@9XT?DV!ESF:Z9WF&N-GW$P34N''UY]67G]#6T:?.\<DL\>\O
MQ\:""(*!C$[(BSS10@B>$>R,/8<WQS;67A0./?C6"[FM5^>]BF*H.O[',0BQ
MZT5$J<2; D2<Z$TF#/D>A6('$O#"H^WVAX@V)%'_!"!0=D^<8%XRK@E%&AXV
MP@[)YZ%-. \NZ*<Q_(A(+' KJ5_0J>(GRTY>&P%B1DXP1!S$J#]4 T:9<HCL
M'C20#:L>"CRG!</B42&:\V#J4:!I1F9?=MIB+#2"^[D,6T3<<H37C5H)S%0:
MF'QNX.I'>X3HF/Q&LK.1EX!HL334>--";$V)NR.I$ :\X@3C#R[9L2'Q1*4N
M)/>8VDJE%JMZ+J+UP:R-%@N9J%UD$>.>3$9]9*4?QX8)#%'2H0CU2ZK2BA6H
MNDJ2CY')Z,.B1B."+T2PF?!%@11EC\^UQ?B:LY&41B@S$P*D!-6(:!38_<CG
MMS/Y%QR*&CO&Q:.11!.R9RAL*@*Z! 1S3FMJ*I>&!"X,$/CJW[BT(,<F]B.S
MP$U@8I[L \FNZJ%NUMJ.P6;3BDXXK%,KAEX'@CO!.(Z-ZT'\ <S?Q'2L)&)9
M0IZ26Y39C.2M.3-B&OPXQA\?PL#A2PJWDY@:A/54.&@(T:I'@O&&>.2#W4KL
M'F49QXWG3&8<A5OUJN?TIK%K<#.XB=](G$]3;/S5?&G64!V<$<&'_'4%T]>@
M0Z%9N_<=SW=^>"/03L2[26PDL'B>_Z*M#=DPR1^J<%=GERZ1U4)$D_]$CF ;
MD2M_>?-@7-EP+8M O%?MGY.8^HI(K%)7F3Z=UG*Z<M.&A4)X0/MX2H,JWCWF
M','E4V E&GM%W_MA(R)Q0 :\HBL]"&J8$R"H2(QU$'JG'Z9K4X47YX&]I4LT
MS( A_'_P 25NA*H=(BPDK4 G X$I+1@S_Z1X55 V-&T/L2F\4)2@J053[09X
M"/ZG37DA?B''_0'7DU5+^0ZVD#]"U(*1R$=PF)Y0>8#TCFV04$0_U& E@HI
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M7 \V_!:V^!I8A1J-C*34 DT0KJ8)AA F+Z\+(*!M5]K-V8J*+>F"S7,0;<3
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M<P\U"TWKI+,1Y?#=E66?MG7Y$RGE>L1ROV*"O-W9&4#<'!%\7YK[A>;^< %
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M.#\P@Z,\I3 -]Y5 ;T_#B:LD<-!'FQ]6* P=& H<(Q?<JKD.OB,SK026MBJ
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MW<$QO@VD]6-:RY#N]=7*-BP^#ZZ!6QB0(-S^VO_97X@N!G+&\=?.1!F85\J
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M[3U\1TYA-W;Y\;KEH9'1;F\%+&,> G&Y5>Z%-VW%-TWBBJ%SMH%&)C/*S+9
MV+&$A'P_OCL)Y%"['?[Q#.$LB;,"V_KY&X@DEI8?.V"@N^"'G>DKP]5-+-$
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M(YLGI@U!%"XV4J]TNW3IQ2';[JL2!8%\X>0!,F8<(0XA'(HVACOJH%68I"F
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M779_QZ _&G.'H"7B E.!V'9P65-["80'1@;^PIZ'"Y4"&JY<GJK%OG:<3.+
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M[N:E&C*0][,!5=3SFQSO]>SJ_PY02P,$%     @ ?8MJ5)%#^[S? P  &QD
M  T   !E>%\S-#$V,C$N:'1M[9G];]HX&,=_7O^*1TC7;1(O>>$M0)$8#0BM
M!014][-)3..[8&>V V5__=DA60N%W:9=>Z-"2"2VO\GSM?UY''!:@5R&[5:
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M8S2E4+I#!^6BI-]QM%NEY*7(/U!+ P04    " !]BVI45A]NWL4&   T'@
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MYL%_!S$[/WZ7GYM6+YR/MN0N3S'1BGGJ/A@33<N!*7 L.H,HE!:+NF+K @:
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M+V]OUL;RK&WT9'.0.)!=O__TU\>%-DA ;ML%*$[\R]_^B7];_ ]02P,$%
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M<</,O3?"3+,/ _[ (U]AVOUBD.[]/U!+ 0(4 Q0    ( 'V+:E0:*=?,%Q\
M "-_ 0 1              "  0    !A8W)X+3(P,C$Q,C,Q+GAS9%!+ 0(4
M Q0    ( 'V+:E1_9?5#C X  +G2   5              "  48?  !A8W)X
M+3(P,C$Q,C,Q7V-A;"YX;6Q02P$"% ,4    " !]BVI47 "GTLEM  "\D@D
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M,C$Q,C,Q7S$P:RYH=&U02P$"% ,4    " !]BVI4Y@GLIK "   !"   #0
M            @ &1-@4 97A?,S0Q-C(P+FAT;5!+ 0(4 Q0    ( 'V+:E21
M0_N\WP,  !L9   -              "  6PY!0!E>%\S-#$V,C$N:'1M4$L!
M A0#%     @ ?8MJ5%8?;M[%!@  -!X   T              ( !=CT% &5X
M7S,T,38R,BYH=&U02P$"% ,4    " !]BVI48A'.@*X&   T'@  #0
M        @ %F1 4 97A?,S0Q-C(S+FAT;5!+ 0(4 Q0    ( 'V+:E1D^D7X
M( 4  &07   -              "  3]+!0!E>%\S-#$V,C0N:'1M4$L! A0#
M%     @ ?8MJ5$/_3[36!0  1"4   T              ( !BE % &5X7S,T
M,S4U,"YH=&U02P$"% ,4    " !]BVI4W2\BPKT9  "BJ0  #0
L    @ &+5@4 97A?,S0S-34Y+FAT;5!+!08     #0 - "H#  !S< 4    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
